<SEC-DOCUMENT>0001683168-25-004546.txt : 20250617
<SEC-HEADER>0001683168-25-004546.hdr.sgml : 20250617
<ACCEPTANCE-DATETIME>20250617160130
ACCESSION NUMBER:		0001683168-25-004546
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		96
CONFORMED PERIOD OF REPORT:	20250331
FILED AS OF DATE:		20250617
DATE AS OF CHANGE:		20250617

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Sonoma Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001367083
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		EIN:				680423298
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33216
		FILM NUMBER:		251053243

	BUSINESS ADDRESS:	
		STREET 1:		5445 CONESTOGA COURT, SUITE 150
		CITY:			BOULDER
		STATE:			CO
		ZIP:			80301
		BUSINESS PHONE:		800-759-9305

	MAIL ADDRESS:	
		STREET 1:		5445 CONESTOGA COURT, SUITE 150
		CITY:			BOULDER
		STATE:			CO
		ZIP:			80301

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Oculus Innovative Sciences, Inc.
		DATE OF NAME CHANGE:	20060622
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>sonoma_i10k-033125.htm
<DESCRIPTION>FORM 10-K FOR MARCH 2025
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:SNOA="http://sonomapharma.com/20250331">
<head>
     <title>SONOMA PHARMACEUTICALS, INC. FORM 10-K</title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_021_US%2DGAAP%2D2024%2D(with%2DECD%2Dand%2DCYD)_rempres -->
<!-- Field: Set; Name: xdx; ID: xdx_037_SNOA_sonomapharma.com_20250331 -->
<!-- Field: Set; Name: xdx; ID: xdx_041_20240401_20250331 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05C_edei%2D%2DDocumentFiscalYearFocus_2025 -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DDocumentFiscalPeriodFocus_FY -->
<!-- Field: Set; Name: xdx; ID: xdx_05D_edei%2D%2DEntityCentralIndexKey_0001367083 -->
<!-- Field: Set; Name: xdx; ID: xdx_07F_SO_sonoma__i10k%2D033125.xdxs -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2024-04-01to2025-03-31" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2024-04-01to2025-03-31" id="Fact000004" name="dei:DocumentFiscalYearFocus">2025</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2024-04-01to2025-03-31" id="Fact000005" name="dei:DocumentFiscalPeriodFocus">FY</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2024-04-01to2025-03-31" id="Fact000006" name="dei:EntityCentralIndexKey">0001367083</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2025-03-31" id="xdx2ixbrl0146" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2024-03-31" id="xdx2ixbrl0147" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0269" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-04-012024-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0277" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-04-012024-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0279" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-04-012024-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0280" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="SNOA:StockIssuedDuringPeriodValueNewIssues1" contextRef="From2023-04-012024-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0285" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="SNOA:StockIssuedDuringPeriodValueNewIssues1" contextRef="From2023-04-012024-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0287" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="SNOA:StockIssuedDuringPeriodValueNewIssues1" contextRef="From2023-04-012024-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0288" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-04-012024-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0293" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-04-012024-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0295" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-04-012024-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0296" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2023-04-012024-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0299" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2023-04-012024-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0301" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2023-04-012024-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0302" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="From2023-04-012024-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0307" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="From2023-04-012024-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0308" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="From2023-04-012024-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0309" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-04-012024-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0313" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-04-012024-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0314" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-04-012024-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0316" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0319" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="SNOA:StockIssuedDuringPeriodValueNewIssues1" contextRef="From2024-04-012025-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0327" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="SNOA:StockIssuedDuringPeriodValueNewIssues1" contextRef="From2024-04-012025-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0329" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="SNOA:StockIssuedDuringPeriodValueNewIssues1" contextRef="From2024-04-012025-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0330" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="SNOA:StockIssuedDuringPeriodValueReverseStockSplits" contextRef="From2024-04-012025-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0335" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="SNOA:StockIssuedDuringPeriodValueReverseStockSplits" contextRef="From2024-04-012025-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0337" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="SNOA:StockIssuedDuringPeriodValueReverseStockSplits" contextRef="From2024-04-012025-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0338" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2024-04-012025-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0343" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2024-04-012025-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0345" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2024-04-012025-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0346" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-04-012025-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0351" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-04-012025-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0353" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-04-012025-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0354" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2024-04-012025-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0357" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2024-04-012025-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0359" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2024-04-012025-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0360" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="From2024-04-012025-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0365" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="From2024-04-012025-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0366" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="From2024-04-012025-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0367" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-04-012025-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0371" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-04-012025-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0372" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-04-012025-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0374" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0377" unitRef="USD" xs:nil="true"></ix:nonFraction>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="snoa-20250331.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2024-04-01to2025-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-06-16">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-06-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012024-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012024-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012024-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012024-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012024-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012025-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012025-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012025-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012025-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-08-28">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-08-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-08-29">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-08-29</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_InvekraMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">SNOA:InvekraMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_custom_InvekraMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">SNOA:InvekraMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_custom_InvekraMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">SNOA:InvekraMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_ProbableCreditLossesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">SNOA:ProbableCreditLossesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_custom_ProbableCreditLossesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">SNOA:ProbableCreditLossesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_custom_ProbableCreditLossesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">SNOA:ProbableCreditLossesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_PotentialDiscountsReturnsDistributorFeesAndRebatesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">SNOA:PotentialDiscountsReturnsDistributorFeesAndRebatesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_custom_PotentialDiscountsReturnsDistributorFeesAndRebatesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">SNOA:PotentialDiscountsReturnsDistributorFeesAndRebatesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_custom_PotentialDiscountsReturnsDistributorFeesAndRebatesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">SNOA:PotentialDiscountsReturnsDistributorFeesAndRebatesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012025-03-31_us-gaap_ShippingAndHandlingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012024-03-31_us-gaap_ShippingAndHandlingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012025-03-31_us-gaap_OtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012024-03-31_us-gaap_OtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012025-03-31_us-gaap_OtherOperatingIncomeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012024-03-31_us-gaap_OtherOperatingIncomeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012025-03-31_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueNetMember_custom_CustomerAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">SNOA:CustomerAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012024-03-31_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueNetMember_custom_CustomerAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">SNOA:CustomerAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012025-03-31_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueNetMember_custom_CustomerBMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">SNOA:CustomerBMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012024-03-31_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueNetMember_custom_CustomerBMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">SNOA:CustomerBMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012025-03-31_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueNetMember_custom_CustomerCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">SNOA:CustomerCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012024-03-31_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueNetMember_custom_CustomerCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">SNOA:CustomerCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012025-03-31_us-gaap_CustomerConcentrationRiskMember_us-gaap_AccountsReceivableMember_custom_CustomerBMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">SNOA:CustomerBMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012024-03-31_us-gaap_CustomerConcentrationRiskMember_us-gaap_AccountsReceivableMember_custom_CustomerBMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">SNOA:CustomerBMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012025-03-31_us-gaap_CustomerConcentrationRiskMember_us-gaap_AccountsReceivableMember_custom_CustomerDMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">SNOA:CustomerDMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012024-03-31_us-gaap_CustomerConcentrationRiskMember_us-gaap_AccountsReceivableMember_custom_CustomerDMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">SNOA:CustomerDMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_us-gaap_OfficeEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_us-gaap_MachineryAndEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_us-gaap_FurnitureAndFixturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012025-03-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012024-03-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012025-03-31_custom_CommonStockUnitsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">SNOA:CommonStockUnitsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012024-03-31_custom_CommonStockUnitsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">SNOA:CommonStockUnitsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-02-01_custom_InsurancePremiumFinancingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">SNOA:InsurancePremiumFinancingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-02-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-302025-02-01_custom_InsurancePremiumFinancingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">SNOA:InsurancePremiumFinancingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-30</xbrli:startDate>
        <xbrli:endDate>2025-02-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_InsurancePremiumFinancingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">SNOA:InsurancePremiumFinancingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-06_custom_InsurancePremiumFinancingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">SNOA:InsurancePremiumFinancingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-02-052024-02-06_custom_InsurancePremiumFinancingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">SNOA:InsurancePremiumFinancingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-02-05</xbrli:startDate>
        <xbrli:endDate>2024-02-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_custom_InsurancePremiumFinancingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">SNOA:InsurancePremiumFinancingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-08-29_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-08-29</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-08-29_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-08-29</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_us-gaap_ConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-252023-10-26_custom_PlacementAgencyAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SNOA:PlacementAgencyAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-25</xbrli:startDate>
        <xbrli:endDate>2023-10-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-252023-10-26_custom_PublicOfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">SNOA:PublicOfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-25</xbrli:startDate>
        <xbrli:endDate>2023-10-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-12-142023-12-15_custom_EquityDistributionAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SNOA:EquityDistributionAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-12-14</xbrli:startDate>
        <xbrli:endDate>2023-12-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-01-102024-01-11_custom_MaximGroupLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SNOA:MaximGroupLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-01-10</xbrli:startDate>
        <xbrli:endDate>2024-01-11</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-11-192024-11-20_custom_MaximGroupLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SNOA:MaximGroupLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-11-19</xbrli:startDate>
        <xbrli:endDate>2024-11-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-09-02_custom_Plan2016Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SNOA:Plan2016Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-09-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-04-012019-03-31_custom_Plan2016Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SNOA:Plan2016Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-04-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-012020-03-31_custom_Plan2016Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SNOA:Plan2016Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012022-03-31_custom_Plan2016Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SNOA:Plan2016Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012025-03-31_custom_Plan2016Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SNOA:Plan2016Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_Plan2016Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SNOA:Plan2016Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012025-03-31_custom_Plan2021Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SNOA:Plan2021Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_Plan2021Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SNOA:Plan2021Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012025-03-31_custom_Plan2024Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SNOA:Plan2024Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_Plan2024Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SNOA:Plan2024Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012025-03-31_us-gaap_StockOptionMember689261046">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_Plan2011Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SNOA:Plan2011Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012025-03-31_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012025-03-31_us-gaap_DomesticCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012024-03-31_us-gaap_DomesticCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012025-03-31_us-gaap_ForeignCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012024-03-31_us-gaap_ForeignCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_us-gaap_DomesticCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_us-gaap_StateAndLocalJurisdictionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_us-gaap_ForeignCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2025-03-31_custom_CaliforniaResearchAndDevelopmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">SNOA:CaliforniaResearchAndDevelopmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_us-gaap_DomesticCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-31_custom_CaliforniaResearchAndDevelopmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">SNOA:CaliforniaResearchAndDevelopmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012025-03-31_custom_HumanCareMember_us-gaap_ProductMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">SNOA:HumanCareMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012024-03-31_custom_HumanCareMember_us-gaap_ProductMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">SNOA:HumanCareMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012025-03-31_custom_AnimalCareMember_us-gaap_ProductMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">SNOA:AnimalCareMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012024-03-31_custom_AnimalCareMember_us-gaap_ProductMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">SNOA:AnimalCareMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012025-03-31_us-gaap_ProductMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012024-03-31_us-gaap_ProductMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012025-03-31_us-gaap_ServiceMember_custom_ServiceAndRoyaltyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">SNOA:ServiceAndRoyaltyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012024-03-31_us-gaap_ServiceMember_custom_ServiceAndRoyaltyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">SNOA:ServiceAndRoyaltyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012025-03-31_us-gaap_SalesRevenueSegmentMember_country_US">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueSegmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012024-03-31_us-gaap_SalesRevenueSegmentMember_country_US">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueSegmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012025-03-31_us-gaap_SalesRevenueSegmentMember_srt_EuropeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueSegmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012024-03-31_us-gaap_SalesRevenueSegmentMember_srt_EuropeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueSegmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012025-03-31_us-gaap_SalesRevenueSegmentMember_srt_AsiaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueSegmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012024-03-31_us-gaap_SalesRevenueSegmentMember_srt_AsiaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueSegmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012025-03-31_us-gaap_SalesRevenueSegmentMember_srt_LatinAmericaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueSegmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:LatinAmericaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012024-03-31_us-gaap_SalesRevenueSegmentMember_srt_LatinAmericaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueSegmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:LatinAmericaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-04-012025-03-31_us-gaap_SalesRevenueSegmentMember_custom_RestOfTheWorldMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueSegmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">SNOA:RestOfTheWorldMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-04-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012024-03-31_us-gaap_SalesRevenueSegmentMember_custom_RestOfTheWorldMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueSegmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">SNOA:RestOfTheWorldMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2024-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2025-01-012025-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001367083</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-01</xbrli:startDate>
        <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
  <ix:relationship fromRefs="Fact000547" toRefs="Footnote000566"/>
  <ix:relationship fromRefs="Fact000559" toRefs="Footnote000566"/>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><a href="#k_001"><span style="font-size: 7pt">Table of Contents</span></a></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Washington, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Form <span id="xdx_904_edei--DocumentType_c20240401__20250331_zHnwqtvaqe4k"><ix:nonNumeric contextRef="From2024-04-01to2025-03-31" id="Fact000013" name="dei:DocumentType">10-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-size: 7pt"><b>(Mark One)</b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 5%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_edei--DocumentAnnualReport_c20240401__20250331_zmWoAJTNR0Cf"><ix:nonNumeric contextRef="From2024-04-01to2025-03-31" format="ixt:booleantrue" id="Fact000014" name="dei:DocumentAnnualReport">&#9746;</ix:nonNumeric></span></span></td>
    <td style="width: 95%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0.8pt 0 0"><b>ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
    EXCHANGE ACT OF 1934</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0.8pt 0 0"><b>&#160;</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0.8pt 0 0"><b>For the fiscal year ended <span id="xdx_90A_edei--DocumentPeriodEndDate_c20240401__20250331_zPyBIbjlliZd"><ix:nonNumeric contextRef="From2024-04-01to2025-03-31" format="ixt:datemonthdayyearen" id="Fact000015" name="dei:DocumentPeriodEndDate"><span id="xdx_907_edei--CurrentFiscalYearEndDate_c20240401__20250331_zLgBgXwOeaD3"><ix:nonNumeric contextRef="From2024-04-01to2025-03-31" format="ixt:datemonthdayen" id="Fact000016" name="dei:CurrentFiscalYearEndDate">March 31</ix:nonNumeric></span>, 2025</ix:nonNumeric></span></b></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 5%; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_edei--DocumentTransitionReport_c20240401__20250331_zzXuMbAEd6fd"><ix:nonNumeric contextRef="From2024-04-01to2025-03-31" format="ixt:booleanfalse" id="Fact000017" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric></span></span></td>
    <td style="width: 95%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0.8pt 0 0"><b>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
    EXCHANGE ACT OF 1934</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0.8pt 0 0; text-indent: 0.5in">&#160;&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0.8pt 0 0"><b>For transition period from _____________ to _____________</b></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Commission File Number: <span id="xdx_906_edei--EntityFileNumber_c20240401__20250331_zXyBjeOGtCa"><ix:nonNumeric contextRef="From2024-04-01to2025-03-31" id="Fact000018" name="dei:EntityFileNumber">001-33216</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 12pt"><b><span id="xdx_90E_edei--EntityRegistrantName_c20240401__20250331_zlkIhadNHZ2l"><ix:nonNumeric contextRef="From2024-04-01to2025-03-31" id="Fact000019" name="dei:EntityRegistrantName">SONOMA PHARMACEUTICALS, INC.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><i>(Exact name of registrant as specified in its charter)</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><i>&#160;</i></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; width: 49%; text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90A_edei--EntityIncorporationStateCountryCode_c20240401__20250331_zEZ778AaH51a"><ix:nonNumeric contextRef="From2024-04-01to2025-03-31" format="ixt-sec:stateprovnameen" id="Fact000020" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="width: 2%; text-align: center; font-size: 10pt">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 49%; text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90B_edei--EntityTaxIdentificationNumber_c20240401__20250331_z93X7Kioi2Ng"><ix:nonNumeric contextRef="From2024-04-01to2025-03-31" id="Fact000021" name="dei:EntityTaxIdentificationNumber">68-0423298</ix:nonNumeric></span></b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(State or other jurisdiction of incorporation or organization)</i></span></td>
    <td style="text-align: center; font-size: 10pt">&#160;</td>
    <td style="text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>(I.R.S. Employer Identification No.)</i></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="xdx_90E_edei--EntityAddressAddressLine1_c20240401__20250331_zBiqmlg31iw5"><ix:nonNumeric contextRef="From2024-04-01to2025-03-31" id="Fact000022" name="dei:EntityAddressAddressLine1">5445 Conestoga Court</ix:nonNumeric></span>, <span id="xdx_90E_edei--EntityAddressAddressLine2_c20240401__20250331_zaDVRLC6LxS3"><ix:nonNumeric contextRef="From2024-04-01to2025-03-31" id="Fact000023" name="dei:EntityAddressAddressLine2">Suite 150</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="xdx_904_edei--EntityAddressCityOrTown_c20240401__20250331_z5QuiDpeA5Yf"><ix:nonNumeric contextRef="From2024-04-01to2025-03-31" id="Fact000024" name="dei:EntityAddressCityOrTown">Boulder</ix:nonNumeric></span>, <span id="xdx_90C_edei--EntityAddressStateOrProvince_c20240401__20250331_z7963OaG1M2b"><ix:nonNumeric contextRef="From2024-04-01to2025-03-31" format="ixt-sec:stateprovnameen" id="Fact000025" name="dei:EntityAddressStateOrProvince">Colorado</ix:nonNumeric></span> <span id="xdx_90E_edei--EntityAddressPostalZipCode_c20240401__20250331_z9nZ5dlrFaB"><ix:nonNumeric contextRef="From2024-04-01to2025-03-31" id="Fact000026" name="dei:EntityAddressPostalZipCode">80301</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><i>(Address of principal executive offices) (Zip Code)</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 20pt"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(<span id="xdx_90C_edei--CityAreaCode_c20240401__20250331_zJx3m0UfpuBg"><ix:nonNumeric contextRef="From2024-04-01to2025-03-31" id="Fact000027" name="dei:CityAreaCode">800</ix:nonNumeric></span>)&#160;<span id="xdx_900_edei--LocalPhoneNumber_c20240401__20250331_zdwWsW0fkL93"><ix:nonNumeric contextRef="From2024-04-01to2025-03-31" id="Fact000028" name="dei:LocalPhoneNumber">759-9305</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><i>(Registrant&#8217;s telephone number, including
area code)</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Securities registered pursuant to Section&#160;12(b)
of the Act:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; width: 37%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_edei--Security12bTitle_c20240401__20250331_zGuZxYVBPd0b" title="Title of 12(b) Security"><ix:nonNumeric contextRef="From2024-04-01to2025-03-31" id="Fact000030" name="dei:Security12bTitle">Common Stock, $0.0001 par value</ix:nonNumeric></span></span></td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 24%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_edei--TradingSymbol_c20240401__20250331_zWnlWzwnUymc" title="Trading Symbol"><ix:nonNumeric contextRef="From2024-04-01to2025-03-31" id="Fact000032" name="dei:TradingSymbol">SNOA</ix:nonNumeric></span></span></td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 37%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The <span id="xdx_903_edei--SecurityExchangeName_c20240401__20250331_zQNIYUpSB8P6" title="Security Exchange Name"><ix:nonNumeric contextRef="From2024-04-01to2025-03-31" format="ixt-sec:exchnameen" id="Fact000034" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Stock&#160;Market LLC</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Title of Each Class)</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Trading Symbol(s))</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Name of Each Exchange on Which Registered)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Securities registered pursuant to Section&#160;12(g)
of the Act:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">None.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Indicate by check mark if the
registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act. Yes &#9744; <span id="xdx_904_edei--EntityWellKnownSeasonedIssuer_c20240401__20250331_z9sQndNcIiP5"><ix:nonNumeric contextRef="From2024-04-01to2025-03-31" id="Fact000035" name="dei:EntityWellKnownSeasonedIssuer">No</ix:nonNumeric></span> &#9746;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Indicate by check mark if the
registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d) of the Act. Yes &#9744; <span id="xdx_905_edei--EntityVoluntaryFilers_c20240401__20250331_zxrVNpYHnhVf"><ix:nonNumeric contextRef="From2024-04-01to2025-03-31" id="Fact000036" name="dei:EntityVoluntaryFilers">No</ix:nonNumeric></span> &#9746;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Indicate by check mark whether
the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934
during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has
been subject to such filing requirements for the past 90&#160;days. <span id="xdx_906_edei--EntityCurrentReportingStatus_c20240401__20250331_z85HzhGBIuoj"><ix:nonNumeric contextRef="From2024-04-01to2025-03-31" id="Fact000037" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span> &#9746; No &#9744;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Indicate by check mark whether
the registrant has submitted electronically every Interactive Data file required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T
(&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit
such files). <span id="xdx_907_edei--EntityInteractiveDataCurrent_c20240401__20250331_zbQu0BkbOegk"><ix:nonNumeric contextRef="From2024-04-01to2025-03-31" id="Fact000038" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span> &#9746; No &#9744;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Indicate by check mark whether
the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging
growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting
company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="width: 62%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large accelerated filer &#9744;</span></td>
    <td style="width: 38%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated filer &#9744;</span></td></tr>
  <tr>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_edei--EntityFilerCategory_c20240401__20250331_zgcRw43VJGH4"><ix:nonNumeric contextRef="From2024-04-01to2025-03-31" format="ixt-sec:entityfilercategoryen" id="Fact000039" name="dei:EntityFilerCategory">Non-accelerated Filer</ix:nonNumeric></span> &#9746;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller reporting company <span id="xdx_902_edei--EntitySmallBusiness_c20240401__20250331_zUVjoT3gs9Rg"><ix:nonNumeric contextRef="From2024-04-01to2025-03-31" format="ixt:booleantrue" id="Fact000040" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></span></td></tr>
  <tr>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging growth company <span id="xdx_906_edei--EntityEmergingGrowthCompany_c20240401__20250331_zjezNmAIKlqf"><ix:nonNumeric contextRef="From2024-04-01to2025-03-31" format="ixt:booleanfalse" id="Fact000041" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">If an emerging growth company,
indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Indicate by check mark whether
the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control
over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that
prepared or issued its audit report. <span id="xdx_907_edei--IcfrAuditorAttestationFlag_c20240401__20250331_zk1z3Lw1rU2"><ix:nonNumeric contextRef="From2024-04-01to2025-03-31" format="ixt:booleanfalse" id="Fact000042" name="dei:IcfrAuditorAttestationFlag">&#9744;</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">If securities are registered
pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing
reflect the correction of an error to previously issued financial statements. <span id="xdx_903_edei--DocumentFinStmtErrorCorrectionFlag_c20240401__20250331_znibauZcQd77" title="Document Financial Statement Error Correction [Flag]"><ix:nonNumeric contextRef="From2024-04-01to2025-03-31" format="ixt:booleanfalse" id="Fact000044" name="dei:DocumentFinStmtErrorCorrectionFlag">&#9744;</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 22.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">Indicate by check mark whether
any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the
registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). &#9744;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Indicate by check mark whether
the registrant is a shell company (as defined in Rule&#160;12b-2 of the Act). Yes &#9744; No <span id="xdx_90D_edei--EntityShellCompany_dbF_c20240401__20250331_zUs8l23Gjm7c"><ix:nonNumeric contextRef="From2024-04-01to2025-03-31" format="ixt:booleanfalse" id="Fact000045" name="dei:EntityShellCompany">&#9746;</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">The aggregate market value of
the voting&#160;and non-voting common stock held by non-affiliates of the registrant on September 30, 2024, was $<span id="xdx_908_edei--EntityPublicFloat_iI_c20240930_z83GO67qUh9h"><ix:nonFraction name="dei:EntityPublicFloat" contextRef="AsOf2024-09-30" id="Fact000046" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,047,199</ix:nonFraction></span> based on a
total of 1,318,306 shares of the registrant&#8217;s common stock held by non-affiliates on September 30, 2024, at the closing price of
$3.07 per share, as reported on the Nasdaq Capital Market.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">There were <span id="xdx_901_edei--EntityCommonStockSharesOutstanding_iI_c20250616_zdOVrfdSyqIa" title="Entity Common Stock, Shares Outstanding"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2025-06-16" id="Fact000048" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,642,765</ix:nonFraction></span> shares of
the registrant&#8217;s common stock issued and outstanding on June 16, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><b>DOCUMENTS INCORPORATED BY REFERENCE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">Items&#160;10 (as to directors
and Section&#160;16(a) Beneficial Ownership Reporting Compliance), 11, 12, 13 and 14 of Part&#160;III will incorporate by reference information
from the registrant&#8217;s proxy statement to be filed with the Securities and Exchange Commission in connection with the solicitation
of proxies for the registrant&#8217;s 2025 annual meeting of stockholders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo; Options: Hidden -->&#160;<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="k_001"></span>TABLE OF CONTENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 10%">&#160;</td>
    <td style="width: 80%">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td colspan="3" style="text-align: center"><a href="#k_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART&#160;I</b></span></a></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 1.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#k_003">Business</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="background-color: rgb(238,238,238)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 1A.</span></td>
    <td style="vertical-align: top"><a href="#k_004"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk Factors</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 1B.</span></td>
    <td style="vertical-align: top"><a href="#k_006"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unresolved Staff Comments</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">36</span></td></tr>
  <tr style="background-color: rgb(238,238,238)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 1C.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#k_007">Cybersecurity</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">36</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 2.</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#k_005">Properties</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">37</span></td></tr>
  <tr style="background-color: rgb(238,238,238)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 3.</span></td>
    <td style="vertical-align: top"><a href="#k_008"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal Proceedings</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">37</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 4.</span></td>
    <td><a href="#k_009"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mine Safety Disclosures</span></a></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</span>7</td></tr>
  <tr style="background-color: rgb(238,238,238)">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td colspan="3" style="text-align: center"><a href="#k_010"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART
    II</b></span></a></td></tr>
  <tr style="background-color: rgb(238,238,238)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 5.</span></td>
    <td style="vertical-align: top"><a href="#k_011"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</span>8</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 6.</span></td>
    <td style="vertical-align: top"><a href="#k_012"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Selected Financial Data</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</span>8</td></tr>
  <tr style="background-color: rgb(238,238,238)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 7.</span></td>
    <td style="vertical-align: top"><a href="#k_013"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</span>8</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 7A.</span></td>
    <td style="vertical-align: top"><a href="#k_014"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quantitative and Qualitative Disclosures About Market Risk</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">43</span></td></tr>
  <tr style="background-color: rgb(238,238,238)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 8.</span></td>
    <td style="vertical-align: top"><a href="#k_015"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Financial Statements and Supplementary Data</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">44</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 9.</span></td>
    <td style="vertical-align: top"><a href="#k_023"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">45</span></td></tr>
  <tr style="background-color: rgb(238,238,238)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 9A.</span></td>
    <td style="vertical-align: top"><a href="#k_024"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Controls and Procedures</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</span>5</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 9B.</span></td>
    <td style="vertical-align: top"><a href="#k_025"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other Information</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</span>6</td></tr>
  <tr style="background-color: rgb(238,238,238)">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td colspan="3" style="text-align: center"><a href="#k_026"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART III</b></span></a></td></tr>
  <tr style="background-color: rgb(238,238,238)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 10.</span></td>
    <td style="vertical-align: top"><a href="#k_027"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors, Executive Officers and Corporate Governance</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</span>7</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 11.</span></td>
    <td style="vertical-align: top"><a href="#k_028"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive Compensation</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">47</span></td></tr>
  <tr style="background-color: rgb(238,238,238)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 12.</span></td>
    <td style="vertical-align: top"><a href="#k_029"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</span>8</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 13.</span></td>
    <td style="vertical-align: top"><a href="#k_030"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain Relationships and Related Transactions, and Director Independence</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</span>8</td></tr>
  <tr style="background-color: rgb(238,238,238)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 14.</span></td>
    <td style="vertical-align: top"><a href="#k_031"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal Accounting Fees and Services</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</span>8</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td colspan="3" style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td colspan="3" style="text-align: center"><a href="#k_032"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART IV</b></span></a></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 15.</span></td>
    <td style="vertical-align: top"><a href="#k_033"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibits, Financial Statement Schedules</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">49</span></td></tr>
  <tr style="background-color: rgb(238,238,238)">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ITEM 16.</span></td>
    <td style="vertical-align: top"><a href="#k_035"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form 10-K Summary</span></a></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">52</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#k_036">Signatures</a></span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">53</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: LowerRoman; Value: 1; Name: PageNo -->i<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="k_002"></span>PART I</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>This report includes &#8220;forward-looking statements.&#8221;
The words &#8220;may,&#8221; &#8220;will,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221;
&#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;aim,&#8221; &#8220;seek,&#8221; &#8220;should,&#8221; &#8220;likely,&#8221; and similar
expressions as they relate to us or our management are intended to identify these forward-looking statements. All statements by Sonoma
regarding expected financial position, revenues, cash flows and other operating results, business strategy, legal proceedings and similar
matters are forward-looking statements. Our expectations expressed or implied in these forward-looking statements may not turn out to
be correct. Our results could be materially different from our expectations because of various risks, including the risks discussed in
this report under &#8220;Part&#160;I&#160;&#8212; Item&#160;1A&#160;&#8212; Risk Factors.&#8221; Any forward-looking statement speaks
only as of the date as of which such statement is made, and, except as required by law, we undertake no obligation to update any forward-looking
statement to reflect events or circumstances, including unanticipated events, after the date as of which such statement was made.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="k_003"></span>ITEM&#160;1.&#160;Business</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Corporate Information</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We originally incorporated as Micromed Laboratories,
Inc. in 1999 under the laws of the State of California. We changed our name to Oculus Innovative Sciences, Inc. in 2001. In December 2006
we reincorporated under the laws of the State of Delaware, and in December 2016 we changed our name to Sonoma Pharmaceuticals, Inc.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our principal executive offices are located at 5445
Conestoga Court, Suite 150, Boulder, Colorado 80301. We have two active wholly-owned subsidiaries: Oculus Technologies of Mexico, S.A.
de C.V., and Sonoma Pharmaceuticals Netherlands, B.V. Our fiscal year end is March 31. Our corporate telephone number is (800) 759-9305.
Our websites are www.sonomapharma.com and www.sonomapharma.eu. The websites and any information contained therein or connected thereto
is not intended to be incorporated into this report.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Overview</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are a global healthcare leader for developing and
producing stabilized hypochlorous acid, or HOCl, products for a wide range of applications, including wound care, eye care, oral care,
dermatological conditions, podiatry, animal health care and non-toxic disinfectants. Our products are clinically proven to reduce itch,
pain, scarring, and irritation safely and without damaging healthy tissue. In-vitro and clinical studies of HOCl show it to safely manage
skin abrasions, lacerations, minor irritations, cuts, and intact skin. We sell our products either directly or via partners in over 55
countries worldwide.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Business Update</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Over the past year, we have continued our focus on
increasing revenues and continuing progress towards profitability. During our most recent fiscal year, our revenues have grown as a result
of continued expansion of our distribution network and customer base, the introduction of new products into multiple markets around the
world, as well as organic growth from existing customers and distributors. We have also focused on expanding and strengthening our regulatory
reach by seeking new approvals and clearances.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Value: 1; Name: PageNo -->1<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Some of our recent business updates include:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We successfully transitioned all of our commercialized products in Europe, including eye care, wound care, scar gel, acne products and atopic dermatitis products to the new European Union (EU) Medical Device Regulation (MDR).</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our manufacturing facility and five of our products were successfully registered with the Medicines &amp; Healthcare products Regulatory Agency (MHRA) in the United Kingdom, including our wound irrigation solution, scar management products, wound hydrogel, and skin exfoliant, and we partnered with a leading health and beauty retailer for the sale of our acne products in over 1,200 U.K. stores.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In January 2025, we partnered with WellSpring Pharmaceutical Corporation for the sale of our Microcyn technology-based products to large retailers in the United States. In March 2025 and June 2025, we expanded our agreement with WellSpring to include additional consumer focused products.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In September and November 2024, we received two new 510(k) clearances from the FDA, including specific over-the-counter indications for the face, eyelid and eyelashes, as well as improved biocompatibility for our Microcyn-based solution and hydrogel.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2024, we announced the relaunch of our prescription eye care product, Acuicyn<sup>&#174;</sup>, our prescription dermatology products Celacyn<sup>&#174;</sup>, Levicyn&#174; and Epicyn<sup>&#174;</sup>, and our over-the-counter Lasercyn<sup>&#174;</sup> Dermal Spray and Lasercyn Gel.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In August 2024, we announced a new distribution agreement with Medline Industries, LP for the marketing and distribution of our wound care products in the United States. In October 2024, we expanded our agreement with Medline for marketing and distribution of our wound care products in Canada, and the sale of OTC wound care products to retailers in both countries.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We continue to invest in research and development,
both in the U.S. and internationally, for our core performance-stabilized hypochlorous acid, or HOCl, technology. We have an active pipeline
of products and we intend to continue to seek new regulatory clearances to expand potential markets for our products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Business Channels</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our core market differentiation is based on being
the leading developer and producer of stabilized hypochlorous acid, or HOCl, solutions. We have been in business for over 20 years, and
in that time, we have developed significant scientific knowledge of how best to develop and manufacture HOCl products backed by decades
of studies and data collection along with manufacturing experience.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We sell our products into many markets both in the
U.S. and internationally. In international markets, we ship a variety of products into over 55 countries. Our core strategy is to work
with partners both in the United States and around the world to market and distribute our products. In some cases, we market and sell
our own products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Dermatology</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have developed unique, differentiated, and safe
dermatologic products that support paths to healing for various dermatologic conditions. Our products are primarily targeted at the treatment
of redness and irritation, the management of scars and symptoms of eczema/atopic dermatitis. In Europe and the United Kingdom, we have
developed products to treat acne. We are strategically focused on introducing innovative new products that are supported by human clinical
data with applications that address specific dermatological procedures currently in demand. In addition, we look for markets where we
can provide effective product line extensions and pricing to new product families.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 4 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In the United States, we relaunched the direct sale
of our prescription and office dispense dermatology products in December 2024, including Epicyn Facial Cleanser, Levicyn Antimicrobial
Dermal Spray, Levicyn Gel, Levicyn Spray Gel, Celacyn Scar Management Gel. We also relaunched <span style="background-color: white">over-the-counter
</span>Lasercyn Dermal Spray and Lasercyn Gel<span style="background-color: white">. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">Other over-the-counter
dermatology products in the United States include Regenacyn<sup>&#174;</sup> Advanced Scar Gel, which is clinically proven to improve the
overall appearance of scars while reducing pain, itch and redness, Reliefacyn<sup>&#174;</sup> Advanced Itch-Burn-Rash-Pain Relief Hydrogel
for the alleviation of red bumps, rashes, shallow skin fissures, peeling, and symptoms of eczema/atopic dermatitis, and Rejuvacyn<sup>&#174;</sup>
Advanced Skin Repair Cooling Mist for management of minor skin irritations following cosmetic procedures as well as daily skin health
and hydration. </span>Rejuvacyn is certified as a Natural Personal Care Product by the Natural Products Association, and Reliefacyn received
the National Eczema Association Seal of Acceptance<sup>TM</sup> in 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In January 2023, we launched a line of office dispense
products exclusively for skin care professionals, including two new prescription strength dermatology products, Reliefacyn&#160;Plus <span style="background-color: white">Advanced
Itch-Burn-Rash-Pain Relief Hydrogel</span> and Rejuvacyn&#160;Plus <span style="background-color: white">Skin Repair Cooling Mist</span>.
These products, along with <span style="background-color: white">Regenacyn Plus Scar Gel,</span> are marketed and sold directly to dermatology
practices and medical spas.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">In January 2024,
we launched Lumacyn<sup>TM</sup> Clarifying Mist, a direct-to-consumer skin care product in the United States. Lumacyn is an all-natural
daily toner to soothe skin, reduce redness and irritation, and manage blemishes by reducing infection.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="background-color: white">Our consumer products are available
through online retailers, our online store and third-party distributors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We sell dermatology products in Europe and Asia through
distributors. In these international markets, we have a network of partners, ranging from country specific distributors to large pharmaceutical
companies to full-service sales and marketing companies. We work with our international partners to create products they can market in
their home country. Some products we develop and manufacture are custom label while others use branding we have already developed. We
have created or co-developed a wide range of products for international markets using our core HOCl technology.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>First Aid and Wound Care</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our HOCl-based wound care products are intended for
the treatment of acute and chronic wounds as well as first- and second-degree burns, and as an intraoperative irrigation treatment. They
work by first removing foreign material and debris from the skin surface and moistening the skin, thereby improving wound healing. Secondly,
our HOCl products assist in the wound healing process by removing microorganisms. HOCl is an important constituent of our innate immune
system, formed and released by the macrophages during phagocytosis. Highly organized cell structures such as human tissue can tolerate
the action of our wound care solution while single-celled microorganisms cannot, making our products advantageous to other wound-irrigation
and antiseptic solutions. Due to its unique chemistry, our wound treatment solution is also much more stable than similar products on
the market and therefore maintains much higher levels of hypochlorous acid over its shelf life.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In the United States, we sell our wound care products
directly to hospitals, physicians, nurses, and other healthcare practitioners and indirectly through non-exclusive distribution arrangements.
In Europe, the Middle East and Asia, we sell our wound care products through a diverse network of distributors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In June 2023, we announced a new application of our
HOCl technology for intraoperative pulse lavage irrigation treatment, which can replace commonly used IV bags in a variety of surgical
procedures. The intraoperative pulse lavage container is designed to be used in combination with a pulse lavage irrigation device, or
flush gun, for abdominal, laparoscopic, orthopedic, and periprosthetic procedures. It is in trial use by hospitals in Europe and launched
in the U.S. in November 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In April 2024, we announced expansion of our Microcyn
Negative Pressure Wound Therapy Solution products line, now available in 250mL, 450mL and 990mL sizes to meet the diverse needs of healthcare
professionals and patients.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 5 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In August, 2024, we entered into a distribution agreement
with Medline Industries, LP, for the marketing and distribution of our wound care products in the United States. The agreement is for
an initial term of five years, subject to automatic one-year renewal periods. In October 2024, we entered into an amendment to the agreement
which allows Medline to also sell our wound care products in Canada, as well as to sell additional over-the-counter wound care products
to retailers in both countries.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><i>Eye Care</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">In the United States, our
prescription product Acuicyn<sup>&#174;</sup> Eyelid &amp; Eyelash Cleanser is an effective solution for symptoms of blepharitis and the
daily hygiene of eyelids and lashes, and helps manage red, itchy, crusty and inflamed eyes. It is strong enough to kill the bacteria that
causes discomfort, fast enough to provide near instant relief, and gentle enough to use as often as needed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">We sell Ocucyn<sup>&#174;</sup>
Eyelid &amp; Eyelash Cleanser to consumers through online retailers, our online store, and third party distributors. Ocucyn is designed
for everyday use as a safe, gentle, and effective solution for good eyelid and eyelash hygiene. In international markets we rely on distribution
partners to sell our eye products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Oral, Dental and Nasal Care </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">We sell a variety
of oral, dental, and nasal products around the world.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In international markets, our product Microdacyn60
Oral Care treats mouth and throat infections and thrush. Microdacyn60 assists in reducing inflammation and pain, provides soothing cough
relief and does not contain any harmful chemicals. It does not stain teeth, is non-irritating, non-sensitizing, has no contraindications
and is ready for use with no mixing or dilution.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our international nasal care product Sinudox&#8482;
based on our HOCl technology is an electrolyzed solution intended for nasal irrigation. Sinudox clears and cleans stuffy, runny noses
and blocked or inflamed sinuses by ancillary ingredients that may have a local antimicrobial effect. We sell Sinudox through international
distributors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Podiatry</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our HOCl-based wound care products are also indicated
for the treatment of diabetic foot ulcers. In the United States, we sell our wound care products directly to podiatrists as well as hospitals,
nurses, and other healthcare practitioners and indirectly through non-exclusive distribution arrangements. In Europe, we sell our wound
care products for podiatric use through a diverse network of distributors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In April 2023, we launched Podiacyn<sup>TM</sup> Advanced
Everyday Foot Care direct to consumers for over-the-counter use in the United States, intended for management of foot odors, infections,
and irritations, as well as daily foot health and hygiene. Podiacyn is available through Amazon.com, our online store and third-party
distributors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Animal Health Care</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">MicrocynAH<sup>&#174;</sup> is an HOCl-based topical
product that cleans, debrides and treats a wide spectrum of animal wounds and infections. It is intended for the safe and rapid treatment
of a variety of animal afflictions including cuts, burns, lacerations, rashes, hot spots, rain rot, post-surgical sites, pink eye symptoms
and wounds to the outer ear.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 6 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For our animal health products sold in the U.S. and
Canada, we partner with Compana Pet Brands. Compana distributes non-prescription products to national pet-store retail chains and farm
animal specialty stores, such as PetSmart, Tractor Supply, PetExpress, and Menards.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">For the Asian
and European markets, in May 2019 we partnered with Petagon an international importer and distributor of quality pet food and products
for an initial term of five years. We supply Petagon with all MicrocynAH products sold by Petagon. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Surface Disinfectants</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our HOCl technology has been formulated as a disinfectant
and sanitizer solution and is sold in numerous countries. It is designed to be used to spray in aerosol format in areas and environments
likely to serve as a breeding ground for the spread of infectious disease, which could result in epidemics or pandemics. The medical-grade
surface disinfectant solution is used in hospitals worldwide to protect doctors and patients. In May 2020, Nanocyn<sup>&#174;</sup> Disinfectant
&amp; Sanitizer received approval to be entered into the Australian Register of Therapeutic Goods, or ARTG, for use against the coronavirus
SARS-CoV-2, or COVID-19, and was also authorized in Canada for use against COVID-19. Nanocyn has also met the stringent environmental
health and social/ethical criteria of Good Environmental Choice Australia, or GECA, becoming one of the very few eco-certified, all-natural
disinfectant solutions in Australia. In 2024, the Australian Therapeutic Goods Administration approved extended claims for Nanocyn for
use against Candida auris (C. auris) and Clostritium Difficile (C. diff.).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Through our partner MicroSafe, we sell hard surface
disinfectant products into Europe, the Middle East and Australia.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In July 2021, we granted MicroSafe the non-exclusive
right to sell and distribute Nanocyn in the United States provided that MicroSafe secure U.S. EPA approval. In April of 2022, MicroSafe
secured the EPA approval for Nanocyn&#174; Disinfectant &amp; Sanitizer, meaning that it can now be sold in the United States as a surface
disinfectant, and it was subsequently added to the EPA&#8217;s list N for use against COVID-19. In June 2022, the EPA added Nanocyn to
List Q as a disinfectant for Emerging Viral Pathogens, including Ebola virus, Mpox, and SARS-CoV-2, and in March 2023 the EPA added Nanocyn
to Lists G and H, for use against Methicillin Resistant Staphylococcus Aureus (MRSA), Salmonella, Norovirus, Poliovirus, and as a fungicide.
Nanocyn also received the Green Seal<sup>&#174;</sup> Certification after surpassing a series of rigorous standards that measure environmental
health, sustainability and product performance. Nanocyn is currently sold by MicroSafe in Europe, the Middle East and Australia.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Employees</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of June 12, 2025, we employed a total of 7 full-time
employees in the United States, and one full-time employee in the Netherlands. Additionally, we had approximately 160 employees in Mexico.
We are not a party to any collective bargaining agreements. We believe relations with employees are very good.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Products</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our products are all classified as medical devices
and categorized as prescription, over-the-counter (OTC) and office dispense products. Below are some of our key products that we either
sell through our own efforts or through partnership agreements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 7 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Dermatology</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In the United States, we offer both prescription and
OTC dermatology products. Our prescription strength products include Epicyn Facial Cleanser, Levicyn Dermal Spray, Levicyn Gel, Levicyn
Spray Gel, Celacyn Scar Management Gel.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><img src="derm.jpg" alt="" style="height: 222px; width: 450px"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We offer Lasercyn Dermal Spray, Lasercyn Gel, Regenacyn
Advanced Scar Gel, Reliefacyn Advanced Itch-Burn-Rash-Pain Relief Hydrogel and Lumacyn Clarifying Mist for OTC purchase in the United
States, and Regenacyn Plus Scar Gel and Reliefacyn Plus Itch-Burn-Rash-Pain Relief Hydrogel for office dispense.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left">
  <td style="width: 25%">&#160;<img src="lasercyn.jpg" alt="" style="height: 207px; width: 150px"/></td>
  <td style="text-align: left; width: 75%; vertical-align: middle"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Lasercyn Post Procedure Gel is intended for the management
of post non-ablative laser therapy procedures, post microdermabrasion therapy and following superficial chemical peels. Both Lasercyn
Gel and Lasercyn Dermal Spray may also be used to relieve itch and pain from minor skin irritations, lacerations, abrasions and minor
burns.</p>
</td></tr>
<tr style="vertical-align: top; text-align: left">
  <td>&#160;</td>
  <td>&#160;</td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 8 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left">
  <td style="text-align: left; vertical-align: middle; width: 25%"><img src="regenacyn.jpg" alt="" style="height: 212px; width: 150px"/>&#160;</td>
  <td style="vertical-align: middle; text-align: justify; width: 75%">Regenacyn Advanced Scar Gel is clinically proven to
improve the overall appearance of scars, burns and keloids while reducing pain and itch.</td></tr>
<tr style="vertical-align: top; text-align: left">
  <td>&#160;</td>
  <td>&#160;</td></tr>
<tr style="vertical-align: top; text-align: left">
  <td style="text-align: left; vertical-align: middle">&#160;<img src="reliefacyn.jpg" alt="" style="height: 219px; width: 150px"/></td>
  <td style="text-align: left; vertical-align: middle"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Reliefacyn Advanced Itch-Burn-Rash-Pain Relief Hydrogel
is intended for the alleviation of red bumps, rashes, shallow skin fissures, sunburn, peeling, and symptoms of eczema/atopic dermatitis.</p>
</td></tr>
<tr style="vertical-align: top; text-align: left">
  <td style="text-align: left; vertical-align: middle">&#160;</td>
  <td style="text-align: left; vertical-align: middle">&#160;</td></tr>
<tr style="vertical-align: top; text-align: left">
  <td style="text-align: left; vertical-align: middle">&#160;<img src="lumacyn.jpg" alt="" style="height: 229px; width: 150px"/></td>
  <td style="text-align: left; vertical-align: middle"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Lumacyn Clarifying Mist is intended for use as a daily
skin toner, to soothe and cleanse the skin, reduce redness, and manage blemishes by reducing infection.</p>
</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 9 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Regenacyn Plus, Reliefacyn Plus, and Rejuvacyn Plus
are prescription-strength products available as office dispense through dermatology practices and medical spas.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Internationally, we offer GramaDerm<sup>&#174;</sup>
Hydrogel and Solution Combo Pack to assist in the treatment of topical mild to moderate acne, Epicyn<sup>&#174;</sup> Scar Management Hydrogel
and Pediacyn<sup>&#174;</sup> Atopic Dermatitis Hydrogel.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Wound Care</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In the United States we offer Microcyn wound and skin care both as an OTC
and prescription product.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Microcyn OTC Advanced Wound &amp; Skin Cleanser is intended for the over-the-counter
management of skin abrasions, lacerations, minor irritations and cuts.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Microcyn Wound Care Management for Professional Use is an HOCl-based topical
line of products designed to stimulate expedited healing by targeting a wide range of pathogens including viruses, fungi, spores and bacteria,
including antibiotic-resistant strains that slow the natural healing of wounds. We offer Microcyn Skin &amp; Wound Spray, Skin &amp; Wound
Hydrogel, Wound Irrigation Solution, and Negative Pressure Wound Therapy Solution.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&#160;<img src="microcyn.jpg" alt="" style="height: 293px; width: 565px"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 10 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Eye, Nasal and Oral Care </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">In the United States, we offer both OTC and prescription eye care products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left">
  <td style="text-align: left; width: 25%; vertical-align: middle">&#160;<img src="acuicyn.jpg" alt="" style="height: 159px; width: 160px"/></td>
  <td style="text-align: left; width: 75%; vertical-align: middle"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Acuiycn Eyelid and Eyelash Hygiene is a prescription HOCl-based solution
that removes encrustation and debris, to help manage red, itchy, crusty, inflamed eyes and symptoms of chronic eye conditions such as
dry eye, contact lens intolerance, blepharitis and meibomian gland dysfunction.</p>
</td></tr>
<tr style="vertical-align: top; text-align: left">
  <td>&#160;</td>
  <td>&#160;</td></tr>
<tr style="vertical-align: top; text-align: left">
  <td style="text-align: left; vertical-align: middle">&#160;<img src="ocucyn.jpg" alt="" style="height: 253px; width: 160px"/></td>
  <td style="text-align: left; vertical-align: middle"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Ocucyn Eyelid and Eyelash Cleanser is an OTC eye care product sold directly
in the United States that provides everyday relief for red, itchy, irritated and swollen eyelids.</p></td></tr>
<tr style="vertical-align: top; text-align: left">
  <td>&#160;</td>
  <td>&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Internationally, we offer Ocudox<sup>TM </sup>for
eye care, Sinudox<sup>TM</sup> for nasal irrigation, and Microdacyn60&#174; Oral Care to support the treatment of mouth and throat infections
and the debridement and moistening of mouth lesions and thrush.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i></i></p>

<!-- Field: Page; Sequence: 11 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Animal Health Care</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In the United States and internationally, our HOCl-based
MicrocynAH line offers topical solutions designed to relieve the common symptoms of hot spots, scratches, skin rashes, post-surgical sites
and irritated animal skin and promote expedited healing for all animals.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our MicrocynVS line is veterinarian-strength animal
care for use in vet clinics and animal hospitals.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&#160;<img src="microcynvs.jpg" alt="" style="height: 169px; width: 650px"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Surface Disinfectants</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Through our partner MicroSafe DMCC, Dubai, we sell
Nanocyn&#174;. Nanocyn is a hospital-grade disinfectant indicated to sterilize hard surfaces by spraying directly onto the surface, for
medical devices by submerging the device in Nanocyn, and also for fumigation into the air.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">When fumigated, Nanocyn has demonstrated the ability
to kill a wide range of airborne pathogens and significantly reduce the spread of infectious disease.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&#160;<img src="nancyn.jpg" alt="" style="height: 191px; width: 350px"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 12 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Research and Development</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Research and development expenses consist primarily
of expenses for clinical studies, personnel, regulatory services and supplies. For the years ended March 31, 2025 and 2024, research and
development expense amounted to $1,814,000 and $1,871,000, respectively. A small percentage of these expenses were borne by our customers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We manufacture all of our products at our facility
in Zapopan, Mexico. We have developed a manufacturing process and conduct quality assurance testing on each production batch in accordance
with current U.S., Mexican and international Current Good Manufacturing Practices. Our facility is required to meet and maintain regulatory
standards applicable to the manufacture of pharmaceutical and medical device products and is certified and complies with U.S. Current
Good Manufacturing Practices, Quality Systems Regulations for medical devices, and International Organization for Standardization, or
ISO, guidelines. Our facility has been approved by the Ministry of Health and is also ISO 13485 certified.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our machines are tested regularly, which is part of
a validation protocol mandated by U.S., Mexican and international Current Good Manufacturing Practices, Quality Systems Regulation, and
ISO requirements. This validation is designed to ensure that the final product is consistently manufactured in accordance with product
specifications at all manufacturing sites. Certain materials and components used in manufacturing are proprietary to Sonoma. All other
raw materials and supplies utilized in the manufacturing process of our products are available from various third-party suppliers in quantities
adequate to meet our needs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We believe we own or have access to sufficient factory
space and equipment to produce an adequate amount of product to meet anticipated future requirements for at least the next two years.
With expansion into new geographic markets, we may establish additional manufacturing facilities to better serve those new markets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Regulatory Approvals and Clearances</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">To date, in the United States we have obtained 22
U.S. Food and Drug Administration, or FDA, clearances permitting the sale of products as medical devices for Section 510(k) of the Federal
Food, Drug and Cosmetic Act.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Outside the United States, we sell products for dermatological
and advanced tissue care with a European Conformity marking, Conformit&#233; Europ&#233;enne, or CE. On January 29, 2025, we received
an updated CE certificate under the new EU Medical Devices Regulation covering all of our commercialized products in Europe.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The following table summarizes
our current material regulatory approvals and clearances by brand.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 37%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Brand</b></span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: top; width: 13%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Approval Type</b></span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 48%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Summary Indication</b></span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>HOCl-based Products:</b></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Microcyn Wound Care Management</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Acuicyn Antimicrobial Eyelid &amp; Eyelash Hygiene</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Epicyn Antimicrobial Facial Cleanser</p></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S. 510(k) </span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under the supervision of a healthcare professional, intended for the cleansing, irrigation, moistening, debridement and removal of foreign material and debris from exudating wounds, acute and chronic dermal lesions including stage I-IV pressure ulcers, stasis ulcers, diabetic ulcers, post-surgical wounds, first-and-second-degree burns, abrasions, minor irritations of the skin, diabetic foot ulcers, ingrown toe nails, grafted/donor sites and exit sites. It is also intended for use to moisten and lubricate wound dressings and for use with devices intended to irrigate wounds.</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 13 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 37%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Microcyn OTC Advanced Wound &amp; Skin Cleanser</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Ocucyn Eyelid &amp; Eyelash Cleanser</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Lumacyn Clarifying Mist</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Podiacyn Advanced Everyday Foot Care</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: top; width: 13%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S. 510(k)</span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: top; text-align: justify; width: 48%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intended for OTC use in the management of skin abrasions, lacerations, minor irritations, cuts and intact skin.</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Levicyn Gel</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Lasercyn Post Procedure Gel</p></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S. 510(k)<br/>
<br/>
<br/>
</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prescription and OTC product intended for the management of post non ablative laser therapy procedures, post microdermabrasion therapy and following superficial chemical peels.&#160;&#160;May also be used to relieve itch and pain from minor skin irritations, lacerations, abrasions and minor burns.</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Celacyn Scar Management Gel</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Regenacyn Plus Scar Gel</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Regenacyn Advanced Scar Gel</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S. 510(k)</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prescription and OTC product intended for the management of old and new hypertrophic and keloid scarring resulting from burns, general surgical procedures and trauma wounds.</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Levicyn SG</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S. 510(k)<br/>
<br/>
<br/>
</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under the supervision of a healthcare professional, intended to manage and relieve the burning, itching and pain experienced with various types of dermatoses, including radiation dermatitis and atopic dermatitis. May be also used to relieve the pain of first and second degree burns. Helps to relieve dry waxy skin by maintaining a moist wound and skin environment, which is beneficial to the healing process.</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Rejuvacyn Plus Skin Repair Cooling Mist</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Rejuvacyn Advanced Skin Repair Cooling Mist</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Lasercyn Gel</p></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S. 510(k)</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prescription and OTC product for the management of post non ablative laser therapy procedures, post microdermabrasion therapy and following superficial chemical peels. May also be used to relieve itch and pain from minor skin irritations, lacerations, abrasions and minor burns. intended for the management of minor skin irritations following post non ablative laser therapy procedures, post microdermabrasion therapy and following superficial chemical peels, and to relieve itch and pain from minor skin irritations, lacerations, abrasions and minor burns.</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Reliefacyn Plus Itch-Burn-Rash-Pain Relief Hydrogel</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Levicyn Dermal Spray</p></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S. 510(k)</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under the supervision of a healthcare professional, indicated to manage and relieve the burning, itching and pain experienced with various types of dermatoses, including radiation dermatitis and atopic dermatitis. May be also used to relieve the pain of first and second degree burns. Helps to relieve dry waxy skin by maintaining a moist wound and skin environment, which is beneficial to the healing process.&#160;&#160;</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Reliefacyn Advanced Itch-Burn-Rash-Pain Relief Hydrogel</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Lasercyn Dermal Spray</p></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S. 510(k)</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intended for OTC use to relieve the burning and itching associated with many common types of skin irritations, lacerations, abrasions and minor burns. Also indicated for the management of irritation and pain from minor burns, including sunburn.</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 14 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 37%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Endocyn Root Canal Irrigation Solution</span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: top; width: 13%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S. 510(k)</span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify; width: 48%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under the supervision of a healthcare professional intended to irrigate, cleanse, and debride root canal systems including the removal of foreign material and debris during root canal therapy. It is also intended to provide for lubrication and irrigation during root canal instrumentation.</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Microdacyn60 Wound Care</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EU CE Mark</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicated for use in surgical wounds (intraoperative and postoperative), acute and chronic wounds, ulcers, cuts, abrasions, and burns. Microdacyn60&#174; Wound Care can be broadly applied within a comprehensive wound treatment.</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Microdacyn60 Hydrogel</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EU CE Mark</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">indicated for use in acute and chronic wounds, ulcers, cuts, abrasions and burns. Can be broadly applied within a comprehensive wound treatment.</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Epicyn Scar Management Hydrogel </span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EU CE Mark</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicated as an adjuvant in the wound healing process with wounds that can only heal by secondary intention in maturation phase. Effective for the management and reduction of new and existing hypertrophic and keloid scars.</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pediacyn Atopic Dermatitis Hydrogel</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EU CE Mark</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicated as an adjuvant in the healing process of wounds that can only heal by secondary intention in the maturation phase. Indicated for the care of lesions associated with atopic dermatitis.</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">GramaDerm Solution</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EU CE Mark</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicated as an adjunct in the topical treatment of mild to moderate acne.</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">GramaDerm Hydrogel</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EU CE Mark</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicated as an adjunct in the topical treatment of mild to moderate acne.</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ocudox</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EU CE Mark</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicated to aid in the treatment and symptoms of blepharitis on the eyelid. Can be used to clean minor cuts and burns of the periocular skin.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Significant Customers</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We rely on certain key customers for a significant
portion of revenues. At March 31, 2025, customer D represented 24% of our net accounts receivable balance. At March 31, 2024, customer
B represented 13% of our net accounts receivable balance and customer D represented 17% of our net accounts receivable balance. For the
year ended March 31, 2025, customer B represented 21% and customer C represented 18% of net revenues. For the year ended March 31, 2024,
customer A represented 17%, customer B represented 15% and customer C represented 14% of net revenues.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 15 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Intellectual Property</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our success depends in part on an ability to obtain
and maintain proprietary protection for product technology and know-how, to operate without infringing proprietary rights of others, and
to prevent others from infringing on our proprietary rights. We seek to protect a proprietary position by, among other methods, filing,
when possible, U.S. and foreign patent applications relating to our technology, inventions and improvements that are important to the
business. We have patented certain aspects of our HOCl technology in the United States and worldwide. We also rely on trade secrets, know-how,
continuing technological innovation, and in-licensing opportunities to develop and maintain a proprietary position.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Although we work diligently to protect proprietary
technology, there are no assurances that any patent will be issued from currently pending patent applications or from future patent applications.
The scope of any patent protection may not exclude competitors or provide competitive advantages, and any patent may not be held valid
if subsequently challenged, and others may claim rights in or ownership of patents and proprietary rights. Furthermore, others may develop
products similar to ours and may duplicate any of the products or design around patents.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have also filed for trademark protection for marks
used with products in each of the following regions: United States, Europe, Canada, Brazil, certain countries in the Middle East and certain
countries in Asia, including Japan, China, Hong Kong, the Republic of Korea, India and Australia. In addition to patents and trademarks,
we rely on trade secret and other intellectual property laws, nondisclosure agreements and other measures to protect intellectual property
rights. We believe that in order to have a competitive advantage, we must develop and maintain the proprietary aspects of technologies.
Employees, consultants and advisors are required to execute confidentiality agreements in connection with their employment, consulting
or advisory relationships. Employees, consultants and advisors with whom we expect to work with are also required to disclose and assign
to us all inventions made in the course of a working relationship with them, while using intellectual property or which relate to our
business. Despite any measures taken to protect our intellectual property, unauthorized parties may attempt to copy aspects of the products
or to wrongfully obtain or use information that is regarded as proprietary.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Competition</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We compete globally across six main channels: dermatology,
eye, nasal and oral care, wound and acute care, podiatry, animal health care and surface disinfectants with our HOCl technology.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Dermatology</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our dermatology products are at the forefront of HOCl-based
solutions, a safe and highly effective active ingredient designed to relieve itching and burning and act as a highly effective antimicrobial
agent. We believe no other solutions on the market provide the same patient benefits at the levels of safety and cost. Our HOCl-based
solutions face significant competition in the United States from prescription products including corticosteroids, topical steroids and
topical antibiotics. Our opportunity as an adjunct to these steroids is based on the insight that many doctors and patients limit steroid
and antibiotic use due to potential side effects. These side effects include bacterial resistance, stinging, burning and inflammation
for topical antibiotics and stretch marks, easy bruising, tearing of the skin and, to a lesser extent, enlarged blood vessels for topical
steroids. Our HOCl-based products are safe, non-toxic and have shown few side effects in clinical studies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Wound and Acute Care Markets</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Similar to our dermatology products, our HOCl-based
wound and acute care solutions provide improved efficacy at lower costs than traditional acute care products. Our HOCl-based solutions
compete with topical anti-infectives and antibiotics, as well as some advanced wound technologies, such as skin substitutes, growth factors
and delayed release silver-based dressings. Our opportunity in this space relative to antibiotics is based on the insight that competing
antibiotic solutions may have resistance-building properties.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 16 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Factors Affecting Competitive Position</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">While some other companies are able to produce small
molecule, HOCl-based formulations, based on our research, their products may become unstable after a relatively short period of time or
have large ranges of effectiveness. We believe our HOCl-based solutions are among the most stable therapeutics available.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Some of our competitors in the dermatology, wound
care, eye, nasal and oral care, podiatry, animal health care and surface disinfectant markets enjoy several competitive advantages. These
include:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 3%">&#160;</td>
    <td style="width: 2%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 95%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">greater name recognition;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">established relationships with healthcare professionals, patients and third-party payors;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">established distribution networks;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">additional product lines and the ability to offer rebates or bundle products to offer discounts or incentives;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">experience in conducting research and development, manufacturing, obtaining regulatory approval for products and marketing; and</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">financial and human resources for product development, sales and marketing and patient support.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Government Regulation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Government authorities in the United States, at the
federal, state and local levels, and foreign countries extensively regulate, among other things, the research, development, testing, manufacture,
labeling, promotion, advertising, distribution, sampling, marketing, and import and export of pharmaceutical products, biologics and medical
devices. All of our products in development will require regulatory approval or clearance by government agencies prior to commercialization.
In particular, human therapeutic products are subject to rigorous pre-clinical and clinical trials and other approval procedures of the
FDA and similar regulatory authorities in foreign countries. Various federal, state, local and foreign statutes and regulations also govern
testing, manufacturing, safety, labeling, storage, distribution and record-keeping related to such products and their marketing. The process
of obtaining these approvals and clearances, and the subsequent process of maintaining substantial compliance with appropriate federal,
state, local, and foreign statutes and regulations, require the expenditure of substantial time and financial resources. In addition,
statutes, rules, regulations and policies may change and new legislation or regulations may be issued that could delay such approvals.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Medical Device Regulation</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">To date, we have received 22 510(k) clearances for
use of products as medical devices in tissue care management, such as cleaning, debridement, lubricating, moistening and dressing, including
for acute and chronic wounds, and in dermatology applications. Any future product candidates or new applications classified as medical
devices will require clearance by the FDA.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Medical devices are subject to FDA clearance and extensive
regulation under the Federal Food Drug and Cosmetic Act. Under the Federal Food Drug and Cosmetic Act, medical devices are classified
into one of three classes: Class I, Class II or Class III. The classification of a device into one of these three classes generally depends
on the degree of risk associated with the medical device and the extent of control needed to ensure safety and effectiveness. Devices
may also be designated unclassified. Unclassified devices are legally marketed pre-amendment devices for which a classification regulation
has yet to be finalized and for which a pre-market approval is not required.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Class I devices are devices for which safety and effectiveness
can be assured by adherence to a set of general controls. These general controls include compliance with the applicable portions of the
FDA&#8217;s Quality System Regulation, which sets forth good manufacturing practice requirements; facility registration, device listing
and product reporting of adverse medical events; truthful and non-misleading labeling; and promotion of the device only for its cleared
or approved intended uses. Class&#160;II devices are also subject to these general controls, and any other special controls as deemed
necessary by the FDA to ensure the safety and effectiveness of the device. Review and clearance by the FDA for these devices is typically
accomplished through the 510(k) pre-market notification procedure. When 510(k) clearance is sought, a sponsor must submit a pre-market
notification demonstrating that the proposed device is substantially equivalent to a legally marketed device. If the FDA agrees that the
proposed device is substantially equivalent to the predicate device, then 510(k) clearance to market will be granted. After a device receives
510(k) clearance, any modification that could significantly affect its safety or effectiveness, or that would constitute a major change
in its intended use, requires a new 510(k) clearance or could require a pre-market approval.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 17 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Clinical trials are almost always required to support
a pre-market approval application and are sometimes required for a 510(k) pre-market notification. These trials generally require submission
of an application for an investigational device exemption. An investigational device exemption must be supported by pre-clinical data,
such as animal and laboratory testing results, which show that the device is safe to test in humans and that the study protocols are scientifically
sound. The FDA must approve an investigational device exemption, in advance, for a specified number of patients, unless the product is
deemed a non-significant risk device and is eligible for more abbreviated investigational device exemption requirements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Both before and after a medical device is commercially
distributed, manufacturers and marketers of the device have ongoing responsibilities under FDA regulations. The FDA reviews design and
manufacturing practices, labeling and record keeping, and manufacturers&#8217; required reports of adverse experiences and other information
to identify potential problems with marketed medical devices. Device manufacturers are subject to periodic and unannounced inspection
by the FDA for compliance with the Quality System Regulation, which sets forth the Current Good Manufacturing Practice requirements that
govern the methods used in, and the facilities and controls used for the design, manufacture, packaging, servicing, labeling, storage,
installation and distribution of all finished medical devices intended for human use.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On November 30, 2023, the FDA issued a proposed rule
to classify certain wound dressings and liquid wound washes containing antimicrobials with a low level of antimicrobial resistance concern,
including hypochlorous acid, into Class II medical devices. If finalized as proposed, we would be required to submit new 510(k) applications
for our products and to demonstrate compliance with special controls that require specific information relating to performance testing
and technical specifications, specific labeling requirements, and other requirements to mitigate the risks to health and demonstrate a
reasonable assurance of safety and effectiveness. Our existing devices could serve as predicates for the new devices. The FDA is proposing
that manufacturers will need to demonstrate compliance with applicable special controls within six months after the effective date of
the rule, when finalized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">FDA regulations prohibit the advertising and promotion
of a medical device for any use outside the scope of a 510(k) clearance or pre-market approval or for unsupported safety or effectiveness
claims. Although the FDA does not regulate physicians&#8217; practice of medicine, the FDA does regulate manufacturer communications with
respect to off-label use.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If the FDA finds that a manufacturer has failed to
comply with FDA laws and regulations or that a medical device is ineffective or poses an unreasonable health risk, it can institute or
seek a wide variety of enforcement actions and remedies, ranging from a public warning letter to more severe actions such as:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 3%">&#160;</td>
    <td style="width: 2%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 95%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">imposing fines, injunctions and civil penalties</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">requiring a recall or seizure of products</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">implementing operating restrictions, which can include a partial suspension or total shutdown of production</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusing requests for 510(k) clearance or pre-market approval of new products</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">withdrawing 510(k) clearance or pre-market approvals already granted</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">criminal prosecution</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The FDA also has the authority to require a company
to repair, replace, or refund the cost of any medical device.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The FDA also administers certain controls over the
export of medical devices from the United States, as international sales of medical devices that have not received FDA clearance are subject
to FDA export requirements. Additionally, each foreign country subjects such medical devices to its own regulatory requirements. In the
European Union, there is a single regulatory approval process and approval is represented by the presence of a CE marking.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 18 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Other Regulation in the United States</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>The Physician Payments Sunshine Act</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Physician Payments Sunshine Act signed into law
in 2010 as part of the Affordable Care Act requires manufacturers of medical devices, drugs, biologicals, and medical supplies for which
payment is available under Medicare or Medicaid to track and report certain payments made to and transfers of value provided to physicians
and teaching hospitals as well as to report certain ownership and investment interests held by physicians and their immediate family members.
These manufacturers must report annually to the Center for Medicare &amp; Medicaid Services any direct or indirect payments and transfers
of value of $13.46 or more, or annual aggregate of $134.54 or more in calendar year 2025, made to physicians or to a third party at the
request of or on behalf of a physician, including dentists. Payment includes: consulting fees, compensation for services other than consulting,
honoraria, gifts, entertainment, food, travel (including the specified destinations), education, research, charitable contribution, royalty
or license, current or prospective ownership or investment interest, direct compensation for serving as faculty or as a speaker for a
medical education program, grants, any other nature of the payment, or other transfer of value. Manufacturers face monetary penalties
for non-compliance. Certain payments related to research must be reported separately. Product samples intended for patient use need not
be reported.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Health Care Coverage and Reimbursement by Third-Party
Payors</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Commercial success in marketing and selling products
depends, in part, on the availability of adequate coverage and reimbursement from third-party health care payors, such as government and
private health insurers and managed care organizations. Third-party payors are increasingly challenging the pricing of medical products
and services. Government and private sector initiatives to limit the growth of health care costs, including price regulation, competitive
pricing, and managed-care arrangements, are continuing in many countries where we do business, including the United States. These changes
are causing the marketplace to be more cost-conscious and focused on the delivery of more cost-effective medical products. Government
programs, including Medicare and Medicaid, private health care insurance companies, and managed-care plans control costs by limiting coverage
and the amount of reimbursement for particular procedures or treatments. This has created an increasing level of price sensitivity among
customers for our products. Some third-party payors also require that a favorable coverage determination be made for new or innovative
medical devices or therapies before they will provide reimbursement of those medical devices or therapies. Even though a new medical product
may have been cleared or approved for commercial distribution, we may find limited demand for the product until adequate coverage and
reimbursement have been obtained from governmental and other third-party payors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Fraud and Abuse Laws</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In the United States, we are subject to various federal
and state laws pertaining to healthcare fraud and abuse, which, among other things, prohibit the offer or acceptance of remuneration intended
to induce or in exchange for the purchase of products or services reimbursed under a federal healthcare program and the submission of
false or fraudulent claims with the government. These laws include the federal Anti-Kickback Statute, the False Claims Act and comparable
state laws. These laws regulate the activities of entities involved in the healthcare industry, such as Sonoma, by limiting the kinds
of financial arrangements such entities may have with healthcare providers who use or recommend the use of medical products, including,
for example, sales and marketing programs, advisory boards and research and educational grants. In addition, in order to ensure that healthcare
entities comply with healthcare laws, the Office of Inspector General of the U.S.&#160;Department of Health and Human Services recommends
that healthcare entities institute effective compliance programs. To assist in the development of effective compliance programs, the Office
of Inspector General has issued model Compliance Program Guidance, materials for a variety of healthcare entities which, among other things,
identify practices to avoid that may implicate the federal Anti-Kickback Statute and other relevant laws and describes elements of an
effective compliance program. While compliance with the Compliance Program Guidance materials is voluntary, a California law requires
pharmaceutical and devices manufacturers to initiate compliance programs that incorporate the Compliance Program Guidance and the July
2002 Pharmaceuticals Research and Manufacturers of America Code on Interactions with Healthcare Professionals.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 19 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Due to the scope and breadth of the provisions of
some of these laws, it is possible that some of our practices might be challenged by the government under one or more of these laws in
the future. Violations of these laws, which are discussed more fully below, can lead to civil and criminal penalties, damages, imprisonment,
fines, exclusion from participation in Medicare, Medicaid and other federal health care programs, and the curtailment or restructuring
of operations. Any such violations could have a material adverse effect on our business, financial condition, results of operations or
cash flows.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Anti-Kickback Laws</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our operations are subject to federal and state anti-kickback
laws. The federal Anti-Kickback Statute prohibits persons from knowingly and willfully soliciting, receiving, offering or providing remuneration
directly or indirectly to induce either the referral of an individual for a good or service reimbursed under a federal healthcare program,
or the furnishing, recommending, or arranging of a good or service, for which payment may be made under a federal healthcare program,
such as Medicare or Medicaid. The definition of &#8220;remuneration&#8221; has been broadly interpreted to include anything of value,
including such items as gifts, discounts, the furnishing of supplies or equipment, waiver of co-payments, and providing anything at less
than its fair market value. Because the Anti-Kickback Statute makes illegal a wide variety of common, even beneficial, business arrangements,
the Office of Inspector General was tasked with issuing regulations, commonly known as &#8220;safe harbors,&#8221; that describe arrangements
where the risk of illegal remuneration is minimal. As long as all of the requirements of a particular safe harbor are strictly met, the
entity engaging in that activity will not be prosecuted under the federal Anti-Kickback Statute. The failure of a transaction or arrangement
to fit precisely within one or more safe harbors does not necessarily mean that it is illegal or that prosecution will be pursued. However,
business arrangements that do not fully satisfy an applicable safe harbor may result in increased scrutiny by government enforcement authorities,
such as the Office of Inspector General. Our agreements to pay compensation to our advisory board members and physicians who provide other
services for us may be subject to challenge to the extent they do not fall within relevant safe harbors under state and federal anti-kickback
laws. In addition, many states have adopted laws similar to the federal Anti-Kickback Statute, which apply to the referral of patients
for health care services reimbursed by Medicaid, and some have adopted such laws with respect to private insurance. Violations of the
Anti-Kickback Statute are subject to significant fines and penalties and may lead to a company being excluded from participating in federal
health care programs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>False Claims Laws</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The federal False Claims Act prohibits knowingly filing
a false claim, knowingly causing the filing of a false claim, or knowingly using false statements to obtain payment from the federal government.
Certain violations of the Anti-Kickback Statute constitute per se violations of the False Claims Act. Under the False Claims Act, such
suits are known as &#8220;qui tam&#8221; actions. Individuals may file suit on behalf of the government and share in any amounts received
by the government pursuant to a settlement. In addition, certain states have enacted laws modeled after the federal False Claims Act under
the Deficit Reduction Act of 2005, where the federal government created financial incentives for states to enact false claims laws consistent
with the federal False Claims Act. As more states enact such laws, we expect the number of qui tam lawsuits to increase. Qui tam actions
have increased significantly in recent years, causing greater numbers of healthcare companies to have to defend false claims actions,
pay fines or be excluded from Medicare, Medicaid or other federal or state government healthcare programs as a result of investigations
arising out of such actions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>HIPAA</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Two federal crimes were created under the Health Insurance
Portability and Accountability Act of 1996, or HIPAA: healthcare fraud and false statements relating to healthcare matters. The healthcare
fraud statute prohibits knowingly and willfully executing a scheme to defraud any healthcare benefit program, including private payors.
The false statements statute prohibits knowingly and willfully falsifying, concealing or covering up a material fact or making any materially
false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 20 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Health Information Privacy and Security</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Individually identifiable health information is subject
to an array of federal and state regulation. Federal rules promulgated pursuant to HIPAA regulate the use and disclosure of health information
by &#8220;covered entities.&#8221; Covered entities include individual and institutional health care providers from which we may receive
individually identifiable health information. These regulations govern, among other things, the use and disclosure of health information
for research purposes, and require the covered entity to obtain the written authorization of the individual before using or disclosing
health information for research. Failure of the covered entity to obtain such authorization could subject the covered entity to civil
and criminal penalties. We may experience delays and complex negotiations in dealing with each entity&#8217;s differing interpretation
of the regulations and what is required for compliance. Also, where our customers or contractors are covered entities, including hospitals,
universities, physicians or clinics, we may be required by the HIPAA regulations to enter into &#8220;business associate&#8221; agreements
that subject the company to certain privacy and security requirements. In addition, many states have laws that apply to the use and disclosure
of health information, and these laws could also affect the manner in which we conduct research and other aspects of business. Such state
laws are not preempted by the federal privacy law when such laws afford greater privacy protection to the individual than the federal
law. While activities to assure compliance with health information privacy laws are a routine business practice, we are unable to predict
the extent to which resources may be diverted in the event of an investigation or enforcement action with respect to such laws.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Foreign Regulation</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Whether or not we obtain FDA approval for a product,
approval of a product by the applicable regulatory authorities of foreign countries must be obtained before clinical trials or marketing
of the product in those countries can begin. The approval process varies from country to country, and the time may be longer or shorter
than that required for FDA approval. The requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement
also vary greatly from country to country. Although governed by the applicable country, clinical trials conducted outside of the United
States typically are administered under a three-phase sequential process similar to that discussed above for medical devices.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>European Union Regulation</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Medical Device Regulation</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our products are classified as medical devices in
the European Union. In order to sell medical device products within the European Union, we are required to comply with the requirements
of the Medical Devices Regulation, and its national implementations, including affixing CE markings on products. The CE marking indicates
a product&#8217;s compliance with EU legislation and so enables the sale of products throughout the European Economic Area, or the EEA,
comprising the 28 Member States of the EU and European Free Trade Association, or EFTA, countries Iceland, Norway, and Liechtenstein.
In order to comply with the Medical Devices Regulation, we must meet certain requirements relating to the safety and performance of products
and, prior to marketing products, we must successfully undergo verification of products&#8217; regulatory compliance, or conformity assessment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Medical Devices Regulation was adopted in the
EU on May 26, 2017 to replace the existing Medical Device Directive, and became applicable on May 26, 2021, with a transition period until
May 26, 2024, which was been extended to December 31, 2028 for non-implantable Class IIb and lower risk devices. Under the new Medical
Devices Regulation, certain devices are classified in higher classes, new devices are classified, and certain new obligations are imposed
on manufacturers and distributors. Manufacturers are required to engage a medical device expert and carry insurance for possible liability
claims. In addition, the pre-market approval and post-market surveillance requirements are enhanced. The European Database for Medical
Devices, or Eudamed, will hold and publish information on medical devices collected from the European Commission and the national authorities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 21 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We successfully transitioned all of our commercialized
products in Europe to the Medical Devices Regulation and received an updated CE certificate for Class IIb wound care solution, wound care
hydrogel and dermatological hydrogel and Class IIa dermatological solution, dermatological hydrogel and eyelid solution, which allows
us to continue to affix CE markings on our products and sell them as medical devices in Europe. We may not be able to maintain the requirements
established for CE markings for any or all of our products or be able to produce these products in a timely and profitable manner while
complying with the requirements of the Medical Devices Regulation and other regulatory requirements. We are subject to continued supervision
and are required to report any serious adverse incidents to the appropriate authorities. We are also required to comply with additional
national requirements that are beyond the scope of the Medical Devices Regulation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>European Good Manufacturing Process</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In the European Union, the manufacture of pharmaceutical
products and clinical trial supplies is subject to good manufacturing practice as set forth in the relevant laws and guidelines. Compliance
with good manufacturing practice is generally assessed by the competent regulatory authorities. They may conduct inspections of relevant
facilities, and review manufacturing procedures, operating systems and personnel qualifications. In addition to obtaining approval for
each product, in many cases each drug manufacturing facility must be approved. Further inspections may occur over the life of the product.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Mexican Regulation</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Ministry of Health is the authority in charge
of sanitary controls in Mexico. Sanitary controls are a group of practices related to the orientation, education, testing, verification
and application of security measures and sanctions exercised by the Ministry of Health. The Ministry of Health is responsible for the
issuance of Official Mexican Standards and specifications for drugs subject to the provisions of the General Health Law, which govern
the process and specifications of drugs, including the obtaining, preparing, manufacturing, maintaining, mixing, conditioning, packaging,
handling, transporting, distributing, storing and supplying of products to the public at large. In addition, a medical device is defined
as a device that may contain antiseptics or germicides used in surgical practice or in the treatment of continuity solutions, skin injuries
or its attachments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Under the General Health Law, a business that manufactures
drugs is either required to obtain a &#8220;Sanitary Authorization&#8221; or to file an &#8220;Operating Notice.&#8221; Our Mexican subsidiary,
Oculus Technologies of Mexico, S.A. de C.V., is considered a business that manufactures medical devices and therefore is not subject to
a Sanitary Authorization, but rather only required to file an Operating Notice.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition to its Operating Notice, our Mexico subsidiary
has obtained a &#8220;Good Processing Practices Certificate&#8221; issued by Mexican Federal Commission for the Protection against Sanitary
Risks, which demonstrates that the manufacturing at our facility located in Zapopan, Mexico, operates in accordance with the applicable
official standards.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, regulatory approval of prices is required
in most countries other than the United States, which could result in lengthy negotiations delaying our ability to commercialize products.
We face the risk that the prices which result from the regulatory approval process would be insufficient to generate an acceptable return.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Available Information</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We make available on sonomapharma.com, free of charge,
copies of our annual reports on Form&#160;10-K, quarterly reports on Form&#160;10-Q, current reports on Form&#160;8-K and amendments to
these reports, as soon as reasonably practicable after electronically filing or furnishing such materials to the Securities and Exchange
Commission, or SEC. Sonomapharma.com and the information contained therein or connected thereto are not intended to be incorporated into
this annual report on Form&#160;10-K. The SEC maintains an Internet site that contains reports, proxy and information statements, and
other information regarding issuers that file electronically with the SEC at www.sec.gov.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 22 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="k_004"></span>ITEM&#160;1A. Risk Factors</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Risks Related to Our Business</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We have a history of losses, we expect to continue
to incur losses and we may never achieve profitability, and our March 31, 2025 audited consolidated financial statements included disclosure
that casts substantial doubt regarding our ability to continue as a going concern.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We reported a net loss of $3,457,000 and $4,835,000
for the years ended March 31, 2025 and 2024, respectively. At March 31, 2025 and 2024, our accumulated deficit amounted to $197,806,000
and $194,349,000, respectively. We had working capital of $8,552,000 and $8,829,000 as of March 31, 2025 and 2024, respectively. During
the years ended March 31, 2025 and 2024, net cash used in operating activities amounted to $88,000 and $2,398,000, respectively. As of
March 31, 2025, we had cash and cash equivalents of $5,374,000.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We spent the most recent years working to reduce our
losses and have made significant progress. However, we expect to continue incurring losses for the foreseeable future. We may never achieve
or sustain profitability. We must raise additional capital to pursue our product development initiatives, penetrate markets for the sale
of our products and continue as a going concern. We cannot provide any assurance that we will raise additional capital. We believe that
we have access to capital resources through possible public or private equity offerings, debt financings, corporate collaborations, or
other means. If we are unable to secure additional capital, we may be required to curtail our research and development initiatives and
take additional measures to reduce costs in order to conserve our cash in amounts sufficient to sustain operations and meet our obligations.
These measures could cause significant delays in our efforts to further commercialize our products, which are critical to the realization
of our business plan and to our future operations. These matters raise substantial doubt about our ability to continue as a going concern
or become profitable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We depend on third party distributors and intend
to continue to license or collaborate with third parties in various potential markets, and events involving these strategic partners or
any future collaboration could delay or prevent us from developing or commercializing products.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our business strategy and our short- and long-term
operating results depend in part on our ability to execute on existing strategic collaborations and to license or partner with new strategic
partners. We believe collaborations allow us to leverage our resources and technologies and to access markets that are compatible with
our own core areas of expertise while avoiding the cost of establishing or maintaining a direct sales force in each market. We may incur
significant costs in the use of third parties and other resources to identify and assist in establishing relationships with potential
collaborators. We currently use distributors for most of our products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have limited control over the amount and timing
of resources that our current partners or any future collaborators devote to our collaborations or potential products. These partners
may breach or terminate their agreements with us or otherwise fail to conduct their collaborative activities successfully and in a timely
manner. Further, our partners may not develop or commercialize products that arise out of our collaborative arrangements or devote sufficient
resources to the development, manufacture, marketing or sale of these products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">To penetrate our target markets, we may need to enter
into additional collaborative agreements to assist in the development and commercialization of products. Establishing strategic collaborations
is difficult and time-consuming. Potential collaborators may reject collaborations based upon their assessment of our financial, regulatory
or intellectual property position and our internal capabilities. Our discussions with potential collaborators may not lead to the establishment
of new collaborations on favorable terms and may have the potential to provide collaborators with access to our key intellectual property
filings and next generation formations. By entering into collaboration, we may preclude opportunities to collaborate with other third
parties who do not wish to associate with our existing third-party strategic partners. Moreover, in the event of termination of a collaboration
agreement, termination negotiations may result in less favorable terms.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 23 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Mexican tax law prevents us from deducting intercompany
interest expense incurred by our Mexico subsidiary Oculus Technologies of Mexico, S.A. de C.V and requires withholding tax on payments
remitted to the US. At the same time, we are unable to recognize tax benefits for foreign tax credits for U.S. tax purposes.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Since 2004, we loaned substantial amounts to our Mexico
subsidiary Oculus Technologies of Mexico, S.A. de C.V. at various interest rates to fund their operations. As of March 31, 2025, our Mexico
subsidiary owes approximately $10.9 million in principal, $8.6 million in technical assistance payments and $26.4 million in accrued interest.
The intercompany loans mature in 2027. There is no guarantee that our Mexican subsidiary will be able to pay any or all of the amounts
due. If we were to forgive the debt or if we were to convert the debt to equity, it would be subject to Mexico income tax at 30%, or approximately
$13.8 million, as well as Mexican withholding tax of 15%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Mexico&#8217;s thin capitalization rules also require
taxpayers to maintain a debt-to-equity ratio of 3:1. Any interest paid to foreign related parties that results in indebtedness exceeding
a ratio of 3:1 to their stockholder&#8217;s equity is not deductible for Mexican corporate income tax purposes and we did not meet that
condition. Therefore, we have not been able to deduct the intercompany interest on our Mexico tax returns since 2004. It has prevented
our Mexico subsidiary from accruing net operating losses in Mexico to offset potential future profits. At the same time the intercompany
interest income in the United States decreases our U.S. net operating losses and reduces our ability to apply these carryforwards to offset
future taxable income in the United States.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, any interest paid to a foreign lender
is subject to Mexico withholding tax of 15%. We also have interest owed on our intercompany technical assistance agreement and royalty
withholding of 10% on our technical assistance agreement. This would amount to approximately $5.1 million in Mexico withholding tax at
March 31, 2025, if all of the interest and technical assistance were to be repaid to us. In general, the foreign related party parent
can then claim a credit for these withholding taxes on their U.S. income tax return. However, because of our substantial U.S. net operating
losses, we are prevented from claiming any credit on any withholding tax for U.S. income tax purposes. Any such failure to pay intercompany
debt, inability to deduct income taxes or apply credits, or liability for tax payments could have a material adverse effect on our business,
financial condition, and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We rely on a number of key customers who may
not consistently purchase our products in the future, and if we lose any one of these customers, our revenues may decline.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Although we have a significant number of customers
in each of the geographic markets that we operate in, we rely on certain key customers for a significant portion of our revenues. For
the year ended March 31, 2025, customer B represented 21% and customer C represented 18% of net revenues. For the year ended March 31,
2024, customer A represented 17%, customer B represented 15% and customer C represented 14% of net revenues. In the future, a small number
of customers may continue to represent a significant portion of our total revenues in any given period. These customers may not consistently
purchase our products at a particular rate over any subsequent period. The loss of any of these customers could adversely affect our revenues.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i></i></b></p>

<!-- Field: Page; Sequence: 24 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>A majority of our business is conducted outside
of the United States, exposing us to additional risks that may not exist in the United States, which in turn could cause our business
and operating results to suffer.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have material international operations in Mexico,
Asia and Europe. During the years ended March 31, 2025 and 2024, approximately 82% and 76% of our total revenue, respectively, were generated
from sales outside of the United States. Our business is highly regulated for the use, marketing and manufacturing of our HOCl-based products
both domestically and internationally. Our international operations are subject to risks, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 3%">&#160;</td>
    <td style="width: 2%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 95%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">local political or economic instability;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">economic downturn or recession;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in exchange rates;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in governmental regulation;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in import/export duties, tariffs, or trade agreements;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">trade restrictions;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">lack of experience in foreign markets;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulties and costs of staffing and managing operations in certain foreign countries;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">work stoppages or other changes in labor conditions;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulties in collecting accounts receivables on a timely basis, or at all; and</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">adverse tax consequences or overlapping tax structures.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We plan to continue to market and sell our products
internationally to respond to customer requirements and market opportunities. We currently have manufacturing facilities in Mexico. Establishing
operations in any foreign country or region presents risks such as those described above as well as risks specific to the particular country
or region. In addition, until a payment history is established over time with customers in a new geographic area or region, the likelihood
of collecting receivables generated by such operations could be less than our expectations. As a result, there is a greater risk that
the reserves set with respect to the collection of such receivables may be inadequate. If our operations in any foreign country are unsuccessful,
we could incur significant losses and we may not achieve profitability.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, changes in policies or laws of the United
States or foreign governments resulting in, among other things, changes in regulations and the approval process, higher taxation, currency
conversion limitations, restrictions on fund transfers or the expropriation of private enterprises, could reduce the anticipated benefits
of our international expansion. If we fail to realize the anticipated revenue growth of our future international operations, our business
and operating results could suffer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i></i></b></p>

<!-- Field: Page; Sequence: 25 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>If we fail to obtain, or experience significant
delays in obtaining, additional regulatory clearances or approvals to market our current or future products, we may be unable to commercialize
these products.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The developing, testing, manufacturing, marketing
and selling of medical technology products is subject to extensive regulation by numerous governmental authorities in the United States
and other countries. The process of obtaining regulatory clearance and approval of medical technology products is costly and time consuming.
Even though their underlying product formulations may be the same or similar, our products are subject to different regulations and approval
processes depending upon their intended use.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The FDA generally clears marketing of a medical device
through the 510(k) pre-market clearance process if it is demonstrated the new product has the same intended use and the same or similar
technological characteristics as another legally marketed Class&#160;II device, such as a device already cleared by the FDA through the
510(k) premarket notification process, and otherwise meets the FDA&#8217;s requirements. Product modifications, including labeling the
product for a new intended use, may require the submission of a new 510(k) clearance and FDA approval before the modified product can
be marketed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On November 30, 2023, the FDA issued a proposed rule
to classify certain wound dressings and liquid wound washes, including hypochlorous acid, into Class II medical devices. If finalized,
we would be required to submit new 510(k) applications for our products and to demonstrate compliance with special controls that require
specific information relating to performance testing and technical specifications, specific labeling requirements, and other requirements.
While we believe we will be able to demonstrate compliance with these special controls if the proposed rule is finalized, there is no
guarantee that the FDA will issue new clearance letters for our products, and the process of obtaining additional clearances may be costly
and time consuming.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, we do not know whether the necessary
approvals or clearances will be granted or delayed for future products. The FDA could request additional information, changes to product
formulation(s) or clinical testing that could adversely affect the time to market and sale of products as drugs. If we do not obtain the
requisite regulatory clearances and approvals, we will be unable to commercialize our products and may never recover any of the substantial
costs we have invested in the development of HOCl.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Distribution of our products outside the United States
is subject to extensive government regulation. These regulations, including the requirements for approvals or clearance to market, the
time required for regulatory review and the sanctions imposed for violations, vary from country to country. We do not know whether we
will obtain regulatory approvals in such countries or that we will not be required to incur significant costs in obtaining or maintaining
these regulatory approvals. In addition, the export by us of certain of our products that have not yet been cleared for domestic commercial
distribution may be subject to FDA export restrictions. Failure to obtain necessary regulatory approvals, the restriction, suspension
or revocation of existing approvals or any other failure to comply with regulatory requirements would have a material adverse effect on
our future business, financial condition, and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>If we fail to comply with ongoing regulatory
requirements, or if we experience unanticipated problems with our products, these products could be subject to restrictions or withdrawal
from the market.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Regulatory approvals or clearances that we currently
have and that we may receive in the future are subject to limitations on the indicated uses for which the products may be marketed, and
any future approvals could contain requirements for potentially costly post-marketing follow-up studies. If the FDA determines that our
promotional materials or activities constitute promotion of an unapproved use or we otherwise fail to comply with FDA regulations, we
may be subject to regulatory enforcement actions, including warning letters, injunctions, seizures, civil fines or criminal penalties.
In addition, the manufacturing, labeling, packaging, adverse event reporting, storing, advertising, promoting, distributing and record-keeping
for approved products are subject to extensive regulation. We are subject to continued supervision by European regulatory agencies relating
to our CE markings and are required to report any serious adverse incidents to the appropriate authorities. Our manufacturing facilities,
processes and specifications are subject to periodic inspection by the FDA, Mexican and other regulatory authorities and, from time to
time, we may receive notices of deficiencies from these agencies as a result of such inspections. Our failure to continue to meet regulatory
standards or to remedy any deficiencies could result in restrictions being imposed on our products or manufacturing processes, fines,
suspension or loss of regulatory approvals or clearances, product recalls, termination of distribution, product seizures or the need to
invest substantial resources to comply with various existing and new requirements. In the more egregious cases, criminal sanctions, civil
penalties, disgorgement of profits or closure of our manufacturing facilities are possible. The subsequent discovery of previously unknown
problems with HOCl, including adverse events of unanticipated severity or frequency, may result in restrictions on the marketing of our
products, and could include voluntary or mandatory recall or withdrawal of products from the market.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 26 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">New government regulations may be enacted and changes
in FDA policies and regulations and, their interpretation and enforcement, could prevent or delay regulatory approval of our products.
We cannot predict the likelihood, nature or extent of adverse government regulation that may arise from future legislation or administrative
action, either in the United States or abroad. Therefore, we do not know whether we will be able to continue to comply with any regulations
or that the costs of such compliance will not have a material adverse effect on our future business, financial condition, and results
of operations. If we are not able to maintain regulatory compliance, we will not be permitted to market our products and our business
would suffer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>If we fail to comply with ongoing regulatory
requirements for our European products under the new Medical Devices Regulation, these products could be subject to withdrawal from the
market.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our products are classified as medical devices in
the European Union (EU). In order to sell medical device products within the European Union, we are required to comply with the requirements
of the Medical Devices Regulation, and its national implementations, including affixing CE markings on products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Medical Devices Regulation was adopted in the
EU on May 26, 2017 to replace the existing Medical Device Directive, and became applicable on May 26, 2021, with a transition period until
extended to December 31, 2028 for non-implantable Class IIb and lower risk devices. We received a CE certificate for 39 of our Class IIB
medical devices under the Medical Device Directive. Under the new Medical Devices Regulation, certain devices are classified in higher
classes, new devices are classified, and certain new obligations are imposed on manufacturers and distributors. In addition, the pre-market
approval and post-market surveillance requirements are enhanced.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have successfully completed transition to the new
Medical Device Regulation (MDR) for all of our commercialized products in Europe, including Microdacyn60&#160;Wound Care and Microdacyn60
Hydrogel, our scar gel product Epicyn<sup>&#174;</sup>, and Pediacyn<sup>&#174;</sup>&#160;for atopic dermatitis, which are each classified
as Class IIb medical devices, and our eye care product Ocudox and acne products GramaDerm Solution and GramaDerm Hydrogel, which are each
classified as Class IIa medical devices. Our nasal product Sinudox, Microdacyn<sup>&#174;</sup> Oral and MucoClyns<sup>&#174;</sup>, a disinfectant,
will not be transitioned without additional studies. We currently have no commercial sales of these products and are evaluating whether
to conduct the additional studies necessary to transition these products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We can provide no assurance that we will be able to
maintain the requirements established for CE markings for any or all of our products in the EU or be able to produce these products in
a timely and profitable manner while complying with the requirements of the Medical Devices Regulation and other regulatory requirements.
Failure to comply with these requirements could result in these products being withdrawn from the market and could have a material negative
impact on our future results.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>If any of our third-party
contractors fail to perform their responsibilities to comply with FDA rules and regulations, the manufacture, marketing and sales of our
products could be delayed, which could decrease our revenues.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Supplying the market with
our HOCl technology products requires us to manage relationships with an increasing number of collaborative partners, suppliers and third-party
contractors. As a result, our success depends partially on the success of these third parties in performing their responsibilities to
comply with FDA rules and regulations. Although we pre-qualify our contractors and we believe that they are fully capable of performing
their contractual obligations, we cannot directly control the adequacy and timeliness of the resources and expertise that they apply to
these activities. For example, we and our suppliers are required to comply with the FDA&#8217;s quality system regulations, which cover
the methods and documentation of the design, testing, production, control, quality assurance, labeling, packaging, storage and shipping
of our products. The FDA enforces the quality system regulation through inspections.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If any of our partners or contractors fail to perform
their obligations in an adequate and timely manner or fail to comply with the FDA&#8217;s rules and regulations, including failure to
comply with quality systems regulations or a corrective action submitted to the FDA after notification by the FDA of a deficiency is deemed
insufficient, then the manufacture, marketing and sales of our products could be delayed. Our products could be detained or seized, the
FDA could order a recall, or require our partner to replace or offer refunds for our products. The FDA could also require our partner,
and depending on our agreement with our partner, us, to notify healthcare professionals and others that the products present unreasonable
risks of substantial harm to the public health. If any of these events occur, the manufacture, marketing and sales of our products could
be delayed which could decrease our revenues.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<!-- Field: Page; Sequence: 27 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>If we fail to comply
with the FDA&#8217;s rules and regulations and are subject to an FDA recall as part of an FDA enforcement action, the associated costs
could have a material adverse effect on our business, financial position, results of operations and cash flows.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Our Company, our products,
the manufacturing facilities for our products, the distribution of our products, and our promotion and marketing materials are subject
to strict and continual review and periodic inspection by the FDA and other regulatory agencies for compliance with pre-approval and post-approval
regulatory requirements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">If we fail to comply with
the FDA&#8217;s rules and regulations, we could be subject to an enforcement action by the FDA. The FDA could undertake regulatory actions,
including seeking a consent decree, recalling or seizing our products, ordering a total or partial shutdown of production, delaying future
marketing clearances or approvals, and withdrawing or suspending certain of our current products from the market. A product recall, restriction,
or withdrawal could result in substantial and unexpected expenditures, destruction of product inventory, and lost revenues due to the
unavailability of one or more of our products for a period of time, which could reduce profitability and cash flow. In addition, a product
recall or withdrawal could divert significant management attention and financial resources. If any of our products are subject to an FDA
recall, we could incur significant costs and suffer economic losses. Production of our products could be suspended and we could be required
to establish inventory reserves to cover estimated inventory losses for all work-in-process and finished goods related to products we,
or our third-party contractors, manufacture. A recall of a material amount of our products could have a significant, unfavorable impact
on our future gross margins.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>If our products fail
to comply with FDA and other governmental regulations, or our products are deemed defective, we may be required to recall our products
and we could suffer adverse public relations that could adversely impact our sales, operating results, and reputation which would adversely
affect our business operations.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">We may be exposed to product
recalls, including voluntary recalls or withdrawals, and adverse public relations if our products are alleged to cause injury or illness,
or if we are alleged to have mislabeled or misbranded our products or otherwise violated governmental regulations. Governmental authorities
can also require product recalls or impose restrictions for product design, manufacturing, labeling, clearance, or other issues. For the
same reasons, we may also voluntarily elect to recall, restrict the use of a product or withdraw products that we consider below our standards,
whether for quality, packaging, appearance or otherwise, in order to protect our brand reputation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Product recalls, product
liability claims, even if unmerited or unsuccessful, or any other events that cause consumers to no longer associate our brand with high
quality and safe products may also result in adverse publicity, hurt the value of our brand, harm our reputation among our customers and
other healthcare professionals who use or recommend the products, lead to a decline in consumer confidence in and demand for our products,
and lead to increased scrutiny by federal and state regulatory agencies of our operations, any of which could have a material adverse
effect on our brand, business, performance, prospects, value, results of operations and financial condition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>If our products do not gain market acceptance,
our business will suffer because we might not be able to fund future operations.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A number of factors may affect the market acceptance
of our products or any other products we develop or acquire, including, among others:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 3%">&#160;</td>
    <td style="width: 2%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 95%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the price of our products relative to other products for the same or similar treatments;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the perception by patients, physicians and other members of the healthcare community of the effectiveness and safety of our products for their indicated applications and treatments;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in practice guidelines and the standard of care for the targeted indication;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to fund our sales and marketing efforts; and</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the effectiveness of our sales and marketing efforts or our partners&#8217; sales and marketing efforts.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 28 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our ability to effectively promote and sell any approved
products will also depend on pricing and cost-effectiveness, including our ability to produce a product at a competitive price and our
ability to obtain sufficient third-party coverage or reimbursement, if any. In addition, our efforts to educate the medical community
on the benefits of our product candidates may require significant resources, may be constrained by FDA rules and policies on product promotion,
and may never be successful. If our products do not gain market acceptance, we may not be able to fund future operations, including developing,
testing and obtaining regulatory approval for new product candidates and expanding our sales and marketing efforts for our approved products,
which would cause our business to suffer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>If our competitors develop products with similar
characteristics to our HOCl technology, we may need to modify or alter our business strategy, which may delay the achievement of our goals.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Competitors have and may continue to develop products
with similar characteristics to our HOCl technology. Such similar products marketed by larger competitors can hinder our or our partners&#8217;
efforts to penetrate the market. As a result, we may be forced to modify or alter our business and regulatory strategy and sales and marketing
plans, as a response to changes in the market, competition and technology limitations, among others. Such modifications may pose additional
delays in achieving our goals.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Negative economic conditions increase the risk
that we could suffer unrecoverable losses on our customers&#8217; accounts receivable which would adversely affect our financial results.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We grant credit to our business customers, which are
primarily located in Mexico, Europe and the United States. Collateral is generally not required for trade receivables. We maintain allowances
for potential credit losses. We rely on certain key customers for a significant portion of revenues. At March 31, 2025, customer D represented
24% of our net accounts receivable balance. At March 31, 2024, customer B represented 13% of our net accounts receivable balance and customer
D represented 17% of our net accounts receivable balance. While we believe we have a varied customer base and have experienced strong
collections in the past, if current economic conditions disproportionately impact any one of our key customers, including reductions in
their purchasing commitments to us or their ability to pay their obligations, it could have a material adverse effect on our revenues
and liquidity. We have not purchased insurance on our accounts receivable balances.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We may experience difficulties in manufacturing
our products, which could prevent us from commercializing one or more of our products.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The machines used to manufacture our products are
complex, use complicated software and must be monitored by highly trained engineers. Slight deviations anywhere in our manufacturing process,
including quality control, labeling, and packaging, could lead to a failure to meet the specifications required by the FDA, the Environmental
Protection Agency, European notified bodies, Mexican regulatory agencies and other foreign regulatory bodies, which may result in lot
failures or product recalls. If we are unable to obtain quality internal and external components, mechanical and electrical parts, if
our software contains defects or is corrupted, or if we are unable to attract and retain qualified technicians to manufacture our products,
our manufacturing output of HOCl, or any other product candidate based on our platform that we may develop, could fail to meet required
standards, our regulatory approvals could be delayed, denied or revoked, and commercialization of one or more of our products may be delayed
or foregone. Manufacturing processes that are used to produce the smaller quantities of HOCl-based products needed for clinical tests
and current commercial sales may not be successfully scaled up to allow production of significant commercial quantities. Any failure to
manufacture our products to required standards on a commercial scale could result in reduced revenues, delays in generating revenue and
increased costs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 29 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Our competitive position depends on our ability
to protect our intellectual property and our proprietary technologies.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our ability to compete and to achieve and maintain
profitability depends on our ability to protect our intellectual property and proprietary technologies. We currently rely on a combination
of patents, patent applications, trademarks, trade secret laws, confidentiality agreements, license agreements and invention assignment
agreements to protect our intellectual property rights. We also rely upon unpatented know-how and continuing technological innovation
to develop and maintain our competitive position. These measures may not be adequate to safeguard our HOCl technology. If we do not protect
our rights adequately, third parties could use our technology, and our ability to compete in the market would be reduced.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our pending patent applications and any patent applications
we may file in the future may not result in issued patents, and we do not know whether any of our in-licensed patents or any additional
patents that might ultimately be issued by the U.S.&#160;Patent and Trademark Office or foreign regulatory body will protect our HOCl
technology. Any claims that are issued may not be sufficiently broad to prevent third parties from producing competing substitutes and
may be infringed, designed around, or invalidated by third parties. Even issued patents may later be found to be invalid or may be modified
or revoked in proceedings instituted by third parties before various patent offices or in courts.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The degree of future protection for our proprietary
rights is more uncertain in part because legal means afford only limited protection and may not adequately protect our rights, and we
will not be able to ensure that:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 3%">&#160;</td>
    <td style="width: 2%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 95%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we were the first to invent the inventions described in patent applications;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we were the first to file patent applications for inventions;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">others will not independently develop similar or alternative technologies or duplicate our products without infringing our intellectual property rights;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any patents licensed or issued to us will provide us with any competitive advantages;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we will develop proprietary technologies that are patentable; or</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the patents of others will not have an adverse effect on our ability to do business.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The policies we use to protect our trade secrets may
not be effective in preventing misappropriation of our trade secrets by others. In addition, confidentiality and invention assignment
agreements executed by our employees, consultants and advisors may not be enforceable or may not provide meaningful protection for our
trade secrets or other proprietary information in the event of unauthorized use or disclosures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We cannot be certain that the steps we have taken
will prevent the misappropriation and use of our intellectual property in the United States, or in foreign countries where the laws may
not protect our proprietary rights as fully as in the United States.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We may face intellectual property infringement
claims that could be time-consuming, costly to defend and could result in our loss of significant rights and, in the case of patent infringement
claims, the assessment of treble damages.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On occasion, we may receive notices of claims of infringement,
misappropriation, or misuse of other parties&#8217; proprietary rights. We may have disputes regarding intellectual property rights with
the parties that have licensed those rights to us. We may also initiate claims to defend our intellectual property. Intellectual property
litigation, regardless of its outcome, is expensive and time-consuming, and could divert management&#8217;s attention from our business
and have a material negative effect on our business, operating results, or financial condition. In addition, the outcome of such litigation
may be unpredictable. If there is a successful claim of infringement against us, we may be required to pay substantial damages, including
treble damages if we were to be found to have willfully infringed a third party&#8217;s patent, to the party claiming infringement, develop
non-infringing technology, stop selling our products or using technology that contains the allegedly infringing intellectual property
or enter into royalty or license agreements that may not be available on acceptable or commercially practical terms, if at all. Our failure
to develop non-infringing technologies or license the proprietary rights on a timely basis could harm our business. In addition, modifying
our products to exclude infringing technologies could require us to seek re-approval or clearance from various regulatory bodies for our
products, which would be costly and time consuming. Also, we may be unaware of pending patent applications that relate to our technology.
Parties making infringement claims on future issued patents may be able to obtain an injunction that would prevent us from selling our
products or using technology that contains the allegedly infringing intellectual property, which could harm our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 30 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We could be required to indemnify third parties
for alleged intellectual property infringement, which could cause us to incur significant costs.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Some of our distribution agreements contain commitments
to indemnify our distributors against liability arising from infringement of third-party intellectual property, such as patents. We may
be required to indemnify our customers for claims made against them or to contribute to license fees they are required to pay. If we are
forced to indemnify for claims or to pay license fees, our business and financial condition could be substantially harmed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Our international operations are subject to
trade policies, tariffs and trade agreements, and recent and future changes could harm our business.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have significant international operations in Mexico
and Europe, and we manufacture all of our products for export from Mexico. New or increased tariffs on goods imported into the United
States, particularly tariffs on products manufactured in Mexico, could adversely affect our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Any changes to existing trade agreements, like the
United States-Mexico-Canada Agreement (USMCA), which went into effect on July 1, 2020 (or subsequent trade agreements), or greater restrictions
on free trade generally, could impact our operations in countries where we manufacture or sell products or source components, or materials,
which could adversely affect our operating results and our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Given the uncertainty regarding the scope and duration
of any trade actions by the U.S. government or other countries, we can provide no assurance that the impact on our operations and results
in the future will not be material. &#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Our sales in international markets subject us
to foreign currency exchange and other risks and costs which could harm our business.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A substantial portion of our revenues are derived
from outside the United States, primarily from Mexico and Europe. We anticipate that revenues from international customers will continue
to represent a substantial portion of our revenues for the foreseeable future. Because we generate revenues in foreign currencies, we
are subject to the effects of exchange rate fluctuations. The functional currency of our Mexican subsidiary is the Mexican Peso and the
functional currency of our Netherlands subsidiary is the Euro. For the preparation of our consolidated financial statements, the financial
results of our foreign subsidiaries are translated into U.S.&#160;dollars using average exchange rates during the applicable period. If
the U.S.&#160;dollar appreciates against the Mexican Peso or the Euro, as applicable, the revenues we recognize from sales by our subsidiaries
will be adversely impacted. Foreign exchange gains or losses as a result of exchange rate fluctuations in any given period could harm
our operating results and negatively impact our revenues. Additionally, if the effective price of our products were to increase as a result
of fluctuations in foreign currency exchange rates, demand for our products could decline and adversely affect our results of operations
and financial condition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 31 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>The markets in which we operate are highly competitive
and subject to rapid technological change. If our competitors are better able to develop and market products that are less expensive or
more effective than any products that we may develop, our commercial opportunity may be reduced or eliminated.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our success depends, in part, upon our ability to
stay at the forefront of technological change and to maintain a competitive position. We compete with large healthcare, pharmaceutical
and biotechnology companies, along with smaller or early-stage companies that have collaborative arrangements with larger pharmaceutical
companies, academic institutions, government agencies and other public and private research organizations. Many of our competitors have
significantly greater financial resources and expertise in research and development, manufacturing, pre-clinical testing, conducting clinical
trials, obtaining regulatory approvals and marketing approved products than we do. Our competitors may:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 3%">&#160;</td>
    <td style="width: 2%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 95%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">develop and patent processes or products earlier than we will;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">develop and commercialize products that are less expensive or more efficient than any products that we may develop;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtain regulatory approvals for competing products more rapidly than we will; and</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">improve upon existing technological approaches or develop new or different approaches that render our technology or products obsolete or non-competitive.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As a result, we may not be able to successfully commercialize
any future products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>The success of our research and development
efforts may depend on our ability to find suitable collaborators to fully exploit our capabilities. If we are unable to establish collaborations
or if these future collaborations are unsuccessful, our research and development efforts may be unsuccessful, which could adversely affect
our results of operations and financial condition.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">An element of our business strategy is to enter into
collaborative or license arrangements under which we license our HOCl technology to other parties for development and commercialization.
We expect to seek collaborators for our potential products because of the expense, effort and expertise required to conduct clinical trials
and further develop those potential product candidates. Because collaboration arrangements are complex to negotiate, we may not be successful
in our attempts to establish these arrangements. If we need third party assistance in identifying and negotiating one or more acceptable
arrangements, it might be costly. Also, we may not have products that are desirable to other parties, or we may be unwilling to license
a potential product because the party interested in it is a competitor. The terms of any arrangements that we establish may not be favorable
to us. Alternatively, potential collaborators may decide against entering into an agreement with us because of our financial, regulatory
or intellectual property position or for scientific, commercial or other reasons. If we are unable to establish collaborative agreements,
we may not be able to develop and commercialize new products, which would adversely affect our business and our revenues.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In order for any of these collaboration or license
arrangements to be successful, we must first identify potential collaborators or licensees whose capabilities complement and integrate
well with ours. We may rely on these arrangements for not only financial resources, but also for expertise or economies of scale that
we expect to need in the future relating to clinical trials, manufacturing, sales and marketing, and for licensing technology rights.
However, it is likely that we will not be able to control the amount and timing of resources that our collaborators or licensees devote
to our programs or potential products. If our collaborators or licensees prove difficult to work with, are less skilled than we originally
expected, or do not devote adequate resources to the program, the relationship will not be successful. If a business combination involving
a collaborator or licensee and a third party were to occur, the effect could be to diminish, terminate or cause delays in development
of a potential product.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 32 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>If we are unable to comply with broad and complex
federal and state fraud and abuse laws, including state and federal anti-kickback laws, we could face substantial penalties and our products
could be excluded from government healthcare programs.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are subject to various federal and state laws pertaining
to healthcare fraud and abuse, which include, among other things, &#8220;anti-kickback&#8221; laws that prohibit payments to induce the
referral of products and services, and &#8220;false claims&#8221; statutes that prohibit the fraudulent billing of federal healthcare
programs. Our operations are subject to the Federal Anti-Kickback Statute, a criminal statute that, subject to certain statutory exceptions,
prohibits any person from knowingly and willfully offering, paying, soliciting or receiving remuneration, directly or indirectly, to induce
or reward a person either (i)&#160;for referring an individual for the furnishing of items or services for which payment may be made in
whole or in part by a government healthcare program such as Medicare or Medicaid, or (ii)&#160;for purchasing, leasing, ordering or arranging
for or recommending the purchasing, leasing or ordering of an item or service for which payment may be made under a government healthcare
program. Because of the breadth of the Federal Anti-Kickback Statute, the Office of Inspector General of the U.S.&#160;Department of Health
and Human Services, was authorized to adopt regulations setting forth additional exceptions to the prohibitions of the statute commonly
known as &#8220;safe harbors.&#8221; If all of the elements of an applicable safe harbor are fully satisfied, an arrangement will not
be subject to prosecution under the Federal Anti-Kickback Statute.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, if there is a change in law, regulation
or administrative or judicial interpretations of these laws, we may have to change our business practices or our existing business practices
could be challenged as unlawful, which could have a negative effect on our business, financial condition and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Healthcare fraud and abuse laws are complex, and even
minor, inadvertent irregularities can potentially give rise to claims that a statute or regulation has been violated. The frequency of
suits to enforce these laws has increased significantly in recent years and has increased the risk that a healthcare company will have
to defend a false claim action, pay fines or be excluded from the Medicare, Medicaid or other federal and state healthcare programs as
a result of an investigation arising out of such action. We cannot guarantee that we will not become subject to such litigation. Any violations
of these laws, or any action against us for violation of these laws, even if we successfully defend against it, could harm our reputation,
be costly to defend and divert management&#8217;s attention from other aspects of our business. Similarly, if the physicians or other
providers or entities with which we do business are found to have violated abuse laws, they may be subject to sanctions, which could also
have a negative impact on us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We may not be able to maintain sufficient product
liability insurance to cover claims against us.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Product liability insurance for the healthcare industry
is generally expensive to the extent it is available at all. We may not be able to maintain such insurance on acceptable terms or be able
to secure increased coverage if the commercialization of our products progresses, nor can we be sure that existing or future claims against
us will be covered by our product liability insurance. Moreover, the existing coverage of our insurance policy or any rights of indemnification
and contribution that we may have may not be sufficient to offset existing or future claims. A successful claim against us with respect
to uninsured liabilities or in excess of insurance coverage and not subject to any indemnification or contribution could have a material
adverse effect on our future business, financial condition, and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Our ability to generate revenue will be diminished
if our partners are unable to obtain acceptable prices or an adequate level of reimbursement from third-party payors, or our partners
may face pricing pressure from private third-party payers, including customers, from rebates and restrictive reimbursement practices.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our partner&#8217;s ability to commercialize our products
successfully will depend in part on the extent to which appropriate coverage and reimbursement levels for the cost of our products and
related treatment are obtained from governmental authorities, private health insurers and other organizations, such as health maintenance
organizations, or HMOs. In the United States, governmental and private payors have limited the growth of health care costs through price
regulation or controls, competitive pricing programs and drug rebate programs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 33 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">There is significant uncertainty concerning third-party
coverage and reimbursement of newly approved medical products. Third-party payors are increasingly challenging the prices charged for
medical products and services. Also, the trend toward managed healthcare in the United States and the concurrent growth of organizations
such as HMOs, as well as the &#8220;Affordable Care Act,&#8221; or any new healthcare laws may result in lower prices for or rejection
of our products. The cost containment measures that healthcare payors and providers are instituting and the effect of any healthcare reform
or changes to managed healthcare could materially and adversely affect our ability to generate revenues.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In the United States and some foreign jurisdictions,
there have been a number of legislative and regulatory proposals to change the health care system in ways that could affect our partner&#8217;s
abilities to sell our products profitably, and thus lead to decreased demand for our products and revenues for us. We were able to negotiate
minimum purchase requirements in certain of our third-party distributor agreements. However, we have limited control over purchases by
our distributors, to meet the minimum purchase thresholds or above the minimum purchase thresholds.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Increasingly, private health insurance companies and
self-insured employers have been raising co-payments required from beneficiaries and looking for other ways to shift more of the cost
burden to manufacturers and patients. This cost shifting has given consumers greater control of medication choices, as they pay for a
larger portion of their prescription costs and may cause consumers to favor lower cost generic alternatives to branded pharmaceuticals.
Additionally, patients continue to face cost reduction pressures that may cause them to curtail their use of, or seek reimbursement for,
our products, to negotiate reduced fees or other concessions or to delay payment. Third-party payors may reduce or limit reimbursement
for our products in the future, such as by withdrawing their coverage policies, canceling any future contracts, reviewing and adjusting
the rate of reimbursement, or imposing limitations on coverage. Any such changes could negatively impact the sales of our products by
our partners, and therefore, have a material adverse effect on our revenues.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Our ability to generate revenue will be diminished
if our partners are unable to manage customer product substitutions for our prescription products.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Similar to other pharmaceutical companies, patients
are increasingly seeking lower-cost substitutes to our products. Even if our patients have a prescription for our product, the pharmacist
may recommend a less expensive product even if that product is less effective or designed for conditions different from what the patient
is seeking to treat. As a result, the patient may choose to abandon purchasing our prescribed product for a less expensive alternative
product resulting in a lost sale for our partners. If the number of consumers substituting our products increases, it could have a material
adverse effect on sales of our products by our partners, and therefore, our revenues, financial position, cash flows and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Our inability to raise additional capital on
acceptable terms in the future may cause us to curtail certain operational activities, including regulatory trials, sales and marketing,
and international operations, in order to reduce costs and sustain the business, and such inability would have a material adverse effect
on our business and financial condition.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We may need to raise additional capital in the future
in order to, among other things:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 3%">&#160;</td>
    <td style="width: 2%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 95%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">increase our sales and marketing efforts to drive market adoption and address competitive developments;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">sustain commercialization of our current products or new products;</span></td></tr>

<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">acquire or license technologies;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">develop new products;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expand our manufacturing capabilities; and</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">finance capital expenditures and our general and administrative expenses.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 34 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our present and future funding requirements will depend
on many factors, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 3%">&#160;</td>
    <td style="width: 2%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 95%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the level of research and development investment required to maintain and improve our technology position;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">cost of filing, prosecuting, defending and enforcing patent claims and other intellectual property rights;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our efforts to acquire or license complementary technologies or acquire complementary businesses;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in product development plans needed to address any difficulties in commercialization;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">competing technological and market developments;&#160;and</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in regulatory policies or laws that affect our operations.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If we raise additional funds by issuing equity securities,
it will result in dilution to our stockholders. Any equity securities issued also may provide for rights, preferences or privileges senior
to those of holders of our common stock. If we raise additional funds by issuing debt securities, these debt securities would have rights,
preferences and privileges senior to those of holders of our common stock, and the terms of the debt securities issued could impose significant
restrictions on our operations. If we raise additional funds through collaborations or licensing arrangements, we might be required to
relinquish significant rights to our technologies or products, or grant licenses on terms that are not favorable to us. A failure to obtain
adequate funds may cause us to curtail certain operational activities, including regulatory trials, sales and marketing, and international
operations, in order to reduce costs and sustain our business, and would have a material adverse effect on our business and financial
condition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Our information technology and infrastructure
may be breached or attacked, which could expose us to liability, damage our reputation, compromise our confidential information or otherwise
adversely affect our business.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In the ordinary course of our business, we collect
and store a limited amount of sensitive data, including intellectual property, our proprietary business information and that of our customers,
suppliers, business partners, and personally identifiable information of our customers and employees, in our data centers and on our networks.
The secure processing, maintenance, and transmission of this information is critical to our operations and business strategy. Despite
our security measures, our information technology and infrastructure may be vulnerable to attacks by hackers or breached due to employee
error, malfeasance or other disruptions. Any such breach could compromise our networks and the information stored there could be accessed,
publicly disclosed, lost or stolen. Any such access, disclosure or other loss of information could result in legal claims or proceedings,
liability under laws that protect the privacy of personal information, and regulatory penalties, disrupt our operations and the services
we provide to customers, and damage our reputation, and cause a loss of confidence in our products and services, which could adversely
affect our business, revenues and competitive position.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Our cash and cash equivalents may be exposed
to failure of our banking institutions.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We maintain our cash at financial institutions, in
balances that exceed current FDIC insurance limits. If the banks where we hold deposits were to become insolvent or enter receivership,
our ability to access our cash, cash equivalents and investments, including transferring funds, making payments or receiving funds, may
be threatened, and this could have a material adverse effect on our business and financial condition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 35 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Risks Related to Our Common Stock</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>The market price of our common stock may be
volatile, and the value of your investment could decline significantly.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The trading price for our common stock has been, and
we expect it to continue to be, volatile. The price at which our common stock trades depends upon a number of factors, including our historical
and anticipated operating results, our financial situation, announcements of new products by us or our competitors, our ability or inability
to raise the additional capital we may need and the terms on which we raise it, and general market and economic conditions. Some of these
factors are beyond our control. Broad market fluctuations may lower the market price of our common stock and affect the volume of trading
in our stock, regardless of our financial condition, results of operations, business or prospects. It is impossible to assure you that
the market price of our shares of common stock will not fall in the future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Our operating results may fluctuate, which could
cause our stock price to decrease.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Fluctuations in our operating results may lead to
fluctuations, including declines, in our share price. Our operating results and our share price may fluctuate from period to period due
to a variety of factors, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 3%">&#160;</td>
    <td style="width: 2%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 95%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">demand by physicians, other medical staff and patients for our HOCl-based products;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinical trial results published by others in our industry and publication of results in peer-reviewed journals or the presentation at medical conferences;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the inclusion or exclusion of our HOCl-based products in large clinical trials conducted by others;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">actual and anticipated fluctuations in our quarterly financial and operating results;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">developments or disputes concerning our intellectual property or other proprietary rights;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">issues in manufacturing our product candidates or products;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">new or less expensive products and services or new technology introduced or offered by our competitors or by us;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reimbursement decisions by third-party payors and announcements of those decisions;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the development and commercialization of product enhancements;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in the regulatory environment;</span></td></tr>

<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top">
    <td style="width: 3%">&#160;</td>
    <td style="width: 2%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 95%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays in establishing new strategic relationships;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs associated with collaborations and new product candidates;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">introduction of technological innovations or new commercial products by us or our competitors;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">litigation or public concern about the safety of our product candidates or products;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in recommendations of securities analysts or lack of analyst coverage;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure to meet analyst expectations regarding our operating results;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">additions or departures of key personnel; and</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">general market conditions.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 36 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Variations in the timing of our future revenues and
expenses could also cause significant fluctuations in our operating results from period to period and may result in unanticipated earning
shortfalls or losses. In addition, The Nasdaq Capital Market, in general, and the market for life sciences companies, in particular, have
experienced significant price and volume fluctuations that have often been unrelated or disproportionate to the operating performance
of those companies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Anti-takeover provisions in our certificate
of incorporation and bylaws and under Delaware law may make it more difficult for stockholders to change our management and may also make
a takeover difficult.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our corporate documents and Delaware law contain provisions
that limit the ability of stockholders to change our management and may also enable our management to resist a takeover. These provisions
include:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 3%">&#160;</td>
    <td style="width: 2%"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="width: 95%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the ability of our Board of Directors to issue and designate, without stockholder approval, the rights of up to 714,286 shares of convertible preferred stock, which rights could be senior to those of common stock;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">limitations on persons authorized to call a special meeting of stockholders; and</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">advance notice procedures required for stockholders to make nominations of candidates for election as directors or to bring matters before meetings of stockholders.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are subject to Section 203 of the Delaware General
Corporation Law, which, subject to certain exceptions, prohibits &#8220;business combinations&#8221; between a publicly-held Delaware
corporation and an &#8220;interested stockholder,&#8221; which is generally defined as a stockholder who became a beneficial owner of
15% or more of a Delaware corporation&#8217;s voting stock for a three-year period following the date that such stockholder became an
interested stockholder.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">These provisions might discourage, delay or prevent
a change of control in our management. These provisions could also discourage proxy contests and make it more difficult for you and other
stockholders to elect directors and cause us to take other corporate actions. In addition, the existence of these provisions, together
with Delaware law, might hinder or delay an attempted takeover other than through negotiations with our Board of Directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Our stockholders may experience substantial
dilution in the value of their investment if we issue additional shares of our capital stock or other securities convertible into common
stock.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our Restated Certificate of Incorporation, as amended,
allows us to issue up to 50,000,000 shares of our common stock and to issue and designate, without stockholder approval, the rights of
up to 714,286 shares of preferred stock. In the event we issue additional shares of our capital stock, dilution to our stockholders could
result. In addition, if we issue and designate a class of convertible preferred stock, these securities may provide for rights, preferences
or privileges senior to those of holders of our common stock. Additionally, if we issue preferred stock, it may convert into common stock
at a ratio of 1:1 or greater because our Restated Certificate of Incorporation, as amended, allows us to designate a conversion ratio
without limitations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Shares issuable upon the exercise of outstanding
options may substantially increase the number of shares available for sale in the public market and depress the price of our common stock.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of March 31, 2025, we had outstanding options to
purchase an aggregate of 73,081 shares of our common stock at a weighted average exercise price of $43.27 per share and a weighted average
contractual term of 8.82 years. In addition, 14,670 shares of our common stock were available on March 31, 2025 for future option grants
under our 2016 Equity Incentive Plan, our 2021 Equity Incentive Plan and our 2024 Equity Incentive Plan. To the extent any additional
options are granted and exercised, there will be further dilution to stockholders and investors. Until the options expire, these holders
will have an opportunity to profit from any increase in the market price of our common stock without assuming the risks of ownership.
Holders of options may convert or exercise these securities at a time when we could obtain additional capital on terms more favorable
than those provided by the options. The exercise of the options will dilute the voting interest of the owners of presently outstanding
shares by adding a substantial number of additional shares of our common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 37 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have filed several registration statements with
the SEC, so that substantially all of the shares of our common stock which are issuable upon the exercise of outstanding warrants and
options may be sold in the public market. The sale of our common stock issued or issuable upon the exercise of the warrants and options
described above, or the perception that such sales could occur, may adversely affect the market price of our common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Our failure to maintain compliance with Nasdaq&#8217;s
continued listing requirements could result in the delisting of our common stock.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If we fail to satisfy the continued listing requirements
of the Nasdaq Capital Market, such as the minimum closing bid price requirement and corporate governance requirements, Nasdaq may take
steps to delist our common stock. The delisting of our common stock from Nasdaq would have a material adverse effect on our access to
capital markets, and any limitation on market liquidity or reduction in the price of its common stock as a result of that delisting would
adversely affect our ability to raise capital on terms acceptable to the Company, if at all.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="k_006"></span>ITEM 1B. Unresolved Staff Comments </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Not Applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="k_007"></span>ITEM 1C. Cybersecurity</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_98D_ecyd--CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_iB_c20240401__20250331_gBFCRMPFAIAMT-FYQD_zcGY9fNqFMg4" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><ix:nonNumeric contextRef="From2024-04-01to2025-03-31" continuedAt="ConU000053-01" escape="true" id="Fact000053" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"><b>Risk Management and Strategy</b></ix:nonNumeric></p>

<div id="xdx_C0D_gBFCRMPFAIAMT-FYQD_zSpL8V6hc0U4"><ix:continuation continuedAt="ConU000053-02" id="ConU000053-01"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:continuation></div>

<div id="xdx_C0B_gBFCRMPFAIAMT-FYQD_zX5lGRklqg38"><ix:continuation continuedAt="ConU000053-03" id="ConU000053-02"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_90C_ecyd--CybersecurityRiskManagementProcessesIntegratedTextBlock_c20240401__20250331_z3rVRRvdf7ug" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-04-01to2025-03-31" escape="true" id="Fact000054" name="cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock">We identify and address <span id="xdx_90B_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20240401__20250331_ziivd5w3h7wl" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-04-01to2025-03-31" format="ixt:booleantrue" id="Fact000055" name="cyd:CybersecurityRiskManagementProcessesIntegratedFlag">cybersecurity</ix:nonNumeric></span> threats and
risks related to our business with an approach that includes assessments by our management and use of an outside consultant to manage
our information technology.</ix:nonNumeric></span> In addition, we rely on operating systems and software from established and reliable <span id="xdx_900_ecyd--CybersecurityRiskManagementThirdPartyEngagedFlag_dbT_c20240401__20250331_zfhxkhEJH5g7" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-04-01to2025-03-31" format="ixt:booleantrue" id="Fact000056" name="cyd:CybersecurityRiskManagementThirdPartyEngagedFlag">third-party</ix:nonNumeric></span> service providers
to provide security. We have employee policies in place designed to reduce risk of cyber-attacks and educate employees on protocol in
the event of a potential cybersecurity incident.</p></ix:continuation></div>

<div id="xdx_C0B_gBFCRMPFAIAMT-FYQD_zSnPubPs42Vc"><ix:continuation continuedAt="ConU000053-04" id="ConU000053-03"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:continuation></div>

<div id="xdx_C08_gBFCRMPFAIAMT-FYQD_zZT0AKh7qa51"><ix:continuation id="ConU000053-04"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_900_ecyd--CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_c20240401__20250331_zkV6fBvn6hD8" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-04-01to2025-03-31" escape="true" id="Fact000057" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock">Currently we are <span id="xdx_900_ecyd--CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_dbF_c20240401__20250331_zGU9Jtn0LpJg" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-04-01to2025-03-31" format="ixt:booleanfalse" id="Fact000058" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">not aware</ix:nonNumeric></span> of any risks from cybersecurity
threats, including as a result of any previous cybersecurity incidents, that have materially affected our business strategy,</ix:nonNumeric></span> results of
operations or financial condition or are reasonably likely to have such a material effect. However, cyber-attacks are increasing in frequency,
sophistication and intensity, and despite our ongoing efforts we cannot eliminate all risks from cybersecurity threats, or provide assurances
that we have not experienced undetected cybersecurity incidents. Please refer to &#8220;Risk Factors&#8221; in Part I, Item 1A of this
Form 10-K for more information on the risks posed to us by cybersecurity threats.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:continuation></div>



<p id="xdx_989_ecyd--CybersecurityRiskBoardOfDirectorsOversightTextBlock_c20240401__20250331_gBFCRBODOTB-CXABT_zdsV0HFf6Di4" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><ix:nonNumeric contextRef="From2024-04-01to2025-03-31" continuedAt="ConU000061-01" escape="true" id="Fact000061" name="cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock"><b>Governance</b></ix:nonNumeric></p>

<div id="xdx_C0E_gBFCRBODOTB-CXABT_zHiJTIuw9ZSg"><ix:continuation continuedAt="ConU000061-02" id="ConU000061-01"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p></ix:continuation></div>

<div id="xdx_C02_gBFCRBODOTB-CXABT_zRJ5t6lFhfjh"><ix:continuation id="ConU000061-02"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_906_ecyd--CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_c20240401__20250331_zbHuE0YuWts1" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-04-01to2025-03-31" escape="true" id="Fact000062" name="cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">The Board of Directors takes an active role, as a
whole, in overseeing management regarding our Company&#8217;s risks, including cybersecurity risks.</ix:nonNumeric></span> <span id="xdx_90E_ecyd--CybersecurityRiskRoleOfManagementTextBlock_c20240401__20250331_zbzRGRCK0URh" class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__"><ix:nonNumeric contextRef="From2024-04-01to2025-03-31" escape="true" id="Fact000063" name="cyd:CybersecurityRiskRoleOfManagementTextBlock">Our management, including our Chief
Executive Officer and our Chief Financial Officer, keeps the Board of Directors apprised of significant risks facing our Company and the
approach being taken to understand, manage, and mitigate such risks, including with respect to potential cybersecurity threats.</ix:nonNumeric></span></p></ix:continuation></div>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 38 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="k_005"></span>ITEM&#160;2.&#160;Properties</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At March 31, 2025, we have a corporate office in Boulder,
Colorado and our manufacturing facility in Zapopan, Mexico. We currently lease the following material properties:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 65%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Locations</b></span></td>
    <td style="vertical-align: top; width: 1%; text-align: justify">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 11%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Rent per month</b></span></td>
    <td style="vertical-align: top; width: 1%; text-align: justify">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 22%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Purpose</b></span></td></tr>
  <tr style="background-color: rgb(238,238,238)">
    <td style="vertical-align: bottom; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1) 5445 Conestoga Court, Unit 150, Boulder, CO 80301</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">USD 3,680</span></td>
    <td style="vertical-align: top; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal executive office</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2) Industria Vidriera 81, &amp; 87 Zapopan Industrial Norte, Zapopan, Jalisco, 45135, Mexico</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MXN 209,811</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office, manufacturing</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(238,238,238)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3) Industria Maderera 106, 115 &amp; 815 Zapopan Industrial Norte, Zapopan, Jalisco, 45135, Mexico</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MXN 213,625</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warehouse</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We believe that our properties will be adequate to
meet our needs for at least the next 12 months.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="k_008"></span>ITEM&#160;3.&#160;Legal Proceedings</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We may be involved in legal matters arising in the
ordinary course of our business including matters involving proprietary technology. While management believes that such matters are currently
insignificant, matters arising in the ordinary course of business for which we are or could become involved in litigation may have a material
adverse effect on our business, financial condition or results of comprehensive (loss) income.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="k_009"></span>ITEM&#160;4.&#160;Mine Safety Disclosures</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Not applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 39 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="k_010"></span>PART&#160;II</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="k_011"></span>ITEM&#160;5.&#160;Market for Registrant&#8217;s Common Equity, Related
Stockholder Matters and Issuer Purchases of Equity Securities</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Market Information</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our common stock is traded on The Nasdaq Capital Market
under the symbol &#8220;SNOA.&#8221; Previously, it traded under the symbol &#8220;OCLS&#8221; until December 6, 2016. Our common stock
has been trading since our initial public offering on January&#160;25, 2007.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Holders</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of <span>June
10,</span> 2025, we had approximately <span>61</span> holders of record of our common stock. Holders
of record include nominees who may hold shares on behalf of multiple owners.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Dividends</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have never declared or paid any cash dividends
on our common stock. We currently anticipate that we will retain all future earnings for the operation of our business and we do not currently
intend to pay any cash dividends on our common stock in the foreseeable future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Securities Authorized for Issuance Under Equity
Compensation Plans</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The information required to be disclosed by Item 201(d)
of Regulation S-K, &#8220;Securities Authorized for Issuance Under Equity Compensation Plans,&#8221; is incorporated herein by reference.
Refer to Item 12 of Part III of this annual report on Form 10-K for additional information.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Recent Sales of Unregistered Securities</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We did not issue any unregistered securities during
the year ended March 31, 2025 and through June 12, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="k_012"></span>ITEM&#160;6.&#160;Selected Financial Data</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As a smaller reporting company, as defined by Rule&#160;12b-2
of the Exchange Act and in Item&#160;10(f)(1) of Regulation&#160;S-K, we are electing scaled disclosure reporting obligations and therefore
are not required to provide the information requested by this Item.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="k_013"></span>ITEM 7. &#160;Management&#8217;s Discussion and
Analysis of Financial Condition and Results of Operations</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Critical Accounting Policies</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of our consolidated financial statements
in conformity with accounting principles generally accepted in the United States of America requires management to exercise its judgment.
We exercise considerable judgment with respect to establishing sound accounting policies and in making estimates and assumptions that
affect the reported amounts of our assets and liabilities, our recognition of revenues and expenses, and disclosure of commitments and
contingencies at the date of the consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On an ongoing basis, we evaluate our estimates and
judgments. Areas in which we exercise significant judgment include, but are not necessarily limited to, our valuation of accounts receivable,
inventory, income taxes, and equity transactions (compensatory and financing).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 40 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We base our estimates and judgments on a variety of
factors including our historical experience, knowledge of our business and industry, current and expected economic conditions, the attributes
of our products, the regulatory environment, and in certain cases, the results of outside appraisals. We periodically re-evaluate our
estimates and assumptions with respect to these judgments and modify our approach when circumstances indicate that modifications are necessary.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">While we believe that the factors we evaluate provide
us with a meaningful basis for establishing and applying sound accounting policies, we cannot guarantee that the results will always be
accurate. Since the determination of these estimates requires the exercise of judgment, actual results could differ from such estimates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For a Summary of all Accounting Policies, please refer
to Notes to Consolidated Financial Statements, Note 3.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Results of Continuing Operations</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Comparison of the Year Ended March 31, 2025 and
2024</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Revenue</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table shows our consolidated total revenue
and revenue by geographic region for the year ended March 31, 2025 and 2024:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Year Ended</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>March 31,</b></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-style: italic">(In thousands, except for percentages)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">$ Change</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">% Change</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 40%; text-align: left">United States</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">2,611</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">3,058</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(447</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">(15%</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Europe</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,523</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,781</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">742</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16%</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>Asia</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,317</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,298</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1%</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Latin America</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,962</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,726</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,236</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">72%</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Rest of the World</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">875</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">872</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">0%</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">14,288</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">12,735</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,553</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">12%</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The decrease in United States revenue of $447,000
for the year ended March 31, 2025, was primarily the result of fluctuations in demand for over-the-counter animal health care products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The increase in Europe revenue for the year ended
March 31, 2025 of $742,000 was the result of a general increase in demand for our products and, more specifically, an increase in demand
for our wound care products due to recent world events.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The increase in Asia revenue of $19,000 for the year
ended March 31, 2025 was primarily due to timing of customer orders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The increase in Latin America revenue for the year
ended March 31, 2025 of $1,236,000 was primarily due to an increase in manufacturing orders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The increase in Rest of World revenue for the year
ended March 31, 2025 of $3,000 was primarily due to timing of customer orders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i></i></b></p>

<!-- Field: Page; Sequence: 41 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Cost of Revenue and Gross Profit</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The cost of revenue and gross profit metrics for the
year ended March 31, 2025 and 2024 are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;<b><i>&#160;</i></b></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Year Ended</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>March 31,</b></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-style: italic">(In thousands, except for percentages)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">$ Change</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">% Change</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 40%">Cost of Revenues</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">8,823</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">7,990</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">883</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">10%</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Cost of Revenue as a % of Revenues</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">62%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">63%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Gross Profit</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">5,465</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">4,745</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">720</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15%</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Gross Profit as a % of Revenues</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">38%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">37%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The gross profit margin of 38% for the year ended
March 31, 2025 was consistent with the prior year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Research and Development Expense</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The research and development expense metrics for the
year ended March 31, 2025 and 2024 are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Year Ended</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>March 31,</b></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-style: italic">(In thousands, except for percentages)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">$ Change</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">% Change</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-indent: -10pt; padding-left: 10pt; text-align: left; width: 40%">Research and Development Expense</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">1,814</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">1,871</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(57</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">(3%</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt; text-align: left">Research and Development Expense as a % of Revenues</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Decrease in research and development expenses for
the year ended March 31, 2025 of $57,000 was primarily due to decreased product development expenses in the U.S. in the current period
and decreased regulatory efforts in Europe following the successful transition to MDR.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Selling, General and Administrative Expense</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The selling, general and administrative expense metrics
for the years ended March 31, 2025 and 2024 are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Year Ended</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>March 31,</b></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-style: italic">(In thousands, except for percentages)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Change</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">% Change</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-indent: -10pt; padding-left: 10pt; text-align: left; width: 40%">Selling, General and Administrative Expense</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">7,361</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">7,575</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(214</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">(3%</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt; text-align: left">Selling, General and Administrative Expense as a % of Revenues</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">52%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">59%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The decrease in selling, general and administrative
expenses for the year ended March 31, 2025 of $214,000 was the result of ongoing efforts to contain expenses across all parts of the company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Other Income (Expense), net</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other income (expense), net for the year ended
March 31, 2025 was $803,000 compared to $(330,000) for the year ended March 31, 2024. The change in other income (expense), net primarily
relates to exchange rate fluctuations and to a lesser extent income of $245,000 for employee retention credits approved from calendar
year 2020. In fiscal 2026 we expect to recognize income of approximately $350,000 related to approved calendar year 2021 employee retention
credits.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 42 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Income Tax (Expense) Benefit</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Income tax (expense) benefit for the years ended
March 31, 2025 and 2024 was $(550,000) and $196,000, respectively. The expense for the current year is primarily related to the use of
our deferred tax asset in Mexico and, to a lesser extent, an increase in our deferred tax asset in Netherlands. The benefit for the prior
year was related to our Mexico deferred tax asset.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Net Loss</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table provides the net loss for each
period along with the computation of basic and diluted net loss per share:&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Year Ended March 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-style: italic; text-align: justify">(In thousands, except per share data)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: justify; padding-bottom: 2.5pt">Net loss</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 13%; text-align: right">(3,457</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 13%; text-align: right">(4,835</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Weighted-average shares outstanding: basic and diluted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,241</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">455</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Net loss per share: basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(2.79</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(10.63</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Liquidity and Capital Resources</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We reported a net loss of $3,457,000 and $4,835,000
for the years ended March 31, 2025 and 2024, respectively. At March 31, 2025 and 2024, our accumulated deficit amounted to $197,806,000
and $194,349,000, respectively. As of March 31, 2025 and 2024, we had cash and cash equivalents of $5,374,000 and $3,128,000, respectively.
Since our inception, substantially all of our operations have been financed through sales of equity securities. Other sources of financing
that we have used to date include our revenues, as well as various loans and the sale of certain assets to customers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Since April 1, 2024, substantially all of our operations
have been financed through cash on hand and proceeds of $3,079,000, net of offering expenses, from the sale of common stock during the
fiscal year ended March 31, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table presents a summary of our consolidated
cash flows for operating, investing and financing activities for the years ended March 31, 2025 and 2024 as well as balances of cash and
cash equivalents and working capital:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year ended March 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-style: italic; text-align: justify">(In thousands)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify">Net cash provided by (used in):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 66%; text-align: justify">Operating activities</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">(88</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">(2,398</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify">Investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(80</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Financing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,030</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,676</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify; padding-bottom: 1pt">Effect of exchange rates on cash</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(616</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">32</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Net change in cash and cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,246</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(692</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify; padding-bottom: 1pt">Cash and cash equivalents, beginning of the period</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,128</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,820</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt">Cash and cash equivalents, end of the period</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,374</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,128</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Working capital <sup>(1)</sup>, end of period</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">8,552</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">8,829</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 3px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(1)</sup></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Defined as current assets minus current liabilities.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 43 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of March 31, 2025 and 2024, we had cash and cash
equivalents of $5,374,000 and $3,128,000, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Net cash used in operating activities during the
year ended March 31, 2025 was $88,000, primarily due to our net loss of $3,457,000, offset by stock compensation of $224,000, a decrease
in accounts receivable of $434,000, a decrease in prepaid expenses of $1,086,000 and an increase in accounts payable of $416,000.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Net cash used in operating activities during the year
ended March 31, 2024 was $2,398,000, primarily due to our net loss of $4,835,000, offset by stock compensation of $516,000, a decrease
in inventory of $184,000, and a decrease in prepaid expenses of $1,107,000.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Net cash used in investing activities for the year
ended March 31, 2025 was $80,000, primarily related to the purchase of capital property and equipment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Net cash used in investing activities for the year
ended March 31, 2024 was $2,000, primarily related to the purchase of capital property and equipment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Net cash provided by financing activities for the
year ended March 31, 2025 was $3,030,000, primarily related to proceeds of $3,079,000 from the sale of common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Net cash provided by financing activities for the
year ended March 31, 2024 was $1,676,000, primarily related to proceeds of $1,784,000 from the sale of common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We believe that we have access to additional capital
resources through possible public or private equity offerings, debt financings, corporate collaborations or other means; however, we cannot
provide any assurance that new financings will be available on commercially acceptable terms, if needed. If the economic climate in the
U.S. deteriorates, our ability to raise additional capital could be negatively impacted. If we are unable to secure additional capital,
we may be required to take additional measures to reduce costs in order to conserve our cash in amounts sufficient to sustain operations
and meet our obligations. These measures could cause significant delays in our continued efforts to commercialize our products, which
is critical to the realization of our plan and future operations. This uncertainty along with our history of losses indicates that there
is substantial doubt about our ability to continue as a going concern within one year after the date that our financial statements are
issued. The accompanying consolidated financial statements do not include any adjustments that may be necessary should we be unable to
continue as a going concern.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Capital Expenditures</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We currently forecast capital expenditures in order
to execute on our business plan and maintain growth; however, the actual amount and timing of such capital expenditures will ultimately
be determined by the volume of business. We currently do not anticipate that a material amount will be purchased for the year ended March
31, 2026. If we purchase capital equipment, we expect to pay cash for those expenditures or to finance them through equipment leases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Material Trends and Uncertainties</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We rely on certain key customers for a significant
portion of our revenues. In the future, a small number of customers may continue to represent a significant portion of our total revenues
in any given period. These customers may not consistently purchase our products at a particular rate over any subsequent period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are exposed to risk from foreign currency devaluation
for both the Mexico Peso and the Euro versus the US dollar. Risk related to foreign currency valuation tends to be unpredictable and can
be affected by various factors outside of our control.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 44 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">We face a substantial Mexico
tax liability, intercompany debt, unpaid technical assistance charges and accrued interest. These amounts are due in 2027. At this time,
management believes there are sufficient assets on the balance sheet to cover any tax obligation without interrupting our operations or
business. We have engaged tax professionals to review all options to limit our exposure to these amounts and to proceed in a manner that
is most advantageous to us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">We also closely monitor global
economic conditions, including the risk of economic downturn or recession, the prospect of new or increased tariffs, as well as overall
consumer sentiment, any of which may impact our financial results.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Use of Estimates</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of consolidated financial statements
in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and
assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent liabilities at the dates of the consolidated
financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from
these estimates. Significant estimates and assumptions include reserves and write-downs related to receivables and inventories, the valuation
allowance relating to the Company&#8217;s deferred tax assets, and the valuation of equity.. Periodically, the Company evaluates and adjusts
estimates accordingly.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Off-Balance Sheet Transactions</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We currently have no off-balance sheet arrangements
that have or are reasonably likely to have a current or future material effect on our financial condition, changes in financial condition,
revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="k_014"></span>ITEM&#160;7A.&#160;Quantitative and Qualitative Disclosures About Market
Risk</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As a smaller reporting company as defined by Rule&#160;12b-2
of the Exchange Act and in Item&#160;10(f)(1) of Regulation&#160;S-K, we are electing scaled disclosure reporting obligations and therefore
are not required to provide the information requested by this Item.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<!-- Field: Page; Sequence: 45 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="k_015"></span>ITEM&#160;8.&#160;Consolidated Financial Statements and Supplementary
Data</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>SONOMA PHARMACEUTICALS, INC. AND SUBSIDIARIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="k_016"></span>INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="width: 94%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 5%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#k_017">Report of Independent Registered Public Accounting Firm</a> (PCAOB No. <span id="xdx_90B_edei--AuditorFirmId_c20240401__20250331_zPLEfjNEQYM4"><ix:nonNumeric contextRef="From2024-04-01to2025-03-31" id="Fact000064" name="dei:AuditorFirmId">215</ix:nonNumeric></span>)</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-1</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><a href="#k_018"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Balance Sheets as of March 31, 2025 and 2024</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-2</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><a href="#k_019"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Statements of Comprehensive Loss for the Years Ended March 31, 2025 and 2024</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-3</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><a href="#k_020"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Statements of Changes in Stockholders&#8217; Equity for the Years Ended March 31, 2025 and 2024</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-4</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><a href="#k_021"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Statements of Cash Flows for the Years Ended March 31, 2025 and 2024</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-5</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><a href="#k_022"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes to Consolidated Financial Statements</span></a></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-6</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b></b></p>

<!-- Field: Page; Sequence: 46 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="k_017"></span>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 245.35pt 0 0">To
the Shareholders and Board of Directors of</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 245.35pt 0 0">Sonoma Pharmaceuticals, Inc.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0">Opinion on the Consolidated Financial Statements</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1.2pt 0 0">We have audited the accompanying consolidated balance sheets
of Sonoma Pharmaceuticals, Inc. and Subsidiaries (the "Company") as of March 31, 2025 and 2024, and the related consolidated
statements of comprehensive loss, changes in stockholders' equity, and cash flows for the years ended March 31, 2025 and 2024, and the
related notes (collectively referred to as the consolidated financial statements). In our opinion, the consolidated financial statements
present fairly, in all material respects, the financial position of the Company as of March 31, 2025 and 2024, and the results of their
operations and cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of
America.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1.2pt 0 0">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0">Substantial Doubt About the Company's Ability to Continue as
a Going Concern</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 4.05pt 0 0">The accompanying consolidated financial statements have been
prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the consolidated financial statements,
the Company has incurred significant losses and negative operating cash flows and needs to raise additional funds to meet its obligations
and sustain its operations. These conditions raise substantial doubt about its ability to continue as a going concern. Management's plans
in regard to these matters are also described in Note 2. The consolidated financial statements do not include any adjustments that might
result from the outcome of this uncertainty.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 4.05pt 0 0">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0">Basis for Opinion</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 4.05pt 0 0">These consolidated financial statements are the responsibility
of the Company's management. Our responsibility is to express an opinion on the Company's consolidated financial statements based on our
audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB")
and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable
rules and regulations of the Securities and Exchange Commission and the PCAOB.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 4.05pt 0 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 4.05pt 0 0">We conducted our audits in accordance with the standards
of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated
financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we
engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding
of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal
control over financial reporting. Accordingly, we express no such opinion.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 4.05pt 0 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Our audits included performing procedures to assess the risks
of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond
to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated
financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management,
as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable
basis for our opinion.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0">Critical
Audit Matters</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Critical audit matters are matters arising from the current
period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee
and that: (1) relate to accounts or disclosures that are material to the consolidated financial statements and (2) involved our
especially challenging, subjective, or complex judgments. We determined that there are no critical audit matters.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>/s/ <span id="xdx_903_edei--AuditorName_c20240401__20250331_zQx1ujJB8MH7"><ix:nonNumeric contextRef="From2024-04-01to2025-03-31" id="Fact000065" name="dei:AuditorName">Frazier &amp; Deeter, LLC</ix:nonNumeric></span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 245.35pt 0 0">We have served as the Company's auditor since 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 245.35pt 0 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 245.35pt 0 0"><span id="xdx_908_edei--AuditorLocation_c20240401__20250331_z3KwVdYhyuw4"><ix:nonNumeric contextRef="From2024-04-01to2025-03-31" id="Fact000066" name="dei:AuditorLocation">Nashville,
Tennessee</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">June 17, 2025</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 47 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Value: 1; Name: PageNo -->1<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>SONOMA PHARMACEUTICALS, INC. AND SUBSIDIARIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="k_018"></span>CONSOLIDATED BALANCE SHEETS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(In thousands, except share amounts)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" id="xdx_304_111_pn3n3_z2p27hKsJZ8f" summary="xdx: Statement - CONSOLIDATED BALANCE SHEETS" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_49E_20250331_zBQ9SFboe3A9" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_490_20240331" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>March 31,</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>2025</b></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>March 31, </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>2024</b></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AssetsAbstract_iB_z6u8KR683kb9" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="font-weight: bold; text-align: center">ASSETS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AssetsCurrentAbstract_iB_zBreovr0cMj7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Current assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i01I_maCznhs_z7ZQ7KdNlRvd" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; width: 66%; text-align: left">Cash and cash equivalents</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2025-03-31" id="Fact000074" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,374</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2024-03-31" id="Fact000075" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,128</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AccountsReceivableNetCurrent_i01I_maCznhs_zFDNkVqNWRN2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Accounts receivable, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2025-03-31" id="Fact000077" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,232</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2024-03-31" id="Fact000078" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,898</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--InventoryNet_i01I_maCznhs_zu1BZkxZteLc" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left">Inventories, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2025-03-31" id="Fact000080" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,915</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2024-03-31" id="Fact000081" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,719</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i01I_maCznhs_zUgyY845tRY1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Prepaid expenses and other current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2025-03-31" id="Fact000083" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,915</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2024-03-31" id="Fact000084" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,541</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--DeferredConsiderationCurrent_i01I_maCznhs_zaIOmkCBqzmk" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Current portion of deferred consideration, net of discount</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="SNOA:DeferredConsiderationCurrent" contextRef="AsOf2025-03-31" id="Fact000086" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">212</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="SNOA:DeferredConsiderationCurrent" contextRef="AsOf2024-03-31" id="Fact000087" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">262</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AssetsCurrent_i01TI_mtCznhs_maCzISr_zrIfZGi20TG1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Total current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2025-03-31" id="Fact000089" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12,648</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2024-03-31" id="Fact000090" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12,548</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentNet_i01I_maCzISr_zvqI6O7GP2i2" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left">Property and equipment, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2025-03-31" id="Fact000092" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">225</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2024-03-31" id="Fact000093" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">365</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--OperatingLeaseRightOfUseAsset_i01I_maCzISr_zpXjirN1p2p9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Operating lease, right of use assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2025-03-31" id="Fact000095" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">84</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2024-03-31" id="Fact000096" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">286</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredIncomeTaxAssetsNet_i01I_maCzISr_zKeCPortgDbj" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left">Deferred tax asset, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredIncomeTaxAssetsNet" contextRef="AsOf2025-03-31" id="Fact000098" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">589</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredIncomeTaxAssetsNet" contextRef="AsOf2024-03-31" id="Fact000099" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,145</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--DeferredConsiderationNoncurrent_i01I_maCzISr_zuqi63wOros3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Deferred consideration, net of discount, less current portion</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SNOA:DeferredConsiderationNoncurrent" contextRef="AsOf2025-03-31" id="Fact000101" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">73</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SNOA:DeferredConsiderationNoncurrent" contextRef="AsOf2024-03-31" id="Fact000102" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">330</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--OtherAssetsNoncurrent_i01I_maCzISr_zUwS9akDnWjf" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Other assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2025-03-31" id="Fact000104" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">74</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2024-03-31" id="Fact000105" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">66</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--Assets_i01TI_mtCzISr_zjItWnEYqgm5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">Total assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2025-03-31" id="Fact000107" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">13,693</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2024-03-31" id="Fact000108" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14,740</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: center">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LiabilitiesCurrentAbstract_iB_zdCbfu02ZkG9" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Current liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AccountsPayableCurrent_i01I_maCzGGc_zMQ7xmlaTUO9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2025-03-31" id="Fact000116" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">953</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2024-03-31" id="Fact000117" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">607</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AccountsPayableAndOtherAccruedLiabilities_i01I_maCzGGc_zyc6rBE1VFdd" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left">Accrued expenses and other current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableAndOtherAccruedLiabilities" contextRef="AsOf2025-03-31" id="Fact000119" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,224</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableAndOtherAccruedLiabilities" contextRef="AsOf2024-03-31" id="Fact000120" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,113</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredRevenueCurrent_i01I_maCzGGc_znkoatfCsux4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Deferred revenue, current portion</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredRevenueCurrent" contextRef="AsOf2025-03-31" id="Fact000122" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">641</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredRevenueCurrent" contextRef="AsOf2024-03-31" id="Fact000123" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">478</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--ShortTermBorrowings_i01I_d0_maCzGGc_z1FM46RSN6Xk" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left">Short-term debt</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShortTermBorrowings" contextRef="AsOf2025-03-31" id="Fact000125" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">220</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShortTermBorrowings" contextRef="AsOf2024-03-31" id="Fact000126" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">323</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--OperatingLeaseLiabilityCurrent_i01I_maCzGGc_zepzC4TTxSd1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Operating lease liabilities, current portion</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2025-03-31" id="Fact000128" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">58</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2024-03-31" id="Fact000129" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">198</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LiabilitiesCurrent_i01TI_mtCzGGc_maCzTDK_zVZ8Mo85kGQc" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 20pt; text-align: left">Total current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2025-03-31" id="Fact000131" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,096</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2024-03-31" id="Fact000132" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,719</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredRevenueNoncurrent_i01I_maCzTDK_z92RBb2oRI92" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Deferred revenue, net of current portion</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredRevenueNoncurrent" contextRef="AsOf2025-03-31" id="Fact000134" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">17</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredRevenueNoncurrent" contextRef="AsOf2024-03-31" id="Fact000135" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">87</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--WithholdingTaxPayable_i01I_maCzTDK_zsaUDPoM9OZk" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Withholding tax payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SNOA:WithholdingTaxPayable" contextRef="AsOf2025-03-31" id="Fact000137" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,142</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SNOA:WithholdingTaxPayable" contextRef="AsOf2024-03-31" id="Fact000138" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,710</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OperatingLeaseLiabilityNoncurrent_i01I_maCzTDK_z967Sys5LL8g" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Operating lease liabilities, less current portion</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2025-03-31" id="Fact000140" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">27</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2024-03-31" id="Fact000141" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">87</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--Liabilities_i01TI_mtCzTDK_maCzz2O_zpBwltiSeYCf" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Total liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2025-03-31" id="Fact000143" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,282</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2024-03-31" id="Fact000144" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,603</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--CommitmentsAndContingencies_i01I_maCzz2O_zpUTlsF9fp84" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Commitments and Contingencies (Note 11)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><b style="display: none"><span style="-sec-ix-hidden: xdx2ixbrl0146">&#8211;</span></b></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><b style="display: none"><span style="-sec-ix-hidden: xdx2ixbrl0147">&#8211;</span></b></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--StockholdersEquityAbstract_iB" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Stockholders&#8217; Equity:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--PreferredStockValue_i01I_d0_maCzB1V_zKdm2R0cEYbj" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 20pt; text-align: left">Convertible preferred stock, $<span id="xdx_901_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pip0_c20250331_zi3tGn8HJUe4" title="Preferred stock, par value"><span id="xdx_901_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pip0_c20240331_zCXM9Zuw7Vy" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2025-03-31" id="Fact000155" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2024-03-31" id="Fact000157" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">0.0001</ix:nonFraction></ix:nonFraction></span></span> par value; <span id="xdx_901_eus-gaap--PreferredStockSharesAuthorized_iI_pip0_c20250331_zHTTSMh463t4" title="Preferred stock, shares authorized"><span id="xdx_90D_eus-gaap--PreferredStockSharesAuthorized_iI_pip0_c20240331_zvGSrEDwyEme" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2025-03-31" id="Fact000159" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2024-03-31" id="Fact000161" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">714,286</ix:nonFraction></ix:nonFraction></span></span> shares authorized at March 31, 2025 and 2024, respectively, <span id="xdx_90B_eus-gaap--PreferredStockSharesIssued_iI_pip0_do_c20250331_z1I2f59p8Qwj" title="Preferred stock, shares issued"><span id="xdx_903_eus-gaap--PreferredStockSharesOutstanding_iI_pip0_do_c20250331_zcg6EP6A9bw9" title="Preferred stock, shares outstanding"><span id="xdx_90E_eus-gaap--PreferredStockSharesIssued_iI_pip0_do_c20240331_zDBXBTEsZ1qb" title="Preferred stock, shares issued"><span id="xdx_905_eus-gaap--PreferredStockSharesOutstanding_iI_pip0_do_c20240331_zwKP9l3eOhCa" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2025-03-31" id="Fact000163" format="ixt-sec:numwordsen" decimals="INF" scale="0" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2025-03-31" id="Fact000165" format="ixt-sec:numwordsen" decimals="INF" scale="0" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2024-03-31" id="Fact000167" format="ixt-sec:numwordsen" decimals="INF" scale="0" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2024-03-31" id="Fact000169" format="ixt-sec:numwordsen" decimals="INF" scale="0" unitRef="Shares">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> shares issued and outstanding at March 31, 2025 and 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2025-03-31" id="Fact000152" format="ixt:zerodash" decimals="-3" scale="3" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2024-03-31" id="Fact000153" format="ixt:zerodash" decimals="-3" scale="3" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--CommonStockValue_i01I_d0_maCzB1V_zUEwoNZQdjN5" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-indent: -10pt; padding-left: 20pt; text-align: left">Common stock, $<span id="xdx_901_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pip0_c20250331_zP017wn8vrPh" title="Common stock, par value"><span id="xdx_90B_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pip0_c20240331_z9yX0Nxxr4f3" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2025-03-31" id="Fact000174" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2024-03-31" id="Fact000176" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">0.0001</ix:nonFraction></ix:nonFraction></span></span> par value; <span id="xdx_905_eus-gaap--CommonStockSharesAuthorized_iI_pip0_c20250331_zorudfzrBVog" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2025-03-31" id="Fact000178" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">50,000,000</ix:nonFraction></span> and <span id="xdx_907_eus-gaap--CommonStockSharesAuthorized_iI_pip0_c20240331_zmsyDd8F5Gal" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2024-03-31" id="Fact000180" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">24,000,000</ix:nonFraction></span> shares authorized at March 31, 2025 and 2024, respectively, <span id="xdx_903_eus-gaap--CommonStockSharesIssued_iI_pip0_c20250331_zPhhx6guJZG2" title="Common stock, shares issued"><span id="xdx_909_eus-gaap--CommonStockSharesOutstanding_iI_pip0_c20250331_z5Co8AmWea61" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2025-03-31" id="Fact000182" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2025-03-31" id="Fact000184" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">1,634,265</ix:nonFraction></ix:nonFraction></span></span> and <span id="xdx_90D_eus-gaap--CommonStockSharesIssued_iI_pip0_c20240331_zmgvdDNkj83b" title="Common stock, shares issued"><span id="xdx_901_eus-gaap--CommonStockSharesOutstanding_iI_pip0_c20240331_zCxnrLMZc4Ce" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2024-03-31" id="Fact000186" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2024-03-31" id="Fact000188" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">780,371</ix:nonFraction></ix:nonFraction></span></span> shares issued and outstanding at March 31, 2025 and 2024, respectively (Note 1) (Note 12)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2025-03-31" id="Fact000171" format="ixt:zerodash" decimals="-3" scale="3" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2024-03-31" id="Fact000172" format="ixt:zerodash" decimals="-3" scale="3" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AdditionalPaidInCapitalCommonStock_i01I_maCzB1V_zekHZ49k0EHj" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 20pt; text-align: left">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="AsOf2025-03-31" id="Fact000190" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">206,593</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="AsOf2024-03-31" id="Fact000191" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">203,209</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--RetainedEarningsAccumulatedDeficit_i01I_maCzB1V_zHBhLvcDmBxj" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-indent: -10pt; padding-left: 20pt; text-align: left">Accumulated deficit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2025-03-31" id="Fact000193" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">197,806</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2024-03-31" id="Fact000194" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">194,349</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_i01I_maCzB1V_z7UpSNBUzH7l" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 20pt; text-align: left">Accumulated other comprehensive loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="AsOf2025-03-31" id="Fact000196" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,376</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="AsOf2024-03-31" id="Fact000197" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,723</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--StockholdersEquity_i01TI_pn3n3_mtCzB1V_maCzz2O_zaok70s1Jrej" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Total stockholders&#8217; equity</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-03-31" id="Fact000199" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,411</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31" id="Fact000200" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,137</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_pn3n3_mtCzz2O_zgxzPQPtjGOl" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">Total liabilities and stockholders&#8217; equity</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2025-03-31" id="Fact000202" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">13,693</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2024-03-31" id="Fact000203" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14,740</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">The accompanying footnotes are an integral part of
these consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<!-- Field: Page; Sequence: 48 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>SONOMA PHARMACEUTICALS, INC. AND SUBSIDIARIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="k_019"></span>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(In thousands, except per share amounts)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<table cellpadding="0" cellspacing="0" id="xdx_30E_113_pn3n3_zyq1UX3iS5b8" summary="xdx: Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_49D_20240401__20250331_zdBlUIoKVGQb" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_496_20230401__20240331_zeicunqQt0vk" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year ended March 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--Revenues_maCz71J_zokhemXdtbJa" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%">Revenues</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2024-04-01to2025-03-31" id="Fact000205" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">14,288</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2023-04-012024-03-31" id="Fact000206" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">12,735</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--CostOfGoodsAndServicesSold_msCz71J_zmDUFVPgiKt7" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Cost of revenues</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="From2024-04-01to2025-03-31" id="Fact000208" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">8,823</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="From2023-04-012024-03-31" id="Fact000209" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,990</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--GrossProfit_iT_mtCz71J_maCz1rs_zLs35i6Xpuze" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Gross profit</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2024-04-01to2025-03-31" id="Fact000211" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,465</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2023-04-012024-03-31" id="Fact000212" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,745</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--OperatingExpensesAbstract_iB_zfIYmDvFtWQh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Operating expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--ResearchAndDevelopmentExpense_i01_maCzF2f_ztfR0ZoOAcz9" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-04-01to2025-03-31" id="Fact000217" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,814</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-04-012024-03-31" id="Fact000218" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,871</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--SellingGeneralAndAdministrativeExpense_i01_maCzF2f_zryaUzrpQ53k" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Selling, general and administrative</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2024-04-01to2025-03-31" id="Fact000220" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,361</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2023-04-012024-03-31" id="Fact000221" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,575</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OperatingExpenses_iT_mtCzF2f_msCz1rs_zJ47VL1UwCc6" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Total operating expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2024-04-01to2025-03-31" id="Fact000223" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,175</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2023-04-012024-03-31" id="Fact000224" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">9,446</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--OperatingIncomeLoss_iT_mtCz1rs_maCzSg5_zmRTsM6WvXEk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Loss from operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2024-04-01to2025-03-31" id="Fact000226" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,710</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2023-04-012024-03-31" id="Fact000227" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,701</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--OtherOperatingIncomeExpenseNet_maCzSg5_z3GbSvhv7ABe" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Other income (expense), net</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherOperatingIncomeExpenseNet" contextRef="From2024-04-01to2025-03-31" id="Fact000229" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">803</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherOperatingIncomeExpenseNet" contextRef="From2023-04-012024-03-31" id="Fact000230" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">330</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_mtCzSg5_maCzuAX_zD9H9gw1nA75" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Loss from operations before income taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2024-04-01to2025-03-31" id="Fact000232" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,907</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2023-04-012024-03-31" id="Fact000233" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">5,031</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--IncomeTaxExpenseBenefit_iN_pn3n3_di_msCzuAX_zSP0hukvjxNg" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Income tax (expense) benefit</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2024-04-01to2025-03-31" id="Fact000235" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">550</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2023-04-012024-03-31" id="Fact000236" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">196</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--NetIncomeLoss_iT_mtCzuAX_zT9Y71lRDiKh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-04-01to2025-03-31" id="Fact000238" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,457</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-04-012024-03-31" id="Fact000239" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,835</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Net loss per share: basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_904_eus-gaap--EarningsPerShareBasic_pip0_c20240401__20250331_zlHwpmXZrbDc" title="Net loss per share: basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ09OU09MSURBVEVEIFNUQVRFTUVOVFMgT0YgQ09NUFJFSEVOU0lWRSBMT1NTAA__"><span id="xdx_904_eus-gaap--EarningsPerShareDiluted_pip0_c20240401__20250331_ztkScawLpcae" title="Net loss per share: diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ09OU09MSURBVEVEIFNUQVRFTUVOVFMgT0YgQ09NUFJFSEVOU0lWRSBMT1NTAA__">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2024-04-01to2025-03-31" id="Fact000241" format="ixt:numdotdecimal" decimals="INF" scale="0" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2024-04-01to2025-03-31" id="Fact000243" format="ixt:numdotdecimal" decimals="INF" scale="0" sign="-" unitRef="USDPShares">2.79</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_906_eus-gaap--EarningsPerShareBasic_pip0_c20230401__20240331_zbx9XjVYq3B4" title="Net loss per share: basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ09OU09MSURBVEVEIFNUQVRFTUVOVFMgT0YgQ09NUFJFSEVOU0lWRSBMT1NTAA__"><span id="xdx_903_eus-gaap--EarningsPerShareDiluted_pip0_c20230401__20240331_zECCQbcTibCh" title="Net loss per share: diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ09OU09MSURBVEVEIFNUQVRFTUVOVFMgT0YgQ09NUFJFSEVOU0lWRSBMT1NTAA__">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2023-04-012024-03-31" id="Fact000245" format="ixt:numdotdecimal" decimals="INF" scale="0" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-04-012024-03-31" id="Fact000247" format="ixt:numdotdecimal" decimals="INF" scale="0" sign="-" unitRef="USDPShares">10.63</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Weighted-average shares outstanding: basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20240401__20250331_zrO9BBZDJYfk" title="Weighted-average number of shares: basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ09OU09MSURBVEVEIFNUQVRFTUVOVFMgT0YgQ09NUFJFSEVOU0lWRSBMT1NTAA__"><span id="xdx_90C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20240401__20250331_zTyRV3v0jxQ8" title="Weighted-average number of shares: diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ09OU09MSURBVEVEIFNUQVRFTUVOVFMgT0YgQ09NUFJFSEVOU0lWRSBMT1NTAA__"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-04-01to2025-03-31" id="Fact000249" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-04-01to2025-03-31" id="Fact000251" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">1,241</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90C_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20230401__20240331_zJ9BqNyfWs1a" title="Weighted-average number of shares: basic" class="xdx_phnt_U3RhdGVtZW50IC0gQ09OU09MSURBVEVEIFNUQVRFTUVOVFMgT0YgQ09NUFJFSEVOU0lWRSBMT1NTAA__"><span id="xdx_90F_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20230401__20240331_zzEESqAG0c7f" title="Weighted-average number of shares: diluted" class="xdx_phnt_U3RhdGVtZW50IC0gQ09OU09MSURBVEVEIFNUQVRFTUVOVFMgT0YgQ09NUFJFSEVOU0lWRSBMT1NTAA__"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-04-012024-03-31" id="Fact000253" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-04-012024-03-31" id="Fact000255" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">455</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--OtherComprehensiveIncomeLossTaxAbstract_iB_zIzD4H9rjVdl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other comprehensive loss:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--NetIncomeLoss_i01_maCzeUq_zOfwUGxXLeY" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left">Net loss</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-04-01to2025-03-31" id="Fact000260" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,457</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-04-012024-03-31" id="Fact000261" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,835</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent_i01_maCzeUq_zVtjsbSmhXEd" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Foreign currency translation adjustments</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" contextRef="From2024-04-01to2025-03-31" id="Fact000263" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,653</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" contextRef="From2023-04-012024-03-31" id="Fact000264" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">695</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_iT_mtCzeUq_zfMhoZaYryej" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 2.5pt">Comprehensive loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="From2024-04-01to2025-03-31" id="Fact000266" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">5,110</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="From2023-04-012024-03-31" id="Fact000267" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,140</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">The accompanying footnotes are an integral part of
these consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<!-- Field: Page; Sequence: 49 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>SONOMA PHARMACEUTICALS, INC. AND SUBSIDIARIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="k_020"></span>CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS&#8217;
EQUITY</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>For the Years Ended March 31, 2025 and 2024</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(In thousands, except share amounts)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" id="xdx_309_114_pn3n3_zwTSYnLvadN8" summary="xdx: Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" id="xdx_4B3_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zarXD5vRWZei" style="text-align: center"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" id="xdx_4BF_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_z8UwNNkOqbI3" style="text-align: center"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" id="xdx_4B3_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_z1qXLsAfn4Ef" style="text-align: center"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" id="xdx_4BC_us-gaap--StatementEquityComponentsAxis_us-gaap--AccumulatedOtherComprehensiveIncomeMember_zVOaNQCWcJl1" style="text-align: center"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" id="xdx_4B0_z8Xw7wJdeUya" style="text-align: center"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 9pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 9pt">Common
    Stock<br/> ($0.0001 par Value)</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 9pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center"><span style="font-size: 9pt">Additional<br/> Paid
    in</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 9pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center"><span style="font-size: 9pt">Accumulated</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 9pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center"><span style="font-size: 9pt">Accumulated Other
    Comprehensive</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2"><span style="font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 9pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 9pt">Shares</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 9pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 9pt">Amount</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 9pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 9pt">Capital</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 9pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 9pt">Deficit</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 9pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 9pt">Loss</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 9pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font-size: 9pt">Total</span></td><td style="padding-bottom: 1pt; font-weight: bold"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_433_c20230401__20240331_eus-gaap--StockholdersEquity_iS_z9EF0asuOtmc" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 34%"><span style="font-size: 9pt">Balance, March 31, 2023</span></td><td style="width: 1%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_989_eus-gaap--SharesOutstanding_iS_pip0_c20230401__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zSkUMpEf9mO5" title="Beginning balance, shares" style="width: 8%; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-03-31_us-gaap_CommonStockMember" id="Fact000275" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">246,678</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 9pt">$</span></td><td style="width: 8%; text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0269">&#8211;</span></span></td><td style="width: 1%; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 9pt">$</span></td><td style="width: 8%; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000270" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">200,909</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 9pt">$</span></td><td style="width: 8%; text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_us-gaap_RetainedEarningsMember" id="Fact000271" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">189,514</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 9pt">)</span></td><td style="width: 1%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 9pt">$</span></td><td style="width: 8%; text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000272" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,418</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 9pt">)</span></td><td style="width: 1%"><span style="font-size: 9pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 9pt">$</span></td><td style="width: 8%; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-03-31" id="Fact000273" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">7,977</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zBVB1OykfqV9" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt; text-align: left"><span style="font-size: 9pt">Proceeds from the sale of common stock, net of offering expenses</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20230401__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zeO76WjgGhgb" title="Proceeds from the sale of common stock, net of offering expenses, shares" style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-04-012024-03-31_us-gaap_CommonStockMember" id="Fact000283" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">425,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0277">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-04-012024-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000278" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,446</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0279">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0280">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-04-012024-03-31" id="Fact000281" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,446</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_40F_ecustom--StockIssuedDuringPeriodValueNewIssues1_zigZN3F7Fuhf" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-indent: -10pt; padding-left: 10pt; text-align: left"><span style="font-size: 9pt">Proceeds from the At-the-Market sale of common stock, net of offering expenses</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_982_ecustom--StockIssuedDuringPeriodSharesNewIssues1_pip0_c20230401__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ziQoIn7WzVHe" title="Proceeds from the At-the-Market sale of common stock, net of offering expenses, shares" style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="SNOA:StockIssuedDuringPeriodSharesNewIssues1" contextRef="From2023-04-012024-03-31_us-gaap_CommonStockMember" id="Fact000291" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">96,154</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0285">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="SNOA:StockIssuedDuringPeriodValueNewIssues1" contextRef="From2023-04-012024-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000286" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">338</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0287">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0288">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="SNOA:StockIssuedDuringPeriodValueNewIssues1" contextRef="From2023-04-012024-03-31" id="Fact000289" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">338</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zUihzD9NkHRg" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt; text-align: left"><span style="font-size: 9pt">Employee stock-based compensation</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0293">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-04-012024-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000294" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">255</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0295">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0296">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2023-04-012024-03-31" id="Fact000297" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">255</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_zRsXiVHsc25h" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-indent: -10pt; padding-left: 10pt; text-align: left"><span style="font-size: 9pt">Stock based compensation related to restricted stock grants</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_98C_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pip0_c20230401__20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zyQ9pwMhyYU3" title="Stock based compensation related to restricted stock grants, shares" style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2023-04-012024-03-31_us-gaap_CommonStockMember" id="Fact000305" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">12,539</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0299">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2023-04-012024-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000300" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">261</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0301">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0302">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2023-04-012024-03-31" id="Fact000303" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">261</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_zxRZzsdzC3s4" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt; text-align: left"><span style="font-size: 9pt">Foreign currency translation adjustment</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0307">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0308">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0309">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="From2023-04-012024-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000310" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">695</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="From2023-04-012024-03-31" id="Fact000311" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">695</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--NetIncomeLoss_z8l7H4id7lx7" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-size: 9pt">Net loss</span></td><td style="padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt">&#8211;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0313">&#8211;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0314">&#8211;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-04-012024-03-31_us-gaap_RetainedEarningsMember" id="Fact000315" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,835</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 9pt">)</span></td><td style="padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0316">&#8211;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-04-012024-03-31" id="Fact000317" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,835</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 9pt">)</span></td></tr>
  <tr id="xdx_439_c20240401__20250331_eus-gaap--StockholdersEquity_iS_zwwJHoNZ6Jz7" style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 9pt">Balance, March 31, 2024</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_98A_eus-gaap--SharesOutstanding_iS_pip0_c20240401__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zq3ABM5SMmQg" title="Beginning balance, shares" style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-03-31_us-gaap_CommonStockMember" id="Fact000325" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">780,371</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0319">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000320" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">203,209</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31_us-gaap_RetainedEarningsMember" id="Fact000321" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">194,349</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">)</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000322" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,723</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">)</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-03-31" id="Fact000323" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">6,137</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_403_ecustom--StockIssuedDuringPeriodValueNewIssues1_z4njBv3gMjU4" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-indent: -10pt; padding-left: 10pt; text-align: left"><span style="font-size: 9pt">Proceeds from the At-the-Market sale of common stock, net of offering expenses</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_98C_ecustom--StockIssuedDuringPeriodSharesNewIssues1_pip0_c20240401__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z6MINHtFWCMa" title="Proceeds from the At-the-Market sale of common stock, net of offering expenses, shares" style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="SNOA:StockIssuedDuringPeriodSharesNewIssues1" contextRef="From2024-04-012025-03-31_us-gaap_CommonStockMember" id="Fact000333" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">816,894</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0327">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="SNOA:StockIssuedDuringPeriodValueNewIssues1" contextRef="From2024-04-012025-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000328" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,079</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0329">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0330">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="SNOA:StockIssuedDuringPeriodValueNewIssues1" contextRef="From2024-04-01to2025-03-31" id="Fact000331" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,079</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_407_ecustom--StockIssuedDuringPeriodValueReverseStockSplits_iNP3custom--ProceedsFromAtthemarketSaleOfCommonStockNetOfOfferingExpensesShares_di_zeGklS369VPd" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt; text-align: left"><span style="font-size: 9pt">Payments for fractional shares related to reverse-split</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesReverseStockSplits_iNP3custom--StockIssuedDuringPeriodValuesReverseStockSplits_pip0_di_c20240401__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zzDJRwpXAB76" title="Payments for fractional shares related to reverse-split, shares" style="text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits" contextRef="From2024-04-012025-03-31_us-gaap_CommonStockMember" id="Fact000341" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">288</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">)</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0335">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="SNOA:StockIssuedDuringPeriodValueReverseStockSplits" contextRef="From2024-04-012025-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000336" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">)</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0337">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0338">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="SNOA:StockIssuedDuringPeriodValueReverseStockSplits" contextRef="From2024-04-01to2025-03-31" id="Fact000339" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">)</span></td></tr>
  <tr id="xdx_406_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_iP3us-gaap--StockIssuedDuringPeriodSharesReverseStockSplits_zzm6NhCkkCB9" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-indent: -10pt; padding-left: 10pt; text-align: left"><span style="font-size: 9pt">Proceeds from the exercise of employee stock options</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iP3us-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_pip0_c20240401__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zqPOyGFkc8X4" title="Proceeds from the exercise of employee stock options, shares" style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2024-04-012025-03-31_us-gaap_CommonStockMember" id="Fact000349" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">27,750</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0343">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2024-04-012025-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000344" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">82</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0345">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0346">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2024-04-01to2025-03-31" id="Fact000347" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">82</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zVxc56FGvGL3" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt; text-align: left"><span style="font-size: 9pt">Employee stock-based compensation</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0351">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-04-012025-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000352" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">170</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0353">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0354">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2024-04-01to2025-03-31" id="Fact000355" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">170</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_zg3EkGDzJH7d" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-indent: -10pt; padding-left: 10pt; text-align: left"><span style="font-size: 9pt">Stock based compensation related to restricted stock grants</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pip0_c20240401__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zh4oJGDaxBlk" title="Stock based compensation related to restricted stock grants, shares" style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2024-04-012025-03-31_us-gaap_CommonStockMember" id="Fact000363" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">9,538</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0357">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2024-04-012025-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000358" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">54</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0359">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0360">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2024-04-01to2025-03-31" id="Fact000361" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">54</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_z7A4UgT3nGki" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -10pt; padding-left: 10pt; text-align: left"><span style="font-size: 9pt">Foreign currency translation adjustment</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">&#8211;</span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0365">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0366">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0367">&#8211;</span></span></td><td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="From2024-04-012025-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000368" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,653</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">)</span></td><td><span style="font-size: 9pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="From2024-04-01to2025-03-31" id="Fact000369" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,653</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 9pt">)</span></td></tr>
  <tr id="xdx_400_eus-gaap--NetIncomeLoss_zatIlUB3MRni" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font-size: 9pt">Net loss</span></td><td style="padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt">&#8211;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0371">&#8211;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0372">&#8211;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-04-012025-03-31_us-gaap_RetainedEarningsMember" id="Fact000373" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,457</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 9pt">)</span></td><td style="padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0374">&#8211;</span></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-04-01to2025-03-31" id="Fact000375" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,457</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font-size: 9pt">)</span></td></tr>
  <tr id="xdx_439_c20240401__20250331_eus-gaap--StockholdersEquity_iE_z9ak94tbsE8k" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="font-size: 9pt">Balance, March 31, 2025</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td id="xdx_980_eus-gaap--SharesOutstanding_iE_pip0_c20240401__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z9t4Qmidg9f7" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2025-03-31_us-gaap_CommonStockMember" id="Fact000383" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">1,634,265</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt"><span style="-sec-ix-hidden: xdx2ixbrl0377">&#8211;</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-03-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000378" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">206,593</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-03-31_us-gaap_RetainedEarningsMember" id="Fact000379" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">197,806</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 9pt">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000380" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,376</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 9pt">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 9pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 9pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 9pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2025-03-31" id="Fact000381" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">4,411</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 9pt">&#160;</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">The accompanying footnotes are an integral part of
these consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<!-- Field: Page; Sequence: 50 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>SONOMA PHARMACEUTICALS, INC. AND SUBSIDIARIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="k_021"></span>CONSOLIDATED STATEMENTS OF CASH FLOWS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>(In&#160;thousands)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<table cellpadding="0" cellspacing="0" id="xdx_309_112_pn3n3_znfyvFKj3Zsk" summary="xdx: Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_498_20240401__20250331_z2z6NRk0CHA2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_49A_20230401__20240331_z7ts1wqzoKp8" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Year Ended </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>March 31,</b></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_zOklIPBTVudh" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="font-weight: bold; text-align: left">Cash flows from operating activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--NetIncomeLoss_maCzZvW_ze6K8gkhD5Wj" style="vertical-align: bottom; background-color: White">
    <td style="width: 66%; text-align: left">Net loss</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-04-01to2025-03-31" id="Fact000388" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,457</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-04-012024-03-31" id="Fact000389" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,835</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_iB_zV3XNO6yObba" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Adjustments to reconcile net loss to net cash used in operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--Depreciation_i01_maCzZvW_zWCUiYjcY9xg" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2024-04-01to2025-03-31" id="Fact000394" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">138</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2023-04-012024-03-31" id="Fact000395" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">176</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--ShareBasedCompensation_i01_maCzZvW_zkioSrDPGKN7" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-04-01to2025-03-31" id="Fact000397" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">224</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-04-012024-03-31" id="Fact000398" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">516</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--IncreaseDecreaseInDeferredIncomeTaxes_i01N_di_msCzZvW_zJtqTFahm4W4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Deferred income tax expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" contextRef="From2024-04-01to2025-03-31" id="Fact000400" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">357</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" contextRef="From2023-04-012024-03-31" id="Fact000401" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">109</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--IncreaseDecreaseInOtherOperatingAssets_i01N_di_msCzZvW_zXdLf76Tf8jl" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left">Operating lease right-of-use asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" contextRef="From2024-04-01to2025-03-31" id="Fact000403" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">174</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" contextRef="From2023-04-012024-03-31" id="Fact000404" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">161</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_iB_z0ru5Zeg9um6" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Changes in operating assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--IncreaseDecreaseInAccountsReceivable_i01N_di_msCzZvW_zHNJLkhFZTKc" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 20pt; text-align: left">Accounts receivable, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2024-04-01to2025-03-31" id="Fact000409" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">434</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2023-04-012024-03-31" id="Fact000410" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">230</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--IncreaseDecreaseInInventories_i01N_di_msCzZvW_zOGPhhd55925" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Inventories, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="From2024-04-01to2025-03-31" id="Fact000412" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">388</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="From2023-04-012024-03-31" id="Fact000413" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">184</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--IncreaseDecreaseInPrepaidExpense_i01N_di_msCzZvW_zBntPoPzifJg" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 20pt; text-align: left">Prepaid expenses and other current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="From2024-04-01to2025-03-31" id="Fact000415" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,086</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="From2023-04-012024-03-31" id="Fact000416" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">1,107</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--IncreaseDecreaseInDeferredCompensation_i01_maCzZvW_zqS6AKc2Jz68" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Deferred consideration, net of discount</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInDeferredCompensation" contextRef="From2024-04-01to2025-03-31" id="Fact000418" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">194</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInDeferredCompensation" contextRef="From2023-04-012024-03-31" id="Fact000419" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">222</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--IncreaseDecreaseInOtherAccountsPayable_i01_maCzZvW_z1eB60KmBY7l" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 20pt; text-align: left">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherAccountsPayable" contextRef="From2024-04-01to2025-03-31" id="Fact000421" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">416</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherAccountsPayable" contextRef="From2023-04-012024-03-31" id="Fact000422" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">278</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_i01_maCzZvW_ziMlUxiCsnoi" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Accrued expenses and other current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" contextRef="From2024-04-01to2025-03-31" id="Fact000424" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">295</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" contextRef="From2023-04-012024-03-31" id="Fact000425" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">19</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--IncreaseDecreaseInWithholdingTaxPayable_i01_maCzZvW_z39BJ1xsx1Jl" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 20pt; text-align: left">Withholding tax payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SNOA:IncreaseDecreaseInWithholdingTaxPayable" contextRef="From2024-04-01to2025-03-31" id="Fact000427" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">432</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SNOA:IncreaseDecreaseInWithholdingTaxPayable" contextRef="From2023-04-012024-03-31" id="Fact000428" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">475</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--IncreaseDecreaseInOperatingLeaseLiability_i01_maCzZvW_z5lCIBGuFTg9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Operating lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2024-04-01to2025-03-31" id="Fact000430" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">174</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2023-04-012024-03-31" id="Fact000431" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">161</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--IncreaseDecreaseInContractWithCustomerLiability_i01_maCzZvW_zGwIAc8PtWU" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1pt">Deferred revenue</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="From2024-04-01to2025-03-31" id="Fact000433" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">181</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="From2023-04-012024-03-31" id="Fact000434" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">355</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iT_pn3n3_mtCzZvW_maCzruR_zKlhMcmA4SLg" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 30pt; text-align: left; padding-bottom: 1pt">Net cash used in operating activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2024-04-01to2025-03-31" id="Fact000436" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">88</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2023-04-012024-03-31" id="Fact000437" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2,398</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_zn3gPaDrz54c" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="font-weight: bold; text-align: left">Cash flows from investing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_i01N_di_msCz64W_zw9VoOAtXfQ7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Purchases of property and equipment</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2024-04-01to2025-03-31" id="Fact000442" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">80</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2023-04-012024-03-31" id="Fact000443" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--NetCashProvidedByUsedInInvestingActivities_iT_mtCz64W_maCzruR_zIubEC2UNPg" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 30pt; text-align: left; padding-bottom: 1pt">Net cash used in investing activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2024-04-01to2025-03-31" id="Fact000445" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">80</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2023-04-012024-03-31" id="Fact000446" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">2</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_zUUE1cRsP9vd" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Cash flows from financing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--ProceedsFromIssuanceOfCommonStock_i01_pn3n3_maCzj8v_zMEh7vWfM435" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left">Proceeds from issuance of common stock, net of offering expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2024-04-01to2025-03-31" id="Fact000451" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,079</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2023-04-012024-03-31" id="Fact000452" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,784</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--ProceedsFromStockOptionsExercised_i01_d0_maCzj8v_zqRZxIDmRxie" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Proceeds from exercise of employee stock options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="From2024-04-01to2025-03-31" id="Fact000454" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">82</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="From2023-04-012024-03-31" id="Fact000455" format="ixt:zerodash" decimals="-3" scale="3" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--PaymentsForFractionalSharesRelatedToReversesplit_i01N_di0_msCzj8v_zS3JmOlzlaVd" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left">Payments for fractional shares related to reverse-split</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="SNOA:PaymentsForFractionalSharesRelatedToReversesplit" contextRef="From2024-04-01to2025-03-31" id="Fact000457" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="SNOA:PaymentsForFractionalSharesRelatedToReversesplit" contextRef="From2023-04-012024-03-31" id="Fact000458" format="ixt:zerodash" decimals="-3" scale="3" sign="-" unitRef="USD">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--RepaymentsOfOtherShortTermDebt_i01N_di_msCzj8v_zGr7J7W53PS7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Principal payments on short-term debt</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:RepaymentsOfOtherShortTermDebt" contextRef="From2024-04-01to2025-03-31" id="Fact000460" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">404</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:RepaymentsOfOtherShortTermDebt" contextRef="From2023-04-012024-03-31" id="Fact000461" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">481</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_ecustom--ProceedsFromInsurancePremiumsFinanced_i01_maCzj8v_z27n4GvfMPHk" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Insurance premiums financed</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="SNOA:ProceedsFromInsurancePremiumsFinanced" contextRef="From2024-04-01to2025-03-31" id="Fact000463" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">274</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="SNOA:ProceedsFromInsurancePremiumsFinanced" contextRef="From2023-04-012024-03-31" id="Fact000464" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">373</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--NetCashProvidedByUsedInFinancingActivities_iT_pn3n3_mtCzj8v_maCzruR_z13pc3wKcLL5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 30pt; text-align: left">Net cash provided by financing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2024-04-01to2025-03-31" id="Fact000466" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,030</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2023-04-012024-03-31" id="Fact000467" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,676</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_maCzruR_zo5BTsNgmrdc" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Effect of exchange rate on cash and cash equivalents</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="From2024-04-01to2025-03-31" id="Fact000469" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">616</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="From2023-04-012024-03-31" id="Fact000470" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">32</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_iT_mtCzruR_zVuYFxCgBev" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net increase (decrease) in cash and cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2024-04-01to2025-03-31" id="Fact000472" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">2,246</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2023-04-012024-03-31" id="Fact000473" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">692</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iS_zHAsE8QsxHbb" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Cash and cash equivalents, beginning of year</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2024-03-31" id="Fact000475" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,128</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2023-03-31" id="Fact000476" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,820</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iE_z3JufGbkn7n2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Cash and cash equivalents, end of year</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2025-03-31" id="Fact000478" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">5,374</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2024-03-31" id="Fact000479" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,128</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--SupplementalCashFlowInformationAbstract_iB_zpu10bSTgt8f" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Supplemental disclosure of cash flow information:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--InterestPaidNet_i01_zrSvo0QER8Ql" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 2.5pt">Cash paid for interest</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2024-04-01to2025-03-31" id="Fact000484" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">11</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2023-04-012024-03-31" id="Fact000485" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">22</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_iB_zJ6GCkLt6Mbc" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="font-weight: bold; text-align: left">Non-cash operating and financing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--InsurancePremiumsFinanced_i01_zveAbHCzLLd4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Insurance premiums financed</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="SNOA:InsurancePremiumsFinanced" contextRef="From2024-04-01to2025-03-31" id="Fact000490" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">274</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="SNOA:InsurancePremiumsFinanced" contextRef="From2023-04-012024-03-31" id="Fact000491" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">373</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">The accompanying footnotes are an integral part of
these consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 51 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>SONOMA PHARMACEUTICALS, INC. AND SUBSIDIARIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="k_022"></span>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<ix:nonNumeric contextRef="From2024-04-01to2025-03-31" escape="true" id="Fact000493" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"><p id="xdx_80C_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zWw5nTTD2XO7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE&#160;1&#160;&#8211; <span id="xdx_82F_zC3DfNmjUtu3">Organization and Recent
Developments</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Organization</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Sonoma Pharmaceuticals, Inc. (the &#8220;Company&#8221;)
was incorporated under the laws of the State of California in April 1999 and was reincorporated under the laws of the State of Delaware
in December 2006. The Company moved its principal office from Petaluma, California to Woodstock, Georgia in June 2020 and to Boulder,
Colorado in October 2022. The Company is a global healthcare leader for developing and producing stabilized hypochlorous acid (&#8220;HOCl&#8221;)
products for a wide range of applications, including wound care, eye, oral and nasal care, dermatological conditions, podiatry, animal
health care, and as a non-toxic disinfectant. The Company&#8217;s products are clinically proven to reduce itch, pain, scarring, and irritation
safely and without damaging healthy tissue. In-vitro and clinical studies of HOCl show it to safely manage skin abrasions, lacerations,
minor irritations, cuts, and intact skin. The Company sells its products either directly or via partners in 55 countries worldwide.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Reverse Stock Split</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Effective August 29, 2024, the Company effected a
reverse stock split of its common stock, par value $0.0001 per share. Every twenty shares of common stock were reclassified and combined
into one share of common stock. No fractional shares were issued as a result of the reverse stock split. Instead, each fractional share
was settled with cash. The reverse stock split reduced the number of shares of the Company&#8217;s common stock outstanding from <span id="xdx_902_eus-gaap--CommonStockSharesOutstanding_iI_c20240828_zLcrIUVAGuY7" title="Common stock outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2024-08-28" id="Fact000495" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">21,174,693</ix:nonFraction></span>
to <span id="xdx_905_eus-gaap--CommonStockSharesOutstanding_iI_c20240829_zp1zq9E67jSc" title="Common stock outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2024-08-29" id="Fact000497" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,058,447</ix:nonFraction></span>. The total number of authorized shares of common stock was not proportionally decreased and the par value per share of the
common stock continues to be $0.0001. The reverse stock split has been retroactively applied to all share and per share amounts in the
consolidated financial statements and accompanying footnotes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-04-01to2025-03-31" escape="true" id="Fact000499" name="us-gaap:SubstantialDoubtAboutGoingConcernTextBlock"><p id="xdx_80E_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_zVYSDyEUIFBf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE&#160;2&#160;&#8211; <span id="xdx_824_zvtIywnGNETg">Liquidity and Financial
Condition</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company reported a net loss of $<span id="xdx_907_eus-gaap--NetIncomeLoss_iN_pn3d_di_c20240401__20250331_zkAVQdrogdM1" title="Net loss"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-04-01to2025-03-31" id="Fact000501" format="ixt:numdotdecimal" decimals="-3" sign="-" unitRef="USD">3,457,000</ix:nonFraction></span> and
$<span id="xdx_902_eus-gaap--NetIncomeLoss_iN_pn3d_di_c20230401__20240331_zo9lYkMPw6E6" title="Net loss"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-04-012024-03-31" id="Fact000503" format="ixt:numdotdecimal" decimals="-3" sign="-" unitRef="USD">4,835,000</ix:nonFraction></span> for the years ended March 31, 2025 and 2024, respectively. At March 31, 2025 and 2024, the Company&#8217;s accumulated deficit
amounted to $<span id="xdx_90C_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn3d_di_c20250331_zY7G5dAk9iBg" title="Accumulated deficit"><ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2025-03-31" id="Fact000505" format="ixt:numdotdecimal" decimals="-3" sign="-" unitRef="USD">197,806,000</ix:nonFraction></span> and $<span id="xdx_905_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn3d_di_c20240331_zPy8nBijmeXd" title="Accumulated deficit"><ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2024-03-31" id="Fact000507" format="ixt:numdotdecimal" decimals="-3" sign="-" unitRef="USD">194,349,000</ix:nonFraction></span>, respectively. The Company had working capital of $<span id="xdx_903_ecustom--WorkingCapital_iI_pn3d_c20250331_zhIEi1pBPDij" title="Working capital"><ix:nonFraction name="SNOA:WorkingCapital" contextRef="AsOf2025-03-31" id="Fact000509" format="ixt:numdotdecimal" decimals="-3" unitRef="USD">8,552,000</ix:nonFraction></span> and $<span id="xdx_90E_ecustom--WorkingCapital_iI_pn3d_c20240331_zFwcigRl0Hm9" title="Working capital"><ix:nonFraction name="SNOA:WorkingCapital" contextRef="AsOf2024-03-31" id="Fact000511" format="ixt:numdotdecimal" decimals="-3" unitRef="USD">8,829,000</ix:nonFraction></span> as of March 31,
2025 and 2024, respectively. During the years ended March 31, 2025 and 2024, net cash used in operating activities amounted to $<span id="xdx_901_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn3d_di_c20240401__20250331_zxNWV6j7Hlkb" title="Net cash used in operating activities"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2024-04-01to2025-03-31" id="Fact000513" format="ixt:numdotdecimal" decimals="-3" sign="-" unitRef="USD">88,000</ix:nonFraction></span>
and $<span id="xdx_902_eus-gaap--NetCashProvidedByUsedInOperatingActivities_pn3d_di_c20230401__20240331_zPpq9JAUOs3l" title="Net cash used in operating activities"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2023-04-012024-03-31" id="Fact000515" format="ixt:numdotdecimal" decimals="-3" sign="-" unitRef="USD">2,398,000</ix:nonFraction></span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Management believes that the Company has access to
additional capital resources through possible public or private equity offerings, debt financings, corporate collaborations or other means;
however, the Company cannot provide any assurance that other new financings will be available on commercially acceptable terms, if needed.
If the economic climate in the U.S. deteriorates, the Company&#8217;s ability to raise additional capital could be negatively impacted.
If the Company is unable to secure additional capital, it may be required to take additional measures to reduce costs in order to conserve
its cash in amounts sufficient to sustain operations and meet its obligations. These measures could cause significant delays in the Company&#8217;s
continued efforts to commercialize its products, which is critical to the realization of its business plan and the future operations of
the Company. This uncertainty along with the Company&#8217;s history of losses indicates that there is substantial doubt about the Company&#8217;s
ability to continue as a going concern within one year after the date that the financial statements are issued. The accompanying consolidated
financial statements do not include any adjustments that may be necessary should the Company be unable to continue as a going concern.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_235_zxnHSMrzkUIi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23D_z4VytCiGuZof" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_236_zq9FjlV142y1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 52 -->
    <div id="xdx_238_zePXKkpWXEXl" style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_230_zNaaZpM15Xl9" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23F_zam0nNrnxM4l" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-04-01to2025-03-31" escape="true" id="Fact000521" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p id="xdx_806_eus-gaap--SignificantAccountingPoliciesTextBlock_zhHolBDxX8Tk" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE&#160;3&#160;&#8211; <span id="xdx_821_zALFjH70BR3h">Summary of Significant Accounting Policies</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<ix:nonNumeric contextRef="From2024-04-01to2025-03-31" escape="true" id="Fact000523" name="us-gaap:ConsolidationPolicyTextBlock"><p id="xdx_841_eus-gaap--ConsolidationPolicyTextBlock_zFCMgRfKpc75" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_867_zWUv3pyVpebg">Principles of Consolidation</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying consolidated financial statements
include the accounts of the Company and its wholly-owned subsidiaries, Aquamed Technologies, Inc. (&#8220;Aquamed&#8221;), Oculus Technologies
of Mexico S.A. de C.V. (&#8220;OTM&#8221;), and Sonoma Pharmaceuticals Netherlands, B.V. (&#8220;SP Europe&#8221;). Aquamed has no current
operations. All significant intercompany accounts and transactions have been eliminated in consolidation. The functional currency for
the Company's wholly-owned subsidiaries incorporated outside the United States (&#8220;U.S.&#8221;) is denominated in local currency.
All intercompany transactions and balances have been eliminated in consolidation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-04-01to2025-03-31" escape="true" id="Fact000525" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock"><p id="xdx_840_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zWO4SrWVIK9i" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i><span id="xdx_86E_z0OSA6GpE8dk">Basis of presentation</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying consolidated financial statements
have been prepared by the Company pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;)
and are in conformity with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;). The Company&#8217;s fiscal year end is
March 31. Unless otherwise stated, all years and dates refer to the fiscal year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i></i></b></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-04-01to2025-03-31" escape="true" id="Fact000527" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p id="xdx_845_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zbi6hHFy5V1j" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i><span id="xdx_86D_z1JpcBObEDKg">Cash and Cash Equivalents</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Cash and cash equivalents include cash on hand and
all highly liquid investments with an original maturity of three months or less when purchased. The Company&#8217;s cash equivalents are
held in prime money market investments with strong sponsor organizations which are monitored on a continuous basis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-04-01to2025-03-31" escape="true" id="Fact000529" name="us-gaap:UseOfEstimates"><p id="xdx_84E_eus-gaap--UseOfEstimates_zARxaseIFqd9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_86C_zuboPzXHnq0j">Use of Estimates</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of consolidated financial statements
in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities
and disclosures of contingent liabilities at the dates of the consolidated financial statements and the reported amounts of revenues and
expenses during the reporting periods. Actual results could differ from these estimates. Significant estimates and assumptions include
reserves and write-downs related to receivables and inventories, the valuation allowance relating to the Company&#8217;s deferred tax
assets and the valuation of equity. Periodically, the Company evaluates and adjusts estimates accordingly.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-04-01to2025-03-31" escape="true" id="Fact000531" name="us-gaap:RevenueRecognitionPolicyTextBlock"><p id="xdx_84A_eus-gaap--RevenueRecognitionPolicyTextBlock_z1wMiCXxsrO2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_863_z48omwCJAjZ">Revenue Recognition</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recognizes revenue in accordance with
Accounting Standards Codification (&#8220;ASC&#8221;), Topic 606 Revenue from Contracts with Customers (&#8220;Topic 606&#8221;). Revenue
is recognized when the Company transfers promised goods or services to the customer, in an amount that reflects the consideration which
the Company expects to receive in exchange for those goods or services. In determining the appropriate amount of revenue to be recognized
as the Company fulfills its obligations under the agreement, the Company performs the following steps: (i)&#160;identification of the
promised goods or services in the contract; (ii)&#160;determination of whether the promised goods or services are performance obligations,
including whether they are distinct in the context of the contract; (iii)&#160;measurement of the transaction price, including the constraint
on variable consideration; (iv)&#160;allocation of the transaction price to the performance obligations; and (v)&#160;recognition of revenue
when (or as) the Company satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable
that it will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company derives the majority of its revenue through
sales of its products directly to end users and to distributors. The Company also sells products to a customer base, including hospitals,
medical centers, doctors, pharmacies, distributors and wholesalers. The Company has also entered into agreements to license its technology
and products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_232_zKlGCGBsrJ8e" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_237_zKEF0Sqf6qdg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23F_znuSC6xkgLx1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 53 -->
    <div id="xdx_238_zhKITyzhADte" style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_234_zVfWTdK0PVrc" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23A_zgg6qzUra0P8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company considers customer purchase orders, which
in some cases are governed by master sales agreements, to be the contracts with a customer. For each contract, the Company considers the
promise to transfer products, each of which are distinct, to be the identified performance obligations. In determining the transaction
price the Company evaluates whether the price is subject to refund or adjustment to determine the net consideration to which it expects
to be entitled.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For all of the Company&#8217;s sales to non-consignment
distribution channels, revenue is recognized when control of the product is transferred to the customer (i.e. when its performance obligation
is satisfied), which typically occurs when title passes to the customer upon shipment but could occur when the customer receives the product
based on the terms of the agreement with the customer. For product sales to its value-added resellers, non-stocking distributors and end-user
customers, the Company grants return privileges to its customers, and because the Company has a long history with its customers, the Company
is able to estimate the amount of product that will be returned.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has entered into consignment arrangements,
in which goods are left in the possession of another party to sell. As products are sold from the customer to third parties, the Company
recognizes revenue based on a variable percentage of a fixed price.&#160; Revenue recognized varies depending on whether a patient is
covered by insurance or is not covered by insurance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Sales to stocking distributors are made under terms
with fixed pricing and limited rights of return (known as &#8220;stock rotation&#8221;) of the Company&#8217;s products held in their
inventory. Revenue from sales to distributors is recognized upon the transfer of control to the distributor.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company assessed the promised goods and services
in the technical support contract with Invekra for a ten-year period as being a distinct service that Invekra can benefit from on its
own and as separately identifiable from any other promises within the contract. Given that the distinct service is not substantially the
same as other goods and services within the Invekra contract, the Company accounted for the distinct service as a performance obligation.
At March 31, 2025, 2024 and 2023, the Company had deferred revenue related to Invekra in the amounts of $<span id="xdx_90A_eus-gaap--DeferredRevenue_iI_c20250331__srt--CounterpartyNameAxis__custom--InvekraMember_zO9rRnEo6sg6" title="Deferred revenue"><ix:nonFraction name="us-gaap:DeferredRevenue" contextRef="AsOf2025-03-31_custom_InvekraMember" id="Fact000537" format="ixt:numdotdecimal" decimals="0" unitRef="USD">69,000</ix:nonFraction></span>, $<span id="xdx_901_eus-gaap--DeferredRevenue_iI_c20240331__srt--CounterpartyNameAxis__custom--InvekraMember_ziXOijcRWpwk" title="Deferred revenue"><ix:nonFraction name="us-gaap:DeferredRevenue" contextRef="AsOf2024-03-31_custom_InvekraMember" id="Fact000539" format="ixt:numdotdecimal" decimals="0" unitRef="USD">152,000</ix:nonFraction></span> and $<span id="xdx_902_eus-gaap--DeferredRevenue_iI_c20230331__srt--CounterpartyNameAxis__custom--InvekraMember_zvSL9N13U10b" title="Deferred revenue"><ix:nonFraction name="us-gaap:DeferredRevenue" contextRef="AsOf2023-03-31_custom_InvekraMember" id="Fact000541" format="ixt:numdotdecimal" decimals="0" unitRef="USD">199,000</ix:nonFraction></span>,
respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-04-01to2025-03-31" escape="true" id="Fact000543" name="us-gaap:ConcentrationRiskCreditRisk"><p id="xdx_84D_eus-gaap--ConcentrationRiskCreditRisk_zqlCuFOr3dfi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_86A_z4W2cjcpOXcj">Concentration of Credit Risk and Major Customers</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Financial instruments that potentially subject the
Company to concentration of credit risk consist principally of cash, cash equivalents and accounts receivable. Cash and cash equivalents
are maintained in financial institutions in the United States, Mexico and the Netherlands. The Company is exposed to credit risk in the
event of default by these financial institutions for amounts in excess of the Federal Deposit Insurance Corporation insured limits. Cash
and cash equivalents held in foreign banks are intentionally kept at minimal levels, and therefore have minimal credit risk associated
with them. We currently have $3,004,000 of deposits above federally insured limits.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table shows major customers revenues
as a percentage of revenue:</p>

<ix:nonNumeric contextRef="From2024-04-01to2025-03-31" escape="true" id="Fact000545" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_zURPyO22S4I1" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B2_zFIfATK9pKB9" style="display: none">Schedule of concentration of risk</span></td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Year Ended March 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: left">Customer A</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b style="display: none"><span style="display: none"></span><span id="xdx_90D_ecustom--ConcentrationRiskPercentage2_pip0_dp_c20240401__20250331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerAMember_fKg_____zm3kWnC3lWsd" title="Concentration risk, percentage"><ix:nonFraction name="SNOA:ConcentrationRiskPercentage2" contextRef="From2024-04-012025-03-31_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueNetMember_custom_CustomerAMember" id="Fact000547" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0</ix:nonFraction></span></b>*%</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right"><span id="xdx_90C_ecustom--ConcentrationRiskPercentage2_pip0_dp_c20230401__20240331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerAMember_zs1bdHhh0kR9" title="Concentration risk, percentage"><ix:nonFraction name="SNOA:ConcentrationRiskPercentage2" contextRef="From2023-04-012024-03-31_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueNetMember_custom_CustomerAMember" id="Fact000549" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">17</ix:nonFraction></span>%</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Customer B</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_ecustom--ConcentrationRiskPercentage2_pip0_dp_c20240401__20250331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerBMember_z4KIjyeKukt9" title="Concentration risk, percentage"><ix:nonFraction name="SNOA:ConcentrationRiskPercentage2" contextRef="From2024-04-012025-03-31_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueNetMember_custom_CustomerBMember" id="Fact000551" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21</ix:nonFraction></span>%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_ecustom--ConcentrationRiskPercentage2_pip0_dp_c20230401__20240331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerBMember_zBZGw8JhTJu7" title="Concentration risk, percentage"><ix:nonFraction name="SNOA:ConcentrationRiskPercentage2" contextRef="From2023-04-012024-03-31_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueNetMember_custom_CustomerBMember" id="Fact000553" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">15</ix:nonFraction></span>%</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Customer C</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_ecustom--ConcentrationRiskPercentage2_pip0_dp_c20240401__20250331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerCMember_zd6MRrjG5LH4" title="Concentration risk, percentage"><ix:nonFraction name="SNOA:ConcentrationRiskPercentage2" contextRef="From2024-04-012025-03-31_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueNetMember_custom_CustomerCMember" id="Fact000555" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">18</ix:nonFraction></span>%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_905_ecustom--ConcentrationRiskPercentage2_pip0_dp_c20230401__20240331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerCMember_zrvShVJuihOl" title="Concentration risk, percentage"><ix:nonFraction name="SNOA:ConcentrationRiskPercentage2" contextRef="From2023-04-012024-03-31_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueNetMember_custom_CustomerCMember" id="Fact000557" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">14</ix:nonFraction></span>%</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table shows major customers accounts
receivable balances as a percentage of net accounts receivables:</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: left">Customer B</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right"><b style="display: none"><span id="xdx_90F_ecustom--ConcentrationRiskPercentage2_pip0_dp_c20240401__20250331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerBMember_fKg_____zSPeLzx9ieyc" title="Concentration risk, percentage"><ix:nonFraction name="SNOA:ConcentrationRiskPercentage2" contextRef="From2024-04-012025-03-31_us-gaap_CustomerConcentrationRiskMember_us-gaap_AccountsReceivableMember_custom_CustomerBMember" id="Fact000559" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0</ix:nonFraction></span></b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*%</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right"><span id="xdx_907_ecustom--ConcentrationRiskPercentage2_pip0_dp_c20230401__20240331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerBMember_zhhrzMCrV01k" title="Concentration risk, percentage"><ix:nonFraction name="SNOA:ConcentrationRiskPercentage2" contextRef="From2023-04-012024-03-31_us-gaap_CustomerConcentrationRiskMember_us-gaap_AccountsReceivableMember_custom_CustomerBMember" id="Fact000561" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">13</ix:nonFraction></span>%</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Customer D</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_ecustom--ConcentrationRiskPercentage2_pip0_dp_c20240401__20250331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerDMember_zRqpvevFHgF6" title="Concentration risk, percentage"><ix:nonFraction name="SNOA:ConcentrationRiskPercentage2" contextRef="From2024-04-012025-03-31_us-gaap_CustomerConcentrationRiskMember_us-gaap_AccountsReceivableMember_custom_CustomerDMember" id="Fact000563" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">24</ix:nonFraction></span>%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_ecustom--ConcentrationRiskPercentage2_pip0_dp_c20230401__20240331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerDMember_zEwXw7xH1If5" title="Concentration risk, percentage"><ix:nonFraction name="SNOA:ConcentrationRiskPercentage2" contextRef="From2023-04-012024-03-31_us-gaap_CustomerConcentrationRiskMember_us-gaap_AccountsReceivableMember_custom_CustomerDMember" id="Fact000565" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">17</ix:nonFraction></span>%</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 4%"><span id="xdx_F09_zisvXV838286" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">* </span></td>
    <td id="xdx_F19_zg6Uo3NevcBg" style="width: 96%"><ix:footnote id="Footnote000566" xml:lang="en-US">% <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents less than
    10%</span></ix:footnote></td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8AB_zKPUBR4dA57j" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:exclude><p id="xdx_232_znxaWKU5cIxl" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23F_zSJOT7582vt4" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23B_z90krGdfs5gj" style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 54 -->
    <div id="xdx_23B_zZ4jU7PUPdD1" style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_239_zoJR2AfZJiT" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_236_zXWhzbRvR9Z6" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-04-01to2025-03-31" escape="true" id="Fact000572" name="us-gaap:ReceivablesPolicyTextBlock"><p id="xdx_84D_eus-gaap--ReceivablesPolicyTextBlock_zPTyarxsC5N9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_860_zTS6l5klpGF">Accounts Receivable</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Trade accounts receivable are recorded net of allowances
for cash discounts for prompt payment, doubtful accounts, and sales returns. Estimates for cash discounts and sales returns are based
on analysis of contractual terms and historical trends.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s policy is to reserve for uncollectible
accounts based on its best estimate of the amount of probable credit losses in its existing accounts receivable. The Company periodically
reviews its accounts receivable to determine whether an allowance for doubtful accounts is necessary based on an analysis of past due
accounts and other factors that may indicate that the realization of an account may be in doubt. Other factors that the Company considers
include its existing contractual obligations, historical payment patterns of its customers and individual customer circumstances, an analysis
of days sales outstanding by customer and geographic region, and a review of the local economic environment and its potential impact on
government funding and reimbursement practices. Account balances deemed to be uncollectible are charged to the allowance after all means
of collection have been exhausted and the potential for recovery is considered remote. The Company did <span id="xdx_909_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pn3p0_do_c20250331__srt--ProductOrServiceAxis__custom--ProbableCreditLossesMember_zW7wAdkE2NY9" title="Allowance for doubtful accounts"><span id="xdx_90F_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pn3p0_do_c20240331__srt--ProductOrServiceAxis__custom--ProbableCreditLossesMember_zYdQNrIU7HM7" title="Allowance for doubtful accounts"><span id="xdx_903_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pn3p0_do_c20230331__srt--ProductOrServiceAxis__custom--ProbableCreditLossesMember_zOc54kajgLh9" title="Allowance for doubtful accounts"><ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivable" contextRef="AsOf2025-03-31_custom_ProbableCreditLossesMember" id="Fact000574" format="ixt-sec:numwordsen" decimals="-3" scale="0" unitRef="USD"><ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivable" contextRef="AsOf2024-03-31_custom_ProbableCreditLossesMember" id="Fact000576" format="ixt-sec:numwordsen" decimals="-3" scale="0" unitRef="USD"><ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivable" contextRef="AsOf2023-03-31_custom_ProbableCreditLossesMember" id="Fact000578" format="ixt-sec:numwordsen" decimals="-3" scale="0" unitRef="USD">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span>t deem it necessary to record
an allowance for doubtful accounts for probable credit losses at March 31, 2025, March 31, 2024 and March 31, 2023. Additionally, at March
31, 2025, 2024 and 2023, the Company has allowances of $<span id="xdx_909_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pn3p0_c20250331__srt--ProductOrServiceAxis__custom--PotentialDiscountsReturnsDistributorFeesAndRebatesMember_zX36jruvOYM2" title="Allowance for doubtful accounts"><ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivable" contextRef="AsOf2025-03-31_custom_PotentialDiscountsReturnsDistributorFeesAndRebatesMember" id="Fact000580" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">8,000</ix:nonFraction></span>, $<span id="xdx_90E_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pn3p0_c20240331__srt--ProductOrServiceAxis__custom--PotentialDiscountsReturnsDistributorFeesAndRebatesMember_zKceXqOGAQn7" title="Allowance for doubtful accounts"><ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivable" contextRef="AsOf2024-03-31_custom_PotentialDiscountsReturnsDistributorFeesAndRebatesMember" id="Fact000582" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">27,000</ix:nonFraction></span> and $<span id="xdx_90B_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pn3p0_c20230331__srt--ProductOrServiceAxis__custom--PotentialDiscountsReturnsDistributorFeesAndRebatesMember_zPChwlnQfONi" title="Allowance for doubtful accounts"><ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivable" contextRef="AsOf2023-03-31_custom_PotentialDiscountsReturnsDistributorFeesAndRebatesMember" id="Fact000584" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">16,000</ix:nonFraction></span>, respectively, related to potential discounts, returns,
distributor fees and rebates. The allowances are included in accounts receivable, net in the accompanying consolidated balance sheets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-04-01to2025-03-31" escape="true" id="Fact000586" name="us-gaap:InventoryPolicyTextBlock"><p id="xdx_846_eus-gaap--InventoryPolicyTextBlock_zZwKbfNYAqn2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_86D_z1WH85EQNkGe">Inventories</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Inventories are stated at the lower of cost, cost
being determined on a standard cost basis (which approximates actual cost on a first-in, first-out basis), or net realizable value.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Due to changing market conditions, estimated future
requirements, age of the inventories on hand and production of new products, the Company regularly reviews inventory quantities on hand
and records a provision to write down excess and obsolete inventory to its estimated net realizable value. At March 31, 2025 and 2024,
the Company recorded provisions to reduce the carrying amounts of inventories to their net realizable value in the amounts of $<span id="xdx_90D_eus-gaap--InventoryValuationReserves_iI_pn3p0_c20250331_zNTLPOQMjbl1" title="Inventory valuation reserves"><ix:nonFraction name="us-gaap:InventoryValuationReserves" contextRef="AsOf2025-03-31" id="Fact000588" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">298,000</ix:nonFraction></span>
and $<span id="xdx_90E_eus-gaap--InventoryValuationReserves_iI_pn3p0_c20240331_zSpzd72K9l4f"><ix:nonFraction name="us-gaap:InventoryValuationReserves" contextRef="AsOf2024-03-31" id="Fact000589" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">296,000</ix:nonFraction></span>, respectively, which is included in inventories, net on the Company&#8217;s accompanying consolidated balance sheets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-04-01to2025-03-31" escape="true" id="Fact000591" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock"><p id="xdx_84C_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zBuZLvGvya3i" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_86E_zwRFaxwCdK11">Financial Assets and Liabilities</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Financial instruments, including cash and cash equivalents,
accounts receivable and accounts payable are carried at cost, which management believes approximates fair value due to the short-term
nature of these instruments. The fair value of capital lease obligations and approximates their carrying amounts as a market rate of interest
is attached to their repayment. The Company measures the fair value of financial assets and liabilities based on the exchange price that
would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset
or liability in an orderly transaction between market participants on the measurement date. The Company maximizes the use of observable
inputs and minimizes the use of unobservable inputs when measuring fair value. The Company uses three levels of inputs that may be used
to measure fair value:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level&#160;1&#160;&#8211; quoted prices in active
markets for identical assets or liabilities;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level&#160;2&#160;&#8211; quoted prices for similar
assets and liabilities in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived
valuations in which all significant inputs and significant value drivers are observable in active markets;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level&#160;3&#160;&#8211; inputs that are unobservable
(for example cash flow modeling inputs based on assumptions).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_235_zPPLgPin6SGg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23D_zLvl4ix8rMK" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23F_z4Q0yGNqPIge" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 55 -->
    <div id="xdx_236_z5ppoYn2x6d4" style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_23A_zM7aMbPoavw9" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23D_zG64AC1bRbDc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 3 liabilities are valued using unobservable
inputs to the valuation methodology that are significant to the measurement of the fair value of the liabilities. For fair value measurements
categorized within Level 3 of the fair value hierarchy, the Company&#8217;s accounting and finance department, who report to the Chief
Financial Officer, determine its valuation policies and procedures. The development and determination of the unobservable inputs for Level
3 fair value measurements and fair value calculations are the responsibility of the Company&#8217;s accounting and finance department
and are approved by the Chief Financial Officer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of March 31, 2025 and 2024, there were <span id="xdx_908_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_pn3p0_do_c20240401__20250331_zEuzx62r1c" title="Transfers in or out of level 3"><span id="xdx_906_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_pn3p0_do_c20230401__20240331_z103ndt1RRJ2" title="Transfers in or out of level 3"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" contextRef="From2024-04-01to2025-03-31" id="Fact000597" format="ixt-sec:numwordsen" decimals="-3" scale="0" unitRef="USD"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" contextRef="From2023-04-012024-03-31" id="Fact000599" format="ixt-sec:numwordsen" decimals="-3" scale="0" unitRef="USD">no</ix:nonFraction></ix:nonFraction></span></span> transfers
in or out of Level 3 from other levels in the fair value hierarchy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-04-01to2025-03-31" escape="true" id="Fact000601" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock"><p id="xdx_84C_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zyAALfoPUln6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_860_zCNI749PVwT8">Property and Equipment</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Property and equipment are stated at cost less accumulated
depreciation. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the
respective assets. Depreciation of leasehold improvements is computed using the straight-line method over the lesser of the estimated
useful life of the improvement or the remaining term of the lease. Estimated useful asset life by classification is as follows:&#160;</p>

<ix:nonNumeric contextRef="From2024-04-01to2025-03-31" escape="true" id="Fact000603" name="SNOA:PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock"><table cellspacing="0" cellpadding="0" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details-Useful lives)" id="xdx_88B_ecustom--PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock_z9YQN5p6tJKg" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B9_zM2xeXOwrCCe" style="display: none">Schedule of property and equipment estimated useful life</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Years</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 86%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office equipment</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 12%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20250331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_z8tCHer5CRwh" title="Useful asset life"><ix:nonNumeric contextRef="AsOf2025-03-31_us-gaap_OfficeEquipmentMember" format="ixt-sec:duryear" id="Fact000605" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">3</ix:nonNumeric></span></span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manufacturing, lab and other equipment</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20250331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zdPY9cCcanw" title="Useful asset life"><ix:nonNumeric contextRef="AsOf2025-03-31_us-gaap_MachineryAndEquipmentMember" format="ixt-sec:duryear" id="Fact000607" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">5</ix:nonNumeric></span></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furniture and fixtures</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20250331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zcEr4Z1vwZIb" title="Useful asset life"><ix:nonNumeric contextRef="AsOf2025-03-31_us-gaap_FurnitureAndFixturesMember" format="ixt-sec:duryear" id="Fact000609" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">7</ix:nonNumeric></span></span></td>
    <td>&#160;</td></tr>
  </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Upon retirement or sale, the cost and related accumulated
depreciation are removed from the consolidated balance sheet and the resulting gain or loss is reflected in operations. Maintenance and
repairs are charged to operations as incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-04-01to2025-03-31" escape="true" id="Fact000611" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"><p id="xdx_84E_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zczGeUAYV3Pf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_86B_zJn9hugvmEM7">Impairment of Long-Lived Assets</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company periodically reviews the carrying values
of its long-lived assets when events or changes in circumstances would indicate that it is more likely than not that their carrying values
may exceed their realizable values, and records impairment charges when considered necessary. Specific potential indicators of impairment
include, but are not necessarily limited to:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a significant decrease in the fair value of an asset;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a significant change in the extent or manner in which an asset is used or a significant physical change in an asset;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a significant adverse change in legal factors or in the business climate that affects the value of an asset;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an adverse action or assessment by the U.S.&#160;Food and Drug Administration or another regulator; and</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an accumulation of costs significantly in excess of the amount originally expected to acquire or construct an asset; and operating or cash flow losses combined with a history of operating or cash flow losses or a projection or forecast that demonstrates continuing losses associated with an income-producing asset.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:exclude><p id="xdx_238_zrICOpCt5lVb" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23D_zlsVA9Y1wIk7" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23C_zMRadpGH44Cg" style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 56 -->
    <div id="xdx_230_zXjU7Ma6axDg" style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_23A_zbuxTe0Wuptj" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_237_zPxttKNiQ9F1" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">When circumstances indicate that an impairment may
have occurred, the Company tests such assets for recoverability by comparing the estimated undiscounted future cash flows expected to
result from the use of such assets and their eventual disposition to their carrying amounts. In estimating these future cash flows, assets
and liabilities are grouped at the lowest level for which there are identifiable cash flows that are largely independent of the cash flows
generated by other such groups. If the undiscounted future cash flows are less than the carrying amount of the asset, an impairment loss,
measured as the excess of the carrying value of the asset over its estimated fair value, will be recognized. The cash flow estimates used
in such calculations are based on estimates and assumptions, using all available information that management believes is reasonable. The
Company did <span id="xdx_90B_eus-gaap--AssetImpairmentCharges_pn3p0_do_c20240401__20250331_zCVjrL7UJIX5" title="Impairment of long lived assets"><span id="xdx_90D_eus-gaap--AssetImpairmentCharges_pn3p0_do_c20230401__20240331_zVkJgRm2Mdkf" title="Impairment of long lived assets"><ix:nonFraction name="us-gaap:AssetImpairmentCharges" contextRef="From2024-04-01to2025-03-31" id="Fact000617" format="ixt-sec:numwordsen" decimals="-3" scale="0" unitRef="USD"><ix:nonFraction name="us-gaap:AssetImpairmentCharges" contextRef="From2023-04-012024-03-31" id="Fact000619" format="ixt-sec:numwordsen" decimals="-3" scale="0" unitRef="USD">no</ix:nonFraction></ix:nonFraction></span></span>t record impairment losses for the years ended March 31, 2025 and 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-04-01to2025-03-31" escape="true" id="Fact000621" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><p id="xdx_845_eus-gaap--ResearchAndDevelopmentExpensePolicy_zrSsLGROXZac" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_86E_zFthTNrrfmVi">Research and Development</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Research and development expenses are charged to operations
as incurred and consists primarily of personnel expenses, clinical and regulatory services and supplies. For the years ended March 31,
2025 and 2024, research and development expense amounted to $<span id="xdx_900_eus-gaap--ResearchAndDevelopmentExpense_pn3p0_c20240401__20250331_zl6YV1lL8wLl" title="Research and development expenses"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2024-04-01to2025-03-31" id="Fact000623" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">1,814,000</ix:nonFraction></span> and $<span id="xdx_903_eus-gaap--ResearchAndDevelopmentExpense_pn3p0_c20230401__20240331_zTfBPPtLwtb1" title="Research and development expenses"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-04-012024-03-31" id="Fact000625" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">1,871,000</ix:nonFraction></span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-04-01to2025-03-31" escape="true" id="Fact000627" name="us-gaap:AdvertisingCostsPolicyTextBlock"><p id="xdx_845_eus-gaap--AdvertisingCostsPolicyTextBlock_zLZeZWIZQEce" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_86D_zxvr5GkT24Gh">Advertising Costs</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Advertising costs are charged to operations as incurred.
Advertising costs amounted to $<span id="xdx_901_eus-gaap--MarketingExpense_pn3p0_c20240401__20250331_zm8yljMrOCJ3" title="Advertising costs"><ix:nonFraction name="us-gaap:MarketingExpense" contextRef="From2024-04-01to2025-03-31" id="Fact000629" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">190,000</ix:nonFraction></span> and $<span id="xdx_901_eus-gaap--MarketingExpense_pn3p0_c20230401__20240331_zy00uSelb4nl" title="Advertising costs"><ix:nonFraction name="us-gaap:MarketingExpense" contextRef="From2023-04-012024-03-31" id="Fact000631" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">156,000</ix:nonFraction></span> for the years ended March 31, 2025 and 2024, respectively. Advertising costs are included
in selling, general and administrative expenses in the accompanying consolidated statements of comprehensive loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-04-01to2025-03-31" escape="true" id="Fact000633" name="SNOA:ShippingAndHandlingCost1PolicyTextBlock"><p id="xdx_848_ecustom--ShippingAndHandlingCost1PolicyTextBlock_zHYgmM3ZqYo5" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i><span id="xdx_86B_zBBmV5Jyaq45">Shipping and Handling Costs</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company classifies amounts billed to customers
related to shipping and handling in sale transactions as product revenues. The corresponding shipping and handling costs incurred are
recorded in cost of product revenues. For the years ended March 31, 2025 and 2024, the Company recorded revenue related to shipping and
handling costs of $<span id="xdx_90E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20240401__20250331__srt--ProductOrServiceAxis__us-gaap--ShippingAndHandlingMember_z1kK9aignMee" title="Revenues"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2024-04-012025-03-31_us-gaap_ShippingAndHandlingMember" id="Fact000635" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">18,000</ix:nonFraction></span> and $<span id="xdx_90B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20230401__20240331__srt--ProductOrServiceAxis__us-gaap--ShippingAndHandlingMember_zEfQQNdAdq9" title="Revenues"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-04-012024-03-31_us-gaap_ShippingAndHandlingMember" id="Fact000637" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">28,000</ix:nonFraction></span>, respectively. These amounts are included in revenues in the accompanying consolidated statements
of comprehensive loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-04-01to2025-03-31" escape="true" id="Fact000639" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"><p id="xdx_848_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zByY8TNCHpb5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_861_zm6POr9eOYzg">Foreign Currency Reporting</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s subsidiary, OTM, uses the local
currency (Mexican Pesos) as its functional currency and its subsidiary, SP Europe, uses the local currency (Euro) as its functional currency.
Assets and liabilities are translated at exchange rates in effect at the balance sheet date, and revenue and expense accounts are translated
at average exchange rates during the period. Resulting translation adjustments amounted to losses of $<span id="xdx_90E_ecustom--OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationLossAdjustmentBeforeTaxPortionAttributableToParent_pn3p0_c20240401__20250331__us-gaap--IncomeStatementLocationAxis__us-gaap--OtherComprehensiveIncomeMember_zbkTsSEsWFL" title="Foreign currency translation adjustment loss"><ix:nonFraction name="SNOA:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationLossAdjustmentBeforeTaxPortionAttributableToParent" contextRef="From2024-04-012025-03-31_us-gaap_OtherComprehensiveIncomeMember" id="Fact000641" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">1,653,000</ix:nonFraction></span> and gains of $<span id="xdx_90D_ecustom--OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainAdjustmentBeforeTaxPortionAttributableToParent_pn3p0_c20230401__20240331__us-gaap--IncomeStatementLocationAxis__us-gaap--OtherComprehensiveIncomeMember_zMXOCNhpjITg" title="Foreign currency translation adjustment gain"><ix:nonFraction name="SNOA:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainAdjustmentBeforeTaxPortionAttributableToParent" contextRef="From2023-04-012024-03-31_us-gaap_OtherComprehensiveIncomeMember" id="Fact000643" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">695,000</ix:nonFraction></span>
for the years ended March 31, 2025 and 2024, respectively. These amounts were recorded in other comprehensive loss in the accompanying
consolidated statements of comprehensive loss for the years ended March 31, 2025 and 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Foreign currency transaction losses relate primarily
to trade payables and receivables and intercompany transactions between subsidiaries OTM and SP Europe. These transactions are expected
to be settled in the foreseeable future. The Company recorded foreign currency transaction gains of $<span id="xdx_90C_eus-gaap--ForeignCurrencyTransactionGainBeforeTax_pn3p0_c20240401__20250331__us-gaap--IncomeStatementLocationAxis__us-gaap--OtherOperatingIncomeExpenseMember_zg09fRLQWx06" title="Foreign currency transaction gain"><ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainBeforeTax" contextRef="From2024-04-012025-03-31_us-gaap_OtherOperatingIncomeExpenseMember" id="Fact000645" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">243,000</ix:nonFraction></span> and losses of $<span id="xdx_904_eus-gaap--ForeignCurrencyTransactionLossBeforeTax_pn3p0_c20230401__20240331__us-gaap--IncomeStatementLocationAxis__us-gaap--OtherOperatingIncomeExpenseMember_zUrCXDQodvIc" title="Foreign currency transaction loss"><ix:nonFraction name="us-gaap:ForeignCurrencyTransactionLossBeforeTax" contextRef="From2023-04-012024-03-31_us-gaap_OtherOperatingIncomeExpenseMember" id="Fact000647" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">825,000</ix:nonFraction></span> for
the years ended March 31, 2025 and 2024, respectively. The related amounts were recorded in other income (expense) in the accompanying
consolidated statements of comprehensive loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_233_z28qrqreFgm3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23F_zKMhV48fyROh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_230_zwdLCno5RPc5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 57 -->
    <div id="xdx_23B_zfVMvMDlNEia" style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_23B_z02QTyhdFlS2" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23D_zv4NjLd3yNj" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-04-01to2025-03-31" escape="true" id="Fact000653" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy"><p id="xdx_84B_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zaj8FWd4iUY5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_869_z5PeiaDESwAl">Stock-Based Compensation</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for share-based awards exchanged
for employee services at the estimated grant date fair value of the award. The Company estimates the fair value of employee stock option
awards using the Black-Scholes option pricing model. The Company amortizes the fair value of employee stock options on a straight-line
basis over the requisite service period of the awards.&#160; Compensation expense includes the impact of forfeitures for all stock options
as incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for equity instruments issued
to non-employees at their fair value on the measurement date. The measurement of stock-based compensation is subject to periodic adjustment
as the underlying equity instrument vests or becomes non-forfeitable. Non-employee stock-based compensation charges are amortized over
the vesting period or as earned.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-04-01to2025-03-31" escape="true" id="Fact000655" name="us-gaap:IncomeTaxPolicyTextBlock"><p id="xdx_841_eus-gaap--IncomeTaxPolicyTextBlock_zNsCtF9G88Tk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_861_zstvjz8290e3">Income Taxes</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Deferred tax assets and liabilities are determined
based on the differences between the financial reporting and tax bases of assets and liabilities and net operating loss and credit carryforwards
using enacted tax rates in effect for the year in which the differences are expected to impact taxable income. Valuation allowances are
established when necessary to reduce deferred tax assets to the amounts expected to be realized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Tax benefits claimed or expected to be claimed on
a tax return are recorded in the Company&#8217;s consolidated financial statements. A tax benefit from an uncertain tax position is only
recognized if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the
technical merits of the position. The tax benefits recognized in the consolidated financial statements from such a position are measured
based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate resolution. Uncertain tax
positions have had no impact on the Company&#8217;s consolidated financial condition, results of comprehensive loss or cash flows.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-04-01to2025-03-31" escape="true" id="Fact000657" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock"><p id="xdx_844_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zlrbnMPJy9x7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_865_zLOGtLVLckb4">Comprehensive Loss</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Other comprehensive loss includes all changes in stockholders&#8217;
equity during a period from non-owner sources and is reported in the consolidated statements of changes in stockholders&#8217; equity.
To date, other comprehensive loss consists of changes in accumulated foreign currency translation adjustments. Accumulated other comprehensive
losses at March 31, 2025 and 2024 were $<span id="xdx_905_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_iNI_pn3p0_di_c20250331_zxCDSkwmUNEb" title="Accumulated other comprehensive loss"><ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="AsOf2025-03-31" id="Fact000659" format="ixt:numdotdecimal" decimals="-3" scale="0" sign="-" unitRef="USD">4,376,000</ix:nonFraction></span> and $<span id="xdx_908_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_iNI_pn3p0_di_c20240331_zgzxoULws9Kc" title="Accumulated other comprehensive loss"><ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="AsOf2024-03-31" id="Fact000661" format="ixt:numdotdecimal" decimals="-3" scale="0" sign="-" unitRef="USD">2,723,000</ix:nonFraction></span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i></i></b></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-04-01to2025-03-31" escape="true" id="Fact000663" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_84F_eus-gaap--EarningsPerSharePolicyTextBlock_zpJt2VoxNfvk" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i><span id="xdx_861_zWe7aV4iEVtg">Net Loss per Share</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company computes basic net loss per share by dividing
net loss per share available to common stockholders by the weighted average number of common shares outstanding for the period and excludes
the effects of any potentially dilutive securities. Diluted earnings per share, if presented, would include the dilution that would occur
upon the exercise or conversion of all potentially dilutive securities into common stock using the &#8220;treasury stock&#8221; and/or
&#8220;if converted&#8221; methods as applicable.</p>

<ix:nonNumeric contextRef="From2024-04-01to2025-03-31" escape="true" id="Fact000665" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_88F_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_pn3n3_zQMVT2I9u4s5" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details - Earnings per share)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8BE_zLPDMRGi4yR4" style="display: none">Schedule of computation of earnings per share</span></td><td>&#160;</td>
    <td colspan="2" id="xdx_493_20240401__20250331_zWUtF7nS72Hj" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_490_20230401__20240331_zbQOYGMhuxv8" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Year Ended March 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-style: italic; text-align: justify">(In thousands, except per share data)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--NetIncomeLoss_zvPHG1sUVEZf" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: justify; padding-bottom: 2.5pt">Net loss</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 13%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2024-04-01to2025-03-31" id="Fact000667" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">3,457</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 13%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-04-012024-03-31" id="Fact000668" format="ixt:numdotdecimal" decimals="-3" scale="3" sign="-" unitRef="USD">4,835</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Weighted-average shares outstanding: basic and diluted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_906_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20240401__20250331_zHmQpmxLzLe2" title="Weighted-average number of shares: basic"><span id="xdx_906_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20240401__20250331_zCDm0AKmLbNf" title="Weighted-average number of shares: diluted"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2024-04-01to2025-03-31" id="Fact000670" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2024-04-01to2025-03-31" id="Fact000672" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">1,241</ix:nonFraction></ix:nonFraction></span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20230401__20240331_zPC1HfhiTm8l" title="Weighted-average number of shares: basic"><span id="xdx_90C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20230401__20240331_zM3Y70VsLL15" title="Weighted-average number of shares: diluted"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-04-012024-03-31" id="Fact000674" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-04-012024-03-31" id="Fact000676" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">455</ix:nonFraction></ix:nonFraction></span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Net loss per share: basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--EarningsPerShareBasic_pip0_c20240401__20250331_zlxfDkaNIuOh" title="Net loss per share: basic"><span id="xdx_908_eus-gaap--EarningsPerShareDiluted_pip0_c20240401__20250331_zuPDGioUbHCl" title="Net loss per share: diluted">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2024-04-01to2025-03-31" id="Fact000678" format="ixt:numdotdecimal" decimals="INF" scale="0" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2024-04-01to2025-03-31" id="Fact000680" format="ixt:numdotdecimal" decimals="INF" scale="0" sign="-" unitRef="USDPShares">2.79</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_eus-gaap--EarningsPerShareBasic_pip0_c20230401__20240331_zIXPvimnH9sj" title="Net loss per share: basic"><span id="xdx_903_eus-gaap--EarningsPerShareDiluted_pip0_c20230401__20240331_z7gXdVrOEh5g" title="Net loss per share: diluted">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2023-04-012024-03-31" id="Fact000682" format="ixt:numdotdecimal" decimals="INF" scale="0" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-04-012024-03-31" id="Fact000684" format="ixt:numdotdecimal" decimals="INF" scale="0" sign="-" unitRef="USDPShares">10.63</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_231_zoNH1TzGnz8h" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_236_zm0Fy7G6zPok" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_230_zIXRStWwupOd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 58 -->
    <div id="xdx_230_zBknsGprwnYg" style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_23B_z42SxufGYAYh" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_230_zVa6aCEAtrGc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The computation of basic and diluted loss per share
for the years ended March 31, 2025 and 2024 excludes the potentially dilutive securities summarized in the table below because their inclusion
would be anti-dilutive.</p>

<ix:nonNumeric contextRef="From2024-04-01to2025-03-31" escape="true" id="Fact000690" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_889_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_pn3n3_zX61miRCNuQg" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details - Antidilutive shares)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8BF_zWNkXJhCOLd9" style="display: none">Schedule of antidilutive shares</span></td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-style: italic">(In thousands)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: left">Common stock to be issued upon exercise of options</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20240401__20250331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zBk6aclmuVK3" title="Antidilutive shares" style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-04-012025-03-31_us-gaap_StockOptionMember" id="Fact000692" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">73</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20230401__20240331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_z0hBUAViGQkk" title="Antidilutive shares" style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-04-012024-03-31_us-gaap_StockOptionMember" id="Fact000694" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">52</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Common stock to be issued upon vesting of restricted stock units</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_d0_c20240401__20250331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockUnitsMember_ze0KvSHOnXyk" title="Antidilutive shares" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-04-012025-03-31_custom_CommonStockUnitsMember" id="Fact000696" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">45</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_d0_c20230401__20240331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockUnitsMember_zvW2tD8pJZB5" title="Antidilutive shares" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-04-012024-03-31_custom_CommonStockUnitsMember" id="Fact000698" format="ixt:zerodash" decimals="-3" scale="3" unitRef="Shares">&#8211;</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20240401__20250331_z61stojKYFSa" title="Antidilutive shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2024-04-01to2025-03-31" id="Fact000700" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">118</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20230401__20240331_z052IKLT9YAg" title="Antidilutive shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-04-012024-03-31" id="Fact000702" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="Shares">52</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-04-01to2025-03-31" escape="true" id="Fact000704" name="SNOA:ConvertiblePreferredStockPolicyTextBlock"><p id="xdx_849_ecustom--ConvertiblePreferredStockPolicyTextBlock_zTSZEVEHfJB1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_863_zpJiJv2ta99c">Convertible Preferred Stock</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company applies the accounting standards for distinguishing
liabilities from equity when determining the classification and measurement of its preferred stock. Shares that are subject to mandatory
redemption (if any) are classified as liability instruments and are measured at fair value. The Company classifies conditionally redeemable
preferred shares, which includes preferred shares that feature redemption rights that are either within the control of the holder or subject
to redemption upon the occurrence of uncertain events not solely within the Company&#8217;s control, as temporary equity. At all other
times, preferred shares are classified as stockholders' equity. There are <span id="xdx_90B_eus-gaap--PreferredStockSharesIssued_iI_pip0_do_c20250331_zD131bkgvo27" title="Preferred stock, shares issued"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2025-03-31" id="Fact000706" format="ixt-sec:numwordsen" decimals="INF" scale="0" unitRef="Shares">no</ix:nonFraction></span> shares issued as of March 31, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-04-01to2025-03-31" escape="true" id="Fact000708" name="us-gaap:SegmentReportingPolicyPolicyTextBlock"><p id="xdx_848_eus-gaap--SegmentReportingPolicyPolicyTextBlock_z8U1KU9n1Ug5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_86F_z1x7JkOJP5u4">Segment Reporting</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has one primary business activity and operate in one reportable
segment. The Company&#8217;s chief operating decision maker (&#8220;CODM&#8221;) is its Chief Executive Officer (&#8220;CEO&#8221;) who
evaluates performance and makes operating decisions about allocating resources based on financial data presented on a consolidated basis.
The measures of profitability and the significant segment expenses reviewed by the CODM are consistent with these financial statements
and footnotes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-04-01to2025-03-31" escape="true" id="Fact000710" name="us-gaap:SubsequentEventsPolicyPolicyTextBlock"><p id="xdx_84D_eus-gaap--SubsequentEventsPolicyPolicyTextBlock_z5blvubMPCZb" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i><span id="xdx_86A_zG2oQtqrhGk6">Subsequent Events</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Management has evaluated subsequent events or transactions
occurring through the date these consolidated financial statements were issued. All events requiring disclosure have been incorporated
into the notes to the consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-04-01to2025-03-31" escape="true" id="Fact000712" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_842_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zaligiqAgjO1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_867_zbiuXHAVh7b2">Recent Accounting Standards</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has evaluated all the recent accounting
standards and determined that none are material to it.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="From2024-04-01to2025-03-31" escape="true" id="Fact000714" name="us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock"><p id="xdx_80F_eus-gaap--LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_zrTV0gwgjkmf" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE&#160;4&#160;&#8211; <span id="xdx_82F_zVS6CHtSiAR3">Accounts Receivable</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Accounts receivable, net consists of the following:</p>

<ix:nonNumeric contextRef="From2024-04-01to2025-03-31" escape="true" id="Fact000716" name="us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_88A_eus-gaap--ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_pn3n3_zsLLptBzYht6" summary="xdx: Disclosure - Accounts Receivable (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8BC_zQEh7Rl2tFKl" style="display: none">Schedule of accounts
    receivable</span></td><td>&#160;</td>
    <td colspan="2" id="xdx_499_20250331_zEzYUvCD1pm" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_490_20240331_zuNI0FO9oKUb" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March&#160;31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AccountsReceivableGrossCurrent_iI_pn3p0_maARNCzw0O_zkniCw3Vrj3a" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: left">Accounts receivable</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableGrossCurrent" contextRef="AsOf2025-03-31" id="Fact000718" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">2,240,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableGrossCurrent" contextRef="AsOf2024-03-31" id="Fact000719" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">2,925,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iNI_pn3p0_di_hsrt--ProductOrServiceAxis__custom--PotentialDiscountsReturnsDistributorFeesAndRebatesMember_msARNCzw0O_z1IyPnEOwFc4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Less: discounts, rebates, distributor fees and returns</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivable" contextRef="AsOf2025-03-31_custom_PotentialDiscountsReturnsDistributorFeesAndRebatesMember" id="Fact000721" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">8,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivable" contextRef="AsOf2024-03-31_custom_PotentialDiscountsReturnsDistributorFeesAndRebatesMember" id="Fact000722" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">27,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--AccountsReceivableNetCurrent_iTI_pn3p0_mtARNCzw0O_zD73MAMoB86d" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total accounts receivable, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2025-03-31" id="Fact000724" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">2,232,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2024-03-31" id="Fact000725" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">2,898,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:exclude><p id="xdx_23D_zNDcCgnKu5f3" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_236_zvjgTOmU7Fna" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_231_zovbs1g8Kcv6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 59 -->
    <div id="xdx_23F_z3TCBFhui5D2" style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_23C_zUfmCkotMQ99" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_237_zXShy9fTDrh8" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-04-01to2025-03-31" escape="true" id="Fact000731" name="us-gaap:InventoryDisclosureTextBlock"><p id="xdx_80E_eus-gaap--InventoryDisclosureTextBlock_zWsxCIu5N09e" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE&#160;5&#160;&#8211; <span id="xdx_822_z6liG334e382">Inventories</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Inventories, net consists of the following:</p>

<ix:nonNumeric contextRef="From2024-04-01to2025-03-31" escape="true" id="Fact000733" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_885_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_pn3n3_zclZDn1Ampdl" summary="xdx: Disclosure - Inventories (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B0_ziSP6Up1QKal" style="display: none">Schedule of inventories</span></td><td>&#160;</td>
    <td colspan="2" id="xdx_49F_20250331_zSUjscxoVyE2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_492_20240331_zTeL1za7t7Yj" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March&#160;31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--InventoryRawMaterialsNetOfReserves_iI_pn3p0_maIGzA0w_z0T6ta6jCeN8" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: left">Raw materials</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:InventoryRawMaterialsNetOfReserves" contextRef="AsOf2025-03-31" id="Fact000735" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">1,395,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:InventoryRawMaterialsNetOfReserves" contextRef="AsOf2024-03-31" id="Fact000736" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">1,802,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--InventoryFinishedGoodsNetOfReserves_iI_pn3p0_maIGzA0w_zjTLh3wPMYD9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Finished goods</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:InventoryFinishedGoodsNetOfReserves" contextRef="AsOf2025-03-31" id="Fact000738" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">1,818,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:InventoryFinishedGoodsNetOfReserves" contextRef="AsOf2024-03-31" id="Fact000739" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">1,213,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--InventoryGross_iTI_pn3p0_mtIGzA0w_maINzHEX_zoa8ualtCGJf" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><b style="display: none">Inventories, gross</b></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InventoryGross" contextRef="AsOf2025-03-31" id="Fact000741" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">3,213,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InventoryGross" contextRef="AsOf2024-03-31" id="Fact000742" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">3,015,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--InventoryValuationReserves_iNI_pn3p0_di_msINzHEX_zXEz7igVfYO5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Less: allowance for obsolete and excess inventory</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:InventoryValuationReserves" contextRef="AsOf2025-03-31" id="Fact000744" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">298,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:InventoryValuationReserves" contextRef="AsOf2024-03-31" id="Fact000745" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">296,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--InventoryNet_iTI_pn3p0_mtINzHEX_zxOU6ZdhLTah" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total inventories</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2025-03-31" id="Fact000747" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">2,915,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2024-03-31" id="Fact000748" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">2,719,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-04-01to2025-03-31" escape="true" id="Fact000750" name="us-gaap:OtherCurrentAssetsTextBlock"><p id="xdx_80E_eus-gaap--OtherCurrentAssetsTextBlock_z1PAeR0uqafh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE&#160;6&#160;&#8211; <span id="xdx_82F_zleE51adNMu">Prepaid Expenses and Other
Current Assets</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Prepaid expenses and other current assets consist
of the following:</p>

<ix:nonNumeric contextRef="From2024-04-01to2025-03-31" escape="true" id="Fact000752" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_881_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_pn3n3_zmpfHru8uDW6" summary="xdx: Disclosure - Prepaid Expenses and Other Current Assets (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B8_zRuyoXDE8aDi" style="display: none">Schedule of prepaid expenses and other current assets</span></td><td>&#160;</td>
    <td colspan="2" id="xdx_498_20250331_zyIttJz1rCjb" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_49D_20240331_zGv05CgxGUmg" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March&#160;31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--PrepaidInsurance_iI_pn3p0_maPEAOAz4GC_z91VyCrIieAb" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: left">Prepaid insurance</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:PrepaidInsurance" contextRef="AsOf2025-03-31" id="Fact000754" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">236,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:PrepaidInsurance" contextRef="AsOf2024-03-31" id="Fact000755" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">340,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--PrepaidTaxes_iI_pn3p0_maPEAOAz4GC_zdmq4l3G0Emf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">VAT prepaid to Mexican tax authorities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidTaxes" contextRef="AsOf2025-03-31" id="Fact000757" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">1,531,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidTaxes" contextRef="AsOf2024-03-31" id="Fact000758" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">3,096,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OtherPrepaidExpenseCurrent_iI_pn3p0_maPEAOAz4GC_zQwxZAIZpNTi" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Other prepaid expenses and other current assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherPrepaidExpenseCurrent" contextRef="AsOf2025-03-31" id="Fact000760" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">148,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherPrepaidExpenseCurrent" contextRef="AsOf2024-03-31" id="Fact000761" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">105,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_pn3p0_mtPEAOAz4GC_zQqBZd3zmPog" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><b style="display: none">Total prepaid expenses and other current assets</b></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2025-03-31" id="Fact000763" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">1,915,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2024-03-31" id="Fact000764" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">3,541,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-04-01to2025-03-31" escape="true" id="Fact000766" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock"><p id="xdx_80B_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_z0ItIUj1HwV9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE&#160;7&#160;&#8211; <span id="xdx_824_zVbZpxxLQum">Property and Equipment</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Property and equipment, net consists of the following:</p>

<ix:nonNumeric contextRef="From2024-04-01to2025-03-31" escape="true" id="Fact000768" name="us-gaap:PropertyPlantAndEquipmentTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_888_eus-gaap--PropertyPlantAndEquipmentTextBlock_pn3n3_zxuNNYxexi9h" summary="xdx: Disclosure - Property and Equipment (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8BD_zs6Z0Myh0Hbi" style="display: none">Schedule of property and equipment, net</span></td><td>&#160;</td>
    <td colspan="2" id="xdx_49E_20250331_z9n1dCl0j75c" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_497_20240331_zR6mXFTmjlm" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March&#160;31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--MachineryAndEquipmentGross_iI_pn3p0_maPPAEGzAkZ_zUBy7HDgQ867" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: left">Manufacturing, lab, and other equipment</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:MachineryAndEquipmentGross" contextRef="AsOf2025-03-31" id="Fact000770" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">1,471,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:MachineryAndEquipmentGross" contextRef="AsOf2024-03-31" id="Fact000771" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">1,776,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentOther_iI_pn3p0_maPPAEGzAkZ_zxcA3GMgbZJa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Office equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentOther" contextRef="AsOf2025-03-31" id="Fact000773" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">217,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentOther" contextRef="AsOf2024-03-31" id="Fact000774" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">236,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--FurnitureAndFixturesGross_iI_pn3p0_maPPAEGzAkZ_z3NHH521HaSd" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Furniture and fixtures</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FurnitureAndFixturesGross" contextRef="AsOf2025-03-31" id="Fact000776" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">121,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FurnitureAndFixturesGross" contextRef="AsOf2024-03-31" id="Fact000777" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">128,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--LeaseholdImprovementsGross_iI_pn3p0_maPPAEGzAkZ_zbSBLjCOr9A1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Leasehold improvements</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LeaseholdImprovementsGross" contextRef="AsOf2025-03-31" id="Fact000779" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">491,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LeaseholdImprovementsGross" contextRef="AsOf2024-03-31" id="Fact000780" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">605,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--PropertyPlantAndEquipmentGross_iTI_pn3p0_mtPPAEGzAkZ_maPPAENzQSU_zKZxcPJYZCbd" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><b style="display: none">Property and equipment, gross</b></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2025-03-31" id="Fact000782" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">2,300,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2024-03-31" id="Fact000783" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">2,745,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3p0_di_msPPAENzQSU_zOs97KtK8Qfk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Less: accumulated depreciation</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2025-03-31" id="Fact000785" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">2,075,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2024-03-31" id="Fact000786" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">2,380,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3p0_mtPPAENzQSU_zK7EHdnHWqpf" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total property and equipment, net <span style="color: #EEEEEE">and equipment, net&#160;</span></span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2025-03-31" id="Fact000788" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">225,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2024-03-31" id="Fact000789" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">365,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Depreciation expense amounted to $<span id="xdx_901_eus-gaap--DepreciationAndAmortization_pn3p0_c20240401__20250331_zfwQMkQNAHb7" title="Depreciation and amortization"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2024-04-01to2025-03-31" id="Fact000791" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">138,000</ix:nonFraction></span> and $<span id="xdx_90C_eus-gaap--DepreciationAndAmortization_pn3p0_c20230401__20240331_zAPtBAVcPSpe" title="Depreciation and amortization"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2023-04-012024-03-31" id="Fact000793" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">176,000</ix:nonFraction></span>
for the years ended March 31, 2025 and 2024, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<ix:exclude><p id="xdx_233_z59IWttaZXK7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p></ix:exclude>

<ix:exclude><p id="xdx_23C_zjPAwnmzBNUa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p></ix:exclude>

<ix:exclude><p id="xdx_237_zvxjdZLzvERc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b></b></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 60 -->
    <div id="xdx_236_z6nrVsTJG8Vb" style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_235_z4kzhsv3njY8" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_231_ztezZNTge9A1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-04-01to2025-03-31" escape="true" id="Fact000799" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"><p id="xdx_80D_eus-gaap--AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_zwQ0M4ycZMub" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE&#160;8&#160;&#8211; <span id="xdx_821_zWNSERa4bEph">Accrued Expenses and Other
Current Liabilities</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Accrued expenses and other current liabilities consist
of the following:</p>

<ix:nonNumeric contextRef="From2024-04-01to2025-03-31" escape="true" id="Fact000801" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_885_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zkHL2a7Xoyx9" summary="xdx: Disclosure - Accrued Expenses and Other Current Liabilities (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B5_zuEwrbCu4g82" style="display: none">Schedule of accrued expenses and other current liabilities</span></td><td>&#160;</td>
    <td colspan="2" id="xdx_49E_20250331_zU8fZsWO8wXj" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_491_20240331_z1rtcf5snPN1" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March&#160;31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_pn3p0_maAPAOAzS7o_zMaukLFPSq68" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: left">Salaries and related costs</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="AsOf2025-03-31" id="Fact000803" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">1,737,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="AsOf2024-03-31" id="Fact000804" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">1,419,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pn3p0_maAPAOAzS7o_zxgsIUe1e6v4" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="AsOf2025-03-31" id="Fact000806" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">487,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="AsOf2024-03-31" id="Fact000807" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">694,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AccountsPayableAndOtherAccruedLiabilities_iTI_pn3p0_mtAPAOAzS7o_zRhlHzF9G3Fk" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total accrued expenses and other current liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableAndOtherAccruedLiabilities" contextRef="AsOf2025-03-31" id="Fact000809" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">2,224,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableAndOtherAccruedLiabilities" contextRef="AsOf2024-03-31" id="Fact000810" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">2,113,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-04-01to2025-03-31" escape="true" id="Fact000812" name="us-gaap:DebtDisclosureTextBlock"><p id="xdx_809_eus-gaap--DebtDisclosureTextBlock_zf3iuuLFGDt6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE&#160;9&#160;&#8211; <span id="xdx_82A_zbSP1oDUQKbl">Debt</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Financing of Insurance Premiums</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 1, 2025, the Company entered into a note
agreement for $<span id="xdx_908_eus-gaap--DebtInstrumentFaceAmount_iI_pn3p0_c20250201__us-gaap--ShortTermDebtTypeAxis__custom--InsurancePremiumFinancingMember_z6D9IZQbc1ce" title="Debt face amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2025-02-01_custom_InsurancePremiumFinancingMember" id="Fact000814" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">274,000</ix:nonFraction></span> with an interest rate of <span id="xdx_906_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pip0_dp_c20250130__20250201__us-gaap--ShortTermDebtTypeAxis__custom--InsurancePremiumFinancingMember_zQLYfHKP5Zqf" title="Debt interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" contextRef="From2025-01-302025-02-01_custom_InsurancePremiumFinancingMember" id="Fact000816" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">7.97</ix:nonFraction></span>% per annum with final payment on <span id="xdx_901_eus-gaap--DebtInstrumentMaturityDateRangeEnd1_dd_c20250130__20250201__us-gaap--ShortTermDebtTypeAxis__custom--InsurancePremiumFinancingMember_zi9ac9vuPvTh" title="Final payment date"><ix:nonNumeric contextRef="From2025-01-302025-02-01_custom_InsurancePremiumFinancingMember" format="ixt:datemonthdayyearen" id="Fact000818" name="us-gaap:DebtInstrumentMaturityDateRangeEnd1">November 1, 2025</ix:nonNumeric></span>. This instrument was issued in
connection with financing insurance premiums. On February 5, 2025, the Company made an initial payment of $<span id="xdx_900_eus-gaap--ProceedsFromShortTermDebt_pn3p0_c20250130__20250201__us-gaap--ShortTermDebtTypeAxis__custom--InsurancePremiumFinancingMember_zwMRdhRcd107" title="Debt initial payment"><ix:nonFraction name="us-gaap:ProceedsFromShortTermDebt" contextRef="From2025-01-302025-02-01_custom_InsurancePremiumFinancingMember" id="Fact000820" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">28,000</ix:nonFraction></span>. The note is payable
in <span id="xdx_90E_eus-gaap--DebtInstrumentPaymentTerms_c20250130__20250201__us-gaap--ShortTermDebtTypeAxis__custom--InsurancePremiumFinancingMember_zBYRsQBFJ2sk" title="Debt payment terms"><ix:nonNumeric contextRef="From2025-01-302025-02-01_custom_InsurancePremiumFinancingMember" id="Fact000822" name="us-gaap:DebtInstrumentPaymentTerms">nine monthly installment payments</ix:nonNumeric></span> of principal and interest of $<span id="xdx_908_eus-gaap--DebtInstrumentPeriodicPayment_pn3p0_c20250130__20250201__us-gaap--ShortTermDebtTypeAxis__custom--InsurancePremiumFinancingMember_z1FOs0u9Hq98" title="Periodic payment"><ix:nonFraction name="us-gaap:DebtInstrumentPeriodicPayment" contextRef="From2025-01-302025-02-01_custom_InsurancePremiumFinancingMember" id="Fact000824" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">28,000</ix:nonFraction></span>, with the first monthly installment beginning <span id="xdx_902_eus-gaap--DebtInstrumentMaturityDateRangeStart1_dd_c20250130__20250201__us-gaap--ShortTermDebtTypeAxis__custom--InsurancePremiumFinancingMember_zuDv6lc2s7T9" title="First installment beginning date"><ix:nonNumeric contextRef="From2025-01-302025-02-01_custom_InsurancePremiumFinancingMember" format="ixt:datemonthdayyearen" id="Fact000826" name="us-gaap:DebtInstrumentMaturityDateRangeStart1">March 1, 2025</ix:nonNumeric></span>.
At March 31, 2025, the outstanding principal on the note amounted to $<span id="xdx_900_eus-gaap--OtherLongTermDebtCurrent_iI_pn3p0_c20250331__us-gaap--ShortTermDebtTypeAxis__custom--InsurancePremiumFinancingMember_zUlksarRYmBb" title="Outstanding principal amount"><ix:nonFraction name="us-gaap:OtherLongTermDebtCurrent" contextRef="AsOf2025-03-31_custom_InsurancePremiumFinancingMember" id="Fact000828" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">220,000</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 6, 2024, the Company entered into a note
agreement for $<span id="xdx_90A_eus-gaap--DebtInstrumentFaceAmount_iI_pn3p0_c20240206__us-gaap--ShortTermDebtTypeAxis__custom--InsurancePremiumFinancingMember_zweZ8YEW6YD3" title="Debt face amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2024-02-06_custom_InsurancePremiumFinancingMember" id="Fact000830" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">373,000</ix:nonFraction></span> with an interest rate of <span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pip0_dp_c20240205__20240206__us-gaap--ShortTermDebtTypeAxis__custom--InsurancePremiumFinancingMember_zMRZjv7rhtOj" title="Debt interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" contextRef="From2024-02-052024-02-06_custom_InsurancePremiumFinancingMember" id="Fact000832" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8.42</ix:nonFraction></span>% per annum with final payment on <span id="xdx_909_eus-gaap--DebtInstrumentMaturityDateRangeEnd1_dd_c20240205__20240206__us-gaap--ShortTermDebtTypeAxis__custom--InsurancePremiumFinancingMember_zmAyTBwnqGdb" title="Final payment date"><ix:nonNumeric contextRef="From2024-02-052024-02-06_custom_InsurancePremiumFinancingMember" format="ixt:datemonthdayyearen" id="Fact000834" name="us-gaap:DebtInstrumentMaturityDateRangeEnd1">November 1, 2024</ix:nonNumeric></span>. This instrument was issued in
connection with financing insurance premiums. The note is payable in <span id="xdx_901_eus-gaap--DebtInstrumentPaymentTerms_c20240205__20240206__us-gaap--ShortTermDebtTypeAxis__custom--InsurancePremiumFinancingMember_zJNB6Y6rdobh" title="Debt payment terms"><ix:nonNumeric contextRef="From2024-02-052024-02-06_custom_InsurancePremiumFinancingMember" id="Fact000836" name="us-gaap:DebtInstrumentPaymentTerms">nine monthly installment payments</ix:nonNumeric></span> of principal and interest of $<span id="xdx_90A_eus-gaap--DebtInstrumentPeriodicPayment_pn3p0_c20240205__20240206__us-gaap--ShortTermDebtTypeAxis__custom--InsurancePremiumFinancingMember_zJNI8vUL2LD6" title="Periodic payment"><ix:nonFraction name="us-gaap:DebtInstrumentPeriodicPayment" contextRef="From2024-02-052024-02-06_custom_InsurancePremiumFinancingMember" id="Fact000838" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">42,000</ix:nonFraction></span>,
with the first installment beginning <span id="xdx_90F_eus-gaap--DebtInstrumentMaturityDateRangeStart1_dd_c20240205__20240206__us-gaap--ShortTermDebtTypeAxis__custom--InsurancePremiumFinancingMember_zpnF6FVVNUhi" title="First installment beginning date"><ix:nonNumeric contextRef="From2024-02-052024-02-06_custom_InsurancePremiumFinancingMember" format="ixt:datemonthdayyearen" id="Fact000840" name="us-gaap:DebtInstrumentMaturityDateRangeStart1">March 1, 2024</ix:nonNumeric></span>. At March 31, 2024, the outstanding principal on the note amounted to $<span id="xdx_906_eus-gaap--OtherLongTermDebtCurrent_iI_pn3p0_c20240331__us-gaap--ShortTermDebtTypeAxis__custom--InsurancePremiumFinancingMember_zArR7BfJnsL7" title="Outstanding principal amount"><ix:nonFraction name="us-gaap:OtherLongTermDebtCurrent" contextRef="AsOf2024-03-31_custom_InsurancePremiumFinancingMember" id="Fact000842" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">323,000</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>&#160;</i></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-04-01to2025-03-31" escape="true" id="Fact000844" name="us-gaap:LesseeOperatingLeasesTextBlock"><p id="xdx_800_eus-gaap--LesseeOperatingLeasesTextBlock_zC5uS6PUIULd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE&#160;10&#160;&#8211; <span id="xdx_826_zY69HiYYyIW6">Leases</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s operating leases are comprised
primarily of facility leases. Balance sheet information related to the Company&#8217;s leases is presented below:</p>

<ix:nonNumeric contextRef="From2024-04-01to2025-03-31" escape="true" id="Fact000846" name="us-gaap:LeaseCostTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--LeaseCostTableTextBlock_pn3n3_zvNwdzhJdoV1" summary="xdx: Disclosure - Leases (Details - Balance sheet information related to leases)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8BE_zVgwzlUfHuE5" style="display: none">Schedule of lease information</span></td><td>&#160;</td>
    <td colspan="2" id="xdx_49A_20250331_zgufW7mhuRC5" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_493_20240331_z7WQg1YtTAif" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">March 31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">March 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LeasesOperatingAbstract_iB_zhAvz7KwSmok" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="font-weight: bold; text-align: justify">Operating leases:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3p0_zC45qOjy3EG1" style="vertical-align: bottom; background-color: White">
    <td style="width: 66%; text-align: justify">Operating lease right-of-use assets</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2025-03-31" id="Fact000851" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">84,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2024-03-31" id="Fact000852" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">286,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pn3p0_zkl11NlOGgGk" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify">Operating lease liabilities &#8211; current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2025-03-31" id="Fact000854" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">58,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2024-03-31" id="Fact000855" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">198,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pn3p0_zALlRW1HaZgj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Operating lease liabilities &#8211; non-current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2025-03-31" id="Fact000857" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">27,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2024-03-31" id="Fact000858" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">87,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Other information related to leases is presented below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Year ended</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>March 31, 2025</b></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year ended<br/> March 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="font-weight: bold; text-align: left">Lease cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 66%; text-align: left">Operating lease cost</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--OperatingLeaseCost_pn3p0_c20240401__20250331_zBwtpOYMj9a7" title="Operating lease cost" style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="From2024-04-01to2025-03-31" id="Fact000860" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">365,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--OperatingLeaseCost_pn3p0_c20230401__20240331_zfY39wOUQiba" title="Operating lease cost" style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="From2023-04-012024-03-31" id="Fact000862" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">380,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Other information:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Operating cash flows from operating leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--OperatingLeaseRightOfUseAssetAmortizationExpense_iN_pn3p0_di_c20240401__20250331_zAZcXdqojH6j" title="Operating cash flows from operating leases" style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" contextRef="From2024-04-01to2025-03-31" id="Fact000864" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">174,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--OperatingLeaseRightOfUseAssetAmortizationExpense_iN_pn3p0_di_c20230401__20240331_z7WHCMHY2tmh" title="Operating cash flows from operating leases" style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" contextRef="From2023-04-012024-03-31" id="Fact000866" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">161,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left">Weighted-average remaining lease term &#8211; operating leases (in months)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtM_c20250331_zRzeA2SONKLh" title="Weighted-average remaining lease term - operating leases (in months)"><ix:nonNumeric contextRef="AsOf2025-03-31" format="ixt-sec:durmonth" id="Fact000868" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">18.6</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtM_c20240331_z21BxoyaMxhe" title="Weighted-average remaining lease term - operating leases (in months)"><ix:nonNumeric contextRef="AsOf2024-03-31" format="ixt-sec:durmonth" id="Fact000870" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">19.7</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Weighted-average discount rate &#8211; operating leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pip0_dp_c20250331_zzOMOER59w7k" title="Weighted-average discount rate - operating leases"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2025-03-31" id="Fact000872" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">6</ix:nonFraction></span>%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pip0_dp_c20240331_zOIx4b0dGIif" title="Weighted-average discount rate - operating leases"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2024-03-31" id="Fact000874" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">6</ix:nonFraction></span>%</td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AA_zOYTYpaACjg1" style="font: 10pt Times New Roman, Times, Serif; margin: 0 180.1pt 0 0">&#160;</p>

<ix:exclude><p id="xdx_239_zrJWsZfG0Qn4" style="font: 10pt Times New Roman, Times, Serif; margin: 0 180.1pt 0 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23F_zf9YSfrTUaZg" style="font: 10pt Times New Roman, Times, Serif; margin: 0 180.1pt 0 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_231_z01HianelI4h" style="font: 10pt Times New Roman, Times, Serif; margin: 0 180.1pt 0 0"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 61 -->
    <div id="xdx_237_zv2fvXEBdKH7" style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_23F_zl88J5dignzf" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23B_zvkxaXxRTJJ7" style="font: 10pt Times New Roman, Times, Serif; margin: 0 180.1pt 0 0">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">As of March 31, 2025, the annual future minimum lease payments of the Company&#8217;s
operating lease liabilities were as follows:</p>

<ix:nonNumeric contextRef="From2024-04-01to2025-03-31" escape="true" id="Fact000880" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_887_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_pn3n3_zyWVFHP7mcj9" summary="xdx: Disclosure - Leases (Details - Minimum operating lease payments)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8BC_zMJZyieoKFmi" style="display: none">Schedule of minimum operating lease liabilities</span></td><td>&#160;</td>
    <td colspan="2" id="xdx_49B_20250331_zvZ7p8HAJc2j" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">For Years Ending March 31,</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3p0_maLOLLPzr9e_zg9ESGkvQgDf" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 83%; text-align: left">2026</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="AsOf2025-03-31" id="Fact000882" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">66,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3p0_maLOLLPzr9e_zyl3qcov8ATg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="AsOf2025-03-31" id="Fact000884" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">15,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pn3p0_maLOLLPzr9e_zXwZBBpZM3s2" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">2028</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="AsOf2025-03-31" id="Fact000886" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">9,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3p0_mtLOLLPzr9e_zzCztFJhxg8e" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total future minimum lease payments, undiscounted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="AsOf2025-03-31" id="Fact000888" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">90,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3p0_di_zN7HJc4WNBEh" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Less: imputed interest</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="AsOf2025-03-31" id="Fact000890" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">5,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--OperatingLeaseLiability_iI_pn3p0_zBzqBni5eROf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total lease liability</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2025-03-31" id="Fact000892" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">85,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-04-01to2025-03-31" escape="true" id="Fact000894" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p id="xdx_809_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zIznzNyWyJjh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE&#160;11&#160;&#8211; <span id="xdx_823_zZJKuFOPQlz2">Commitments and Contingencies</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Legal Matters</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company may be involved in legal matters arising
in the ordinary course of business including matters involving proprietary technology. While management believes that such matters are
currently insignificant, matters arising in the ordinary course of business for which the Company is or could become involved in litigation
may have a material adverse effect on its business and financial condition of comprehensive loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Employment Agreements</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has employment agreements in place with
two of its key executives. These executive employment agreements provide, among other things, for the payment of up to eighteen months
of severance compensation for terminations under certain circumstances.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of March 31, 2025, with respect to these agreements,
aggregated annual salaries was $<span id="xdx_907_eus-gaap--OfficersCompensation_pn3p0_c20240401__20250331_zlQsSql2MIYi" title="Annual salaries"><ix:nonFraction name="us-gaap:OfficersCompensation" contextRef="From2024-04-01to2025-03-31" id="Fact000896" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">586,000</ix:nonFraction></span> and potential severance payments to these key executives was $<span id="xdx_90A_ecustom--PotentialSeverancePayments_iI_pn3p0_c20250331_z9m8vl2LFuya" title="Potential severance payments"><ix:nonFraction name="SNOA:PotentialSeverancePayments" contextRef="AsOf2025-03-31" id="Fact000898" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">1,300,000</ix:nonFraction></span>, if triggered.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-04-01to2025-03-31" escape="true" id="Fact000900" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_80E_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zNBRq5QPJgRi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE&#160;12&#160;&#8211; <span id="xdx_82F_zs30ER1LAR56">Stockholders&#8217; Equity</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Authorized Capital</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Effective August 29, 2024, the Company increased its
authorized shares from <span id="xdx_90B_eus-gaap--CommonStockSharesAuthorized_iI_pip0_c20240829__srt--RangeAxis__srt--MinimumMember_zCSblRwPg4Kj" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2024-08-29_srt_MinimumMember" id="Fact000902" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">24,000,000</ix:nonFraction></span> to <span id="xdx_909_eus-gaap--CommonStockSharesAuthorized_iI_pip0_c20240829__srt--RangeAxis__srt--MaximumMember_zpDGzBELJzz8" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2024-08-29_srt_MaximumMember" id="Fact000904" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">50,000,000</ix:nonFraction></span> shares of common stock with a par value of $<span id="xdx_90C_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20240829_zMVH3ouVABuh" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2024-08-29" id="Fact000906" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span> per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Additionally, the Company is authorized to issue <span id="xdx_903_eus-gaap--PreferredStockSharesAuthorized_iI_pip0_c20250331__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zGMo66xNomC" title="Convertible preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2025-03-31_us-gaap_ConvertiblePreferredStockMember" id="Fact000908" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">714,286</ix:nonFraction></span>
shares of convertible preferred stock with a par value of $<span id="xdx_909_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20250331__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zwr5d8BXwey6" title="Convertible preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2025-03-31_us-gaap_ConvertiblePreferredStockMember" id="Fact000910" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span> per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Description of Common Stock</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Each share of common stock has the right to one vote.
The holders of common stock are entitled to dividends when funds are legally available and when declared by the board of directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_232_zRQsLg79pTY6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_230_zKuIGNxqDutl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23C_zGA7m9Nh8o3b" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 62 -->
    <div id="xdx_231_zytew6VRjrhc" style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_239_zfJIKeyAd1rd" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23B_zrPlqGCHWTlb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Description of Series B Convertible Preferred
Stock</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On October 18, 2016, the Company&#8217;s board of
directors approved, and the Company entered into, a Section 382 rights agreement, or the Rights Agreement, with Computershare Inc., or
the Rights Agent. The Rights Agreement provides for a dividend of one preferred stock purchase right, or a Right, for each share of common
stock, par value $0.0001 per share, of the Company outstanding on November 1, 2016, or the Record Date. Each Right entitles the holder
to purchase from the Company one one-thousandth of a share of Series B Preferred Stock, par value $0.0001 per share, or the Preferred
Stock, for a purchase price of $10.00, subject to adjustment as provided in the Rights Agreement. The description and terms of the rights
are set forth in the Rights Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In connection with the adoption of the Rights Agreement,
the Company&#8217;s board of directors adopted a Certificate of Designation of Series B Preferred Stock. The Certificate of Designation
was filed with the Secretary of State of the State of Delaware and became effective on October 18, 2016.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s board of directors adopted the
Rights Agreement to protect shareholder value by guarding against a potential limitation on the Company&#8217;s ability to use its net
operating loss carryforwards, or NOLs, and other tax benefits, which may be used to reduce potential future income tax obligations. The
Company has experienced and continues to experience substantial operating losses, and under the Internal Revenue Code of 1986, as amended,
and rules promulgated thereunder, the Company may &#8220;carry forward&#8221; these NOLs and other tax benefits in certain circumstances
to offset any current and future earnings and thus reduce our income tax liability, subject to certain requirements and restrictions.
To the extent that the NOLs and other tax benefits do not otherwise become limited, the Company believes that it will be able to carry
forward a significant amount of NOLs and other tax benefits, and therefore these NOLs and other tax benefits could be a substantial asset
to the Company. However, if the Company experiences an &#8220;ownership change,&#8221; as defined in Section 382 of the Code, its ability
to use its NOLs and other tax benefits will be substantially limited. Generally, an ownership change would occur if our shareholders who
own, or are deemed to own, 5% or more of the Company&#8217;s common stock increase their collective ownership in the Company by more than
50% over a rolling three-year period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Sale of Common Stock</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On October 26, 2023, the Company entered into a placement
agency agreement with Maxim Group LLC (&#8220;Maxim&#8221;) pursuant to which Maxim agreed to use its reasonable best efforts to solicit
offers to purchase up to an aggregate of 425,000 shares of the Company&#8217;s common stock, par value $0.0001 per share.&#160; The Company
agreed to pay Maxim a cash fee equal to 8.0% of the gross proceeds from the offering, plus reimbursement of up to $<span id="xdx_903_eus-gaap--LegalFees_pn3p0_c20231025__20231026__us-gaap--TypeOfArrangementAxis__custom--PlacementAgencyAgreementMember_zgkJeKmteNn3" title="Legal fees and other expenses"><ix:nonFraction name="us-gaap:LegalFees" contextRef="From2023-10-252023-10-26_custom_PlacementAgencyAgreementMember" id="Fact000916" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">75,000</ix:nonFraction></span> of legal fees
and other expenses. Additionally, on October 26, 2023, the Company entered into a securities purchase agreement with the purchasers party
thereto for the sale and issuance of an aggregate of up to 425,000 shares of the Company&#8217;s common stock at a public offering price
of $4.00 per share. The closing of the offering occurred on October 30, 2023. In connection with the offering, the Company sold <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20231025__20231026__us-gaap--SubsidiarySaleOfStockAxis__custom--PublicOfferingMember_zSqya5SkFv61" title="Stock issued new, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-10-252023-10-26_custom_PublicOfferingMember" id="Fact000918" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">425,000</ix:nonFraction></span>
shares of the Company&#8217;s common stock for aggregate gross proceeds of $<span id="xdx_905_ecustom--ProceedsFromIssuanceOfCommonStockGross_pn3p0_c20231025__20231026__us-gaap--SubsidiarySaleOfStockAxis__custom--PublicOfferingMember_z5Zvy5nyafxl" title="Proceeds from sale of stock, gross"><ix:nonFraction name="SNOA:ProceedsFromIssuanceOfCommonStockGross" contextRef="From2023-10-252023-10-26_custom_PublicOfferingMember" id="Fact000920" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">1,700,000</ix:nonFraction></span> and net proceeds of $<span id="xdx_900_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn3p0_c20231025__20231026__us-gaap--SubsidiarySaleOfStockAxis__custom--PublicOfferingMember_zETqH2yfExl7" title="Proceeds from sale of stock, net"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2023-10-252023-10-26_custom_PublicOfferingMember" id="Fact000922" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">1,446,000</ix:nonFraction></span>, after deducting
placement agent fees and other estimated offering expenses paid by the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On December 15, 2023, the Company entered into an
Equity Distribution Agreement (the &#8220;Agreement&#8221;), with Maxim pursuant to which the Company may offer and sell, from time to
time, through Maxim, as sales agent or principal, shares of its common stock, $0.0001 par value per share. Subject to the terms and conditions
of the Agreement, Maxim will use commercially reasonable efforts consistent with its normal trading and sales practices, applicable state
and federal law, rules and regulations and the rules of the Nasdaq Capital Market to sell shares from time to time based upon the Company&#8217;s
instructions, including any price, time or size limits specified by the Company. Under the Agreement, Maxim may sell shares by any method
deemed to be an &#8220;at the market&#8221; offering as defined in Rule 415 under the U.S. Securities Act of 1933, as amended, or any
other method permitted by law, including in privately negotiated transactions. Maxim&#8217;s obligations to sell shares under the Agreement
are subject to satisfaction of certain conditions, including customary closing conditions for transactions of this nature. The Company
will pay Maxim a commission of 3% of the aggregate gross proceeds from each sale of shares and has agreed to provide Maxim with customary
indemnification and contribution rights. The Company also agreed to reimburse Maxim for certain specified expenses of up to $<span id="xdx_90B_eus-gaap--LegalFees_pn3p0_c20231214__20231215__us-gaap--TypeOfArrangementAxis__custom--EquityDistributionAgreementMember_zNJUJvAUgosh" title="Legal fees and other expenses"><ix:nonFraction name="us-gaap:LegalFees" contextRef="From2023-12-142023-12-15_custom_EquityDistributionAgreementMember" id="Fact000924" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">20,000</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<ix:exclude><p id="xdx_23E_zEfdv2F68KDl" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p></ix:exclude>

<ix:exclude><p id="xdx_23C_z411qsWlU7Ff" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p></ix:exclude>

<ix:exclude><p id="xdx_23E_zZ0ey4tYSNK3" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b></b></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 63 -->
    <div id="xdx_233_zOefA1614WP5" style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_237_zx1i9gZcH0Ee" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23B_zPDn6vA3gHvg" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In
connection with the</span> A<span style="font-family: Times New Roman, Times, Serif">greement that the Company entered into on December
15, 2023 with Maxim, on January 11, 2024, the Company sold <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20240110__20240111__dei--LegalEntityAxis__custom--MaximGroupLLCMember_zSmkghBrYNS8" title="Stock issued new, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-01-102024-01-11_custom_MaximGroupLLCMember" id="Fact000930" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">96,154</ix:nonFraction></span> shares of its common stock for gross proceeds of $<span id="xdx_909_ecustom--ProceedsFromIssuanceOfCommonStockGross_pn3p0_c20240110__20240111__dei--LegalEntityAxis__custom--MaximGroupLLCMember_z1jGynMJqfx3" title="Proceeds from sale of stock, gross"><ix:nonFraction name="SNOA:ProceedsFromIssuanceOfCommonStockGross" contextRef="From2024-01-102024-01-11_custom_MaximGroupLLCMember" id="Fact000932" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">392,000</ix:nonFraction></span> and net proceeds
of $<span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn3p0_c20240110__20240111__dei--LegalEntityAxis__custom--MaximGroupLLCMember_zkG4yvQpN5Ff" title="Proceeds from sale of stock, net"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2024-01-102024-01-11_custom_MaximGroupLLCMember" id="Fact000934" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">338,000</ix:nonFraction></span> after deducting commissions and other estimated offering expenses paid by the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In connection with the Agreement that the Company
entered into on December 15, 2023 with Maxim, as amended, from May 13, 2024 to November 20, 2024 the Company sold <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20241119__20241120__dei--LegalEntityAxis__custom--MaximGroupLLCMember_zdXXzV6fRGLf" title="Stock issued new, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2024-11-192024-11-20_custom_MaximGroupLLCMember" id="Fact000936" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">816,894</ix:nonFraction></span> shares of its
common stock for gross proceeds of $<span id="xdx_90B_ecustom--ProceedsFromIssuanceOfCommonStockGross_pn3p0_c20241119__20241120__dei--LegalEntityAxis__custom--MaximGroupLLCMember_zATTioopjeic" title="Proceeds from sale of stock, gross"><ix:nonFraction name="SNOA:ProceedsFromIssuanceOfCommonStockGross" contextRef="From2024-11-192024-11-20_custom_MaximGroupLLCMember" id="Fact000938" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">3,325,000</ix:nonFraction></span> and net proceeds of $<span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn3p0_c20241119__20241120__dei--LegalEntityAxis__custom--MaximGroupLLCMember_zZpbSZerThTc" title="Proceeds from sale of stock, net"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2024-11-192024-11-20_custom_MaximGroupLLCMember" id="Fact000940" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">3,079,000</ix:nonFraction></span> after deducting commissions and other offering expenses paid
by the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-04-01to2025-03-31" escape="true" id="Fact000942" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"><p id="xdx_802_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zqaVTI7J934i" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE&#160;13&#160;&#8211; <span id="xdx_82E_zjPQGi9SFVM1">Stock-Based Compensation</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>2016 Stock Plan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 2, 2016, upon recommendation of the board,
the stockholders approved the Company&#8217;s 2016 Equity Incentive Plan (the &#8220;2016 Plan&#8221;). The 2016 Plan is effective as
of September 2, 2016 and has a ten year term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The 2016 Plan provides for the grant of options, including
incentive stock options as defined in Section 422 of the Internal Revenue Code to employees, stock appreciation rights, restricted awards,
performance share awards and performance compensation awards to employees, non-employee directors, advisors and consultants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Options issued under the 2016 Plan generally have
a ten-year term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In accordance with the 2016 Plan, the stated exercise
price of an employee incentive stock option or a non-statutory stock option shall not be less than 100% of the estimated fair market value
of a share of common stock on the date of grant. An employee who owns more than 10% of the total combined voting power of all classes
of outstanding stock of the Company shall not be eligible for the grant of an employee incentive stock option unless such grant satisfies
the requirements of Section 422(c)(5) of the Internal Revenue Code.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Shares subject to awards that expire unexercised or
are forfeited or terminated for any other reason will again become available for issuance under the 2016 Plan. No participant in the 2016
Plan can receive more than 11,112 option grants, or other awards with respect to more than 13,334 shares in the aggregate in any calendar
year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The board has authorized <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pip0_c20160902__us-gaap--PlanNameAxis__custom--Plan2016Member_zxqGZiKKFJWh" title="Shares initially authorized for issuance"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="AsOf2016-09-02_custom_Plan2016Member" id="Fact000944" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">2,222</ix:nonFraction></span> of the Company&#8217;s
common stock for issuance under the 2016 Plan, in addition to automatic increases provided for in the 2016 Plan through April 1, 2026.
The number of shares of the Company&#8217;s common stock reserved for issuance under the 2016 Plan will automatically increase, with no
further action by the stockholders, at the beginning of each fiscal year by an amount equal to the lesser of (i) 8% of the outstanding
shares of the Company&#8217;s common stock on the last day of the immediately preceding year, or (ii) an amount determined by the Company&#8217;s
board of directors. During the year ended March 31, 2019, the board of directors approved an increase of <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_pip0_c20180401__20190331__us-gaap--PlanNameAxis__custom--Plan2016Member_zCvCujZ2cDWc" title="Increase in shares authorized for issuance"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" contextRef="From2018-04-012019-03-31_custom_Plan2016Member" id="Fact000946" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">243</ix:nonFraction></span> shares authorized for issuance.
During the year ended March 31, 2020, the board of directors approved an increase of <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_pip0_c20190401__20200331__us-gaap--PlanNameAxis__custom--Plan2016Member_zXVt45xp6Gv5" title="Increase in shares authorized for issuance"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" contextRef="From2019-04-012020-03-31_custom_Plan2016Member" id="Fact000948" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">5,266</ix:nonFraction></span> shares authorized for issuance. During the
year ended March 31, 2022, the board of directors approved an increase of <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_pip0_c20210401__20220331__us-gaap--PlanNameAxis__custom--Plan2016Member_zAvMSHuQS47c" title="Increase in shares authorized for issuance"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" contextRef="From2021-04-012022-03-31_custom_Plan2016Member" id="Fact000950" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">8,372</ix:nonFraction></span> shares authorized for issuance. During the year ended
March 31, 2025, the board of directors approved an increase of <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_pip0_c20240401__20250331__us-gaap--PlanNameAxis__custom--Plan2016Member_z3ysErvDxxOg" title="Increase in shares authorized for issuance"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" contextRef="From2024-04-012025-03-31_custom_Plan2016Member" id="Fact000952" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">62,429</ix:nonFraction></span> shares authorized for issuance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At March 31, 2025 there were <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pip0_c20250331__us-gaap--PlanNameAxis__custom--Plan2016Member_zoaKrrBxjFh6" title="Shares available for future issuance"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2025-03-31_custom_Plan2016Member" id="Fact000954" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">9,670</ix:nonFraction></span> shares available
for future issuance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<ix:exclude><p id="xdx_23C_z8ZNi7maaf0f" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p></ix:exclude>

<ix:exclude><p id="xdx_233_zvFtSueJ42Ai" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p></ix:exclude>

<ix:exclude><p id="xdx_23A_zBr3Wey1vOFh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i></i></b></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 64 -->
    <div id="xdx_233_zWtvfI8cbxqi" style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_23B_zxlWWr46nOCb" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23C_zkIEIg50W7F1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>2021 Stock Plan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 21, 2021, upon recommendation of the
board, the stockholders approved the Company&#8217;s 2021 Equity Incentive Plan (the &#8220;2021 Plan&#8221;). The 2021 Plan is effective
as of September 21, 2021 and has a five year term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The 2021 Plan provides for the grant of options, including
incentive stock options as defined in Section 422 of the Internal Revenue Code to employees, stock appreciation rights, restricted awards,
performance share awards and performance compensation awards to employees, non-employee directors, advisors and consultants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Options issued under the 2021 Plan generally have
a ten-year term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In accordance with the 2021 Plan, the stated exercise
price of an employee incentive stock option or a non-statutory stock option shall not be less than 100% of the estimated fair market value
of a share of common stock on the date of grant. An employee who owns more than 10% of the total combined voting power of all classes
of outstanding stock of the Company shall not be eligible for the grant of an employee incentive stock option unless such grant satisfies
the requirements of Section 422(c)(5) of the Internal Revenue Code.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Shares subject to awards that expire unexercised or
are forfeited or terminated for any other reason will again become available for issuance under the 2021 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The board has authorized <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_pip0_c20240401__20250331__us-gaap--PlanNameAxis__custom--Plan2021Member_zzQUdcMErmH" title="Increase in shares authorized for issuance"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" contextRef="From2024-04-012025-03-31_custom_Plan2021Member" id="Fact000960" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">50,000</ix:nonFraction></span> shares of the Company&#8217;s
common stock for issuance under the 2021 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At March 31, 2025, there were <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pip0_do_c20250331__us-gaap--PlanNameAxis__custom--Plan2021Member_zRLuMUs7S8P1" title="Shares available for future issuance"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2025-03-31_custom_Plan2021Member" id="Fact000962" format="ixt-sec:numwordsen" decimals="INF" scale="0" unitRef="Shares">no</ix:nonFraction></span> shares available
for future issuance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>2024 Stock Plan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On August 23, 2024, upon recommendation of the board,
the stockholders approved the Company&#8217;s 2024 Equity Incentive Plan (the &#8220;2024 Plan&#8221;). The 2024 Plan is effective as
of August 23, 2024 and has a five year term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The 2024 Plan provides for the grant of options, including
incentive stock options as defined in Section 422 of the Internal Revenue Code to employees, stock appreciation rights, restricted awards,
performance share awards and performance compensation awards to employees, non-employee directors, advisors and consultants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Options issued under the 2024 Plan generally have
a ten-year term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In accordance with the 2024 Plan, the stated exercise
price of an employee incentive stock option or a non-statutory stock option shall not be less than 100% of the estimated fair market value
of a share of common stock on the date of grant. An employee who owns more than 10% of the total combined voting power of all classes
of outstanding stock of the Company shall not be eligible for the grant of an employee incentive stock option unless such grant satisfies
the requirements of Section 422(c)(5) of the Internal Revenue Code.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Shares subject to awards that expire unexercised or
are forfeited or terminated for any other reason will again become available for issuance under the 2024 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_237_zoEtUhplAqOh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23B_zwizgqLY7Hzg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_232_zB4bplZ6F20d" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 65 -->
    <div id="xdx_233_zXkRv9c99Zkj" style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_23A_zr6fka0CRxlf" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_236_zp7GlxgRxSq1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The board has authorized <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_pip0_c20240401__20250331__us-gaap--PlanNameAxis__custom--Plan2024Member_zexGw4wqr2y4" title="Increase in shares authorized for issuance"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" contextRef="From2024-04-012025-03-31_custom_Plan2024Member" id="Fact000968" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">50,000</ix:nonFraction></span> shares of the Company&#8217;s
common stock for issuance under the 2024 Plan, in addition to automatic increases provided for in the 2024 Plan through April 1, 2029.
The number of shares of the Company&#8217;s common stock reserved for issuance under the 2024 Plan will automatically increase, with no
further action by the stockholders, at the beginning of each fiscal year by an amount equal to the lesser of (i) 5% of the outstanding
shares of the Company&#8217;s common stock on the last day of the immediately preceding year, or (ii) an amount determined by the Company&#8217;s
board of directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At March 31, 2025, there were <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pip0_c20250331__us-gaap--PlanNameAxis__custom--Plan2024Member_z2upLwOU6v24" title="Shares available for future issuance"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2025-03-31_custom_Plan2024Member" id="Fact000970" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">5,000</ix:nonFraction></span> shares available
for future issuance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Stock-Based Compensation</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company issues service, performance and market-based
stock options to employees and non-employees. The Company estimates the fair value of service and performance stock option awards using
the Black-Scholes option pricing model. The Company estimates the fair value of market-based stock option awards using a Monte-Carlo simulation.
Compensation expense for stock option awards is amortized on a straight-line basis over the awards&#8217; vesting period. Compensation
expense includes the impact of forfeitures as they are incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The expected term of the stock options represents
the average period the stock options are expected to remain outstanding and is based on the expected term calculated using the approach
prescribed by&#160;SEC Staff Accounting Bulletin No.&#160;110 for &#8220;plain vanilla&#8221; options. The expected stock price volatility
for the Company&#8217;s stock options was determined by using an average of the historical volatilities of the Company. The Company will
continue to analyze the stock price volatility and expected term assumptions as more data for the Company&#8217;s common stock and exercise
patterns become available. The risk-free interest rate assumption is based on the U.S. Treasury instruments whose term was consistent
with the expected term of the Company&#8217;s stock options. The expected dividend assumption is based on the Company&#8217;s history
and expectation of dividend payouts.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company estimated the fair value of employee and
non-employee stock options using the Black-Scholes option pricing model. The fair value of employee stock options is being amortized on
a straight-line basis over the requisite service periods of the respective awards. The fair value of employee stock options was estimated
using the following weighted-average assumptions:</p>

<ix:nonNumeric contextRef="From2024-04-01to2025-03-31" escape="true" id="Fact000972" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_886_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zY4u1rsQxBC1" summary="xdx: Disclosure - Stock-Based Compensation (Details-Assumptions)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8BC_zxRpjcQAdiuh" style="display: none">Schedule of weighted-average assumptions of fair value of employee stock options</span></td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended March&#160;31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: left">Fair value of the Company&#8217;s common stock on date of grant</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240401__20250331_zGhb9ITzBBfg" title="Fair value of the Company common stock on date of grant" style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2024-04-01to2025-03-31" id="Fact000974" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.68</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230401__20240331_zQT76tpBxat2" title="Fair value of the Company common stock on date of grant" style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2023-04-012024-03-31" id="Fact000976" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.19</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240401__20250331_zz1tLX7P3m1h" title="Expected term"><ix:nonNumeric contextRef="From2024-04-01to2025-03-31" format="ixt-sec:duryear" id="Fact000978" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.68</ix:nonNumeric></span> yrs</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230401__20240331_zNtg5cM8buT3" title="Expected term"><ix:nonNumeric contextRef="From2023-04-012024-03-31" format="ixt-sec:duryear" id="Fact000980" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.56</ix:nonNumeric></span> yrs</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_c20240401__20250331_zAHBKkyLo7a2" title="Risk-free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2024-04-01to2025-03-31" id="Fact000982" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.57</ix:nonFraction></span>%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_c20230401__20240331_zBmVeKzH6EEl" title="Risk-free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2023-04-012024-03-31" id="Fact000984" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.87</ix:nonFraction></span>%</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pip0_dp_c20240401__20250331_zPNIAMZmm0Z5" title="Dividend yield"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2024-04-01to2025-03-31" id="Fact000986" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.00</ix:nonFraction></span>%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pip0_dp_c20230401__20240331_zYyY5GWkLyDj" title="Dividend yield"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2023-04-012024-03-31" id="Fact000988" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.00</ix:nonFraction></span>%</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>Volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20240401__20250331_zpjBiJ86d2wi" title="Volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2024-04-01to2025-03-31" id="Fact000990" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">109.91</ix:nonFraction></span>%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20230401__20240331_zkYcvPwPB4cd" title="Volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2023-04-012024-03-31" id="Fact000992" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">98.40</ix:nonFraction></span>%</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Fair value of options granted</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20240401__20250331_zWkfRIVKSqya" title="Fair value of options granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2024-04-01to2025-03-31" id="Fact000994" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.23</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20230401__20240331_zyXYILnWUOD4" title="Fair value of options granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2023-04-012024-03-31" id="Fact000996" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.15</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p id="xdx_8AD_zibMZQ3bT4Oi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the years ended March 31, 2025 and 2024, the
Company incurred $<span id="xdx_90F_eus-gaap--ShareBasedCompensation_pn3p0_c20240401__20250331_ztOeGi3NmJva" title="Stock-based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-04-01to2025-03-31" id="Fact000998" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">224,000</ix:nonFraction></span> and $<span id="xdx_906_eus-gaap--ShareBasedCompensation_pn3p0_c20230401__20240331_zhxIVoMAiJLb" title="Stock-based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-04-012024-03-31" id="Fact001000" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">516,000</ix:nonFraction></span>, respectively of stock-based compensation expense. All stock-based compensation expense incurred
is included in selling, general and administrative expense in the accompanying consolidated statements of comprehensive loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At March 31, 2025, there were unrecognized compensation
costs of $<span id="xdx_90F_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pn3p0_c20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zIJ36kpkF3za" title="Unrecognized compensation costs"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="AsOf2025-03-31_us-gaap_StockOptionMember" id="Fact001002" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">250,000</ix:nonFraction></span> related to stock options which is expected to be recognized over a weighted-average amortization period of <span id="xdx_904_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zTrGlGieQKqi" title="Weighted average amortization period"><ix:nonNumeric contextRef="From2024-04-012025-03-31_us-gaap_StockOptionMember689261046" format="ixt-sec:duryear" id="Fact001004" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">1.58</ix:nonNumeric></span> years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<ix:exclude><p id="xdx_237_za0myQbQPBo7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p></ix:exclude>

<ix:exclude><p id="xdx_235_z0yPCe59Xdml" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p></ix:exclude>

<ix:exclude><p id="xdx_239_zqJnTvPFr4K6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i></i></b></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 66 -->
    <div id="xdx_23E_znThG7gluybi" style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_236_z29O9qwF1ot9" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_232_zmKKDLSlEw67" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Stock-Based Award Activity</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Stock-based awards outstanding at March 31, 2025 under
the various plans are as follows:</p>

<ix:nonNumeric contextRef="From2024-04-01to2025-03-31" escape="true" id="Fact001010" name="SNOA:ScheduleOfStockbasedAwardsOutstandingByPlanTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_882_ecustom--ScheduleOfStockbasedAwardsOutstandingByPlanTableTextBlock_zGog1iJpO2lc" summary="xdx: Disclosure - Stock-Based Compensation (Details-Plans)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 50%">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8BA_zn1GUR3OtfLc" style="display: none">Schedule of stock based awards outstanding by plan</span></td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-weight: bold">Plan</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Stock Options</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 72%">2011 Plan</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20250331__us-gaap--PlanNameAxis__custom--Plan2011Member_zLSscwD521wg" title="Options outstanding" style="width: 24%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2025-03-31_custom_Plan2011Member" id="Fact001012" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,998</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>2016 Plan</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20250331__us-gaap--PlanNameAxis__custom--Plan2016Member_zhseAxtwgM5j" title="Options outstanding" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2025-03-31_custom_Plan2016Member" id="Fact001014" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">38,942</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 1pt">2021 Plan</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20250331__us-gaap--PlanNameAxis__custom--Plan2021Member_zaRZrqjGQqB9" title="Options outstanding" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2025-03-31_custom_Plan2021Member" id="Fact001016" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">30,141</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20250331_zcMREqnMHgh7" title="Options outstanding" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2025-03-31" id="Fact001018" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">73,081</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>


<p style="margin: 0">&#160;</p>

<p style="margin: 0">Stock options award activity is as follows:</p>

<p style="margin: 0"></p>

<ix:nonNumeric contextRef="From2024-04-01to2025-03-31" escape="true" id="Fact001020" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_881_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_pn3n3_zSphkuHyCIVj" summary="xdx: Disclosure - Stock-Based Compensation (Details-Option activity)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span id="xdx_8BF_zYoPp0tHSJnk" style="display: none">Schedule of options activity</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of<br/> Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted-<br/> Average<br/> Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted-<br/> Average<br/> Contractual Term</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Aggregate<br/> Intrinsic<br/> Value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 40%">Outstanding at April 1, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pip0_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zx9V5kvM8KD3" title="Number of options outstanding, beginning balance" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2024-03-31_us-gaap_StockOptionMember" id="Fact001022" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">51,675</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pip0_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zVFOi2NIYw16" title="Weighted-average exercise price options outstanding, beginning balance" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-03-31_us-gaap_StockOptionMember" id="Fact001024" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">62.60</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Options granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pip0_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zKZ1qZMvkHa6" title="Number of options granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2024-04-012025-03-31_us-gaap_StockOptionMember689261046" id="Fact001026" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">49,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pip0_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z12GzOa621Y1" title="Weighted-average exercise price, options granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2024-04-012025-03-31_us-gaap_StockOptionMember689261046" id="Fact001028" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">2.68</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Options exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pip0_di0_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z8CdCaZvxUol" title="Number of options exercised" style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2024-04-012025-03-31_us-gaap_StockOptionMember689261046" id="Fact001030" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">27,750</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pip0_d0_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zBHb21k4LAZb" title="Weighted-average exercise price, options exercised" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2024-04-012025-03-31_us-gaap_StockOptionMember689261046" id="Fact001032" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">2.99</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Options forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pip0_di_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zCoWwKK0Syta" title="Number of options forfeited" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" contextRef="From2024-04-012025-03-31_us-gaap_StockOptionMember689261046" id="Fact001034" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">250</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pip0_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zisavVve5yL4" title="Weighted-average exercise price, options forfeited" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2024-04-012025-03-31_us-gaap_StockOptionMember689261046" id="Fact001036" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">3.60</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Options expired</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pip0_di_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zkzyXbnj5cO2" title="Number of options expired" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextRef="From2024-04-012025-03-31_us-gaap_StockOptionMember689261046" id="Fact001038" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">94</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pip0_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zM1KFBXrAAv3" title="Weighted-average exercise price, options expired" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2024-04-012025-03-31_us-gaap_StockOptionMember689261046" id="Fact001040" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">1,485.96</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Outstanding at March 31, 2025</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pip0_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zsJbOoemMG29" title="Number of options outstanding, ending balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2025-03-31_us-gaap_StockOptionMember" id="Fact001042" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">73,081</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pip0_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zhtM1O6FwxM9" title="Weighted-average exercise price options outstanding, ending balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2025-03-31_us-gaap_StockOptionMember" id="Fact001044" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">43.27</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zTNjH8QDnwOh" title="Weighted- average contractual term outstanding"><ix:nonNumeric contextRef="From2024-04-012025-03-31_us-gaap_StockOptionMember689261046" format="ixt-sec:duryear" id="Fact001046" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">8.82</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_pip0_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zg8EMUdCHLDe" title="Aggregate intrinsic value per share, outstanding" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" contextRef="From2024-04-012025-03-31_us-gaap_StockOptionMember689261046" id="Fact001048" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">2.19</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 2.5pt">Exercisable at March 31, 2025</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pip0_c20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zW1C8HV0YNn9" title="Number of options, exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2025-03-31_us-gaap_StockOptionMember" id="Fact001050" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">39,751</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pip0_c20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zYki2puJa73b" title="Weighted-average exercise price, exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2025-03-31_us-gaap_StockOptionMember" id="Fact001052" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">74.86</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z7P2HxCcDvoi" title="Weighted- average contractual term, exercisable"><ix:nonNumeric contextRef="From2024-04-012025-03-31_us-gaap_StockOptionMember689261046" format="ixt-sec:duryear" id="Fact001054" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">7.71</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableInPeriodGrantDateIntrinsicValue_pip0_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zBANKWSBcXd6" title="Aggregate intrinsic value per share, exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="SNOA:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableInPeriodGrantDateIntrinsicValue" contextRef="From2024-04-012025-03-31_us-gaap_StockOptionMember689261046" id="Fact001056" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">2.19</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The aggregate intrinsic value of stock options is
calculated as the difference between the exercise price of the underlying stock options and the fair value of the Company&#8217;s common
stock, or $<span id="xdx_908_eus-gaap--SharePrice_iI_pip0_c20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zJpIuheUoJa5"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2025-03-31_us-gaap_StockOptionMember" id="Fact001057" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">2.19</ix:nonFraction></span> and $<span id="xdx_904_eus-gaap--SharePrice_iI_pip0_c20240331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zIeqOGEM4xSl"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2024-03-31_us-gaap_StockOptionMember" id="Fact001058" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">3.40</ix:nonFraction></span> per share at March 31, 2025 and 2024, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Restricted stock award activity is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>



<p style="margin: 0"></p>

<ix:nonNumeric contextRef="From2024-04-01to2025-03-31" escape="true" id="Fact001060" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_885_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_pn3n3_zNHiu2hCpU8i" summary="xdx: Disclosure - Stock-Based Compensation (Details-Restricted stock activity)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span id="xdx_8B8_zLuSztfe4RUj" style="display: none">Schedule of unvested restricted stock activity</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1.8pt 0 0; text-align: center"><b>Number&#160;of</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1.8pt 0 0; text-align: center"><b>Shares</b></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1.8pt 0 0; text-align: center"><b>Weighted</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1.8pt 0 0; text-align: center"><b>Average Award</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1.8pt 0 0; text-align: center"><b>Date Fair Value</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1.8pt 0 0; text-align: center"><b>per Share</b></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Unvested restricted stock awards outstanding at April 1, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pip0_d0_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zucBrBhKZoA8" title="Number of unvested restricted stock awards outstanding, beginning balance" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2024-03-31_us-gaap_RestrictedStockMember" id="Fact001062" format="ixt:zerodash" decimals="INF" scale="0" unitRef="Shares">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pip0_d0_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zXq3ujbUAXXf" title="Weighted-average award date fair value per share, unvested RSAs outstanding, beginning balance" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2024-03-31_us-gaap_RestrictedStockMember" id="Fact001064" format="ixt:zerodash" decimals="INF" scale="0" unitRef="USDPShares">&#8211;</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 66%; text-align: left">Restricted stock awards granted</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pip0_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zuse3bs8vKrd" title="Number of restricted stock awards granted" style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2024-04-012025-03-31_us-gaap_RestrictedStockMember" id="Fact001066" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">54,538</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pip0_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zYJzBOqrstdg" title="Weighted-average award date fair value per share, unvested RSAs granted" style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2024-04-012025-03-31_us-gaap_RestrictedStockMember" id="Fact001068" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">2.92</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Restricted stock awards vested</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pip0_di_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zNlWPajOM1qa" title="Number of restricted stock awards vested" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="From2024-04-012025-03-31_us-gaap_RestrictedStockMember" id="Fact001070" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">9,538</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pip0_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zspybwAIX0A1" title="Weighted-average award date fair value per share, unvested RSAs vested" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="From2024-04-012025-03-31_us-gaap_RestrictedStockMember" id="Fact001072" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">4.08</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Unvested restricted stock awards outstanding at March 31, 2025</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pip0_d0_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zTz3dcreSpfl" title="Number of unvested restricted stock awards outstanding, ending balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2025-03-31_us-gaap_RestrictedStockMember" id="Fact001074" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="Shares">45,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pip0_d0_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zvKukhiSkyRd" title="Weighted-average award date fair value per share, unvested RSAs outstanding, ending balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2025-03-31_us-gaap_RestrictedStockMember" id="Fact001076" format="ixt:numdotdecimal" decimals="INF" scale="0" unitRef="USDPShares">2.68</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A tax benefit of $<span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense_pn3p0_c20240401__20250331_z4UcHHZeO55e" title="Stock based compensation options exercised"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense" contextRef="From2024-04-01to2025-03-31" id="Fact001078" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">123,000</ix:nonFraction></span> has been recognized relating
to stock-based compensation as a result of non-qualified stock options and restricted stock exercised during the year ending March 31,
2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company issues new shares of common stock upon
exercise of stock options or release of restricted stock awards.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_239_zvpAhgfWslLh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_237_zV9PoMqR5e0i" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_230_zNumUPc7IZ43" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 67 -->
    <div id="xdx_23A_zWdxPdzQiXze" style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_238_zhoTtx9NyLTa" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_230_zZeHvfZx7Sd1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-04-01to2025-03-31" escape="true" id="Fact001084" name="us-gaap:IncomeTaxDisclosureTextBlock"><p id="xdx_804_eus-gaap--IncomeTaxDisclosureTextBlock_zedWN5cZZZs6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE&#160;14&#160;&#8211; <span id="xdx_823_zJW1lCrxp84k">Income Taxes</span> </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The income tax provision (benefit) is based on the
following net taxable loss before income taxes, which are from domestic and foreign sources:</p>

<ix:nonNumeric contextRef="From2024-04-01to2025-03-31" escape="true" id="Fact001086" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_889_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_pn3n3_zcjFSUccZDn9" summary="xdx: Disclosure - Income Taxes (Details-Income source)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B2_z5FF0boDHmEf" style="display: none">Schedule of income tax provision from domestic and foreign sources</span></td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended March&#160;31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%">Domestic</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--ProfitLoss_pn3p0_c20240401__20250331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zaqDwFXvz53h" title="Income before income taxes" style="width: 13%; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2024-04-012025-03-31_us-gaap_DomesticCountryMember" id="Fact001088" format="ixt:numdotdecimal" decimals="-3" scale="0" sign="-" unitRef="USD">161,000</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--ProfitLoss_pn3p0_c20230401__20240331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zfy1yQUfOI45" title="Income before income taxes" style="width: 13%; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2023-04-012024-03-31_us-gaap_DomesticCountryMember" id="Fact001090" format="ixt:numdotdecimal" decimals="-3" scale="0" sign="-" unitRef="USD">364,000</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Foreign</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ProfitLoss_pn3p0_c20240401__20250331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zmKIf3SeJEt8" title="Income before income taxes" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2024-04-012025-03-31_us-gaap_ForeignCountryMember" id="Fact001092" format="ixt:numdotdecimal" decimals="-3" scale="0" sign="-" unitRef="USD">2,749,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ProfitLoss_pn3p0_c20230401__20240331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zpQOWqkgmACd" title="Income before income taxes" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2023-04-012024-03-31_us-gaap_ForeignCountryMember" id="Fact001094" format="ixt:numdotdecimal" decimals="-3" scale="0" sign="-" unitRef="USD">4,559,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 2.5pt">Totals</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--ProfitLoss_pn3p0_c20240401__20250331_zL608gH8ruN4" title="Income before income taxes" style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2024-04-01to2025-03-31" id="Fact001096" format="ixt:numdotdecimal" decimals="-3" scale="0" sign="-" unitRef="USD">2,910,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--ProfitLoss_pn3p0_c20230401__20240331_zwRRhstxQIgh" title="Income before income taxes" style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2023-04-012024-03-31" id="Fact001098" format="ixt:numdotdecimal" decimals="-3" scale="0" sign="-" unitRef="USD">4,923,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The federal, state and foreign income tax provisions
are summarized as follows:</p>

<ix:nonNumeric contextRef="From2024-04-01to2025-03-31" escape="true" id="Fact001100" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_88B_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_pn3n3_zY3IfRNnScvg" summary="xdx: Disclosure - Income Taxes (Details-Income tax expense)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B8_zK0DBnlPZPF4" style="display: none">Schedule of federal, state and foreign income tax provisions</span></td><td>&#160;</td>
    <td colspan="2" id="xdx_499_20240401__20250331_zLPdh3S4pOu9" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_492_20230401__20240331_z6oO3rsxphrf" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended March&#160;31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_iB" style="vertical-align: bottom">
    <td>Current:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_pn3p0_zIiMUP5oZdub" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%">State</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">(<ix:nonFraction name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="From2024-04-01to2025-03-31" id="Fact001105" format="ixt:numdotdecimal" decimals="-3" scale="0" sign="-" unitRef="USD">2,000</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">(<ix:nonFraction name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="From2023-04-012024-03-31" id="Fact001106" format="ixt:numdotdecimal" decimals="-3" scale="0" sign="-" unitRef="USD">2,000</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_iB_zurQPAtm8yfa" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>Deferred:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredForeignIncomeTaxExpenseBenefit_pn3p0_zW00FLkegDSl" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Foreign</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" contextRef="From2024-04-01to2025-03-31" id="Fact001111" format="ixt:numdotdecimal" decimals="-3" scale="0" sign="-" unitRef="USD">548,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" contextRef="From2023-04-012024-03-31" id="Fact001112" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">198,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredIncomeTaxExpenseBenefit_pn3p0_zkoNXLQiTdf3" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total income tax (expense) benefit</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="From2024-04-01to2025-03-31" id="Fact001114" format="ixt:numdotdecimal" decimals="-3" scale="0" sign="-" unitRef="USD">550,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="From2023-04-012024-03-31" id="Fact001115" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">196,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A reconciliation of the statutory federal income tax
rate to the Company&#8217;s effective tax rate for continuing operations is as follows:</p>

<ix:nonNumeric contextRef="From2024-04-01to2025-03-31" escape="true" id="Fact001117" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_881_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zLZHeGGJZM7" summary="xdx: Disclosure - Income Taxes (Details-Reconciliation of tax rate)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B4_z25lFhUBWLG3" style="display: none">Schedule of reconciliation of federal    income
tax rate to effective rate</span></td><td>&#160;</td>
    <td colspan="2" id="xdx_491_20240401__20250331_z6UIQyLeALFh" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_492_20230401__20240331_zm0B4uZCEXcg" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year&#160;Ended&#160;March&#160;31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pip0_dp_marate_zPKHIxaxLhfg" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: left">Expected federal statutory rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2024-04-01to2025-03-31" id="Fact001119" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21.0</ix:nonFraction>%</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2023-04-012024-03-31" id="Fact001120" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21.0</ix:nonFraction>%</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_iN_pip0_dpi_zLGNa2ul5tS" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">State income taxes, net of federal benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="From2024-04-01to2025-03-31" id="Fact001122" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">0.1</ix:nonFraction>%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="From2023-04-012024-03-31" id="Fact001123" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">0.2</ix:nonFraction>%</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_pip0_dp_zq7UbDuEbcV3" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Foreign earnings taxed at different rates</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" contextRef="From2024-04-01to2025-03-31" id="Fact001125" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">6.7</ix:nonFraction>%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" contextRef="From2023-04-012024-03-31" id="Fact001126" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">7.9</ix:nonFraction>%</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpense_iN_pip0_dpi_zX26ez95xmM5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Effect of permanent differences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" contextRef="From2024-04-01to2025-03-31" id="Fact001128" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">7.4</ix:nonFraction>%</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" contextRef="From2023-04-012024-03-31" id="Fact001129" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5.8</ix:nonFraction>%</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_pip0_dp_zcpP6WRnYoO3" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Effect of intercompany interest permanent differences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" contextRef="From2024-04-01to2025-03-31" id="Fact001131" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">30.2</ix:nonFraction>%</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" contextRef="From2023-04-012024-03-31" id="Fact001132" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">20.1</ix:nonFraction>%</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_ecustom--TrueupsOfStateDeferredAssets_pip0_dp_z1qn3IWDXl72" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">True-up of state deferred assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="SNOA:TrueupsOfStateDeferredAssets" contextRef="From2024-04-01to2025-03-31" id="Fact001134" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">68.4</ix:nonFraction>%</td><td style="padding-bottom: 1pt; text-align: left">)&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="SNOA:TrueupsOfStateDeferredAssets" contextRef="From2023-04-012024-03-31" id="Fact001135" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">1.5</ix:nonFraction>%</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_iN_dpi_zwRb7XBckbC6" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><b style="display: none">Total effective rate</b></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" contextRef="From2024-04-01to2025-03-31" id="Fact001137" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">78.2</ix:nonFraction>%</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" contextRef="From2023-04-012024-03-31" id="Fact001138" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">1.7</ix:nonFraction>%</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pip0_dp_zqgwwIqZ9PR3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Change in valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2024-04-01to2025-03-31" id="Fact001140" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">59.3</ix:nonFraction>%</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2023-04-012024-03-31" id="Fact001141" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2.3</ix:nonFraction>%</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pip0_dp_mtrate_zp1DtXOARE7e" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 2.5pt">Totals</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2024-04-01to2025-03-31" id="Fact001143" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">18.9</ix:nonFraction>%</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2023-04-012024-03-31" id="Fact001144" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.0</ix:nonFraction>%</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_23D_zMlY3xtnJn7b" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_239_zwwsfqNdIsFg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23E_zfjkY68OFih2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_23E_zOmPsl0mSpmi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_239_zMnnW30ovTJh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 68 -->
    <div id="xdx_23F_zR5d0n0Fs8Uf" style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_237_zkFHmXZgqbr3" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_231_zzZuLwgN79Xh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The tax effects of temporary differences that give
rise to significant components of our deferred tax assets consist of:</p>

<ix:nonNumeric contextRef="From2024-04-01to2025-03-31" escape="true" id="Fact001152" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_884_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_pn3n3_zMbRIQ1dE2a" summary="xdx: Disclosure - Income Taxes (Details-Deferred taxes)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B5_zFibXnib7PU" style="display: none">Schedule of deferred tax assets</span></td><td>&#160;</td>
    <td colspan="2" id="xdx_491_20250331_z5oBANAgAPQ1" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_49B_20240331_zHpcMumE8sni" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March&#160;31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsGrossAbstract_iB" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Deferred tax assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_i01I_pn3p0_maDTAGz412_zRUpdLmRE6Di" style="vertical-align: bottom; background-color: White">
    <td style="width: 66%; text-align: left">Net operating loss carryforwards</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2025-03-31" id="Fact001157" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">26,456,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2024-03-31" id="Fact001158" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">28,692,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_i01I_pn3p0_maDTAGz412_zaF4wlPfWEJ5" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Research and development tax credit carryforwards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="AsOf2025-03-31" id="Fact001160" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">1,749,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="AsOf2024-03-31" id="Fact001161" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">1,796,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_i01I_pn3p0_maDTAGz412_zhtpPCQnkvC5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="AsOf2025-03-31" id="Fact001163" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">879,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="AsOf2024-03-31" id="Fact001164" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">913,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_i01I_pn3p0_maDTAGz412_z8KAJqvbqdDa" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Reserves and accruals</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" contextRef="AsOf2025-03-31" id="Fact001166" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">618,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" contextRef="AsOf2024-03-31" id="Fact001167" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">659,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseOther_i01I_pn3p0_d0_maDTAGz412_z6yxVYR8k8cc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther" contextRef="AsOf2025-03-31" id="Fact001169" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">41,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther" contextRef="AsOf2024-03-31" id="Fact001170" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">52,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--DeferredTaxAssetsLeaseLiability_i01I_pn3p0_maDTAGz412_zjeSqDemov7e" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Lease liability</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="SNOA:DeferredTaxAssetsLeaseLiability" contextRef="AsOf2025-03-31" id="Fact001172" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">10,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="SNOA:DeferredTaxAssetsLeaseLiability" contextRef="AsOf2024-03-31" id="Fact001173" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">22,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--DeferredTaxAssetsGross_i01TI_pn3p0_mtDTAGz412_maDTANzqCr_zmB7ZrzLMHd6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Gross deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2025-03-31" id="Fact001175" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">29,753,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="AsOf2024-03-31" id="Fact001176" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">32,134,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsValuationAllowance_i01NI_pn3p0_di_msDTANzqCr_zKS1XlHQajH" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Less valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2025-03-31" id="Fact001178" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">29,062,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2024-03-31" id="Fact001179" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">30,836,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsNet_i01TI_pn3p0_mtDTANzqCr_maDTALNzfiK_zFtiYZAiwxp9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Total deferred tax assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2025-03-31" id="Fact001181" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">691,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2024-03-31" id="Fact001182" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">1,298,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--DeferredTaxLiabilitiesAbstract_i01B" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Deferred tax liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--DeferredTaxLiabilitiesPropertyPlantAndEquipment_i02NI_pn3p0_di_maDITLzfJx_zRys7CZb6wh6" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Fixed assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" contextRef="AsOf2025-03-31" id="Fact001187" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">6,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" contextRef="AsOf2024-03-31" id="Fact001188" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">10,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxLiabilitiesPrepaidExpenses_i02NI_pn3p0_di_maDITLzfJx_z2P9APkIY1qe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Prepaid expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesPrepaidExpenses" contextRef="AsOf2025-03-31" id="Fact001190" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">86,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesPrepaidExpenses" contextRef="AsOf2024-03-31" id="Fact001191" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">121,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40C_ecustom--DeferredTaxLiabilitiesRightOfUseAsset_i02NI_pn3p0_di_maDITLzfJx_zLmjoR5HOfA3" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Right of use asset</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="SNOA:DeferredTaxLiabilitiesRightOfUseAsset" contextRef="AsOf2025-03-31" id="Fact001193" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">10,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="SNOA:DeferredTaxLiabilitiesRightOfUseAsset" contextRef="AsOf2024-03-31" id="Fact001194" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">22,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--DeferredIncomeTaxLiabilities_i02NTI_pn3p0_di_mtDITLzfJx_msDTALNzfiK_zBs9h4F8yDXb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Gross deferred tax liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="AsOf2025-03-31" id="Fact001196" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">102,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="AsOf2024-03-31" id="Fact001197" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">153,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsLiabilitiesNet_i02TI_pn3p0_d0_mtDTALNzfiK_zPIPHtQKKgv7" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 2.5pt">Net deferred tax assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="AsOf2025-03-31" id="Fact001199" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">589,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="AsOf2024-03-31" id="Fact001200" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">1,145,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of March 31, 2025, we have net operating loss carryforwards
for federal, state and foreign income tax purposes of approximately $<span id="xdx_902_eus-gaap--OperatingLossCarryforwards_iI_pn3p0_c20250331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zfq1HKeJ42D" title="Net operating loss carryforwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2025-03-31_us-gaap_DomesticCountryMember" id="Fact001202" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">107,700,000</ix:nonFraction></span>, $<span id="xdx_908_eus-gaap--OperatingLossCarryforwards_iI_pn3p0_c20250331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zhHglQJqAhal" title="Net operating loss carryforwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2025-03-31_us-gaap_StateAndLocalJurisdictionMember" id="Fact001204" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">42,800,000</ix:nonFraction></span> and $<span id="xdx_904_eus-gaap--OperatingLossCarryforwards_iI_pn3p0_c20250331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zve7MpTT3qd4" title="Net operating loss carryforwards"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2025-03-31_us-gaap_ForeignCountryMember" id="Fact001206" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">800,000</ix:nonFraction></span>, respectively. Due to the Tax
Cuts and Job Act, federal NOL generated after March 31, 2018 have an indefinite life. Federal NOL generated on and before March 31, 2017
began to expire in 2024, if not utilized. State NOLs will begin to expire in the year 2026, if not utilized. Foreign NOLs will carry forward
for 10 years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 467.4pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of March 31, 2025, we had federal and California
research and development credit carryforward of approximately $<span id="xdx_901_eus-gaap--TaxCreditCarryforwardAmount_iI_pn3p0_c20250331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zWvzoyaJ6Nz2" title="Research credit carryforwards"><ix:nonFraction name="us-gaap:TaxCreditCarryforwardAmount" contextRef="AsOf2025-03-31_us-gaap_DomesticCountryMember" id="Fact001208" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">950,000</ix:nonFraction></span> and $<span id="xdx_905_eus-gaap--TaxCreditCarryforwardAmount_iI_pn3p0_c20250331__us-gaap--IncomeTaxAuthorityAxis__custom--CaliforniaResearchAndDevelopmentMember_zHEI3RDlYn2a" title="Research credit carryforwards"><ix:nonFraction name="us-gaap:TaxCreditCarryforwardAmount" contextRef="AsOf2025-03-31_custom_CaliforniaResearchAndDevelopmentMember" id="Fact001210" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">790,000</ix:nonFraction></span>, respectively. As of March 31, 2024, we had federal
and California research and development credit carryforward of approximately $<span id="xdx_908_eus-gaap--TaxCreditCarryforwardAmount_iI_pn3p0_c20240331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_ziW095B2ybtd" title="Research credit carryforwards"><ix:nonFraction name="us-gaap:TaxCreditCarryforwardAmount" contextRef="AsOf2024-03-31_us-gaap_DomesticCountryMember" id="Fact001212" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">1,006,000</ix:nonFraction></span> and $<span id="xdx_90D_eus-gaap--TaxCreditCarryforwardAmount_iI_pn3p0_c20240331__us-gaap--IncomeTaxAuthorityAxis__custom--CaliforniaResearchAndDevelopmentMember_zishS8NiTAL2" title="Research credit carryforwards"><ix:nonFraction name="us-gaap:TaxCreditCarryforwardAmount" contextRef="AsOf2024-03-31_custom_CaliforniaResearchAndDevelopmentMember" id="Fact001214" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">790,000</ix:nonFraction></span> respectively. The federal research
and development credits began to expire in 2024 while the California research and development credits have no expiration date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Section 382 of the Internal Revenue Code limits the
use of the federal net operating losses in certain situations where changes occur in stock ownership of a company. If the Company should
have an ownership change of more than 50% of the value of the Company's capital stock, utilization of the carryforwards could be restricted.
The Company is not aware of any changes in ownership that would result in a change in control under Internal Revenue Code section 382.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company released the valuation allowance recorded
against its Netherlands deferred tax assets as of March 31, 2024. Given its recent history of earnings, current earnings and anticipated
future earnings, the Company concluded that there is sufficient positive evidence available to reach a conclusion that the valuation allowance
is no longer needed in the Netherlands. The release of the valuation allowance resulted in the recognition of deferred tax assets of $114,000.
The Company, after considering all available evidence, fully reserved against all deferred tax assets in the U.S. since it is more likely
than not such benefits will not be realized in future periods. The Company will continue to evaluate its deferred tax assets to determine
whether any changes in circumstances could affect the realization of their future benefit.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:exclude><p id="xdx_238_zjObE1ga2kBh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_235_zwzk3YVomgy2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_232_zpC6u1aRbQe2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 69 -->
    <div id="xdx_231_zfwyLEFd4cN2" style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_230_zs1Twojd07n5" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_234_zI8PW8mN2Fh1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has filed tax returns for federal, state
and foreign jurisdictions. The Company&#8217;s evaluation of uncertain tax matters was performed for tax years ended through March 31,
2025. Generally, the Company is subject to audit for the years ended March 31, 2023, 2022 and 2021. The Company has elected to retain
its existing accounting policy with respect to the treatment of interest and penalties attributable to income taxes, and continues to
reflect interest and penalties attributable to income taxes, to the extent they arise, as a component of its income tax provision or benefit
as well as its outstanding income tax assets and liabilities. The Company believes that its income tax positions and deductions would
be sustained on audit and does not anticipate any adjustments to result in a material change to its financial position.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-04-01to2025-03-31" escape="true" id="Fact001220" name="us-gaap:CompensationAndEmployeeBenefitPlansTextBlock"><p id="xdx_808_eus-gaap--CompensationAndEmployeeBenefitPlansTextBlock_zSA62saGIjH6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE&#160;15&#160;&#8211; <span id="xdx_826_zVp4npyxuGrb">Employee Benefit Plan</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has a program to contribute and administer
a qualified 401(k) plan. Under the 401(k) plan, the Company matches employee contributions to the plan up to 4% of the employee&#8217;s
salary. Company contributions to the plan amounted to an aggregate of $<span id="xdx_901_eus-gaap--PensionAndOtherPostretirementBenefitContributions_pn3p0_c20240401__20250331_znY7Eb9LV075" title="Company contributions to 401(k) plan"><ix:nonFraction name="us-gaap:PensionAndOtherPostretirementBenefitContributions" contextRef="From2024-04-01to2025-03-31" id="Fact001222" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">88,000</ix:nonFraction></span> and $<span id="xdx_900_eus-gaap--PensionAndOtherPostretirementBenefitContributions_pn3p0_c20230401__20240331_zeqX3ySD2Ypk" title="Company contributions to 401(k) plan"><ix:nonFraction name="us-gaap:PensionAndOtherPostretirementBenefitContributions" contextRef="From2023-04-012024-03-31" id="Fact001224" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">82,000</ix:nonFraction></span> for the years ended March 31, 2025 and 2024,
respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2024-04-01to2025-03-31" escape="true" id="Fact001226" name="us-gaap:RevenueFromContractWithCustomerTextBlock"><p id="xdx_808_eus-gaap--RevenueFromContractWithCustomerTextBlock_zJ0nuwunqaQ3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE&#160;16 &#8211; <span id="xdx_82E_zAXtTEVvYdf1">Revenue Disaggregation</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company generates product revenues from products
which are sold into the human and animal healthcare markets, and the Company generates service revenues from laboratory testing services
which are provided to medical device manufacturers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table presents the Company&#8217;s disaggregated revenues
by source:</p>

<ix:nonNumeric contextRef="From2024-04-01to2025-03-31" escape="true" id="Fact001228" name="us-gaap:DisaggregationOfRevenueTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_881_eus-gaap--DisaggregationOfRevenueTableTextBlock_pn3n3_zG7aKFsAn6Li" summary="xdx: Disclosure - Revenue Disaggregation (Details - Disaggregation of revenue)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B2_zDo0500DkMY" style="display: none">Schedule of disaggregated revenue by  source</span></td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended March 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Product:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; width: 66%; text-align: left">Human Care</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20240401__20250331__us-gaap--StatementBusinessSegmentsAxis__custom--HumanCareMember__srt--ProductOrServiceAxis__us-gaap--ProductMember_zbMuKtD4qDf2" title="Revenues" style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2024-04-012025-03-31_custom_HumanCareMember_us-gaap_ProductMember" id="Fact001230" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">12,079,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20230401__20240331__us-gaap--StatementBusinessSegmentsAxis__custom--HumanCareMember__srt--ProductOrServiceAxis__us-gaap--ProductMember_z3G9EVURUamd" title="Revenues" style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-04-012024-03-31_custom_HumanCareMember_us-gaap_ProductMember" id="Fact001232" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">10,110,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Animal Care</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20240401__20250331__us-gaap--StatementBusinessSegmentsAxis__custom--AnimalCareMember__srt--ProductOrServiceAxis__us-gaap--ProductMember_z2ec75gSQ7P3" title="Revenues" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2024-04-012025-03-31_custom_AnimalCareMember_us-gaap_ProductMember" id="Fact001234" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">1,653,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20230401__20240331__us-gaap--StatementBusinessSegmentsAxis__custom--AnimalCareMember__srt--ProductOrServiceAxis__us-gaap--ProductMember_zi4RFG28E6V6" title="Revenues" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-04-012024-03-31_custom_AnimalCareMember_us-gaap_ProductMember" id="Fact001236" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">2,203,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Total Product Revenue</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20240401__20250331__srt--ProductOrServiceAxis__us-gaap--ProductMember_ze5f1aVNo9jb" title="Revenues" style="text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2024-04-012025-03-31_us-gaap_ProductMember" id="Fact001238" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">13,732,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20230401__20240331__srt--ProductOrServiceAxis__us-gaap--ProductMember_zuOZtvvttFw5" title="Revenues" style="text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-04-012024-03-31_us-gaap_ProductMember" id="Fact001240" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">12,313,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Service/Royalty</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20240401__20250331__srt--ProductOrServiceAxis__us-gaap--ServiceMember__us-gaap--StatementBusinessSegmentsAxis__custom--ServiceAndRoyaltyMember_zQxKYFNwyoEk" title="Revenues" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2024-04-012025-03-31_us-gaap_ServiceMember_custom_ServiceAndRoyaltyMember" id="Fact001242" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">556,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20230401__20240331__srt--ProductOrServiceAxis__us-gaap--ServiceMember__us-gaap--StatementBusinessSegmentsAxis__custom--ServiceAndRoyaltyMember_ztIKU2csL1ml" title="Revenues" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-04-012024-03-31_us-gaap_ServiceMember_custom_ServiceAndRoyaltyMember" id="Fact001244" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">422,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20240401__20250331_zVNwjt92tag8" title="Revenues" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2024-04-01to2025-03-31" id="Fact001246" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">14,288,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20230401__20240331_z2tLug2zuoQd" title="Revenues" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-04-012024-03-31" id="Fact001248" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">12,735,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table shows the Company&#8217;s revenues
by geographic region:</p>

<ix:nonNumeric contextRef="From2024-04-01to2025-03-31" escape="true" id="Fact001250" name="us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_881_eus-gaap--ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_pn3n3_zhVgq0GAig38" summary="xdx: Disclosure - Revenue Disaggregation (Details - Geographic regions)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B4_zCeSA7dcCsne" style="display: none">Schedule of revenues by geographic region</span></td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended March 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: left">United States</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20240401__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__country--US_z9btNfmBsoK9" title="Revenues" style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2024-04-012025-03-31_us-gaap_SalesRevenueSegmentMember_country_US" id="Fact001252" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">2,611,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20230401__20240331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__country--US_zvRAAqzLQbB3" title="Revenues" style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-04-012024-03-31_us-gaap_SalesRevenueSegmentMember_country_US" id="Fact001254" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">3,058,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Europe</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20240401__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__srt--EuropeMember_zsnbz3JUVMJ6" title="Revenues" style="text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2024-04-012025-03-31_us-gaap_SalesRevenueSegmentMember_srt_EuropeMember" id="Fact001256" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">5,523,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20230401__20240331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__srt--EuropeMember_zKC94FNbtO5h" title="Revenues" style="text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-04-012024-03-31_us-gaap_SalesRevenueSegmentMember_srt_EuropeMember" id="Fact001258" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">4,781,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>Asia</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20240401__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__srt--AsiaMember_zmWtWTGuRhA" title="Revenues" style="text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2024-04-012025-03-31_us-gaap_SalesRevenueSegmentMember_srt_AsiaMember" id="Fact001260" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">2,317,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20230401__20240331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__srt--AsiaMember_zuAakEMFLsQ1" title="Revenues" style="text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-04-012024-03-31_us-gaap_SalesRevenueSegmentMember_srt_AsiaMember" id="Fact001262" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">2,298,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Latin America</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20240401__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__srt--LatinAmericaMember_zE2pJaE0as7b" title="Revenues" style="text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2024-04-012025-03-31_us-gaap_SalesRevenueSegmentMember_srt_LatinAmericaMember" id="Fact001264" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">2,962,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20230401__20240331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__srt--LatinAmericaMember_zFA9UIPKkVyd" title="Revenues" style="text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-04-012024-03-31_us-gaap_SalesRevenueSegmentMember_srt_LatinAmericaMember" id="Fact001266" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">1,726,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Rest of the World</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20240401__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__custom--RestOfTheWorldMember_zenVN9BBNG07" title="Revenues" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2024-04-012025-03-31_us-gaap_SalesRevenueSegmentMember_custom_RestOfTheWorldMember" id="Fact001268" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">875,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20230401__20240331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__custom--RestOfTheWorldMember_znhzNmIb6zW9" title="Revenues" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-04-012024-03-31_us-gaap_SalesRevenueSegmentMember_custom_RestOfTheWorldMember" id="Fact001270" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">872,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20240401__20250331_zDcse8CR7OM" title="Revenues" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2024-04-01to2025-03-31" id="Fact001272" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">14,288,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20230401__20240331_zfxc6Qh44bMg" title="Revenues" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-04-012024-03-31" id="Fact001274" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">12,735,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><p id="xdx_81D_zKqdNh5n2fn6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 70 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="k_023"></span>ITEM&#160;9.&#160;Changes in and Disagreements with Accountants
on Accounting and Financial Disclosures</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">None.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="k_024"></span>ITEM&#160;9A.&#160;Controls and Procedures</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Evaluation of Disclosure Controls and Procedures</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We maintain disclosure controls and procedures that
are designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is recorded,
processed, summarized, and reported within the time periods specified in the SEC&#8217;s rules and forms, and that such information is
accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to
allow timely decisions regarding required disclosure.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We carried out an evaluation, under the supervision
and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness
of the design and operation of our disclosure controls and procedures (as defined in Rules&#160;13a-15(e) and 15d-15(e) under the Exchange
Act) as of the end of our most recent fiscal quarter. Based upon this evaluation, our Chief Executive Officer and Chief Financial Officer
concluded that our disclosure controls and procedures were effective as of March 31, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Evaluation of Internal Control over Financial Reporting</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="background-color: white">Our management
is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in the Exchange
Act Rule&#160;13a-15(f) and 15d-15(f). </span>Because of its inherent limitations, internal control over financial reporting is not intended
to provide absolute assurance that a misstatement of our financial statements would be prevented or detected. <span style="background-color: white">Under
the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we conducted
an evaluation of the effectiveness of our internal control over financial reporting based on the framework in the&#160;<i>2013 Internal
Control&#160;&#8212; Integrated Framework</i>&#160;issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based
on our evaluation, our management concluded that our internal control over financial reporting was effective as of March 31, 2025. We
have determined that there were adequate spreadsheet controls, an adequate separation of duties with preparation and review of the reported
numbers, and adequate analysis of revenue reporting among other things. We believe we have taken steps to correct this and the controls
have been working for a sufficient period of time to remove this weakness.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Management&#8217;s Remediation Measures</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Management, with oversight from the Audit Committee
of our Board of Directors, is actively engaged in remediation efforts to address the material weaknesses identified&#160;in the management&#8217;s
evaluation of internal controls and procedures. Management has taken a number of actions to remediate the material weaknesses described
above, including the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Improved monitoring and risk assessment activities to address these control deficiencies.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hired an experienced Chief Financial Officer and Controller in 2023.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Separated the preparation of the financial reports from review of the financial reports.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Implemented additional process-level controls over revenue recognition of new contracts.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Developed and delivered further internal controls training to individuals associated with these control deficiencies and enhanced training provided to all personnel who have financial reporting or internal control responsibilities in these areas. The training includes a review of individual roles and responsibilities related to internal controls, proper oversight and reemphasizes the importance of completing the control procedures.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Did a detailed review of income taxes and our intercompany agreements which uncovered the fact that we should be accruing withholding taxes that will be paid to Mexico when intercompany interest and technical assistance payments are made to Mexico from the United States and that we will not be eligible for a tax credit in the United States because of our net operating loss positions.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 71 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Value: 45; Name: PageNo -->45<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">These improvements were targeted at strengthening
our internal control over financial reporting and remediating the material weaknesses. We remain committed to an effective internal control
environment, and management believes that these actions and the improvements management expects to achieve as a result effectively remediated
the material weaknesses. The material weaknesses in our internal control over financial reporting are considered remediated and the controls
have operated for a sufficient period of time and management has concluded, through testing that these controls operate effectively. As
of the date of filing this Annual Report on Form 10-K, management has evaluated these additional controls and determined they are operating
effectively. We have hired appropriate accounting staff to establish effective internal controls and processes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Changes in Internal Control over Financial Reporting</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">There were changes in our internal control over financial
reporting during the three months ended March 31, 2025 that have materially affected, or are reasonably likely to materially affect, our
internal control over financial reporting. Sufficient time has elapsed to make the determination these controls are operating effectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="k_025"></span>ITEM&#160;9B.&#160;Other Information</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Equity Awards</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 12, 2025, the Compensation Committee of
the Board of Directors approved an equity award of 13,500 Restricted Stock Units (RSUs) to each of Ms. Trombly, Mr. Dvonch and Mr. Thornton,
to be issued on June 19, 2025. The RSUs vest on the third anniversary of the grant date or upon change of control or as otherwise provided
in an executive officer&#8217;s employment agreement.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the quarter ended March 31, 2025, no director
or officer <span id="xdx_905_eecd--Rule10b51ArrAdoptedFlag_dbF_c20250101__20250331_zs5YebVATqY9" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><span id="xdx_908_eecd--NonRule10b51ArrAdoptedFlag_dbF_c20250101__20250331_zsJkG2gFh9zd" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><ix:nonNumeric contextRef="From2025-01-012025-03-31" format="ixt:booleanfalse" id="Fact001275" name="ecd:Rule10b51ArrAdoptedFlag"><ix:nonNumeric contextRef="From2025-01-012025-03-31" format="ixt:booleanfalse" id="Fact001276" name="ecd:NonRule10b51ArrAdoptedFlag">adopted</ix:nonNumeric></ix:nonNumeric></span></span> or <span id="xdx_90D_eecd--Rule10b51ArrTrmntdFlag_dbF_c20250101__20250331_zVL7Toj5HkJd" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><span id="xdx_909_eecd--NonRule10b51ArrTrmntdFlag_dbF_c20250101__20250331_zQEL5j1EVPFg" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><ix:nonNumeric contextRef="From2025-01-012025-03-31" format="ixt:booleanfalse" id="Fact001277" name="ecd:Rule10b51ArrTrmntdFlag"><ix:nonNumeric contextRef="From2025-01-012025-03-31" format="ixt:booleanfalse" id="Fact001278" name="ecd:NonRule10b51ArrTrmntdFlag">terminated</ix:nonNumeric></ix:nonNumeric></span></span> any Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement, as each term is defined in
Item 408(a) of Regulation S-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 72 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="k_026"></span>PART&#160;III</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="k_027"></span>ITEM&#160;10.&#160;Directors, Executive Officers and Corporate Governance</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The information required by this Item is incorporated
by reference to the definitive proxy statement for our 2025 Annual Meeting of Stockholders to be filed with the Securities and Exchange
Commission within 120&#160;days after the end of our fiscal year ended March 31, 2025 (the &#8220;2025 Proxy Statement&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Item&#160;405 of Regulation&#160;S-K requires the
disclosure of, based upon our review of the forms submitted to us during and with respect to our most recent fiscal year, any known failure
by any director, officer, or beneficial owner of more than ten percent of any class of our securities, or any other person subject to
Section 16 of the Exchange Act (&#8220;reporting person&#8221;) to file timely a report required by Section 16(a) of the Exchange Act.
This disclosure is contained in the section entitled &#8220;Section&#160;16(a) Beneficial Ownership Reporting Compliance&#8221; in the
2024 Proxy Statement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Code of Business Conduct</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have adopted a Code of Business Conduct that applies
to all of our officers, directors, and employees, including our Chief Executive Officer, Chief Financial Officer, and other employees
who perform financial or accounting functions. The Code of Business Conduct sets forth the basic principles that guide the business conduct
of our employees. On November 5, 2024, our board of directors adopted changes to our Code of Business Conduct. The changes to the Code
of Business Conduct were made to update the code to current best practices. In addition to some clerical changes, the Code of Business
Conduct now explicitly reflects the definition of &#8220;code of ethics&#8221; in Item 406 of Regulation S-K. The Code also updates reporting
procedures, including updates to our anonymous reporting hotline. We filed our Code of Business Conduct with the Securities and Exchange
Commission as exhibit 14.1 to the current report on Form 8-K on November 7, 2024, and it is also available on our website at http://www.ir.sonomapharma.com/governance-documents.
We will provide any person, without charge, copies of our Code of Business Conduct and Ethics upon request. Such requests should be in
writing and addressed to: Sonoma Pharmaceuticals, Inc., Attention: Chief Financial Officer, 5445 Conestoga Court, Suite 150, Boulder,
Colorado 80301.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">To date, there have been no waivers under our Code
of Business Conduct. We intend to disclose future amendments to certain provisions of our Code of Business Conduct or any waivers, if
and when granted, of our Code of Business Conduct on our website at http://www.sonomapharma.com within four business days following the
date of such amendment or waiver.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Procedures for Nominating Directors</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">There have been no material changes to the procedures
by which stockholders may recommend nominees to our Board of Directors.&#160;The Board of Directors will consider candidates for director
positions that are recommended by any of our stockholders. Any such recommendation for a director nomination should be provided to our
Secretary. The recommended candidate should be submitted to us in writing and addressed to Sonoma Pharmaceuticals, Inc., Attention: Secretary,
5445 Conestoga Court, Suite 150, Boulder, Colorado 80301. The recommendation should include the following information: name of candidate;
address, phone and fax number of candidate; a statement signed by the candidate certifying that the candidate wishes to be considered
for nomination to our Board of Directors and stating why the candidate believes that he or she would be a valuable addition to our Board
of Directors; a summary of the candidate&#8217;s work experience for the prior five years and the number of shares of our stock beneficially
owned by the candidate.&#160;&#160;The Board will evaluate the recommended candidate and shall determine whether or not to proceed with
the candidate in accordance with our procedures. We reserve the right to change our procedures at any time to comply with the requirements
of applicable laws.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="k_028"></span>ITEM&#160;11.&#160;Executive Compensation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The information required by this Item is incorporated by reference to the
2025 Proxy Statement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 73 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="k_029"></span>ITEM&#160;12.&#160;Security Ownership of Certain Beneficial Owners and
Management and Related Stockholder Matters</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The information required by this Item is incorporated by reference to the
2025 Proxy Statement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The information required to be disclosed by Item 201(d)
of Regulation S-K, &#8220;Securities Authorized for Issuance Under Equity Compensation Plans,&#8221; appears under the caption &#8220;Equity
Compensation Plan Information&#8221; in the 2024 Proxy Statement and such information is incorporated by reference into this report.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="k_030"></span>ITEM&#160;13.&#160;Certain Relationships, Related Transactions, and
Director Independence</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The information required by this Item is incorporated by reference to the
2025 Proxy Statement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="k_031"></span>ITEM&#160;14.&#160;Principal Accounting Fees and Services</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The information required by this Item is incorporated by reference to the
2025 Proxy Statement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<!-- Field: Page; Sequence: 74 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="k_032"></span>PART&#160;IV</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="k_033"></span>ITEM 15. Exhibits, Financial Statement Schedules</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>(a)&#160;Documents filed as part of this report</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>(1)&#160;&#160;&#160; <i>Financial Statements</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Reference is made to the Index to Consolidated Financial
Statements of Sonoma Pharmaceuticals, Inc. under Item 8 of Part II hereof.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>(2)&#160;&#160;&#160; <i>Financial Statement Schedules</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Financial statement schedules have been omitted that are not applicable
or not required or because the information is included elsewhere in the Consolidated Financial Statements or the Notes thereto.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>(b) Exhibits</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="k_034"></span>Exhibit Index</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit No.</b></span></td>
    <td style="border-bottom: black 1pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td style="width: 90%; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000095013407013693/f31114exv3w1xiy.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">Restated Certificate of Incorporation of Oculus Innovative Sciences, Inc., effective January 30, 2006</span></a> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(included as exhibit 3.1 of the Company&#8217;s Annual Report on Form 10-K filed June 20, 2007, and incorporated herein by reference).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000095013408013005/f41943dedef14a.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">Certificate of Amendment of Restated Certificate of Incorporation of Oculus Innovative Sciences, Inc., effective October 22, 2008</span></a> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(included as exhibit A in the Company&#8217;s Definitive Proxy Statement on Schedule 14A filed July 21, 2008, and incorporated herein by reference).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000101968713000950/oculus_8k-ex0301.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">Certificate of Amendment of Restated Certificate of Incorporation of Oculus Innovative Sciences, Inc., as amended, effective March 29, 2013</span></a> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(included as exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed March 22, 2013, and incorporated herein by reference).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.5</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000101968714004634/oculus_ex0301.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">Certificate of Amendment of Restated Certificate of Incorporation of Oculus Innovative Sciences, Inc., as amended, effective December 4, 2014</span></a> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(included as exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed December 8, 2014, and incorporated herein by reference).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.6</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000101968715003810/oculus_8k-ex0301.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">Certificate of Amendment of Restated Certificate of Incorporation of Oculus Innovative Sciences, Inc., as amended, effective October 22, 2015</span></a> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(included as exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed October 27, 2015, and incorporated herein by reference).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.7</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000101968716006784/oculus_8k-ex0301.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">Certificate of Amendment of Restated Certificate of Incorporation of Oculus Innovative Sciences, Inc., as amended, effective June 24, 2016</span></a> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(included as exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed June 28, 2016, and incorporated herein by reference).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.8</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000168316816000874/sonomaex0301.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">Certificate of Amendment of Restated Certificate of Incorporation of Sonoma Pharmaceuticals, Inc., as amended, effective December 6, 2016</span></a> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(included as exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed December 7, 2016, and incorporated herein by reference).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.9</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000168316816000874/sonomaex0302.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">Amended and Restated Bylaws, as amended, of Sonoma Pharmaceuticals, Inc., effective December 6, 2016</span></a> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(included as exhibit 3.2 to the Company&#8217;s Current Report on Form 8-K filed December 7, 2016, and incorporated herein by reference).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.10</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000168316824004275/sonoma_ex0310.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">Amendment No. 1 to Amended and Restated Bylaws, as amended, of Sonoma Pharmaceuticals, Inc., effective June 14, 2024</span></a> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(included as exhibit 3.10 to the Company&#8217;s Annual Report on Form 10-K filed June 17, 2024, and incorporated herein by reference).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.11</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000101968712001481/oculus_8k-ex0402.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">Certificate of Designation of Preferences, Rights and Limitations of Series A 0% Convertible Preferred Stock, filed with the Delaware Secretary of State on April 24, 2012</span></a> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(included as exhibit 4.2 to the Company&#8217;s Current Report on Form 8-K, filed April 25, 2012, and incorporated herein by reference).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.12</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000168316816000348/oculus_8k-ex0301.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">Certificate of Designation of Series B Preferred Stock, effective October 18, 2016</span></a> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(included as exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed October 21, 2016, and incorporated herein by references).</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 75 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: center; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.13</span></td>
    <td style="text-align: justify; width: 90%"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000168316819001947/sonoma_ex0301.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">Certificate of Amendment of Restated Certificate of Incorporation of Sonoma Pharmaceuticals, Inc., as amended, effective June 19, 2019</span></a> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(included as exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed June 19, 2019, and incorporated herein by reference).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.14</span></td>
    <td style="text-align: justify"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001367083/000168316824006053/sonoma_8k.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">Certificate of Amendment of Restated Certificate of Incorporation of Sonoma Pharmaceuticals, Inc., as amended, effective August</span></a> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">29, 2024</span> (included as exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed August 28, 2024, and incorporated herein by reference).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000168316817001670/sonoma_ex0401.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">Specimen Common Stock Certificate</span></a> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(included as exhibit 4.1 to the Company&#8217;s Annual Report on Form 10-K filed June 28, 2017, and incorporated herein by reference).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000168316816000348/oculus_8k-ex0401.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">Section 382 Rights Agreement, dated as of October 18, 2016, between Oculus Innovative Sciences, Inc. and Computershare Inc., which includes the Form of Certificate of Designation of Series B Preferred Stock as Exhibit A, the Form of Right Certificate as Exhibit B and the Summary of Rights to Purchase Preferred Stock as Exhibit C</span></a> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(included as exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K filed October 21, 2016, and incorporated herein by reference).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000095013406017848/f21666a1exv10w1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">Form of Indemnification Agreement between Oculus Innovative Sciences, Inc. and its officers and directors</span></a> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(included as exhibit 10.1 to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-135584), as amended, declared effective on January 24, 2007, and incorporated herein by reference).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000095013406012612/f21666orexv10w10.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">Office Lease Agreement, dated May 18, 2006, between Oculus Technologies of Mexico, S.A. de C.V. and Antonio Sergio Arturo Fernandez Valenzuela (translated from Spanish</span></a><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">) (included as exhibit 10.10 to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-135584), as amended, declared effective on January 24, 2007, and incorporated herein by reference).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000095013406012612/f21666orexv10w11.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">Office Lease Agreement, dated July 2003, between Oculus Innovative Sciences, B.V. and Artikona Holding B.V. (translated from Dutch)</span></a> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(included as exhibit 10.11 to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-135584), as amended, declared effective on January 24, 2007, and incorporated herein by reference).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000095013406012612/f21666orexv10w20.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">Form of Director Agreement</span></a> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(included as exhibit 10.20 to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-135584), as amended, declared effective on January 24, 2007, and incorporated herein by reference).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000095013408011240/f41055exv10w44.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">Amendment to Office Lease Agreement, effective February 15, 2008, by and between Oculus Innovative Sciences Netherlands B.V. and Artikona Holding B.V. (translated from Dutch)</span></a> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(included as exhibit 10.44 to the Company&#8217;s Annual Report on Form 10-K filed June 13, 2008, and incorporated herein by reference).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6&#8224;</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000101968716005552/oculus_8k-ex1001.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">Exclusive Sales and Distribution Agreement, dated November 6, 2015, by and between Oculus Innovative Sciences, Inc. and Manna Pro Products, LLC</span></a> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(included as exhibit 10.1 to the Company&#8217;s 8-K filed March 23, 2016 and incorporated herein by reference).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7&#8224;</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000168316816000424/oculus_ex1001.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">Asset Purchase Agreement dated October 27, 2016, between Oculus Innovative Sciences, Inc. and Invekra, S.A.P.I de C.V.</span></a> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(included as exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed October 31, 2016, and incorporated herein by reference).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8&#8224;</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000168316816000424/oculus_ex1002.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">Amendment Agreement to Acquisition Option dated October 27, 2016, by and between More Pharma Corporation S. de R.L. de C.V. and Oculus Technologies of Mexico, S.A. de C.V.</span></a> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(included as exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K filed October 31, 2016, and incorporated herein by reference).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000101968716007052/oculus_def14a-072716.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">2016 Equity Incentive Plan</span></a> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(included as exhibit A to the Company&#8217;s Definitive Proxy Statement on Schedule 14A filed July 29, 2016, and incorporated herein by reference).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10&#11832;+</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000168316819001691/sonoma_8k-ex1001.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">Asset Purchase Agreement dated May 14, 2019, between Sonoma Pharmaceuticals, Inc. and Petagon, Ltd.</span></a> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(included as exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed May 22, 2019, and incorporated herein by reference).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11&#11832;+</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000168316820000599/sonoma_ex1001.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">Asset Purchase Agreement dated February 21, 2020, between Sonoma Pharmaceuticals, Inc. and MicroSafe Group, DMCC</span></a> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(included as exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed February 27, 2020, and incorporated herein by reference.)</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12&#11832;+</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000168316820001735/sonoma_8k-ex1001.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">License, Distribution and Supply Agreement by and between Sonoma Pharmaceuticals, Inc. and Brill International, S.L. dated May 19, 2020</span></a> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(included as exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed May 26, 2020, and incorporated herein by reference.)</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13&#11832;</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000168316820002539/sonoma_ex1001.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">Licensing Agreement between Sonoma Pharmaceuticals, Inc. and MicroSafe Group, effective July 27, 2020</span></a> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(included as exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed August 6, 2020, and incorporated herein by reference).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.14</span></td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1367083/000168316821003161/sonoma_def14a.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">2021 Equity Incentive Plan</span></a> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(included as appendix on the Company&#8217;s Definitive Proxy Statement on Schedule 14A filed July 29, 2021 and incorporated herein by reference).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.15</span></td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1367083/000168316824004552/sonoma_def14a.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">2024 Equity Incentive Plan</span></a> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(included as appendix on the Company&#8217;s Definitive Proxy Statement on Schedule 14A filed July 1, 2024 and incorporated herein by reference).</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 76 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.16+&#11832;</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000168316821005361/snoa_ex1001.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">Exclusive License and Distribution Agreement between the Company and Dyamed Biotech Pte Ltd., dated November 4, 2021</span></a><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;(included as exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed November 9, 2021, and incorporated herein by reference).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.17+&#11832;</span></td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1367083/000168316822000342/snoa_ex1002.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">Exclusive License and Distribution Agreement between Sonoma Pharmaceuticals, Inc. and Anlicare International dated January 18, 2022</span></a><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;(included as exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K filed January 20, 2022, and incorporated herein by reference).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.18</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000168316822008716/sonoma_ex1001.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">Sonoma Pharmaceuticals, Inc. Non-Employee Director Compensation Program and Stock Ownership Guidelines, revised by the Board of Directors on December 29, 2022</span></a> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(included as exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed December 30, 2022, and incorporated herein by reference).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.19</span></td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1367083/000168316823004323/sonoma_ex1038.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">Amended and Restated Employment Agreement by and between the Company and Amy Trombly, dated June 16, 2023</span></a> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(included as exhibit 10.38 to the Company&#8217;s Annual Report on Form 10-K filed June 21, 2023, and incorporated herein by reference).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.20</span></td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1367083/000168316823004323/sonoma_ex1039.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">Amended and Restated Employment Agreement by and between the Company and Bruce Thornton, dated June 16, 2023</span></a> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(included as exhibit 10.39 to the Company&#8217;s Annual Report on Form 10-K filed June 21, 2023, and incorporated herein by reference).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.21</span></td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1367083/000168316823007982/sonoma_ex1038.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: blue">First Amendment to the Lease between the Company and Westland Development Services, Inc., dated June 21, 2023</span></a> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(included as exhibit 10.38 to the Company&#8217;s Quarterly Report on Form 10-Q filed November 13, 2023, and incorporated herein by reference).</span></td></tr>

<tr style="vertical-align: top">
    <td style="width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.22</span></td>
    <td style="width: 90%; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1367083/000168316823008898/sonoma_ex0101.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity Distribution Agreement, by and between Sonoma Pharmaceuticals, Inc. and Maxim Group LLC, dated December 15, 2023</span></a> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(included as exhibit 1.1 to the Company&#8217;s Current Report on Form 8-K filed December 15, 2023, and incorporated herein by reference).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.23</span></td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/0001367083/000168316824000781/sonoma_ex1041.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Offer letter to Jerome Dvonch dated February 7, 2024</span></a> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(included as exhibit 10.41 to the Company&#8217;s Quarterly Report on Form 10-Q filed February 8, 2024, and incorporated herein by reference).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.24</span></td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/0001367083/000168316824000781/sonoma_ex1042.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Offer letter to John Dal Poggetto dated February 7, 2024</span></a> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(included as exhibit 10.42 to the Company&#8217;s Quarterly Report on Form 10-Q filed February 8, 2024 and incorporated herein by reference).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.25</span></td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1367083/000168316824001399/sonoma_ex0101.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment No. 1 to Equity Distribution Agreement, by and between Sonoma Pharmaceuticals, Inc. and Maxim Group LLC., dated March 8, 2024</span></a> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(included as exhibit 1.1 to the Company&#8217;s Current Report on Form 8-K filed March 8, 2024, and incorporated herein by reference).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.26&#11832;+</span></td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1367083/000168316824005938/sonoma_ex1001.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Distribution Agreement, dated August 19, 2024, by and between Sonoma Pharmaceuticals, Inc. and Medline Industries, LP</span></a> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(included as exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed August 21, 2024, and incorporated herein by reference).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.27+</span></td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1367083/000168316824007283/sonoma_ex1001.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment No. 1 to Distribution Agreement, dated October 17, 2024, by and between Sonoma Pharmaceuticals, Inc. and Medline Industries, LP</span></a> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(included as exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed October 22, 2024, and incorporated herein by reference).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.28&#11832;+</span></td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1367083/000168316825000611/sonoma_ex1001.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Master Supply Agreement, dated January 29, 2025, by and between Sonoma Pharmaceuticals, Inc. and WellSpring Pharmaceutical Corporation</span></a> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(included as exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed January 30, 2025, and incorporated herein by reference).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.29&#11832;+</span></td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1367083/000168316825001857/sonoma_ex1001.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment No. 1 to Master Supply Agreement, dated March 21, 2025, by and between Sonoma Pharmaceuticals, Inc. and WellSpring Pharmaceutical Corporation</span></a> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(included as exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed March 25, 2025, and incorporated herein by reference).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.30&#11832;+*</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="sonoma_ex1030.htm">Amendment No. 2 to Master Supply Agreement, dated June 2, 2025, by and between Sonoma Pharmaceuticals, Inc. and WellSpring Pharmaceutical Corporation.</a></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.31&#11832;+*</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="sonoma_ex1031.htm">Distribution and Supply Agreement, effective March 28, 2025, by and between Sonoma Pharmaceuticals, Inc. and Phase One Health, LLC.</a></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.1</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1367083/000168316824007708/sonoma_ex1401.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Code of Business Conduct, as revised and adopted on November 5, 2024</span></a> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(included as exhibit 14.1 to the Company&#8217;s Quarterly Report on Form 10-Q filed November 7, 2024, and incorporated herein by reference).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19*</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="sonoma_ex1900.htm">Sonoma Pharmaceuticals, Inc. Policy as to Trades in the Company&#8217;s Securities by Company Personnel and Treatment of Confidential Information, as amended on December 20, 2023.</a></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.1</span></td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1367083/000168316817001670/sonoma_ex-2101.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">List of Subsidiaries</span></a> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(included as exhibit 21.1 to the Company&#8217;s Annual Report on Form 10-K June 28, 2017, and incorporated herein by reference).</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1*</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="sonoma_ex2301.htm">Consent of Frazier &amp; Deeter, LLC, independent registered public accounting firm.</a></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1*</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="sonoma_ex3101.htm">Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2*</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="sonoma_ex3102.htm">Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1*</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="sonoma_ex3201.htm">Certification of Officers pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 77 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: center; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #212529">97</span></td>
    <td style="text-align: justify; width: 90%"><a href="https://www.sec.gov/Archives/edgar/data/0001367083/000168316824004275/sonoma_ex9700.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #0A58CA">Sonoma Pharmaceuticals, Inc. Compensation Clawback Policy</span></a> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(included as Exhibit 97 to the Company&#8217;s Annual Report on Form 10-K filed June 17, 2024, and incorporated herein by reference)<span style="color: #212529">.</span></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS*</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH*</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Schema Document</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL*</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF*</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB*</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE*</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Presentation Linkbase Document </span></td></tr>
  <tr style="vertical-align: top">
    <td style="white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104*</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page Interactive Data File (formatted in inline XBRL, and included in exhibit 101).</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b></b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="width: 95%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed herewith.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8224;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidential treatment has been granted with respect to certain portions of this agreement.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#11832;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain portions of the exhibit have been omitted to preserve the confidentiality of such information. The Company will furnish copies of any such information to the SEC upon request.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">+</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The schedules to the exhibit have been omitted from this filing pursuant to Item 601(a)(5)&#160;of Regulation S-K.&#160; The Company will furnish copies of any such schedules to the SEC upon request.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Copies of above exhibits not contained herein are
available to any stockholder, upon payment of a reasonable per page fee, upon written request to: Chief Financial Officer, Sonoma Pharmaceuticals,
Inc., 5445 Conestoga Court, Suite 150, Boulder, Colorado 80301.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>(c)&#160;Financial Statements and Schedules</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Reference is made to Item&#160;15(a)(2) above.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span id="k_035"></span>ITEM 16. Form 10-K Summary</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">None.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 78 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 0; margin-bottom: 0"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 0; margin-bottom: 0"><p style="margin: 0 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="k_036"></span>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to the requirements of Section&#160;13 or
15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SONOMA PHARMACEUTICALS, INC.</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="width: 50%">&#160;</td>
    <td style="width: 5%">&#160;</td>
    <td style="width: 35%">&#160;</td>
    <td style="width: 10%">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: June 17, 2025</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Amy Trombly</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0.8pt 0 0; text-align: center">Amy Trombly</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0.8pt 0 0; text-align: center">President and Chief Executive Officer,</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0.8pt 0 0; text-align: center">(Principal Executive Officer)</p></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: June 17, 2025</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Jerome Dvonch</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jerome Dvonch</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Principal Financial and</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Principal Accounting Officer</p></td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to the requirements of the Securities Exchange
Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates
indicated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; width: 25%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Signature</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 48%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 25%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date</b></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/&#160;Amy Trombly</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">President, Chief Executive Officer </span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 17, 2025</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amy Trombly</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Executive Officer)</span></td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Jerome Dvonch</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 17, 2025</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jerome Dvonch</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Financial and Principal Accounting Officer)</span></td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/&#160;Jay Edward Birnbaum</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 17, 2025</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jay Edward Birnbaum</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/&#160;Philippe Weigerstorfer</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 17, 2025</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Philippe Weigerstorfer</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/&#160;Jerry McLaughlin</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 17, 2025</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jerry McLaughlin</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<!-- Field: Page; Sequence: 79; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- 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 -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.30
<SEQUENCE>2
<FILENAME>sonoma_ex1030.htm
<DESCRIPTION>AMENDMENT NO. 2 TO MASTER SUPPLY AGREEMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 10.30</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>[Certain identified information has been excluded
from the exhibit because it both (i) is not material and (ii) is the type that the company treats as private or confidential.]</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>Amendment
No.2 to Master Supply Agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-variant: small-caps">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">This Amendment No. 2 to Master Supply Agreement (this &ldquo;<U>Amendment</U>&rdquo;)
is entered into as of June 2, 2025 (the &ldquo;<U>Amendment Effective Date</U>&rdquo;) by and between Sonoma Pharmaceuticals, Inc., a
Delaware corporation having a place of business at <FONT STYLE="font-size: 10pt">5445 Conestoga Court, Suite 150, Boulder, Colorado 80301</FONT>
(&ldquo;<U>Supplier</U>&rdquo;), and Wellspring Pharmaceutical Corporation, a Delaware corporation, having a place of business at 5911
N. Honore Ave, Suite 211, Sarasota, Florida 34243 (&ldquo;<U>Distributor</U>&rdquo; and, together with Supplier, the &ldquo;<U>Parties</U>&rdquo;
and each a &ldquo;<U>Party</U>&rdquo;).</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps">Whereas, </FONT>Supplier
and Distributor have entered into that certain Master Supply Agreement, dated January 29, 2025, as amended on March 21, 2025 by Amendment
No. 1 to Master Supply Agreement (as amended, the &ldquo;<U>Supply Agreement</U>&rdquo;), pursuant to which Supplier appointed Distributor
as Supplier&rsquo;s exclusive distributor of the Products through the Channels in the Field in the Territory for sale for the Permitted
Use (as each term is defined in the Supply Agreement);</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps">Whereas, </FONT>Supplier
now desires to grant Distributor certain rights with respect to the distribution of additional products in additional fields through the
Channels in the Territory;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-variant: small-caps">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps">Now, Therefore,
</FONT>in consideration of the foregoing premises and the mutual promises and covenants set forth below, the Parties mutually agree as
follows:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">1.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Attachment A</U> to the Supply Agreement is hereby amended and replaced in its entirety with <U>Attachment A</U> attached hereto.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">2.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Section 4.4</U> to the Supply Agreement is hereby amended and replaced in its entirety with the following:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in"><FONT STYLE="font-size: 10pt"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">4.4</FONT> <U>Invoicing</U>.
Supplier shall invoice Distributor for Products on the date Supplier ships Products. Supplier shall invoice Distributor directly for all
shipments by Supplier to any Subdistributor made at Distributor&rsquo;s request. Supplier&rsquo;s invoices are due and payable in U.S.
Dollars within [__________] ([____]) days after the date of Supplier&rsquo;s invoice, without deduction, suspension or set-off for any
reason whatsoever. Distributor shall notify Supplier in writing of any dispute with any amount owed in connection with a Purchase Order
(along with substantiating documentation and a reasonably detailed description of the dispute) within [__________] ([____]) days from
the receipt of Products by Distributor. The Parties shall seek to resolve any such disputes expeditiously and in good faith. Notwithstanding
anything to the contrary, Distributor and Supplier shall continue performing their obligations under this Agreement during any such dispute,
including Distributor&rsquo;s obligation to pay all due and undisputed invoice amounts in accordance with the terms of this Agreement</FONT>.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">3.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Distributor shall pay Supplier an upfront labeling fee of <FONT STYLE="font-size: 10pt">[______________] USD ($[__________])</FONT>
per SKU for label printing, labeling, and packaging of each Product added to <U>Attachment A</U> pursuant to this Amendment, which shall
be due upon submission of the initial Purchase Order for such Product.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">4.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>All other terms of the Supply Agreement shall remain in full force and effect.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">5.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>For convenience of the Parties hereto, this Amendment may be executed in one or more counterparts, each of which shall be deemed
an original for all purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; font-size: 10pt"><FONT STYLE="font-variant: small-caps"><B>Distributor</B></FONT></TD>
    <TD STYLE="width: 50%; font-size: 10pt"><FONT STYLE="font-variant: small-caps"><B>Supplier</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-variant: small-caps">Wellspring Pharmaceutical Corporation</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-variant: small-caps">Sonoma Pharmaceuticals, Inc.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">By: <U>/s/ Casey G. Davis&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Name: Casey G. Davis</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Title: VP Supply Chain</P></TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">By: <U>/s/ Amy Trombly&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Name: Amy Trombly</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Title: Chief Executive Officer</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">Date:&nbsp;&nbsp;June 2, 2025</TD>
    <TD STYLE="font-size: 10pt">Date:&nbsp;&nbsp;June 3, 2025</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.31
<SEQUENCE>3
<FILENAME>sonoma_ex1031.htm
<DESCRIPTION>DISTRIBUTION AND SUPPLY AGREEMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 10.31</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><BR>
[Certain identified information has been excluded from the exhibit because it both (i) is not material and (ii) is the type that the company
treats as private or confidential.]</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>Distribution
and Supply Agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-variant: small-caps">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-variant: small-caps">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">This Distribution and Supply Agreement is entered into as of March 28,
2025 (the &ldquo;Effective Date&rdquo;) by and between Sonoma Pharmaceuticals, Inc., a Delaware corporation having a place of business
at 5445 Conestoga Court, Suite 150, Boulder, Colorado 80301 (&ldquo;Supplier&rdquo;) and Phase One Health, LLC, a Tennessee limited liability
company having a place of business at 2815 Brick Church Pike, Nashville, Tennessee 37207 (&ldquo;Distributor&rdquo;).</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps">Whereas, </FONT>Supplier
manufactures certain products based on the Proprietary Rights (as such term is defined below) and subject to the Label Claims as approved
by the Government Authorities, which it is willing to supply to Distributor on the terms and subject to the conditions of this Agreement;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps">Whereas, </FONT>as
between Distributor and Supplier, all right, title and interest in and to Supplier&rsquo;s Proprietary Rights (as such term is defined
below) related to the Products and Supplier&rsquo;s business remains with Supplier.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps">Whereas</FONT>,
Distributor wishes to obtain from Supplier rights to distribute the Products in the Territory through the Channels (as such term is defined
below);</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-variant: small-caps">Now, Therefore,
</FONT>in consideration of the foregoing premises and the mutual promises and covenants set forth below, the Parties mutually agree as
follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">1.</TD><TD><U>Definitions</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&ldquo;<U>Affiliate</U>&rdquo; means, with respect to
any person or entity (a) any other person or corporation directly or indirectly controlling, controlled by, or under common control with
a Party to this Agreement, or (b) any partnership, joint venture or other entity directly or indirectly controlled by, controlling, or
under common control with, a Party to this Agreement but in each case only for so long as such ownership or control shall continue. For
purposes of this definition, the term &ldquo;control&rdquo; as applied to any person or entity means the possession, directly or indirectly,
of the power to direct or cause the direction of the management of that person or entity, whether through ownership of voting securities
or otherwise.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&ldquo;<U>Agreement</U>&rdquo; means this Distribution
and Supply Agreement, as amended from time to time by both parties.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&ldquo;<U>Business Day</U>&rdquo; means a day (excluding
Saturdays, Sundays and public holidays) on which banks are generally open for business in the United States of America for the transaction
of normal banking business.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&ldquo;<U>Channels</U>&rdquo; means healthcare professionals,
hospitals, pharmacies, wound care centers, and plastic surgery centers.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&ldquo;<U>Distribution Rights</U>&rdquo; shall have the
meaning assigned to it under Section 2.1 of this Agreement.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&ldquo;<U>Effective Date</U>&rdquo; has the meaning ascribed
thereto in the preamble.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&ldquo;<U>Field</U>&rdquo; means all fields and uses
permitted under the applicable approved 510(k) preclearance submission, including without limitation the cleansing, irrigation, moistening,
debridement and removal of foreign material and debris from exudating wounds, acute and chronic dermal lesions including stage I-IV pressure
ulcers, stasis ulcers, diabetic ulcers, post-surgical wounds, first- and second-degree burns, abrasions, minor irritations of the skin,
diabetic foot ulcers, ingrown toe nails, grafted/donor sites and exit sites, moistening and lubrication of wound dressings, and use with
devices intended to irrigate wounds.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&ldquo;<U>Government Authority</U>&rdquo; means any federal,
state, foreign, or other public authority, exercising governmental powers and having jurisdiction in connection with this Agreement; and
all statutes, laws, ordinances, regulations, orders, decrees, permits, licenses, approvals, writs, process and rules issued thereby that
may operate in connection with this Agreement in the Territory.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&ldquo;<U>Initial Term</U>&rdquo; shall have the meaning
set forth in Section 10.1.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&ldquo;<U>Label Claims</U>&rdquo; means the label claims
obtained for a Product and instructions for use as approved by the Government Authority or the Food and Drug Administration.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&ldquo;<U>Marketing Authorization</U>&rdquo; means the
permit, authorization and/or license for the Products issued by the relevant health authorities in the Territory, the underlying applications
thereto, and any supplements and amendments to such Government Authorizations that authorize the holder of such license to market and
sell the Products in the Territory.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&ldquo;<U>Party</U>&rdquo; shall mean each of Supplier
and Distributor.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&ldquo;<U>Permitted Use</U>&rdquo; means use in accordance
with applicable Label Claims.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&ldquo;<U>Patents</U>&rdquo; means the patent(s) owned
by Supplier.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&ldquo;<U>Patent Applications</U>&rdquo; means the patent
application(s) filed by Supplier.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&ldquo;<U>Proprietary Rights</U>&rdquo; means the Trade
Names, Trademark(s), Trademark Application(s), Patent(s), Patent Application(s), copyrights, trade secret rights and all other intellectual
and industrial property rights of any sort related to a Party&rsquo;s products or business.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&ldquo;<U>Product</U>&rdquo; means the hypochlorous-acid
based products, in the volumes and packaging specified on <U>Attachment A</U> of this Agreement. The Parties agree that they may, from
time to time and by mutual written agreement, include new Products in such <U>Attachment A</U>; provided, however, that pricing must be
agreed to by the Parties before adding any new Product to such <U>Attachment A</U>.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&ldquo;<U>Purchase Price</U>&rdquo; shall have the meaning
assigned to it under Section 4.2 of this Agreement.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&ldquo;<U>Recall</U>&rdquo; shall have the meaning assigned
to it under Section 7.3 of this Agreement.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&ldquo;<U>Subdistributor</U>&rdquo; means any third party
appointed to act for Distributor in promoting, marketing, selling and distributing the Products in the Territory for the Permitted Use
as permitted under Section 2.2 hereof.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&ldquo;<U>Term</U>&rdquo; means the Initial Term and
any extension thereof pursuant to Section 10.1 hereof.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&ldquo;<U>Territory</U>&rdquo; means the United States.
The Parties will engage in good faith discussions to mutually expand the Territory to include other countries, subject to the Sonoma&rsquo;s
existing distribution agreements. Any expansion of the Territory must be mutually agreed in writing.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&ldquo;<U>Trademark(s)</U>&rdquo; means the trademark
application(s) filed by a Party, any derivatives thereof, any other symbols related to a Party&rsquo;s products and all goodwill associated
therewith.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&ldquo;<U>Trade Names</U>&rdquo; means any name under
which a Party markets a product or service or that a Party uses in connection with its business.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">2.</TD><TD><U>Distribution Rights and Limitations</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">2.1</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Distribution Rights</U>. On the terms and subject to the conditions of this Agreement, Supplier hereby appoints Distributor,
and Distributor hereby accepts appointment as Supplier&rsquo;s distributor of the Products through the Channels in the Field in the Territory
for sale for the Permitted Use in accordance with the terms of this Agreement (the &ldquo;<U>Distribution Rights</U>&rdquo;). Distributor
may promote Products on its company website, however, Distributor may not promote, sell or distribute Products on third-party operated
websites (e.g. Amazon). Distributor shall not have any right to, and shall not, promote, market, import, offer for sale, sell and/or distribute
or use any Products outside of the Channels, outside of the Field or outside of the Territory or for any use outside of the Permitted
Use.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">2.2</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Limitation on Rights</U>. The Distribution Rights are limited to, and may be exercised by Distributor and/or its permitted Subdistributor,
solely for the purpose of promoting, marketing, importing, offering for sale, selling and/or distributing the Products for the Permitted
Use, through the Channels, in the Field, in the Territory. Distributor shall have no right to distribute or sell Products outside the
Channels. Distributor and any Subdistributor shall not have any right to and shall not promote, import, export, market, offer for sale,
sell or distribute any Products outside of the Channels or outside of the Territory or for any use other than the Permitted Use. Distributor
may appoint Subdistributors, but only pursuant to written agreements with third parties reasonably acceptable to Supplier, which agreements
shall contain obligations of the third party materially similar to the obligations of Distributor hereunder, and no less favorable to
Supplier&rsquo;s rights than the provisions contained in this Agreement. Any Subdistributor shall be subject to Supplier&rsquo;s prior
written approval which may be withdrawn in the event Subdistributor breaches any term of this Agreement. Distributor shall be liable to
Supplier for acts or omissions of any Subdistributor not in conformity with the terms of this Agreement or any agreement between Distributor
and any Subdistributor.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">2.3</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Non-Exclusive</U>. Nothing in this Agreement shall mean (a) that Distributor is the exclusive distributor of the Products on
behalf of Supplier, or (b) that Supplier is the exclusive source of hypochlorous acid-based products for Distributor, provided that Distributor
shall not source the Products set forth on Attachment A from another party during the Term of this Agreement. Subject to the provisions
set forth in Section 3.1 and 3.3, Distributor shall not be required to purchase any monthly minimum amount of Products or pay any monthly
minimum to Supplier.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">3.</TD><TD><U>Purchase Orders and Delivery</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">3.1</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Forecast</U>. Within five (5) days after the Effective Date, and on the first day of each quarter, Distributor shall provide
Supplier with a written non-binding rolling forecast, by month and by Product, of the quantities of Products Distributor expects Supplier
to ship to Distributor for each month covered by the forecast.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">3.2</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Terms and Conditions</U>. Purchase Orders by Distributor shall be subject to acceptance by Supplier at Boulder, Colorado, or
such other place(s) as may be designated by Supplier. Except as modified by this Agreement, all Purchase Orders shall be accepted subject
to (a) minimum purchase quantities specified in <U>Attachment A</U>, and (b) to the terms and conditions of Supplier&rsquo;s Terms and
Conditions of Sale (&ldquo;General Terms and Conditions&rdquo;), a copy of which is attached hereto as <U>Attachment B</U> and incorporated
herein by reference. In the event of any inconsistency between the General Terms and Conditions and any provision of this Agreement, this
Agreement shall be controlling.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">3.3</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Purchase Orders</U>. Distributor shall submit to Supplier firm purchase orders for Products in writing (each, a &ldquo;Purchase
Order&rdquo;) at least [__________] ([______]) calendar days before the delivery date requested by Distributor. Unless agreed to by Supplier,
such quantity orders shall not be materially different from the quantities in Distributor&rsquo;s forecast provided to Supplier pursuant
to Section 3.1 above.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">3.3.1</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Each Purchase Order shall specify (i) Distributor&rsquo;s order number; the quantity ordered per Product (the &ldquo;Order Line
Item&rdquo;), (iii) the applicable purchase price per Order Line Item or a clear reference to the applicable price under this Agreement,
and (iv) requested delivery date, which shall be at least [__________] ([______]) days after the date the Supplier receives the Purchase
Order.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">3.3.2</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Each Purchase Order shall be subject to acceptance by Supplier. Upon receipt of any Purchase Order from Distributor, Supplier shall
promptly (but in any event no later than [____] business days) notify Distributor in writing of its acceptance or rejection of the Purchase
Order and, if rejected, of the reasons for its rejection.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">3.3.3</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Any Purchase Order submitted by Distributor and accepted by Supplier in writing shall be binding upon the Parties and may not be
modified, rescinded or cancelled by either Party without the prior written consent of the other Party.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">3.4</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Shipment</U>. Subject to the terms and conditions of this Agreement, Supplier shall use commercially reasonable efforts to fill
(by full or partial shipment) Distributor&rsquo;s orders for Products for the Territory. Distributor shall use its best efforts to purchase
from Supplier at least the number of units that equals a full truck load, approximately 13,000-20,000 units depending on size. Shipping
terms are F.O.B. from Supplier&rsquo;s facility in Zapopan, Mexico.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">3.5</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Packaging and Labeling</U>. Supplier shall be responsible for all packaging and labeling of Products purchased under the Agreement.
Distributor shall not modify, alter, remove, or add to, or authorize Subdistributor or other third party to modify, alter, remove or add
to, any labeling of any Product without the prior written consent of Supplier. Supplier shall have the right to modify the Product packaging
and labeling at any time, including, without limitation, to address modifications required or suggested by the relevant Government Authority
issuing the Market Authorization; <I>except that</I> Supplier shall not modify the presentation of Distributor Trademarks or Trade Names
appearing on the packaging unless so authorized by Distributor.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">3.6</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Residual Shelf Life</U>. The Product supplied to the Distributor shall have a residual shelf life at the time of dispatch of
[___]% of the maximum shelf life for the Product.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">3.7</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Storage, Handling</U>. Supplier has provided to Distributor all required shipping, storage and handling conditions for each
Product, and Distributor shall comply with all such requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">4.</TD><TD><U>Pricing and Payment</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">4.1</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Labeling and Onboarding Fees</U>. Distributor shall pay Supplier a non-refundable labeling fee of $[________________] per Product
prior to the initial Purchase Order for such Product. Labelling fees for the PhaseOne Skin and Wound Cleanser 40mL and 8 oz Products are
due upon execution of this Agreement. With respect to the 450 mL Product, Distributor shall pay Supplier an additional one-time non-refundable
onboarding fee of $[________________], payable in three tranches: $[________________] upon execution of this Agreement, $[________________]
due [__________] ([______]) days from execution of this Agreement, and $[________________] due [__________] ([______]) days from execution
of this Agreement. Distributor shall pay Supplier $[________________] for each proprietary name required to be registered with the U.S.
Food and Drug Administration, with the initial $[________________] for the <FONT STYLE="text-transform: uppercase">PhaseOne</FONT> name
due upon execution of the Agreement; furthermore, the Parties shall proceed with registering the OMNIPHASE and NEUTROPHASE names at a
mutually agreeable time. If Distributor requests any changes to labeling or packaging of the Product or the Marketing Authorization, Supplier
may charge additional fees to cover any such costs and expenses.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">4.2</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Purchase Price</U>. The current purchase price for each Product (&ldquo;<U>Purchase Price</U>&rdquo;) is set forth on <U>Attachment
A</U>.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">4.3</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Purchase Price Changes</U>. Supplier will notify Distributor before raising the Purchase Prices, but Supplier shall have the
right to increase Purchase Prices of Products [_____________________________________].</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">4.4</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Invoicing</U>. Supplier shall invoice Distributor for Products on the date Supplier ships Products. Supplier shall invoice Distributor
directly for all shipments by Supplier to any Subdistributor made at Distributor&rsquo;s request. Supplier&rsquo;s invoices are due and
payable in U.S. Dollars within [__________] ([______]) days after the date of Supplier&rsquo;s invoice in accordance with the General
Terms and Conditions, without deduction, suspension or set-off for any reason whatsoever. Distributor shall notify Supplier of any disputed
amount within [__________] ([______]) days after the date of Supplier&rsquo;s invoice, and any such dispute shall be addressed by the
Parties without being subject to Section 4.5. In the event of non-payment or late payments, Supplier reserves the right to change its
payment terms or terminate this Agreement. In the event Supplier elects to change its payment terms, it will notify Distributor in writing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">4.5 Any undisputed balance remaining unpaid after the
due date may be subject to a service charge of [_____]% per month until paid, but in no event shall such charge exceed the rate permitted
by applicable law. Distributor&rsquo;s failure to make undisputed payments within sixty (60) days of the date of invoice shall be deemed
a material breach and default of this Agreement. If legal action or collection proceedings are necessary to enforce Distributor&rsquo;s
undisputed payment obligations, Distributor shall be liable for Supplier&rsquo;s reasonable and necessary costs relating to invoice collection,
including, all court costs, filing fees and attorney&rsquo;s fees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">5.</TD><TD><U>Marketing and Sales</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">5.1</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Marketing</U>. Distributor agrees to use all commercially reasonable efforts to successfully promote and sell Products for the
Permitted Use in the Field in the Territory in accordance with the Marketing Authorizations on a continuing basis. During the Term, Distributor
agrees not to promote, market, distribute or sell any products that are competitive with the Products.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">5.2</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Compliance with Laws</U>. Each Party agrees to ascertain and materially comply with all applicable laws and regulations and
standards of industry or professional conduct in connection with the manufacture, use, marketing, offer for sale, sale, distribution and
promotion of the Products, including, without limitation, those applicable to exportation, importation, product claims, labeling, approvals,
registrations and notifications.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">5.3</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Compliance with Label Claims, Etc.</U> Distributor agrees to market the Products consistent with all applicable Label Claims.
Distributor shall not, and shall cause its Affiliates not, to make any representations or warranties relating to the Products except for
those approved by Supplier or on the label. Distributor agrees not to make, and agrees to cause its Subdistributors not to make, any representation
or warranty, whether oral or in writing, regarding the Products that is not consistent with the Label Claims authorized for the Product
in the Field in the Territory. Distributor will receive approval from the supplier of all claims and language used to describe the product.
To the extent Distributor uses language, claims or other artwork or communications that have not been approved in writing by the Supplier,
Distributor will be solely responsible for any and all recalls, damages, or expenses resulting from use of such language, claims and/or
communications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">5.4</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Marketing Materials</U>. Distributor shall supply all sales and marketing material in the Territory at its sole expense and,
upon Supplier&rsquo;s request, shall obtain Supplier&rsquo;s written approval before using any such material. Supplier shall not unreasonably
withhold or delay this approval. Use of Supplier&rsquo;s name on Distributor&rsquo;s website or social media pages shall remain subject
to Supplier&rsquo;s approval at any time. Should Supplier determine, in its own discretion, that the use of Supplier&rsquo;s name by Distributor
is misleading or harmful to Supplier&rsquo;s brand reputation, Distributor shall take necessary steps to remove or modify such references
to Supplier&rsquo;s name to Supplier&rsquo;s satisfaction. Supplier shall supply Distributor, as reasonably requested from time to time,
with information required in order to prepare sales and marketing materials. Supplier will support the Distributor with a reasonable quantity
of samples, brochures or additional marketing and/or promotional materials.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">5.5</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Government Contracts</U>. Distributor shall not resell Products to any Governmental Authority or its respective agencies without
express written approval from Supplier, other than to VA or publicly-owned hospitals. Unless otherwise separately agreed to in writing
between Supplier and Distributor, no provisions required in any US government contract or subcontract related thereto shall be a part
of this Agreement, imposed on or binding on Supplier, and this Agreement is not deemed an acceptance of any government provisions that
may be included or referenced in Distributor&rsquo;s request for quotation, Purchase Order, or any other document.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">6.</TD><TD><U>Intellectual Property</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">6.1</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>No Rights to Intellectual Property</U>. Unless otherwise expressly set forth in this Section, this Agreement shall not be interpreted
or construed to transfer, assign, license or grant to a Party or any third party any right to or under any patent, trade secret, trademark,
trade&nbsp;name or other intellectual property right of the other Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">6.2</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Identification of Supplier Rights</U>. Distributor shall properly identify and accurately describe all Products as products
of Supplier. Distributor shall not alter, remove, deface or obscure any notice of any Proprietary Right of Supplier that appears on any
Product and shall not add to any Product any other trade name, trademark or notice of any other person or entity without the prior written
consent of Supplier. Distributor shall not rebottle or repackage any Product.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">6.3</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>No Use of Supplier Trade Names and Trademarks</U>. Neither Distributor nor any Distributor Affiliate or Subdistributor shall,
either during the Term nor after expiration, termination or dissolution of this Agreement, use a company name (whether in its charter
documents or otherwise) that includes the element &ldquo;Oculus&rdquo; , &ldquo;Sonoma&rdquo; and / or Microcyn&reg; (technology) or any
other Trademark or Trade Name of Supplier (collectively, &ldquo;Supplier Marks&rdquo;) that is similar to or could be confused with any
Supplier Mark. Neither Distributor nor any Subdistributor is authorized to license or permit any third party to use a name or trademark
which includes a Supplier Mark or any word or words that is similar to, could be confused with, or is disparaging of any Supplier Mark.
Distributor may use the name Microcyn<SUP>&reg;</SUP> technology in marketing materials following Supplier&rsquo;s review and approval
pursuant to Section 5.4.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">6.4</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Distributor Trade Names and Trademarks</U>. Supplier may print and use the Trademarks and Trade Names of Distributor (including
PHASE ONE&reg;, OMNIPHASE&reg;, and NEUTROPHASE&reg;) (collectively the &ldquo;Distributor Marks&rdquo;) solely in connection with the
manufacture of the Products and/or product packaging for sale to Distributor (or Distributor&rsquo;s Subdistributors) under this Agreement.
Aside from such license, neither Supplier nor any Supplier Affiliate shall, either during the Term nor after expiration, termination or
dissolution of this Agreement, use the Distributor Marks, or any trademark or trade name that is similar to or likely to cause confusion
with any of the Distributor Marks. Supplier is not authorized to license or permit any third party to use the Distributor Marks, or any
trademark or trade name that is similar to or likely to cause confusion with any of the Distributor Marks.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">6.5</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Protection of Proprietary Rights</U>. Each Party shall comply with all directives issued by the other Party respecting the use
or protection of the other Party&rsquo;s Proprietary Rights and shall not use or suffer the use of any of the same in any manner which
contravenes the other Party&rsquo;s directives or which otherwise may, in the other Party&rsquo;s opinion, tend to lessen the value thereof,
or impair the goodwill or reputation of the other Party, of any Affiliate of the other Party, and/or of its respective products and/or
services. Without limiting the foregoing, Distributor shall further refrain from reverse engineering or otherwise attempting to discern
the trade secret information of the Product, nor will Distributor permit any third party to do any of the foregoing.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">6.6</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Assistance with Intellectual Property Matters</U>. Each Party, if requested by the other Party, shall assist the other Party
in registering or otherwise protecting the other Party&rsquo;s Proprietary Rights within the Territory, all strictly in the other Party&rsquo;s
name and for the other Party&rsquo;s benefit. Such assistance shall be at the requesting Party&rsquo;s expense for out-of-pocket costs.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">6.7</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Notice of Infringement</U>. Each Party shall immediately notify the other Party of any infringement, misuse, misappropriation,
tort, unfair competition, passing off or violation relating to any Proprietary Right of the other Party that comes to the notifying Party&rsquo;s
attention. In the event of any such infringement, misuse, misappropriation, tort, unfair competition, passing off or violation relating
to the activities of one of the Parties or a Party&rsquo;s Affiliates, that Party shall take all steps reasonably requested by the other
Party to terminate any such infringement, misuse, misappropriation, tort, unfair competition, passing off or violation.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">6.8</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Proceedings</U>. Each Party shall have exclusive control over the commencement, prosecution and settlement of any legal proceeding
with respect to any infringement, misuse, misappropriation, tort, unfair competition, passing off or violation relating to any patent,
trade secret, trademark, trade&nbsp;name or other Proprietary Rights of that Party. In connection with any such legal proceeding, the
other Party shall provide such assistance related to such proceeding as the owning Party may reasonably request; provided that the owning
Party shall reimburse the expenses reasonably incurred by the other Party in providing such assistance in accordance with the owning Party&rsquo;s
request for the same. Neither Party shall have any right to commence, prosecute or settle any legal proceeding with respect to any infringement,
misuse, misappropriation, act of tort, unfair competition, passing off or violation relating to any Proprietary Rights of the other Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">7.</TD><TD><U>Non-Conformities and Recall</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">7.1</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Non-Conformities</U>. Upon delivery of the Products, Distributor shall inspect the Products and shall notify the Supplier promptly,
and no later than ten (10) Business Days after the delivery date, by email or written communication delivered as provided herein, of any
shortages or non-conformity of the delivered Products apparent from a visual inspection. Distributor shall include supporting evidence
and documents reasonably acceptable to Supplier to support any such shortages or nonconformities. With respect to shortages or nonconformity
discoverable by way of visual inspection, the Product shall be deemed to have been delivered in good saleable condition after expiry of
said ten (10) Business Day period after the delivery date to Distributor.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">Upon request of Supplier, Distributor shall make available to Supplier
samples of the Products which Distributor believes to be defective. In case of non-conformity to the Marketing Authorization(s) of any
quantity of the Product delivered pursuant hereto, Supplier shall replace, at its expense, the quantities concerned within twenty (20)
Business Days from receipt of the relevant notice and supporting documentation from Distributor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">7.2</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Traceability and Complaints</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">7.2.1</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>During the Term, and for a period of 5 (five) years after the end of the Term, Distributor shall keep and maintain records of all
sales and other distributions of Products made by Distributor or its Subdistributors sufficient to effectively, efficiently and economically
implement any Recall or investigation of any Product, but at a minimum containing information about:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>(i)</TD><TD>Product description;</TD></TR>
                                                                                                                                         <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
                                                                                                                                         <TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-weight: normal">(ii)</FONT></TD><TD><FONT STYLE="font-weight: normal">Customer identification (name and location); and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD></TD><TD><FONT STYLE="font-weight: normal">(iii)</FONT></TD><TD><FONT STYLE="font-weight: normal">Shipping date.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">All complaints received by Distributor shall be communicated to Supplier
within two (2) Business Days. All traceability information accompanied by the complaint shall be made available to Supplier.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">7.2.2</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Upon Supplier&rsquo;s request, Distributor shall make such records available to Supplier and otherwise cooperate as reasonably
required to effectively, efficiently and economically implement any Recall or investigation.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">7.3</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Recalls</U>. The Parties shall cooperate fully with one another in any of the following events involving a recall of Product
resulting in a market withdrawal covered by this Agreement, including any correction, post-sale warning or mailing of information (a &ldquo;<U>Recall</U>&rdquo;):</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">7.3.1</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>A Recall is requested or ordered by Government Authority issued due to the Products not meeting the Label Claims or manufacturing
related issues or Supplier requests a Recall for Product quality or manufacturing related issues;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">7.3.2</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>A Recall is requested or ordered by a Government Authority issued due to off-Label promotion, illegal marketing or misrepresentation
of Product quality; and</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">7.3.3</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Any Recall other than those specified in Sections 7.3.1 and 7.3.2 above.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">Each Party shall inform the other Party in writing on a reasonably timely
basis in light of the events concerning any Product related issues that have the potential to result in a Recall in the Territory or elsewhere
if impacting this Agreement. Supplier and Distributor and its Subdistributors shall further cooperate with one another using reasonable
efforts and acting in good faith in conducting a Recall. The Parties will provide reasonable assistance to each other to investigate the
root cause(s) related to a Recall subject to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">The out-of-pocket costs and expenses incurred in connection with a Recall
under subsection 7.3.1 shall be borne by Supplier; the out-of-pocket costs and expenses incurred in connection with a Recall under subsection
7.3.2 shall be borne by Distributor; the out-of-pocket costs and expenses incurred in connection with a Recall under subsection (7.3.3)
shall be borne by Supplier and Distributor on a 50%-50% basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">8.</TD><TD><U>Confidentiality</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">8.1</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Confidential Information</U>. All information disclosed or exchanged by the Parties under this Agreement, including all intellectual
property related to the Products, shall constitute confidential information of the disclosing Party (the &ldquo;Confidential Information&rdquo;).
Each Party agrees (i) to hold the other Party&rsquo;s Confidential Information in confidence and to take all reasonable precautions to
protect such Confidential Information (including, without limitation, all precautions each Party employs with respect to its confidential
materials, but in no case less than reasonable care), (ii) not to disclose such Confidential Information other than to its employees and
agents who need to know such information and who are informed of the confidential nature of such information and bound by confidentiality
and non-use obligations regarding such information, (iii) not to divulge any such Confidential Information or any information derived
therefrom to any third person; provided, however, that if disclosure is required by a competent Government Authority, prior to such disclosure,
the receiving Party shall give prompt written to the disclosing Party sufficient to allow the disclosing Party the opportunity to pursue
its legal and equitable remedies regarding such potential disclosure, and the receiving Party shall (A) assert the confidential nature
of the Confidential Information to the Government Authority; (B) seek an appropriate protective order and/or narrow the scope of such
order to only that portion of the Confidential Information which is required by law to be disclosed; (C) use its reasonable best efforts
to obtain confidential treatment for any Confidential Information that is so disclosed; and (D) cooperate fully with the disclosing Party
in protecting such disclosure; and (iv) not to remove or export from the United States and/or the Territory or re-export any such Confidential
Information or any direct product thereof (e.g., Products by whomever made) unless expressly consented to in writing by the other Party
and except in compliance with all licenses and approvals required under applicable local and foreign export laws and regulations. Any
employee given access to any such Confidential Information must have a legitimate &ldquo;need to know&rdquo; and shall be similarly bound
in writing. Without granting any right or license, the Parties agree that the foregoing sub-sections (i), (ii), (iii) and (iv) shall not
apply with respect to information the other Party can document (W) is in or (through no improper action or inaction by the other Party,
agent or employee enters) the public domain, or (X) was rightfully in its possession or known by it prior to receipt from the disclosing
Party, or (Y) was rightfully disclosed to it by another person without a duty of confidentiality owed to the other Party, or (Z) was independently
developed by it, by persons without access to such information and without use of any information of the other Party. Each Party must
promptly notify the other Party of any information it believes comes within any circumstance listed in the immediately preceding sentence
and will bear the burden of proving the existence of any such circumstance by clear and convincing evidence including contemporaneous
written records. The Parties&rsquo; obligations under this Section 8 shall terminate five (5) years after the termination or expiration
of this Agreement. Distributor shall use the Confidential Information solely to promote, distribute, and sell the Product through the
Channels for the Permitted Use in the Field in the Territory.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">8.2</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Return of Confidential Information</U>. Immediately upon termination of this Agreement, at the written request of Supplier,
Distributor will turn over, or shall cause to have turned over, to Supplier all Confidential Information received from the other Party
and all documents or media containing any such Confidential Information, and any and all copies or extracts thereof.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">8.3</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Remedies; Equitable Relief</U>. The Parties acknowledge and agree that due to the unique nature of their Confidential Information,
there can be no adequate remedy at law for any breach of its obligations hereunder, that any such breach may allow the non-breaching Party
or third parties to unfairly compete with the non-breaching Party resulting in irreparable harm to the non-breaching Party, and therefore,
that upon any such breach or any threat thereof, the non-breaching Party shall be entitled to appropriate equitable relief in addition
to whatever remedies it might have at law and to be indemnified by the breaching Party from any damages and expenses (including reasonable
and documented attorney&rsquo;s fees), in connection with any breach or enforcement of each Party&rsquo;s obligations hereunder or the
unauthorized use or release of any such Confidential Information. Each Party will notify the other in writing immediately upon the occurrence
of any such unauthorized release or other breach. Any breach of this Section 8 will constitute a material breach of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">9.</TD><TD><U>Representations, Warranties, Indemnification and Insurance</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">9.1</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Supplier&rsquo;s Representations</U>. Supplier hereby represents and warrants the following:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">(a)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>It is a corporation duly organized, validly existing and in good standing under the laws of Delaware;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">(b)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>It has the legal power and authority to enter into and be bound by the terms and conditions of this Agreement and to perform its
obligations under this Agreement;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">(c)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>It has taken all necessary action to authorize the execution and delivery of this Agreement. This Agreement has been duly executed
and delivered on behalf of it and constitutes a legal, valid, binding obligation, enforceable against it in accordance with its terms;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">(d)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>It is not subject to any legal, contractual or other restrictions, limitations or conditions which conflict with its rights and
obligations under this Agreement or which might affect adversely its ability to perform under this Agreement;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">(e)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>To the best of its knowledge, there are no investigations, adverse third party allegations, claims or actions against it, including
any proceedings or any pending or threatened action against it by or before any Government Authority, relating to the Product;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">(f)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>The execution and delivery of this Agreement will not (i) violate Supplier&rsquo;s charter documents or other organizational document,
(ii) conflict with or result in a violation or breach of, or constitute a default under, any contract, agreement or instrument to which
it is a party or by which it is bound, or (iii) violate or conflict with any law, rule, regulation, judgment, order or decree of any court
applicable to it; and</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">(g)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Supplier represents and warrants that all Product will be manufactured in accordance with good manufacturing practices and when
supplied will comply with the Label Claims.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">9.2</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Distributor&rsquo;s Representations</U>. Distributor hereby represents and warrants the following:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">(a)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>It is a limited liability company duly organized, validly existing and in good standing under the laws of Tennessee;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">(b)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Its legal representative is empowered with the necessary sufficient authority to bind the Distributor under the terms hereof;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">(c)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Distributor has taken all necessary action on its part to authorize the execution and delivery of this Agreement. This Agreement
has been duly executed and delivered on behalf of Distributor and constitutes a legal, valid, binding obligation, enforceable against
Distributor in accordance with its terms;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">(d)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Distributor is not subject to any legal, contractual or other restrictions, limitations or conditions that conflict with its rights
and obligations under this Agreement or that might affect adversely its ability to perform under this Agreement;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">(e)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>To the best of its knowledge, there are no investigations, adverse third party allegations, claims or actions against it, including
any proceedings or any pending or threatened action against it by any Governmental Authority that may limit or in any manner affect the
compliance by Distributor of the obligations undertaken hereunder;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">(f)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>The execution and delivery of this Agreement will not (i) violate the charter documents or other organizational documents of Distributor,
(ii) conflict with or result in a violation or breach of, or constitute a default under, any contract, agreement or instrument to which
Distributor is a party or by which it is bound, or (iii) violate or conflict with any law, rule, regulation, judgment, order or decree
of any court applicable to Distributor;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">(g)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>As of the Effective Date, there are no claims pending or, to Distributor&rsquo;s knowledge, threatened against Distributor or any
of its Affiliates or Subdistributors by any third party, which might affect adversely its ability to perform under this Agreement. Distributor
represents that it has not been notified of, nor does have knowledge of, any circumstances or set of circumstances that would put Distributor
in any such situation;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">(h)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Distributor represents and warrants that the Product will be used, promoted, marketed, imported, offered for sale, sold and/or
distributed in accordance with good practices and in material compliance with applicable law and Marketing Authorizations; and</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">(i)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>Distributor represents and warrants that it owns all right, title, and interest in and to the Distributor Marks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">9.3</TD><TD><U>Mutual Representations.</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">9.3.1</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>The Parties understand and agree to comply with the U.S. Foreign Corrupt Practices Act, as revised, which prohibits the promise,
payment or giving of anything of value, either directly or indirectly, to any government official for the purpose of obtaining or retaining
business or any improper advantage. For purposes of this Section, &ldquo;government official&rdquo; means:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">(a)</FONT>any official,
officer, representative, or employee of any non-U.S. government department, agency or instrumentality (including any government-owned
or controlled commercial enterprise), or</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">(b)</FONT>any official
of a public international organization or political party or candidate for political office.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">The Parties shall furthermore ensure that their Affiliates that have rights
or obligations under this Agreement understand and agree to comply with the U.S. Foreign Corrupt Practices Act, as revised with regard
to activities performed under this Agreement.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">9.3.2</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT>The Parties, their Affiliates and their shareholders are not engaged in or in any manner whatsoever related to illegal or illicit
acts or activities and the financial resources used for the compliance of the obligations undertaken hereunder derive from legal activities
and sources. The Parties further represent that they are in full compliance with all applicable laws, rules and regulations that are applicable
to their activities.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">9.4</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Supplier Indemnification</U>. Supplier hereby agrees to defend, hold harmless and indemnify Distributor and its agents, directors,
officers and employees from and against any liability or loss or liability for any and all judgments, claims, causes of action, suits,
proceedings, losses, damages, demands, fees, expenses, fines, penalties or costs (including reasonable attorney&rsquo;s fees, costs and
disbursements) resulting from suits, claims, actions and demands, in each case brought by a third party arising out of: (a) a breach of
any of Supplier&rsquo;s representations and warranties under Section 9.1 or 9.3 or of any warranty contained in the General Terms and
Conditions, (b) any bodily harm or death caused by defects in materials or workmanship of Products, or on-label use of the Product, or
(c) infringement, misuse, misappropriation, tort, unfair competition, passing off or violation by Supplier&rsquo;s Products or Supplier
Marks of any patent, trade secret, trademark, trade name or other intellectual property right of any third party.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">9.5</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Distributor Indemnification</U>. Distributor hereby agrees to defend, hold harmless and indemnify Supplier, its Affiliates,
and their respective agents, directors, officers and employees from and against any liability or loss or liability for any and all judgments,
claims, causes of actions, suits proceedings, losses, damages, demands, fees, expenses, fines, penalties or costs (including reasonable
attorney&rsquo;s fees, costs, and disbursements), resulting from suits, claims, actions and demands, in each case brought by a third-party
arising out of: (a) any breach of Distributor&rsquo;s obligations under this Agreement, (b) a breach of any of Distributor&rsquo;s representations
and warranties under Section 9.2 or 9.3, (c) Product claims, representations or warranties, whether written or oral, made or alleged to
be made by Distributor, Distributor&rsquo;s Subdistributor or any of their respective agents of in advertising, publicity, promotion or
sale of any Product where such product claims, representations or warranties were not provided by or approved by Supplier or are inconsistent
with the Label Claims, (d) any infringement, misuse, misappropriation or violation of any intellectual property right of any third party
by any trademark or trade name used by Distributor or any of its Subdistributors or agents, (e) off-label promotion, marketing sale or
distribution of the Products and any bodily harm or death caused by the off-label promotion, marketing, sale or distribution of the Product
by Distributor, or (f) negligent handling by Distributor or any its Subdistributors or their respective agents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">9.6</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Insurance</U>. Each Party agrees to maintain general commercial and product liability insurance consistent with industry standards
for a product of this nature. Distributor shall provide Supplier with evidence of such coverage upon written request.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">9.7</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Warranties Disclaimer; Non-Reliance</U>. EXCEPT FOR THE LIMITED EXPRESS WARRANTIES DESCRIBED IN SECTION 9.1, (A) NEITHER SUPPLIER
NOR ANY PERSON ON SUPPLIER&rsquo;S BEHALF HAS MADE OR MAKES ANY EXPRESS OR IMPLIED REPRESENTATION OR WARRANTY WHATSOEVER, INCLUDING ANY WARRANTIES
OF: (i) MERCHANTABILITY; OR (ii) FITNESS FOR A PARTICULAR PURPOSE; OR (iii) TITLE; OR (iv) NON-INFRINGEMENT WHETHER ARISING BY LAW, COURSE
OF DEALING, COURSE OF PERFORMANCE, USAGE OF TRADE OR OTHERWISE, ALL OF WHICH ARE EXPRESSLY DISCLAIMED, AND (B) DISTRIBUTOR ACKNOWLEDGES
THAT IT HAS NOT RELIED ON ANY REPRESENTATION OR WARRANTY MADE BY SUPPLIER, OR ANY OTHER PERSON ON SUPPLIER&rsquo;S BEHALF, EXCEPT AS SPECIFICALLY
DESCRIBED IN SECTION 9.1 OF THIS AGREEMENT.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">10.</TD><TD><U>Term and Termination</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">10.1</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Term</U>. The initial term of this Agreement shall be two (2) years from its Effective Date (the &ldquo;Initial Term&rdquo;)
and shall be automatically renewed for two successive one-year terms without the need of any notice or modification, unless (a) terminated
by either Party as provided in this Section 10, or (b) one Party gives notice to the other Party of its intent to terminate the Agreement
with one hundred eighty (180) days&rsquo; notice prior to the end of the then-current term.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">10.2</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Termination by Either Party</U>. Either Party may terminate this Agreement:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">10.2.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;
</FONT>Upon [__________] ([______]) days&rsquo; written notice of material breach to the breaching party, which, if such breach is capable
of cure, such breach is not cured in such [__________] ([______]) day period; provided, however, that breach by Distributor of the provisions
of Section 2 (Distribution Rights), Section 6 (Intellectual Property), or Section 8 (Confidentiality) shall not be capable of cure;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">10.2.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;
</FONT>Immediately if the other party ceases to do business, or otherwise terminates its business operations; or</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">10.2.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;
</FONT>Immediately if the other shall seek protection under any bankruptcy, receivership, trust deed, creditors arrangement, composition,
or comparable proceeding, or if any such proceeding is instituted against the other (and not dismissed within [__________] ([______])
days).</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">10.2.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;
</FONT>In the event that the agreement is discontinued or terminated in accordance with the terms of this Agreement, Supplier has the
discretion to purchase back any inventory or allow Distributor to continue to sell existing inventory for a period to be agreed upon by
the Parties, not to exceed 365 days.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">10.3</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Termination by Supplier</U>. Supplier may terminate this Agreement upon [__________] ([______]) days&rsquo; written notice to
Distributor if the Distributor shall fail to promptly secure or renew any license, registration, permit, authorization or approval necessary
for the conduct of its business in the manner contemplated by this Agreement, or if any such license, registration, permit, authorization,
or approval is revoked or suspended and not reinstated within [__________] ([______]) days or, in the sole determination of Supplier,
Distributor is not making diligent efforts to effect such reinstatement.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">10.4</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>No Liability</U>. Neither Party shall incur any liability whatsoever for any damage, loss or expense of any kind suffered or
incurred by the other (or for any compensation to the other) arising from or incident to any termination of this Agreement by such Party
that complies with the terms of the Agreement whether or not such Party is aware of any such damage, loss or expense.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">10.5</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Survival</U>. Except to the extent expressly provided to the contrary, the following provisions shall survive the termination
of this Agreement: Sections 1, 6.7, 7.2, 8, 9.4, 9.5, 10.4, 10.5, 11 and <U>Attachment C</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">11.</TD><TD><U>Miscellaneous</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">11.1</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Liability</U>. Nothing in this Agreement shall be effective to limit or restrict any liability of any Party in respect of (i)
death, personal injury, loss or claim resulting from fraud, gross negligence or willful misconduct as otherwise prohibited by law; or
(ii) any fraudulent or negligent misrepresentation.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">Subject to clauses (i) and (ii) above, the Parties will not be liable to
the other for any punitive, incidental, special, indirect or consequential damages, including loss of profits, revenue or income, diminution
in value or loss of business reputation or opportunity relating to the breach or alleged breach of this Agreement.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">The Parties acknowledge that monetary damages may be inadequate for a breach
of this Agreement by any Party. Accordingly, the Parties agree that any other Party may seek the granting of injunctive relief as one
of the remedies available to it in respect of any breach by any Party.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">11.2</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Entire Agreement</U>. This Agreement, together with its Attachments, which by this reference are incorporated herein, contains
the entire agreement of the Parties regarding the subject matter hereof and supersedes all prior agreements, understandings and negotiations
regarding the same. This Agreement may not be modified or supplemented except by a written instrument signed by the Parties. Furthermore,
it is the intention of the Parties that this Agreement shall be controlling over additional or different terms of any Purchase Order or
similar Distributor document, even if accepted in writing by the Parties, and waivers and amendments shall be effective only if made by
negotiated waiver agreements referencing this Agreement and clearly understood by the Parties to be an amendment or waiver</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">11.3</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Severability</U>. If any provision of this Agreement shall be held illegal or unenforceable, that provision shall be limited
or eliminated to the minimum extent necessary so that this Agreement shall otherwise remain in full force and effect.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">11.4</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Further Assurances</U>. Each Party hereto agrees to execute, acknowledge and deliver such further instruments, and to do all
such other acts as may be reasonably necessary or appropriate in order to carry out the purposes and intent of this Agreement.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">11.5</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Use of Party&rsquo;s Name</U>. Except as provided in this Agreement, or right, express or implied, is granted by this Agreement
to either Party to use in any manner the name or trademark of the other.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">11.6</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Assignment</U>. This Agreement may not be assigned by either Party without the prior consent of the other Party (and any attempt
to do so will be void), which consent shall not be unreasonably withheld, condition or delayed. Any attempted or purported assignment
or transfer of rights infringe the provisions of this Section and shall be null and void.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">11.7</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Notices</U>. All notices, consents, or approvals required by this Agreement shall be in writing sent by certified or registered
mail, postage prepaid, or through a reputable expedited courier service, to the Parties at the addresses set forth in the preamble of
this Agreement or such other addresses as may be designated in writing by the respective Parties. Notice shall be deemed effective on
the date of confirmed receipt shown on the return receipt or on the third day following delivery to a reputable courier.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">11.8</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Relationship of the Parties</U>. All Parties are independent contractors under this Agreement. Nothing contained in this Agreement
is intended nor is to be construed so as to constitute Supplier and Distributor as partners, agents or joint venturers with respect to
this Agreement. Neither Party hereto shall have any express or implied right or authority to assume or create any obligations on behalf
of or in the name of the other Party or to bind the other Party to any contract, agreement or undertaking with any third party.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in"><FONT STYLE="display: inline-block; width: 0.5in; float: left; white-space:nowrap">11.9</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
</FONT><U>Waiver</U>. The waiver by either Party of a breach of any provisions contained herein shall be in writing and shall in no way
be construed as a waiver of any subsequent breach of such provisions or the waiver of the provision itself.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">11.10<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;
</FONT><U>Dispute Resolution and Applicable Law</U>. Any dispute regarding this Agreement shall be governed by and construed in accordance
with the law of the State of Colorado, without regard to conflict of law principles. Each of the Parties hereby consents to the exclusive
jurisdiction of the federal and state courts in Boulder County, Colorado, U.S.A. over any and all disputes arising hereunder. Further
each of the Parties hereby expressly and irrevocably waives any claims or defense in any such action or proceeding based on any alleged
lack of personal jurisdiction, improper venue, forum non-conveniens or any similar basis.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">11.11<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;
</FONT><U>Captions</U>. Section captions are for convenience only and in no way are to be construed to define, limit or affect the construction
or interpretation hereof.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">11.12<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;
</FONT><U>Force Majeure</U>. A Party shall not be liable for nonperformance or delay in performance (other than obligations regarding
payment, confidentiality and Distribution Rights) caused by any event reasonably beyond the control of such Party including, but not limited
to, wars, hostilities, revolutions, riots, civil commotion, national emergency, strikes, lockouts, epidemics, fire, flood, earthquake,
force of nature, explosion, embargo, or any other Act of God, or any law, proclamation, regulation, ordinance, or other act or order of
any court, government or governmental agency.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">11.13<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;
</FONT><U>Counterparts</U>. This Agreement may be executed in two or more counterparts, in original all of which shall be considered one
and the same agreement, and all of which shall become effective when one or more such counterparts have been signed by each of the Parties
and delivered to the other Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; font-size: 10pt"><FONT STYLE="font-variant: small-caps"><B>Distributor</B></FONT></TD>
    <TD STYLE="width: 50%; font-size: 10pt"><FONT STYLE="font-variant: small-caps"><B>Supplier</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-variant: small-caps">Phase One Health, LLC</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-variant: small-caps">Sonoma Pharmaceuticals, Inc.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">By: _____________________________________</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Name: __________________________________</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Title: ___________________________________</P></TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">By: <U>&nbsp;&nbsp;&nbsp;/s/ Amy
    Trombly&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Name: Amy Trombly</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Title: Chief Executive Officer</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">Date: ___________________________________</TD>
    <TD STYLE="font-size: 10pt">Date:&nbsp;&nbsp;3/28/2025</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.</TD><TD>Attachments</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-weight: normal"><U>Attachment
A</U> - Products and Pricing</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><U>Attachment B</U> <B>- </B>Supplier&rsquo;s General Terms and Conditions</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 13; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-19
<SEQUENCE>4
<FILENAME>sonoma_ex1900.htm
<DESCRIPTION>INSIDER TRADING POLICY
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 19</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Sonoma
pharmaceuticals, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Policy as to Trades in the Company&rsquo;s Securities
by Company Personnel</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>and</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Treatment of Confidential Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">As amended on December 20, 2023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">Purpose</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Both the Securities and Exchange
Commission (the &ldquo;SEC&rdquo;) and Congress are very concerned about maintaining the fairness of the U.S. securities markets. The
securities laws are continually reviewed and amended to prevent people from taking unfair advantage and to increase the punishment for
those who do. These laws require publicly-traded companies to have clear policies on insider trading. If companies like ours do not take
active steps to adopt preventive policies and procedures covering securities trades by Company personnel, the consequences could be severe.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, we are adopting
this Policy as to Trades in the Company&rsquo;s Securities by Company Personnel and Treatment of Confidential Information (the &ldquo;Insider
Trading Policy&rdquo;) to avoid even the appearance of improper conduct on the part of anyone employed by or associated with our Company
(not just so-called insiders). We have all worked hard to establish our reputation for integrity and ethical conduct. We cannot afford
to have it damaged.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">The Consequences</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The consequences of insider
trading violations can be substantial:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>For individuals</I></B>
who trade on inside information (or tip information to others):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">A jail term of up to 20 years;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">A civil penalty of up to three times the profit gained or loss avoided; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">A criminal fine (no matter how small the profit) of up to $5 million.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B><I>For a company</I></B>
(as well as possibly any supervisory person) that fails to take appropriate steps to prevent illegal trading:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">A civil penalty of the greater of $1 million or three times the profit gained or loss avoided as a result
of the employee&rsquo;s violation; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">A criminal penalty of up to $25 million.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Further, if an employee violates
the Company&rsquo;s insider trading policy, Company imposed sanctions, including dismissal for cause, could result. Needless to say, any
of the above consequences, even an SEC investigation that does not result in prosecution, can tarnish one&rsquo;s reputation and irreparably
damage a career. Finally, remember that there are no limits on the size of a transaction that will trigger insider trading liability.
In the past, relatively small trades have resulted in SEC investigations and lawsuits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">Our Policy</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>No Trading on the Basis
of Material Non-Public Information</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If a member of the Board of
Directors, officer or any employee has material non-public information (often referred to as &ldquo;insider information&rdquo;) relating
to our Company, it is our policy that neither that person nor any related person may buy or sell securities of the Company or engage in
any other action to take advantage of, or pass on to others, that information. This policy also applies to information relating to any
other company, including our customers, collaborators, partners or suppliers, obtained in the course of employment at the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Transactions that may be necessary
or justifiable for independent reasons (such as the need to raise money for an emergency expenditure) are no exception. Even the appearance
of an improper transaction must be avoided to preserve our reputation for adhering to the highest standards of conduct.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>What is Material Information?</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Material information&rdquo;
is any information that a reasonable investor would consider important in deciding whether to buy, hold or sell securities of the Company.
In short, &ldquo;material information&rdquo; includes any information that reasonably could affect the price of our securities. Either
positive or negative information may be material. It can be information about the Company or about a company with which we do business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><I>Examples:</I> Common examples of
information that will frequently be regarded as material are:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 27pt"><FONT STYLE="font-family: Symbol">-</FONT></TD><TD STYLE="text-align: justify">projections of future earnings or losses;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 27pt"><FONT STYLE="font-family: Symbol">-</FONT></TD><TD STYLE="text-align: justify">news of a possible merger, acquisition or tender offer;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 27pt"><FONT STYLE="font-family: Symbol">-</FONT></TD><TD STYLE="text-align: justify">significant new products or delays in new product introduction or development;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 27pt"><FONT STYLE="font-family: Symbol">-</FONT></TD><TD STYLE="text-align: justify">the results of clinical trials (positive or negative) or research efforts;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 27pt"><FONT STYLE="font-family: Symbol">-</FONT></TD><TD STYLE="text-align: justify">a change in reimbursement policy (positive or negative) by a significant third-party payor;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 27pt"><FONT STYLE="font-family: Symbol">-</FONT></TD><TD STYLE="text-align: justify">plans to raise additional capital through stock sales or otherwise;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 27pt"><FONT STYLE="font-family: Symbol">-</FONT></TD><TD STYLE="text-align: justify">the gain or loss of a significant collaborator or supplier;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 27pt"><FONT STYLE="font-family: Symbol">-</FONT></TD><TD STYLE="text-align: justify">significant regulatory actions concerning products;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 27pt"><FONT STYLE="font-family: Symbol">-</FONT></TD><TD STYLE="text-align: justify">discoveries, or grants or allowances or disallowances of patents;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 27pt"><FONT STYLE="font-family: Symbol">-</FONT></TD><TD STYLE="text-align: justify">changes in management;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 27pt"><FONT STYLE="font-family: Symbol">-</FONT></TD><TD STYLE="text-align: justify">news of a significant sale of assets;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 27pt"><FONT STYLE="font-family: Symbol">-</FONT></TD><TD STYLE="text-align: justify">impending bankruptcy or financial liquidity problems; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 27pt"><FONT STYLE="font-family: Symbol">-</FONT></TD><TD STYLE="text-align: justify">changes in dividend policies or the declaration of a stock split.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>Twenty-Twenty Hindsight
</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Remember, if your securities
transactions become the subject of scrutiny, they will be viewed after-the-fact with the benefit of hindsight. As a result, before engaging
in any transaction you should carefully consider how regulators and others might view your transaction in hindsight.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>Transactions by Family
Members</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The same restrictions apply
to your family members and others living in your household. Employees are expected to be responsible for the compliance of their immediate
family and personal household.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B><I>Do Not Pass Information to Others</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Whether the information is proprietary information
about our Company or information that could have an impact on our stock price, employees must not pass the information on to others. It
is illegal to advise others to trade on the basis of undisclosed material information. Liability in these cases can extend to both the
&ldquo;tippee&rdquo; &mdash; the person to whom the insider disclosed inside information &mdash; and you, as the &ldquo;tipper,&rdquo;
and will apply whether or not you derive any benefit from another&rsquo;s actions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>When Information is Public</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As you can appreciate, it
is also improper for any employee to enter a trade immediately after the Company has made a public announcement of material information,
including earnings releases. We impose certain &ldquo;trading blackouts&rdquo; to ensure that the Company&rsquo;s stockholders and the
investing public will be afforded the time to receive the information and act upon it. These are discussed below under the heading &ldquo;Trading
Blackouts.&rdquo; To avoid the appearance of impropriety, as a general rule, you should not engage in any transaction until at least one
full trading day has passed following the release of the information. Thus, if an announcement were made after the market close on a Monday,
Wednesday generally would be the first day on which you would be able to trade. If an announcement were made after the market close on
a Friday, Tuesday generally would be the first eligible trading day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>Pre-Clearance of Trades</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To provide assistance in preventing
inadvertent violations and avoiding even the appearance of an improper transaction (which could result, for example, where an employee
engages in a trade while unaware of a pending major development), all officers and certain employees in a position to have access to material
non-public information are subject to pre-clearance in writing by our General Counsel, of all transactions in Company securities (acquisitions,
dispositions, transfers, etc.). You must submit a written request for pre-clearance of a transaction no later than three business days
before the proposed date of execution of the transaction. You will be notified if you are one of the specified employees subject to this
policy. Pre-clearance is subject to a five business day expiration and must be renewed by the applicant after five business days to be
valid.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pre-clearance does not relieve
anyone of their responsibility under SEC rules. All employees, whether subject to pre-clearance or not, are responsible for adherence
to this Insider Trading Policy, including, but not limited to: not trading on insider information; not trading during trading blackout
periods; not trading for two full trading days after earnings announcements; and not trading in securities on a short-term basis. Employees
normally not subject to pre-clearance are still responsible for written pre-clearance for the sale of stock purchased in the open market
and that has been owned less than six months. If any employee is in doubt of whether or not pre-clearance is required, the employee should
inquire with our General Counsel or obtain pre-clearance as a cautionary measure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Members of the Board of Directors
must give our General Counsel notice of their intention to initiate a transaction prior to doing so.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>Trading Blackouts</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From time to time, the Company
may require that members of the Board of Directors, officers, selected employees and others suspend trading because of developments known
to the Company and not yet disclosed to the public. In that event, these persons are advised not to engage in any transaction involving
the purchase or sale of the Company&rsquo;s securities during that period and should not disclose to others the fact that they have been
suspended from trading. The Company will also require the following mandatory trading blackouts:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><B><I>Earnings Trading Blackouts</I></B> &ndash; All members of the Board of Directors, officers, and
designated employees will be subject to a stock trading blackout period beginning at the end of a fiscal quarter until two full trading
days have passed after earnings for that quarter are released.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Of course, no trading should
be done at any time that a member of the Board of Directors, officer or employee is actually aware of a major undisclosed corporate development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>Options</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Cash exercise of options currently
can be done at any time. This policy also does not apply to the exercise of a tax withholding right pursuant to which you elect to have
the Company withhold shares subject to an option to satisfy tax withholding requirements. Same day sales and exercises of options are
subject to trading windows, as are any other market sale for the purpose of generating the cash needed to pay the exercise price of an
option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>Exception for Approved
10b5-1 Plans</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Trades by members of the Board
of Directors, officers or employees in the Company&rsquo;s securities that are executed pursuant to an approved 10b5-1 trading plan (a
&ldquo;Trading Plan&rdquo;) are not subject to the prohibition on trading on the basis of material non-public information contained in
this Insider Trading Policy or to the restrictions set forth above relating to pre-clearance (or, in the case of Board members, prior
notification) procedures and blackout periods.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SEC Rule 10b5-1 provides an
affirmative defense from insider trading liability under the federal securities laws for trading plans that meet certain requirements.
It does not prevent someone from bringing a lawsuit. This Insider Trading Policy permits individuals to adopt Trading Plans with brokers
that outline a pre-set plan for trading of the Company&rsquo;s securities, including the exercise of options. Trading Plans are to be
implemented only during open windows and when the individual is not aware of any material non-public information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any Trading Plan must comply
with SEC Rule 10b5-1 and be approved in writing in advance by our General Counsel, and the establishment of such a Trading Plan with respect
to an individual may be publicly announced by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Establishing a Trading Plan
does not exempt individuals from complying with the Section 16 six-month short swing profit rules or liability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>Revocation/Amendments
to Plans</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">An individual may revoke his
or her Trading Plan at any time. Revocation is effected upon written notice to the broker. However, if the individual terminates the Trading
Plan after the first option exercise or stock sale, then the individual must cancel all outstanding Trading Plans and agree not to enter
into another Trading Plan until six months after termination of the Trading Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under certain circumstances,
a Trading Plan must be revoked. This includes circumstances such as the announcement of a merger or the occurrence of an event that would
cause the transaction either to violate the law or to have an adverse effect on the Company. The General Counsel or any stock administrator
of the Company is authorized to notify the broker in such circumstances, thereby insulating the insider in the event of revocation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Amendments to Trading Plans
will not be allowed once the Trading Plan is in place.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>Post-Termination Transactions</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This policy continues to apply
to your transactions in Company securities even after you have terminated employment. If you are in possession of material non-public
information when your employment terminates, you may not trade in Company securities until that information has become public or is no
longer material.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">Additional Prohibited Transactions</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe it is improper
and inappropriate for any Company personnel to engage in short-term or speculative transactions involving Company securities. We believe
that this trading can reflect badly on the Company and that Company personnel should not engage in any types of transactions that are
commonly viewed as a form of &ldquo;betting&rdquo; for or against the Company. Accordingly, it is the Company&rsquo;s policy that members
of the Board of Directors, officers and employees should not engage in any of the following activities with respect to securities of the
Company:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><B><I>Director and officer cashless exercise</I></B> &ndash; In response to the restrictions set forth
in the Sarbanes-Oxley Act of 2002, the Company will not arrange with brokers to administer cashless exercises on behalf of directors and
officers of the Company. Directors and officers of the Company may only utilize the cashless exercise feature of their options if (i)
the director or officer retains a broker independently of the Company, (ii) the Company&rsquo;s involvement is limited to confirming that
it will deliver the stock promptly upon payment of the exercise price and (iii) the director or officer uses a &ldquo;T+2&rdquo; cashless
exercise arrangement, in which the Company agrees to deliver stock against the payment of the purchase price on the same day the sale
of the stock underlying the option settles. Under a T+2 cashless exercise, a stock broker, the issuer, and the transfer agent of the issuer
work together to make all transactions settle simultaneously. This approach is to avoid any inference that the Company has &ldquo;extended
credit&rdquo; in the form of a personal loan to the director or executive officer. Any employee who has any questions about cashless exercises
may obtain additional guidance from our General Counsel.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><B><I>Director and officer trading during pension and 401(k) plan blackout periods</I></B> &ndash; In
response to the restrictions set forth in the Sarbanes-Oxley Act of 2002, directors and officers of the Company are prohibited from trading
Company securities during pension and 401(k) plan blackouts, if any.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><B><I>Trading in securities on a short-term basis </I></B>&mdash; As a general rule, any Company securities
purchased in the open market (i.e., not including stock purchased upon exercise of an employee stock option) should be held for a minimum
of six months and ideally longer. The top executives and members of the Board of Directors of the Company are already subject to the SEC&rsquo;s
&ldquo;short-swing&rdquo; profit rule, which penalizes sales and purchases inside of any six-month period. Any employee who wishes to
sell Company securities that were purchased in the open market and that has been owned less than six months must obtain prior written
clearance from our General Counsel. You must submit a written request for pre-clearance of a transaction no later than three business
days before the proposed date of execution of the transaction.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><B><I>Purchases of Company securities on margin </I></B>&mdash; This means borrowing from a brokerage
firm, bank or other entity in order to buy Company securities (other than in connection with a so-called &ldquo;cashless&rdquo; exercise
of options under the Company&rsquo;s stock plans).</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><B><I>Short sales of Company securities </I></B>&mdash; This involves selling Company securities that
you do not own in the expectation that the price of the securities will fall, or as part of an arbitrage transaction.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><B><I>Buying or selling puts or calls on Company securities</I></B> &mdash; This includes options trading
on any of the stock exchanges or futures exchanges.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">Confidential Information
and Communications with the Media</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unauthorized disclosure of
internal information relating to the Company (including information regarding products, the Company&rsquo;s suppliers or customers) could
cause competitive harm to the Company and in some cases could result in liability for the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>Unauthorized Disclosure</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Company personnel should not
disclose internal information about the Company to <U>anyone</U> outside the Company, except as required in the performance of regular
duties for the Company. In this regard, Company employees are prohibited from posting internal information about the Company on a &ldquo;bulletin
board&rdquo; on the Internet or communicating about the Company and its business in Internet-based &ldquo;chat&rdquo; rooms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>Communications With the
Media, Securities Analysts And Investors</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Communications on behalf of
the Company with the media, securities analysts and investors must be made only by specifically designated representatives of the Company.
Unless you have been expressly authorized to make such communications, if you receive any inquiry relating to the Company from the media,
a securities analyst or an investor, you should refer the inquiry to our General Counsel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>Safeguarding Confidential
Information</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Care must be taken to safeguard
the confidentiality of internal information. For example, sensitive documents should not be left lying on desks, and visitors should not
be left unattended in offices containing internal company documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>Rumors</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Rumors concerning the business
and affairs of the Company may circulate from time to time. Our general policy is not to comment upon rumors. Individual employees should
also refrain from commenting upon or responding to rumors and should refer any requests for comments or responses to our General Counsel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">Company Assistance</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any person who has any questions
about specific transactions may obtain additional guidance from our Chief Financial Officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Remember, however, the ultimate
responsibility for adhering to this Insider Trading Policy and avoiding improper transactions rests with you. In this regard, it is imperative
that you use your best judgment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">Modifications</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Insider Trading Policy
has been approved by the Company's Board of Directors. Officers of the Company may, from time to time, make non-substantive modifications
to this Insider Trading Policy (including, without limitation, substitution of the names of the appropriate contact persons within the
Company) without prior approval of the Company&rsquo;s Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">Acknowledgements</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All employees will be required
to acknowledge their understanding of, and an intent to comply with, this Insider Trading Policy</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><U>ACKNOWLEDGMENT</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">I have received and read a
copy of the Sonoma Pharmaceuticals Policy as to Trades in the Company&rsquo;s Securities by Company Personnel and Treatment of Confidential
Information (&ldquo;Insider Trading Policy&rdquo;) and I understand and agree to comply with the specific requirements of the Insider
Trading Policy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="padding-bottom: 1pt; width: 15%">&nbsp;</TD>
  <TD STYLE="padding-bottom: 1pt; width: 15%">Signed:</TD>
  <TD STYLE="border-bottom: Black 1pt solid; width: 50%">&nbsp;</TD>
  <TD STYLE="padding-bottom: 1pt; width: 20%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
  <TD STYLE="padding-bottom: 1pt">Printed Name:</TD>
  <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
  <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
  <TD STYLE="padding-bottom: 1pt">Date:</TD>
  <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
  <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>5
<FILENAME>sonoma_ex2301.htm
<DESCRIPTION>CONSENT OF FRAZIER & DEETER, LLC, INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM.
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Exhibit 23.1</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">CONSENT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We consent to the incorporation by reference in the Registration Statement of Sonoma Pharmaceuticals, Inc. on Form S-3 (File No. 333-275311),
Form S-8 (File No. 333-262144), Form S-8 (File No. 333-228898), Form S-8 (File No. 333-219058), Form S-8 (File No. 333-214760), Form S-8
(File No. 333-205171), Form S-8 (File No. 333-171412), Form S-8 (File No. 333-182263), Form S-8 (File No. 333-195530), Form S-8 (File
No. 333-194314), Form S-8 (File No. 333-163988), Form S-8 (File No. 333-235708), Form S-8 (File No. 333-141017), Form S-8 (File No. 333-280268),
and Form S-8 (File No. 333-283992) of our report dated June 17, 2025, with respect to our audit of the consolidated financial statements
of Sonoma Pharmaceuticals, Inc. and Subsidiaries as of March 31, 2025 and 2024 and for the years then ended, which report is included
in this Annual Report on Form 10-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>/s/ Frazier &amp; Deeter, LLC</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Nashville, Tennessee</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">June 17, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>sonoma_ex3101.htm
<DESCRIPTION>CERTIFICATION OF CHIEF EXECUTIVE OFFICER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 31.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT
TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(18 U.S.C. SECTION 1350)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">I, Amy Trombly, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">1. I have reviewed this annual report on Form 10-K
of Sonoma Pharmaceuticals, Inc. for the year ended March 31, 2025;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">2. Based on my knowledge, this report does not contain
any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances
under which such statements were made, not misleading with respect to the period covered by this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">3. Based on my knowledge, the financial statements,
and other financial information included in this report, fairly present in all material respects the financial condition, results of operations
and cash flows of the registrant as of, and for, the periods presented in this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">4. The registrant&rsquo;s other certifying officer
and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e)
and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant
and have:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(a) Designed such disclosure controls and procedures,
or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to
the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the
period in which this report is being prepared;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(b) Designed such internal control over financial
reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance
regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with
generally accepted accounting principles;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(c) Evaluated the effectiveness of the registrant&rsquo;s
disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and
procedures, as of the end of the period covered by this report based on such evaluation; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(d) Disclosed in this report any change in the registrant&rsquo;s
internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant's fourth
fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s
internal control over financial reporting; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">5. The registrant&rsquo;s other certifying officer
and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors
and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(a) All significant deficiencies and material weaknesses
in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s
ability to record, process, summarize and report financial information; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(b) Any fraud, whether or not material, that involves
management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 3%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/<U>s/ Amy Trombly&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></FONT></TD>
    <TD STYLE="width: 8%; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: June 17, 2025</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amy Trombly</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Executive Officer)</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>sonoma_ex3102.htm
<DESCRIPTION>CERTIFICATION OF CHIEF FINANCIAL OFFICER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 31.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT
TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(18 U.S.C. SECTION 1350)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">I, Jerome Dvonch, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">1. I have reviewed this annual report on Form 10-K
of Sonoma Pharmaceuticals, Inc. for the year ended March 31, 2025;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">2. Based on my knowledge, this report does not contain
any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances
under which such statements were made, not misleading with respect to the period covered by this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">3. Based on my knowledge, the financial statements,
and other financial information included in this report, fairly present in all material respects the financial condition, results of operations
and cash flows of the registrant as of, and for, the periods presented in this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">4. The registrant&rsquo;s other certifying officer
and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e)
and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant
and have:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(a) Designed such disclosure controls and procedures,
or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to
the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the
period in which this report is being prepared;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(b) Designed such internal control over financial
reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance
regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with
generally accepted accounting principles;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(c) Evaluated the effectiveness of the registrant&rsquo;s
disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and
procedures, as of the end of the period covered by this report based on such evaluation; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(d) Disclosed in this report any change in the registrant&rsquo;s
internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant's fourth
fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s
internal control over financial reporting; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">5. The registrant&rsquo;s other certifying officer
and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors
and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(a) All significant deficiencies and material weaknesses
in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s
ability to record, process, summarize and report financial information; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(b) Any fraud, whether or not material, that involves
management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 3%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>/s/ Jerome Dvonch&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></FONT></TD>
    <TD STYLE="width: 8%; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: June 17, 2025</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jerome Dvonch</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Chief Financial Officer</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(Principal Financial Officer and Principal Accounting
    Officer)</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>sonoma_ex3201.htm
<DESCRIPTION>CERTIFICATIONS
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 32.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CERTIFICATION PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(18 U.S.C. SECTION 1350)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to section 906 of the Sarbanes-Oxley Act
of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), the undersigned officers of Sonoma Pharmaceuticals,
Inc., a Delaware corporation (the &ldquo;Company&rdquo;), do hereby certify, to such officers&rsquo; knowledge, that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Annual Report on Form 10-K for the year ended
March 31, 2025 (the &ldquo;Form 10-K&rdquo;) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities
Exchange Act of 1934, and the information contained in the Form 10-K fairly presents, in all material respects, the financial condition
and results of operations of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: June 17, 2025</FONT></TD>
    <TD STYLE="width: 3%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>/s/ Amy Trombly&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></FONT></TD>
    <TD STYLE="width: 8%; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Amy Trombly</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Chief Executive Officer</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(Principal Executive Officer)</P></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: June 17, 2025</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>/s/ Jerome Dvonch&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Jerome Dvonch</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Chief Financial Officer</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(Principal Financial Officer and Principal Accounting
    Officer)</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>snoa-20250331.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.0c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +Kopo7xRiXgen8uEbXpMOaePKaPty5522YkxvmR9fTkqvy8kuyj9CCPxf9GG0TAA -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:SNOA="http://sonomapharma.com/20250331" elementFormDefault="qualified" targetNamespace="http://sonomapharma.com/20250331">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://sonomapharma.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sonomapharma.com/role/ConsolidatedBalanceSheets" id="ConsolidatedBalanceSheets">
          <link:definition>00000002 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sonomapharma.com/role/ConsolidatedBalanceSheetsParenthetical" id="ConsolidatedBalanceSheetsParenthetical">
          <link:definition>00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sonomapharma.com/role/ConsolidatedStatementsOfComprehensiveLoss" id="ConsolidatedStatementsOfComprehensiveLoss">
          <link:definition>00000004 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sonomapharma.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" id="ConsolidatedStatementsOfChangesInStockholdersEquity">
          <link:definition>00000005 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows" id="ConsolidatedStatementsOfCashFlows">
          <link:definition>00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sonomapharma.com/role/CybersecurityRiskManagementAndStrategyDisclosure" id="CybersecurityRiskManagementAndStrategyDisclosure">
          <link:definition>999007 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sonomapharma.com/role/OrganizationAndRecentDevelopments" id="OrganizationAndRecentDevelopments">
          <link:definition>999008 - Disclosure - Organization and Recent Developments</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sonomapharma.com/role/LiquidityAndFinancialCondition" id="LiquidityAndFinancialCondition">
          <link:definition>999009 - Disclosure - Liquidity and Financial Condition</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sonomapharma.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
          <link:definition>999010 - Disclosure - Summary of Significant Accounting Policies</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sonomapharma.com/role/AccountsReceivable" id="AccountsReceivable">
          <link:definition>999011 - Disclosure - Accounts Receivable</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sonomapharma.com/role/Inventories" id="Inventories">
          <link:definition>999012 - Disclosure - Inventories</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sonomapharma.com/role/PrepaidExpensesAndOtherCurrentAssets" id="PrepaidExpensesAndOtherCurrentAssets">
          <link:definition>999013 - Disclosure - Prepaid Expenses and Other Current Assets</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sonomapharma.com/role/PropertyAndEquipment" id="PropertyAndEquipment">
          <link:definition>999014 - Disclosure - Property and Equipment</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sonomapharma.com/role/AccruedExpensesAndOtherCurrentLiabilities" id="AccruedExpensesAndOtherCurrentLiabilities">
          <link:definition>999015 - Disclosure - Accrued Expenses and Other Current Liabilities</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sonomapharma.com/role/Debt" id="Debt">
          <link:definition>999016 - Disclosure - Debt</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sonomapharma.com/role/Leases" id="Leases">
          <link:definition>999017 - Disclosure - Leases</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sonomapharma.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
          <link:definition>999018 - Disclosure - Commitments and Contingencies</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sonomapharma.com/role/StockholdersEquity" id="StockholdersEquity">
          <link:definition>999019 - Disclosure - Stockholders&#8217; Equity</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sonomapharma.com/role/Stock-basedCompensation" id="Stock-basedCompensation">
          <link:definition>999020 - Disclosure - Stock-Based Compensation</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sonomapharma.com/role/IncomeTaxes" id="IncomeTaxes">
          <link:definition>999021 - Disclosure - Income Taxes</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sonomapharma.com/role/EmployeeBenefitPlan" id="EmployeeBenefitPlan">
          <link:definition>999022 - Disclosure - Employee Benefit Plan</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sonomapharma.com/role/RevenueDisaggregation" id="RevenueDisaggregation">
          <link:definition>999023 - Disclosure - Revenue Disaggregation</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
          <link:definition>999025 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
          <link:definition>999026 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sonomapharma.com/role/AccountsReceivableTables" id="AccountsReceivableTables">
          <link:definition>999027 - Disclosure - Accounts Receivable (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sonomapharma.com/role/InventoriesTables" id="InventoriesTables">
          <link:definition>999028 - Disclosure - Inventories (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sonomapharma.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" id="PrepaidExpensesAndOtherCurrentAssetsTables">
          <link:definition>999029 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sonomapharma.com/role/PropertyAndEquipmentTables" id="PropertyAndEquipmentTables">
          <link:definition>999030 - Disclosure - Property and Equipment (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sonomapharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" id="AccruedExpensesAndOtherCurrentLiabilitiesTables">
          <link:definition>999031 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sonomapharma.com/role/LeasesTables" id="LeasesTables">
          <link:definition>999032 - Disclosure - Leases (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sonomapharma.com/role/Stock-basedCompensationTables" id="Stock-basedCompensationTables">
          <link:definition>999033 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sonomapharma.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
          <link:definition>999034 - Disclosure - Income Taxes (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sonomapharma.com/role/RevenueDisaggregationTables" id="RevenueDisaggregationTables">
          <link:definition>999035 - Disclosure - Revenue Disaggregation (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sonomapharma.com/role/OrganizationAndRecentDevelopmentsDetailsNarrative" id="OrganizationAndRecentDevelopmentsDetailsNarrative">
          <link:definition>999036 - Disclosure - Organization and Recent Developments (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sonomapharma.com/role/LiquidityAndFinancialConditionDetailsNarrative" id="LiquidityAndFinancialConditionDetailsNarrative">
          <link:definition>999037 - Disclosure - Liquidity and Financial Condition (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails" id="SummaryOfSignificantAccountingPoliciesDetails">
          <link:definition>999038 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-usefulLives" id="SummaryOfSignificantAccountingPoliciesDetails-usefulLives">
          <link:definition>999039 - Disclosure - Summary of Significant Accounting Policies (Details-Useful lives)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-EarningsPerShare" id="SummaryOfSignificantAccountingPoliciesDetails-EarningsPerShare">
          <link:definition>999040 - Disclosure - Summary of Significant Accounting Policies (Details - Earnings per share)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-AntidilutiveShares" id="SummaryOfSignificantAccountingPoliciesDetails-AntidilutiveShares">
          <link:definition>999041 - Disclosure - Summary of Significant Accounting Policies (Details - Antidilutive shares)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" id="SummaryOfSignificantAccountingPoliciesDetailsNarrative">
          <link:definition>999042 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sonomapharma.com/role/AccountsReceivableDetails" id="AccountsReceivableDetails">
          <link:definition>999043 - Disclosure - Accounts Receivable (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sonomapharma.com/role/InventoriesDetails" id="InventoriesDetails">
          <link:definition>999044 - Disclosure - Inventories (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sonomapharma.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails" id="PrepaidExpensesAndOtherCurrentAssetsDetails">
          <link:definition>999045 - Disclosure - Prepaid Expenses and Other Current Assets (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sonomapharma.com/role/PropertyAndEquipmentDetails" id="PropertyAndEquipmentDetails">
          <link:definition>999046 - Disclosure - Property and Equipment (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sonomapharma.com/role/PropertyAndEquipmentDetailsNarrative" id="PropertyAndEquipmentDetailsNarrative">
          <link:definition>999047 - Disclosure - Property and Equipment (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sonomapharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails" id="AccruedExpensesAndOtherCurrentLiabilitiesDetails">
          <link:definition>999048 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sonomapharma.com/role/DebtDetailsNarrative" id="DebtDetailsNarrative">
          <link:definition>999049 - Disclosure - Debt (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sonomapharma.com/role/LeasesDetails-BalanceSheetInformationRelatedToLeases" id="LeasesDetails-BalanceSheetInformationRelatedToLeases">
          <link:definition>999050 - Disclosure - Leases (Details - Balance sheet information related to leases)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sonomapharma.com/role/LeasesDetails-MinimumOperatingLeasePayments" id="LeasesDetails-MinimumOperatingLeasePayments">
          <link:definition>999051 - Disclosure - Leases (Details - Minimum operating lease payments)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sonomapharma.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
          <link:definition>999052 - Disclosure - Commitments and Contingencies (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sonomapharma.com/role/StockholdersEquityDetailsNarrative" id="StockholdersEquityDetailsNarrative">
          <link:definition>999053 - Disclosure - Stockholders&#8217; Equity (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sonomapharma.com/role/Stock-basedCompensationDetails-assumptions" id="Stock-basedCompensationDetails-assumptions">
          <link:definition>999054 - Disclosure - Stock-Based Compensation (Details-Assumptions)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sonomapharma.com/role/Stock-basedCompensationDetails-plans" id="Stock-basedCompensationDetails-plans">
          <link:definition>999055 - Disclosure - Stock-Based Compensation (Details-Plans)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sonomapharma.com/role/Stock-basedCompensationDetails-optionActivity" id="Stock-basedCompensationDetails-optionActivity">
          <link:definition>999056 - Disclosure - Stock-Based Compensation (Details-Option activity)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sonomapharma.com/role/Stock-basedCompensationDetails-restrictedStockActivity" id="Stock-basedCompensationDetails-restrictedStockActivity">
          <link:definition>999057 - Disclosure - Stock-Based Compensation (Details-Restricted stock activity)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sonomapharma.com/role/Stock-basedCompensationDetailsNarrative" id="Stock-basedCompensationDetailsNarrative">
          <link:definition>999058 - Disclosure - Stock-Based Compensation (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sonomapharma.com/role/IncomeTaxesDetails-incomeSource" id="IncomeTaxesDetails-incomeSource">
          <link:definition>999059 - Disclosure - Income Taxes (Details-Income source)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sonomapharma.com/role/IncomeTaxesDetails-incomeTaxExpense" id="IncomeTaxesDetails-incomeTaxExpense">
          <link:definition>999060 - Disclosure - Income Taxes (Details-Income tax expense)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sonomapharma.com/role/IncomeTaxesDetails-reconciliationOfTaxRate" id="IncomeTaxesDetails-reconciliationOfTaxRate">
          <link:definition>999061 - Disclosure - Income Taxes (Details-Reconciliation of tax rate)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes" id="IncomeTaxesDetails-deferredTaxes">
          <link:definition>999062 - Disclosure - Income Taxes (Details-Deferred taxes)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sonomapharma.com/role/IncomeTaxesDetailsNarrative" id="IncomeTaxesDetailsNarrative">
          <link:definition>999063 - Disclosure - Income Taxes (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sonomapharma.com/role/EmployeeBenefitPlanDetailsNarrative" id="EmployeeBenefitPlanDetailsNarrative">
          <link:definition>999064 - Disclosure - Employee Benefit Plan (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sonomapharma.com/role/RevenueDisaggregationDetails-DisaggregationOfRevenue" id="RevenueDisaggregationDetails-DisaggregationOfRevenue">
          <link:definition>999065 - Disclosure - Revenue Disaggregation (Details - Disaggregation of revenue)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://sonomapharma.com/role/RevenueDisaggregationDetails-GeographicRegions" id="RevenueDisaggregationDetails-GeographicRegions">
          <link:definition>999066 - Disclosure - Revenue Disaggregation (Details - Geographic regions)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="snoa-20250331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="snoa-20250331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="snoa-20250331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="snoa-20250331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
    <import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
    <import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" />
    <import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
    <import namespace="http://xbrl.sec.gov/cyd/2024" schemaLocation="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd" />
    <element id="SNOA_InvekraMember" name="InvekraMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_ProbableCreditLossesMember" name="ProbableCreditLossesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_PotentialDiscountsReturnsDistributorFeesAndRebatesMember" name="PotentialDiscountsReturnsDistributorFeesAndRebatesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_CustomerAMember" name="CustomerAMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_CustomerBMember" name="CustomerBMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_CustomerCMember" name="CustomerCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_CustomerDMember" name="CustomerDMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_CommonStockUnitsMember" name="CommonStockUnitsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_InsurancePremiumFinancingMember" name="InsurancePremiumFinancingMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_PlacementAgencyAgreementMember" name="PlacementAgencyAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_PublicOfferingMember" name="PublicOfferingMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_EquityDistributionAgreementMember" name="EquityDistributionAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_MaximGroupLLCMember" name="MaximGroupLLCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_Plan2016Member" name="Plan2016Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_Plan2021Member" name="Plan2021Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_Plan2024Member" name="Plan2024Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_Plan2011Member" name="Plan2011Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_CaliforniaResearchAndDevelopmentMember" name="CaliforniaResearchAndDevelopmentMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_HumanCareMember" name="HumanCareMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_AnimalCareMember" name="AnimalCareMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_ServiceAndRoyaltyMember" name="ServiceAndRoyaltyMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_RestOfTheWorldMember" name="RestOfTheWorldMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_DeferredConsiderationCurrent" name="DeferredConsiderationCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_DeferredConsiderationNoncurrent" name="DeferredConsiderationNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_WithholdingTaxPayable" name="WithholdingTaxPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_StockIssuedDuringPeriodValueNewIssues1" name="StockIssuedDuringPeriodValueNewIssues1" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_StockIssuedDuringPeriodSharesNewIssues1" name="StockIssuedDuringPeriodSharesNewIssues1" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_ProceedsFromAtthemarketSaleOfCommonStockNetOfOfferingExpensesShares" name="ProceedsFromAtthemarketSaleOfCommonStockNetOfOfferingExpensesShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_StockIssuedDuringPeriodValueReverseStockSplits" name="StockIssuedDuringPeriodValueReverseStockSplits" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_StockIssuedDuringPeriodValuesReverseStockSplits" name="StockIssuedDuringPeriodValuesReverseStockSplits" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_IncreaseDecreaseInWithholdingTaxPayable" name="IncreaseDecreaseInWithholdingTaxPayable" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_PaymentsForFractionalSharesRelatedToReversesplit" name="PaymentsForFractionalSharesRelatedToReversesplit" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_ProceedsFromInsurancePremiumsFinanced" name="ProceedsFromInsurancePremiumsFinanced" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_InsurancePremiumsFinanced" name="InsurancePremiumsFinanced" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_ShippingAndHandlingCost1PolicyTextBlock" name="ShippingAndHandlingCost1PolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_ConvertiblePreferredStockPolicyTextBlock" name="ConvertiblePreferredStockPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock" name="PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_ScheduleOfStockbasedAwardsOutstandingByPlanTableTextBlock" name="ScheduleOfStockbasedAwardsOutstandingByPlanTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_WorkingCapital" name="WorkingCapital" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_ConcentrationRiskPercentage2" name="ConcentrationRiskPercentage2" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationLossAdjustmentBeforeTaxPortionAttributableToParent" name="OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationLossAdjustmentBeforeTaxPortionAttributableToParent" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainAdjustmentBeforeTaxPortionAttributableToParent" name="OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainAdjustmentBeforeTaxPortionAttributableToParent" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_PotentialSeverancePayments" name="PotentialSeverancePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_ProceedsFromIssuanceOfCommonStockGross" name="ProceedsFromIssuanceOfCommonStockGross" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableInPeriodGrantDateIntrinsicValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableInPeriodGrantDateIntrinsicValue" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_TrueupsOfStateDeferredAssets" name="TrueupsOfStateDeferredAssets" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_DeferredTaxAssetsLeaseLiability" name="DeferredTaxAssetsLeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="SNOA_DeferredTaxLiabilitiesRightOfUseAsset" name="DeferredTaxLiabilitiesRightOfUseAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>snoa-20250331_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.0c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://sonomapharma.com/role/Cover" xlink:href="snoa-20250331.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/ConsolidatedBalanceSheets" xlink:href="snoa-20250331.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="snoa-20250331.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/ConsolidatedStatementsOfComprehensiveLoss" xlink:href="snoa-20250331.xsd#ConsolidatedStatementsOfComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" xlink:href="snoa-20250331.xsd#ConsolidatedStatementsOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="snoa-20250331.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:href="snoa-20250331.xsd#CybersecurityRiskManagementAndStrategyDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/OrganizationAndRecentDevelopments" xlink:href="snoa-20250331.xsd#OrganizationAndRecentDevelopments" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/LiquidityAndFinancialCondition" xlink:href="snoa-20250331.xsd#LiquidityAndFinancialCondition" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="snoa-20250331.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/AccountsReceivable" xlink:href="snoa-20250331.xsd#AccountsReceivable" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/Inventories" xlink:href="snoa-20250331.xsd#Inventories" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:href="snoa-20250331.xsd#PrepaidExpensesAndOtherCurrentAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/PropertyAndEquipment" xlink:href="snoa-20250331.xsd#PropertyAndEquipment" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:href="snoa-20250331.xsd#AccruedExpensesAndOtherCurrentLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/Debt" xlink:href="snoa-20250331.xsd#Debt" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/Leases" xlink:href="snoa-20250331.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/CommitmentsAndContingencies" xlink:href="snoa-20250331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/StockholdersEquity" xlink:href="snoa-20250331.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/Stock-basedCompensation" xlink:href="snoa-20250331.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/IncomeTaxes" xlink:href="snoa-20250331.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/EmployeeBenefitPlan" xlink:href="snoa-20250331.xsd#EmployeeBenefitPlan" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/RevenueDisaggregation" xlink:href="snoa-20250331.xsd#RevenueDisaggregation" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="snoa-20250331.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="snoa-20250331.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/AccountsReceivableTables" xlink:href="snoa-20250331.xsd#AccountsReceivableTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/InventoriesTables" xlink:href="snoa-20250331.xsd#InventoriesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:href="snoa-20250331.xsd#PrepaidExpensesAndOtherCurrentAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/PropertyAndEquipmentTables" xlink:href="snoa-20250331.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:href="snoa-20250331.xsd#AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/LeasesTables" xlink:href="snoa-20250331.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/Stock-basedCompensationTables" xlink:href="snoa-20250331.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/IncomeTaxesTables" xlink:href="snoa-20250331.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/RevenueDisaggregationTables" xlink:href="snoa-20250331.xsd#RevenueDisaggregationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/OrganizationAndRecentDevelopmentsDetailsNarrative" xlink:href="snoa-20250331.xsd#OrganizationAndRecentDevelopmentsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/LiquidityAndFinancialConditionDetailsNarrative" xlink:href="snoa-20250331.xsd#LiquidityAndFinancialConditionDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:href="snoa-20250331.xsd#SummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-usefulLives" xlink:href="snoa-20250331.xsd#SummaryOfSignificantAccountingPoliciesDetails-usefulLives" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-EarningsPerShare" xlink:href="snoa-20250331.xsd#SummaryOfSignificantAccountingPoliciesDetails-EarningsPerShare" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-AntidilutiveShares" xlink:href="snoa-20250331.xsd#SummaryOfSignificantAccountingPoliciesDetails-AntidilutiveShares" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="snoa-20250331.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/AccountsReceivableDetails" xlink:href="snoa-20250331.xsd#AccountsReceivableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/InventoriesDetails" xlink:href="snoa-20250331.xsd#InventoriesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails" xlink:href="snoa-20250331.xsd#PrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/PropertyAndEquipmentDetails" xlink:href="snoa-20250331.xsd#PropertyAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/PropertyAndEquipmentDetailsNarrative" xlink:href="snoa-20250331.xsd#PropertyAndEquipmentDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:href="snoa-20250331.xsd#AccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/DebtDetailsNarrative" xlink:href="snoa-20250331.xsd#DebtDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/LeasesDetails-BalanceSheetInformationRelatedToLeases" xlink:href="snoa-20250331.xsd#LeasesDetails-BalanceSheetInformationRelatedToLeases" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/LeasesDetails-MinimumOperatingLeasePayments" xlink:href="snoa-20250331.xsd#LeasesDetails-MinimumOperatingLeasePayments" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="snoa-20250331.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/StockholdersEquityDetailsNarrative" xlink:href="snoa-20250331.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/Stock-basedCompensationDetails-assumptions" xlink:href="snoa-20250331.xsd#Stock-basedCompensationDetails-assumptions" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/Stock-basedCompensationDetails-plans" xlink:href="snoa-20250331.xsd#Stock-basedCompensationDetails-plans" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/Stock-basedCompensationDetails-optionActivity" xlink:href="snoa-20250331.xsd#Stock-basedCompensationDetails-optionActivity" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/Stock-basedCompensationDetails-restrictedStockActivity" xlink:href="snoa-20250331.xsd#Stock-basedCompensationDetails-restrictedStockActivity" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/Stock-basedCompensationDetailsNarrative" xlink:href="snoa-20250331.xsd#Stock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/IncomeTaxesDetails-incomeSource" xlink:href="snoa-20250331.xsd#IncomeTaxesDetails-incomeSource" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/IncomeTaxesDetails-incomeTaxExpense" xlink:href="snoa-20250331.xsd#IncomeTaxesDetails-incomeTaxExpense" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/IncomeTaxesDetails-reconciliationOfTaxRate" xlink:href="snoa-20250331.xsd#IncomeTaxesDetails-reconciliationOfTaxRate" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes" xlink:href="snoa-20250331.xsd#IncomeTaxesDetails-deferredTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/IncomeTaxesDetailsNarrative" xlink:href="snoa-20250331.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/EmployeeBenefitPlanDetailsNarrative" xlink:href="snoa-20250331.xsd#EmployeeBenefitPlanDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/RevenueDisaggregationDetails-DisaggregationOfRevenue" xlink:href="snoa-20250331.xsd#RevenueDisaggregationDetails-DisaggregationOfRevenue" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/RevenueDisaggregationDetails-GeographicRegions" xlink:href="snoa-20250331.xsd#RevenueDisaggregationDetails-GeographicRegions" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/ConsolidatedBalanceSheets" xlink:title="00000002 - Statement - CONSOLIDATED BALANCE SHEETS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_DeferredConsiderationCurrent" xlink:label="loc_SNOADeferredConsiderationCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_SNOADeferredConsiderationCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="loc_us-gaapDeferredIncomeTaxAssetsNet" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapDeferredIncomeTaxAssetsNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_DeferredConsiderationNoncurrent" xlink:label="loc_SNOADeferredConsiderationNoncurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_SNOADeferredConsiderationNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:label="loc_us-gaapAccountsPayableAndOtherAccruedLiabilities" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableAndOtherAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaapDeferredRevenueCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapDeferredRevenueCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermBorrowings" xlink:label="loc_us-gaapShortTermBorrowings" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapShortTermBorrowings" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaapDeferredRevenueNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapDeferredRevenueNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_WithholdingTaxPayable" xlink:label="loc_SNOAWithholdingTaxPayable" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_SNOAWithholdingTaxPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/ConsolidatedStatementsOfComprehensiveLoss" xlink:title="00000004 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_us-gaapRevenues" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaapCostOfGoodsAndServicesSold" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_us-gaapCostOfGoodsAndServicesSold" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherOperatingIncomeExpenseNet" xlink:label="loc_us-gaapOtherOperatingIncomeExpenseNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapOtherOperatingIncomeExpenseNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" xlink:label="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" xlink:title="00000005 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS&apos; EQUITY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows" xlink:title="00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:label="loc_us-gaapIncreaseDecreaseInDeferredIncomeTaxes" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInDeferredIncomeTaxes" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDeferredCompensation" xlink:label="loc_us-gaapIncreaseDecreaseInDeferredCompensation" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInDeferredCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInOtherAccountsPayable" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherAccountsPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_IncreaseDecreaseInWithholdingTaxPayable" xlink:label="loc_SNOAIncreaseDecreaseInWithholdingTaxPayable" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_SNOAIncreaseDecreaseInWithholdingTaxPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" />
      <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaapIncreaseDecreaseInContractWithCustomerLiability" />
      <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_PaymentsForFractionalSharesRelatedToReversesplit" xlink:label="loc_SNOAPaymentsForFractionalSharesRelatedToReversesplit" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_SNOAPaymentsForFractionalSharesRelatedToReversesplit" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfOtherShortTermDebt" xlink:label="loc_us-gaapRepaymentsOfOtherShortTermDebt" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapRepaymentsOfOtherShortTermDebt" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_ProceedsFromInsurancePremiumsFinanced" xlink:label="loc_SNOAProceedsFromInsurancePremiumsFinanced" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_SNOAProceedsFromInsurancePremiumsFinanced" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:title="999007 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/OrganizationAndRecentDevelopments" xlink:title="999008 - Disclosure - Organization and Recent Developments" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/LiquidityAndFinancialCondition" xlink:title="999009 - Disclosure - Liquidity and Financial Condition" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="999010 - Disclosure - Summary of Significant Accounting Policies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/AccountsReceivable" xlink:title="999011 - Disclosure - Accounts Receivable" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/Inventories" xlink:title="999012 - Disclosure - Inventories" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:title="999013 - Disclosure - Prepaid Expenses and Other Current Assets" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/PropertyAndEquipment" xlink:title="999014 - Disclosure - Property and Equipment" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:title="999015 - Disclosure - Accrued Expenses and Other Current Liabilities" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/Debt" xlink:title="999016 - Disclosure - Debt" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/Leases" xlink:title="999017 - Disclosure - Leases" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/CommitmentsAndContingencies" xlink:title="999018 - Disclosure - Commitments and Contingencies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/StockholdersEquity" xlink:title="999019 - Disclosure - Stockholders&#8217; Equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/Stock-basedCompensation" xlink:title="999020 - Disclosure - Stock-Based Compensation" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/IncomeTaxes" xlink:title="999021 - Disclosure - Income Taxes" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/EmployeeBenefitPlan" xlink:title="999022 - Disclosure - Employee Benefit Plan" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/RevenueDisaggregation" xlink:title="999023 - Disclosure - Revenue Disaggregation" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="999025 - Disclosure - Summary of Significant Accounting Policies (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="999026 - Disclosure - Summary of Significant Accounting Policies (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/AccountsReceivableTables" xlink:title="999027 - Disclosure - Accounts Receivable (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/InventoriesTables" xlink:title="999028 - Disclosure - Inventories (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:title="999029 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/PropertyAndEquipmentTables" xlink:title="999030 - Disclosure - Property and Equipment (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:title="999031 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/LeasesTables" xlink:title="999032 - Disclosure - Leases (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/Stock-basedCompensationTables" xlink:title="999033 - Disclosure - Stock-Based Compensation (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/IncomeTaxesTables" xlink:title="999034 - Disclosure - Income Taxes (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/RevenueDisaggregationTables" xlink:title="999035 - Disclosure - Revenue Disaggregation (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/OrganizationAndRecentDevelopmentsDetailsNarrative" xlink:title="999036 - Disclosure - Organization and Recent Developments (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/LiquidityAndFinancialConditionDetailsNarrative" xlink:title="999037 - Disclosure - Liquidity and Financial Condition (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:title="999038 - Disclosure - Summary of Significant Accounting Policies (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-usefulLives" xlink:title="999039 - Disclosure - Summary of Significant Accounting Policies (Details-Useful lives)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-EarningsPerShare" xlink:title="999040 - Disclosure - Summary of Significant Accounting Policies (Details - Earnings per share)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-AntidilutiveShares" xlink:title="999041 - Disclosure - Summary of Significant Accounting Policies (Details - Antidilutive shares)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999042 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/AccountsReceivableDetails" xlink:title="999043 - Disclosure - Accounts Receivable (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableGrossCurrent" xlink:label="loc_us-gaapAccountsReceivableGrossCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccountsReceivableNetCurrent" xlink:to="loc_us-gaapAccountsReceivableGrossCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="loc_us-gaapAllowanceForDoubtfulAccountsReceivable" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccountsReceivableNetCurrent" xlink:to="loc_us-gaapAllowanceForDoubtfulAccountsReceivable" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/InventoriesDetails" xlink:title="999044 - Disclosure - Inventories (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryGross" xlink:label="loc_us-gaapInventoryGross" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="loc_us-gaapInventoryRawMaterialsNetOfReserves" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapInventoryGross" xlink:to="loc_us-gaapInventoryRawMaterialsNetOfReserves" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaapInventoryFinishedGoodsNetOfReserves" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapInventoryGross" xlink:to="loc_us-gaapInventoryFinishedGoodsNetOfReserves" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapInventoryNet" xlink:to="loc_us-gaapInventoryGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryValuationReserves" xlink:label="loc_us-gaapInventoryValuationReserves" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapInventoryNet" xlink:to="loc_us-gaapInventoryValuationReserves" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails" xlink:title="999045 - Disclosure - Prepaid Expenses and Other Current Assets (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidInsurance" xlink:label="loc_us-gaapPrepaidInsurance" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaapPrepaidInsurance" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidTaxes" xlink:label="loc_us-gaapPrepaidTaxes" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaapPrepaidTaxes" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaapOtherPrepaidExpenseCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaapOtherPrepaidExpenseCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/PropertyAndEquipmentDetails" xlink:title="999046 - Disclosure - Property and Equipment (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MachineryAndEquipmentGross" xlink:label="loc_us-gaapMachineryAndEquipmentGross" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:to="loc_us-gaapMachineryAndEquipmentGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentOther" xlink:label="loc_us-gaapPropertyPlantAndEquipmentOther" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:to="loc_us-gaapPropertyPlantAndEquipmentOther" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesGross" xlink:label="loc_us-gaapFurnitureAndFixturesGross" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:to="loc_us-gaapFurnitureAndFixturesGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="loc_us-gaapLeaseholdImprovementsGross" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:to="loc_us-gaapLeaseholdImprovementsGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/PropertyAndEquipmentDetailsNarrative" xlink:title="999047 - Disclosure - Property and Equipment (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:title="999048 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:label="loc_us-gaapAccountsPayableAndOtherAccruedLiabilities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccountsPayableAndOtherAccruedLiabilities" xlink:to="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccountsPayableAndOtherAccruedLiabilities" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/DebtDetailsNarrative" xlink:title="999049 - Disclosure - Debt (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/LeasesDetails-BalanceSheetInformationRelatedToLeases" xlink:title="999050 - Disclosure - Leases (Details - Balance sheet information related to leases)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/LeasesDetails-MinimumOperatingLeasePayments" xlink:title="999051 - Disclosure - Leases (Details - Minimum operating lease payments)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="999052 - Disclosure - Commitments and Contingencies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/StockholdersEquityDetailsNarrative" xlink:title="999053 - Disclosure - Stockholders&#8217; Equity (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/Stock-basedCompensationDetails-assumptions" xlink:title="999054 - Disclosure - Stock-Based Compensation (Details-Assumptions)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/Stock-basedCompensationDetails-plans" xlink:title="999055 - Disclosure - Stock-Based Compensation (Details-Plans)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/Stock-basedCompensationDetails-optionActivity" xlink:title="999056 - Disclosure - Stock-Based Compensation (Details-Option activity)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/Stock-basedCompensationDetails-restrictedStockActivity" xlink:title="999057 - Disclosure - Stock-Based Compensation (Details-Restricted stock activity)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="999058 - Disclosure - Stock-Based Compensation (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/IncomeTaxesDetails-incomeSource" xlink:title="999059 - Disclosure - Income Taxes (Details-Income source)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/IncomeTaxesDetails-incomeTaxExpense" xlink:title="999060 - Disclosure - Income Taxes (Details-Income tax expense)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/IncomeTaxesDetails-reconciliationOfTaxRate" xlink:title="999061 - Disclosure - Income Taxes (Details-Reconciliation of tax rate)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes" xlink:title="999062 - Disclosure - Income Taxes (Details-Deferred taxes)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseOther" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseOther" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_DeferredTaxAssetsLeaseLiability" xlink:label="loc_SNOADeferredTaxAssetsLeaseLiability" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_SNOADeferredTaxAssetsLeaseLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaapDeferredIncomeTaxLiabilities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="loc_us-gaapDeferredTaxLiabilitiesPropertyPlantAndEquipment" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredIncomeTaxLiabilities" xlink:to="loc_us-gaapDeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:label="loc_us-gaapDeferredTaxLiabilitiesPrepaidExpenses" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredIncomeTaxLiabilities" xlink:to="loc_us-gaapDeferredTaxLiabilitiesPrepaidExpenses" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_DeferredTaxLiabilitiesRightOfUseAsset" xlink:label="loc_SNOADeferredTaxLiabilitiesRightOfUseAsset" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredIncomeTaxLiabilities" xlink:to="loc_SNOADeferredTaxLiabilitiesRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaapDeferredTaxAssetsNet" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaapDeferredIncomeTaxLiabilities" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/IncomeTaxesDetailsNarrative" xlink:title="999063 - Disclosure - Income Taxes (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/EmployeeBenefitPlanDetailsNarrative" xlink:title="999064 - Disclosure - Employee Benefit Plan (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/RevenueDisaggregationDetails-DisaggregationOfRevenue" xlink:title="999065 - Disclosure - Revenue Disaggregation (Details - Disaggregation of revenue)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/RevenueDisaggregationDetails-GeographicRegions" xlink:title="999066 - Disclosure - Revenue Disaggregation (Details - Geographic regions)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>snoa-20250331_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.0c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://sonomapharma.com/role/Cover" xlink:href="snoa-20250331.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/ConsolidatedBalanceSheets" xlink:href="snoa-20250331.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="snoa-20250331.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/ConsolidatedStatementsOfComprehensiveLoss" xlink:href="snoa-20250331.xsd#ConsolidatedStatementsOfComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" xlink:href="snoa-20250331.xsd#ConsolidatedStatementsOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="snoa-20250331.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:href="snoa-20250331.xsd#CybersecurityRiskManagementAndStrategyDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/OrganizationAndRecentDevelopments" xlink:href="snoa-20250331.xsd#OrganizationAndRecentDevelopments" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/LiquidityAndFinancialCondition" xlink:href="snoa-20250331.xsd#LiquidityAndFinancialCondition" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="snoa-20250331.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/AccountsReceivable" xlink:href="snoa-20250331.xsd#AccountsReceivable" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/Inventories" xlink:href="snoa-20250331.xsd#Inventories" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:href="snoa-20250331.xsd#PrepaidExpensesAndOtherCurrentAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/PropertyAndEquipment" xlink:href="snoa-20250331.xsd#PropertyAndEquipment" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:href="snoa-20250331.xsd#AccruedExpensesAndOtherCurrentLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/Debt" xlink:href="snoa-20250331.xsd#Debt" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/Leases" xlink:href="snoa-20250331.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/CommitmentsAndContingencies" xlink:href="snoa-20250331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/StockholdersEquity" xlink:href="snoa-20250331.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/Stock-basedCompensation" xlink:href="snoa-20250331.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/IncomeTaxes" xlink:href="snoa-20250331.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/EmployeeBenefitPlan" xlink:href="snoa-20250331.xsd#EmployeeBenefitPlan" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/RevenueDisaggregation" xlink:href="snoa-20250331.xsd#RevenueDisaggregation" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="snoa-20250331.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="snoa-20250331.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/AccountsReceivableTables" xlink:href="snoa-20250331.xsd#AccountsReceivableTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/InventoriesTables" xlink:href="snoa-20250331.xsd#InventoriesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:href="snoa-20250331.xsd#PrepaidExpensesAndOtherCurrentAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/PropertyAndEquipmentTables" xlink:href="snoa-20250331.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:href="snoa-20250331.xsd#AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/LeasesTables" xlink:href="snoa-20250331.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/Stock-basedCompensationTables" xlink:href="snoa-20250331.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/IncomeTaxesTables" xlink:href="snoa-20250331.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/RevenueDisaggregationTables" xlink:href="snoa-20250331.xsd#RevenueDisaggregationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/OrganizationAndRecentDevelopmentsDetailsNarrative" xlink:href="snoa-20250331.xsd#OrganizationAndRecentDevelopmentsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/LiquidityAndFinancialConditionDetailsNarrative" xlink:href="snoa-20250331.xsd#LiquidityAndFinancialConditionDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:href="snoa-20250331.xsd#SummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-usefulLives" xlink:href="snoa-20250331.xsd#SummaryOfSignificantAccountingPoliciesDetails-usefulLives" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-EarningsPerShare" xlink:href="snoa-20250331.xsd#SummaryOfSignificantAccountingPoliciesDetails-EarningsPerShare" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-AntidilutiveShares" xlink:href="snoa-20250331.xsd#SummaryOfSignificantAccountingPoliciesDetails-AntidilutiveShares" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="snoa-20250331.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/AccountsReceivableDetails" xlink:href="snoa-20250331.xsd#AccountsReceivableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/InventoriesDetails" xlink:href="snoa-20250331.xsd#InventoriesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails" xlink:href="snoa-20250331.xsd#PrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/PropertyAndEquipmentDetails" xlink:href="snoa-20250331.xsd#PropertyAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/PropertyAndEquipmentDetailsNarrative" xlink:href="snoa-20250331.xsd#PropertyAndEquipmentDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:href="snoa-20250331.xsd#AccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/DebtDetailsNarrative" xlink:href="snoa-20250331.xsd#DebtDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/LeasesDetails-BalanceSheetInformationRelatedToLeases" xlink:href="snoa-20250331.xsd#LeasesDetails-BalanceSheetInformationRelatedToLeases" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/LeasesDetails-MinimumOperatingLeasePayments" xlink:href="snoa-20250331.xsd#LeasesDetails-MinimumOperatingLeasePayments" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="snoa-20250331.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/StockholdersEquityDetailsNarrative" xlink:href="snoa-20250331.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/Stock-basedCompensationDetails-assumptions" xlink:href="snoa-20250331.xsd#Stock-basedCompensationDetails-assumptions" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/Stock-basedCompensationDetails-plans" xlink:href="snoa-20250331.xsd#Stock-basedCompensationDetails-plans" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/Stock-basedCompensationDetails-optionActivity" xlink:href="snoa-20250331.xsd#Stock-basedCompensationDetails-optionActivity" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/Stock-basedCompensationDetails-restrictedStockActivity" xlink:href="snoa-20250331.xsd#Stock-basedCompensationDetails-restrictedStockActivity" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/Stock-basedCompensationDetailsNarrative" xlink:href="snoa-20250331.xsd#Stock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/IncomeTaxesDetails-incomeSource" xlink:href="snoa-20250331.xsd#IncomeTaxesDetails-incomeSource" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/IncomeTaxesDetails-incomeTaxExpense" xlink:href="snoa-20250331.xsd#IncomeTaxesDetails-incomeTaxExpense" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/IncomeTaxesDetails-reconciliationOfTaxRate" xlink:href="snoa-20250331.xsd#IncomeTaxesDetails-reconciliationOfTaxRate" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes" xlink:href="snoa-20250331.xsd#IncomeTaxesDetails-deferredTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/IncomeTaxesDetailsNarrative" xlink:href="snoa-20250331.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/EmployeeBenefitPlanDetailsNarrative" xlink:href="snoa-20250331.xsd#EmployeeBenefitPlanDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/RevenueDisaggregationDetails-DisaggregationOfRevenue" xlink:href="snoa-20250331.xsd#RevenueDisaggregationDetails-DisaggregationOfRevenue" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/RevenueDisaggregationDetails-GeographicRegions" xlink:href="snoa-20250331.xsd#RevenueDisaggregationDetails-GeographicRegions" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosureWithAdditionalMeasures" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosureWithAdditionalMeasures" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpTable" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsToCompensation" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpAdjustmentsToCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/TabularListsByExecutiveCategory" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#TabularListsByExecutiveCategory" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/TabularListMeasures" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#TabularListMeasures" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpMeasures" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpMeasures" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpExecutiveCategoriesOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpExecutiveCategoriesOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpAdjustmentsOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#IndividualsOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/AwardTypeOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTypeOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#TradingArrangmentsOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ForgoneRecoveries" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ForgoneRecoveries" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/OutstandingRecoveries" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#OutstandingRecoveries" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardsCloseToMnpiDisc" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardsCloseToMnpiDisc" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangementsByInd" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangemenstByInd" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/Defaults" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#Defaults" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/ConsolidatedBalanceSheets" xlink:title="00000002 - Statement - CONSOLIDATED BALANCE SHEETS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/ConsolidatedStatementsOfComprehensiveLoss" xlink:title="00000004 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" xlink:title="00000005 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS&apos; EQUITY">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_StockIssuedDuringPeriodValueNewIssues1" xlink:label="loc_SNOAStockIssuedDuringPeriodValueNewIssues1_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SNOAStockIssuedDuringPeriodValueNewIssues1_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_StockIssuedDuringPeriodSharesNewIssues1" xlink:label="loc_SNOAStockIssuedDuringPeriodSharesNewIssues1_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SNOAStockIssuedDuringPeriodSharesNewIssues1_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_60" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_60" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_60" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_ProceedsFromAtthemarketSaleOfCommonStockNetOfOfferingExpensesShares" xlink:label="loc_SNOAProceedsFromAtthemarketSaleOfCommonStockNetOfOfferingExpensesShares_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SNOAProceedsFromAtthemarketSaleOfCommonStockNetOfOfferingExpensesShares_60" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_StockIssuedDuringPeriodValueReverseStockSplits" xlink:label="loc_SNOAStockIssuedDuringPeriodValueReverseStockSplits_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SNOAStockIssuedDuringPeriodValueReverseStockSplits_60" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_StockIssuedDuringPeriodValuesReverseStockSplits" xlink:label="loc_SNOAStockIssuedDuringPeriodValuesReverseStockSplits_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SNOAStockIssuedDuringPeriodValuesReverseStockSplits_60" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesReverseStockSplits_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesReverseStockSplits_60" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_60" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_60" xlink:type="arc" order="17" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows" xlink:title="00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:title="999007 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/OrganizationAndRecentDevelopments" xlink:title="999008 - Disclosure - Organization and Recent Developments" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/LiquidityAndFinancialCondition" xlink:title="999009 - Disclosure - Liquidity and Financial Condition" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="999010 - Disclosure - Summary of Significant Accounting Policies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/AccountsReceivable" xlink:title="999011 - Disclosure - Accounts Receivable" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/Inventories" xlink:title="999012 - Disclosure - Inventories" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:title="999013 - Disclosure - Prepaid Expenses and Other Current Assets" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/PropertyAndEquipment" xlink:title="999014 - Disclosure - Property and Equipment" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:title="999015 - Disclosure - Accrued Expenses and Other Current Liabilities" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/Debt" xlink:title="999016 - Disclosure - Debt" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/Leases" xlink:title="999017 - Disclosure - Leases" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/CommitmentsAndContingencies" xlink:title="999018 - Disclosure - Commitments and Contingencies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/StockholdersEquity" xlink:title="999019 - Disclosure - Stockholders&#8217; Equity" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/Stock-basedCompensation" xlink:title="999020 - Disclosure - Stock-Based Compensation" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/IncomeTaxes" xlink:title="999021 - Disclosure - Income Taxes" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/EmployeeBenefitPlan" xlink:title="999022 - Disclosure - Employee Benefit Plan" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/RevenueDisaggregation" xlink:title="999023 - Disclosure - Revenue Disaggregation" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="999025 - Disclosure - Summary of Significant Accounting Policies (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="999026 - Disclosure - Summary of Significant Accounting Policies (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/AccountsReceivableTables" xlink:title="999027 - Disclosure - Accounts Receivable (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/InventoriesTables" xlink:title="999028 - Disclosure - Inventories (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:title="999029 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/PropertyAndEquipmentTables" xlink:title="999030 - Disclosure - Property and Equipment (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:title="999031 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/LeasesTables" xlink:title="999032 - Disclosure - Leases (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/Stock-basedCompensationTables" xlink:title="999033 - Disclosure - Stock-Based Compensation (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/IncomeTaxesTables" xlink:title="999034 - Disclosure - Income Taxes (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/RevenueDisaggregationTables" xlink:title="999035 - Disclosure - Revenue Disaggregation (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/OrganizationAndRecentDevelopmentsDetailsNarrative" xlink:title="999036 - Disclosure - Organization and Recent Developments (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/LiquidityAndFinancialConditionDetailsNarrative" xlink:title="999037 - Disclosure - Liquidity and Financial Condition (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:title="999038 - Disclosure - Summary of Significant Accounting Policies (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductInformationLineItems" xlink:label="loc_us-gaapProductInformationLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="loc_us-gaapScheduleOfProductInformationTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapScheduleOfProductInformationTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaapCustomerConcentrationRiskMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapCustomerConcentrationRiskMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaapSalesRevenueNetMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapSalesRevenueNetMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaapAccountsReceivableMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapAccountsReceivableMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis" xlink:label="loc_srtMajorCustomersAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtMajorCustomersAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srtNameOfMajorCustomerDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtMajorCustomersAxis" xlink:to="loc_srtNameOfMajorCustomerDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srtNameOfMajorCustomerDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtMajorCustomersAxis" xlink:to="loc_srtNameOfMajorCustomerDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_CustomerAMember" xlink:label="loc_SNOACustomerAMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_SNOACustomerAMember_0" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_CustomerBMember" xlink:label="loc_SNOACustomerBMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_SNOACustomerBMember_20" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_CustomerCMember" xlink:label="loc_SNOACustomerCMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_SNOACustomerCMember_40" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_CustomerDMember" xlink:label="loc_SNOACustomerDMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_SNOACustomerDMember_80" xlink:type="arc" order="83" />
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_ConcentrationRiskPercentage2" xlink:label="loc_SNOAConcentrationRiskPercentage2_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_SNOAConcentrationRiskPercentage2_110" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-usefulLives" xlink:title="999039 - Disclosure - Summary of Significant Accounting Policies (Details-Useful lives)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaapOfficeEquipmentMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapOfficeEquipmentMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaapMachineryAndEquipmentMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapMachineryAndEquipmentMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_40" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-EarningsPerShare" xlink:title="999040 - Disclosure - Summary of Significant Accounting Policies (Details - Earnings per share)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-AntidilutiveShares" xlink:title="999041 - Disclosure - Summary of Significant Accounting Policies (Details - Antidilutive shares)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_CommonStockUnitsMember" xlink:label="loc_SNOACommonStockUnitsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_SNOACommonStockUnitsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_70" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999042 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="loc_us-gaapScheduleOfProductInformationTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapScheduleOfProductInformationTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srtCounterpartyNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtCounterpartyNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_InvekraMember" xlink:label="loc_SNOAInvekraMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_SNOAInvekraMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtProductOrServiceAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_ProbableCreditLossesMember" xlink:label="loc_SNOAProbableCreditLossesMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_SNOAProbableCreditLossesMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_PotentialDiscountsReturnsDistributorFeesAndRebatesMember" xlink:label="loc_SNOAPotentialDiscountsReturnsDistributorFeesAndRebatesMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_SNOAPotentialDiscountsReturnsDistributorFeesAndRebatesMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShippingAndHandlingMember" xlink:label="loc_us-gaapShippingAndHandlingMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_us-gaapShippingAndHandlingMember_130" xlink:type="arc" order="131" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeMember" xlink:label="loc_us-gaapOtherComprehensiveIncomeMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapOtherComprehensiveIncomeMember_150" xlink:type="arc" order="151" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherOperatingIncomeExpenseMember" xlink:label="loc_us-gaapOtherOperatingIncomeExpenseMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapOtherOperatingIncomeExpenseMember_170" xlink:type="arc" order="171" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaapDeferredRevenue_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapDeferredRevenue_200" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="loc_us-gaapAllowanceForDoubtfulAccountsReceivable_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAllowanceForDoubtfulAccountsReceivable_200" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryValuationReserves" xlink:label="loc_us-gaapInventoryValuationReserves_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapInventoryValuationReserves_200" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_200" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaapAssetImpairmentCharges_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAssetImpairmentCharges_200" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_200" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketingExpense" xlink:label="loc_us-gaapMarketingExpense_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapMarketingExpense_200" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_200" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationLossAdjustmentBeforeTaxPortionAttributableToParent" xlink:label="loc_SNOAOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationLossAdjustmentBeforeTaxPortionAttributableToParent_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_SNOAOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationLossAdjustmentBeforeTaxPortionAttributableToParent_200" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainAdjustmentBeforeTaxPortionAttributableToParent" xlink:label="loc_SNOAOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainAdjustmentBeforeTaxPortionAttributableToParent_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_SNOAOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainAdjustmentBeforeTaxPortionAttributableToParent_200" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainBeforeTax_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapForeignCurrencyTransactionGainBeforeTax_200" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionLossBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionLossBeforeTax_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapForeignCurrencyTransactionLossBeforeTax_200" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax_200" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued_200" xlink:type="arc" order="13" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/AccountsReceivableDetails" xlink:title="999043 - Disclosure - Accounts Receivable (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:label="loc_us-gaapAccountsNotesAndLoansReceivableLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:label="loc_us-gaapScheduleOfAccountsNotesLoansAndFinancingReceivableTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAccountsNotesAndLoansReceivableLineItems" xlink:to="loc_us-gaapScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="loc_srtProductOrServiceAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_PotentialDiscountsReturnsDistributorFeesAndRebatesMember" xlink:label="loc_SNOAPotentialDiscountsReturnsDistributorFeesAndRebatesMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_SNOAPotentialDiscountsReturnsDistributorFeesAndRebatesMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableGrossCurrent" xlink:label="loc_us-gaapAccountsReceivableGrossCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccountsNotesAndLoansReceivableLineItems" xlink:to="loc_us-gaapAccountsReceivableGrossCurrent_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="loc_us-gaapAllowanceForDoubtfulAccountsReceivable_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccountsNotesAndLoansReceivableLineItems" xlink:to="loc_us-gaapAllowanceForDoubtfulAccountsReceivable_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccountsNotesAndLoansReceivableLineItems" xlink:to="loc_us-gaapAccountsReceivableNetCurrent_50" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/InventoriesDetails" xlink:title="999044 - Disclosure - Inventories (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails" xlink:title="999045 - Disclosure - Prepaid Expenses and Other Current Assets (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/PropertyAndEquipmentDetails" xlink:title="999046 - Disclosure - Property and Equipment (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/PropertyAndEquipmentDetailsNarrative" xlink:title="999047 - Disclosure - Property and Equipment (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:title="999048 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/DebtDetailsNarrative" xlink:title="999049 - Disclosure - Debt (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaapShortTermDebtTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapShortTermDebtTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_InsurancePremiumFinancingMember" xlink:label="loc_SNOAInsurancePremiumFinancingMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_SNOAInsurancePremiumFinancingMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="loc_us-gaapDebtInstrumentInterestRateDuringPeriod_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateDuringPeriod_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDateRangeEnd1" xlink:label="loc_us-gaapDebtInstrumentMaturityDateRangeEnd1_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDateRangeEnd1_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromShortTermDebt" xlink:label="loc_us-gaapProceedsFromShortTermDebt_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapProceedsFromShortTermDebt_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentPaymentTerms" xlink:label="loc_us-gaapDebtInstrumentPaymentTerms_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentPaymentTerms_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="loc_us-gaapDebtInstrumentPeriodicPayment_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentPeriodicPayment_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDateRangeStart1" xlink:label="loc_us-gaapDebtInstrumentMaturityDateRangeStart1_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDateRangeStart1_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLongTermDebtCurrent" xlink:label="loc_us-gaapOtherLongTermDebtCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapOtherLongTermDebtCurrent_70" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/LeasesDetails-BalanceSheetInformationRelatedToLeases" xlink:title="999050 - Disclosure - Leases (Details - Balance sheet information related to leases)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/LeasesDetails-MinimumOperatingLeasePayments" xlink:title="999051 - Disclosure - Leases (Details - Minimum operating lease payments)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="999052 - Disclosure - Commitments and Contingencies (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/StockholdersEquityDetailsNarrative" xlink:title="999053 - Disclosure - Stockholders&#8217; Equity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapScheduleOfStockByClassTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaapConvertiblePreferredStockMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapConvertiblePreferredStockMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_PlacementAgencyAgreementMember" xlink:label="loc_SNOAPlacementAgencyAgreementMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_SNOAPlacementAgencyAgreementMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_EquityDistributionAgreementMember" xlink:label="loc_SNOAEquityDistributionAgreementMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_SNOAEquityDistributionAgreementMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_PublicOfferingMember" xlink:label="loc_SNOAPublicOfferingMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_SNOAPublicOfferingMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_MaximGroupLLCMember" xlink:label="loc_SNOAMaximGroupLLCMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_SNOAMaximGroupLLCMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_100" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_100" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_100" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_100" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaapLegalFees_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapLegalFees_100" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_100" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_ProceedsFromIssuanceOfCommonStockGross" xlink:label="loc_SNOAProceedsFromIssuanceOfCommonStockGross_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_SNOAProceedsFromIssuanceOfCommonStockGross_100" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_100" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/Stock-basedCompensationDetails-assumptions" xlink:title="999054 - Disclosure - Stock-Based Compensation (Details-Assumptions)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/Stock-basedCompensationDetails-plans" xlink:title="999055 - Disclosure - Stock-Based Compensation (Details-Plans)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_Plan2011Member" xlink:label="loc_SNOAPlan2011Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_SNOAPlan2011Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_Plan2016Member" xlink:label="loc_SNOAPlan2016Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_SNOAPlan2016Member_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_Plan2021Member" xlink:label="loc_SNOAPlan2021Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_SNOAPlan2021Member_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_50" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/Stock-basedCompensationDetails-optionActivity" xlink:title="999056 - Disclosure - Stock-Based Compensation (Details-Option activity)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_40" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_40" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_40" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_40" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_40" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_40" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_40" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_40" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_40" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_40" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableInPeriodGrantDateIntrinsicValue" xlink:label="loc_SNOAShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableInPeriodGrantDateIntrinsicValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_SNOAShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableInPeriodGrantDateIntrinsicValue_40" xlink:type="arc" order="17" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/Stock-basedCompensationDetails-restrictedStockActivity" xlink:title="999057 - Disclosure - Stock-Based Compensation (Details-Restricted stock activity)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_40" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="999058 - Disclosure - Stock-Based Compensation (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_Plan2016Member" xlink:label="loc_SNOAPlan2016Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_SNOAPlan2016Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_Plan2021Member" xlink:label="loc_SNOAPlan2021Member_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_SNOAPlan2021Member_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_Plan2024Member" xlink:label="loc_SNOAPlan2024Member_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_SNOAPlan2024Member_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapStockOptionMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_160" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_160" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_160" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensation_160" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_160" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_160" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharePrice_160" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense_160" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/IncomeTaxesDetails-incomeSource" xlink:title="999059 - Disclosure - Income Taxes (Details-Income source)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaapDomesticCountryMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapDomesticCountryMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaapForeignCountryMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapForeignCountryMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapProfitLoss_70" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/IncomeTaxesDetails-incomeTaxExpense" xlink:title="999060 - Disclosure - Income Taxes (Details-Income tax expense)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/IncomeTaxesDetails-reconciliationOfTaxRate" xlink:title="999061 - Disclosure - Income Taxes (Details-Reconciliation of tax rate)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes" xlink:title="999062 - Disclosure - Income Taxes (Details-Deferred taxes)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/IncomeTaxesDetailsNarrative" xlink:title="999063 - Disclosure - Income Taxes (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaapDomesticCountryMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapDomesticCountryMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaapStateAndLocalJurisdictionMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapStateAndLocalJurisdictionMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaapForeignCountryMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapForeignCountryMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_CaliforniaResearchAndDevelopmentMember" xlink:label="loc_SNOACaliforniaResearchAndDevelopmentMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_SNOACaliforniaResearchAndDevelopmentMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaapTaxCreditCarryforwardAmount_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapTaxCreditCarryforwardAmount_70" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/EmployeeBenefitPlanDetailsNarrative" xlink:title="999064 - Disclosure - Employee Benefit Plan (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/RevenueDisaggregationDetails-DisaggregationOfRevenue" xlink:title="999065 - Disclosure - Revenue Disaggregation (Details - Disaggregation of revenue)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaapDisaggregationOfRevenueLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaapDisaggregationOfRevenueTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDisaggregationOfRevenueLineItems" xlink:to="loc_us-gaapDisaggregationOfRevenueTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaapStatementBusinessSegmentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDisaggregationOfRevenueTable" xlink:to="loc_us-gaapStatementBusinessSegmentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_HumanCareMember" xlink:label="loc_SNOAHumanCareMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_SNOAHumanCareMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_AnimalCareMember" xlink:label="loc_SNOAAnimalCareMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_SNOAAnimalCareMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_ServiceAndRoyaltyMember" xlink:label="loc_SNOAServiceAndRoyaltyMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_SNOAServiceAndRoyaltyMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDisaggregationOfRevenueTable" xlink:to="loc_srtProductOrServiceAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaapProductMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_us-gaapProductMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ServiceMember" xlink:label="loc_us-gaapServiceMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_us-gaapServiceMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDisaggregationOfRevenueLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_110" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/RevenueDisaggregationDetails-GeographicRegions" xlink:title="999066 - Disclosure - Revenue Disaggregation (Details - Geographic regions)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaapDisaggregationOfRevenueLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaapDisaggregationOfRevenueTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDisaggregationOfRevenueLineItems" xlink:to="loc_us-gaapDisaggregationOfRevenueTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDisaggregationOfRevenueTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueSegmentMember" xlink:label="loc_us-gaapSalesRevenueSegmentMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapSalesRevenueSegmentMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDisaggregationOfRevenueTable" xlink:to="loc_srtStatementGeographicalAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US" xlink:label="loc_countryUS_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryUS_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EuropeMember" xlink:label="loc_srtEuropeMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_srtEuropeMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_AsiaMember" xlink:label="loc_srtAsiaMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_srtAsiaMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LatinAmericaMember" xlink:label="loc_srtLatinAmericaMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_srtLatinAmericaMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_RestOfTheWorldMember" xlink:label="loc_SNOARestOfTheWorldMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_SNOARestOfTheWorldMember_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDisaggregationOfRevenueLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_130" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpExecutiveCategoriesOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/AwardTypeOnly">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>snoa-20250331_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.0c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CounterpartyNameAxis_lbl" xml:lang="en-US">Counterparty Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_InvekraMember" xlink:label="SNOA_InvekraMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_InvekraMember" xlink:to="SNOA_InvekraMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_InvekraMember_lbl" xml:lang="en-US">Invekra [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US">Product and Service [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_ProbableCreditLossesMember" xlink:label="SNOA_ProbableCreditLossesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_ProbableCreditLossesMember" xlink:to="SNOA_ProbableCreditLossesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_ProbableCreditLossesMember_lbl" xml:lang="en-US">Probable Credit Losses [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_PotentialDiscountsReturnsDistributorFeesAndRebatesMember" xlink:label="SNOA_PotentialDiscountsReturnsDistributorFeesAndRebatesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_PotentialDiscountsReturnsDistributorFeesAndRebatesMember" xlink:to="SNOA_PotentialDiscountsReturnsDistributorFeesAndRebatesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_PotentialDiscountsReturnsDistributorFeesAndRebatesMember_lbl" xml:lang="en-US">Potential Discounts Returns Distributor Fees And Rebates [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShippingAndHandlingMember" xlink:label="us-gaap_ShippingAndHandlingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShippingAndHandlingMember" xlink:to="us-gaap_ShippingAndHandlingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShippingAndHandlingMember_lbl" xml:lang="en-US">Shipping and Handling [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeMember" xlink:label="us-gaap_OtherComprehensiveIncomeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeMember" xlink:to="us-gaap_OtherComprehensiveIncomeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeMember_lbl" xml:lang="en-US">Other Comprehensive Income (Loss) [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherOperatingIncomeExpenseMember" xlink:label="us-gaap_OtherOperatingIncomeExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherOperatingIncomeExpenseMember" xlink:to="us-gaap_OtherOperatingIncomeExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherOperatingIncomeExpenseMember_lbl" xml:lang="en-US">Other Operating Income (Expense) [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MajorCustomersAxis_lbl" xml:lang="en-US">Customer [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_CustomerAMember" xlink:label="SNOA_CustomerAMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_CustomerAMember" xlink:to="SNOA_CustomerAMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_CustomerAMember_lbl" xml:lang="en-US">Customer A [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_CustomerBMember" xlink:label="SNOA_CustomerBMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_CustomerBMember" xlink:to="SNOA_CustomerBMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_CustomerBMember_lbl" xml:lang="en-US">Customer B [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_CustomerCMember" xlink:label="SNOA_CustomerCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_CustomerCMember" xlink:to="SNOA_CustomerCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_CustomerCMember_lbl" xml:lang="en-US">Customer C [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableMember_lbl" xml:lang="en-US">Accounts Receivable [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_CustomerDMember" xlink:label="SNOA_CustomerDMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_CustomerDMember" xlink:to="SNOA_CustomerDMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_CustomerDMember_lbl" xml:lang="en-US">Customer D [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xml:lang="en-US">Office Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="us-gaap_MachineryAndEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MachineryAndEquipmentMember" xlink:to="us-gaap_MachineryAndEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MachineryAndEquipmentMember_lbl" xml:lang="en-US">Machinery and Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Equity Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_CommonStockUnitsMember" xlink:label="SNOA_CommonStockUnitsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_CommonStockUnitsMember" xlink:to="SNOA_CommonStockUnitsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_CommonStockUnitsMember_lbl" xml:lang="en-US">Common Stock Units [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTypeAxis_lbl" xml:lang="en-US">Short-Term Debt, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_InsurancePremiumFinancingMember" xlink:label="SNOA_InsurancePremiumFinancingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_InsurancePremiumFinancingMember" xlink:to="SNOA_InsurancePremiumFinancingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_InsurancePremiumFinancingMember_lbl" xml:lang="en-US">Insurance Premium Financing [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xml:lang="en-US">Convertible Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_PlacementAgencyAgreementMember" xlink:label="SNOA_PlacementAgencyAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_PlacementAgencyAgreementMember" xlink:to="SNOA_PlacementAgencyAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_PlacementAgencyAgreementMember_lbl" xml:lang="en-US">Placement Agency Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_PublicOfferingMember" xlink:label="SNOA_PublicOfferingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_PublicOfferingMember" xlink:to="SNOA_PublicOfferingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_PublicOfferingMember_lbl" xml:lang="en-US">Public Offering [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_EquityDistributionAgreementMember" xlink:label="SNOA_EquityDistributionAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_EquityDistributionAgreementMember" xlink:to="SNOA_EquityDistributionAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_EquityDistributionAgreementMember_lbl" xml:lang="en-US">Equity Distribution Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_MaximGroupLLCMember" xlink:label="SNOA_MaximGroupLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_MaximGroupLLCMember" xlink:to="SNOA_MaximGroupLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_MaximGroupLLCMember_lbl" xml:lang="en-US">Maxim Group L L C [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_Plan2016Member" xlink:label="SNOA_Plan2016Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_Plan2016Member" xlink:to="SNOA_Plan2016Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_Plan2016Member_lbl" xml:lang="en-US">Plan 2016 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_Plan2021Member" xlink:label="SNOA_Plan2021Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_Plan2021Member" xlink:to="SNOA_Plan2021Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_Plan2021Member_lbl" xml:lang="en-US">Plan 2021 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_Plan2024Member" xlink:label="SNOA_Plan2024Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_Plan2024Member" xlink:to="SNOA_Plan2024Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_Plan2024Member_lbl" xml:lang="en-US">Plan 2024 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_Plan2011Member" xlink:label="SNOA_Plan2011Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_Plan2011Member" xlink:to="SNOA_Plan2011Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_Plan2011Member_lbl" xml:lang="en-US">Plan 2011 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US">Restricted Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US">Income Tax Jurisdiction [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US">Domestic Tax Jurisdiction [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCountryMember" xlink:to="us-gaap_ForeignCountryMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCountryMember_lbl" xml:lang="en-US">Foreign Tax Jurisdiction [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_CaliforniaResearchAndDevelopmentMember" xlink:label="SNOA_CaliforniaResearchAndDevelopmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_CaliforniaResearchAndDevelopmentMember" xlink:to="SNOA_CaliforniaResearchAndDevelopmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_CaliforniaResearchAndDevelopmentMember_lbl" xml:lang="en-US">California Research And Development [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_StatementBusinessSegmentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementBusinessSegmentsAxis_lbl" xml:lang="en-US">Segments [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_HumanCareMember" xlink:label="SNOA_HumanCareMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_HumanCareMember" xlink:to="SNOA_HumanCareMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_HumanCareMember_lbl" xml:lang="en-US">Human Care [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductMember" xlink:to="us-gaap_ProductMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductMember_lbl" xml:lang="en-US">Product [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_AnimalCareMember" xlink:label="SNOA_AnimalCareMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_AnimalCareMember" xlink:to="SNOA_AnimalCareMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_AnimalCareMember_lbl" xml:lang="en-US">Animal Care [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ServiceMember" xlink:label="us-gaap_ServiceMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ServiceMember" xlink:to="us-gaap_ServiceMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ServiceMember_lbl" xml:lang="en-US">Service [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_ServiceAndRoyaltyMember" xlink:label="SNOA_ServiceAndRoyaltyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_ServiceAndRoyaltyMember" xlink:to="SNOA_ServiceAndRoyaltyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_ServiceAndRoyaltyMember_lbl" xml:lang="en-US">Service And Royalty [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueSegmentMember" xlink:label="us-gaap_SalesRevenueSegmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueSegmentMember" xlink:to="us-gaap_SalesRevenueSegmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueSegmentMember_lbl" xml:lang="en-US">Revenue, Segment Benchmark [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US" xlink:label="country_US" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_US_lbl" xml:lang="en-US">UNITED STATES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EuropeMember" xlink:label="srt_EuropeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_EuropeMember" xlink:to="srt_EuropeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_EuropeMember_lbl" xml:lang="en-US">Europe [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_AsiaMember" xlink:label="srt_AsiaMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_AsiaMember" xlink:to="srt_AsiaMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_AsiaMember_lbl" xml:lang="en-US">Asia [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LatinAmericaMember" xlink:label="srt_LatinAmericaMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_LatinAmericaMember" xlink:to="srt_LatinAmericaMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_LatinAmericaMember_lbl" xml:lang="en-US">Latin America [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_RestOfTheWorldMember" xlink:label="SNOA_RestOfTheWorldMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_RestOfTheWorldMember" xlink:to="SNOA_RestOfTheWorldMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_RestOfTheWorldMember_lbl" xml:lang="en-US">Rest Of The World [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US">Auditor Firm ID</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="dei_AuditorName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US">Auditor Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US">Auditor Location</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts receivable, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventories, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_DeferredConsiderationCurrent" xlink:label="SNOA_DeferredConsiderationCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_DeferredConsiderationCurrent" xlink:to="SNOA_DeferredConsiderationCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_DeferredConsiderationCurrent_lbl" xml:lang="en-US">Current portion of deferred consideration, net of discount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease, right of use assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet_lbl" xml:lang="en-US">Deferred tax asset, net</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_DeferredConsiderationNoncurrent" xlink:label="SNOA_DeferredConsiderationNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_DeferredConsiderationNoncurrent" xlink:to="SNOA_DeferredConsiderationNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_DeferredConsiderationNoncurrent_lbl" xml:lang="en-US">Deferred consideration, net of discount, less current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilities_lbl" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xml:lang="en-US">Deferred revenue, current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermBorrowings" xlink:label="us-gaap_ShortTermBorrowings" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermBorrowings" xlink:to="us-gaap_ShortTermBorrowings_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermBorrowings_lbl" xml:lang="en-US">Short-term debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating lease liabilities, current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueNoncurrent" xlink:to="us-gaap_DeferredRevenueNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xml:lang="en-US">Deferred revenue, net of current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_WithholdingTaxPayable" xlink:label="SNOA_WithholdingTaxPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_WithholdingTaxPayable" xlink:to="SNOA_WithholdingTaxPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_WithholdingTaxPayable_lbl" xml:lang="en-US">Withholding tax payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease liabilities, less current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and Contingencies (Note 11)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders&#8217; Equity:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Convertible preferred stock, $0.0001 par value; 714,286 shares authorized at March 31, 2025 and 2024, respectively, no shares issued and outstanding at March 31, 2025 and 2024</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.0001 par value; 50,000,000 and 24,000,000 shares authorized at March 31, 2025 and 2024, respectively, 1,634,265 and 780,371 shares issued and outstanding at March 31, 2025 and 2024, respectively (Note 1) (Note 12)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xml:lang="en-US">Cost of revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US">Gross profit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Selling, general and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherOperatingIncomeExpenseNet" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="us-gaap_OtherOperatingIncomeExpenseNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet_lbl" xml:lang="en-US">Other income (expense), net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Loss from operations before income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income tax (expense) benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Net loss per share: basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Net loss per share: diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted-average number of shares: basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted-average number of shares: diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossTaxAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxAbstract_lbl" xml:lang="en-US">Other comprehensive loss:</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent_lbl" xml:lang="en-US">Foreign currency translation adjustments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Comprehensive loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Beginning balance, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Beginning balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Proceeds from the sale of common stock, net of offering expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Proceeds from the sale of common stock, net of offering expenses, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_StockIssuedDuringPeriodValueNewIssues1" xlink:label="SNOA_StockIssuedDuringPeriodValueNewIssues1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_StockIssuedDuringPeriodValueNewIssues1" xlink:to="SNOA_StockIssuedDuringPeriodValueNewIssues1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_StockIssuedDuringPeriodValueNewIssues1_lbl" xml:lang="en-US">Proceeds from the At-the-Market sale of common stock, net of offering expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_StockIssuedDuringPeriodSharesNewIssues1" xlink:label="SNOA_StockIssuedDuringPeriodSharesNewIssues1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_StockIssuedDuringPeriodSharesNewIssues1" xlink:to="SNOA_StockIssuedDuringPeriodSharesNewIssues1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_StockIssuedDuringPeriodSharesNewIssues1_lbl" xml:lang="en-US">Proceeds from the At-the-Market sale of common stock, net of offering expenses, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Employee stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xml:lang="en-US">Stock based compensation related to restricted stock grants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xml:lang="en-US">Stock based compensation related to restricted stock grants, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl" xml:lang="en-US">Foreign currency translation adjustment</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_ProceedsFromAtthemarketSaleOfCommonStockNetOfOfferingExpensesShares" xlink:label="SNOA_ProceedsFromAtthemarketSaleOfCommonStockNetOfOfferingExpensesShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_ProceedsFromAtthemarketSaleOfCommonStockNetOfOfferingExpensesShares" xlink:to="SNOA_ProceedsFromAtthemarketSaleOfCommonStockNetOfOfferingExpensesShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_ProceedsFromAtthemarketSaleOfCommonStockNetOfOfferingExpensesShares_lbl" xml:lang="en-US">[custom:ProceedsFromAtthemarketSaleOfCommonStockNetOfOfferingExpensesShares]</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_StockIssuedDuringPeriodValueReverseStockSplits" xlink:label="SNOA_StockIssuedDuringPeriodValueReverseStockSplits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_StockIssuedDuringPeriodValueReverseStockSplits" xlink:to="SNOA_StockIssuedDuringPeriodValueReverseStockSplits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="SNOA_StockIssuedDuringPeriodValueReverseStockSplits_lbl" xml:lang="en-US">Payments for fractional shares related to reverse-split</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_StockIssuedDuringPeriodValuesReverseStockSplits" xlink:label="SNOA_StockIssuedDuringPeriodValuesReverseStockSplits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_StockIssuedDuringPeriodValuesReverseStockSplits" xlink:to="SNOA_StockIssuedDuringPeriodValuesReverseStockSplits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_StockIssuedDuringPeriodValuesReverseStockSplits_lbl" xml:lang="en-US">[custom:StockIssuedDuringPeriodValuesReverseStockSplits]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_lbl" xml:lang="en-US">Payments for fractional shares related to reverse-split, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from the exercise of employee stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from the exercise of employee stock options, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Ending balance, value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Ending balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:label="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:to="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_lbl" xml:lang="en-US">Deferred income tax expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xml:lang="en-US">Operating lease right-of-use asset</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Accounts receivable, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Inventories, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDeferredCompensation" xlink:label="us-gaap_IncreaseDecreaseInDeferredCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredCompensation" xlink:to="us-gaap_IncreaseDecreaseInDeferredCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredCompensation_lbl" xml:lang="en-US">Deferred consideration, net of discount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayable_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_IncreaseDecreaseInWithholdingTaxPayable" xlink:label="SNOA_IncreaseDecreaseInWithholdingTaxPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_IncreaseDecreaseInWithholdingTaxPayable" xlink:to="SNOA_IncreaseDecreaseInWithholdingTaxPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="SNOA_IncreaseDecreaseInWithholdingTaxPayable_lbl" xml:lang="en-US">Withholding tax payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US">Operating lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xml:lang="en-US">Deferred revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from investing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchases of property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from issuance of common stock, net of offering expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from exercise of employee stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_PaymentsForFractionalSharesRelatedToReversesplit" xlink:label="SNOA_PaymentsForFractionalSharesRelatedToReversesplit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_PaymentsForFractionalSharesRelatedToReversesplit" xlink:to="SNOA_PaymentsForFractionalSharesRelatedToReversesplit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="SNOA_PaymentsForFractionalSharesRelatedToReversesplit_lbl" xml:lang="en-US">Payments for fractional shares related to reverse-split</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfOtherShortTermDebt" xlink:label="us-gaap_RepaymentsOfOtherShortTermDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfOtherShortTermDebt" xlink:to="us-gaap_RepaymentsOfOtherShortTermDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfOtherShortTermDebt_lbl" xml:lang="en-US">Principal payments on short-term debt</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_ProceedsFromInsurancePremiumsFinanced" xlink:label="SNOA_ProceedsFromInsurancePremiumsFinanced" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_ProceedsFromInsurancePremiumsFinanced" xlink:to="SNOA_ProceedsFromInsurancePremiumsFinanced_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_ProceedsFromInsurancePremiumsFinanced_lbl" xml:lang="en-US">Insurance premiums financed</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Effect of exchange rate on cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash and cash equivalents, beginning of year</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xml:lang="en-US">Cash and cash equivalents, end of year</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Cash paid for interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Non-cash operating and financing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_InsurancePremiumsFinanced" xlink:label="SNOA_InsurancePremiumsFinanced" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_InsurancePremiumsFinanced" xlink:to="SNOA_InsurancePremiumsFinanced_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="SNOA_InsurancePremiumsFinanced_lbl" xml:lang="en-US">Insurance premiums financed</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl" xml:lang="en-US">Cybersecurity Risk Management, Strategy, and Governance [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Management Processes Integrated [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Processes Integrated [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl" xml:lang="en-US">Cybersecurity Risk Management Third Party Engaged [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl" xml:lang="en-US">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Board of Directors Oversight [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl" xml:lang="en-US">Cybersecurity Risk Role of Management [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">Organization and Recent Developments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl" xml:lang="en-US">Liquidity and Financial Condition</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesAbstract" xlink:label="us-gaap_ReceivablesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_ReceivablesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesAbstract_lbl" xml:lang="en-US">Receivables [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:to="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl" xml:lang="en-US">Accounts Receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US">Inventories</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_lbl" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCurrentAssetsTextBlock" xlink:label="us-gaap_OtherCurrentAssetsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentAssetsTextBlock" xlink:to="us-gaap_OtherCurrentAssetsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCurrentAssetsTextBlock_lbl" xml:lang="en-US">Prepaid Expenses and Other Current Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">Property and Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xml:lang="en-US">Accrued Expenses and Other Current Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">Debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesAbstract_lbl" xml:lang="en-US">Leases [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Stock-Based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xml:lang="en-US">Employee Benefit Plan</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xml:lang="en-US">Revenue Disaggregation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems" xlink:label="ecd_InsiderTradingArrLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="ecd_InsiderTradingArrLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTradingArrLineItems_lbl" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="ecd_Rule10b51ArrAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrAdoptedFlag" xlink:to="ecd_Rule10b51ArrAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Rule10b51ArrAdoptedFlag_lbl" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="ecd_NonRule10b51ArrAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrAdoptedFlag" xlink:to="ecd_NonRule10b51ArrAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonRule10b51ArrAdoptedFlag_lbl" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="ecd_Rule10b51ArrTrmntdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrTrmntdFlag" xlink:to="ecd_Rule10b51ArrTrmntdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Rule10b51ArrTrmntdFlag_lbl" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="ecd_NonRule10b51ArrTrmntdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrTrmntdFlag" xlink:to="ecd_NonRule10b51ArrTrmntdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonRule10b51ArrTrmntdFlag_lbl" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Principles of Consolidation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of presentation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentration of Credit Risk and Major Customers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="us-gaap_ReceivablesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesPolicyTextBlock" xlink:to="us-gaap_ReceivablesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ReceivablesPolicyTextBlock_lbl" xml:lang="en-US">Accounts Receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US">Inventories</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Financial Assets and Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property and Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdvertisingCostsPolicyTextBlock" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="us-gaap_AdvertisingCostsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock_lbl" xml:lang="en-US">Advertising Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_ShippingAndHandlingCost1PolicyTextBlock" xlink:label="SNOA_ShippingAndHandlingCost1PolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_ShippingAndHandlingCost1PolicyTextBlock" xlink:to="SNOA_ShippingAndHandlingCost1PolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_ShippingAndHandlingCost1PolicyTextBlock_lbl" xml:lang="en-US">Shipping and Handling Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US">Foreign Currency Reporting</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Stock-Based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US">Comprehensive Loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Net Loss per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_ConvertiblePreferredStockPolicyTextBlock" xlink:label="SNOA_ConvertiblePreferredStockPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_ConvertiblePreferredStockPolicyTextBlock" xlink:to="SNOA_ConvertiblePreferredStockPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_ConvertiblePreferredStockPolicyTextBlock_lbl" xml:lang="en-US">Convertible Preferred Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Segment Reporting</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:label="us-gaap_SubsequentEventsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:to="us-gaap_SubsequentEventsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Subsequent Events</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recent Accounting Standards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_lbl" xml:lang="en-US">Schedule of concentration of risk</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:label="SNOA_PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:to="SNOA_PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock_lbl" xml:lang="en-US">Schedule of property and equipment estimated useful life</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Schedule of computation of earnings per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of antidilutive shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_lbl" xml:lang="en-US">Schedule of accounts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US">Schedule of inventories</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xml:lang="en-US">Schedule of prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of property and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of accrued expenses and other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US">Schedule of lease information</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Schedule of minimum operating lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of weighted-average assumptions of fair value of employee stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_ScheduleOfStockbasedAwardsOutstandingByPlanTableTextBlock" xlink:label="SNOA_ScheduleOfStockbasedAwardsOutstandingByPlanTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_ScheduleOfStockbasedAwardsOutstandingByPlanTableTextBlock" xlink:to="SNOA_ScheduleOfStockbasedAwardsOutstandingByPlanTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_ScheduleOfStockbasedAwardsOutstandingByPlanTableTextBlock_lbl" xml:lang="en-US">Schedule of stock based awards outstanding by plan</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of options activity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of unvested restricted stock activity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xml:lang="en-US">Schedule of income tax provision from domestic and foreign sources</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US">Schedule of federal, state and foreign income tax provisions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of reconciliation of federal income tax rate to effective rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xml:lang="en-US">Schedule of disaggregated revenue by source</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xlink:label="us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xlink:to="us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_lbl" xml:lang="en-US">Schedule of revenues by geographic region</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_2_lbl" xml:lang="en-US">Common stock outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetIncomeLoss_3_lbl" xml:lang="en-US">Net loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_2_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_WorkingCapital" xlink:label="SNOA_WorkingCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_WorkingCapital" xlink:to="SNOA_WorkingCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_WorkingCapital_lbl" xml:lang="en-US">Working capital</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_3_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="us-gaap_ScheduleOfProductInformationTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfProductInformationTable" xlink:to="us-gaap_ScheduleOfProductInformationTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfProductInformationTable_lbl" xml:lang="en-US">Nature of Operation, Product Information, Concentration of Risk [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductInformationLineItems" xlink:label="us-gaap_ProductInformationLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductInformationLineItems" xlink:to="us-gaap_ProductInformationLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductInformationLineItems_lbl" xml:lang="en-US">Product Information [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_ConcentrationRiskPercentage2" xlink:label="SNOA_ConcentrationRiskPercentage2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_ConcentrationRiskPercentage2" xlink:to="SNOA_ConcentrationRiskPercentage2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_ConcentrationRiskPercentage2_lbl" xml:lang="en-US">Concentration risk, percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Useful asset life</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenue" xlink:to="us-gaap_DeferredRevenue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredRevenue_lbl" xml:lang="en-US">Deferred revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xml:lang="en-US">Allowance for doubtful accounts</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryValuationReserves" xlink:label="us-gaap_InventoryValuationReserves" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryValuationReserves" xlink:to="us-gaap_InventoryValuationReserves_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryValuationReserves_lbl" xml:lang="en-US">Inventory valuation reserves</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_lbl" xml:lang="en-US">Transfers in or out of level 3</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetImpairmentCharges" xlink:to="us-gaap_AssetImpairmentCharges_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xml:lang="en-US">Impairment of long lived assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xml:lang="en-US">Research and development expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketingExpense" xlink:label="us-gaap_MarketingExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketingExpense" xlink:to="us-gaap_MarketingExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketingExpense_lbl" xml:lang="en-US">Advertising costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US">Revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationLossAdjustmentBeforeTaxPortionAttributableToParent" xlink:label="SNOA_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationLossAdjustmentBeforeTaxPortionAttributableToParent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationLossAdjustmentBeforeTaxPortionAttributableToParent" xlink:to="SNOA_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationLossAdjustmentBeforeTaxPortionAttributableToParent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationLossAdjustmentBeforeTaxPortionAttributableToParent_lbl" xml:lang="en-US">Foreign currency translation adjustment loss</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainAdjustmentBeforeTaxPortionAttributableToParent" xlink:label="SNOA_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainAdjustmentBeforeTaxPortionAttributableToParent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainAdjustmentBeforeTaxPortionAttributableToParent" xlink:to="SNOA_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainAdjustmentBeforeTaxPortionAttributableToParent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainAdjustmentBeforeTaxPortionAttributableToParent_lbl" xml:lang="en-US">Foreign currency translation adjustment gain</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainBeforeTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainBeforeTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainBeforeTax_lbl" xml:lang="en-US">Foreign currency transaction gain</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionLossBeforeTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionLossBeforeTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionLossBeforeTax_lbl" xml:lang="en-US">Foreign currency transaction loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2_lbl" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_lbl" xml:lang="en-US">Accounts and Financing Receivables [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:label="us-gaap_AccountsNotesAndLoansReceivableLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="us-gaap_AccountsNotesAndLoansReceivableLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsNotesAndLoansReceivableLineItems_lbl" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableGrossCurrent" xlink:label="us-gaap_AccountsReceivableGrossCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableGrossCurrent" xlink:to="us-gaap_AccountsReceivableGrossCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableGrossCurrent_lbl" xml:lang="en-US">Accounts receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_2_lbl" xml:lang="en-US">Less: discounts, rebates, distributor fees and returns</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_2_lbl" xml:lang="en-US">Total accounts receivable, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" xml:lang="en-US">Raw materials</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" xml:lang="en-US">Finished goods</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryGross" xlink:label="us-gaap_InventoryGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryGross" xlink:to="us-gaap_InventoryGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_InventoryGross_lbl" xml:lang="en-US">Inventories, gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryValuationReserves" xlink:to="us-gaap_InventoryValuationReserves_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InventoryValuationReserves_2_lbl" xml:lang="en-US">Less: allowance for obsolete and excess inventory</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_InventoryNet_2_lbl" xml:lang="en-US">Total inventories</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidInsurance_lbl" xml:lang="en-US">Prepaid insurance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidTaxes" xlink:label="us-gaap_PrepaidTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidTaxes" xlink:to="us-gaap_PrepaidTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidTaxes_lbl" xml:lang="en-US">VAT prepaid to Mexican tax authorities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xml:lang="en-US">Other prepaid expenses and other current assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2_lbl" xml:lang="en-US">Total prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MachineryAndEquipmentGross" xlink:label="us-gaap_MachineryAndEquipmentGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MachineryAndEquipmentGross" xlink:to="us-gaap_MachineryAndEquipmentGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MachineryAndEquipmentGross_lbl" xml:lang="en-US">Manufacturing, lab, and other equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentOther" xlink:label="us-gaap_PropertyPlantAndEquipmentOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentOther" xlink:to="us-gaap_PropertyPlantAndEquipmentOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentOther_lbl" xml:lang="en-US">Office equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesGross" xlink:label="us-gaap_FurnitureAndFixturesGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesGross" xlink:to="us-gaap_FurnitureAndFixturesGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesGross_lbl" xml:lang="en-US">Furniture and fixtures</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="us-gaap_LeaseholdImprovementsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsGross" xlink:to="us-gaap_LeaseholdImprovementsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsGross_lbl" xml:lang="en-US">Leasehold improvements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Property and equipment, gross</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Less: accumulated depreciation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xml:lang="en-US">Total property and equipment, net and equipment, net&#160;</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US">Salaries and related costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Other</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilities_2_lbl" xml:lang="en-US">Total accrued expenses and other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="us-gaap_ScheduleOfShortTermDebtTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_ScheduleOfShortTermDebtTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShortTermDebtTable_lbl" xml:lang="en-US">Short-Term Debt [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="us-gaap_ShortTermDebtLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ShortTermDebtLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtLineItems_lbl" xml:lang="en-US">Short-Term Debt [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Debt face amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl" xml:lang="en-US">Debt interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDateRangeEnd1" xlink:label="us-gaap_DebtInstrumentMaturityDateRangeEnd1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDateRangeEnd1" xlink:to="us-gaap_DebtInstrumentMaturityDateRangeEnd1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMaturityDateRangeEnd1_lbl" xml:lang="en-US">Final payment date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromShortTermDebt" xlink:label="us-gaap_ProceedsFromShortTermDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromShortTermDebt" xlink:to="us-gaap_ProceedsFromShortTermDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromShortTermDebt_lbl" xml:lang="en-US">Debt initial payment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentPaymentTerms" xlink:label="us-gaap_DebtInstrumentPaymentTerms" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPaymentTerms" xlink:to="us-gaap_DebtInstrumentPaymentTerms_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentPaymentTerms_lbl" xml:lang="en-US">Debt payment terms</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="us-gaap_DebtInstrumentPeriodicPayment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPeriodicPayment" xlink:to="us-gaap_DebtInstrumentPeriodicPayment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentPeriodicPayment_lbl" xml:lang="en-US">Periodic payment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDateRangeStart1" xlink:label="us-gaap_DebtInstrumentMaturityDateRangeStart1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDateRangeStart1" xlink:to="us-gaap_DebtInstrumentMaturityDateRangeStart1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMaturityDateRangeStart1_lbl" xml:lang="en-US">First installment beginning date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLongTermDebtCurrent" xlink:label="us-gaap_OtherLongTermDebtCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLongTermDebtCurrent" xlink:to="us-gaap_OtherLongTermDebtCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLongTermDebtCurrent_lbl" xml:lang="en-US">Outstanding principal amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesOperatingAbstract" xlink:label="us-gaap_LeasesOperatingAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_LeasesOperatingAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesOperatingAbstract_lbl" xml:lang="en-US">Operating leases:</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_2_lbl" xml:lang="en-US">Operating lease right-of-use assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_2_lbl" xml:lang="en-US">Operating lease liabilities &#8211; current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_2_lbl" xml:lang="en-US">Operating lease liabilities &#8211; non-current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Operating lease cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xml:lang="en-US">Operating cash flows from operating leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Weighted-average remaining lease term - operating leases (in months)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Weighted-average discount rate - operating leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2026</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2027</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">2028</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total future minimum lease payments, undiscounted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less: imputed interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Total lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficersCompensation" xlink:label="us-gaap_OfficersCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficersCompensation" xlink:to="us-gaap_OfficersCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OfficersCompensation_lbl" xml:lang="en-US">Annual salaries</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_PotentialSeverancePayments" xlink:label="SNOA_PotentialSeverancePayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_PotentialSeverancePayments" xlink:to="SNOA_PotentialSeverancePayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_PotentialSeverancePayments_lbl" xml:lang="en-US">Potential severance payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US">Stock, Class of Stock [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US">Class of Stock [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_2_lbl" xml:lang="en-US">Convertible preferred stock, shares authorized</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_2_lbl" xml:lang="en-US">Convertible preferred stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LegalFees" xlink:label="us-gaap_LegalFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalFees" xlink:to="us-gaap_LegalFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LegalFees_lbl" xml:lang="en-US">Legal fees and other expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xml:lang="en-US">Stock issued new, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_ProceedsFromIssuanceOfCommonStockGross" xlink:label="SNOA_ProceedsFromIssuanceOfCommonStockGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_ProceedsFromIssuanceOfCommonStockGross" xlink:to="SNOA_ProceedsFromIssuanceOfCommonStockGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_ProceedsFromIssuanceOfCommonStockGross_lbl" xml:lang="en-US">Proceeds from sale of stock, gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xml:lang="en-US">Proceeds from sale of stock, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Fair value of the Company common stock on date of grant</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend yield</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Fair value of options granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Options outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Number of options outstanding, beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted-average exercise price options outstanding, beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Number of options granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted-average exercise price, options granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xml:lang="en-US">Number of options exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted-average exercise price, options exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xml:lang="en-US">Number of options forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted-average exercise price, options forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xml:lang="en-US">Number of options expired</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted-average exercise price, options expired</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Number of options outstanding, ending balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted-average exercise price options outstanding, ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted- average contractual term outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_lbl" xml:lang="en-US">Aggregate intrinsic value per share, outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Number of options, exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted-average exercise price, exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted- average contractual term, exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableInPeriodGrantDateIntrinsicValue" xlink:label="SNOA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableInPeriodGrantDateIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableInPeriodGrantDateIntrinsicValue" xlink:to="SNOA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableInPeriodGrantDateIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableInPeriodGrantDateIntrinsicValue_lbl" xml:lang="en-US">Aggregate intrinsic value per share, exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Number of unvested restricted stock awards outstanding, beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted-average award date fair value per share, unvested RSAs outstanding, beginning balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_2_lbl" xml:lang="en-US">Number of restricted stock awards granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted-average award date fair value per share, unvested RSAs granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Number of restricted stock awards vested</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted-average award date fair value per share, unvested RSAs vested</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xml:lang="en-US">Number of unvested restricted stock awards outstanding, ending balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xml:lang="en-US">Weighted-average award date fair value per share, unvested RSAs outstanding, ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US">Shares initially authorized for issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US">Increase in shares authorized for issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Shares available for future issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US">Unrecognized compensation costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Weighted average amortization period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Share Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense_lbl" xml:lang="en-US">Stock based compensation options exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Income before income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_lbl" xml:lang="en-US">Current:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xml:lang="en-US">State</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_lbl" xml:lang="en-US">Deferred:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Foreign</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Total income tax (expense) benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Expected federal statutory rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State income taxes, net of federal benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xml:lang="en-US">Foreign earnings taxed at different rates</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xml:lang="en-US">Effect of permanent differences</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_lbl" xml:lang="en-US">Effect of intercompany interest permanent differences</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_TrueupsOfStateDeferredAssets" xlink:label="SNOA_TrueupsOfStateDeferredAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_TrueupsOfStateDeferredAssets" xlink:to="SNOA_TrueupsOfStateDeferredAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_TrueupsOfStateDeferredAssets_lbl" xml:lang="en-US">True-up of state deferred assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl" xml:lang="en-US">Total effective rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Totals</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xml:lang="en-US">Deferred tax assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US">Research and development tax credit carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xml:lang="en-US">Reserves and accruals</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_lbl" xml:lang="en-US">Other deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_DeferredTaxAssetsLeaseLiability" xlink:label="SNOA_DeferredTaxAssetsLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_DeferredTaxAssetsLeaseLiability" xlink:to="SNOA_DeferredTaxAssetsLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_DeferredTaxAssetsLeaseLiability_lbl" xml:lang="en-US">Lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Gross deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Less valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Total deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xml:lang="en-US">Deferred tax liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xml:lang="en-US">Fixed assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:label="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:to="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_lbl" xml:lang="en-US">Prepaid expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_DeferredTaxLiabilitiesRightOfUseAsset" xlink:label="SNOA_DeferredTaxLiabilitiesRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_DeferredTaxLiabilitiesRightOfUseAsset" xlink:to="SNOA_DeferredTaxLiabilitiesRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="SNOA_DeferredTaxLiabilitiesRightOfUseAsset_lbl" xml:lang="en-US">Right of use asset</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US">Gross deferred tax liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US">Net deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xml:lang="en-US">Research credit carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionAndOtherPostretirementBenefitContributions" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitContributions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitContributions" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitContributions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitContributions_lbl" xml:lang="en-US">Company contributions to 401(k) plan</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueTable_lbl" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_lbl" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationLossAdjustmentBeforeTaxPortionAttributableToParent" xlink:to="SNOA_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationLossAdjustmentBeforeTaxPortionAttributableToParent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="SNOA_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationLossAdjustmentBeforeTaxPortionAttributableToParent_doc" xml:lang="en-US">Foreign currency translation loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Equity, Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrossProfit_2_lbl" xml:lang="en-US">Gross Profit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_2_lbl" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_StockIssuedDuringPeriodValueReverseStockSplits" xlink:to="SNOA_StockIssuedDuringPeriodValueReverseStockSplits_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_StockIssuedDuringPeriodValueReverseStockSplits_2_lbl" xml:lang="en-US">StockIssuedDuringPeriodValueReverseStockSplits</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits_2_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Reverse Stock Splits</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:to="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_2_lbl" xml:lang="en-US">Increase (Decrease) in Deferred Income Taxes</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_2_lbl" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayable_2_lbl" xml:lang="en-US">Increase (Decrease) in Other Accounts Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_2_lbl" xml:lang="en-US">Increase (Decrease) in Other Accounts Payable and Accrued Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_IncreaseDecreaseInWithholdingTaxPayable" xlink:to="SNOA_IncreaseDecreaseInWithholdingTaxPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_IncreaseDecreaseInWithholdingTaxPayable_2_lbl" xml:lang="en-US">IncreaseDecreaseInWithholdingTaxPayable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_PaymentsForFractionalSharesRelatedToReversesplit" xlink:to="SNOA_PaymentsForFractionalSharesRelatedToReversesplit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_PaymentsForFractionalSharesRelatedToReversesplit_2_lbl" xml:lang="en-US">PaymentsForFractionalSharesRelatedToReversesplit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfOtherShortTermDebt" xlink:to="us-gaap_RepaymentsOfOtherShortTermDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfOtherShortTermDebt_2_lbl" xml:lang="en-US">Repayments of Other Short-Term Debt</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_InsurancePremiumsFinanced" xlink:to="SNOA_InsurancePremiumsFinanced_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_InsurancePremiumsFinanced_2_lbl" xml:lang="en-US">InsurancePremiumsFinanced</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesPolicyTextBlock" xlink:to="us-gaap_ReceivablesPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesPolicyTextBlock_2_lbl" xml:lang="en-US">Receivable [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryPolicyTextBlock_2_lbl" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_2_lbl" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_2_lbl" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_2_lbl" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenue" xlink:to="us-gaap_DeferredRevenue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenue_2_lbl" xml:lang="en-US">Deferred Revenue</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2_lbl" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryGross" xlink:to="us-gaap_InventoryGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryGross_2_lbl" xml:lang="en-US">Inventory, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_2_lbl" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_2_lbl" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Periodic Reduction</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Reconciling Items, Percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2_lbl" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_2_lbl" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_2_lbl" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:to="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_2_lbl" xml:lang="en-US">Deferred Tax Liabilities, Prepaid Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SNOA_DeferredTaxLiabilitiesRightOfUseAsset" xlink:to="SNOA_DeferredTaxLiabilitiesRightOfUseAsset_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="SNOA_DeferredTaxLiabilitiesRightOfUseAsset_2_lbl" xml:lang="en-US">DeferredTaxLiabilitiesRightOfUseAsset</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_2_lbl" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_2_lbl" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_2_lbl" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>snoa-20250331_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.0c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://sonomapharma.com/role/Cover" xlink:href="snoa-20250331.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/ConsolidatedBalanceSheets" xlink:href="snoa-20250331.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="snoa-20250331.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/ConsolidatedStatementsOfComprehensiveLoss" xlink:href="snoa-20250331.xsd#ConsolidatedStatementsOfComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" xlink:href="snoa-20250331.xsd#ConsolidatedStatementsOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="snoa-20250331.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:href="snoa-20250331.xsd#CybersecurityRiskManagementAndStrategyDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/OrganizationAndRecentDevelopments" xlink:href="snoa-20250331.xsd#OrganizationAndRecentDevelopments" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/LiquidityAndFinancialCondition" xlink:href="snoa-20250331.xsd#LiquidityAndFinancialCondition" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="snoa-20250331.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/AccountsReceivable" xlink:href="snoa-20250331.xsd#AccountsReceivable" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/Inventories" xlink:href="snoa-20250331.xsd#Inventories" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:href="snoa-20250331.xsd#PrepaidExpensesAndOtherCurrentAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/PropertyAndEquipment" xlink:href="snoa-20250331.xsd#PropertyAndEquipment" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:href="snoa-20250331.xsd#AccruedExpensesAndOtherCurrentLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/Debt" xlink:href="snoa-20250331.xsd#Debt" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/Leases" xlink:href="snoa-20250331.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/CommitmentsAndContingencies" xlink:href="snoa-20250331.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/StockholdersEquity" xlink:href="snoa-20250331.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/Stock-basedCompensation" xlink:href="snoa-20250331.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/IncomeTaxes" xlink:href="snoa-20250331.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/EmployeeBenefitPlan" xlink:href="snoa-20250331.xsd#EmployeeBenefitPlan" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/RevenueDisaggregation" xlink:href="snoa-20250331.xsd#RevenueDisaggregation" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="snoa-20250331.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="snoa-20250331.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/AccountsReceivableTables" xlink:href="snoa-20250331.xsd#AccountsReceivableTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/InventoriesTables" xlink:href="snoa-20250331.xsd#InventoriesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:href="snoa-20250331.xsd#PrepaidExpensesAndOtherCurrentAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/PropertyAndEquipmentTables" xlink:href="snoa-20250331.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:href="snoa-20250331.xsd#AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/LeasesTables" xlink:href="snoa-20250331.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/Stock-basedCompensationTables" xlink:href="snoa-20250331.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/IncomeTaxesTables" xlink:href="snoa-20250331.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/RevenueDisaggregationTables" xlink:href="snoa-20250331.xsd#RevenueDisaggregationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/OrganizationAndRecentDevelopmentsDetailsNarrative" xlink:href="snoa-20250331.xsd#OrganizationAndRecentDevelopmentsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/LiquidityAndFinancialConditionDetailsNarrative" xlink:href="snoa-20250331.xsd#LiquidityAndFinancialConditionDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:href="snoa-20250331.xsd#SummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-usefulLives" xlink:href="snoa-20250331.xsd#SummaryOfSignificantAccountingPoliciesDetails-usefulLives" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-EarningsPerShare" xlink:href="snoa-20250331.xsd#SummaryOfSignificantAccountingPoliciesDetails-EarningsPerShare" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-AntidilutiveShares" xlink:href="snoa-20250331.xsd#SummaryOfSignificantAccountingPoliciesDetails-AntidilutiveShares" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="snoa-20250331.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/AccountsReceivableDetails" xlink:href="snoa-20250331.xsd#AccountsReceivableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/InventoriesDetails" xlink:href="snoa-20250331.xsd#InventoriesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails" xlink:href="snoa-20250331.xsd#PrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/PropertyAndEquipmentDetails" xlink:href="snoa-20250331.xsd#PropertyAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/PropertyAndEquipmentDetailsNarrative" xlink:href="snoa-20250331.xsd#PropertyAndEquipmentDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:href="snoa-20250331.xsd#AccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/DebtDetailsNarrative" xlink:href="snoa-20250331.xsd#DebtDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/LeasesDetails-BalanceSheetInformationRelatedToLeases" xlink:href="snoa-20250331.xsd#LeasesDetails-BalanceSheetInformationRelatedToLeases" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/LeasesDetails-MinimumOperatingLeasePayments" xlink:href="snoa-20250331.xsd#LeasesDetails-MinimumOperatingLeasePayments" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="snoa-20250331.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/StockholdersEquityDetailsNarrative" xlink:href="snoa-20250331.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/Stock-basedCompensationDetails-assumptions" xlink:href="snoa-20250331.xsd#Stock-basedCompensationDetails-assumptions" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/Stock-basedCompensationDetails-plans" xlink:href="snoa-20250331.xsd#Stock-basedCompensationDetails-plans" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/Stock-basedCompensationDetails-optionActivity" xlink:href="snoa-20250331.xsd#Stock-basedCompensationDetails-optionActivity" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/Stock-basedCompensationDetails-restrictedStockActivity" xlink:href="snoa-20250331.xsd#Stock-basedCompensationDetails-restrictedStockActivity" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/Stock-basedCompensationDetailsNarrative" xlink:href="snoa-20250331.xsd#Stock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/IncomeTaxesDetails-incomeSource" xlink:href="snoa-20250331.xsd#IncomeTaxesDetails-incomeSource" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/IncomeTaxesDetails-incomeTaxExpense" xlink:href="snoa-20250331.xsd#IncomeTaxesDetails-incomeTaxExpense" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/IncomeTaxesDetails-reconciliationOfTaxRate" xlink:href="snoa-20250331.xsd#IncomeTaxesDetails-reconciliationOfTaxRate" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes" xlink:href="snoa-20250331.xsd#IncomeTaxesDetails-deferredTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/IncomeTaxesDetailsNarrative" xlink:href="snoa-20250331.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/EmployeeBenefitPlanDetailsNarrative" xlink:href="snoa-20250331.xsd#EmployeeBenefitPlanDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/RevenueDisaggregationDetails-DisaggregationOfRevenue" xlink:href="snoa-20250331.xsd#RevenueDisaggregationDetails-DisaggregationOfRevenue" xlink:type="simple" />
    <link:roleRef roleURI="http://sonomapharma.com/role/RevenueDisaggregationDetails-GeographicRegions" xlink:href="snoa-20250331.xsd#RevenueDisaggregationDetails-GeographicRegions" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ErrCompDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTimingDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingPoliciesProc" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_deiIcfrAuditorAttestationFlag" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiIcfrAuditorAttestationFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="loc_deiDocumentFinStmtErrorCorrectionFlag" />
      <link:presentationArc order="590" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFinStmtErrorCorrectionFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="loc_deiAuditorFirmId" />
      <link:presentationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorFirmId" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="loc_deiAuditorName" />
      <link:presentationArc order="610" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="loc_deiAuditorLocation" />
      <link:presentationArc order="620" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorLocation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/ConsolidatedBalanceSheets" xlink:title="00000002 - Statement - CONSOLIDATED BALANCE SHEETS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_DeferredConsiderationCurrent" xlink:label="loc_SNOADeferredConsiderationCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_SNOADeferredConsiderationCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="loc_us-gaapDeferredIncomeTaxAssetsNet" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapDeferredIncomeTaxAssetsNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_DeferredConsiderationNoncurrent" xlink:label="loc_SNOADeferredConsiderationNoncurrent" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_SNOADeferredConsiderationNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:label="loc_us-gaapAccountsPayableAndOtherAccruedLiabilities" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableAndOtherAccruedLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaapDeferredRevenueCurrent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapDeferredRevenueCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermBorrowings" xlink:label="loc_us-gaapShortTermBorrowings" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapShortTermBorrowings" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaapDeferredRevenueNoncurrent" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapDeferredRevenueNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_WithholdingTaxPayable" xlink:label="loc_SNOAWithholdingTaxPayable" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_SNOAWithholdingTaxPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/ConsolidatedStatementsOfComprehensiveLoss" xlink:title="00000004 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapRevenues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaapCostOfGoodsAndServicesSold" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapCostOfGoodsAndServicesSold" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherOperatingIncomeExpenseNet" xlink:label="loc_us-gaapOtherOperatingIncomeExpenseNet" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOtherOperatingIncomeExpenseNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossTaxAbstract" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossTaxAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_2" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherComprehensiveIncomeLossTaxAbstract" xlink:to="loc_us-gaapNetIncomeLoss_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" xlink:label="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherComprehensiveIncomeLossTaxAbstract" xlink:to="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" xlink:title="00000005 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS&apos; EQUITY">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_StockIssuedDuringPeriodValueNewIssues1" xlink:label="loc_SNOAStockIssuedDuringPeriodValueNewIssues1" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SNOAStockIssuedDuringPeriodValueNewIssues1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_StockIssuedDuringPeriodSharesNewIssues1" xlink:label="loc_SNOAStockIssuedDuringPeriodSharesNewIssues1" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SNOAStockIssuedDuringPeriodSharesNewIssues1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_ProceedsFromAtthemarketSaleOfCommonStockNetOfOfferingExpensesShares" xlink:label="loc_SNOAProceedsFromAtthemarketSaleOfCommonStockNetOfOfferingExpensesShares" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SNOAProceedsFromAtthemarketSaleOfCommonStockNetOfOfferingExpensesShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_StockIssuedDuringPeriodValueReverseStockSplits" xlink:label="loc_SNOAStockIssuedDuringPeriodValueReverseStockSplits" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SNOAStockIssuedDuringPeriodValueReverseStockSplits" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_StockIssuedDuringPeriodValuesReverseStockSplits" xlink:label="loc_SNOAStockIssuedDuringPeriodValuesReverseStockSplits" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_SNOAStockIssuedDuringPeriodValuesReverseStockSplits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesReverseStockSplits" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesReverseStockSplits" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows" xlink:title="00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:label="loc_us-gaapIncreaseDecreaseInDeferredIncomeTaxes" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInDeferredIncomeTaxes" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDeferredCompensation" xlink:label="loc_us-gaapIncreaseDecreaseInDeferredCompensation" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInDeferredCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInOtherAccountsPayable" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherAccountsPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_IncreaseDecreaseInWithholdingTaxPayable" xlink:label="loc_SNOAIncreaseDecreaseInWithholdingTaxPayable" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_SNOAIncreaseDecreaseInWithholdingTaxPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaapIncreaseDecreaseInContractWithCustomerLiability" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_PaymentsForFractionalSharesRelatedToReversesplit" xlink:label="loc_SNOAPaymentsForFractionalSharesRelatedToReversesplit" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_SNOAPaymentsForFractionalSharesRelatedToReversesplit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfOtherShortTermDebt" xlink:label="loc_us-gaapRepaymentsOfOtherShortTermDebt" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapRepaymentsOfOtherShortTermDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_ProceedsFromInsurancePremiumsFinanced" xlink:label="loc_SNOAProceedsFromInsurancePremiumsFinanced" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_SNOAProceedsFromInsurancePremiumsFinanced" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapEffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaapInterestPaidNet" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapInterestPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_InsurancePremiumsFinanced" xlink:label="loc_SNOAInsurancePremiumsFinanced" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_SNOAInsurancePremiumsFinanced" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:title="999007 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="loc_cydCybersecurityRiskManagementStrategyAndGovernanceAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="loc_cydCybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="loc_cydCybersecurityRiskManagementProcessesIntegratedTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="loc_cydCybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="loc_cydCybersecurityRiskManagementProcessesIntegratedFlag" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="loc_cydCybersecurityRiskManagementProcessesIntegratedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="loc_cydCybersecurityRiskManagementThirdPartyEngagedFlag" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="loc_cydCybersecurityRiskManagementThirdPartyEngagedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="loc_cydCybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="loc_cydCybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="loc_cydCybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="loc_cydCybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="loc_cydCybersecurityRiskBoardOfDirectorsOversightTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="loc_cydCybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="loc_cydCybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="loc_cydCybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="loc_cydCybersecurityRiskRoleOfManagementTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cydCybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="loc_cydCybersecurityRiskRoleOfManagementTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/OrganizationAndRecentDevelopments" xlink:title="999008 - Disclosure - Organization and Recent Developments">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/LiquidityAndFinancialCondition" xlink:title="999009 - Disclosure - Liquidity and Financial Condition">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="loc_us-gaapSubstantialDoubtAboutGoingConcernTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapSubstantialDoubtAboutGoingConcernTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="999010 - Disclosure - Summary of Significant Accounting Policies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/AccountsReceivable" xlink:title="999011 - Disclosure - Accounts Receivable">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesAbstract" xlink:label="loc_us-gaapReceivablesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:label="loc_us-gaapLoansNotesTradeAndOtherReceivablesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapReceivablesAbstract" xlink:to="loc_us-gaapLoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/Inventories" xlink:title="999012 - Disclosure - Inventories">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaapInventoryDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:title="999013 - Disclosure - Prepaid Expenses and Other Current Assets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCurrentAssetsTextBlock" xlink:label="loc_us-gaapOtherCurrentAssetsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapOtherCurrentAssetsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/PropertyAndEquipment" xlink:title="999014 - Disclosure - Property and Equipment">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:title="999015 - Disclosure - Accrued Expenses and Other Current Liabilities">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="loc_us-gaapAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/Debt" xlink:title="999016 - Disclosure - Debt">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaapDebtDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/Leases" xlink:title="999017 - Disclosure - Leases">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeasesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeasesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/CommitmentsAndContingencies" xlink:title="999018 - Disclosure - Commitments and Contingencies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/StockholdersEquity" xlink:title="999019 - Disclosure - Stockholders&#8217; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/Stock-basedCompensation" xlink:title="999020 - Disclosure - Stock-Based Compensation">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/IncomeTaxes" xlink:title="999021 - Disclosure - Income Taxes">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/EmployeeBenefitPlan" xlink:title="999022 - Disclosure - Employee Benefit Plan">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaapCompensationAndRetirementDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="loc_us-gaapCompensationAndEmployeeBenefitPlansTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCompensationAndRetirementDisclosureAbstract" xlink:to="loc_us-gaapCompensationAndEmployeeBenefitPlansTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/RevenueDisaggregation" xlink:title="999023 - Disclosure - Revenue Disaggregation">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaapRevenueFromContractWithCustomerAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="loc_us-gaapRevenueFromContractWithCustomerTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract" xlink:to="loc_us-gaapRevenueFromContractWithCustomerTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:title="995445 - Disclosure - Insider Trading Arrangements">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems" xlink:label="loc_ecdInsiderTradingArrLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="loc_ecdRule10b51ArrAdoptedFlag" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdRule10b51ArrAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="loc_ecdNonRule10b51ArrAdoptedFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdNonRule10b51ArrAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="loc_ecdRule10b51ArrTrmntdFlag" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdRule10b51ArrTrmntdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="loc_ecdNonRule10b51ArrTrmntdFlag" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdNonRule10b51ArrTrmntdFlag" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="999025 - Disclosure - Summary of Significant Accounting Policies (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaapConsolidationPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConsolidationPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaapRevenueRecognitionPolicyTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapRevenueRecognitionPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaapConcentrationRiskCreditRisk" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConcentrationRiskCreditRisk" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="loc_us-gaapReceivablesPolicyTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapReceivablesPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaapInventoryPolicyTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapInventoryPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdvertisingCostsPolicyTextBlock" xlink:label="loc_us-gaapAdvertisingCostsPolicyTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapAdvertisingCostsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_ShippingAndHandlingCost1PolicyTextBlock" xlink:label="loc_SNOAShippingAndHandlingCost1PolicyTextBlock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_SNOAShippingAndHandlingCost1PolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaapForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="loc_us-gaapComprehensiveIncomePolicyPolicyTextBlock" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_ConvertiblePreferredStockPolicyTextBlock" xlink:label="loc_SNOAConvertiblePreferredStockPolicyTextBlock" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_SNOAConvertiblePreferredStockPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:label="loc_us-gaapSubsequentEventsPolicyPolicyTextBlock" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSubsequentEventsPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="999026 - Disclosure - Summary of Significant Accounting Policies (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="loc_us-gaapSchedulesOfConcentrationOfRiskByRiskFactorTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:label="loc_SNOAPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_SNOAPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/AccountsReceivableTables" xlink:title="999027 - Disclosure - Accounts Receivable (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesAbstract" xlink:label="loc_us-gaapReceivablesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:label="loc_us-gaapScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapReceivablesAbstract" xlink:to="loc_us-gaapScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/InventoriesTables" xlink:title="999028 - Disclosure - Inventories (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaapScheduleOfInventoryCurrentTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:title="999029 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/PropertyAndEquipmentTables" xlink:title="999030 - Disclosure - Property and Equipment (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:title="999031 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/LeasesTables" xlink:title="999032 - Disclosure - Leases (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaapLeaseCostTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLeaseCostTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/Stock-basedCompensationTables" xlink:title="999033 - Disclosure - Stock-Based Compensation (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_ScheduleOfStockbasedAwardsOutstandingByPlanTableTextBlock" xlink:label="loc_SNOAScheduleOfStockbasedAwardsOutstandingByPlanTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_SNOAScheduleOfStockbasedAwardsOutstandingByPlanTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/IncomeTaxesTables" xlink:title="999034 - Disclosure - Income Taxes (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="loc_us-gaapScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaapScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/RevenueDisaggregationTables" xlink:title="999035 - Disclosure - Revenue Disaggregation (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaapRevenueFromContractWithCustomerAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="loc_us-gaapDisaggregationOfRevenueTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract" xlink:to="loc_us-gaapDisaggregationOfRevenueTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xlink:label="loc_us-gaapScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract" xlink:to="loc_us-gaapScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/OrganizationAndRecentDevelopmentsDetailsNarrative" xlink:title="999036 - Disclosure - Organization and Recent Developments (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/LiquidityAndFinancialConditionDetailsNarrative" xlink:title="999037 - Disclosure - Liquidity and Financial Condition (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_WorkingCapital" xlink:label="loc_SNOAWorkingCapital" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_SNOAWorkingCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_2" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_2" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:title="999038 - Disclosure - Summary of Significant Accounting Policies (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="loc_us-gaapScheduleOfProductInformationTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfProductInformationTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductInformationLineItems" xlink:label="loc_us-gaapProductInformationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapProductInformationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaapCustomerConcentrationRiskMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapCustomerConcentrationRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaapSalesRevenueNetMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapSalesRevenueNetMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaapAccountsReceivableMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapAccountsReceivableMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis" xlink:label="loc_srtMajorCustomersAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtMajorCustomersAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srtNameOfMajorCustomerDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtMajorCustomersAxis" xlink:to="loc_srtNameOfMajorCustomerDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_CustomerAMember" xlink:label="loc_SNOACustomerAMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_SNOACustomerAMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_CustomerBMember" xlink:label="loc_SNOACustomerBMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_SNOACustomerBMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_CustomerCMember" xlink:label="loc_SNOACustomerCMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_SNOACustomerCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_CustomerDMember" xlink:label="loc_SNOACustomerDMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_SNOACustomerDMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_ConcentrationRiskPercentage2" xlink:label="loc_SNOAConcentrationRiskPercentage2" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_SNOAConcentrationRiskPercentage2" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-usefulLives" xlink:title="999039 - Disclosure - Summary of Significant Accounting Policies (Details-Useful lives)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaapOfficeEquipmentMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapOfficeEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaapMachineryAndEquipmentMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapMachineryAndEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-EarningsPerShare" xlink:title="999040 - Disclosure - Summary of Significant Accounting Policies (Details - Earnings per share)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-AntidilutiveShares" xlink:title="999041 - Disclosure - Summary of Significant Accounting Policies (Details - Antidilutive shares)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_CommonStockUnitsMember" xlink:label="loc_SNOACommonStockUnitsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_SNOACommonStockUnitsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="999042 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="loc_us-gaapScheduleOfProductInformationTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfProductInformationTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srtCounterpartyNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtCounterpartyNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srtRepurchaseAgreementCounterpartyNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtCounterpartyNameAxis" xlink:to="loc_srtRepurchaseAgreementCounterpartyNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_InvekraMember" xlink:label="loc_SNOAInvekraMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRepurchaseAgreementCounterpartyNameDomain" xlink:to="loc_SNOAInvekraMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtProductOrServiceAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_ProbableCreditLossesMember" xlink:label="loc_SNOAProbableCreditLossesMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_SNOAProbableCreditLossesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_PotentialDiscountsReturnsDistributorFeesAndRebatesMember" xlink:label="loc_SNOAPotentialDiscountsReturnsDistributorFeesAndRebatesMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_SNOAPotentialDiscountsReturnsDistributorFeesAndRebatesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShippingAndHandlingMember" xlink:label="loc_us-gaapShippingAndHandlingMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_us-gaapShippingAndHandlingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeMember" xlink:label="loc_us-gaapOtherComprehensiveIncomeMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapOtherComprehensiveIncomeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherOperatingIncomeExpenseMember" xlink:label="loc_us-gaapOtherOperatingIncomeExpenseMember" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapOtherOperatingIncomeExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaapDeferredRevenue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapDeferredRevenue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="loc_us-gaapAllowanceForDoubtfulAccountsReceivable" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAllowanceForDoubtfulAccountsReceivable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryValuationReserves" xlink:label="loc_us-gaapInventoryValuationReserves" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapInventoryValuationReserves" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaapAssetImpairmentCharges" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAssetImpairmentCharges" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketingExpense" xlink:label="loc_us-gaapMarketingExpense" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapMarketingExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationLossAdjustmentBeforeTaxPortionAttributableToParent" xlink:label="loc_SNOAOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationLossAdjustmentBeforeTaxPortionAttributableToParent" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_SNOAOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationLossAdjustmentBeforeTaxPortionAttributableToParent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainAdjustmentBeforeTaxPortionAttributableToParent" xlink:label="loc_SNOAOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainAdjustmentBeforeTaxPortionAttributableToParent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_SNOAOtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainAdjustmentBeforeTaxPortionAttributableToParent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainBeforeTax" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapForeignCurrencyTransactionGainBeforeTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionLossBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionLossBeforeTax" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapForeignCurrencyTransactionLossBeforeTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/AccountsReceivableDetails" xlink:title="999043 - Disclosure - Accounts Receivable (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesAbstract" xlink:label="loc_us-gaapReceivablesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:label="loc_us-gaapScheduleOfAccountsNotesLoansAndFinancingReceivableTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapReceivablesAbstract" xlink:to="loc_us-gaapScheduleOfAccountsNotesLoansAndFinancingReceivableTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:label="loc_us-gaapAccountsNotesAndLoansReceivableLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="loc_us-gaapAccountsNotesAndLoansReceivableLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="loc_srtProductOrServiceAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_PotentialDiscountsReturnsDistributorFeesAndRebatesMember" xlink:label="loc_SNOAPotentialDiscountsReturnsDistributorFeesAndRebatesMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_SNOAPotentialDiscountsReturnsDistributorFeesAndRebatesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableGrossCurrent" xlink:label="loc_us-gaapAccountsReceivableGrossCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountsNotesAndLoansReceivableLineItems" xlink:to="loc_us-gaapAccountsReceivableGrossCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="loc_us-gaapAllowanceForDoubtfulAccountsReceivable" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountsNotesAndLoansReceivableLineItems" xlink:to="loc_us-gaapAllowanceForDoubtfulAccountsReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountsNotesAndLoansReceivableLineItems" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/InventoriesDetails" xlink:title="999044 - Disclosure - Inventories (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="loc_us-gaapInventoryRawMaterialsNetOfReserves" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryRawMaterialsNetOfReserves" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaapInventoryFinishedGoodsNetOfReserves" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryFinishedGoodsNetOfReserves" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryGross" xlink:label="loc_us-gaapInventoryGross" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryValuationReserves" xlink:label="loc_us-gaapInventoryValuationReserves" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryValuationReserves" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails" xlink:title="999045 - Disclosure - Prepaid Expenses and Other Current Assets (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidInsurance" xlink:label="loc_us-gaapPrepaidInsurance" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapPrepaidInsurance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidTaxes" xlink:label="loc_us-gaapPrepaidTaxes" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapPrepaidTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaapOtherPrepaidExpenseCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapOtherPrepaidExpenseCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/PropertyAndEquipmentDetails" xlink:title="999046 - Disclosure - Property and Equipment (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MachineryAndEquipmentGross" xlink:label="loc_us-gaapMachineryAndEquipmentGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapMachineryAndEquipmentGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentOther" xlink:label="loc_us-gaapPropertyPlantAndEquipmentOther" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesGross" xlink:label="loc_us-gaapFurnitureAndFixturesGross" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapFurnitureAndFixturesGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="loc_us-gaapLeaseholdImprovementsGross" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapLeaseholdImprovementsGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/PropertyAndEquipmentDetailsNarrative" xlink:title="999047 - Disclosure - Property and Equipment (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:title="999048 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:label="loc_us-gaapAccountsPayableAndOtherAccruedLiabilities" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccountsPayableAndOtherAccruedLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/DebtDetailsNarrative" xlink:title="999049 - Disclosure - Debt (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapShortTermDebtLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaapShortTermDebtTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapShortTermDebtTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_InsurancePremiumFinancingMember" xlink:label="loc_SNOAInsurancePremiumFinancingMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_SNOAInsurancePremiumFinancingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="loc_us-gaapDebtInstrumentInterestRateDuringPeriod" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateDuringPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDateRangeEnd1" xlink:label="loc_us-gaapDebtInstrumentMaturityDateRangeEnd1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDateRangeEnd1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromShortTermDebt" xlink:label="loc_us-gaapProceedsFromShortTermDebt" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapProceedsFromShortTermDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentPaymentTerms" xlink:label="loc_us-gaapDebtInstrumentPaymentTerms" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentPaymentTerms" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="loc_us-gaapDebtInstrumentPeriodicPayment" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentPeriodicPayment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDateRangeStart1" xlink:label="loc_us-gaapDebtInstrumentMaturityDateRangeStart1" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDateRangeStart1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLongTermDebtCurrent" xlink:label="loc_us-gaapOtherLongTermDebtCurrent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapOtherLongTermDebtCurrent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/LeasesDetails-BalanceSheetInformationRelatedToLeases" xlink:title="999050 - Disclosure - Leases (Details - Balance sheet information related to leases)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesOperatingAbstract" xlink:label="loc_us-gaapLeasesOperatingAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLeasesOperatingAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaapOperatingLeaseCost" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/LeasesDetails-MinimumOperatingLeasePayments" xlink:title="999051 - Disclosure - Leases (Details - Minimum operating lease payments)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="999052 - Disclosure - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficersCompensation" xlink:label="loc_us-gaapOfficersCompensation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOfficersCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_PotentialSeverancePayments" xlink:label="loc_SNOAPotentialSeverancePayments" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_SNOAPotentialSeverancePayments" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/StockholdersEquityDetailsNarrative" xlink:title="999053 - Disclosure - Stockholders&#8217; Equity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfStockByClassTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapClassOfStockLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_srtRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaapConvertiblePreferredStockMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_PlacementAgencyAgreementMember" xlink:label="loc_SNOAPlacementAgencyAgreementMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_SNOAPlacementAgencyAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_EquityDistributionAgreementMember" xlink:label="loc_SNOAEquityDistributionAgreementMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_SNOAEquityDistributionAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_PublicOfferingMember" xlink:label="loc_SNOAPublicOfferingMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_SNOAPublicOfferingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_deiLegalEntityAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_MaximGroupLLCMember" xlink:label="loc_SNOAMaximGroupLLCMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_SNOAMaximGroupLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaapLegalFees" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapLegalFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_ProceedsFromIssuanceOfCommonStockGross" xlink:label="loc_SNOAProceedsFromIssuanceOfCommonStockGross" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_SNOAProceedsFromIssuanceOfCommonStockGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/Stock-basedCompensationDetails-assumptions" xlink:title="999054 - Disclosure - Stock-Based Compensation (Details-Assumptions)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/Stock-basedCompensationDetails-plans" xlink:title="999055 - Disclosure - Stock-Based Compensation (Details-Plans)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_Plan2011Member" xlink:label="loc_SNOAPlan2011Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_SNOAPlan2011Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_Plan2016Member" xlink:label="loc_SNOAPlan2016Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_SNOAPlan2016Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_Plan2021Member" xlink:label="loc_SNOAPlan2021Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_SNOAPlan2021Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/Stock-basedCompensationDetails-optionActivity" xlink:title="999056 - Disclosure - Stock-Based Compensation (Details-Option activity)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableInPeriodGrantDateIntrinsicValue" xlink:label="loc_SNOAShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableInPeriodGrantDateIntrinsicValue" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_SNOAShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableInPeriodGrantDateIntrinsicValue" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/Stock-basedCompensationDetails-restrictedStockActivity" xlink:title="999057 - Disclosure - Stock-Based Compensation (Details-Restricted stock activity)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="999058 - Disclosure - Stock-Based Compensation (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_Plan2016Member" xlink:label="loc_SNOAPlan2016Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_SNOAPlan2016Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_Plan2021Member" xlink:label="loc_SNOAPlan2021Member" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_SNOAPlan2021Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_Plan2024Member" xlink:label="loc_SNOAPlan2024Member" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_SNOAPlan2024Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/IncomeTaxesDetails-incomeSource" xlink:title="999059 - Disclosure - Income Taxes (Details-Income source)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaapDomesticCountryMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapDomesticCountryMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaapForeignCountryMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapForeignCountryMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/IncomeTaxesDetails-incomeTaxExpense" xlink:title="999060 - Disclosure - Income Taxes (Details-Income tax expense)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:label="loc_us-gaapCurrentFederalStateAndLocalTaxExpenseBenefitAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapCurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapCurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:label="loc_us-gaapDeferredFederalStateAndLocalTaxExpenseBenefitAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredForeignIncomeTaxExpenseBenefit" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredIncomeTaxExpenseBenefit" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredIncomeTaxExpenseBenefit" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/IncomeTaxesDetails-reconciliationOfTaxRate" xlink:title="999061 - Disclosure - Income Taxes (Details-Reconciliation of tax rate)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_TrueupsOfStateDeferredAssets" xlink:label="loc_SNOATrueupsOfStateDeferredAssets" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_SNOATrueupsOfStateDeferredAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes" xlink:title="999062 - Disclosure - Income Taxes (Details-Deferred taxes)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:label="loc_us-gaapDeferredTaxAssetsGrossAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsGrossAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsGrossAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsGrossAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsGrossAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsGrossAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseOther" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsGrossAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_DeferredTaxAssetsLeaseLiability" xlink:label="loc_SNOADeferredTaxAssetsLeaseLiability" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsGrossAbstract" xlink:to="loc_SNOADeferredTaxAssetsLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsGrossAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsGrossAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsGrossAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="loc_us-gaapDeferredTaxLiabilitiesAbstract" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsGrossAbstract" xlink:to="loc_us-gaapDeferredTaxLiabilitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="loc_us-gaapDeferredTaxLiabilitiesPropertyPlantAndEquipment" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxLiabilitiesAbstract" xlink:to="loc_us-gaapDeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:label="loc_us-gaapDeferredTaxLiabilitiesPrepaidExpenses" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxLiabilitiesAbstract" xlink:to="loc_us-gaapDeferredTaxLiabilitiesPrepaidExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_DeferredTaxLiabilitiesRightOfUseAsset" xlink:label="loc_SNOADeferredTaxLiabilitiesRightOfUseAsset" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxLiabilitiesAbstract" xlink:to="loc_SNOADeferredTaxLiabilitiesRightOfUseAsset" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaapDeferredIncomeTaxLiabilities" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxLiabilitiesAbstract" xlink:to="loc_us-gaapDeferredIncomeTaxLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxLiabilitiesAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/IncomeTaxesDetailsNarrative" xlink:title="999063 - Disclosure - Income Taxes (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaapDomesticCountryMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapDomesticCountryMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaapStateAndLocalJurisdictionMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapStateAndLocalJurisdictionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaapForeignCountryMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapForeignCountryMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_CaliforniaResearchAndDevelopmentMember" xlink:label="loc_SNOACaliforniaResearchAndDevelopmentMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_SNOACaliforniaResearchAndDevelopmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaapTaxCreditCarryforwardAmount" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEffectiveIncomeTaxRateReconciliationLineItems" xlink:to="loc_us-gaapTaxCreditCarryforwardAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/EmployeeBenefitPlanDetailsNarrative" xlink:title="999064 - Disclosure - Employee Benefit Plan (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaapCompensationAndRetirementDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionAndOtherPostretirementBenefitContributions" xlink:label="loc_us-gaapPensionAndOtherPostretirementBenefitContributions" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCompensationAndRetirementDisclosureAbstract" xlink:to="loc_us-gaapPensionAndOtherPostretirementBenefitContributions" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/RevenueDisaggregationDetails-DisaggregationOfRevenue" xlink:title="999065 - Disclosure - Revenue Disaggregation (Details - Disaggregation of revenue)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaapRevenueFromContractWithCustomerAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaapDisaggregationOfRevenueTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract" xlink:to="loc_us-gaapDisaggregationOfRevenueTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaapDisaggregationOfRevenueLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisaggregationOfRevenueTable" xlink:to="loc_us-gaapDisaggregationOfRevenueLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaapStatementBusinessSegmentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisaggregationOfRevenueTable" xlink:to="loc_us-gaapStatementBusinessSegmentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaapSegmentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementBusinessSegmentsAxis" xlink:to="loc_us-gaapSegmentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_HumanCareMember" xlink:label="loc_SNOAHumanCareMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_SNOAHumanCareMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_AnimalCareMember" xlink:label="loc_SNOAAnimalCareMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_SNOAAnimalCareMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_ServiceAndRoyaltyMember" xlink:label="loc_SNOAServiceAndRoyaltyMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSegmentDomain" xlink:to="loc_SNOAServiceAndRoyaltyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisaggregationOfRevenueTable" xlink:to="loc_srtProductOrServiceAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaapProductMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_us-gaapProductMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ServiceMember" xlink:label="loc_us-gaapServiceMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_us-gaapServiceMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisaggregationOfRevenueLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://sonomapharma.com/role/RevenueDisaggregationDetails-GeographicRegions" xlink:title="999066 - Disclosure - Revenue Disaggregation (Details - Geographic regions)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaapRevenueFromContractWithCustomerAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaapDisaggregationOfRevenueTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRevenueFromContractWithCustomerAbstract" xlink:to="loc_us-gaapDisaggregationOfRevenueTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaapDisaggregationOfRevenueLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisaggregationOfRevenueTable" xlink:to="loc_us-gaapDisaggregationOfRevenueLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisaggregationOfRevenueTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueSegmentMember" xlink:label="loc_us-gaapSalesRevenueSegmentMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapSalesRevenueSegmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisaggregationOfRevenueTable" xlink:to="loc_srtStatementGeographicalAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US" xlink:label="loc_countryUS" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryUS" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EuropeMember" xlink:label="loc_srtEuropeMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_srtEuropeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_AsiaMember" xlink:label="loc_srtAsiaMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_srtAsiaMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LatinAmericaMember" xlink:label="loc_srtLatinAmericaMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_srtLatinAmericaMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="snoa-20250331.xsd#SNOA_RestOfTheWorldMember" xlink:label="loc_SNOARestOfTheWorldMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_SNOARestOfTheWorldMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisaggregationOfRevenueLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>derm.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 derm.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" %E M,# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M(\+?:<Q'(E0Y_&N^KS[Q:^S[$?1U->@(<H/I6!8M%%% !1110 4444 %%%%
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M.M:W+3N=+\+1M\2Q_C_(UZC7F'PP4?\ "1QGV/\ (UZ?4&\=@HHHH*"BBB@
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M 5]1D5O:'K#:@&25 DJ]AT(J0-&BBB@ HHHH **** "BBB@ K.\6G'AC4/\
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M\6@^E)[ >/?$.,&60'G@UY-);_\ %5P<9!:O8O'\8D,C#T->3%"OBNVXSF0
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M?%:VD.W]_%)P.V!6+W*1ZW1115F@4444 %%%% !1110 4444 <?\1SF<>H0
M?G7EWB%L3-CW'ZBO3_'R&[O66,;BJ@8'K7G?B/0;M<L8B![D4T!Q]R-EP/\
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M. /_ -=>?7P=:<I22W_O-?\ #%4J].,4K_@BQHQ:W@9)+A+ARQ.Y3G [5CN
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M9\+V,AYJG:^7(X!8#-68P/.VH25[5BX1>MC1,]2^%7Q:&E7 L[^)%MY<8G4
M,IZ?-ZBO8(Y!*@92&5AD$'(-?,VF1$[01VKV#X->*3=61TR9LO;KNASW7T_"
MLFK;&D7='=4444B@HHHH **** .>\??ZJV_WC7,NP&>?TKQG_@J;\:_%'P8\
M+>$)O#&K2Z3)J%W/'.R11OYBJBD#YU;N3TKXIU#]N_XM(X \9W@'H+2V_P#C
M=?>Y#P'C\SP<<70G!1E?=N^CMTB^W<_%N,_&_(^&\TJ95C:5652'*VXJ+7O)
M26\T]GV/T=\1-F(@C-<#K_.^O@^]_;C^*URN7\8WC9_Z=K<?^TZY_5_VSOB<
MX.?%MV?^W:#_ .(KUWX8YG'>I3^^7_R)\O3^DQPU)V6'K_\ @-/_ .6'W3>G
M]34<. ^,U^>FI?MF_$Y2<>++K_P&@_\ B*J+^VO\4%;(\67/_@+;_P#QNH7A
MQF*T]I#[Y?\ R)Z4/I#\/25U0K?^ P_^6'Z8:"1YPKT/PPV(5%?E!I/[<7Q3
M1P1XLG'_ &YV_P#\;KL- _X*!?%FS"X\4;_]^QMS_P"R4X^&>9RVG#[Y?_(D
M5/I%\-P^.C67_;L/_EA^JJ./*QUJYX6;_BH+8C^__0U^8EK_ ,%(OBU#%DZY
MI\F/[^FPG_V6O7/V*?V\?B%\6?VE_"_AW6KK29M-U&:19A'8)%(<1.PPPZ<@
M5Q9AX<YKAJ$\1-P<8IMV;V2O_*=N4_2 X8Q^,HX&C&JIU91C&\(VO)I*]IO2
M[/T?HHHK\Z/W4**** /*_P!J)#J7AVVL2W[MV\QQZ@5A_"7PXM])#&H4+"N1
MGL36M^T7EKV #.!$/YU:^!L D,O ) '/I0!E_%CQ+8_#SPY>:SJ3&.STV,M,
MX&2 /0>IKY]3_@H?X7))70]<..G"#/ZU[?\ M9>%9?B'\+==T"RFABO;Y55#
M*<*,,#S^%?)EK^P;XED89U;1.?1G/]*]#!4\+*+==V9\7Q)BL^IUXQRJG>-M
M79/6[TU\K'H__#PWPZQ^7P]K3?5HQ_6IX?V_M E&?^$>U@9_VT/]:X2U_P""
M?WB!L$ZYHZ9]G/\ 2M6T_P""?&O%?^1@TC'^Y)_A7<Z67OK^9\Y]<XSM=4__
M "6!UJ_MX>'I!DZ#K7X-'_C0/VYO#)8%]*UF,'U5#C]:YZ/_ ()\^( ORZ]H
MY^H<?TJ.[_X)]^)P!MUG0VX_O./Z4OJ^7]_Q8EF'&BWI?^2Q.L7]M_P>PRT.
MJQ?[T&?Y&M#0OVYO D<Y$E_=VV01F2U;'Z5Y7JO[!'C"-#Y=[HDNWTF89_,5
MA:E^PYXX@7"?V1(/:Z _I4O"8![3_$M9YQ;!^]AK_P#;G^3/HFP_;=\ 21X'
MB&.#!QM:-QC]*]$E\=6WB_0--U2SN8[RUC*SPSQ-D.,]<_2OA+5/V./'EDS!
M=/M9L=?+N5.:^J?V1O!>H>$/@5:Z1J\#6]Y;I/NC<@E.217'B\-0A%2HSN?1
M<.YQFV*Q$J68X?D5KIV:ZK35ON?4=M*)[>-P<AU##\13ZH>%IC<>&[%SU:!/
MY5?K@/LPHHHH ***AO[^+3;5YIF"1H,DGI0!*[B-26(  R23C%<SXC^)>EV$
M4D(#7S,"I2/[I]B3Q7+>+O&]SXBD9$)ALU;Y4!PS^[?X5S%S+M''%!+8GB'6
MY]3U*26*&*TB;A(HR1M'N>YKGM6M+S4,_OF4@<'>3BM2=^_>J\DIYJDB6SC[
M_P (:I+*?^)DX&?3-1P>$=4A=2-09L>V*ZV24 #-,\X'IQ6\6S-LS+:RU&",
M!I&<CIESBO1/AA\0(O#D"1:E81O(G2YBYD [@YZUQOG$''45-;W&XGKQ1*[W
M!,^@]#\166OV_F6LR2#N,\CZBK]>!Z1JUQI=PDUM*\,B]&4XKU3P)\04\31"
M"8"*\4=.T@]1_A6#BT:PE?0ZBB@=**DL**** "N/^,WQ#\*_ _X=ZSXP\4W%
MGIVCZ- ;FZN9R%  Z 9ZL3@ =R:[ ]*_$W_@Y^_:UU+5OBAX9^#UC=RP:)IM
MFNL:I%&Y"W<[DB)7QU"J,@'N:SJU%3@YOH=.$P[KU531XG^TA_P7W_: D^-7
MB&7P;XEL=!\*2W;'3+&31;:=8(,_+\[J221R23WKDG_X.!_VDX9P)/&'AV96
MP#N\/6A_DM<_^PG^R/X(^)3QZ_\ $[6K^'3)1FUT^&;8NT'AG/?/I74?ME_"
M'X%^!;58_ ]M</=G)+.^Y17FSJU)4_;*7R/65"E"HZ+C<D?_ (+T_M$2KG^W
M/"DB]06\/6_^%-3_ (+R_M!E@IUCPH,GDCP] ?Z5\CZ]J2VET8K9(PON :;I
M.HRQR*Q2!@#WCKPJN:8B%WSL]^EE6&;7N(^U-/\ ^"W/[1-QM9_$7AR+(X"^
M';;(_P#':OO_ ,%KOVCB&*>,](@.,#R] M1C_P <KY;\):TFK30I<11A7. 5
M7D&OK/\ 9S^"7@/Q?I8EUD;7QT_&N'#9IC:\^6-5KU/4KY5E^'ASNDF:7P8_
MX+%_M ZK\4-$;7O&<^L:2EW&;JQM]-MH$GCS\REE0$ CWK]Q?@C\2=#^,'@2
MQ\0:(8S!=H-Z#[T3XY4^XK\,_CA\'_"W@Z?=H$A39RI0U]J_\$,/C3?ZAJVN
M>&+RX>6!H?-C4G(#*<9_*OJ,MK5;N%65V?'YMA*/)[:A'E78_2FBCK17LGSH
M4444 %%%% !1110 5E^-_P#D4-2_Z]W_ )5J5E^-_P#D4-2_Z]W_ )4+="9X
M>AVM[9J97#/P:AI\/WZZD]3A5TB>/O7.3(/[<O#WW_T%=''WKG6)?6+T]A)C
M]!2J"4FV68D/'%6K=2,5!".E6H1P*PEV-[K8N6Z#)(&,U;A0YJM;?<%7(>M2
MM!W+-JIS[8JRBA5&*@M_Z583[HH W/!'_(?B/;!_E7=RR"*)G/W5!)^E<)X(
M&=:B^A_E77^(I#%X>O&!(*P,>/I1?L:Q>AXEJ]XVL:M<W;<F>5FS[9X_2JWD
M>8V!4D9Q$!1')Y;'W]>U=D;1.2;,#Q;8BU (.T$9%<K*2V<5U7C:X^T1+GJ*
MY"68Q@FDW<2UU! T,V:VM$B-RRDFL17,[ Y(Q72^"H?-D8'G%939KKH=#IUI
M@9 )KH_!EV='\2V<X'&\(W;@\50CMEC48&.*G1O)56'56##\#6+9HGT/;@<T
M4RV;=;H?50:?0;(**** "BBB@#PW]MO]EFT_:@T70+6ZUFYT<:1/+,K0VZS>
M9O4#!!88QBOFS5?^"2NE[@1XYU')]=+3_P".5]T^-?\ 5V_U/]*Y+5.JU]/E
M?%6:X*BL-A:SC!7LK1>[OU3>Y^?<0>&/#&<8N>/S+"*I5E:\N::O9)+122T2
MML?&-U_P27T]8SCQU>X'KI*?_':YK7O^"5-G K;?&]TWUTI?_CM?<5[_ *@U
MR7B)"8VP">.U>A+CG/>M?_R6'_R)\^O!7@J+TP*_\#J__)GPGK7_  3"MX7.
M/&<WXZ8/_CM8X_X)F1NX"^,G_P#!:/\ XY7V)KQVR_=W5C*A>;C@52XUSG_G
M]_Y+'_Y$[8>#G""6F#7_ ('4_P#DSYHTG_@E_P";(H'C/'UTS_[975:1_P $
MJIIU!3QK$/KIA_\ CE?16A)M8<5W7AX_NQUK:/'&=QVK?^2Q_P C&KX*\&U-
M)8/_ ,J5/_DSY37_ ()-WS1Y7QO9X(Z'3G_^+KO_ -D[_@GC>_!;]H;PYXCE
M\4V>H1Z9,[M ED\;29C9>I8XZU])6W^K'TJ_X*_Y'"S_ -\_^@FHQG&^<UZ$
MZ-2K>,DT_=CL]'T,L%X+\(8/%TL7A\*XSIRC*+]I4=FFFG9R:W1ZK1117P9^
MOA1110!Y=\?X ]S"Q[1?UJ;X$C8\X]0*;\?/]9%_UR_K1\#F*M/]* *?Q%@!
MO+ICUWYKF;11@8KK/B(,FZ;U8Y_.N3M>@H+CL:EB,JH[GI7C7QH_;+TGX;>/
M;G0EU;3+.XTW F2:91(S$9P0>@KV6Q&5'TKQ']I7_@G+X2_:=\;Q^)+C4;[0
M=6E58[R2VA21;M5& 2&Z,!QFO+SGAS^W,-]0ECZF"3:;J4U>6GV>Z3ZM:Z6V
MN>=F.:9A@*7UG+,)#$U%]B<G!6>[3VNNSTM?K8C\5?\ !3OP-\+M&\'W6N)=
M75IXJ>YB-]821R0V;0#+;DSO8MT&T8'<BJZ_\%AO@9-I\4\FMZ[;0SG$33:1
M(!+QR5()# ' .,\GC/6O7OAE^R_X/^&'@#2_#UAI<<UGI<3HDD^&DD+_ 'V)
MQU;O[<5M3?!;PP;5(GT>R:*(J8U,2D1$=-N1Q^%=^$PLL+0AAG6=9P27/))2
MG;3F:6B;W9U4JM6K!5:].,)R5W&+;C%]4F]6EW/'/!W_  4M^$WQ&\:Z5X<T
M[5-937=9N/LMO9W6E202!\D#=G@ D$9&>0:]AOP.F.AJI/\ "#PU;ZW;:BND
M6?VVR8O;S&%2\+'JRG&03ZCU/K5J[.5S6[-8F5>_+,V/6MSPSF+2I64=8I<_
ME6'??ZYJW_"XSI,O_7*3^518N3T/5/!O_(JZ?_UP7^5:59_A,8\,V'_7!/Y5
MH4S,**** "N"^)&OM?7_ -CB;,-N<OCNW_UJ[;5+P:?IT\YZ1(6_(5Y3<3/<
M.SM\SR$L3WYH$V5)8S(_3CVJM=VQ/4'%:]E9^8PR.<U8N]- @.1GBBY!QET@
M1L'CM5*8X-:VL0JDQ_&L:=R0:N/F9ME:=QOZTPN *)B-W6HG.16J F1@36A9
M0>:!@5F0]173^'X$DC'3C-5L3(A6U9!R"*NV%W+I]Q'-$Q26)MRD5>GLE$7M
M522$#I0]="CV#PGKR^(=%AN!@.PPZ^C#K6E7GGPAU)HM4FM2QV2IO /J*]#K
MFDK,WB] HHHI# ]*_G"_X.%[AY_^"G_C%78D1:?8*N?X1Y(XK^CT]*_GU_X+
M]_L^^(_%?_!1KQ1JVGBPDMK_ $VQ**\Y20;8MIR,8_6LZV#K8F#IT(N3[(NG
MG>!RN:Q.858TX;7D[*[V5V?/?A3Q1+:^"].CC<JH@0<'KQ7&>-)I=7N7S*Q;
M/)STKK-*^'FLZ=X<M(7@4RPQ*C!) 2"!65J'PWUV61W_ +/E.3UR.?UKRJN3
MYE3C_!G_ . O_(].GQIPW7G[N.HO_N)#_P"2/*/$GAB6POH)U?=Y@YI+&*0W
M2ALA>IYKO_%/PQUVY6!4TVX?9G) !Q^M9$?PL\012_\ (*NL>N!7S.*R_,)-
MIT)?^ O_ "/I,+Q!DMDXXRDU_P!?(_YFOX'A47T(X"C+G\*]W^'/BZ33+4*K
M,!TXKQ+PIX'\16-ZC-IKB+8RN7.#SZ5Z;X/TO4-.4++$8P5QM."/Q-8Y?D>8
M*5_8S_\  9?Y'9C.+LC5.T\927_<2'^9WWB?Q VHVN7D((Z9-?6O_!#2X_XR
M!N-C?>@E!]^E?$^H02SQ!/E+'IEN*^Q_^"'5_'HO[3<>FS.#<W5M-(@7D8&,
MYK[3 9+CZ?[VK2DDM;M-?F?#YAQIP_6_V6CC:4IR=E&,XMM]DDV?L512 8'-
M+7HG"%%%% !1110 4444 %9?C?\ Y%#4O^O=_P"5:E97C?\ Y%#4?^N#?RIK
M<3/$*?#]^F4Z([6R:Z$<'0FW%>E<ZI(U2]SWD!_05T0^;&*YW&-7O/\ ?_I1
M/8<5U+\/2K4/054B[5;A' KG;-/M%VV^X*N0]:IVPP@S5R'I2++5N>1]*MQC
M/Y55MQ\P^E6H^/RH W?!(VZU%CW_ )5U/BI]OAN_/86[G_QTURW@O_D-18]_
MY5U7BF/S/#5\ISAK=P?^^34ZVTW-8:(^2_\ AH*SC=D.GW.4)7B08-7;;XTV
M=ZHVV=RI([L*?!\ M#E&\R7P9SN.'[UH0? O1X4PL]_[9*U^,U*/BA&JVJE%
MPOI\.W0^KE+AN2^&5_F<)\0OCWIVC0%Y;.\<*.0NW_&O.;S]K'1E8C^SM2Q]
M8_\ &O4_B;^SWI.JVI5[J^0$8X*_X5Y;=_LJ:(2<WVH=?]G_  KS\1_Q%GVC
M]C[%Q_[<.K#OA-1_>\]_F,@_:ST?/&G:E^<?^->A_"7X_:?XCD;RK*[0CDEB
MO]#7G</[*6B%N+_4,_1?\*]1^$'[.VDZ+_J;R^)/7=M_PK&/_$6E4C[7V/+U
M^ Z*W^J3A^ZY^;_MX[EOBW:00[FMK@@#U%5H_CA9W,J1+8W0,CA!EEP,G%;D
MWP3TV2  W5X3]1_A51O@?I=O*LHGNV:-@P!8<D&NM4_$V5:-YT5"ZO\ #>W4
MXK\.J+5I7^9])6?_ !YQ?[@_E4E166?LD6>/D'\JEK]R6VI\D%%%%, HHHH
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MT(2=Q &"#FL>?QQ^U7X,\-M'>:GXYUK3]2T?0M7U75;7PK:R:IH(F,@OX;*
M*J2R1@1Y1@S#).*^]/%_P9\,:Q'<17FGRRQ7*RK(/MLZ\2NKN 0^1ED4\8QC
MC&3EL'@30(8;E%M&Q>&1I<SR'=YBJK]6XR%4<=,<8KZV$$]V>_SNVB/A6+Q_
M^USKW@*_U&#5/&&B7GAWPQ_:VE6__",6C7'B6<:DT4,=U&4;RYFM2KR11D'C
MH.:ZOQ=\4/VJ_A_J6HZ)<:Q\2[[PK8>(W7_A)M \&6E[K<R2:?'-;P);[?+:
MU^UL\;R!25"@$]Z^T-+^'6BW<\K/9%C/-]H=C-)DOE#D'/ S&G X^7IR:[GP
M5\.=)T62.2U@FA:*)8%Q<RD!%9F P6QU=N>IS2Y'W+;,G]AC4_&WB3]EGP3J
M_P 19=5'C74=)BDUBWO[9+:2"X^;=F-5&QCQE>GIBO9_!(SXQL_]X_\ H)K%
M\,Z':^&M%@L;.,Q6MLNV-"Q;:,D]22>];?@G_D<;/_>/_H)JI+W#GD_>7J>J
M4445YYV!1110!YG\??O0_P#7+G\Z3X%D$7>>X7%-_:!)'E8[Q?UIOP*DQ/-Z
M%1F@ ^(G$5U_UT.?S%<E;X&,=*['XD$+!=9QRY(_,5Y]KGBG3/!F@7FK:SJ-
MGI.E6""2ZO+J01PVZ9QN9CT&2*"DSH]/_A^E:MK]T5\=>'_V[]7^+7[6WA[P
MYX7:'2? >DPZS<>(I+FW6>\O_L./FC8']W$0=W3<<>]?1'[+_P"TQX-_; ^%
M5IXU\ :F^L>'+V>6VBN6B,19XV*N-IYX(-4B3TV#[H^M/N/N5GQ>*]':VGG7
M6=&:WLW\JXE%_$8[=_[KMNPI]CBN'_:>_:B\*?LM_"V_\5>()Y[ZWT_RB]AI
M92XOY4D<*KI%NR4R<ENF*JX':WM8MU]RIM0\;:-:BP2ZU;2["XU&U6[@MKN\
MBAN'C9 ^=C,#P#S]*RKWQ;HR6L$QUK1A!=%O(E^W1;+C'WMC;L-COCIWJ65$
MBOERY/J:WO"ASI$OM#*?TKD;[QEHI1W76]%9$*[F2^B<)N^[DACC=VSUKKO"
MS!="N6&"/(E(/;I4LJ6IZOX5_P"1:L/^N"?RJ_5'PR,>';'_ *X)_P"@BKU!
MF%%%% &!\3-8M]&\'74ES/%;1L4CWR.$4%F ')]:\\2=+AU:*2.13W1@P_2E
M_;N\*W_C+]FO6['3;9[N[>2!UB3[S!95)Q^%?GA_8OBKPG-\T'B#3V4]%\Z,
M#\N*]+!Y>L1#F4[/L=%+#>TC=,_1VTG\H@8P:74=5$<1!. .O<FOSRL?BSXP
MTA@(_$&OP^H-P_\ 6M-?VA?&J* ?%.ID#LTH)_45V/(:G2:*> FNI]EZO<^9
M+D\#K6-=7 3/>OD.[_:1\:HPSXCO#]64_P!*Q;[]IKQNK''B*YX_V4_PH_L*
MLOM+\?\ (QE@9KJ?8\]T"W:F>=GOBOB>Y_:C\<[SCQ#-_P!\)_A4:?M0>.BV
M#XCN?^^4_P *I9+6_F7X_P"1FL-(^X86ST.>*W='NVA5=I'N*^"[?]I'QM)C
M/B:_QZ!E']*L1_'[QI,"#XGU;!'02X_I5K(ZO62_$KZI)]4?H,E_+.!D=:BG
MND1<NZ1CK\S 5^?DOQ'\6ZP=S:SXAGX_AGD/'X4VW\.^*O$<GRVWB&\+=V$S
M@_G3EDKBKRFC6.!?61^A_P ./'NC1_$+3K$:I8F]N6>..!9E9W.TG@ Y[&O:
MQTK\[?V(?@3XJTK]HGP[JU[I%Q965E)(\LEP0C$&-AP,Y/)]*_1(<"O(QU"%
M*HHPE?0BK25-I)W"BBBN(S$89!K\\/\ @H]_P3A\2_M+_M'7GBC1]<TFTBDL
MX8/L]RK;@47&<CUK]$#T->9_$0[?%EQ_NK_*N[+\95PM7VM%V=CYWB?A_!9S
M@OJ>/BY0NGHVM5Z'Y97W_!&GXKPIFWN/#ET ,C%T4S^8K U?_@DG\9]/5L:=
MHTBKR-NHKS^E?K79 &U7('W1UKYX_:S_ &Q8_P!G_P"(^GZ%+IU],MY"DB-%
M:M*MR7XVJ1W!XP*]+,.-LPPU+VM.C*L[I<M.'-+UM=:+=OL?FN)\&.$:4?:X
MBI*C'O*HE&[V5VGJ^A^>&J?\$W/C!I6?,T+3^.NW44K"N?V#/BJC$'0[7(/_
M #_+7T_^TG^U)\8_A_\ M%Z[#H?@^[U[P1;:-!<VL(T^-4MYF$9D=Y-XDE8;
MFQ&I4C'/8GSN_P#VW/C+ BSW'P7=/M"*R1QS-));G>JL)0'P<YXP?EP<YQ3G
MQ+BI^\TON?\ F>GA_!W(Z<;1J5/OC_\ (GEVF_\ !/SXL7A 30[,9];]172Z
M+_P3!^,.K, ND:5'NZ%]17BO0='_ &Q/C99P&[/P@M)+<R[%MENF-RJD'Y\^
M8%8+C)QURH&,U]8?L5_$KQ7\7O@Y8Z_XR\/)X5UJ[EE5M-"D-"J2%58@LV-P
M .,\9K2EQ-BUHE'[G_F75\',CGK.=3_P*/\ \B?&^D_\$>?BW>;3.WAZV!ZD
MW>_'Y"OI/_@G+_P3>\6?LV?M(V?B?6M8T>Y@@M)86@MMQ<E@.YXKZSTX8@7M
MS6WX&.?%\?NI_E58S/\ &5Z+IRM9K6R*RGPFX?R_%T\9AX3<X---ROJO+0]&
M4Y&:6@# HKY@_5 HHHH **** "BBB@ K+\;<^$=1_P"N#?RK4K+\;?\ (I:C
M_P!<&_E30GL>'THZ&DI1T-;HX6K(GBZ+]*YYO^0S>?[_ /2NABZ+]*YX_P#(
M9O/]_P#I1/84&]B[%VJ[ X '%4HNU6H.<#Z5SFUM;E^!@W/8U<AZ'%4H%* @
M@@KG.:N0'/0]:"K%RW^_5I.M58%*O@]15I.M)L#=\$_\AN'\?Y5U7B49T"^_
MZXM_*N4\%G&M1?C_ "KJ_$O_ "+M[_UQ;^5$36#T/$+5L*OO5M&POK52V'RK
M5D'"?A75)Z(P1X]^T]^T)I7PB:"UNKFQAN[B,RA;B4(-N<9 )!/->&^+OV_?
M _@GPQHVJZI<2O::QK*Z*]Q:E98;.5HS)OD(/RK@8'4DD "O2OVY_P!B_P -
M_M9:59'5+J]TO4],#1V][;*K$(W)1E;@C//M7(_"+]C+P+\&?A_:>'K73?[3
M2WN#>O=WN'FGN#MS(<<*0$4 #H!CN:\*CPWB:>82SAYI.<)>[]6=-*$=-)*=
M]^NUW>ST./\ M#$RJO"3PD8TUJJO.W)^7):R^^W4XZT_X*G?!''F-XHOXH_[
M[Z1<A<C[XSMZID;@.FX>M>R_LT_MY?#/XP>,;#0M!U'5Y]7U)BL-M/I$]NQ
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M5AW!KQKQ#^R=\-KZ96/@W1X'P &M@]L0%.0/W;+T/\SZFM(Q;V(<K:GY4?\
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MX;!/*Y]JJ2:92U1K?##_ (*[Z;=:E\<KWXK7>E>'_#OPV\5)H&D36%LTEQJ
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M&--^\W%?[/#5K=+]WNK.ZZ:G'/)\K5[O;7XWM]Y](V?Q:M)0I7P_8+]9'/\
M6M"W^*,$C #0],R>F0Q_K7BOP^^,/AOX@ZS/IVBZDE]=VEI;WTJHC!5@G7=$
MX) SN'..HKN[)MDJ'T/2O>CQAGU.7LL7)1EIHZ<(O7;[!PSRG!2]ZFKKU?\
MF>]?LY>,1KGQ"C@_L^RM<1.=T2G=T]<U[KXG_P"1=O?^N#_R-?-_[*;;OB;&
M?6!_Y"OH[Q4<>&K_ /ZX/_*OZU\(,PKXS(?;8B5Y<\ELEV[)'YIQ/0A2QG)!
M65D>(6^#%ST _I7X_?MS> +'XA?\%?/'UKJ?A:V\2VL=EHC,9O%B: ;!650T
MJEG43$#G8,GCWK]@+=@8OK7B'QQ_X)J?!']H[XDR^+_&7@FWU?Q/>")9;XW]
MS#)((@ GRI(%^4 =J_6)[(^5BC\\_P!IG_@I?^T+X;UO]H:]\(>)/AK9^%/@
M!K+I]@U6V7[=JMFMPT*0Q-GYFV@$L>2< <FO*+C_ (*!6W@W_@H%X\^.(\'6
MDMX?@18>)_LXWK/)/.EFJPL<X\H/(,G&=B^M?6=O_P $0?!_Q"_: ^+GBKXR
M:#I7B'2/$GB>36?#:V>IS120V[R2,T5P$(!!!CRISTZBO9Y_V"?A1%\7-6\<
MMX6M7UK6_#:^$;R.20M8RZ4L:1BV^SGY NR-1D<\4>9,FMCY:_9D^-_[7OQZ
M_9_U'X@IXK^#,D?B+PI<^(?#>CV%O]HOX+B-B8[>1.!AU5E)R2K%1U-3?L2?
M\%A/B?\ M;1WKZ#;:;ID'P[^&MWKWC1Y=/SNUN,RJL29^Y'D0\=\OZ5[K^S7
M_P $N?@[^QKX[U/QK\,_"EW:>*WLIX;1;C6)Y;=-X)$"JQVHC,%!+;L#D5:_
MX))_\$WYOV</@7\2K'XFV^CW_C#XQZO>7OB:/2Y_]&BLY-RQ6D4B@$*%>1B1
MC#2>U<U=^Z:T[,L_L:?M=_&#XX_&[1/"GBWQ#I%O:>,/!:>*;&YTRP1);'$N
MS#!L@EN<]NF*^Z[LYB/U%>?_  [_ &3/A[\*/$VC:WH&@QV6J:)HPT"PN3=2
MR-#9!MWD@,Q!YYR03[UZ%<1YAZ]ZQAV-&>O6O_'K'_NC^524RU_X]H_]T?RI
M]=!04444 %%%% &'XU_U=O\ 4_TKD=4_UBUUWC7_ %=O]3_2N1U4_O%^E;TM
MS*ILSS'5=-\3:,+^XT^WE#-+(7\Z;SQ.K3 JT<>3@K'D8XSD<'%8'B35?%OV
M*5C!:+*#A4^RE@0(-Y/W_P"*3Y1Z>]>N7C8CXKD_$IRK'VKYJ/#'LYWI8FJH
M_P JDDNO1);WU[M7=WJ=TLVYK<]*#?>VO3N^G3[MCPWQ/XK\16 VR6"/('90
MR6LC"X^9,  $[,*S')R#MK%UC4-5M_"=O()+]+G[7)O$<1,CH&;:N0K;<_+@
M[2#P#C.:]+\1?ZQJQ$8F2NU9'7<9IXF;O'E5^FVNC5WI;IIO=MMW#,*=XM48
MZ.[\_+R6O^6RMD>'/&NN7U[<16EFKF*4PX>V?]QAD&YFSM<_,V57&-M=UI_B
MGQ'8M>/]DB9+4857M619&\T(JJY;#;E(;@<=*B\/1K"X"JJAFW' QD^M=WX?
M'R+GG%9RR'%S@^;&34M=5LM[:=;7OKH^R5K;+,:*>E"-O^&Z_P"6OF];]'IJ
M21V,2RL'F5 '8# +8YP/3-:7@KCQA9_[Y_\ 035"V_U0J_X*_P"1QL_]\_\
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M\VWD_>&/;]:](\,>-+^.1?+TLM&LFP*,[B.0/;M^M<UX8L8X+QG6)%>7!=@
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MTWXO_P"16U#_ *]W_E7R[^QO-N^+:CGFUD_I7U%XN./#-_\ ]<'_ )5_H3X
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MUK]C #_AH;2_^N,O\A7DUO\ ,%QVQ7K/[& _XR'TP]_(E'Z"OF>!/^2DP/\
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M7SR\'>$D_P#=;_\ ;\__ )(]3_7O.WI[;_R6/^1XII_[&MN3^\UN< =Q"/\
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M<_\ C"G_ -?*GZ'XKQW_ ,C;_MV)^6VN-C4IQZ.1^M4FZ&K6LNQU.XSWD/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>lasercyn.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 lasercyn.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" %[ 1(# 2(  A$! Q$!_\0
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MHHH **** "BBB@ HHHH **** "BBB@ HHHH S?$N'@AC/(>09'K35MVD3 &
M!Q5C5.);<G!!?&/PJ2@#"UO2I9;0EL#;[UYMXOC,%C<P# $A&3W%>M:T2;8J
M.AKR_P =Q[@X'85+T8'C?BJ$QP[!T#9KT;1=7@U+X):3;K-$T]E<.KH&&X#L
M<?C7G_CA2L;8Z@FK7@2,V^D,Z''RX/T)%9R:1I#<^E/A+=-<^ K LQ8J&4$^
M@)KI*Y/X+L6^']EGU?\ ]"-=96D=C-[A1115 %%%% !1110 4444 %%%!X%
M!17,:[\4;+2IGBABGO7C.&,8 13]362_QJ<.<:9Q[S@'^5-(#O:*X:W^-"%Q
MYVGS*I[QN'KK-#\0VOB*S$UK)O7H1C!4^A%%@+M%%%( HHHH **** "BBB@
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M<K=77?\ >MG_ +ZEKK= 8!_^!' _*E)78T>YVUS'>0++$ZR1N,JRG(-/K"\
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M'98\C<15G5O^"F7P,M)S')\0]+$@:5"JV]PQ7R\;F.(SA2""K=&'*DBM ?\
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M3XCZS2G_ ,B-714S,**** "LKQ;J M=.\L'#3<'_ '>]:M<GXPN/.U79SA%
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M^)E4?@04445)J%%%% !1110!@_$KGPA<?[R?^A"O$[#_ )#$G_7<5[9\2O\
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M^/M6_7/?"IBWP^TPGJ8S_P"A&NAH)"BBB@ KC]>_Y#%Q_O5V%<=KW_(8N/\
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M</VQ_P#@L'\$?V(/CE9> O'6KZTNO7=C_:=U_9NF/>PZ3 P;RFN&4_(9"IP
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M8)2CAXV3W_']6W_P#DQF+JXAIU'>VQV_PDYTR[/K-G]!76UR7PC_ .03<_\
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M]#7I_P 1VV^&W_ZZ+_.O/7MO/M3Z#G-)F4OB+A8MH<8]$R?RKRGXA#&KP?\
M7+^M>I7,GDZ.H[E<5Y=\2AC4X?\ KE_6OG^)O]P?JOS/8R?_ 'A>C,:/J*T;
M?[HK-MAD@>M:< Q@#Z5^9SW/KD2ZLK2>&=15 S,UG.%"]<^6V,>^:_&;X"_
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M";Y[[1KYGQQ<8&.@^45W=>??L]\Z#J'_ %\_^RBO0:JE656*J1V9@Z?(^5]
MHHHK004444 %%%% '/\ Q)./#C>\B_SKC=/A$EK@#D@UV/Q*;'AWZRK_ %KD
MM"P7"XSG@T,RGN9.L70BM43J>E><?$E]VI0G_IE_6N[\1[X+MD/ 4G&:X'XA
MG=JD&.28OZU\]Q/_ +@_5?F>OD_^\+YF3;<;36G!SCW-9MLI.WBM&W.,#N*_
M,Y*[T/KRX;&'4+22WN(HY[>=#'+%(H9)%(P5(/!!':JFC?#+PUHUK';VGAW0
M;:WAA%ND<>GPJJ1CD( %X4'G'2M&V!&/8U;A')/I4-26HTDR&U\.:=IT<:V^
MGZ? L8P@CMHT"?3 X_"II)7MT(1B@QC"_*"/PJ9W55!9T7 _B8"LK4?$NG6L
M3-+J%E$!Q\TRC^M8U,1"&M227JTC2%*3?NK\!EV<FLV]^Y^-5M3^)&@6B$OJ
M]AQV64-_*N:U3XX>'(1@7DDI_P!B(FN&KGN6T=:N(@O62_S.B& Q,O@IR?R9
M@?M.M*OP>U#[/$\]R;BV$,:$!I&\]/E!*L <9Y(Q[CK7U=\+6Q\+M)!!#?9N
M1Z=:^3-4_:*TJ$GR+6\FQ[!/UKZD^">MCQ!\'=!O5C,8NK,2;"<E<DU];P!Q
M'E^/QU3#8.JIRC%MVOM>*WM;\3Q>)<MQ&'P\:M:'*F[*_HSU;PFNSPU8C_IB
MM:-4/"O_ "+EE_UQ7^57Z_5SXL**** "O+O&PSXHO?\ ?_H*]1KR[QK_ ,C5
M>_[_ /05X.?_ ,&/J>EEG\1^GZG(W>6N7QZUFZ@,IQUS6G<?\?3_ %K,U XC
M)]*^:/8D]3B_%70UP6J#+_C7>>*&W!JX/5>'S[UTTC%C+)=K+]:ZWPVN2I]J
MY.Q;++]:ZOPV3D#VKIE?E-$M#M](X6M%ON5FZ1]T?3^E:1^Y7*W<KH>I?L_?
M\@"__P"OG_V45W]<#^S^,>'[_P![G_V45WU?79?_ +M#T/G,3_%E8****[3
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M0M/V-=.)'F:Q?./18U6O9A:\YP*EB79U%.'@]P?%W^I1?K*?_P D0^-<Z?\
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M.N5>.2[!+,V/8T@-FY\2Q9;:>_8U1F\1(Q/!)JK'I<2C)!)/J:G2)(1PBXH
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M\5?%VMR!;724@!Z&3+D?@ !^M;&G:1\0_$$P"S+;HQZQP= ?J: /6M)UT:;
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M%9&H:8)688]Q70-'QZU&;8$]/TH X;4O!XNE/R]>M8E[\+1>@ (,#]:]2DM
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C **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>regenacyn.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 regenacyn.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" %, .L# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]_**** "B
MD8X%<AXT^/G@[X>AO[8\0Z99%/O!Y<D?4#-95:U.DN:I))>;L73ISG+E@FWY
M'845\\^)_P#@JG\"/"5R8;SQ]IXE!VB.*"65V/H%523^ KMM#_:_\#^(M)M+
MZTU&X>UOHUEA:2SDA9D/0E' 9<^X'KT(KR<1Q+E-"'M*V)A%7M=R6[V6^YV1
MRK&MV5*5_1GJ%%< O[3G@L_>UA(B>SQL/Z5:MOVB/!MTI9-?L2H]20?Y5SPX
MPR*3M'&TK_\ 7R'^8Y91CHZNC+_P%_Y':T5Q\/Q^\&W#$)XCTLD=09<8_.KD
M7Q@\+S_<U_2FS_T\J*UH\59+6_A8RE+TJ0?Y,SEE^*C\5*2_[=?^1TE%8L'Q
M&T"Y'R:UI3?2Z3_&K$/C#2I_NZGI[?[MPAS^M>A#,\'/X*L7Z27^9B\/56\7
M]S-*BJ2>(K&3[MY:,/:93_6IEU.W<<3PG_@8K>.)HRVFOO1FX26Z)Z*B%Y&>
M1)&1_O4HN%_O+^=:*<7LR6F244PSKV9?SIRN''!!^AJKH!:*,Y%->14&20!3
M =141OH1_P M4^FX4QM3A!XD7\Z +%%5UU*%O^6B_G4JW".."#GT- #Z*0."
M:6@ HHHH **** "BB@]* .6^,_C.;P#\.M0U.WC26: *%5C@'+ ?UKY<\0_&
MG6?$TC+(;2W@;^"*!/YD9KZ(_:?.?@UJP/\ TS_]#%?)WD^9(%&1NZGTK\"\
M6,[S'#YA3PF%K2A"4$VHNUWS26ZUZ>A^E<%Y?AJN%E7JP3DI-7:OT1)I6F6R
MWTE^+:U2Y<G]\L*K)_WT!FN5?4#-KNI>8'<_:6Y8$UV;Y2,    8Q7 &65-9
MU'##_CX.%#?K7\^\<1DL'2@VV[N[>M]#]#RU)SE9:&DMQN.!N&<<CC\_6AV&
MW)P,<AA_#]15..[#R$@D<X.1C!Z<_GVI8YSSURI((_S^'YC\/S*<E_7]?UT/
M946/NPETI3 ) _''J/4>U9Y06^,@8;D'U%7"ZL%/=>@'\)QV_P ]_>H+U5N4
M8X"N#R/?OCV/^>M>#F6#51.<=_S.BE4?P]"!F!;/;ZT>9Z,1]#BH-^>1R*5V
MV\'@^E?,\CM>QVI(M0WSP !79<=,-@U+%KMU"V5N)>F/OGBL[<1WH\X5O#$5
MH6Y)-6[-DRIP^TKFHGB;4(UPNH7JCT$[?XU*/'.L18"ZKJ  ':X;G]:QMV>]
M&X^M:PQ^*CI&I)?-DK#TGO%?<C:'C[6QTU;4?QG;_&MGP5\:/$7A;Q+8W<6J
M7<@@E5FCDE)21<\J?8BN+$G/6IK:0>>@.-I/->AEN<YA1QE*M3K34E*+3YGN
MFO,RQ& PTZ<H2IIII]$?H3X$\?1^+[-'0@EQGW%>2Z[\7]1U/7KPABL:S.B+
MN. JL0/Y5-^S!<M-H\?)P ,<^U<1"^^_N#ZRR'_QXU_K54J-5(176_Z'\K4J
M<90DVMK'7V?Q%U$N,R<YS]*V;'XC7_F[C)S]:XBR_P!<:V+%1MYZDXKL2.6Y
MVEO\0+RY #LK5HV_BV58&<@ JN>.W%<C:P[%49[^E:K#%A.!U\IL?]\FI&=M
M\/O':>+[!75@3C(/K74*<BO#?V7+AI=+B#DG !ZU[DGW10 M%%% !1110 44
M4'@4 >=_M/<_!W51Z[/_ $,5\KV<627]L"OJC]IT_P#%GM4/^Y_Z&*^49X[J
MZ3[-:O)$P02L\:!F49P!SQSSS7X'XEX*IB<^HTZ47*7LU9)-MOFET6I^F\'U
MHT\NG*;LN9ZO1;(EN;CR$+-C%>9^:9-8O\<L;D@8]/ES^A_4>E=K/>RRVCQ2
ML#/"VV4A<9[@X[9'4?6N'M9<ZMJ!!7_7-@?R/XMC\!7\W\>5WRQI2Z-_?8_2
M,J@K-]T7S)YH&2?W@P2>K?YR?SHM[HOMR<ETP?<C )_')J Y\PMR%4<#^7Z
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M?)>,N93>D7&48N\M'LUJ>/G\Z=/#QQ%2JJ;IR34FKJ]FK-;NZ;6FO7H/\*_
M3Q$^MP27ML--MK>19))I)5^10<D@ ]>*Y_XMZY;^(_B-JMW:L'MY)L(XZ.%4
M+G\2*]3U3X"ZYJ]KY-SXONYX3U1T<JWU&_FO(/'7AP>#_%%]IJ2M.+-]GF$;
M2_ .<=NM?:^)'"F)X<R*&"HX&I0P]2K&4IU:M.I.4U":C%*GI&,8N=W:[;6O
M0\SA[,Z688QU)5XSG&+248RBDFU=OFU;;2ZZ&%=8')ZUG7SX7\*NW!+')!!K
M+U%S@G(Z5^(4(W=C[E'/Z_+O=L=#S7(W8S=?D/UKJ=9DPI)-<O<$"<'(%?49
M>M$D:1/N+P2O_$EM1V\E/_0171P#CZUS_@L8T:V'81(!_P!\BNCC3<1BO]/L
MC5L+#T7Y'\I9N_WS?F7E&Q .P&*MP*4/;FJJ#(':K5O(0>:]M'D7-2P_U K1
ML_\ 5FLRS=BF,8K1M#QCM4M:C+5^-VB7@]8)!_XX:S?V6&_XDD..G%:5XW_$
MJNAZPR?^@FLO]E3C181Z8I >XKT%%"]!10 4444 %'2BCK0!P/[2)S\)-3P>
MZ?\ H8KY5U34)8K=8+.2Q2\D!E/VE693&N,J O.23C/;DX-?5/[2?_)(]3'^
MY_Z&*^36N88=4U"25&5;.U1S+G"@$.3^0%?@_B9EKQV;T\.KV]FF[.VG-+];
M'Z1PE5C#+Y.3M[[_ "1F75Q'=VXFMY&,+_-&R_> _P 1_2N&MH!/KFHG9+<,
MLS?,_"+]:Z;P+J8USPC#<^4T2/++L .3MWG!!_']*YFV8S:S?D++-MG)W2G;
M&O\ C^=?RSQY@:F$MA:RM*,K-73U7I>_K9KS/U#**T*M-5:;O%K\'ZV+C8>)
M23Y@<CG&#,1V'HHJ16QC# -(22<<;NY'LHZ>],WGRBY?>3P748S_ +*C^M1W
M4P'[H?>X#$=% Z(/8=_>OS>=:-.//+^NW]?.[UOZRBV["3R"24E00H "CT I
MF,T#@49S7S=2<IR<GNS9)!7MWA#6-0\-_L\P7FE1B:Y@D9V41A\+YOSG'^[7
MB-=]X ^,</A?P+J6B7D,K)/%+]FEC&=C.I&&&>A/<=.:_6?!SB/!91FF*>-K
MNA[7#U(1J+>,WRRC9]+\MD]KV/FN*<OK8O#TE1AS\E2,G%]5JG^?W'I^K>,=
M5M/'N@)!$;G1-<@&X+%DPOC);?\ 0C@^]>'?%VQGTOXAZM#/.]Q+YVXR-]Y@
M5!&<>@('X5Z;\,OCWHNG^"K6SU:>:"ZL(_+R(RPE4?=(([XXYKR7X@^*AXW\
M9ZCJBJ4BNI/W2GJ$ "C\<"OTKQGXFRG-N&\/7PV-]M4K5555/FNZ2=*TX-7T
M2FKI-*UVHZ7OX?"678K"9C4A*AR1A#E<K?&U*\7_ . [V[*^IS=PY#'.36/J
MC (WN:U[@X+#M6/JARO'K7\UX;<_3$<WX@D 3@]:Y:YN +A >I('ZUU&OH,'
MT%<=J_RR KU'/ZU]9EL59(I-W/M!/BQIOA+3"DT<K-;IL'F,(Q(RC&!U/.*I
MVO[6-FRC&AW0/8%CS^E:W@^TM]7MTU"Z@BENKM%DE;8 ,D#@#TKK[2>VLE&R
MV@Z=D%?Z;Y5:=&,J;Y59>9_*69)1JN-365_0X5/VJ?,QY?AJ^D/L&_PJ[9?M
M+WM[+LB\'ZJS^@C<D_I7I&G>*)K$!H5CC8=,#'%:%MXZO4D\Q6VN3DD<&O:Y
M'W/+<TWHK'G]I\?M:  ;P7K*@]S _P#A6UI?QXNI"HE\,ZE!GJSQ/@?I7>VG
MQ'U-T"M<R;?=LU=M_%4\H^8JV?:E839R7C_XOV_AKPK"T")>7>JQE(EA+$6Y
M*X._(X(S]WJ:Z;]EW3Y+71XO,5AC')%1^+/(\0>%M0AN8(740M(#L&5*C<"/
M?(KJO@9+!/X=@:+;T'2D,]%7H**** "BBB@ H)P*** . _:2Y^$>IG_<_P#0
MQ7QO\4KF\7PN]O9K"/MK&*X>16/R8X QW]N_2OLC]I(X^$FI_P# /_0Q7S1_
MPAM[<R!&\M%894EN&'K7X[QAC,5A.)*&,P]#VW+35XZI.[G:[6VJNNET?>9%
M0IU\GJ4*E3V;E)Z[](WTZZ:?,XGPQI*:!X:M;)5*"WC *K^9_'_Z]<< 9-6O
MPJRR 7!PTIP@/K7J_B7P;-H&G_:))X2<@%%SNR?3V%>17#.=<OP[,V)R0"<X
MK^2?$^>*I5/:8Z'+4G)R:T^T[^=NNA^KY%[)TE"A*\8I+[K+YER:X,9.&$DI
MX\P=$'HH[?6H(@0W.:3<?4U*@ZU^)5L1.H]=NW]?GN?1Q2BAU &*.:*YVP2"
MO<?@)X"TG_A!4U:[M;:YN;EY,O<*&6)%., '@=,DUX=7NWP%T!]:^%5S;W%R
MTEA?M+#Y(7:T.>&(;WZXQQ7[S]'7"TZ_%,U.A&M*-&;CS6M&2<;-WOO?ENDV
MN:]MSXKCNK*GEJ<9N"<XIVO=K6ZT^_Y'1O<^#G&2?#G'M#7S[\7FM(?B'J?V
M'[/]E+J8_(P(_N+TQQUSTKTZ?]D_3\G;JUV >Q@3_&O)/B)X;C\&^++W2XY6
MG6T8*'9<%LJ#T_&OLO''$<1U,FHK.<LI8:'M5:=.<9-ODG[K2U2M=W\D<'!=
M++HXN;PF)G5ERZJ2:25UK^GS.=N#N#&L?5.%X[5K2@\UD:EG&/6OYHPRLS]-
M1SFMC,9KC]579(.^3_6NRUH$(01C%<C>2#^T(@?X77^8KZS+%=I#;L?;7@8>
M7X?M5/!$*9'_  $5T60%ZC@9-9_A=?*M(MJJ25Z$=<UT<5P8"6&=O!QZ\8'X
MDU_IAE%6,*$8]E8_E?-:;E7<NY#$P$2\CI5ZT<!#P03_ "IR2.(E3=R%5 1Q
MD]Q^%7DNFDE^1F^>0%>>,#J?IQ7M+$JUK?U_7YGE>R["6P#KUQWK5LP-A^8#
MVIFFS%C&=QV'<3SQC/%7K&1V4<G QU_W3_\ 6K/ZUMIO_DF5['S"Z .B:@.Q
MMI/_ $$U>_9BNFDT",%NBCBFW66T2]/7=:R=>?X*K?LLOC1H@3SM%:QE=7,W
M&VA[>.110O0450@HHHH *#THHH X']H]&E^$NIJN=S% /KO%?-S>%]:U%B9/
M..!PSR\?SKZ1_:2)7X2ZF1P1L(/I\PKY>U#6[R=%4W,P  7"N0/TK\*\3Z^#
MAF$5B^=W@K*,E%/WI;W3/TG@ZG6E@I>RY?B>K5WM';5$.O>#+O3--DNIWB*I
MCY0^YCDXKR*XP?$>H9Z>>U>F:K/+=SLTLC.< <GVP*\RNO\ D8=0]?..:_D[
MQ.GA9TX/"0<8W>[NWY]+=-#]2R6-5)JL[R\E8FV#WI\?>FTY.AK\9/<>PZB@
M=**FV@D%=[\)=1\8ZK;G3?#]SY%G;L7=W1?+B+>I()R?05P5>U_#O73\//@"
M^KV]LEQ.TSN5)P"2X0%L<X %?K7@UET<3G=2M6Q-3#T:-*=2I*DW&;A'EO%-
M:V;:;LF[+36Q\UQ5B)4L)&$*<:DYSC&*DDU=WU=_F5->?X@Z+K=IIT6LP7MW
M=V\MPJI"BC$>,CE>ISQ7CWB35+OQ!KMS=:B2U[*W[W*A3D<8('3I7O>K^(I5
M^)_@FX,0D?4M/E1@.!&7"$L/8$5Y-\<[)+#XIZHB*%61EE( QRR@G]:_1_&C
M)G#+JF+P^+K5*5+$1I^SJ3E-+FH1J0DN:^NLKZO25M+'D<(8I/$1I5*4(RE3
M<N:*2O:;BUITT5O0X6X!#, .*R=1YB_&MBX;YF]JQ]3.% ]>:_G/#[GZ,<UX
MC<HCGOCCVK@-3N)!JEO\P_UBY_[Z%=]XB(8,#]*\]U7Y=9MN5'[Y,9&?XA7V
MN0P4JD;]T3-^ZS]!?#*#[%&2,_)SD]>/\,_I6]*IC5B^1MY..H.!G\22![5Q
M=QXADT&VMUB1-\_0NA8$@@!>HQD]^<=\UVEK*D]M')SM<*WJ3GD*/5CQGTK_
M $5R;&T:KGAX/WH)7\KZ_P!?U;^9LSHSARUFM)7_  T+<<>W:.#G"8'';.T>
M@'<]ZM6ZF4#"A@PX _C'_LJ#]:@CB)$:G&[A..1\S9;'X8KQ[XD_M9:;H'C#
M4-*A++]AF-O*ZW$*[V3@C!.< YXKS.->,\%PS@5CL7"=2[45&"3DW9OJTDE;
M5M]>M]<\IRFMF%;V-&RLKMMV2_K^O+W>TRR#^,,/F)&T.!_)!^M:EHQ,8&<@
M_>R,-@]S[GL/2OG[2OVT],T_X>^*M:N[#5-57PII4VLRVVG+'=7=Y'$,LB(K
M?,W(P.!4'A#_ (*D_!S7/#6BWMYXAN-(GU:VAN/L9M);UH#(H<QF:V66%Y$0
MJ\FQV\I74OM!KNX5XBH<09=3S7!1DH2OI)6DFG9IJ[U7DVGO?J<^98">"K/#
MU;-KMK?M_7_#'TO,P?0[XG@^1(/I\IJC^RR=VC1'V%>?>$OVS_AG\3'NM)T+
MQ*M]?O;R+'"+&YCWG#* "T8&3PPYY5E;[K GT+]E:/&B0^RBOLH1:BDSR).[
M/<EZ"BA>@HJB0HHHH *#THHH X+]HT9^$NJ_[J_^A"OE";+$<G%?6'[1G_))
M]4^B?^ABOE"Y!20BOYU\85_PHTFOY/\ VZ1^J<"V^I37][]$5+L MGVKS2]'
M_%1ZCQSYQKTNY%>:W>6\1:EQ_P MC7\L>('^ZT_7]#]-R_XV24Z/O3:='WK\
MD/6>PZBBBI;$D%>K? ;XH6&D:1+H>JRQP1/(7ADEQY9#?>1L\ ?7WKRFO7_@
MU\)= \8^!H[W4+-Y[MYI$+"9EX!&.!7[#X&4L[GQ,GD,J:J1A)R52_)*%XJ4
M7RIO6Z:MU5_(^7XQE@XY<_KRERMJSC:Z>MGJ=WK'C+PYX?MUO)KW3\VT92+R
MF1Y O]U .?3@5\W>/O$[>,_%U[J3*T0NI,HF<E5  4?D*][/[.WA7G_0)EST
M_P!)>N=^(_[-^EKX?N+G1Q-;W=LAD$;/O67 R5YY!QWK^A/%S@[CKB/ *+I4
M(4:-ZCITY3<I24;7O*$4VHW26GS=CXCA/.,CR_$:3FYS]WFDDDE?:R;W>[/!
M;@8W5CZKT6MB?D''I63J(+1?0YK^+\/N?M)S'B"/;&Q/4\BO/=5);7+0!D ^
MT1YSV^85Z-XD7,?X5YWJ%FTWB&R"A<&YC)_[[%?<\.M.M"_=?FC.K\#MV/O'
M4FL[/PU<WUW"TBV,1?8K[3+T^3/4@G Q_*I$\2^,IH8!%X4L8#(H^1M14-&O
MIC'R^])J=B^I>#M4AB$;/+ 44,XC7=_#N8\#G!!HCUGQXMM$)=)\-G<!N7[6
MVZ0_WL+G.:_N#%3J0Q:4)UH1<4VZ--2N^9KWY.G.VB7*M.N^A^!.$94]H2:E
MM4FU;1?"E*/G?Y'=PL1'$V !M"-M^Z./N+W)]Z^*OVMO^"7VH?$+XJZKXI\(
MF"Z&MSFZO+)[I8#;SMC=Y9;AE)YQG()-?;*HY6,.-LFT913EAQST^Z/\YJQ:
M,4)(8*JC:&7HOL@[GW-?K^4YK5P%7VM))NUFI*Z?JM+/YK[C\GXJX3P'$.$^
MIX^Z2?,G%VDGY/5:K?1_>?+'[(W_  30L/A5X.\3_P#"7/9WM]XLLQIES:;5
MNX(+7<'D5MWRLS;0#C@8&#GIZ[X=_P""?'P]T"\@N-/\.>&+":.U^QXCT2$$
M0B.>-8\C!X6903U81 $G<:];L(C+. %58XQR,@^^,^O<_05MVB;AU%:8G&5<
M;B)8JLDF^B5E\EV7W]7J;9)DF$R; T\NP*:A"^[NVWNV^K>_;HM#SGPQ^RIX
M0^&>EW4^C:-I6G):>=>QK;VFQ@^P\Y#=>O;I@8P *] _99 &AP\?PBK&N''A
MK5/^O.;_ - -5_V6AC0X/]U?Y5!Z9[91110 4444 %!.!110!PO[0XW_  HU
M3/HG_H0KX[^)GCK3_A9X-OO$6JI<S6%@8P\<&/,<NZJ,9XXSD_2OL7]H4?\
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MI&II&+4X7L]6M=&?B_#W[NC/$RK5(6E9*$.?>.[]UV[+T/H"V1(;:-8O]6J
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MZ-H%G/?RW+6\N_*IY:+DRL=P"9<[5P#D(Q (88L7NL_$VWMGCAT/09[JW?\
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M6L:_^+?AS0%O8[_4TL([*[6PD-PCHTT[1K*JJ2/F!1@=R\=>1@U_4M/X5?\
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=2^E'E+Z4ZB@!HB4'I3@,444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>reliefacyn.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 reliefacyn.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" $U -0# 2(  A$! Q$!_\0
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M=M./RK.L_NBM"#_4/_NG^59LHL_!;QZ_B[1T+G+ <_6N^KPS]E><G3V'J?\
M&O<D^Z* %HHHH **** "BBB@#@OVD"?^%4:@,<%H_P ?G%?(6KZN9-<>U4DQ
MJNUEV=&QG.[/Z8KZ\_:2 /PIO^#]^/\ ]#%?&&L$P>/FRPVS1D@%_P")<Y^4
M>Q'7GBN'$*[OY'D9C\7R.;U]B?']ICH;5\_]]"M$/M.2:R_$)(\<V6.]L_\
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MM>?MXZI_P4,U^'1]#^$/AJVU*[<"TN+2R>_U]QZ><@7CU&PC^=6O#G_!*?\
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M3_:6'>S_  #_ %EP'63^YGM>K06UWX?NVGMX6^SIYRMMY4KSQ7J/PEO[>_\
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MH:[L):*;D[7\[:'U^4.,:<W.5KVZ\NFMWYV\M3]C[5S.BL,8<;L8QC-:5NN
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M67P,\'L,FOD?]O#]C:Q_8.^)7PR?X=>,-6UC6M=@^T17 EA6:TO8WC56B:/
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M5K&URMD'FU*%%,[(LBQ EN7*.K8ZX8'H116QM:47"RU"OFV*G%TVEJK;&AJ
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MN#5Y,\R_:\_:1\#_ +*WP+U3Q)\0)G.A3L=.^QQ0>?-J3RJP\A(\@-N4/G)
M"@DFOR*'A[]E?PEH=G\6O#>J^-_%5II/B.UM8OAQK-W;V4L&YVD5RP#O/;(
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M+:[O(-1G2.ZMW$US$TQ25O,A;) G<;?N=#MSDFX<FTPY8/XST?7OVUO &D^
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M!*^<6!/RGG&?>-$\467COPEIVMZ;.9]/U6VCN[=\8+1N 1D=B,X([$&OD/\
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MW5\$D-7LW@/]GKX*6IU72?#_ (?\.A=>M#;7MLKR,]U;^:SM& [;MGF%B0N
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M,FVYZJ*E3]DZU!^X"*]W\H4JH%[4":/"Q^RA:#^!0/2G']E&S_N)7N>!Z"C
M]!0,\(N?V3[5XR%1?\_A7+ZU^R4ZR9B3:">PQ7T]M'I36A##&* L?)T_[+6H
MC[KW! _VVIA_9IUF$?+<7RX])7KZT^S)_=7\J1K5&'W5_*GS,GE1\E?\,X:U
M(/FN[_G_ *:O2Q?LQ:G*WSS7+C/\3L:^L_L4?]U?RH%F@Z*/RH;;#E/E[0/V
M5)TU!7D5B,\[LU] _#OP>GA/2HX0H! P:Z'R .R_E3U7:.U(H7I1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
.4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>lumacyn.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 lumacyn.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" %B .@# 2(  A$! Q$!_\0
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M-_R";$#_ *YT+Q6I_P#/LTCP3?[9];'XDZ /^8QI?_@4G^-(WQ,T((2-9TH
M$#F[C'7\:^1)OA/X<8<:39_]^ZHWOP:\-7B!9-)MV4'(5%V[J;\5::U=,N/
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M(&Z+7C'[:C^7\,[,^EZO\Q7LW9?F'!Z5XE^W)*T7PIMBH_Y?4Y]/F%>=F_\
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M?M-7<L$:_ 2(R9S@R1@+C@YY[GG\:]U_8C_:+^)O[0)US_A8G@(>#18';%C
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M&'_T):\[.?\ <JW^%G9EG^\0]2:-\W !Z8Z?A5^UD5+=,<  5ED_Z0,=E/\
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M)X:OK'4+93N*V(53GW P*^NQLE+$\\8Z'Y5[R@^8\A_;9.V-,^M?*_Q4NO\
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M@)_^O2JV3[ &OPU?6[<M=1271'W\8\T4V<-\6I2WQ,^&WH-8C_\ 1B5]A/\
M>'U-?'GQ2Y^)GPX'&1J\9Q_VT2OL-_OCZFOW;PU;>63_ ,9\#Q1_&7I^H]#\
MU/IB?>%/K],9\T%%%% !2/\ =-+2/]V@3V(_X_PKXW_X*]'_ (H701ZW1_\
M0:^R/XOPKXU_X*]D_P#"&^'5 ^_=MSZ?+FO"XE?^Q,^GX15\THV/B3P/>K;>
M,80Q !?DGH*[?]L7]D?4/VU_V;9/"ND7"Z?X@LKI+JSE?D3H&SA"?N]!TKS#
M3;O[+XLM&()620A@.N/:L_\ X*7_ +6GBC]E;]E;3)_#%W+ILNO:G%!<W2#?
M/;0;P"1GIP3W[5^4</5:G]ITX4IJ-VM]C]7XSJ*$*G,NA]&>-?V(_B#HGPS\
M"Z[X?V/KNE:0NBZI;K?-]IE8(J*0>N/E->W?\$U/V;M9_9C^'6I6?B1TDUC5
MKHW*6<4N\@G)^=NN>>]?!7[)/P-^/7Q ^$5IXHMX?%EQ8ZFOGVUT]S(1<(W(
MD^]^/XU]V_\ !,?X=>/?A7\/=?L_B']I;5+J]!MOM,C.QB()SN/(/3I7Z1Q
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M\M?%M]I<9]:_#,94;Q1^KY7!*@K'SYK"8UM_K7;_ +-MN1^TSX#;(_Y"UO\
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M.. QP6^E?-GQ+!D63(*MSE3P0/7Z5^48AIXCF6Q]_E[2I<IX%JO&MM]:[O\
M9S&/VD_ ?_86@_\ 1BUPNJA3KSJ)(V8'H#7>?LY(7_:4\"#IC5H.O_71:^KR
M#7&TWYGMXY_\)=5>1^X2=OJ?YU*.IJ)3A@/<_P Z>'&XU_1$MXG\QKXI#)UV
MH<?I7RM_P5EG\GX#:.Q:)#_:B_-(VU0,<\^OI[U]5#(9LD;37R?_ ,%<G*_
MW1?E1U.JCAAD?=KR.(&XX*L]_<?Y'HY33YL;35^J/RQ_:SUWQI/\;+,Z#_;2
MZ%:PC^RQ9*YD^U$$2?:@/X0N,;L\USFI_&[XN-\'+71=#T'Q!)XUCU=Y[RYF
MMG5)[9'4J(_]D@-R.N:]M\1^(8K74[R*$2R1"</&SL59>1G..N15O0O%DMI<
MS-$SQR&0M"VXL4!ZC)[>U?@]+-8+#Q4:2;\S]JQ&7)N+4NA\_P _BG]HRZU&
M]\46Z:I;65Y&EO\ V:8VWP,HP6 [<\UUW@OP3^T!%\('UZZ\47J>)9[K;'92
M1D@P$G)P3U'':OH#1_$-Q:W D23SAC<6D<@D]_EZ5H+XC6.1?WAD:W/F0,[D
M'<>2I'IFN?$Y].$=*$#'^S9?S'S)XKUW]H[PKJ<K^&KJYU#2K>$01K<PD>=*
MV&+;SD\'(KUG]CGQ?\6K+X[W\/C?3O$&W4M+D_M8S1N;&RO-IV>2Q^51]PX&
M.M>IZ?XDC:5&5Q'<'NSG9$.^%Z$Y]:ZO0?&%Q),ML9GF23FYNB?FF/KMZ>GY
M5Y<N*&U;ZO"YG4RB;UYSY4\&:S^U/::S:1:B^M30Z=<.D:BR8?;XSP'8]L Y
MQSTJQI^@?M!>*=$\>:?=:EXGC_T^VGT^XD,ELRAY3YL:'/(50.GK7V+#XLN;
MDNJF<1J, &1@9C_>)_A^@JU;^)KVUMD02M+(G(:3I@_>4_0=#WK&IQ.O9.+H
M17IN8+*)QDI<UT:?PKTF?1]=^%EA?7,MS<VKP&XG=R\CR_)D,3R>:^\95RIK
MX,\,+Y?QC\#QQREXI[])?F/(.]3^5?>CG@YK]C\+,5[;+:DN7E]\^'XTAR8Z
M*\@B.,#VJ2HXP=P/M4E?J5K'QJ=[W"BBB@9F/)M;%-,^ 30\B?C4,TR^6WTH
M%+8GEO#A3GFOC/\ X+"7@'AKPCQUNY/_ $6:^N[F["*.:^-/^"OEZ)/#?ACG
M[DSLOL=A&:\+BG_<F?6<'+_A3HGP5I>H/;^)XMN1G'(ZBO$]6_X(7> ?B[\0
M=;\21>-]5@U37+N6\N(0D3"'S&+2?EFO8(E6_P!4DMWD,8GM]F\=4W @D>]0
M?"3]E_Q]\/?$%W?^$M8T:26_L[JR,%T92C1SIM%PW^VH^;Z]J_(LHQN(P[G+
M#U>3]3]8XMR^AB:S=:GSV1J_#'_@WQTV#PD39?$F?RC$5C98H=Q7_OFOI/\
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M=+I"+C@AH\;ON[@<]N*\#^ W@_Q3\"?VJ_B?X*\92Z2^IZQ;#Q#'ID0+VVF
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M&;E!TYYKZIT:\5]9T7=@$:E'Q_P,5]+EGL_[1@J:ZG%B<76^JSYG>Z/L.^O
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M@+*KZ=>@_>N=,WGZY/'Z5YF35.3-JJ_O,QKZP7R/EKPZPT[]J=C+P\MJ,?\
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M]N)#%"EJ=IQ\BML. 3T!S7USX4UV74KGP1>3L7_T-<G/ .U:_1']I#_@D/\
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M*9G''3Q'L]VV%?-L)R)*9\%M&)?VQ[9C\HC20X/'\+5]->!?AYJ_CSQ?X?\
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MS>=Y@L9759:6%C[?2G4U5P>M.KZ5*RL>(@HHHIC"BBB@ (S33$"<C(/M3J*
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3H!%Z&GXQ110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>microcyn.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 microcyn.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $L D,# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M84444 %%%% !1110 4444 %%%% !1110 444R65(5W.P4>] #Z*J_P!I6_\
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M*W]UB ,9]A5R./"1\]'IMRF8?O9X_J* .OLM/M[* )%& O7GDFH-9@4V18*
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M\T<-3Q-PL':.&D_^WE_DS]"0KY^ZWY4H5C_"WY5^>P\=^(_^AAU/_P #9/\
M&GCQ[XC_ .AAU/\ \#)/\:O^QI_SK[C'_B*&&_Z!)?\ @2_R/T&.1_"?RI Q
MS7Y_-\3O%=O$3'XDU($>MTQ_F:=%\;?'5O\ <\4Z@/K(#_,5#R>HMI(ZZ?B9
M@9_%AYKYI_Y'Z!^8,5$[\U\)Q_'SX@+!&1XHO2><YV'//TJY;?M*?$"U>,'6
M$G]?/MD;/Z5#RBNMI+\?\CJI^).52=I4JB^4?_DC] ]#.=.3ZG^=:%<K\+M6
MFUWP'H^H7)4W-S LLFP8&X]<#M755XC5G9GZK3FJL(SCLTG]X4444C0****
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M6A*3U3I[6[.]]3GPW#_#.81<\/@)TTM+58\K;\DI/3S^XF'[(?A]AQJVI_\
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MM)C'VGQ'J*%S\J^7&2?PQ7I8C/,!@Z;KXFHH06[>B7S9^4_Z@9_57)"DF_\
M$O\ ,^<0>*6(_(*^G[;]E'PU=VZ2P^(K^2-^%;;'R?3IUJQ%^R!H@C &NZE_
MW[3_  KHIYQ@ZT(U*<[Q:NFM4T]FF<<O#W/XMQ=)7_Q1_P SY2O?NJ:CL?\
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MCF$9?8E_X"SYI_:#^!]UXS\-_#[2[K2-+TGQE>7=SIDT?AJ%HK);"?YKA7(
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ML^G^?Y5\]#]IZ5EVMX<4J>"/[0DQ_P"@U)_PTY-_T /_ "H/_P#$TO[*Q/\
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MW_"W]!M]4O+&36=,CN+>=H6AN)6A<,#C'S#!^M?0+_<;Z5^8/Q6&?B/XD/\
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M6A9BPD@VGACGG/I61XA_9)UTZ+X?L])N]/FD@MI8[Q=0O+D+#=.P/VR$J>9
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MB:\FO9;JQM!F?47NRMRJL+@C<2 #\F,<<5Z]/][ID_7%4M,M==2ZBDO[V"2
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MMC YQC!!!KX2-&=6NX4UKJ?V%5S+#9?E%+%8^5H<L+O5ZM+M=[G4KX<>*_\
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MP=I*S((Q\]?HS\ ^/AAH@SG_ $:/^5?G,A^>OT8^ QQ\,-#/K;1G]*^>S?\
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M0XI<BDI-U*P#P:4FF9I<TP' X-*#VJ,&G T /S29 IN:-U #^U)T--W#UI:
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M#0L7ADM9Q"?#N=596I86K\XR_5(\I\B*-&V11K@?PH!7?_LZG_B[VB_]M/\
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MO[>8 I*C@]-K UWUYH&F:@"+K3K6X!Z^9"K?S%9+_#?PP_31+2/_ *Y)Y?\
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MF/0VMTR@?0'(H @X-'![U(GPRNK=<0>);\C_ *>8XY3^9%-/P_UA?N^(0?\
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ML<[L8K<TSX8^'=+E$JV1N9QSYMU*TK9_X$373Q0I"H5%"*.P%)E)&+::9=,
M9"(_QS6G%9"/JQ8U:HI#$"A1P*6BB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
J**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>acuicyn.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 acuicyn.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %L 6X# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **3I7,^._B#HGP]T9]2UJ\6VB&0D8YDE;^ZB]S5PA*I)0@KM]#*K5IT(.K5
MDHQ6K;T21OWU]#IUK+<W$J001 L\DC;54#N37SEXK_;*T_3/$5S9Z/I?]JZ?
M#\HO!)M\QN^ >WOWKP_XQ?'W7/BK=26RLVFZ"K?N[&-N9/0R'N?;I7F-N<.U
M?I.6<+P4.?'ZM_93V]6NOX>I^#<0>(=7VGLLGTBMYM7OZ)[+S>K\CZS@_;6M
MCCS?#\R_[K@_UJ_#^VCHK#]YI%TOX _UKY$/3--/%>Q+AC+7M%KYL^4AXAY]
M'><7_P!NK]+'V3'^V9X7/W[*\0_]<_\ Z]6H?VQ?!TF-Z7,8]XF_PKXI8X-,
M:L'PKE[V<E\U_D=D/$C.EO&#_P"W7_\ )'W+'^UWX$?[US,GUB;_  J]%^U5
MX EQG5 G^\I']*^"":8>M82X3P72<OO7^1V0\2LU7Q4J;^4O_DC]!XOVF?A_
M+_S'8%_WCBKT/[07@.8?+XAL_P#OZ*_.@K@9I-O/05@^$\-TJR_#_(ZX^)F/
M^UAX?^3?YL_22'XW>"9_N^(;'G_ILO\ C5R+XL>$ION:[9'_ +;+_C7YG[1Z
M"@(".@K)\)4NE9_<CHCXFXC[6%C_ .!/_)GZ>1?$'P[-]S6+1O\ MJ*M1^+]
M&E/R:E;-])!7Y=CY>,X^AJ1+B2,C;+(OT8BLWPBNE?\ \E_X)O'Q.E]K"?\
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M>NNU\;M-?Z5FBBYH;;M)MC_L5?K-\.G.CV_T/\ZTJM; %%%%, HHHH ****
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M=PCO(%E4'UPP(S[UY]#\6'LM ^TQZ1?:W%IVFP7>I7H>.-E,B;E&W^)L<G'
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M_A;H/K5GQ4?WD7U7^=5?#!Y'UJUXKX:/\/YU/09T:?<7Z4ZF1',:'_9%/K0
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MU'_LU4EZI_P'_P!%FKDP^8?4?R:J:GYD^J_^BS4@B:USL3TPG_HLUL6?3/\
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M^+_Y\O\ \"C_ )A_KKEO_05#_P  J?Y'T0WC'2"#_I+?]^S33XQTDY_TEO\
MOV:^=C^U=8D<>!K;\;H__$TP_M6VF<CP19_C<G_XFC^P,7_SZ?\ X%'_ #%_
MKKEO_05'_P  J?Y'T9_PF6D?\_#?]^S2CQGI/_/P_P#W[-?.!_:NMST\#V7_
M ($'_P")H_X:O@P?^*'L?_ @_P#Q-/\ U?Q?_/I_^!1_S)_UVRW_ *"8_P#@
M%3_(^D!XTTC/_'P__?LTX>--)!_U[G_MF:^;#^U@F>/!&G_C<-_\30/VLN1_
MQ1&G?^!#?_$T_P#5[%_\^G_X%'_,G_7C+?\ H)C_ . 5/\CZ5'C72,_ZY_\
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M[K0]RAA5!:ZD'B/Q5K'B*^FOM3>>_O),LT\K[F8UR%IJLIU-5-JX;=UQ7;$
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M<,<G Z]/TJ_K4%JG+7S2_0S>75).SC"R\I/]?ZU.G\&Z?8Z?HD3:>)1;7/\
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MG%J_Q+;TM<_1C3;KP%930RJFCQ/$P=6.HH,$=#][K706/C7X<:2 5D\.P8!
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MNQ]I^5F+9.WTYIC_ !/BD^]ISCZ2C_"H3\0X)#_QY2@?[XKAJ\0Y/4=W7_\
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MD,35BY_PUMI;1_)NS?F^M]5>5Y/!^E:QIEW<P:A=2365M!%#;JW(9RH,ASW
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MX?YF\?#3,W\5:FOG+_Y$^.57 [U( =U?:-O^R!X:CQOW-]7-:$/[)_A./[T
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&%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>ocucyn.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ocucyn.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" )^ 9,# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH ***8TT:'#.JGW.* 'T4Q94?[KJWT.:?
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MC% 'I]%%%( HHHH **** "BBB@ HHHH **** "BBB@ K*\5_\BMK'_7G-_Z
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M+I9+[V=*K-O]W'WG\S"OM7?5=5EO[XO<32,7?<>6- U@QO\ -$K*#\B_W/\
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M;I3_ '[AOZ&L&XN[B[/[Z>2;_KHY;^=1D#KT]Z0\#!YKT8PA#X4D<[E*6[
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M (F$&,??7^8K,49(YP.E:FDC_B809QC>,?F* /4**** "BBB@ HHHH ****
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M_P#(!TW_ *]H_P#T$5_.)X)A:3Q7HJ)\SO>PJ..Y<5_1[HBE-&L%/46\8_\
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M110!^*'QSQ_PN#QB7&/^)G/C'^^:\XO,.<;\GKGTKTKX[XC^,/C ,Q_Y",W
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MV_9T^)GBSP+K'Q O-,N?[,MH3=27>H2'SKA>.4#?,PYZ^U>2%B ">A'&*\O
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MMSPM#^T+KXVYW)&P_*OG=YMIQ@[L\$=J^E/V_(FB_:$U1P/D:"(G\J\X\0>
MWU3PW;:II.FA/*C0,T1&)%QRY]\U]QAI)487[(\FI\3,E-5O+K2FOK:Q_MC3
MI@(]0TTC=Y3CC> .5SV(JM\4-06TM!# +BV34_)G>QNE'F1)%'LCW'L<E^/3
M!KE]-U_4?#&H/<:9>2V=T,@O$>OL:R=2U*[UB[GN+VXDGN9CN>9SDD_6NZ,'
MS7,&S.8Y5=PR?O U'*05.5W*<\8Y!_R:L,%$8R,;5QG%4Y5+A@<XQCCKVKNB
M<\C$\0[A"@( 7ICN:Y>Y )V@X]*ZCQ%&/(C?/(. *Y>X^^, <5[-#^&C@?\
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M?+J&A:6]SJX+!=2OW\V9%(Y"]A^ S7L.T=?\FFJ6.3CCMFO*_P!H+]H7P]\
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M-Q.,CI2%\X&>O<5J4(,E01CC]:>O'<9ZY-(!Z8!_G2L QVK\F>QY%(!N<D9
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M#^=?2=?,G[#[J?"VK*!MPZ9_6OINOY>QT%3Q,XKN?K%)\T$PHHHKA-0HHHH
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MRN><CM3RG;/'<TUB0",@C'Z5J6A"P]U]J61P8^,EC07"C.!GZT$[AD$#MFD
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MAAC5W\X'!5Q]S]16+XG8:UI]IJ;\W<;-;77'.Y?NL?J/Y&NV#=[,QD<?."Y
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MUY=MHLP[' YKDICN/09QQBNK\0MFU4;>2<C(X_"N2E.<$YS7L8?^&<,_XC&
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ML5[17C_[*D"V_P &])53D9;FO8*_F_$ZUIV[L_2X?"@HHHKF+"BBB@ HHHH
M**** "BBB@ HHHH _/#_ (*:QK'XP\*2'@M;./UKX>NL'(W$=^E?=/\ P4X
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MQ7Z'@JDYX>$JJM)I779]3YS$14:C4=BU>KM$/&W=&&Z8SUJJT@! Z#O5B]!
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M'KNO2;2U_=RSY08!!8X(K++N2EBZU##3YJ4;6UNDWNDS2O>5*$ZBM-W^:,:
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M&3UJ)R2.12-40'.[VJ*1L9YJ5N!4$F,>WM4/8Z(GH'PL1'\-^/6?'&F+C/\
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MLO\ CS@_ZYK_ "J>HK88MHAZ(/Y5+7Q9Z04444 %%%% !1110 4444 %%%%
M!1110!\D?\%*5+?!/3,=1JB<^GRFOS 9FCW<9'?WK]1O^"D2L?@9:E< C48^
M?P-?EL[D/C&5(SDU]AE?^[KU9YM?XSU72TTSXBZ9I]C"0E];P$ $[>1Z5R>A
M>(-0^'_B)[6]B;[.[XFAE/WATS[UR^FZG/I%]%<VLACD0Y!6O;GL]#^*OAFU
M:YNH+?75B)\S<,@CMCO7<U[/1ZQ?X&.LMMSSWXM:+H<0L-9T"4-;ZD7,EN.
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M<\^QKU+61<$DK$+_ "DBH9""3Q4TG0#\L5!+R*AG5$[GP-)CX=^-EZ[HH_\
MT*N+T:9+-4DU"U:2Q8$*6!PQ]OI76^#2!X"\8#//EQG'_ JR?#!L]8LQIMW=
M"%VW+&)%R@)[^QKQ72YIS:>M_P!$;2=HK3^KLU_^$ LM>T>)](,;718_-YH
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MMLF[ &X\?C7U?^R%&'^*'AT Y!NDY]:G%T7"FVS:E-29^MU%%%?%GI!1110
M4444 %%%% !1110 4444 %%%% 'SU^WA!YW[-_B!O[CQM_X]7Y$/)N&#R <X
M4<BOVJ_:;\$77Q"^"/B?1;$ W4MOYD8/<J=V/TK\6]4LI;.[EMIU\N:%BKJP
MP00>AKZW*))T91\SS\0O>3,XJ78@]"?RHVA6+(=QZ;J1PV<KR#P0::Q"G:>
M>OI]*]TX1)E"AO,[G^ U3FR57G:RGD8ZXJWEMN-V<\<BJL@#G.""!U/>M40S
M)U\J; G&_P";J1TKD)OEVY(R>XKK]=7%AT8^ASQ7(3KP"I^@%>QA_P"&>=4_
MB$!8%O<T[  )]?:D&3SGYCUR*;C)Z?45L *>F.3TP: 2&QWZ<T@!R!N( ]*
M<$GJU!0,0&VCE?2M+3_$>HZ7;RV]K<M'%(/F'45GYX'!'';I0V !G&*AI,#1
M?Q)=R B1+>5CG+/$,G./\!39O$%ZX9-ZQ YR(T"YSUK.?G&3QBDRIS@XR*GE
M0Q)I&E=GD<NQY))R34);J%Z>IJ4KT!Y'J:8Z8Z9(^E,M6*[@\G-,<?)NZ]JG
M88R,=:ADP0!@8%2;197D!8\5!+P*L'BJ\O(.>*SEL=,3J?"<WE^"_%2G!#)'
MS^-<1&2N"#@CG(KN/"D>_P $^*"%R55,D?6N) ^45Y]%/GGZ_HCJ7]?B=EX5
M^(FH: ABD5;RV+!B)>6_.O2-+U?PCXNTRY:^6&SO61<R.-K!O48ZUX6F"545
MNVH A .,XKM]E&6J=GY'%62CJD>N:O\ "32@OGV.K^3;K"96\X;\@#J"/6O-
M)KZ98TMA<NT,#$Q[1@?45$E_<0J5CG= 5VE0YY'I5<$]!D9YKII1E'XW<XV[
M[*QK6_B35;20/%J-RKY#9$AZ]C6G'\1_$<4Z3#5)3(B[5)5>!Z#BN84_*#C/
MTHSNSQQ71R4Y;Q1%VNIT<GCW7[K'F:E([!709 SM?[PS[U@A=Q]^IS3%.[/5
M3_.G*V !P/:KC&,?A5B7<['PG>1:?=:%>NBB"VO )G;@<]_RKT7QC\2M?T.<
MVEM:0K;KPDA^;(['WKQS2KZ*U)M[@N]E,<O&#CGL?PKM]&\17D%M96]S#;:[
M9-\L6^3;+&.P)KP<QPTJBO%ZG30FHNS,U-;\5:I?BRDN9HGE8N8@-N=W.<5K
MZE=C2;>.W$C.;?F1LYS(1Z^U5[GQO+;7@%M9V^FXRKON\R1^V >U<_=:FVH2
M*FPA1R"#R3[UQ8+ RI/GGJ;5L0I>[$W-$/FON)+EFSE?>OKK]CJ(O\3_  X"
MI&+I.:^1?#4;^:I*G&<GTK[$_8WB/_"T= ."2+E1R:YLRO[.5CJP_0_5NBBB
MOS\]@**** "BBB@ HHHH **** "BBB@ HHHH 1E#J58 @C!![U^?7[:O[&-U
M+>WGC;P;:^=$^9;RPB4E@>I8 =J_0:F2Q)-&T<BAT8896&01Z5U8?$3PT^>!
MG."FK,_G[N8I+<R1N"DJM@AEP1[4PDOEL G'Y^]?HA^VA^Q''=VU[XV\#VH6
M=,RWFFQCAAU+(*_/":)X7995:)T^4JPP1SWK[G#8B&)ASP_X8\BI!P=F1EB.
M6Y52.G>JD^0&*D+WY[U9DX7:%&0/7K56X1O+.1CD=.M=B,69NM,9=/RIR.HS
M7)3' &#G\*Z?6L&%L$AN,CM7,S 9'MZ5[6&_AGF5?C*[J">>,4@X(]?:G9SD
M8P.^>])MVX':MF"8TA1R?3'%)GYONA0.M*YP3W)ZTH!<C)Q]:DH0_GWX-(?F
M*@\9_2D(Y '&>](WW3^6?2@8Y0I]#U.,]Z:0-HZ#OBE12SK&%W,W0#J:ZNQ^
M&FM7EG]I,0AC\P1 ,>2:RG*,?B8TF]CE7. -N,U%N'.3U[UVVN?#'4-&ETZ)
MI$D-W)Y0(XV-Z&NAT_X,(ES$USJ$5QCEH8^_MFL95Z:5[FD82;M8\D95P3D8
M]Z@D&,<$^]=]%X96P&O1WUMY:QH3 7ZCGC%<&ZX'4X-6I*6Q<2JQ.<U7D'//
M%6W&!_*JLQ(ZU+V.J#N='X5G,7A3Q,N[:&C4<?6N04# [\5OZ,Y3PUKF#U"U
MRT-WC ;\Z\FGBJ=*K*%1VN=JBVKHOVT>^9>X)Z"MU<QJ._8BJ'A\+->QG*XW
M 9;I^->BQ^'].U+5+R$R>5Y, <>5RK-[5ZOM8)7OH<%:[ERG%R*-P8#I2!CV
MZCO6F_A^^$*2K TD;DA2HR35+[/(;@PB-A(#@ICG-=,>5[,Y->I$N4Q[^E2'
M XSSUP*D>PN(@N^)U#=,KBFK&H)^;%=$(WV(;%#9;@X8CIVI!C/7D]J7RP<<
MYIRQJQX;YO:M.5DW0 @N,XQGICK5G30POH'#;3OXQUXJ (%89.[%7-*A\V_@
M5<;V8D#\*RJ1]QBB[R5BM,2UP[E<KN.?7K6C8J0XR0,]_2LZ8%9'S@,KD?K6
MC9L)2@X'.<XZUE#E:LS.5TU8[/P^V^5.@ X)K[&_8VB9_B;H!QP+D?-^%?'.
MA,@8!CPIX]_>OM[]A+3/[7^)NGNHRMN#(3GCBOE<UJTX4Y*^I[N&4G9L_3FB
MBBOSP]D**** "BBB@ HHHH **** "BBB@ HHHH **** &NBRHR.H9&&"K#((
MK\^_VV_V+G9KWQSX*M-R8,M]IT0Y![NH]/:OT&IDL23Q-'(@>-QM96&01Z5U
M8;$3PT^>!G."J*S/Y]V@<EE<$2 D,N,&JESE2B@GZXZU^A?[8G[#,T4U[XS\
M 6VY#F6\TQ!R!U9E_P *_/Z\@EMWFBD#)*K%2CC!4^E?>X;$4\3#G@_^ >+5
MA*F[,Y_6$9K0G@@$YKEY0 HSQD9KJ=='EVS<'<Q (%<M+T4]>U?18?\ AGCU
M?XA!TR.P[FF!"2.13CC:<]^_K0 ?I@5J,8_"Y[]ZZ^X\(Z:G@O\ M:._=[G*
MKY93"DGJ >^*X\C'MFNDUOQQ<ZQH-EI36D$-O; !6C7!)]?K6,U)M<IHK=3K
M_%7@31K+PAIL]DKM>.T0EE)[, 2<>U:MK\//#EG<P&8HIB8EOM,HVW"!<[AZ
M<UY+/KNH7,/E2W4C0@ ;2>  ,"J<US--LWRN^!@;F)P/2N?V4VK.1:DK['0W
M5Q96/C2*\$<26JW6[R8CD(H/2NMN?BE'I!OXH6DNF:9WC4_ZO#=#7EVPX)Q2
M!6[@>E7*C&5N82DUL=3XG^(U_K]W:3*#"EJ<HI.?F]:R'\5:O+(7^VRJ^2?D
M.*S3&2I/8]J<JD# 7I^M4H1BK)"<KZDEWJ]]>JXN;F24MU+'-4"N5.>:LLBI
MG<<8Z\U \T'/S@MV YJ)5*=-:M(N-WLBJZ$(>PJM)&0*Z;3O"^LZP!]@T6_O
M5/&Z*V<C^5>I_#7]DWXA?$[48[;3O#%Y&3U:Y0QC'XBN:6*I<K?-HCIAS7M8
M\9TFU:3PEK+*I.,9XKB@ V !\QXQ7[-?##_@EEHMK\-[RR\1WS1:SJ$7S>4,
MK V./K7P-^T!^Q=X@_9J\6O%JZM=Z5*Y-E?*/ED ]?0U\75Q4*M:3@[GM1BX
MQ5SP;3[-;*V02KAV&>>U7+?4GM9M\<K1MC&5/7ZU>U"-!N#+NYZUBNJC[N#S
MCBJ6*G%63L9.DI.[.HTKQ]>:9"L;1QSH#U/!J#2M<A_MU[R;*>8&RSG.">]<
M\=P7&WCV%,X# =#^="Q=1=1>QB^AZC;>.-,<Q)<R;F";3)LZ =JP].U'0I+N
M^EN[?<LDQ,>21A<5Q?G D>HXIZ3,!@X(-:1Q4H[.Q+HI[H[G55TRZ@T]M,F@
M0Q/EHV^\Q)''O7/^))(5UR\6U 6('(VG@'O64LW 88X[CM0)EW'S&Y/!)'6M
M8XVHOMO[R?81[$HD.?O8& <^U:7A]R^JPY)/!Z?0UE"6)5X!*^OH*T_#DRG6
M8FV]B ?PK>&.GS).;%["-MAL:J\[JW3)P3]:T+&;#!,YQT;%4@&^V-E> Q.?
M45IVJ)')AOE Y" 5WXK$RIPO%G+0I*4M4=1X=*S2KP7YY(K]%/\ @G1I0;QA
M?70!_=VQ[=,U^>7AK$4J"-, GDBOUA_X)Z^![C2/ =]KMW"T1O7"0[ASM'4U
M\EBJG-%MGK0C9GUQ1117C'2%%%% !1110 4444 %%%% !1110 4444 %%%%
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MSU2HYOR.V,;!1116)04444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M;!1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
B%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>microcynvs.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 microcynvs.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" "V KT# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MKNX^7<3QZ5N5%<*'@=3R".])C1SD9$JDH0W./EYI?+;)&T\>U)::<T3_ .B
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MCVF1<H P]1S6OJT:R6<@8$BL>QL[F%6^QA53=GYCFLB@V/Y>><?[M0.S>_\
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MEIY<;KC'S5>JR HHHH **** "BBB@ HHHH **** "BBD)Q0 M%("",T%@*
MU6OA(T#B(@/CN:AO[\P,(XQ\S#.[MBJ\!:;Y=V6'>C</(X2_\?SV$LD$I(,1
MP?W;G]0*Y#7_ (H2QHQ 9^1M'E2#)SCTKW!++:=S+'CO\HS2-;QS9_<1,!ZH
M#_2GRB;2W,GP#:7-IX=B^UG$LI\W8#G:#R*ZA>E<W=WKZ?PH"MU('!-3Z#XG
MM]4F: MLN ,[6ZFCEL-:[&]13?,7UI=PSBD M%)D49S0 M%%)F@!:*0'-+0
M4444 -;I7-^+3(R6<:$^4TI\U0,Y&./UKI6Y%<=K,SKK4X61E554XSQG%)[
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MW[2/A\M'>?!>UO\ :Q -O)G<-QZ<]<5]R7"_(QR<8/%<3I3E+B,,3L#$$!B
M!DG%933>QW87$4Z#?M**G?O?3[CY5E_:V^+UGG[?\"=2'?\ <%SD?A_6H?\
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M0]#FNE6]N)Y\ND)^\5&>M?7G4$ $CUS7F/@E==!LAXE^R_VN)F$GV,GRPO\
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MX[6.4"WT 1>86CFEM+ACY8/&Y>@P,5PNE_LH^+=1TQ;C0/B9#=V[9V7%M=W
M1FSST? QCI534?V9/&$=Q FI_%RRMF1M[Q2ZA/F4 '(92_3G/X5S\U2]K'T4
ML+@F^=8A;=I'TYX'M+BS\)V<=ZL278W>:((FBC)SGA3SWK:M6Q<Q<'EL<"N"
M\'^(_#?@'P-I.C:CXTM=8GT^%8YKYG,DDC<G.!D]\#Z5W>G3QW<EK/$Q:WF
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M9#+J?Q%^&4EVH(,WEB0@'J<Y-?E1XW^'/@_3?".H>([#PK:W@BR'L;>\DC>
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MSX@B*V^X!%%<L2>W"L<UXHW_  4H\4ZZOF:Q\+[2X:!?FDT/Q)]G"\<Y#_\
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ME?W%P<=QD9K:TO3+N>7,J&)<\D]3]:Z_9QUH\H>I(I6B];%VCV?WC$CV@ '
M'84H3'<FGA:-G/6G>P)6T1DZMI?VDB1!N?OD5DRV-RA.P2CZ'/ZUUA7T.*:(
MO<U+BGN.]NGXG'-:W['.Z8?C4L6GWCLIQ(2>I<YS76^7[TNSWS4\D5T"_8SK
M*Q:WB ."3R<GD'ZU#>6$QS);G#'@@GK6L8\T"( Y[UI?I8E:._*CA]9\.6VI
M975-'M=07H/M%NLO'U(KCM1^"WP]OY2UQX!T:1CU(LL?RKV@Q[@02:41CCD\
M4N6+W1U1Q-:'PR?WGB-K\%/ ]C()+/X?Z-$Z_=9;(-CWYKI;#PA<V2&/3M)M
MM,0C'^C1)#_(5Z08B>]'EG&,T)16R">)K35I2;^;.?\ #?ADZ/OGN9/M%XXV
ME@<A1V KHE7%)Y?!&2*=CB@YAC GOBL>_P!'$C-);JHW#Y@1UK;VTFP9HT>X
M[)[G(2Z9=;@5$BXZ8. *8;'4$# 2R_,<G)SFNRV4% >M3RQ70?-);'*6UA=,
MZA@X4^];<%FT"C<P=F)W$]35_P L#I2[*I6CLA-N7Q69D7EA,75[=P&Q@C.
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M]^E:)3BA5Q326]@>J )@YS3J**8@HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
7 **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>nancyn.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 nancyn.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #; 9(# 2(  A$! Q$!_\0
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M[4N^@8^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M]?N[JY_QMK0TK1G5&_?2_*M>8>F<;K&M_P!I:S+.K?(OR1?-5NSN5=-WS/\
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M_%^RI^\?2Y5CY8W#^TD<["GSUJV;LB_>K)A^Y6G;?<6O.D>J6][_ -ZC>_\
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M%GQB_9>^%'P@BC\7?V5!#-<WKM=7%]NNII7E??\ ND;^+=_=KY*!] ?F;;>
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MU:^GOV!D_P! \:R_]-X$_P#'*\[-\OH4\#[7D]XZ,KQU>>+Y.?W3ZJO/NO\
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M^YM3L7_[ARUJ_:)/[U'G-_>H]I(GD*4.B:G;2^;%?6R2[=F_["J/4KV>O?\
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M>^E7R;/]&:CW"R*F.ZI5C^SKS_GA)3)M*OG1_P#1FI^Z08]SJ5F\7^BLN_\
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B% !1110 FVEHHH **** "H]FT_+4E% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Jun. 16, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--03-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">SONOMA PHARMACEUTICALS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001367083<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">68-0423298<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">5445 Conestoga Court<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Boulder<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CO<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">80301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">759-9305<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SNOA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,047,199<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,642,765<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Frazier & Deeter, LLC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Nashville,
Tennessee<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 5,374<span></span>
</td>
<td class="nump">$ 3,128<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">2,232<span></span>
</td>
<td class="nump">2,898<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories, net</a></td>
<td class="nump">2,915<span></span>
</td>
<td class="nump">2,719<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,915<span></span>
</td>
<td class="nump">3,541<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SNOA_DeferredConsiderationCurrent', window );">Current portion of deferred consideration, net of discount</a></td>
<td class="nump">212<span></span>
</td>
<td class="nump">262<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">12,648<span></span>
</td>
<td class="nump">12,548<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">225<span></span>
</td>
<td class="nump">365<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease, right of use assets</a></td>
<td class="nump">84<span></span>
</td>
<td class="nump">286<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax asset, net</a></td>
<td class="nump">589<span></span>
</td>
<td class="nump">1,145<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SNOA_DeferredConsiderationNoncurrent', window );">Deferred consideration, net of discount, less current portion</a></td>
<td class="nump">73<span></span>
</td>
<td class="nump">330<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">74<span></span>
</td>
<td class="nump">66<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">13,693<span></span>
</td>
<td class="nump">14,740<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">953<span></span>
</td>
<td class="nump">607<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">2,224<span></span>
</td>
<td class="nump">2,113<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue, current portion</a></td>
<td class="nump">641<span></span>
</td>
<td class="nump">478<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term debt</a></td>
<td class="nump">220<span></span>
</td>
<td class="nump">323<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current portion</a></td>
<td class="nump">58<span></span>
</td>
<td class="nump">198<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">4,096<span></span>
</td>
<td class="nump">3,719<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SNOA_WithholdingTaxPayable', window );">Withholding tax payable</a></td>
<td class="nump">5,142<span></span>
</td>
<td class="nump">4,710<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, less current portion</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">9,282<span></span>
</td>
<td class="nump">8,603<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies (Note 11)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Convertible preferred stock, $0.0001 par value; 714,286 shares authorized at March 31, 2025 and 2024, respectively, no shares issued and outstanding at March 31, 2025 and 2024</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 50,000,000 and 24,000,000 shares authorized at March 31, 2025 and 2024, respectively, 1,634,265 and 780,371 shares issued and outstanding at March 31, 2025 and 2024, respectively (Note 1) (Note 12)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">206,593<span></span>
</td>
<td class="nump">203,209<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(197,806)<span></span>
</td>
<td class="num">(194,349)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(4,376)<span></span>
</td>
<td class="num">(2,723)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">4,411<span></span>
</td>
<td class="nump">6,137<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 13,693<span></span>
</td>
<td class="nump">$ 14,740<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SNOA_DeferredConsiderationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SNOA_DeferredConsiderationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SNOA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SNOA_DeferredConsiderationNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SNOA_DeferredConsiderationNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SNOA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SNOA_WithholdingTaxPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SNOA_WithholdingTaxPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SNOA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred and payable to vendors for goods and services received, and accrued liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(10)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">714,286<span></span>
</td>
<td class="nump">714,286<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">24,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">1,634,265<span></span>
</td>
<td class="nump">780,371<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">1,634,265<span></span>
</td>
<td class="nump">780,371<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 14,288<span></span>
</td>
<td class="nump">$ 12,735<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of revenues</a></td>
<td class="nump">8,823<span></span>
</td>
<td class="nump">7,990<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">5,465<span></span>
</td>
<td class="nump">4,745<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">1,814<span></span>
</td>
<td class="nump">1,871<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">7,361<span></span>
</td>
<td class="nump">7,575<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">9,175<span></span>
</td>
<td class="nump">9,446<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(3,710)<span></span>
</td>
<td class="num">(4,701)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other income (expense), net</a></td>
<td class="nump">803<span></span>
</td>
<td class="num">(330)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss from operations before income taxes</a></td>
<td class="num">(2,907)<span></span>
</td>
<td class="num">(5,031)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (expense) benefit</a></td>
<td class="num">(550)<span></span>
</td>
<td class="nump">196<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (3,457)<span></span>
</td>
<td class="num">$ (4,835)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share: basic</a></td>
<td class="num">$ (2.79)<span></span>
</td>
<td class="num">$ (10.63)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share: diluted</a></td>
<td class="num">$ (2.79)<span></span>
</td>
<td class="num">$ (10.63)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average number of shares: basic</a></td>
<td class="nump">1,241<span></span>
</td>
<td class="nump">455<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average number of shares: diluted</a></td>
<td class="nump">1,241<span></span>
</td>
<td class="nump">455<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTaxAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (3,457)<span></span>
</td>
<td class="num">$ (4,835)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent', window );">Foreign currency translation adjustments</a></td>
<td class="num">(1,653)<span></span>
</td>
<td class="nump">695<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive loss</a></td>
<td class="num">$ (5,110)<span></span>
</td>
<td class="num">$ (4,140)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax, after reclassification adjustments of gain (loss) on foreign currency translation adjustments, on foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>AOCI Attributable to Parent [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Mar. 31, 2023</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 200,909<span></span>
</td>
<td class="num">$ (189,514)<span></span>
</td>
<td class="num">$ (3,418)<span></span>
</td>
<td class="nump">$ 7,977<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Mar. 31, 2023</a></td>
<td class="nump">246,678<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Proceeds from the sale of common stock, net of offering expenses</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,446<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,446<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Proceeds from the sale of common stock, net of offering expenses, shares</a></td>
<td class="nump">425,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SNOA_StockIssuedDuringPeriodValueNewIssues1', window );">Proceeds from the At-the-Market sale of common stock, net of offering expenses</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">338<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">338<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SNOA_StockIssuedDuringPeriodSharesNewIssues1', window );">Proceeds from the At-the-Market sale of common stock, net of offering expenses, shares</a></td>
<td class="nump">96,154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Employee stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">255<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">255<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Stock based compensation related to restricted stock grants</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">261<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">261<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Stock based compensation related to restricted stock grants, shares</a></td>
<td class="nump">12,539<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">695<span></span>
</td>
<td class="nump">695<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(4,835)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(4,835)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Mar. 31, 2024</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">203,209<span></span>
</td>
<td class="num">(194,349)<span></span>
</td>
<td class="num">(2,723)<span></span>
</td>
<td class="nump">6,137<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Mar. 31, 2024</a></td>
<td class="nump">780,371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SNOA_StockIssuedDuringPeriodValueNewIssues1', window );">Proceeds from the At-the-Market sale of common stock, net of offering expenses</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3,079<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,079<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SNOA_StockIssuedDuringPeriodSharesNewIssues1', window );">Proceeds from the At-the-Market sale of common stock, net of offering expenses, shares</a></td>
<td class="nump">816,894<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Employee stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">170<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">170<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Stock based compensation related to restricted stock grants</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">54<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">54<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Stock based compensation related to restricted stock grants, shares</a></td>
<td class="nump">9,538<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,653)<span></span>
</td>
<td class="num">(1,653)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(3,457)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(3,457)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SNOA_StockIssuedDuringPeriodValueReverseStockSplits', window );">Payments for fractional shares related to reverse-split</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits', window );">Payments for fractional shares related to reverse-split, shares</a></td>
<td class="num">(288)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Proceeds from the exercise of employee stock options</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">82<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">82<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Proceeds from the exercise of employee stock options, shares</a></td>
<td class="nump">27,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Mar. 31, 2025</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 206,593<span></span>
</td>
<td class="num">$ (197,806)<span></span>
</td>
<td class="num">$ (4,376)<span></span>
</td>
<td class="nump">$ 4,411<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Mar. 31, 2025</a></td>
<td class="nump">1,634,265<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SNOA_StockIssuedDuringPeriodSharesNewIssues1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SNOA_StockIssuedDuringPeriodSharesNewIssues1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SNOA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SNOA_StockIssuedDuringPeriodValueNewIssues1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SNOA_StockIssuedDuringPeriodValueNewIssues1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SNOA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SNOA_StockIssuedDuringPeriodValueReverseStockSplits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SNOA_StockIssuedDuringPeriodValueReverseStockSplits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SNOA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reduction in the number of shares during the period as a result of a reverse stock split.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (3,457)<span></span>
</td>
<td class="num">$ (4,835)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">138<span></span>
</td>
<td class="nump">176<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">224<span></span>
</td>
<td class="nump">516<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes', window );">Deferred income tax expense</a></td>
<td class="nump">357<span></span>
</td>
<td class="num">(109)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Operating lease right-of-use asset</a></td>
<td class="nump">174<span></span>
</td>
<td class="nump">161<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable, net</a></td>
<td class="nump">434<span></span>
</td>
<td class="num">(230)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories, net</a></td>
<td class="num">(388)<span></span>
</td>
<td class="nump">184<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,086<span></span>
</td>
<td class="nump">1,107<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredCompensation', window );">Deferred consideration, net of discount</a></td>
<td class="nump">194<span></span>
</td>
<td class="nump">222<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">416<span></span>
</td>
<td class="num">(278)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">295<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SNOA_IncreaseDecreaseInWithholdingTaxPayable', window );">Withholding tax payable</a></td>
<td class="nump">432<span></span>
</td>
<td class="nump">475<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(174)<span></span>
</td>
<td class="num">(161)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">181<span></span>
</td>
<td class="nump">355<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(88)<span></span>
</td>
<td class="num">(2,398)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(80)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(80)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of offering expenses</a></td>
<td class="nump">3,079<span></span>
</td>
<td class="nump">1,784<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of employee stock options</a></td>
<td class="nump">82<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SNOA_PaymentsForFractionalSharesRelatedToReversesplit', window );">Payments for fractional shares related to reverse-split</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfOtherShortTermDebt', window );">Principal payments on short-term debt</a></td>
<td class="num">(404)<span></span>
</td>
<td class="num">(481)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SNOA_ProceedsFromInsurancePremiumsFinanced', window );">Insurance premiums financed</a></td>
<td class="nump">274<span></span>
</td>
<td class="nump">373<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">3,030<span></span>
</td>
<td class="nump">1,676<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate on cash and cash equivalents</a></td>
<td class="num">(616)<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">2,246<span></span>
</td>
<td class="num">(692)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of year</a></td>
<td class="nump">3,128<span></span>
</td>
<td class="nump">3,820<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of year</a></td>
<td class="nump">5,374<span></span>
</td>
<td class="nump">3,128<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Non-cash operating and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SNOA_InsurancePremiumsFinanced', window );">Insurance premiums financed</a></td>
<td class="nump">$ 274<span></span>
</td>
<td class="nump">$ 373<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SNOA_IncreaseDecreaseInWithholdingTaxPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SNOA_IncreaseDecreaseInWithholdingTaxPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SNOA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SNOA_InsurancePremiumsFinanced">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SNOA_InsurancePremiumsFinanced</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SNOA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SNOA_PaymentsForFractionalSharesRelatedToReversesplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SNOA_PaymentsForFractionalSharesRelatedToReversesplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SNOA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SNOA_ProceedsFromInsurancePremiumsFinanced">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SNOA_ProceedsFromInsurancePremiumsFinanced</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SNOA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478345/912-310-45-11<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the obligation created by employee agreements whereby earned compensation will be paid in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligations classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfOtherShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for the payment of debt classified as other, maturing within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfOtherShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingArrLineItems', window );"><strong>Insider Trading Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingArrLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingArrLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management and Strategy Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text"><b>Risk Management and Strategy</b><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90C_ecyd--CybersecurityRiskManagementProcessesIntegratedTextBlock_c20240401__20250331_z3rVRRvdf7ug">We identify and address <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90B_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20240401__20250331_ziivd5w3h7wl">cybersecurity</span> threats and
risks related to our business with an approach that includes assessments by our management and use of an outside consultant to manage
our information technology.</span> In addition, we rely on operating systems and software from established and reliable <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_900_ecyd--CybersecurityRiskManagementThirdPartyEngagedFlag_dbT_c20240401__20250331_zfhxkhEJH5g7">third-party</span> service providers
to provide security. We have employee policies in place designed to reduce risk of cyber-attacks and educate employees on protocol in
the event of a potential cybersecurity incident.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_900_ecyd--CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_c20240401__20250331_zkV6fBvn6hD8">Currently we are <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_900_ecyd--CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_dbF_c20240401__20250331_zGU9Jtn0LpJg">not aware</span> of any risks from cybersecurity
threats, including as a result of any previous cybersecurity incidents, that have materially affected our business strategy,</span> results of
operations or financial condition or are reasonably likely to have such a material effect. However, cyber-attacks are increasing in frequency,
sophistication and intensity, and despite our ongoing efforts we cannot eliminate all risks from cybersecurity threats, or provide assurances
that we have not experienced undetected cybersecurity incidents. Please refer to &#8220;Risk Factors&#8221; in Part I, Item 1A of this
Form 10-K for more information on the risks posed to us by cybersecurity threats.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock', window );">Cybersecurity Risk Management Processes Integrated [Text Block]</a></td>
<td class="text">We identify and address <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90B_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20240401__20250331_ziivd5w3h7wl">cybersecurity</span> threats and
risks related to our business with an approach that includes assessments by our management and use of an outside consultant to manage
our information technology.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag', window );">Cybersecurity Risk Management Processes Integrated [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag', window );">Cybersecurity Risk Management Third Party Engaged [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</a></td>
<td class="text">Currently we are <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_900_ecyd--CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_dbF_c20240401__20250331_zGU9Jtn0LpJg">not aware</span> of any risks from cybersecurity
threats, including as a result of any previous cybersecurity incidents, that have materially affected our business strategy,<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock', window );">Cybersecurity Risk Board of Directors Oversight [Text Block]</a></td>
<td class="text"><b>Governance</b><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_906_ecyd--CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_c20240401__20250331_zbHuE0YuWts1">The Board of Directors takes an active role, as a
whole, in overseeing management regarding our Company&#8217;s risks, including cybersecurity risks.</span> <span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90E_ecyd--CybersecurityRiskRoleOfManagementTextBlock_c20240401__20250331_zbzRGRCK0URh">Our management, including our Chief
Executive Officer and our Chief Financial Officer, keeps the Board of Directors apprised of significant risks facing our Company and the
approach being taken to understand, manage, and mitigate such risks, including with respect to potential cybersecurity threats.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text">The Board of Directors takes an active role, as a
whole, in overseeing management regarding our Company&#8217;s risks, including cybersecurity risks.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskRoleOfManagementTextBlock', window );">Cybersecurity Risk Role of Management [Text Block]</a></td>
<td class="text">Our management, including our Chief
Executive Officer and our Chief Financial Officer, keeps the Board of Directors apprised of significant risks facing our Company and the
approach being taken to understand, manage, and mitigate such risks, including with respect to potential cybersecurity threats.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementThirdPartyEngagedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskRoleOfManagementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskRoleOfManagementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Recent Developments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization and Recent Developments</a></td>
<td class="text"><p id="xdx_80C_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zWw5nTTD2XO7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE&#160;1&#160;&#8211; <span id="xdx_82F_zC3DfNmjUtu3">Organization and Recent
Developments</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Organization</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Sonoma Pharmaceuticals, Inc. (the &#8220;Company&#8221;)
was incorporated under the laws of the State of California in April 1999 and was reincorporated under the laws of the State of Delaware
in December 2006. The Company moved its principal office from Petaluma, California to Woodstock, Georgia in June 2020 and to Boulder,
Colorado in October 2022. The Company is a global healthcare leader for developing and producing stabilized hypochlorous acid (&#8220;HOCl&#8221;)
products for a wide range of applications, including wound care, eye, oral and nasal care, dermatological conditions, podiatry, animal
health care, and as a non-toxic disinfectant. The Company&#8217;s products are clinically proven to reduce itch, pain, scarring, and irritation
safely and without damaging healthy tissue. In-vitro and clinical studies of HOCl show it to safely manage skin abrasions, lacerations,
minor irritations, cuts, and intact skin. The Company sells its products either directly or via partners in 55 countries worldwide.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Reverse Stock Split</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Effective August 29, 2024, the Company effected a
reverse stock split of its common stock, par value $0.0001 per share. Every twenty shares of common stock were reclassified and combined
into one share of common stock. No fractional shares were issued as a result of the reverse stock split. Instead, each fractional share
was settled with cash. The reverse stock split reduced the number of shares of the Company&#8217;s common stock outstanding from <span id="xdx_902_eus-gaap--CommonStockSharesOutstanding_iI_c20240828_zLcrIUVAGuY7" title="Common stock outstanding">21,174,693</span>
to <span id="xdx_905_eus-gaap--CommonStockSharesOutstanding_iI_c20240829_zp1zq9E67jSc" title="Common stock outstanding">1,058,447</span>. The total number of authorized shares of common stock was not proportionally decreased and the par value per share of the
common stock continues to be $0.0001. The reverse stock split has been retroactively applied to all share and per share amounts in the
consolidated financial statements and accompanying footnotes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liquidity and Financial Condition<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock', window );">Liquidity and Financial Condition</a></td>
<td class="text"><p id="xdx_80E_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_zVYSDyEUIFBf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE&#160;2&#160;&#8211; <span id="xdx_824_zvtIywnGNETg">Liquidity and Financial
Condition</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company reported a net loss of $<span id="xdx_907_eus-gaap--NetIncomeLoss_iN_pn3d_di_c20240401__20250331_zkAVQdrogdM1" title="Net loss">3,457,000</span> and
$<span id="xdx_902_eus-gaap--NetIncomeLoss_iN_pn3d_di_c20230401__20240331_zo9lYkMPw6E6" title="Net loss">4,835,000</span> for the years ended March 31, 2025 and 2024, respectively. At March 31, 2025 and 2024, the Company&#8217;s accumulated deficit
amounted to $<span id="xdx_90C_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn3d_di_c20250331_zY7G5dAk9iBg" title="Accumulated deficit">197,806,000</span> and $<span id="xdx_905_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn3d_di_c20240331_zPy8nBijmeXd" title="Accumulated deficit">194,349,000</span>, respectively. The Company had working capital of $<span id="xdx_903_ecustom--WorkingCapital_iI_pn3d_c20250331_zhIEi1pBPDij" title="Working capital">8,552,000</span> and $<span id="xdx_90E_ecustom--WorkingCapital_iI_pn3d_c20240331_zFwcigRl0Hm9" title="Working capital">8,829,000</span> as of March 31,
2025 and 2024, respectively. During the years ended March 31, 2025 and 2024, net cash used in operating activities amounted to $<span id="xdx_901_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn3d_di_c20240401__20250331_zxNWV6j7Hlkb" title="Net cash used in operating activities">88,000</span>
and $<span id="xdx_902_eus-gaap--NetCashProvidedByUsedInOperatingActivities_pn3d_di_c20230401__20240331_zPpq9JAUOs3l" title="Net cash used in operating activities">2,398,000</span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Management believes that the Company has access to
additional capital resources through possible public or private equity offerings, debt financings, corporate collaborations or other means;
however, the Company cannot provide any assurance that other new financings will be available on commercially acceptable terms, if needed.
If the economic climate in the U.S. deteriorates, the Company&#8217;s ability to raise additional capital could be negatively impacted.
If the Company is unable to secure additional capital, it may be required to take additional measures to reduce costs in order to conserve
its cash in amounts sufficient to sustain operations and meet its obligations. These measures could cause significant delays in the Company&#8217;s
continued efforts to commercialize its products, which is critical to the realization of its business plan and the future operations of
the Company. This uncertainty along with the Company&#8217;s history of losses indicates that there is substantial doubt about the Company&#8217;s
ability to continue as a going concern within one year after the date that the financial statements are issued. The accompanying consolidated
financial statements do not include any adjustments that may be necessary should the Company be unable to continue as a going concern.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>











<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205-40/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubstantialDoubtAboutGoingConcernTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p id="xdx_806_eus-gaap--SignificantAccountingPoliciesTextBlock_zhHolBDxX8Tk" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE&#160;3&#160;&#8211; <span id="xdx_821_zALFjH70BR3h">Summary of Significant Accounting Policies</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p id="xdx_841_eus-gaap--ConsolidationPolicyTextBlock_zFCMgRfKpc75" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_867_zWUv3pyVpebg">Principles of Consolidation</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying consolidated financial statements
include the accounts of the Company and its wholly-owned subsidiaries, Aquamed Technologies, Inc. (&#8220;Aquamed&#8221;), Oculus Technologies
of Mexico S.A. de C.V. (&#8220;OTM&#8221;), and Sonoma Pharmaceuticals Netherlands, B.V. (&#8220;SP Europe&#8221;). Aquamed has no current
operations. All significant intercompany accounts and transactions have been eliminated in consolidation. The functional currency for
the Company's wholly-owned subsidiaries incorporated outside the United States (&#8220;U.S.&#8221;) is denominated in local currency.
All intercompany transactions and balances have been eliminated in consolidation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_840_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zWO4SrWVIK9i" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i><span id="xdx_86E_z0OSA6GpE8dk">Basis of presentation</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying consolidated financial statements
have been prepared by the Company pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;)
and are in conformity with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;). The Company&#8217;s fiscal year end is
March 31. Unless otherwise stated, all years and dates refer to the fiscal year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i></i></b></p>

<p id="xdx_845_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zbi6hHFy5V1j" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i><span id="xdx_86D_z1JpcBObEDKg">Cash and Cash Equivalents</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Cash and cash equivalents include cash on hand and
all highly liquid investments with an original maturity of three months or less when purchased. The Company&#8217;s cash equivalents are
held in prime money market investments with strong sponsor organizations which are monitored on a continuous basis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_84E_eus-gaap--UseOfEstimates_zARxaseIFqd9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_86C_zuboPzXHnq0j">Use of Estimates</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of consolidated financial statements
in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities
and disclosures of contingent liabilities at the dates of the consolidated financial statements and the reported amounts of revenues and
expenses during the reporting periods. Actual results could differ from these estimates. Significant estimates and assumptions include
reserves and write-downs related to receivables and inventories, the valuation allowance relating to the Company&#8217;s deferred tax
assets and the valuation of equity. Periodically, the Company evaluates and adjusts estimates accordingly.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p id="xdx_84A_eus-gaap--RevenueRecognitionPolicyTextBlock_z1wMiCXxsrO2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_863_z48omwCJAjZ">Revenue Recognition</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recognizes revenue in accordance with
Accounting Standards Codification (&#8220;ASC&#8221;), Topic 606 Revenue from Contracts with Customers (&#8220;Topic 606&#8221;). Revenue
is recognized when the Company transfers promised goods or services to the customer, in an amount that reflects the consideration which
the Company expects to receive in exchange for those goods or services. In determining the appropriate amount of revenue to be recognized
as the Company fulfills its obligations under the agreement, the Company performs the following steps: (i)&#160;identification of the
promised goods or services in the contract; (ii)&#160;determination of whether the promised goods or services are performance obligations,
including whether they are distinct in the context of the contract; (iii)&#160;measurement of the transaction price, including the constraint
on variable consideration; (iv)&#160;allocation of the transaction price to the performance obligations; and (v)&#160;recognition of revenue
when (or as) the Company satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable
that it will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company derives the majority of its revenue through
sales of its products directly to end users and to distributors. The Company also sells products to a customer base, including hospitals,
medical centers, doctors, pharmacies, distributors and wholesalers. The Company has also entered into agreements to license its technology
and products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>











<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company considers customer purchase orders, which
in some cases are governed by master sales agreements, to be the contracts with a customer. For each contract, the Company considers the
promise to transfer products, each of which are distinct, to be the identified performance obligations. In determining the transaction
price the Company evaluates whether the price is subject to refund or adjustment to determine the net consideration to which it expects
to be entitled.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For all of the Company&#8217;s sales to non-consignment
distribution channels, revenue is recognized when control of the product is transferred to the customer (i.e. when its performance obligation
is satisfied), which typically occurs when title passes to the customer upon shipment but could occur when the customer receives the product
based on the terms of the agreement with the customer. For product sales to its value-added resellers, non-stocking distributors and end-user
customers, the Company grants return privileges to its customers, and because the Company has a long history with its customers, the Company
is able to estimate the amount of product that will be returned.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has entered into consignment arrangements,
in which goods are left in the possession of another party to sell. As products are sold from the customer to third parties, the Company
recognizes revenue based on a variable percentage of a fixed price.&#160; Revenue recognized varies depending on whether a patient is
covered by insurance or is not covered by insurance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Sales to stocking distributors are made under terms
with fixed pricing and limited rights of return (known as &#8220;stock rotation&#8221;) of the Company&#8217;s products held in their
inventory. Revenue from sales to distributors is recognized upon the transfer of control to the distributor.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company assessed the promised goods and services
in the technical support contract with Invekra for a ten-year period as being a distinct service that Invekra can benefit from on its
own and as separately identifiable from any other promises within the contract. Given that the distinct service is not substantially the
same as other goods and services within the Invekra contract, the Company accounted for the distinct service as a performance obligation.
At March 31, 2025, 2024 and 2023, the Company had deferred revenue related to Invekra in the amounts of $<span id="xdx_90A_eus-gaap--DeferredRevenue_iI_c20250331__srt--CounterpartyNameAxis__custom--InvekraMember_zO9rRnEo6sg6" title="Deferred revenue">69,000</span>, $<span id="xdx_901_eus-gaap--DeferredRevenue_iI_c20240331__srt--CounterpartyNameAxis__custom--InvekraMember_ziXOijcRWpwk" title="Deferred revenue">152,000</span> and $<span id="xdx_902_eus-gaap--DeferredRevenue_iI_c20230331__srt--CounterpartyNameAxis__custom--InvekraMember_zvSL9N13U10b" title="Deferred revenue">199,000</span>,
respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_84D_eus-gaap--ConcentrationRiskCreditRisk_zqlCuFOr3dfi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_86A_z4W2cjcpOXcj">Concentration of Credit Risk and Major Customers</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Financial instruments that potentially subject the
Company to concentration of credit risk consist principally of cash, cash equivalents and accounts receivable. Cash and cash equivalents
are maintained in financial institutions in the United States, Mexico and the Netherlands. The Company is exposed to credit risk in the
event of default by these financial institutions for amounts in excess of the Federal Deposit Insurance Corporation insured limits. Cash
and cash equivalents held in foreign banks are intentionally kept at minimal levels, and therefore have minimal credit risk associated
with them. We currently have $3,004,000 of deposits above federally insured limits.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table shows major customers revenues
as a percentage of revenue:</p>

<table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_zURPyO22S4I1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B2_zFIfATK9pKB9" style="display: none">Schedule of concentration of risk</span></td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Year Ended March 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: left">Customer A</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b style="display: none"><span style="display: none"></span><span id="xdx_90D_ecustom--ConcentrationRiskPercentage2_pip0_dp_c20240401__20250331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerAMember_fKg_____zm3kWnC3lWsd" title="Concentration risk, percentage">0</span></b>*%</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right"><span id="xdx_90C_ecustom--ConcentrationRiskPercentage2_pip0_dp_c20230401__20240331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerAMember_zs1bdHhh0kR9" title="Concentration risk, percentage">17</span>%</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Customer B</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_ecustom--ConcentrationRiskPercentage2_pip0_dp_c20240401__20250331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerBMember_z4KIjyeKukt9" title="Concentration risk, percentage">21</span>%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_ecustom--ConcentrationRiskPercentage2_pip0_dp_c20230401__20240331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerBMember_zBZGw8JhTJu7" title="Concentration risk, percentage">15</span>%</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Customer C</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_ecustom--ConcentrationRiskPercentage2_pip0_dp_c20240401__20250331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerCMember_zd6MRrjG5LH4" title="Concentration risk, percentage">18</span>%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_905_ecustom--ConcentrationRiskPercentage2_pip0_dp_c20230401__20240331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerCMember_zrvShVJuihOl" title="Concentration risk, percentage">14</span>%</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table shows major customers accounts
receivable balances as a percentage of net accounts receivables:</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: left">Customer B</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right"><b style="display: none"><span id="xdx_90F_ecustom--ConcentrationRiskPercentage2_pip0_dp_c20240401__20250331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerBMember_fKg_____zSPeLzx9ieyc" title="Concentration risk, percentage">0</span></b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*%</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right"><span id="xdx_907_ecustom--ConcentrationRiskPercentage2_pip0_dp_c20230401__20240331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerBMember_zhhrzMCrV01k" title="Concentration risk, percentage">13</span>%</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Customer D</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_ecustom--ConcentrationRiskPercentage2_pip0_dp_c20240401__20250331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerDMember_zRqpvevFHgF6" title="Concentration risk, percentage">24</span>%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_ecustom--ConcentrationRiskPercentage2_pip0_dp_c20230401__20240331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerDMember_zEwXw7xH1If5" title="Concentration risk, percentage">17</span>%</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 4%"><span id="xdx_F09_zisvXV838286" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">* </span></td>
    <td id="xdx_F19_zg6Uo3NevcBg" style="width: 96%">% <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents less than
    10%</span></td></tr>
  </table>
<p id="xdx_8AB_zKPUBR4dA57j" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>











<p id="xdx_84D_eus-gaap--ReceivablesPolicyTextBlock_zPTyarxsC5N9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_860_zTS6l5klpGF">Accounts Receivable</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Trade accounts receivable are recorded net of allowances
for cash discounts for prompt payment, doubtful accounts, and sales returns. Estimates for cash discounts and sales returns are based
on analysis of contractual terms and historical trends.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s policy is to reserve for uncollectible
accounts based on its best estimate of the amount of probable credit losses in its existing accounts receivable. The Company periodically
reviews its accounts receivable to determine whether an allowance for doubtful accounts is necessary based on an analysis of past due
accounts and other factors that may indicate that the realization of an account may be in doubt. Other factors that the Company considers
include its existing contractual obligations, historical payment patterns of its customers and individual customer circumstances, an analysis
of days sales outstanding by customer and geographic region, and a review of the local economic environment and its potential impact on
government funding and reimbursement practices. Account balances deemed to be uncollectible are charged to the allowance after all means
of collection have been exhausted and the potential for recovery is considered remote. The Company did <span id="xdx_909_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pn3p0_do_c20250331__srt--ProductOrServiceAxis__custom--ProbableCreditLossesMember_zW7wAdkE2NY9" title="Allowance for doubtful accounts"><span id="xdx_90F_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pn3p0_do_c20240331__srt--ProductOrServiceAxis__custom--ProbableCreditLossesMember_zYdQNrIU7HM7" title="Allowance for doubtful accounts"><span id="xdx_903_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pn3p0_do_c20230331__srt--ProductOrServiceAxis__custom--ProbableCreditLossesMember_zOc54kajgLh9" title="Allowance for doubtful accounts">no</span></span></span>t deem it necessary to record
an allowance for doubtful accounts for probable credit losses at March 31, 2025, March 31, 2024 and March 31, 2023. Additionally, at March
31, 2025, 2024 and 2023, the Company has allowances of $<span id="xdx_909_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pn3p0_c20250331__srt--ProductOrServiceAxis__custom--PotentialDiscountsReturnsDistributorFeesAndRebatesMember_zX36jruvOYM2" title="Allowance for doubtful accounts">8,000</span>, $<span id="xdx_90E_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pn3p0_c20240331__srt--ProductOrServiceAxis__custom--PotentialDiscountsReturnsDistributorFeesAndRebatesMember_zKceXqOGAQn7" title="Allowance for doubtful accounts">27,000</span> and $<span id="xdx_90B_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pn3p0_c20230331__srt--ProductOrServiceAxis__custom--PotentialDiscountsReturnsDistributorFeesAndRebatesMember_zPChwlnQfONi" title="Allowance for doubtful accounts">16,000</span>, respectively, related to potential discounts, returns,
distributor fees and rebates. The allowances are included in accounts receivable, net in the accompanying consolidated balance sheets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_846_eus-gaap--InventoryPolicyTextBlock_zZwKbfNYAqn2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_86D_z1WH85EQNkGe">Inventories</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Inventories are stated at the lower of cost, cost
being determined on a standard cost basis (which approximates actual cost on a first-in, first-out basis), or net realizable value.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Due to changing market conditions, estimated future
requirements, age of the inventories on hand and production of new products, the Company regularly reviews inventory quantities on hand
and records a provision to write down excess and obsolete inventory to its estimated net realizable value. At March 31, 2025 and 2024,
the Company recorded provisions to reduce the carrying amounts of inventories to their net realizable value in the amounts of $<span id="xdx_90D_eus-gaap--InventoryValuationReserves_iI_pn3p0_c20250331_zNTLPOQMjbl1" title="Inventory valuation reserves">298,000</span>
and $<span id="xdx_90E_eus-gaap--InventoryValuationReserves_iI_pn3p0_c20240331_zSpzd72K9l4f">296,000</span>, respectively, which is included in inventories, net on the Company&#8217;s accompanying consolidated balance sheets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_84C_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zBuZLvGvya3i" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_86E_zwRFaxwCdK11">Financial Assets and Liabilities</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Financial instruments, including cash and cash equivalents,
accounts receivable and accounts payable are carried at cost, which management believes approximates fair value due to the short-term
nature of these instruments. The fair value of capital lease obligations and approximates their carrying amounts as a market rate of interest
is attached to their repayment. The Company measures the fair value of financial assets and liabilities based on the exchange price that
would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset
or liability in an orderly transaction between market participants on the measurement date. The Company maximizes the use of observable
inputs and minimizes the use of unobservable inputs when measuring fair value. The Company uses three levels of inputs that may be used
to measure fair value:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level&#160;1&#160;&#8211; quoted prices in active
markets for identical assets or liabilities;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level&#160;2&#160;&#8211; quoted prices for similar
assets and liabilities in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived
valuations in which all significant inputs and significant value drivers are observable in active markets;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level&#160;3&#160;&#8211; inputs that are unobservable
(for example cash flow modeling inputs based on assumptions).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>











<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 3 liabilities are valued using unobservable
inputs to the valuation methodology that are significant to the measurement of the fair value of the liabilities. For fair value measurements
categorized within Level 3 of the fair value hierarchy, the Company&#8217;s accounting and finance department, who report to the Chief
Financial Officer, determine its valuation policies and procedures. The development and determination of the unobservable inputs for Level
3 fair value measurements and fair value calculations are the responsibility of the Company&#8217;s accounting and finance department
and are approved by the Chief Financial Officer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of March 31, 2025 and 2024, there were <span id="xdx_908_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_pn3p0_do_c20240401__20250331_zEuzx62r1c" title="Transfers in or out of level 3"><span id="xdx_906_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_pn3p0_do_c20230401__20240331_z103ndt1RRJ2" title="Transfers in or out of level 3">no</span></span> transfers
in or out of Level 3 from other levels in the fair value hierarchy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_84C_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zyAALfoPUln6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_860_zCNI749PVwT8">Property and Equipment</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Property and equipment are stated at cost less accumulated
depreciation. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the
respective assets. Depreciation of leasehold improvements is computed using the straight-line method over the lesser of the estimated
useful life of the improvement or the remaining term of the lease. Estimated useful asset life by classification is as follows:&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_88B_ecustom--PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock_z9YQN5p6tJKg" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details-Useful lives)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B9_zM2xeXOwrCCe" style="display: none">Schedule of property and equipment estimated useful life</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Years</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 86%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office equipment</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 12%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20250331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_z8tCHer5CRwh" title="Useful asset life">3</span></span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manufacturing, lab and other equipment</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20250331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zdPY9cCcanw" title="Useful asset life">5</span></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furniture and fixtures</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20250331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zcEr4Z1vwZIb" title="Useful asset life">7</span></span></td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Upon retirement or sale, the cost and related accumulated
depreciation are removed from the consolidated balance sheet and the resulting gain or loss is reflected in operations. Maintenance and
repairs are charged to operations as incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_84E_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zczGeUAYV3Pf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_86B_zJn9hugvmEM7">Impairment of Long-Lived Assets</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company periodically reviews the carrying values
of its long-lived assets when events or changes in circumstances would indicate that it is more likely than not that their carrying values
may exceed their realizable values, and records impairment charges when considered necessary. Specific potential indicators of impairment
include, but are not necessarily limited to:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a significant decrease in the fair value of an asset;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a significant change in the extent or manner in which an asset is used or a significant physical change in an asset;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a significant adverse change in legal factors or in the business climate that affects the value of an asset;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an adverse action or assessment by the U.S.&#160;Food and Drug Administration or another regulator; and</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an accumulation of costs significantly in excess of the amount originally expected to acquire or construct an asset; and operating or cash flow losses combined with a history of operating or cash flow losses or a projection or forecast that demonstrates continuing losses associated with an income-producing asset.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>











<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">When circumstances indicate that an impairment may
have occurred, the Company tests such assets for recoverability by comparing the estimated undiscounted future cash flows expected to
result from the use of such assets and their eventual disposition to their carrying amounts. In estimating these future cash flows, assets
and liabilities are grouped at the lowest level for which there are identifiable cash flows that are largely independent of the cash flows
generated by other such groups. If the undiscounted future cash flows are less than the carrying amount of the asset, an impairment loss,
measured as the excess of the carrying value of the asset over its estimated fair value, will be recognized. The cash flow estimates used
in such calculations are based on estimates and assumptions, using all available information that management believes is reasonable. The
Company did <span id="xdx_90B_eus-gaap--AssetImpairmentCharges_pn3p0_do_c20240401__20250331_zCVjrL7UJIX5" title="Impairment of long lived assets"><span id="xdx_90D_eus-gaap--AssetImpairmentCharges_pn3p0_do_c20230401__20240331_zVkJgRm2Mdkf" title="Impairment of long lived assets">no</span></span>t record impairment losses for the years ended March 31, 2025 and 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_845_eus-gaap--ResearchAndDevelopmentExpensePolicy_zrSsLGROXZac" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_86E_zFthTNrrfmVi">Research and Development</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Research and development expenses are charged to operations
as incurred and consists primarily of personnel expenses, clinical and regulatory services and supplies. For the years ended March 31,
2025 and 2024, research and development expense amounted to $<span id="xdx_900_eus-gaap--ResearchAndDevelopmentExpense_pn3p0_c20240401__20250331_zl6YV1lL8wLl" title="Research and development expenses">1,814,000</span> and $<span id="xdx_903_eus-gaap--ResearchAndDevelopmentExpense_pn3p0_c20230401__20240331_zTfBPPtLwtb1" title="Research and development expenses">1,871,000</span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_845_eus-gaap--AdvertisingCostsPolicyTextBlock_zLZeZWIZQEce" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_86D_zxvr5GkT24Gh">Advertising Costs</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Advertising costs are charged to operations as incurred.
Advertising costs amounted to $<span id="xdx_901_eus-gaap--MarketingExpense_pn3p0_c20240401__20250331_zm8yljMrOCJ3" title="Advertising costs">190,000</span> and $<span id="xdx_901_eus-gaap--MarketingExpense_pn3p0_c20230401__20240331_zy00uSelb4nl" title="Advertising costs">156,000</span> for the years ended March 31, 2025 and 2024, respectively. Advertising costs are included
in selling, general and administrative expenses in the accompanying consolidated statements of comprehensive loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_848_ecustom--ShippingAndHandlingCost1PolicyTextBlock_zHYgmM3ZqYo5" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i><span id="xdx_86B_zBBmV5Jyaq45">Shipping and Handling Costs</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company classifies amounts billed to customers
related to shipping and handling in sale transactions as product revenues. The corresponding shipping and handling costs incurred are
recorded in cost of product revenues. For the years ended March 31, 2025 and 2024, the Company recorded revenue related to shipping and
handling costs of $<span id="xdx_90E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20240401__20250331__srt--ProductOrServiceAxis__us-gaap--ShippingAndHandlingMember_z1kK9aignMee" title="Revenues">18,000</span> and $<span id="xdx_90B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20230401__20240331__srt--ProductOrServiceAxis__us-gaap--ShippingAndHandlingMember_zEfQQNdAdq9" title="Revenues">28,000</span>, respectively. These amounts are included in revenues in the accompanying consolidated statements
of comprehensive loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_848_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zByY8TNCHpb5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_861_zm6POr9eOYzg">Foreign Currency Reporting</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s subsidiary, OTM, uses the local
currency (Mexican Pesos) as its functional currency and its subsidiary, SP Europe, uses the local currency (Euro) as its functional currency.
Assets and liabilities are translated at exchange rates in effect at the balance sheet date, and revenue and expense accounts are translated
at average exchange rates during the period. Resulting translation adjustments amounted to losses of $<span id="xdx_90E_ecustom--OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationLossAdjustmentBeforeTaxPortionAttributableToParent_pn3p0_c20240401__20250331__us-gaap--IncomeStatementLocationAxis__us-gaap--OtherComprehensiveIncomeMember_zbkTsSEsWFL" title="Foreign currency translation adjustment loss">1,653,000</span> and gains of $<span id="xdx_90D_ecustom--OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainAdjustmentBeforeTaxPortionAttributableToParent_pn3p0_c20230401__20240331__us-gaap--IncomeStatementLocationAxis__us-gaap--OtherComprehensiveIncomeMember_zMXOCNhpjITg" title="Foreign currency translation adjustment gain">695,000</span>
for the years ended March 31, 2025 and 2024, respectively. These amounts were recorded in other comprehensive loss in the accompanying
consolidated statements of comprehensive loss for the years ended March 31, 2025 and 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Foreign currency transaction losses relate primarily
to trade payables and receivables and intercompany transactions between subsidiaries OTM and SP Europe. These transactions are expected
to be settled in the foreseeable future. The Company recorded foreign currency transaction gains of $<span id="xdx_90C_eus-gaap--ForeignCurrencyTransactionGainBeforeTax_pn3p0_c20240401__20250331__us-gaap--IncomeStatementLocationAxis__us-gaap--OtherOperatingIncomeExpenseMember_zg09fRLQWx06" title="Foreign currency transaction gain">243,000</span> and losses of $<span id="xdx_904_eus-gaap--ForeignCurrencyTransactionLossBeforeTax_pn3p0_c20230401__20240331__us-gaap--IncomeStatementLocationAxis__us-gaap--OtherOperatingIncomeExpenseMember_zUrCXDQodvIc" title="Foreign currency transaction loss">825,000</span> for
the years ended March 31, 2025 and 2024, respectively. The related amounts were recorded in other income (expense) in the accompanying
consolidated statements of comprehensive loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>











<p id="xdx_84B_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zaj8FWd4iUY5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_869_z5PeiaDESwAl">Stock-Based Compensation</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for share-based awards exchanged
for employee services at the estimated grant date fair value of the award. The Company estimates the fair value of employee stock option
awards using the Black-Scholes option pricing model. The Company amortizes the fair value of employee stock options on a straight-line
basis over the requisite service period of the awards.&#160; Compensation expense includes the impact of forfeitures for all stock options
as incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for equity instruments issued
to non-employees at their fair value on the measurement date. The measurement of stock-based compensation is subject to periodic adjustment
as the underlying equity instrument vests or becomes non-forfeitable. Non-employee stock-based compensation charges are amortized over
the vesting period or as earned.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_841_eus-gaap--IncomeTaxPolicyTextBlock_zNsCtF9G88Tk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_861_zstvjz8290e3">Income Taxes</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Deferred tax assets and liabilities are determined
based on the differences between the financial reporting and tax bases of assets and liabilities and net operating loss and credit carryforwards
using enacted tax rates in effect for the year in which the differences are expected to impact taxable income. Valuation allowances are
established when necessary to reduce deferred tax assets to the amounts expected to be realized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Tax benefits claimed or expected to be claimed on
a tax return are recorded in the Company&#8217;s consolidated financial statements. A tax benefit from an uncertain tax position is only
recognized if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the
technical merits of the position. The tax benefits recognized in the consolidated financial statements from such a position are measured
based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate resolution. Uncertain tax
positions have had no impact on the Company&#8217;s consolidated financial condition, results of comprehensive loss or cash flows.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_844_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zlrbnMPJy9x7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_865_zLOGtLVLckb4">Comprehensive Loss</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Other comprehensive loss includes all changes in stockholders&#8217;
equity during a period from non-owner sources and is reported in the consolidated statements of changes in stockholders&#8217; equity.
To date, other comprehensive loss consists of changes in accumulated foreign currency translation adjustments. Accumulated other comprehensive
losses at March 31, 2025 and 2024 were $<span id="xdx_905_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_iNI_pn3p0_di_c20250331_zxCDSkwmUNEb" title="Accumulated other comprehensive loss">4,376,000</span> and $<span id="xdx_908_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_iNI_pn3p0_di_c20240331_zgzxoULws9Kc" title="Accumulated other comprehensive loss">2,723,000</span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i></i></b></p>

<p id="xdx_84F_eus-gaap--EarningsPerSharePolicyTextBlock_zpJt2VoxNfvk" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i><span id="xdx_861_zWe7aV4iEVtg">Net Loss per Share</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company computes basic net loss per share by dividing
net loss per share available to common stockholders by the weighted average number of common shares outstanding for the period and excludes
the effects of any potentially dilutive securities. Diluted earnings per share, if presented, would include the dilution that would occur
upon the exercise or conversion of all potentially dilutive securities into common stock using the &#8220;treasury stock&#8221; and/or
&#8220;if converted&#8221; methods as applicable.</p>

<table cellpadding="0" cellspacing="0" id="xdx_88F_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_pn3n3_zQMVT2I9u4s5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details - Earnings per share)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8BE_zLPDMRGi4yR4" style="display: none">Schedule of computation of earnings per share</span></td><td>&#160;</td>
    <td colspan="2" id="xdx_493_20240401__20250331_zWUtF7nS72Hj" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_490_20230401__20240331_zbQOYGMhuxv8" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Year Ended March 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-style: italic; text-align: justify">(In thousands, except per share data)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--NetIncomeLoss_zvPHG1sUVEZf" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: justify; padding-bottom: 2.5pt">Net loss</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 13%; text-align: right">(3,457</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 13%; text-align: right">(4,835</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Weighted-average shares outstanding: basic and diluted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_906_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20240401__20250331_zHmQpmxLzLe2" title="Weighted-average number of shares: basic"><span id="xdx_906_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20240401__20250331_zCDm0AKmLbNf" title="Weighted-average number of shares: diluted">1,241</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20230401__20240331_zPC1HfhiTm8l" title="Weighted-average number of shares: basic"><span id="xdx_90C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20230401__20240331_zM3Y70VsLL15" title="Weighted-average number of shares: diluted">455</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Net loss per share: basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--EarningsPerShareBasic_pip0_c20240401__20250331_zlxfDkaNIuOh" title="Net loss per share: basic"><span id="xdx_908_eus-gaap--EarningsPerShareDiluted_pip0_c20240401__20250331_zuPDGioUbHCl" title="Net loss per share: diluted">(2.79</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_eus-gaap--EarningsPerShareBasic_pip0_c20230401__20240331_zIXPvimnH9sj" title="Net loss per share: basic"><span id="xdx_903_eus-gaap--EarningsPerShareDiluted_pip0_c20230401__20240331_z7gXdVrOEh5g" title="Net loss per share: diluted">(10.63</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>











<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The computation of basic and diluted loss per share
for the years ended March 31, 2025 and 2024 excludes the potentially dilutive securities summarized in the table below because their inclusion
would be anti-dilutive.</p>

<table cellpadding="0" cellspacing="0" id="xdx_889_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_pn3n3_zX61miRCNuQg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details - Antidilutive shares)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8BF_zWNkXJhCOLd9" style="display: none">Schedule of antidilutive shares</span></td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-style: italic">(In thousands)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: left">Common stock to be issued upon exercise of options</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20240401__20250331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zBk6aclmuVK3" style="width: 13%; text-align: right" title="Antidilutive shares">73</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20230401__20240331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_z0hBUAViGQkk" style="width: 13%; text-align: right" title="Antidilutive shares">52</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Common stock to be issued upon vesting of restricted stock units</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_d0_c20240401__20250331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockUnitsMember_ze0KvSHOnXyk" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive shares">45</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_d0_c20230401__20240331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockUnitsMember_zvW2tD8pJZB5" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive shares">&#8211;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20240401__20250331_z61stojKYFSa" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive shares">118</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20230401__20240331_z052IKLT9YAg" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive shares">52</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p id="xdx_849_ecustom--ConvertiblePreferredStockPolicyTextBlock_zTSZEVEHfJB1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_863_zpJiJv2ta99c">Convertible Preferred Stock</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company applies the accounting standards for distinguishing
liabilities from equity when determining the classification and measurement of its preferred stock. Shares that are subject to mandatory
redemption (if any) are classified as liability instruments and are measured at fair value. The Company classifies conditionally redeemable
preferred shares, which includes preferred shares that feature redemption rights that are either within the control of the holder or subject
to redemption upon the occurrence of uncertain events not solely within the Company&#8217;s control, as temporary equity. At all other
times, preferred shares are classified as stockholders' equity. There are <span id="xdx_90B_eus-gaap--PreferredStockSharesIssued_iI_pip0_do_c20250331_zD131bkgvo27" title="Preferred stock, shares issued">no</span> shares issued as of March 31, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_848_eus-gaap--SegmentReportingPolicyPolicyTextBlock_z8U1KU9n1Ug5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_86F_z1x7JkOJP5u4">Segment Reporting</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has one primary business activity and operate in one reportable
segment. The Company&#8217;s chief operating decision maker (&#8220;CODM&#8221;) is its Chief Executive Officer (&#8220;CEO&#8221;) who
evaluates performance and makes operating decisions about allocating resources based on financial data presented on a consolidated basis.
The measures of profitability and the significant segment expenses reviewed by the CODM are consistent with these financial statements
and footnotes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_84D_eus-gaap--SubsequentEventsPolicyPolicyTextBlock_z5blvubMPCZb" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i><span id="xdx_86A_zG2oQtqrhGk6">Subsequent Events</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Management has evaluated subsequent events or transactions
occurring through the date these consolidated financial statements were issued. All events requiring disclosure have been incorporated
into the notes to the consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_842_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zaligiqAgjO1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_867_zbiuXHAVh7b2">Recent Accounting Standards</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has evaluated all the recent accounting
standards and determined that none are material to it.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Receivable<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock', window );">Accounts Receivable</a></td>
<td class="text"><p id="xdx_80F_eus-gaap--LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_zrTV0gwgjkmf" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE&#160;4&#160;&#8211; <span id="xdx_82F_zVS6CHtSiAR3">Accounts Receivable</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Accounts receivable, net consists of the following:</p>

<table cellpadding="0" cellspacing="0" id="xdx_88A_eus-gaap--ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_pn3n3_zsLLptBzYht6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Accounts Receivable (Details)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8BC_zQEh7Rl2tFKl" style="display: none">Schedule of accounts
    receivable</span></td><td>&#160;</td>
    <td colspan="2" id="xdx_499_20250331_zEzYUvCD1pm" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_490_20240331_zuNI0FO9oKUb" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March&#160;31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AccountsReceivableGrossCurrent_iI_pn3p0_maARNCzw0O_zkniCw3Vrj3a" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: left">Accounts receivable</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">2,240,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">2,925,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iNI_pn3p0_di_hsrt--ProductOrServiceAxis__custom--PotentialDiscountsReturnsDistributorFeesAndRebatesMember_msARNCzw0O_z1IyPnEOwFc4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Less: discounts, rebates, distributor fees and returns</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(8,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(27,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--AccountsReceivableNetCurrent_iTI_pn3p0_mtARNCzw0O_zD73MAMoB86d" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total accounts receivable, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,232,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,898,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>











<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for claims held for amounts due to entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/310-10/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventories</a></td>
<td class="text"><p id="xdx_80E_eus-gaap--InventoryDisclosureTextBlock_zWsxCIu5N09e" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE&#160;5&#160;&#8211; <span id="xdx_822_z6liG334e382">Inventories</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Inventories, net consists of the following:</p>

<table cellpadding="0" cellspacing="0" id="xdx_885_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_pn3n3_zclZDn1Ampdl" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Inventories (Details)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B0_ziSP6Up1QKal" style="display: none">Schedule of inventories</span></td><td>&#160;</td>
    <td colspan="2" id="xdx_49F_20250331_zSUjscxoVyE2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_492_20240331_zTeL1za7t7Yj" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March&#160;31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--InventoryRawMaterialsNetOfReserves_iI_pn3p0_maIGzA0w_z0T6ta6jCeN8" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: left">Raw materials</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">1,395,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">1,802,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--InventoryFinishedGoodsNetOfReserves_iI_pn3p0_maIGzA0w_zjTLh3wPMYD9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Finished goods</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,818,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,213,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--InventoryGross_iTI_pn3p0_mtIGzA0w_maINzHEX_zoa8ualtCGJf" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><b style="display: none">Inventories, gross</b></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,213,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,015,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--InventoryValuationReserves_iNI_pn3p0_di_msINzHEX_zXEz7igVfYO5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Less: allowance for obsolete and excess inventory</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(298,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(296,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--InventoryNet_iTI_pn3p0_mtINzHEX_zxOU6ZdhLTah" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total inventories</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,915,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,719,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/330/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCurrentAssetsTextBlock', window );">Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><p id="xdx_80E_eus-gaap--OtherCurrentAssetsTextBlock_z1PAeR0uqafh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE&#160;6&#160;&#8211; <span id="xdx_82F_zleE51adNMu">Prepaid Expenses and Other
Current Assets</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Prepaid expenses and other current assets consist
of the following:</p>

<table cellpadding="0" cellspacing="0" id="xdx_881_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_pn3n3_zmpfHru8uDW6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Prepaid Expenses and Other Current Assets (Details)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B8_zRuyoXDE8aDi" style="display: none">Schedule of prepaid expenses and other current assets</span></td><td>&#160;</td>
    <td colspan="2" id="xdx_498_20250331_zyIttJz1rCjb" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_49D_20240331_zGv05CgxGUmg" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March&#160;31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--PrepaidInsurance_iI_pn3p0_maPEAOAz4GC_z91VyCrIieAb" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: left">Prepaid insurance</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">236,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">340,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--PrepaidTaxes_iI_pn3p0_maPEAOAz4GC_zdmq4l3G0Emf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">VAT prepaid to Mexican tax authorities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,531,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,096,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OtherPrepaidExpenseCurrent_iI_pn3p0_maPEAOAz4GC_zQwxZAIZpNTi" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Other prepaid expenses and other current assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">148,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">105,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_pn3p0_mtPEAOAz4GC_zQqBZd3zmPog" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><b style="display: none">Total prepaid expenses and other current assets</b></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,915,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,541,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p id="xdx_80B_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_z0ItIUj1HwV9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE&#160;7&#160;&#8211; <span id="xdx_824_zVbZpxxLQum">Property and Equipment</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Property and equipment, net consists of the following:</p>

<table cellpadding="0" cellspacing="0" id="xdx_888_eus-gaap--PropertyPlantAndEquipmentTextBlock_pn3n3_zxuNNYxexi9h" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Property and Equipment (Details)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8BD_zs6Z0Myh0Hbi" style="display: none">Schedule of property and equipment, net</span></td><td>&#160;</td>
    <td colspan="2" id="xdx_49E_20250331_z9n1dCl0j75c" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_497_20240331_zR6mXFTmjlm" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March&#160;31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--MachineryAndEquipmentGross_iI_pn3p0_maPPAEGzAkZ_zUBy7HDgQ867" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: left">Manufacturing, lab, and other equipment</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">1,471,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">1,776,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentOther_iI_pn3p0_maPPAEGzAkZ_zxcA3GMgbZJa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Office equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">217,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">236,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--FurnitureAndFixturesGross_iI_pn3p0_maPPAEGzAkZ_z3NHH521HaSd" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Furniture and fixtures</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">121,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">128,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--LeaseholdImprovementsGross_iI_pn3p0_maPPAEGzAkZ_zbSBLjCOr9A1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Leasehold improvements</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">491,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">605,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--PropertyPlantAndEquipmentGross_iTI_pn3p0_mtPPAEGzAkZ_maPPAENzQSU_zKZxcPJYZCbd" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><b style="display: none">Property and equipment, gross</b></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,300,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,745,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3p0_di_msPPAENzQSU_zOs97KtK8Qfk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Less: accumulated depreciation</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(2,075,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(2,380,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3p0_mtPPAENzQSU_zK7EHdnHWqpf" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total property and equipment, net <span style="color: #EEEEEE">and equipment, net&#160;</span></span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">225,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">365,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Depreciation expense amounted to $<span id="xdx_901_eus-gaap--DepreciationAndAmortization_pn3p0_c20240401__20250331_zfwQMkQNAHb7" title="Depreciation and amortization">138,000</span> and $<span id="xdx_90C_eus-gaap--DepreciationAndAmortization_pn3p0_c20230401__20240331_zAPtBAVcPSpe" title="Depreciation and amortization">176,000</span>
for the years ended March 31, 2025 and 2024, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>











<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><p id="xdx_80D_eus-gaap--AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_zwQ0M4ycZMub" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE&#160;8&#160;&#8211; <span id="xdx_821_zWNSERa4bEph">Accrued Expenses and Other
Current Liabilities</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Accrued expenses and other current liabilities consist
of the following:</p>

<table cellpadding="0" cellspacing="0" id="xdx_885_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zkHL2a7Xoyx9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Accrued Expenses and Other Current Liabilities (Details)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B5_zuEwrbCu4g82" style="display: none">Schedule of accrued expenses and other current liabilities</span></td><td>&#160;</td>
    <td colspan="2" id="xdx_49E_20250331_zU8fZsWO8wXj" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_491_20240331_z1rtcf5snPN1" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March&#160;31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_pn3p0_maAPAOAzS7o_zMaukLFPSq68" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: left">Salaries and related costs</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">1,737,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">1,419,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pn3p0_maAPAOAzS7o_zxgsIUe1e6v4" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">487,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">694,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AccountsPayableAndOtherAccruedLiabilities_iTI_pn3p0_mtAPAOAzS7o_zRhlHzF9G3Fk" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total accrued expenses and other current liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,224,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,113,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text"><p id="xdx_809_eus-gaap--DebtDisclosureTextBlock_zf3iuuLFGDt6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE&#160;9&#160;&#8211; <span id="xdx_82A_zbSP1oDUQKbl">Debt</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Financing of Insurance Premiums</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 1, 2025, the Company entered into a note
agreement for $<span id="xdx_908_eus-gaap--DebtInstrumentFaceAmount_iI_pn3p0_c20250201__us-gaap--ShortTermDebtTypeAxis__custom--InsurancePremiumFinancingMember_z6D9IZQbc1ce" title="Debt face amount">274,000</span> with an interest rate of <span id="xdx_906_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pip0_dp_c20250130__20250201__us-gaap--ShortTermDebtTypeAxis__custom--InsurancePremiumFinancingMember_zQLYfHKP5Zqf" title="Debt interest rate">7.97</span>% per annum with final payment on <span id="xdx_901_eus-gaap--DebtInstrumentMaturityDateRangeEnd1_dd_c20250130__20250201__us-gaap--ShortTermDebtTypeAxis__custom--InsurancePremiumFinancingMember_zi9ac9vuPvTh" title="Final payment date">November 1, 2025</span>. This instrument was issued in
connection with financing insurance premiums. On February 5, 2025, the Company made an initial payment of $<span id="xdx_900_eus-gaap--ProceedsFromShortTermDebt_pn3p0_c20250130__20250201__us-gaap--ShortTermDebtTypeAxis__custom--InsurancePremiumFinancingMember_zwMRdhRcd107" title="Debt initial payment">28,000</span>. The note is payable
in <span id="xdx_90E_eus-gaap--DebtInstrumentPaymentTerms_c20250130__20250201__us-gaap--ShortTermDebtTypeAxis__custom--InsurancePremiumFinancingMember_zBYRsQBFJ2sk" title="Debt payment terms">nine monthly installment payments</span> of principal and interest of $<span id="xdx_908_eus-gaap--DebtInstrumentPeriodicPayment_pn3p0_c20250130__20250201__us-gaap--ShortTermDebtTypeAxis__custom--InsurancePremiumFinancingMember_z1FOs0u9Hq98" title="Periodic payment">28,000</span>, with the first monthly installment beginning <span id="xdx_902_eus-gaap--DebtInstrumentMaturityDateRangeStart1_dd_c20250130__20250201__us-gaap--ShortTermDebtTypeAxis__custom--InsurancePremiumFinancingMember_zuDv6lc2s7T9" title="First installment beginning date">March 1, 2025</span>.
At March 31, 2025, the outstanding principal on the note amounted to $<span id="xdx_900_eus-gaap--OtherLongTermDebtCurrent_iI_pn3p0_c20250331__us-gaap--ShortTermDebtTypeAxis__custom--InsurancePremiumFinancingMember_zUlksarRYmBb" title="Outstanding principal amount">220,000</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 6, 2024, the Company entered into a note
agreement for $<span id="xdx_90A_eus-gaap--DebtInstrumentFaceAmount_iI_pn3p0_c20240206__us-gaap--ShortTermDebtTypeAxis__custom--InsurancePremiumFinancingMember_zweZ8YEW6YD3" title="Debt face amount">373,000</span> with an interest rate of <span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pip0_dp_c20240205__20240206__us-gaap--ShortTermDebtTypeAxis__custom--InsurancePremiumFinancingMember_zMRZjv7rhtOj" title="Debt interest rate">8.42</span>% per annum with final payment on <span id="xdx_909_eus-gaap--DebtInstrumentMaturityDateRangeEnd1_dd_c20240205__20240206__us-gaap--ShortTermDebtTypeAxis__custom--InsurancePremiumFinancingMember_zmAyTBwnqGdb" title="Final payment date">November 1, 2024</span>. This instrument was issued in
connection with financing insurance premiums. The note is payable in <span id="xdx_901_eus-gaap--DebtInstrumentPaymentTerms_c20240205__20240206__us-gaap--ShortTermDebtTypeAxis__custom--InsurancePremiumFinancingMember_zJNB6Y6rdobh" title="Debt payment terms">nine monthly installment payments</span> of principal and interest of $<span id="xdx_90A_eus-gaap--DebtInstrumentPeriodicPayment_pn3p0_c20240205__20240206__us-gaap--ShortTermDebtTypeAxis__custom--InsurancePremiumFinancingMember_zJNI8vUL2LD6" title="Periodic payment">42,000</span>,
with the first installment beginning <span id="xdx_90F_eus-gaap--DebtInstrumentMaturityDateRangeStart1_dd_c20240205__20240206__us-gaap--ShortTermDebtTypeAxis__custom--InsurancePremiumFinancingMember_zpnF6FVVNUhi" title="First installment beginning date">March 1, 2024</span>. At March 31, 2024, the outstanding principal on the note amounted to $<span id="xdx_906_eus-gaap--OtherLongTermDebtCurrent_iI_pn3p0_c20240331__us-gaap--ShortTermDebtTypeAxis__custom--InsurancePremiumFinancingMember_zArR7BfJnsL7" title="Outstanding principal amount">323,000</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>&#160;</i></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text"><p id="xdx_800_eus-gaap--LesseeOperatingLeasesTextBlock_zC5uS6PUIULd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE&#160;10&#160;&#8211; <span id="xdx_826_zY69HiYYyIW6">Leases</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s operating leases are comprised
primarily of facility leases. Balance sheet information related to the Company&#8217;s leases is presented below:</p>

<table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--LeaseCostTableTextBlock_pn3n3_zvNwdzhJdoV1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Leases (Details - Balance sheet information related to leases)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8BE_zVgwzlUfHuE5" style="display: none">Schedule of lease information</span></td><td>&#160;</td>
    <td colspan="2" id="xdx_49A_20250331_zgufW7mhuRC5" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_493_20240331_z7WQg1YtTAif" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">March 31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">March 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LeasesOperatingAbstract_iB_zhAvz7KwSmok" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="font-weight: bold; text-align: justify">Operating leases:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3p0_zC45qOjy3EG1" style="vertical-align: bottom; background-color: White">
    <td style="width: 66%; text-align: justify">Operating lease right-of-use assets</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">84,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">286,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pn3p0_zkl11NlOGgGk" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify">Operating lease liabilities &#8211; current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">58,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">198,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pn3p0_zALlRW1HaZgj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Operating lease liabilities &#8211; non-current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">27,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">87,000</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Other information related to leases is presented below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Year ended</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>March 31, 2025</b></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year ended<br/> March 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="font-weight: bold; text-align: left">Lease cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 66%; text-align: left">Operating lease cost</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--OperatingLeaseCost_pn3p0_c20240401__20250331_zBwtpOYMj9a7" style="width: 13%; text-align: right" title="Operating lease cost">365,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--OperatingLeaseCost_pn3p0_c20230401__20240331_zfY39wOUQiba" style="width: 13%; text-align: right" title="Operating lease cost">380,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Other information:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Operating cash flows from operating leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--OperatingLeaseRightOfUseAssetAmortizationExpense_iN_pn3p0_di_c20240401__20250331_zAZcXdqojH6j" style="text-align: right" title="Operating cash flows from operating leases">(174,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--OperatingLeaseRightOfUseAssetAmortizationExpense_iN_pn3p0_di_c20230401__20240331_z7WHCMHY2tmh" style="text-align: right" title="Operating cash flows from operating leases">(161,000</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left">Weighted-average remaining lease term &#8211; operating leases (in months)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtM_c20250331_zRzeA2SONKLh" title="Weighted-average remaining lease term - operating leases (in months)">18.6</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtM_c20240331_z21BxoyaMxhe" title="Weighted-average remaining lease term - operating leases (in months)">19.7</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Weighted-average discount rate &#8211; operating leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pip0_dp_c20250331_zzOMOER59w7k" title="Weighted-average discount rate - operating leases">6</span>%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pip0_dp_c20240331_zOIx4b0dGIif" title="Weighted-average discount rate - operating leases">6</span>%</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AA_zOYTYpaACjg1" style="font: 10pt Times New Roman, Times, Serif; margin: 0 180.1pt 0 0">&#160;</p>











<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">As of March 31, 2025, the annual future minimum lease payments of the Company&#8217;s
operating lease liabilities were as follows:</p>

<table cellpadding="0" cellspacing="0" id="xdx_887_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_pn3n3_zyWVFHP7mcj9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Leases (Details - Minimum operating lease payments)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8BC_zMJZyieoKFmi" style="display: none">Schedule of minimum operating lease liabilities</span></td><td>&#160;</td>
    <td colspan="2" id="xdx_49B_20250331_zvZ7p8HAJc2j" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">For Years Ending March 31,</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3p0_maLOLLPzr9e_zg9ESGkvQgDf" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 83%; text-align: left">2026</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">66,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3p0_maLOLLPzr9e_zyl3qcov8ATg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pn3p0_maLOLLPzr9e_zXwZBBpZM3s2" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">2028</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">9,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3p0_mtLOLLPzr9e_zzCztFJhxg8e" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total future minimum lease payments, undiscounted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">90,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3p0_di_zN7HJc4WNBEh" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Less: imputed interest</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(5,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--OperatingLeaseLiability_iI_pn3p0_zBzqBni5eROf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total lease liability</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">85,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p id="xdx_809_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zIznzNyWyJjh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE&#160;11&#160;&#8211; <span id="xdx_823_zZJKuFOPQlz2">Commitments and Contingencies</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Legal Matters</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company may be involved in legal matters arising
in the ordinary course of business including matters involving proprietary technology. While management believes that such matters are
currently insignificant, matters arising in the ordinary course of business for which the Company is or could become involved in litigation
may have a material adverse effect on its business and financial condition of comprehensive loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Employment Agreements</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has employment agreements in place with
two of its key executives. These executive employment agreements provide, among other things, for the payment of up to eighteen months
of severance compensation for terminations under certain circumstances.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of March 31, 2025, with respect to these agreements,
aggregated annual salaries was $<span id="xdx_907_eus-gaap--OfficersCompensation_pn3p0_c20240401__20250331_zlQsSql2MIYi" title="Annual salaries">586,000</span> and potential severance payments to these key executives was $<span id="xdx_90A_ecustom--PotentialSeverancePayments_iI_pn3p0_c20250331_z9m8vl2LFuya" title="Potential severance payments">1,300,000</span>, if triggered.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders&#8217; Equity</a></td>
<td class="text"><p id="xdx_80E_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zNBRq5QPJgRi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE&#160;12&#160;&#8211; <span id="xdx_82F_zs30ER1LAR56">Stockholders&#8217; Equity</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Authorized Capital</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Effective August 29, 2024, the Company increased its
authorized shares from <span id="xdx_90B_eus-gaap--CommonStockSharesAuthorized_iI_pip0_c20240829__srt--RangeAxis__srt--MinimumMember_zCSblRwPg4Kj" title="Common stock, shares authorized">24,000,000</span> to <span id="xdx_909_eus-gaap--CommonStockSharesAuthorized_iI_pip0_c20240829__srt--RangeAxis__srt--MaximumMember_zpDGzBELJzz8" title="Common stock, shares authorized">50,000,000</span> shares of common stock with a par value of $<span id="xdx_90C_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20240829_zMVH3ouVABuh" title="Common stock, par value">0.0001</span> per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Additionally, the Company is authorized to issue <span id="xdx_903_eus-gaap--PreferredStockSharesAuthorized_iI_pip0_c20250331__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zGMo66xNomC" title="Convertible preferred stock, shares authorized">714,286</span>
shares of convertible preferred stock with a par value of $<span id="xdx_909_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20250331__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zwr5d8BXwey6" title="Convertible preferred stock, par value">0.0001</span> per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Description of Common Stock</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Each share of common stock has the right to one vote.
The holders of common stock are entitled to dividends when funds are legally available and when declared by the board of directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>











<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Description of Series B Convertible Preferred
Stock</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On October 18, 2016, the Company&#8217;s board of
directors approved, and the Company entered into, a Section 382 rights agreement, or the Rights Agreement, with Computershare Inc., or
the Rights Agent. The Rights Agreement provides for a dividend of one preferred stock purchase right, or a Right, for each share of common
stock, par value $0.0001 per share, of the Company outstanding on November 1, 2016, or the Record Date. Each Right entitles the holder
to purchase from the Company one one-thousandth of a share of Series B Preferred Stock, par value $0.0001 per share, or the Preferred
Stock, for a purchase price of $10.00, subject to adjustment as provided in the Rights Agreement. The description and terms of the rights
are set forth in the Rights Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In connection with the adoption of the Rights Agreement,
the Company&#8217;s board of directors adopted a Certificate of Designation of Series B Preferred Stock. The Certificate of Designation
was filed with the Secretary of State of the State of Delaware and became effective on October 18, 2016.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s board of directors adopted the
Rights Agreement to protect shareholder value by guarding against a potential limitation on the Company&#8217;s ability to use its net
operating loss carryforwards, or NOLs, and other tax benefits, which may be used to reduce potential future income tax obligations. The
Company has experienced and continues to experience substantial operating losses, and under the Internal Revenue Code of 1986, as amended,
and rules promulgated thereunder, the Company may &#8220;carry forward&#8221; these NOLs and other tax benefits in certain circumstances
to offset any current and future earnings and thus reduce our income tax liability, subject to certain requirements and restrictions.
To the extent that the NOLs and other tax benefits do not otherwise become limited, the Company believes that it will be able to carry
forward a significant amount of NOLs and other tax benefits, and therefore these NOLs and other tax benefits could be a substantial asset
to the Company. However, if the Company experiences an &#8220;ownership change,&#8221; as defined in Section 382 of the Code, its ability
to use its NOLs and other tax benefits will be substantially limited. Generally, an ownership change would occur if our shareholders who
own, or are deemed to own, 5% or more of the Company&#8217;s common stock increase their collective ownership in the Company by more than
50% over a rolling three-year period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Sale of Common Stock</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On October 26, 2023, the Company entered into a placement
agency agreement with Maxim Group LLC (&#8220;Maxim&#8221;) pursuant to which Maxim agreed to use its reasonable best efforts to solicit
offers to purchase up to an aggregate of 425,000 shares of the Company&#8217;s common stock, par value $0.0001 per share.&#160; The Company
agreed to pay Maxim a cash fee equal to 8.0% of the gross proceeds from the offering, plus reimbursement of up to $<span id="xdx_903_eus-gaap--LegalFees_pn3p0_c20231025__20231026__us-gaap--TypeOfArrangementAxis__custom--PlacementAgencyAgreementMember_zgkJeKmteNn3" title="Legal fees and other expenses">75,000</span> of legal fees
and other expenses. Additionally, on October 26, 2023, the Company entered into a securities purchase agreement with the purchasers party
thereto for the sale and issuance of an aggregate of up to 425,000 shares of the Company&#8217;s common stock at a public offering price
of $4.00 per share. The closing of the offering occurred on October 30, 2023. In connection with the offering, the Company sold <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20231025__20231026__us-gaap--SubsidiarySaleOfStockAxis__custom--PublicOfferingMember_zSqya5SkFv61" title="Stock issued new, shares">425,000</span>
shares of the Company&#8217;s common stock for aggregate gross proceeds of $<span id="xdx_905_ecustom--ProceedsFromIssuanceOfCommonStockGross_pn3p0_c20231025__20231026__us-gaap--SubsidiarySaleOfStockAxis__custom--PublicOfferingMember_z5Zvy5nyafxl" title="Proceeds from sale of stock, gross">1,700,000</span> and net proceeds of $<span id="xdx_900_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn3p0_c20231025__20231026__us-gaap--SubsidiarySaleOfStockAxis__custom--PublicOfferingMember_zETqH2yfExl7" title="Proceeds from sale of stock, net">1,446,000</span>, after deducting
placement agent fees and other estimated offering expenses paid by the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On December 15, 2023, the Company entered into an
Equity Distribution Agreement (the &#8220;Agreement&#8221;), with Maxim pursuant to which the Company may offer and sell, from time to
time, through Maxim, as sales agent or principal, shares of its common stock, $0.0001 par value per share. Subject to the terms and conditions
of the Agreement, Maxim will use commercially reasonable efforts consistent with its normal trading and sales practices, applicable state
and federal law, rules and regulations and the rules of the Nasdaq Capital Market to sell shares from time to time based upon the Company&#8217;s
instructions, including any price, time or size limits specified by the Company. Under the Agreement, Maxim may sell shares by any method
deemed to be an &#8220;at the market&#8221; offering as defined in Rule 415 under the U.S. Securities Act of 1933, as amended, or any
other method permitted by law, including in privately negotiated transactions. Maxim&#8217;s obligations to sell shares under the Agreement
are subject to satisfaction of certain conditions, including customary closing conditions for transactions of this nature. The Company
will pay Maxim a commission of 3% of the aggregate gross proceeds from each sale of shares and has agreed to provide Maxim with customary
indemnification and contribution rights. The Company also agreed to reimburse Maxim for certain specified expenses of up to $<span id="xdx_90B_eus-gaap--LegalFees_pn3p0_c20231214__20231215__us-gaap--TypeOfArrangementAxis__custom--EquityDistributionAgreementMember_zNJUJvAUgosh" title="Legal fees and other expenses">20,000</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>











<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">In
connection with the</span> A<span style="font-family: Times New Roman, Times, Serif">greement that the Company entered into on December
15, 2023 with Maxim, on January 11, 2024, the Company sold <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20240110__20240111__dei--LegalEntityAxis__custom--MaximGroupLLCMember_zSmkghBrYNS8" title="Stock issued new, shares">96,154</span> shares of its common stock for gross proceeds of $<span id="xdx_909_ecustom--ProceedsFromIssuanceOfCommonStockGross_pn3p0_c20240110__20240111__dei--LegalEntityAxis__custom--MaximGroupLLCMember_z1jGynMJqfx3" title="Proceeds from sale of stock, gross">392,000</span> and net proceeds
of $<span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn3p0_c20240110__20240111__dei--LegalEntityAxis__custom--MaximGroupLLCMember_zkG4yvQpN5Ff" title="Proceeds from sale of stock, net">338,000</span> after deducting commissions and other estimated offering expenses paid by the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In connection with the Agreement that the Company
entered into on December 15, 2023 with Maxim, as amended, from May 13, 2024 to November 20, 2024 the Company sold <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20241119__20241120__dei--LegalEntityAxis__custom--MaximGroupLLCMember_zdXXzV6fRGLf" title="Stock issued new, shares">816,894</span> shares of its
common stock for gross proceeds of $<span id="xdx_90B_ecustom--ProceedsFromIssuanceOfCommonStockGross_pn3p0_c20241119__20241120__dei--LegalEntityAxis__custom--MaximGroupLLCMember_zATTioopjeic" title="Proceeds from sale of stock, gross">3,325,000</span> and net proceeds of $<span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn3p0_c20241119__20241120__dei--LegalEntityAxis__custom--MaximGroupLLCMember_zZpbSZerThTc" title="Proceeds from sale of stock, net">3,079,000</span> after deducting commissions and other offering expenses paid
by the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p id="xdx_802_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zqaVTI7J934i" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE&#160;13&#160;&#8211; <span id="xdx_82E_zjPQGi9SFVM1">Stock-Based Compensation</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>2016 Stock Plan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 2, 2016, upon recommendation of the board,
the stockholders approved the Company&#8217;s 2016 Equity Incentive Plan (the &#8220;2016 Plan&#8221;). The 2016 Plan is effective as
of September 2, 2016 and has a ten year term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The 2016 Plan provides for the grant of options, including
incentive stock options as defined in Section 422 of the Internal Revenue Code to employees, stock appreciation rights, restricted awards,
performance share awards and performance compensation awards to employees, non-employee directors, advisors and consultants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Options issued under the 2016 Plan generally have
a ten-year term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In accordance with the 2016 Plan, the stated exercise
price of an employee incentive stock option or a non-statutory stock option shall not be less than 100% of the estimated fair market value
of a share of common stock on the date of grant. An employee who owns more than 10% of the total combined voting power of all classes
of outstanding stock of the Company shall not be eligible for the grant of an employee incentive stock option unless such grant satisfies
the requirements of Section 422(c)(5) of the Internal Revenue Code.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Shares subject to awards that expire unexercised or
are forfeited or terminated for any other reason will again become available for issuance under the 2016 Plan. No participant in the 2016
Plan can receive more than 11,112 option grants, or other awards with respect to more than 13,334 shares in the aggregate in any calendar
year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The board has authorized <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pip0_c20160902__us-gaap--PlanNameAxis__custom--Plan2016Member_zxqGZiKKFJWh" title="Shares initially authorized for issuance">2,222</span> of the Company&#8217;s
common stock for issuance under the 2016 Plan, in addition to automatic increases provided for in the 2016 Plan through April 1, 2026.
The number of shares of the Company&#8217;s common stock reserved for issuance under the 2016 Plan will automatically increase, with no
further action by the stockholders, at the beginning of each fiscal year by an amount equal to the lesser of (i) 8% of the outstanding
shares of the Company&#8217;s common stock on the last day of the immediately preceding year, or (ii) an amount determined by the Company&#8217;s
board of directors. During the year ended March 31, 2019, the board of directors approved an increase of <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_pip0_c20180401__20190331__us-gaap--PlanNameAxis__custom--Plan2016Member_zCvCujZ2cDWc" title="Increase in shares authorized for issuance">243</span> shares authorized for issuance.
During the year ended March 31, 2020, the board of directors approved an increase of <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_pip0_c20190401__20200331__us-gaap--PlanNameAxis__custom--Plan2016Member_zXVt45xp6Gv5" title="Increase in shares authorized for issuance">5,266</span> shares authorized for issuance. During the
year ended March 31, 2022, the board of directors approved an increase of <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_pip0_c20210401__20220331__us-gaap--PlanNameAxis__custom--Plan2016Member_zAvMSHuQS47c" title="Increase in shares authorized for issuance">8,372</span> shares authorized for issuance. During the year ended
March 31, 2025, the board of directors approved an increase of <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_pip0_c20240401__20250331__us-gaap--PlanNameAxis__custom--Plan2016Member_z3ysErvDxxOg" title="Increase in shares authorized for issuance">62,429</span> shares authorized for issuance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At March 31, 2025 there were <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pip0_c20250331__us-gaap--PlanNameAxis__custom--Plan2016Member_zoaKrrBxjFh6" title="Shares available for future issuance">9,670</span> shares available
for future issuance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>











<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>2021 Stock Plan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 21, 2021, upon recommendation of the
board, the stockholders approved the Company&#8217;s 2021 Equity Incentive Plan (the &#8220;2021 Plan&#8221;). The 2021 Plan is effective
as of September 21, 2021 and has a five year term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The 2021 Plan provides for the grant of options, including
incentive stock options as defined in Section 422 of the Internal Revenue Code to employees, stock appreciation rights, restricted awards,
performance share awards and performance compensation awards to employees, non-employee directors, advisors and consultants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Options issued under the 2021 Plan generally have
a ten-year term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In accordance with the 2021 Plan, the stated exercise
price of an employee incentive stock option or a non-statutory stock option shall not be less than 100% of the estimated fair market value
of a share of common stock on the date of grant. An employee who owns more than 10% of the total combined voting power of all classes
of outstanding stock of the Company shall not be eligible for the grant of an employee incentive stock option unless such grant satisfies
the requirements of Section 422(c)(5) of the Internal Revenue Code.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Shares subject to awards that expire unexercised or
are forfeited or terminated for any other reason will again become available for issuance under the 2021 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The board has authorized <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_pip0_c20240401__20250331__us-gaap--PlanNameAxis__custom--Plan2021Member_zzQUdcMErmH" title="Increase in shares authorized for issuance">50,000</span> shares of the Company&#8217;s
common stock for issuance under the 2021 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At March 31, 2025, there were <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pip0_do_c20250331__us-gaap--PlanNameAxis__custom--Plan2021Member_zRLuMUs7S8P1" title="Shares available for future issuance">no</span> shares available
for future issuance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>2024 Stock Plan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On August 23, 2024, upon recommendation of the board,
the stockholders approved the Company&#8217;s 2024 Equity Incentive Plan (the &#8220;2024 Plan&#8221;). The 2024 Plan is effective as
of August 23, 2024 and has a five year term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The 2024 Plan provides for the grant of options, including
incentive stock options as defined in Section 422 of the Internal Revenue Code to employees, stock appreciation rights, restricted awards,
performance share awards and performance compensation awards to employees, non-employee directors, advisors and consultants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Options issued under the 2024 Plan generally have
a ten-year term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In accordance with the 2024 Plan, the stated exercise
price of an employee incentive stock option or a non-statutory stock option shall not be less than 100% of the estimated fair market value
of a share of common stock on the date of grant. An employee who owns more than 10% of the total combined voting power of all classes
of outstanding stock of the Company shall not be eligible for the grant of an employee incentive stock option unless such grant satisfies
the requirements of Section 422(c)(5) of the Internal Revenue Code.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Shares subject to awards that expire unexercised or
are forfeited or terminated for any other reason will again become available for issuance under the 2024 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>











<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The board has authorized <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_pip0_c20240401__20250331__us-gaap--PlanNameAxis__custom--Plan2024Member_zexGw4wqr2y4" title="Increase in shares authorized for issuance">50,000</span> shares of the Company&#8217;s
common stock for issuance under the 2024 Plan, in addition to automatic increases provided for in the 2024 Plan through April 1, 2029.
The number of shares of the Company&#8217;s common stock reserved for issuance under the 2024 Plan will automatically increase, with no
further action by the stockholders, at the beginning of each fiscal year by an amount equal to the lesser of (i) 5% of the outstanding
shares of the Company&#8217;s common stock on the last day of the immediately preceding year, or (ii) an amount determined by the Company&#8217;s
board of directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At March 31, 2025, there were <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pip0_c20250331__us-gaap--PlanNameAxis__custom--Plan2024Member_z2upLwOU6v24" title="Shares available for future issuance">5,000</span> shares available
for future issuance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Stock-Based Compensation</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company issues service, performance and market-based
stock options to employees and non-employees. The Company estimates the fair value of service and performance stock option awards using
the Black-Scholes option pricing model. The Company estimates the fair value of market-based stock option awards using a Monte-Carlo simulation.
Compensation expense for stock option awards is amortized on a straight-line basis over the awards&#8217; vesting period. Compensation
expense includes the impact of forfeitures as they are incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The expected term of the stock options represents
the average period the stock options are expected to remain outstanding and is based on the expected term calculated using the approach
prescribed by&#160;SEC Staff Accounting Bulletin No.&#160;110 for &#8220;plain vanilla&#8221; options. The expected stock price volatility
for the Company&#8217;s stock options was determined by using an average of the historical volatilities of the Company. The Company will
continue to analyze the stock price volatility and expected term assumptions as more data for the Company&#8217;s common stock and exercise
patterns become available. The risk-free interest rate assumption is based on the U.S. Treasury instruments whose term was consistent
with the expected term of the Company&#8217;s stock options. The expected dividend assumption is based on the Company&#8217;s history
and expectation of dividend payouts.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company estimated the fair value of employee and
non-employee stock options using the Black-Scholes option pricing model. The fair value of employee stock options is being amortized on
a straight-line basis over the requisite service periods of the respective awards. The fair value of employee stock options was estimated
using the following weighted-average assumptions:</p>

<table cellpadding="0" cellspacing="0" id="xdx_886_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zY4u1rsQxBC1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock-Based Compensation (Details-Assumptions)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8BC_zxRpjcQAdiuh" style="display: none">Schedule of weighted-average assumptions of fair value of employee stock options</span></td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended March&#160;31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: left">Fair value of the Company&#8217;s common stock on date of grant</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240401__20250331_zGhb9ITzBBfg" style="width: 13%; text-align: right" title="Fair value of the Company common stock on date of grant">2.68</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230401__20240331_zQT76tpBxat2" style="width: 13%; text-align: right" title="Fair value of the Company common stock on date of grant">0.19</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240401__20250331_zz1tLX7P3m1h" title="Expected term">5.68</span> yrs</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230401__20240331_zNtg5cM8buT3" title="Expected term">5.56</span> yrs</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_c20240401__20250331_zAHBKkyLo7a2" title="Risk-free interest rate">4.57</span>%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_c20230401__20240331_zBmVeKzH6EEl" title="Risk-free interest rate">3.87</span>%</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pip0_dp_c20240401__20250331_zPNIAMZmm0Z5" title="Dividend yield">0.00</span>%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pip0_dp_c20230401__20240331_zYyY5GWkLyDj" title="Dividend yield">0.00</span>%</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>Volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20240401__20250331_zpjBiJ86d2wi" title="Volatility">109.91</span>%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20230401__20240331_zkYcvPwPB4cd" title="Volatility">98.40</span>%</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Fair value of options granted</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20240401__20250331_zWkfRIVKSqya" style="text-align: right" title="Fair value of options granted">2.23</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20230401__20240331_zyXYILnWUOD4" style="text-align: right" title="Fair value of options granted">0.15</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AD_zibMZQ3bT4Oi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the years ended March 31, 2025 and 2024, the
Company incurred $<span id="xdx_90F_eus-gaap--ShareBasedCompensation_pn3p0_c20240401__20250331_ztOeGi3NmJva" title="Stock-based compensation">224,000</span> and $<span id="xdx_906_eus-gaap--ShareBasedCompensation_pn3p0_c20230401__20240331_zhxIVoMAiJLb" title="Stock-based compensation">516,000</span>, respectively of stock-based compensation expense. All stock-based compensation expense incurred
is included in selling, general and administrative expense in the accompanying consolidated statements of comprehensive loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At March 31, 2025, there were unrecognized compensation
costs of $<span id="xdx_90F_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pn3p0_c20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zIJ36kpkF3za" title="Unrecognized compensation costs">250,000</span> related to stock options which is expected to be recognized over a weighted-average amortization period of <span id="xdx_904_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zTrGlGieQKqi" title="Weighted average amortization period">1.58</span> years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>











<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Stock-Based Award Activity</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Stock-based awards outstanding at March 31, 2025 under
the various plans are as follows:</p>

<table cellpadding="0" cellspacing="0" id="xdx_882_ecustom--ScheduleOfStockbasedAwardsOutstandingByPlanTableTextBlock_zGog1iJpO2lc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 50%" summary="xdx: Disclosure - Stock-Based Compensation (Details-Plans)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8BA_zn1GUR3OtfLc" style="display: none">Schedule of stock based awards outstanding by plan</span></td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-weight: bold">Plan</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Stock Options</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 72%">2011 Plan</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20250331__us-gaap--PlanNameAxis__custom--Plan2011Member_zLSscwD521wg" style="width: 24%; text-align: right" title="Options outstanding">3,998</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>2016 Plan</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20250331__us-gaap--PlanNameAxis__custom--Plan2016Member_zhseAxtwgM5j" style="text-align: right" title="Options outstanding">38,942</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 1pt">2021 Plan</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20250331__us-gaap--PlanNameAxis__custom--Plan2021Member_zaRZrqjGQqB9" style="border-bottom: Black 1pt solid; text-align: right" title="Options outstanding">30,141</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20250331_zcMREqnMHgh7" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding">73,081</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="margin: 0">&#160;</p>

<p style="margin: 0">Stock options award activity is as follows:</p>

<p style="margin: 0"></p>

<table cellpadding="0" cellspacing="0" id="xdx_881_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_pn3n3_zSphkuHyCIVj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock-Based Compensation (Details-Option activity)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span id="xdx_8BF_zYoPp0tHSJnk" style="display: none">Schedule of options activity</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of<br/> Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted-<br/> Average<br/> Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted-<br/> Average<br/> Contractual Term</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Aggregate<br/> Intrinsic<br/> Value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 40%">Outstanding at April 1, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pip0_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zx9V5kvM8KD3" style="width: 11%; text-align: right" title="Number of options outstanding, beginning balance">51,675</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pip0_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zVFOi2NIYw16" style="width: 11%; text-align: right" title="Weighted-average exercise price options outstanding, beginning balance">62.60</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Options granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pip0_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zKZ1qZMvkHa6" style="text-align: right" title="Number of options granted">49,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pip0_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z12GzOa621Y1" style="text-align: right" title="Weighted-average exercise price, options granted">2.68</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Options exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pip0_di0_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z8CdCaZvxUol" style="text-align: right" title="Number of options exercised">(27,750</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pip0_d0_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zBHb21k4LAZb" style="text-align: right" title="Weighted-average exercise price, options exercised">2.99</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Options forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pip0_di_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zCoWwKK0Syta" style="text-align: right" title="Number of options forfeited">(250</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pip0_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zisavVve5yL4" style="text-align: right" title="Weighted-average exercise price, options forfeited">3.60</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Options expired</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pip0_di_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zkzyXbnj5cO2" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options expired">(94</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pip0_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zM1KFBXrAAv3" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted-average exercise price, options expired">1,485.96</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Outstanding at March 31, 2025</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pip0_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zsJbOoemMG29" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options outstanding, ending balance">73,081</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pip0_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zhtM1O6FwxM9" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-average exercise price options outstanding, ending balance">43.27</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zTNjH8QDnwOh" title="Weighted- average contractual term outstanding">8.82</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_pip0_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zg8EMUdCHLDe" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value per share, outstanding">2.19</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 2.5pt">Exercisable at March 31, 2025</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pip0_c20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zW1C8HV0YNn9" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options, exercisable">39,751</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pip0_c20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zYki2puJa73b" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-average exercise price, exercisable">74.86</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z7P2HxCcDvoi" title="Weighted- average contractual term, exercisable">7.71</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableInPeriodGrantDateIntrinsicValue_pip0_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zBANKWSBcXd6" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value per share, exercisable">2.19</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The aggregate intrinsic value of stock options is
calculated as the difference between the exercise price of the underlying stock options and the fair value of the Company&#8217;s common
stock, or $<span id="xdx_908_eus-gaap--SharePrice_iI_pip0_c20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zJpIuheUoJa5">2.19</span> and $<span id="xdx_904_eus-gaap--SharePrice_iI_pip0_c20240331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zIeqOGEM4xSl">3.40</span> per share at March 31, 2025 and 2024, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Restricted stock award activity is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>



<p style="margin: 0"></p>

<table cellpadding="0" cellspacing="0" id="xdx_885_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_pn3n3_zNHiu2hCpU8i" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock-Based Compensation (Details-Restricted stock activity)">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span id="xdx_8B8_zLuSztfe4RUj" style="display: none">Schedule of unvested restricted stock activity</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1.8pt 0 0; text-align: center"><b>Number&#160;of</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1.8pt 0 0; text-align: center"><b>Shares</b></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1.8pt 0 0; text-align: center"><b>Weighted</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1.8pt 0 0; text-align: center"><b>Average Award</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1.8pt 0 0; text-align: center"><b>Date Fair Value</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1.8pt 0 0; text-align: center"><b>per Share</b></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Unvested restricted stock awards outstanding at April 1, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pip0_d0_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zucBrBhKZoA8" style="text-align: right" title="Number of unvested restricted stock awards outstanding, beginning balance">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pip0_d0_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zXq3ujbUAXXf" style="text-align: right" title="Weighted-average award date fair value per share, unvested RSAs outstanding, beginning balance">&#8211;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 66%; text-align: left">Restricted stock awards granted</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pip0_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zuse3bs8vKrd" style="width: 13%; text-align: right" title="Number of restricted stock awards granted">54,538</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pip0_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zYJzBOqrstdg" style="width: 13%; text-align: right" title="Weighted-average award date fair value per share, unvested RSAs granted">2.92</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Restricted stock awards vested</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pip0_di_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zNlWPajOM1qa" style="border-bottom: Black 1pt solid; text-align: right" title="Number of restricted stock awards vested">(9,538</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pip0_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zspybwAIX0A1" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted-average award date fair value per share, unvested RSAs vested">4.08</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Unvested restricted stock awards outstanding at March 31, 2025</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pip0_d0_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zTz3dcreSpfl" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of unvested restricted stock awards outstanding, ending balance">45,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pip0_d0_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zvKukhiSkyRd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-average award date fair value per share, unvested RSAs outstanding, ending balance">2.68</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A tax benefit of $<span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense_pn3p0_c20240401__20250331_z4UcHHZeO55e" title="Stock based compensation options exercised">123,000</span> has been recognized relating
to stock-based compensation as a result of non-qualified stock options and restricted stock exercised during the year ending March 31,
2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company issues new shares of common stock upon
exercise of stock options or release of restricted stock awards.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>











<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p id="xdx_804_eus-gaap--IncomeTaxDisclosureTextBlock_zedWN5cZZZs6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE&#160;14&#160;&#8211; <span id="xdx_823_zJW1lCrxp84k">Income Taxes</span> </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The income tax provision (benefit) is based on the
following net taxable loss before income taxes, which are from domestic and foreign sources:</p>

<table cellpadding="0" cellspacing="0" id="xdx_889_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_pn3n3_zcjFSUccZDn9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details-Income source)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B2_z5FF0boDHmEf" style="display: none">Schedule of income tax provision from domestic and foreign sources</span></td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended March&#160;31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%">Domestic</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--ProfitLoss_pn3p0_c20240401__20250331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zaqDwFXvz53h" style="width: 13%; text-align: right" title="Income before income taxes">(161,000</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--ProfitLoss_pn3p0_c20230401__20240331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zfy1yQUfOI45" style="width: 13%; text-align: right" title="Income before income taxes">(364,000</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Foreign</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ProfitLoss_pn3p0_c20240401__20250331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zmKIf3SeJEt8" style="border-bottom: Black 1pt solid; text-align: right" title="Income before income taxes">(2,749,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ProfitLoss_pn3p0_c20230401__20240331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zpQOWqkgmACd" style="border-bottom: Black 1pt solid; text-align: right" title="Income before income taxes">(4,559,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 2.5pt">Totals</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--ProfitLoss_pn3p0_c20240401__20250331_zL608gH8ruN4" style="border-bottom: Black 2.5pt double; text-align: right" title="Income before income taxes">(2,910,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--ProfitLoss_pn3p0_c20230401__20240331_zwRRhstxQIgh" style="border-bottom: Black 2.5pt double; text-align: right" title="Income before income taxes">(4,923,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The federal, state and foreign income tax provisions
are summarized as follows:</p>

<table cellpadding="0" cellspacing="0" id="xdx_88B_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_pn3n3_zY3IfRNnScvg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details-Income tax expense)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B8_zK0DBnlPZPF4" style="display: none">Schedule of federal, state and foreign income tax provisions</span></td><td>&#160;</td>
    <td colspan="2" id="xdx_499_20240401__20250331_zLPdh3S4pOu9" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_492_20230401__20240331_z6oO3rsxphrf" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended March&#160;31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_iB" style="vertical-align: bottom">
    <td>Current:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_pn3p0_zIiMUP5oZdub" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%">State</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">(2,000</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">(2,000</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_iB_zurQPAtm8yfa" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>Deferred:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredForeignIncomeTaxExpenseBenefit_pn3p0_zW00FLkegDSl" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Foreign</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(548,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">198,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredIncomeTaxExpenseBenefit_pn3p0_zkoNXLQiTdf3" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total income tax (expense) benefit</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(550,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">196,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A reconciliation of the statutory federal income tax
rate to the Company&#8217;s effective tax rate for continuing operations is as follows:</p>

<table cellpadding="0" cellspacing="0" id="xdx_881_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zLZHeGGJZM7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details-Reconciliation of tax rate)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B4_z25lFhUBWLG3" style="display: none">Schedule of reconciliation of federal    income
tax rate to effective rate</span></td><td>&#160;</td>
    <td colspan="2" id="xdx_491_20240401__20250331_z6UIQyLeALFh" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_492_20230401__20240331_zm0B4uZCEXcg" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year&#160;Ended&#160;March&#160;31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pip0_dp_marate_zPKHIxaxLhfg" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: left">Expected federal statutory rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right">21.0%</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right">21.0%</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_iN_pip0_dpi_zLGNa2ul5tS" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">State income taxes, net of federal benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.1%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.2%</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_pip0_dp_zq7UbDuEbcV3" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Foreign earnings taxed at different rates</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.7%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.9%</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpense_iN_pip0_dpi_zX26ez95xmM5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Effect of permanent differences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7.4%</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5.8%</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_pip0_dp_zcpP6WRnYoO3" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Effect of intercompany interest permanent differences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(30.2%</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(20.1%</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_ecustom--TrueupsOfStateDeferredAssets_pip0_dp_z1qn3IWDXl72" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">True-up of state deferred assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(68.4%</td><td style="padding-bottom: 1pt; text-align: left">)&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1.5%</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_iN_dpi_zwRb7XBckbC6" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><b style="display: none">Total effective rate</b></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(78.2%</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.7%</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pip0_dp_zqgwwIqZ9PR3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Change in valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(59.3%</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2.3%</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pip0_dp_mtrate_zp1DtXOARE7e" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 2.5pt">Totals</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(18.9%</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">4.0%</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>















<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The tax effects of temporary differences that give
rise to significant components of our deferred tax assets consist of:</p>

<table cellpadding="0" cellspacing="0" id="xdx_884_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_pn3n3_zMbRIQ1dE2a" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details-Deferred taxes)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B5_zFibXnib7PU" style="display: none">Schedule of deferred tax assets</span></td><td>&#160;</td>
    <td colspan="2" id="xdx_491_20250331_z5oBANAgAPQ1" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_49B_20240331_zHpcMumE8sni" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March&#160;31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsGrossAbstract_iB" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Deferred tax assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_i01I_pn3p0_maDTAGz412_zRUpdLmRE6Di" style="vertical-align: bottom; background-color: White">
    <td style="width: 66%; text-align: left">Net operating loss carryforwards</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">26,456,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">28,692,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_i01I_pn3p0_maDTAGz412_zaF4wlPfWEJ5" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Research and development tax credit carryforwards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,749,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,796,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_i01I_pn3p0_maDTAGz412_zhtpPCQnkvC5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">879,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">913,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_i01I_pn3p0_maDTAGz412_z8KAJqvbqdDa" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Reserves and accruals</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">618,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">659,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseOther_i01I_pn3p0_d0_maDTAGz412_z6yxVYR8k8cc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">41,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">52,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--DeferredTaxAssetsLeaseLiability_i01I_pn3p0_maDTAGz412_zjeSqDemov7e" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Lease liability</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">10,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">22,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--DeferredTaxAssetsGross_i01TI_pn3p0_mtDTAGz412_maDTANzqCr_zmB7ZrzLMHd6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Gross deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">29,753,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">32,134,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsValuationAllowance_i01NI_pn3p0_di_msDTANzqCr_zKS1XlHQajH" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Less valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(29,062,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(30,836,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsNet_i01TI_pn3p0_mtDTANzqCr_maDTALNzfiK_zFtiYZAiwxp9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Total deferred tax assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">691,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">1,298,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--DeferredTaxLiabilitiesAbstract_i01B" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Deferred tax liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--DeferredTaxLiabilitiesPropertyPlantAndEquipment_i02NI_pn3p0_di_maDITLzfJx_zRys7CZb6wh6" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Fixed assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(10,000</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxLiabilitiesPrepaidExpenses_i02NI_pn3p0_di_maDITLzfJx_z2P9APkIY1qe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Prepaid expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(86,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(121,000</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40C_ecustom--DeferredTaxLiabilitiesRightOfUseAsset_i02NI_pn3p0_di_maDITLzfJx_zLmjoR5HOfA3" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Right of use asset</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(10,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(22,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--DeferredIncomeTaxLiabilities_i02NTI_pn3p0_di_mtDITLzfJx_msDTALNzfiK_zBs9h4F8yDXb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Gross deferred tax liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(102,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(153,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsLiabilitiesNet_i02TI_pn3p0_d0_mtDTALNzfiK_zPIPHtQKKgv7" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 2.5pt">Net deferred tax assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">589,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,145,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of March 31, 2025, we have net operating loss carryforwards
for federal, state and foreign income tax purposes of approximately $<span id="xdx_902_eus-gaap--OperatingLossCarryforwards_iI_pn3p0_c20250331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zfq1HKeJ42D" title="Net operating loss carryforwards">107,700,000</span>, $<span id="xdx_908_eus-gaap--OperatingLossCarryforwards_iI_pn3p0_c20250331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zhHglQJqAhal" title="Net operating loss carryforwards">42,800,000</span> and $<span id="xdx_904_eus-gaap--OperatingLossCarryforwards_iI_pn3p0_c20250331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zve7MpTT3qd4" title="Net operating loss carryforwards">800,000</span>, respectively. Due to the Tax
Cuts and Job Act, federal NOL generated after March 31, 2018 have an indefinite life. Federal NOL generated on and before March 31, 2017
began to expire in 2024, if not utilized. State NOLs will begin to expire in the year 2026, if not utilized. Foreign NOLs will carry forward
for 10 years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 467.4pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of March 31, 2025, we had federal and California
research and development credit carryforward of approximately $<span id="xdx_901_eus-gaap--TaxCreditCarryforwardAmount_iI_pn3p0_c20250331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zWvzoyaJ6Nz2" title="Research credit carryforwards">950,000</span> and $<span id="xdx_905_eus-gaap--TaxCreditCarryforwardAmount_iI_pn3p0_c20250331__us-gaap--IncomeTaxAuthorityAxis__custom--CaliforniaResearchAndDevelopmentMember_zHEI3RDlYn2a" title="Research credit carryforwards">790,000</span>, respectively. As of March 31, 2024, we had federal
and California research and development credit carryforward of approximately $<span id="xdx_908_eus-gaap--TaxCreditCarryforwardAmount_iI_pn3p0_c20240331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_ziW095B2ybtd" title="Research credit carryforwards">1,006,000</span> and $<span id="xdx_90D_eus-gaap--TaxCreditCarryforwardAmount_iI_pn3p0_c20240331__us-gaap--IncomeTaxAuthorityAxis__custom--CaliforniaResearchAndDevelopmentMember_zishS8NiTAL2" title="Research credit carryforwards">790,000</span> respectively. The federal research
and development credits began to expire in 2024 while the California research and development credits have no expiration date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Section 382 of the Internal Revenue Code limits the
use of the federal net operating losses in certain situations where changes occur in stock ownership of a company. If the Company should
have an ownership change of more than 50% of the value of the Company's capital stock, utilization of the carryforwards could be restricted.
The Company is not aware of any changes in ownership that would result in a change in control under Internal Revenue Code section 382.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company released the valuation allowance recorded
against its Netherlands deferred tax assets as of March 31, 2024. Given its recent history of earnings, current earnings and anticipated
future earnings, the Company concluded that there is sufficient positive evidence available to reach a conclusion that the valuation allowance
is no longer needed in the Netherlands. The release of the valuation allowance resulted in the recognition of deferred tax assets of $114,000.
The Company, after considering all available evidence, fully reserved against all deferred tax assets in the U.S. since it is more likely
than not such benefits will not be realized in future periods. The Company will continue to evaluate its deferred tax assets to determine
whether any changes in circumstances could affect the realization of their future benefit.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>











<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has filed tax returns for federal, state
and foreign jurisdictions. The Company&#8217;s evaluation of uncertain tax matters was performed for tax years ended through March 31,
2025. Generally, the Company is subject to audit for the years ended March 31, 2023, 2022 and 2021. The Company has elected to retain
its existing accounting policy with respect to the treatment of interest and penalties attributable to income taxes, and continues to
reflect interest and penalties attributable to income taxes, to the extent they arise, as a component of its income tax provision or benefit
as well as its outstanding income tax assets and liabilities. The Company believes that its income tax positions and deductions would
be sustained on audit and does not anticipate any adjustments to result in a material change to its financial position.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">Employee Benefit Plan</a></td>
<td class="text"><p id="xdx_808_eus-gaap--CompensationAndEmployeeBenefitPlansTextBlock_zSA62saGIjH6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE&#160;15&#160;&#8211; <span id="xdx_826_zVp4npyxuGrb">Employee Benefit Plan</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has a program to contribute and administer
a qualified 401(k) plan. Under the 401(k) plan, the Company matches employee contributions to the plan up to 4% of the employee&#8217;s
salary. Company contributions to the plan amounted to an aggregate of $<span id="xdx_901_eus-gaap--PensionAndOtherPostretirementBenefitContributions_pn3p0_c20240401__20250331_znY7Eb9LV075" title="Company contributions to 401(k) plan">88,000</span> and $<span id="xdx_900_eus-gaap--PensionAndOtherPostretirementBenefitContributions_pn3p0_c20230401__20240331_zeqX3ySD2Ypk" title="Company contributions to 401(k) plan">82,000</span> for the years ended March 31, 2025 and 2024,
respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 710<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/710/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 712<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/712/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/715/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Disaggregation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue Disaggregation</a></td>
<td class="text"><p id="xdx_808_eus-gaap--RevenueFromContractWithCustomerTextBlock_zJ0nuwunqaQ3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE&#160;16 &#8211; <span id="xdx_82E_zAXtTEVvYdf1">Revenue Disaggregation</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company generates product revenues from products
which are sold into the human and animal healthcare markets, and the Company generates service revenues from laboratory testing services
which are provided to medical device manufacturers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table presents the Company&#8217;s disaggregated revenues
by source:</p>

<table cellpadding="0" cellspacing="0" id="xdx_881_eus-gaap--DisaggregationOfRevenueTableTextBlock_pn3n3_zG7aKFsAn6Li" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Revenue Disaggregation (Details - Disaggregation of revenue)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B2_zDo0500DkMY" style="display: none">Schedule of disaggregated revenue by  source</span></td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended March 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Product:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; width: 66%; text-align: left">Human Care</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20240401__20250331__us-gaap--StatementBusinessSegmentsAxis__custom--HumanCareMember__srt--ProductOrServiceAxis__us-gaap--ProductMember_zbMuKtD4qDf2" style="width: 13%; text-align: right" title="Revenues">12,079,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20230401__20240331__us-gaap--StatementBusinessSegmentsAxis__custom--HumanCareMember__srt--ProductOrServiceAxis__us-gaap--ProductMember_z3G9EVURUamd" style="width: 13%; text-align: right" title="Revenues">10,110,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Animal Care</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20240401__20250331__us-gaap--StatementBusinessSegmentsAxis__custom--AnimalCareMember__srt--ProductOrServiceAxis__us-gaap--ProductMember_z2ec75gSQ7P3" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues">1,653,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20230401__20240331__us-gaap--StatementBusinessSegmentsAxis__custom--AnimalCareMember__srt--ProductOrServiceAxis__us-gaap--ProductMember_zi4RFG28E6V6" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues">2,203,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Total Product Revenue</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20240401__20250331__srt--ProductOrServiceAxis__us-gaap--ProductMember_ze5f1aVNo9jb" style="text-align: right" title="Revenues">13,732,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20230401__20240331__srt--ProductOrServiceAxis__us-gaap--ProductMember_zuOZtvvttFw5" style="text-align: right" title="Revenues">12,313,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Service/Royalty</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20240401__20250331__srt--ProductOrServiceAxis__us-gaap--ServiceMember__us-gaap--StatementBusinessSegmentsAxis__custom--ServiceAndRoyaltyMember_zQxKYFNwyoEk" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues">556,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20230401__20240331__srt--ProductOrServiceAxis__us-gaap--ServiceMember__us-gaap--StatementBusinessSegmentsAxis__custom--ServiceAndRoyaltyMember_ztIKU2csL1ml" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues">422,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20240401__20250331_zVNwjt92tag8" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenues">14,288,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20230401__20240331_z2tLug2zuoQd" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenues">12,735,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table shows the Company&#8217;s revenues
by geographic region:</p>

<table cellpadding="0" cellspacing="0" id="xdx_881_eus-gaap--ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_pn3n3_zhVgq0GAig38" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Revenue Disaggregation (Details - Geographic regions)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B4_zCeSA7dcCsne" style="display: none">Schedule of revenues by geographic region</span></td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended March 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: left">United States</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20240401__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__country--US_z9btNfmBsoK9" style="width: 13%; text-align: right" title="Revenues">2,611,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20230401__20240331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__country--US_zvRAAqzLQbB3" style="width: 13%; text-align: right" title="Revenues">3,058,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Europe</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20240401__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__srt--EuropeMember_zsnbz3JUVMJ6" style="text-align: right" title="Revenues">5,523,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20230401__20240331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__srt--EuropeMember_zKC94FNbtO5h" style="text-align: right" title="Revenues">4,781,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>Asia</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20240401__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__srt--AsiaMember_zmWtWTGuRhA" style="text-align: right" title="Revenues">2,317,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20230401__20240331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__srt--AsiaMember_zuAakEMFLsQ1" style="text-align: right" title="Revenues">2,298,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Latin America</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20240401__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__srt--LatinAmericaMember_zE2pJaE0as7b" style="text-align: right" title="Revenues">2,962,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20230401__20240331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__srt--LatinAmericaMember_zFA9UIPKkVyd" style="text-align: right" title="Revenues">1,726,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Rest of the World</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20240401__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__custom--RestOfTheWorldMember_zenVN9BBNG07" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues">875,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20230401__20240331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__custom--RestOfTheWorldMember_znhzNmIb6zW9" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues">872,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20240401__20250331_zDcse8CR7OM" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenues">14,288,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20230401__20240331_zfxc6Qh44bMg" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenues">12,735,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-15<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><p id="xdx_841_eus-gaap--ConsolidationPolicyTextBlock_zFCMgRfKpc75" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_867_zWUv3pyVpebg">Principles of Consolidation</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying consolidated financial statements
include the accounts of the Company and its wholly-owned subsidiaries, Aquamed Technologies, Inc. (&#8220;Aquamed&#8221;), Oculus Technologies
of Mexico S.A. de C.V. (&#8220;OTM&#8221;), and Sonoma Pharmaceuticals Netherlands, B.V. (&#8220;SP Europe&#8221;). Aquamed has no current
operations. All significant intercompany accounts and transactions have been eliminated in consolidation. The functional currency for
the Company's wholly-owned subsidiaries incorporated outside the United States (&#8220;U.S.&#8221;) is denominated in local currency.
All intercompany transactions and balances have been eliminated in consolidation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of presentation</a></td>
<td class="text"><p id="xdx_840_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zWO4SrWVIK9i" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i><span id="xdx_86E_z0OSA6GpE8dk">Basis of presentation</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying consolidated financial statements
have been prepared by the Company pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;)
and are in conformity with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;). The Company&#8217;s fiscal year end is
March 31. Unless otherwise stated, all years and dates refer to the fiscal year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i></i></b></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p id="xdx_845_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zbi6hHFy5V1j" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i><span id="xdx_86D_z1JpcBObEDKg">Cash and Cash Equivalents</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Cash and cash equivalents include cash on hand and
all highly liquid investments with an original maturity of three months or less when purchased. The Company&#8217;s cash equivalents are
held in prime money market investments with strong sponsor organizations which are monitored on a continuous basis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p id="xdx_84E_eus-gaap--UseOfEstimates_zARxaseIFqd9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_86C_zuboPzXHnq0j">Use of Estimates</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of consolidated financial statements
in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities
and disclosures of contingent liabilities at the dates of the consolidated financial statements and the reported amounts of revenues and
expenses during the reporting periods. Actual results could differ from these estimates. Significant estimates and assumptions include
reserves and write-downs related to receivables and inventories, the valuation allowance relating to the Company&#8217;s deferred tax
assets and the valuation of equity. Periodically, the Company evaluates and adjusts estimates accordingly.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p id="xdx_84A_eus-gaap--RevenueRecognitionPolicyTextBlock_z1wMiCXxsrO2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_863_z48omwCJAjZ">Revenue Recognition</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recognizes revenue in accordance with
Accounting Standards Codification (&#8220;ASC&#8221;), Topic 606 Revenue from Contracts with Customers (&#8220;Topic 606&#8221;). Revenue
is recognized when the Company transfers promised goods or services to the customer, in an amount that reflects the consideration which
the Company expects to receive in exchange for those goods or services. In determining the appropriate amount of revenue to be recognized
as the Company fulfills its obligations under the agreement, the Company performs the following steps: (i)&#160;identification of the
promised goods or services in the contract; (ii)&#160;determination of whether the promised goods or services are performance obligations,
including whether they are distinct in the context of the contract; (iii)&#160;measurement of the transaction price, including the constraint
on variable consideration; (iv)&#160;allocation of the transaction price to the performance obligations; and (v)&#160;recognition of revenue
when (or as) the Company satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable
that it will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company derives the majority of its revenue through
sales of its products directly to end users and to distributors. The Company also sells products to a customer base, including hospitals,
medical centers, doctors, pharmacies, distributors and wholesalers. The Company has also entered into agreements to license its technology
and products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>











<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company considers customer purchase orders, which
in some cases are governed by master sales agreements, to be the contracts with a customer. For each contract, the Company considers the
promise to transfer products, each of which are distinct, to be the identified performance obligations. In determining the transaction
price the Company evaluates whether the price is subject to refund or adjustment to determine the net consideration to which it expects
to be entitled.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For all of the Company&#8217;s sales to non-consignment
distribution channels, revenue is recognized when control of the product is transferred to the customer (i.e. when its performance obligation
is satisfied), which typically occurs when title passes to the customer upon shipment but could occur when the customer receives the product
based on the terms of the agreement with the customer. For product sales to its value-added resellers, non-stocking distributors and end-user
customers, the Company grants return privileges to its customers, and because the Company has a long history with its customers, the Company
is able to estimate the amount of product that will be returned.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has entered into consignment arrangements,
in which goods are left in the possession of another party to sell. As products are sold from the customer to third parties, the Company
recognizes revenue based on a variable percentage of a fixed price.&#160; Revenue recognized varies depending on whether a patient is
covered by insurance or is not covered by insurance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Sales to stocking distributors are made under terms
with fixed pricing and limited rights of return (known as &#8220;stock rotation&#8221;) of the Company&#8217;s products held in their
inventory. Revenue from sales to distributors is recognized upon the transfer of control to the distributor.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company assessed the promised goods and services
in the technical support contract with Invekra for a ten-year period as being a distinct service that Invekra can benefit from on its
own and as separately identifiable from any other promises within the contract. Given that the distinct service is not substantially the
same as other goods and services within the Invekra contract, the Company accounted for the distinct service as a performance obligation.
At March 31, 2025, 2024 and 2023, the Company had deferred revenue related to Invekra in the amounts of $<span id="xdx_90A_eus-gaap--DeferredRevenue_iI_c20250331__srt--CounterpartyNameAxis__custom--InvekraMember_zO9rRnEo6sg6" title="Deferred revenue">69,000</span>, $<span id="xdx_901_eus-gaap--DeferredRevenue_iI_c20240331__srt--CounterpartyNameAxis__custom--InvekraMember_ziXOijcRWpwk" title="Deferred revenue">152,000</span> and $<span id="xdx_902_eus-gaap--DeferredRevenue_iI_c20230331__srt--CounterpartyNameAxis__custom--InvekraMember_zvSL9N13U10b" title="Deferred revenue">199,000</span>,
respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk and Major Customers</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--ConcentrationRiskCreditRisk_zqlCuFOr3dfi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_86A_z4W2cjcpOXcj">Concentration of Credit Risk and Major Customers</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Financial instruments that potentially subject the
Company to concentration of credit risk consist principally of cash, cash equivalents and accounts receivable. Cash and cash equivalents
are maintained in financial institutions in the United States, Mexico and the Netherlands. The Company is exposed to credit risk in the
event of default by these financial institutions for amounts in excess of the Federal Deposit Insurance Corporation insured limits. Cash
and cash equivalents held in foreign banks are intentionally kept at minimal levels, and therefore have minimal credit risk associated
with them. We currently have $3,004,000 of deposits above federally insured limits.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table shows major customers revenues
as a percentage of revenue:</p>

<table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_zURPyO22S4I1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B2_zFIfATK9pKB9" style="display: none">Schedule of concentration of risk</span></td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Year Ended March 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: left">Customer A</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b style="display: none"><span style="display: none"></span><span id="xdx_90D_ecustom--ConcentrationRiskPercentage2_pip0_dp_c20240401__20250331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerAMember_fKg_____zm3kWnC3lWsd" title="Concentration risk, percentage">0</span></b>*%</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right"><span id="xdx_90C_ecustom--ConcentrationRiskPercentage2_pip0_dp_c20230401__20240331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerAMember_zs1bdHhh0kR9" title="Concentration risk, percentage">17</span>%</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Customer B</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_ecustom--ConcentrationRiskPercentage2_pip0_dp_c20240401__20250331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerBMember_z4KIjyeKukt9" title="Concentration risk, percentage">21</span>%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_ecustom--ConcentrationRiskPercentage2_pip0_dp_c20230401__20240331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerBMember_zBZGw8JhTJu7" title="Concentration risk, percentage">15</span>%</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Customer C</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_ecustom--ConcentrationRiskPercentage2_pip0_dp_c20240401__20250331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerCMember_zd6MRrjG5LH4" title="Concentration risk, percentage">18</span>%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_905_ecustom--ConcentrationRiskPercentage2_pip0_dp_c20230401__20240331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerCMember_zrvShVJuihOl" title="Concentration risk, percentage">14</span>%</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table shows major customers accounts
receivable balances as a percentage of net accounts receivables:</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: left">Customer B</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right"><b style="display: none"><span id="xdx_90F_ecustom--ConcentrationRiskPercentage2_pip0_dp_c20240401__20250331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerBMember_fKg_____zSPeLzx9ieyc" title="Concentration risk, percentage">0</span></b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*%</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right"><span id="xdx_907_ecustom--ConcentrationRiskPercentage2_pip0_dp_c20230401__20240331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerBMember_zhhrzMCrV01k" title="Concentration risk, percentage">13</span>%</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Customer D</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_ecustom--ConcentrationRiskPercentage2_pip0_dp_c20240401__20250331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerDMember_zRqpvevFHgF6" title="Concentration risk, percentage">24</span>%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_ecustom--ConcentrationRiskPercentage2_pip0_dp_c20230401__20240331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerDMember_zEwXw7xH1If5" title="Concentration risk, percentage">17</span>%</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 4%"><span id="xdx_F09_zisvXV838286" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">* </span></td>
    <td id="xdx_F19_zg6Uo3NevcBg" style="width: 96%">% <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents less than
    10%</span></td></tr>
  </table>
<p id="xdx_8AB_zKPUBR4dA57j" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>











<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesPolicyTextBlock', window );">Accounts Receivable</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--ReceivablesPolicyTextBlock_zPTyarxsC5N9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_860_zTS6l5klpGF">Accounts Receivable</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Trade accounts receivable are recorded net of allowances
for cash discounts for prompt payment, doubtful accounts, and sales returns. Estimates for cash discounts and sales returns are based
on analysis of contractual terms and historical trends.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s policy is to reserve for uncollectible
accounts based on its best estimate of the amount of probable credit losses in its existing accounts receivable. The Company periodically
reviews its accounts receivable to determine whether an allowance for doubtful accounts is necessary based on an analysis of past due
accounts and other factors that may indicate that the realization of an account may be in doubt. Other factors that the Company considers
include its existing contractual obligations, historical payment patterns of its customers and individual customer circumstances, an analysis
of days sales outstanding by customer and geographic region, and a review of the local economic environment and its potential impact on
government funding and reimbursement practices. Account balances deemed to be uncollectible are charged to the allowance after all means
of collection have been exhausted and the potential for recovery is considered remote. The Company did <span id="xdx_909_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pn3p0_do_c20250331__srt--ProductOrServiceAxis__custom--ProbableCreditLossesMember_zW7wAdkE2NY9" title="Allowance for doubtful accounts"><span id="xdx_90F_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pn3p0_do_c20240331__srt--ProductOrServiceAxis__custom--ProbableCreditLossesMember_zYdQNrIU7HM7" title="Allowance for doubtful accounts"><span id="xdx_903_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pn3p0_do_c20230331__srt--ProductOrServiceAxis__custom--ProbableCreditLossesMember_zOc54kajgLh9" title="Allowance for doubtful accounts">no</span></span></span>t deem it necessary to record
an allowance for doubtful accounts for probable credit losses at March 31, 2025, March 31, 2024 and March 31, 2023. Additionally, at March
31, 2025, 2024 and 2023, the Company has allowances of $<span id="xdx_909_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pn3p0_c20250331__srt--ProductOrServiceAxis__custom--PotentialDiscountsReturnsDistributorFeesAndRebatesMember_zX36jruvOYM2" title="Allowance for doubtful accounts">8,000</span>, $<span id="xdx_90E_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pn3p0_c20240331__srt--ProductOrServiceAxis__custom--PotentialDiscountsReturnsDistributorFeesAndRebatesMember_zKceXqOGAQn7" title="Allowance for doubtful accounts">27,000</span> and $<span id="xdx_90B_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pn3p0_c20230331__srt--ProductOrServiceAxis__custom--PotentialDiscountsReturnsDistributorFeesAndRebatesMember_zPChwlnQfONi" title="Allowance for doubtful accounts">16,000</span>, respectively, related to potential discounts, returns,
distributor fees and rebates. The allowances are included in accounts receivable, net in the accompanying consolidated balance sheets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text"><p id="xdx_846_eus-gaap--InventoryPolicyTextBlock_zZwKbfNYAqn2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_86D_z1WH85EQNkGe">Inventories</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Inventories are stated at the lower of cost, cost
being determined on a standard cost basis (which approximates actual cost on a first-in, first-out basis), or net realizable value.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Due to changing market conditions, estimated future
requirements, age of the inventories on hand and production of new products, the Company regularly reviews inventory quantities on hand
and records a provision to write down excess and obsolete inventory to its estimated net realizable value. At March 31, 2025 and 2024,
the Company recorded provisions to reduce the carrying amounts of inventories to their net realizable value in the amounts of $<span id="xdx_90D_eus-gaap--InventoryValuationReserves_iI_pn3p0_c20250331_zNTLPOQMjbl1" title="Inventory valuation reserves">298,000</span>
and $<span id="xdx_90E_eus-gaap--InventoryValuationReserves_iI_pn3p0_c20240331_zSpzd72K9l4f">296,000</span>, respectively, which is included in inventories, net on the Company&#8217;s accompanying consolidated balance sheets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Financial Assets and Liabilities</a></td>
<td class="text"><p id="xdx_84C_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zBuZLvGvya3i" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_86E_zwRFaxwCdK11">Financial Assets and Liabilities</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Financial instruments, including cash and cash equivalents,
accounts receivable and accounts payable are carried at cost, which management believes approximates fair value due to the short-term
nature of these instruments. The fair value of capital lease obligations and approximates their carrying amounts as a market rate of interest
is attached to their repayment. The Company measures the fair value of financial assets and liabilities based on the exchange price that
would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset
or liability in an orderly transaction between market participants on the measurement date. The Company maximizes the use of observable
inputs and minimizes the use of unobservable inputs when measuring fair value. The Company uses three levels of inputs that may be used
to measure fair value:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level&#160;1&#160;&#8211; quoted prices in active
markets for identical assets or liabilities;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level&#160;2&#160;&#8211; quoted prices for similar
assets and liabilities in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived
valuations in which all significant inputs and significant value drivers are observable in active markets;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level&#160;3&#160;&#8211; inputs that are unobservable
(for example cash flow modeling inputs based on assumptions).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>











<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 3 liabilities are valued using unobservable
inputs to the valuation methodology that are significant to the measurement of the fair value of the liabilities. For fair value measurements
categorized within Level 3 of the fair value hierarchy, the Company&#8217;s accounting and finance department, who report to the Chief
Financial Officer, determine its valuation policies and procedures. The development and determination of the unobservable inputs for Level
3 fair value measurements and fair value calculations are the responsibility of the Company&#8217;s accounting and finance department
and are approved by the Chief Financial Officer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of March 31, 2025 and 2024, there were <span id="xdx_908_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_pn3p0_do_c20240401__20250331_zEuzx62r1c" title="Transfers in or out of level 3"><span id="xdx_906_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_pn3p0_do_c20230401__20240331_z103ndt1RRJ2" title="Transfers in or out of level 3">no</span></span> transfers
in or out of Level 3 from other levels in the fair value hierarchy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p id="xdx_84C_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zyAALfoPUln6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_860_zCNI749PVwT8">Property and Equipment</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Property and equipment are stated at cost less accumulated
depreciation. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the
respective assets. Depreciation of leasehold improvements is computed using the straight-line method over the lesser of the estimated
useful life of the improvement or the remaining term of the lease. Estimated useful asset life by classification is as follows:&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_88B_ecustom--PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock_z9YQN5p6tJKg" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details-Useful lives)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B9_zM2xeXOwrCCe" style="display: none">Schedule of property and equipment estimated useful life</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Years</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 86%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office equipment</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 12%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20250331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_z8tCHer5CRwh" title="Useful asset life">3</span></span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manufacturing, lab and other equipment</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20250331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zdPY9cCcanw" title="Useful asset life">5</span></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furniture and fixtures</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20250331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zcEr4Z1vwZIb" title="Useful asset life">7</span></span></td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Upon retirement or sale, the cost and related accumulated
depreciation are removed from the consolidated balance sheet and the resulting gain or loss is reflected in operations. Maintenance and
repairs are charged to operations as incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><p id="xdx_84E_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zczGeUAYV3Pf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_86B_zJn9hugvmEM7">Impairment of Long-Lived Assets</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company periodically reviews the carrying values
of its long-lived assets when events or changes in circumstances would indicate that it is more likely than not that their carrying values
may exceed their realizable values, and records impairment charges when considered necessary. Specific potential indicators of impairment
include, but are not necessarily limited to:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a significant decrease in the fair value of an asset;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a significant change in the extent or manner in which an asset is used or a significant physical change in an asset;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a significant adverse change in legal factors or in the business climate that affects the value of an asset;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an adverse action or assessment by the U.S.&#160;Food and Drug Administration or another regulator; and</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Symbol; font-size: 10pt">&#183;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an accumulation of costs significantly in excess of the amount originally expected to acquire or construct an asset; and operating or cash flow losses combined with a history of operating or cash flow losses or a projection or forecast that demonstrates continuing losses associated with an income-producing asset.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>











<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">When circumstances indicate that an impairment may
have occurred, the Company tests such assets for recoverability by comparing the estimated undiscounted future cash flows expected to
result from the use of such assets and their eventual disposition to their carrying amounts. In estimating these future cash flows, assets
and liabilities are grouped at the lowest level for which there are identifiable cash flows that are largely independent of the cash flows
generated by other such groups. If the undiscounted future cash flows are less than the carrying amount of the asset, an impairment loss,
measured as the excess of the carrying value of the asset over its estimated fair value, will be recognized. The cash flow estimates used
in such calculations are based on estimates and assumptions, using all available information that management believes is reasonable. The
Company did <span id="xdx_90B_eus-gaap--AssetImpairmentCharges_pn3p0_do_c20240401__20250331_zCVjrL7UJIX5" title="Impairment of long lived assets"><span id="xdx_90D_eus-gaap--AssetImpairmentCharges_pn3p0_do_c20230401__20240331_zVkJgRm2Mdkf" title="Impairment of long lived assets">no</span></span>t record impairment losses for the years ended March 31, 2025 and 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><p id="xdx_845_eus-gaap--ResearchAndDevelopmentExpensePolicy_zrSsLGROXZac" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_86E_zFthTNrrfmVi">Research and Development</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Research and development expenses are charged to operations
as incurred and consists primarily of personnel expenses, clinical and regulatory services and supplies. For the years ended March 31,
2025 and 2024, research and development expense amounted to $<span id="xdx_900_eus-gaap--ResearchAndDevelopmentExpense_pn3p0_c20240401__20250331_zl6YV1lL8wLl" title="Research and development expenses">1,814,000</span> and $<span id="xdx_903_eus-gaap--ResearchAndDevelopmentExpense_pn3p0_c20230401__20240331_zTfBPPtLwtb1" title="Research and development expenses">1,871,000</span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Advertising Costs</a></td>
<td class="text"><p id="xdx_845_eus-gaap--AdvertisingCostsPolicyTextBlock_zLZeZWIZQEce" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_86D_zxvr5GkT24Gh">Advertising Costs</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Advertising costs are charged to operations as incurred.
Advertising costs amounted to $<span id="xdx_901_eus-gaap--MarketingExpense_pn3p0_c20240401__20250331_zm8yljMrOCJ3" title="Advertising costs">190,000</span> and $<span id="xdx_901_eus-gaap--MarketingExpense_pn3p0_c20230401__20240331_zy00uSelb4nl" title="Advertising costs">156,000</span> for the years ended March 31, 2025 and 2024, respectively. Advertising costs are included
in selling, general and administrative expenses in the accompanying consolidated statements of comprehensive loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SNOA_ShippingAndHandlingCost1PolicyTextBlock', window );">Shipping and Handling Costs</a></td>
<td class="text"><p id="xdx_848_ecustom--ShippingAndHandlingCost1PolicyTextBlock_zHYgmM3ZqYo5" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i><span id="xdx_86B_zBBmV5Jyaq45">Shipping and Handling Costs</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company classifies amounts billed to customers
related to shipping and handling in sale transactions as product revenues. The corresponding shipping and handling costs incurred are
recorded in cost of product revenues. For the years ended March 31, 2025 and 2024, the Company recorded revenue related to shipping and
handling costs of $<span id="xdx_90E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20240401__20250331__srt--ProductOrServiceAxis__us-gaap--ShippingAndHandlingMember_z1kK9aignMee" title="Revenues">18,000</span> and $<span id="xdx_90B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20230401__20240331__srt--ProductOrServiceAxis__us-gaap--ShippingAndHandlingMember_zEfQQNdAdq9" title="Revenues">28,000</span>, respectively. These amounts are included in revenues in the accompanying consolidated statements
of comprehensive loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Reporting</a></td>
<td class="text"><p id="xdx_848_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zByY8TNCHpb5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_861_zm6POr9eOYzg">Foreign Currency Reporting</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s subsidiary, OTM, uses the local
currency (Mexican Pesos) as its functional currency and its subsidiary, SP Europe, uses the local currency (Euro) as its functional currency.
Assets and liabilities are translated at exchange rates in effect at the balance sheet date, and revenue and expense accounts are translated
at average exchange rates during the period. Resulting translation adjustments amounted to losses of $<span id="xdx_90E_ecustom--OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationLossAdjustmentBeforeTaxPortionAttributableToParent_pn3p0_c20240401__20250331__us-gaap--IncomeStatementLocationAxis__us-gaap--OtherComprehensiveIncomeMember_zbkTsSEsWFL" title="Foreign currency translation adjustment loss">1,653,000</span> and gains of $<span id="xdx_90D_ecustom--OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainAdjustmentBeforeTaxPortionAttributableToParent_pn3p0_c20230401__20240331__us-gaap--IncomeStatementLocationAxis__us-gaap--OtherComprehensiveIncomeMember_zMXOCNhpjITg" title="Foreign currency translation adjustment gain">695,000</span>
for the years ended March 31, 2025 and 2024, respectively. These amounts were recorded in other comprehensive loss in the accompanying
consolidated statements of comprehensive loss for the years ended March 31, 2025 and 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Foreign currency transaction losses relate primarily
to trade payables and receivables and intercompany transactions between subsidiaries OTM and SP Europe. These transactions are expected
to be settled in the foreseeable future. The Company recorded foreign currency transaction gains of $<span id="xdx_90C_eus-gaap--ForeignCurrencyTransactionGainBeforeTax_pn3p0_c20240401__20250331__us-gaap--IncomeStatementLocationAxis__us-gaap--OtherOperatingIncomeExpenseMember_zg09fRLQWx06" title="Foreign currency transaction gain">243,000</span> and losses of $<span id="xdx_904_eus-gaap--ForeignCurrencyTransactionLossBeforeTax_pn3p0_c20230401__20240331__us-gaap--IncomeStatementLocationAxis__us-gaap--OtherOperatingIncomeExpenseMember_zUrCXDQodvIc" title="Foreign currency transaction loss">825,000</span> for
the years ended March 31, 2025 and 2024, respectively. The related amounts were recorded in other income (expense) in the accompanying
consolidated statements of comprehensive loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>











<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><p id="xdx_84B_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zaj8FWd4iUY5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_869_z5PeiaDESwAl">Stock-Based Compensation</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for share-based awards exchanged
for employee services at the estimated grant date fair value of the award. The Company estimates the fair value of employee stock option
awards using the Black-Scholes option pricing model. The Company amortizes the fair value of employee stock options on a straight-line
basis over the requisite service period of the awards.&#160; Compensation expense includes the impact of forfeitures for all stock options
as incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for equity instruments issued
to non-employees at their fair value on the measurement date. The measurement of stock-based compensation is subject to periodic adjustment
as the underlying equity instrument vests or becomes non-forfeitable. Non-employee stock-based compensation charges are amortized over
the vesting period or as earned.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p id="xdx_841_eus-gaap--IncomeTaxPolicyTextBlock_zNsCtF9G88Tk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_861_zstvjz8290e3">Income Taxes</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Deferred tax assets and liabilities are determined
based on the differences between the financial reporting and tax bases of assets and liabilities and net operating loss and credit carryforwards
using enacted tax rates in effect for the year in which the differences are expected to impact taxable income. Valuation allowances are
established when necessary to reduce deferred tax assets to the amounts expected to be realized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Tax benefits claimed or expected to be claimed on
a tax return are recorded in the Company&#8217;s consolidated financial statements. A tax benefit from an uncertain tax position is only
recognized if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the
technical merits of the position. The tax benefits recognized in the consolidated financial statements from such a position are measured
based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate resolution. Uncertain tax
positions have had no impact on the Company&#8217;s consolidated financial condition, results of comprehensive loss or cash flows.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><p id="xdx_844_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zlrbnMPJy9x7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_865_zLOGtLVLckb4">Comprehensive Loss</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Other comprehensive loss includes all changes in stockholders&#8217;
equity during a period from non-owner sources and is reported in the consolidated statements of changes in stockholders&#8217; equity.
To date, other comprehensive loss consists of changes in accumulated foreign currency translation adjustments. Accumulated other comprehensive
losses at March 31, 2025 and 2024 were $<span id="xdx_905_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_iNI_pn3p0_di_c20250331_zxCDSkwmUNEb" title="Accumulated other comprehensive loss">4,376,000</span> and $<span id="xdx_908_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_iNI_pn3p0_di_c20240331_zgzxoULws9Kc" title="Accumulated other comprehensive loss">2,723,000</span>, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i></i></b></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Share</a></td>
<td class="text"><p id="xdx_84F_eus-gaap--EarningsPerSharePolicyTextBlock_zpJt2VoxNfvk" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i><span id="xdx_861_zWe7aV4iEVtg">Net Loss per Share</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company computes basic net loss per share by dividing
net loss per share available to common stockholders by the weighted average number of common shares outstanding for the period and excludes
the effects of any potentially dilutive securities. Diluted earnings per share, if presented, would include the dilution that would occur
upon the exercise or conversion of all potentially dilutive securities into common stock using the &#8220;treasury stock&#8221; and/or
&#8220;if converted&#8221; methods as applicable.</p>

<table cellpadding="0" cellspacing="0" id="xdx_88F_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_pn3n3_zQMVT2I9u4s5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details - Earnings per share)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8BE_zLPDMRGi4yR4" style="display: none">Schedule of computation of earnings per share</span></td><td>&#160;</td>
    <td colspan="2" id="xdx_493_20240401__20250331_zWUtF7nS72Hj" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_490_20230401__20240331_zbQOYGMhuxv8" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Year Ended March 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-style: italic; text-align: justify">(In thousands, except per share data)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--NetIncomeLoss_zvPHG1sUVEZf" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: justify; padding-bottom: 2.5pt">Net loss</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 13%; text-align: right">(3,457</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 13%; text-align: right">(4,835</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Weighted-average shares outstanding: basic and diluted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_906_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20240401__20250331_zHmQpmxLzLe2" title="Weighted-average number of shares: basic"><span id="xdx_906_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20240401__20250331_zCDm0AKmLbNf" title="Weighted-average number of shares: diluted">1,241</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20230401__20240331_zPC1HfhiTm8l" title="Weighted-average number of shares: basic"><span id="xdx_90C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20230401__20240331_zM3Y70VsLL15" title="Weighted-average number of shares: diluted">455</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Net loss per share: basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--EarningsPerShareBasic_pip0_c20240401__20250331_zlxfDkaNIuOh" title="Net loss per share: basic"><span id="xdx_908_eus-gaap--EarningsPerShareDiluted_pip0_c20240401__20250331_zuPDGioUbHCl" title="Net loss per share: diluted">(2.79</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_eus-gaap--EarningsPerShareBasic_pip0_c20230401__20240331_zIXPvimnH9sj" title="Net loss per share: basic"><span id="xdx_903_eus-gaap--EarningsPerShareDiluted_pip0_c20230401__20240331_z7gXdVrOEh5g" title="Net loss per share: diluted">(10.63</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>











<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The computation of basic and diluted loss per share
for the years ended March 31, 2025 and 2024 excludes the potentially dilutive securities summarized in the table below because their inclusion
would be anti-dilutive.</p>

<table cellpadding="0" cellspacing="0" id="xdx_889_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_pn3n3_zX61miRCNuQg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details - Antidilutive shares)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8BF_zWNkXJhCOLd9" style="display: none">Schedule of antidilutive shares</span></td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-style: italic">(In thousands)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: left">Common stock to be issued upon exercise of options</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20240401__20250331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zBk6aclmuVK3" style="width: 13%; text-align: right" title="Antidilutive shares">73</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20230401__20240331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_z0hBUAViGQkk" style="width: 13%; text-align: right" title="Antidilutive shares">52</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Common stock to be issued upon vesting of restricted stock units</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_d0_c20240401__20250331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockUnitsMember_ze0KvSHOnXyk" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive shares">45</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_d0_c20230401__20240331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockUnitsMember_zvW2tD8pJZB5" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive shares">&#8211;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20240401__20250331_z61stojKYFSa" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive shares">118</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20230401__20240331_z052IKLT9YAg" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive shares">52</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SNOA_ConvertiblePreferredStockPolicyTextBlock', window );">Convertible Preferred Stock</a></td>
<td class="text"><p id="xdx_849_ecustom--ConvertiblePreferredStockPolicyTextBlock_zTSZEVEHfJB1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_863_zpJiJv2ta99c">Convertible Preferred Stock</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company applies the accounting standards for distinguishing
liabilities from equity when determining the classification and measurement of its preferred stock. Shares that are subject to mandatory
redemption (if any) are classified as liability instruments and are measured at fair value. The Company classifies conditionally redeemable
preferred shares, which includes preferred shares that feature redemption rights that are either within the control of the holder or subject
to redemption upon the occurrence of uncertain events not solely within the Company&#8217;s control, as temporary equity. At all other
times, preferred shares are classified as stockholders' equity. There are <span id="xdx_90B_eus-gaap--PreferredStockSharesIssued_iI_pip0_do_c20250331_zD131bkgvo27" title="Preferred stock, shares issued">no</span> shares issued as of March 31, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text"><p id="xdx_848_eus-gaap--SegmentReportingPolicyPolicyTextBlock_z8U1KU9n1Ug5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_86F_z1x7JkOJP5u4">Segment Reporting</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has one primary business activity and operate in one reportable
segment. The Company&#8217;s chief operating decision maker (&#8220;CODM&#8221;) is its Chief Executive Officer (&#8220;CEO&#8221;) who
evaluates performance and makes operating decisions about allocating resources based on financial data presented on a consolidated basis.
The measures of profitability and the significant segment expenses reviewed by the CODM are consistent with these financial statements
and footnotes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsPolicyPolicyTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--SubsequentEventsPolicyPolicyTextBlock_z5blvubMPCZb" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i><span id="xdx_86A_zG2oQtqrhGk6">Subsequent Events</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Management has evaluated subsequent events or transactions
occurring through the date these consolidated financial statements were issued. All events requiring disclosure have been incorporated
into the notes to the consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Standards</a></td>
<td class="text"><p id="xdx_842_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zaligiqAgjO1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_867_zbiuXHAVh7b2">Recent Accounting Standards</span></i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has evaluated all the recent accounting
standards and determined that none are material to it.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SNOA_ConvertiblePreferredStockPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SNOA_ConvertiblePreferredStockPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SNOA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SNOA_ShippingAndHandlingCost1PolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SNOA_ShippingAndHandlingCost1PolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SNOA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 35<br> -Topic 720<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483406/720-35-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 330<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478411/912-330-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/330/tableOfContent<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 270<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482989/270-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481569/310-20-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reporting subsequent events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Schedule of concentration of risk</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_zURPyO22S4I1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B2_zFIfATK9pKB9" style="display: none">Schedule of concentration of risk</span></td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Year Ended March 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: left">Customer A</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b style="display: none"><span style="display: none"></span><span id="xdx_90D_ecustom--ConcentrationRiskPercentage2_pip0_dp_c20240401__20250331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerAMember_fKg_____zm3kWnC3lWsd" title="Concentration risk, percentage">0</span></b>*%</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right"><span id="xdx_90C_ecustom--ConcentrationRiskPercentage2_pip0_dp_c20230401__20240331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerAMember_zs1bdHhh0kR9" title="Concentration risk, percentage">17</span>%</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Customer B</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_ecustom--ConcentrationRiskPercentage2_pip0_dp_c20240401__20250331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerBMember_z4KIjyeKukt9" title="Concentration risk, percentage">21</span>%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_ecustom--ConcentrationRiskPercentage2_pip0_dp_c20230401__20240331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerBMember_zBZGw8JhTJu7" title="Concentration risk, percentage">15</span>%</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Customer C</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_ecustom--ConcentrationRiskPercentage2_pip0_dp_c20240401__20250331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerCMember_zd6MRrjG5LH4" title="Concentration risk, percentage">18</span>%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_905_ecustom--ConcentrationRiskPercentage2_pip0_dp_c20230401__20240331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerCMember_zrvShVJuihOl" title="Concentration risk, percentage">14</span>%</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table shows major customers accounts
receivable balances as a percentage of net accounts receivables:</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: left">Customer B</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right"><b style="display: none"><span id="xdx_90F_ecustom--ConcentrationRiskPercentage2_pip0_dp_c20240401__20250331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerBMember_fKg_____zSPeLzx9ieyc" title="Concentration risk, percentage">0</span></b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*%</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right"><span id="xdx_907_ecustom--ConcentrationRiskPercentage2_pip0_dp_c20230401__20240331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerBMember_zhhrzMCrV01k" title="Concentration risk, percentage">13</span>%</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Customer D</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_ecustom--ConcentrationRiskPercentage2_pip0_dp_c20240401__20250331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerDMember_zRqpvevFHgF6" title="Concentration risk, percentage">24</span>%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_ecustom--ConcentrationRiskPercentage2_pip0_dp_c20230401__20240331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerDMember_zEwXw7xH1If5" title="Concentration risk, percentage">17</span>%</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 4%"><span id="xdx_F09_zisvXV838286" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">* </span></td>
    <td id="xdx_F19_zg6Uo3NevcBg" style="width: 96%">% <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents less than
    10%</span></td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SNOA_PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock', window );">Schedule of property and equipment estimated useful life</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_88B_ecustom--PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock_z9YQN5p6tJKg" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details-Useful lives)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B9_zM2xeXOwrCCe" style="display: none">Schedule of property and equipment estimated useful life</span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Years</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 86%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office equipment</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 12%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20250331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_z8tCHer5CRwh" title="Useful asset life">3</span></span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manufacturing, lab and other equipment</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20250331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zdPY9cCcanw" title="Useful asset life">5</span></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furniture and fixtures</span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20250331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zcEr4Z1vwZIb" title="Useful asset life">7</span></span></td>
    <td>&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of computation of earnings per share</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_88F_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_pn3n3_zQMVT2I9u4s5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details - Earnings per share)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8BE_zLPDMRGi4yR4" style="display: none">Schedule of computation of earnings per share</span></td><td>&#160;</td>
    <td colspan="2" id="xdx_493_20240401__20250331_zWUtF7nS72Hj" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_490_20230401__20240331_zbQOYGMhuxv8" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Year Ended March 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-style: italic; text-align: justify">(In thousands, except per share data)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--NetIncomeLoss_zvPHG1sUVEZf" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: justify; padding-bottom: 2.5pt">Net loss</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 13%; text-align: right">(3,457</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 13%; text-align: right">(4,835</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Weighted-average shares outstanding: basic and diluted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_906_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20240401__20250331_zHmQpmxLzLe2" title="Weighted-average number of shares: basic"><span id="xdx_906_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20240401__20250331_zCDm0AKmLbNf" title="Weighted-average number of shares: diluted">1,241</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20230401__20240331_zPC1HfhiTm8l" title="Weighted-average number of shares: basic"><span id="xdx_90C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20230401__20240331_zM3Y70VsLL15" title="Weighted-average number of shares: diluted">455</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify; padding-bottom: 2.5pt">Net loss per share: basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--EarningsPerShareBasic_pip0_c20240401__20250331_zlxfDkaNIuOh" title="Net loss per share: basic"><span id="xdx_908_eus-gaap--EarningsPerShareDiluted_pip0_c20240401__20250331_zuPDGioUbHCl" title="Net loss per share: diluted">(2.79</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_eus-gaap--EarningsPerShareBasic_pip0_c20230401__20240331_zIXPvimnH9sj" title="Net loss per share: basic"><span id="xdx_903_eus-gaap--EarningsPerShareDiluted_pip0_c20230401__20240331_z7gXdVrOEh5g" title="Net loss per share: diluted">(10.63</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of antidilutive shares</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_889_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_pn3n3_zX61miRCNuQg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details - Antidilutive shares)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8BF_zWNkXJhCOLd9" style="display: none">Schedule of antidilutive shares</span></td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-style: italic">(In thousands)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: left">Common stock to be issued upon exercise of options</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20240401__20250331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zBk6aclmuVK3" style="width: 13%; text-align: right" title="Antidilutive shares">73</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20230401__20240331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_z0hBUAViGQkk" style="width: 13%; text-align: right" title="Antidilutive shares">52</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Common stock to be issued upon vesting of restricted stock units</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_d0_c20240401__20250331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockUnitsMember_ze0KvSHOnXyk" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive shares">45</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_d0_c20230401__20240331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockUnitsMember_zvW2tD8pJZB5" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive shares">&#8211;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20240401__20250331_z61stojKYFSa" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive shares">118</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20230401__20240331_z052IKLT9YAg" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive shares">52</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SNOA_PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SNOA_PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SNOA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-16<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Receivable (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock', window );">Schedule of accounts receivable</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_88A_eus-gaap--ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_pn3n3_zsLLptBzYht6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Accounts Receivable (Details)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8BC_zQEh7Rl2tFKl" style="display: none">Schedule of accounts
    receivable</span></td><td>&#160;</td>
    <td colspan="2" id="xdx_499_20250331_zEzYUvCD1pm" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_490_20240331_zuNI0FO9oKUb" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March&#160;31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AccountsReceivableGrossCurrent_iI_pn3p0_maARNCzw0O_zkniCw3Vrj3a" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: left">Accounts receivable</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">2,240,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">2,925,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iNI_pn3p0_di_hsrt--ProductOrServiceAxis__custom--PotentialDiscountsReturnsDistributorFeesAndRebatesMember_msARNCzw0O_z1IyPnEOwFc4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Less: discounts, rebates, distributor fees and returns</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(8,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(27,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--AccountsReceivableNetCurrent_iTI_pn3p0_mtARNCzw0O_zD73MAMoB86d" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total accounts receivable, net</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,232,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,898,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of inventories</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_885_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_pn3n3_zclZDn1Ampdl" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Inventories (Details)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B0_ziSP6Up1QKal" style="display: none">Schedule of inventories</span></td><td>&#160;</td>
    <td colspan="2" id="xdx_49F_20250331_zSUjscxoVyE2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_492_20240331_zTeL1za7t7Yj" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March&#160;31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--InventoryRawMaterialsNetOfReserves_iI_pn3p0_maIGzA0w_z0T6ta6jCeN8" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: left">Raw materials</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">1,395,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">1,802,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--InventoryFinishedGoodsNetOfReserves_iI_pn3p0_maIGzA0w_zjTLh3wPMYD9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Finished goods</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,818,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,213,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--InventoryGross_iTI_pn3p0_mtIGzA0w_maINzHEX_zoa8ualtCGJf" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><b style="display: none">Inventories, gross</b></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,213,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,015,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--InventoryValuationReserves_iNI_pn3p0_di_msINzHEX_zXEz7igVfYO5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Less: allowance for obsolete and excess inventory</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(298,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(296,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--InventoryNet_iTI_pn3p0_mtINzHEX_zxOU6ZdhLTah" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total inventories</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,915,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,719,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Schedule of prepaid expenses and other current assets</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_881_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_pn3n3_zmpfHru8uDW6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Prepaid Expenses and Other Current Assets (Details)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B8_zRuyoXDE8aDi" style="display: none">Schedule of prepaid expenses and other current assets</span></td><td>&#160;</td>
    <td colspan="2" id="xdx_498_20250331_zyIttJz1rCjb" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_49D_20240331_zGv05CgxGUmg" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March&#160;31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--PrepaidInsurance_iI_pn3p0_maPEAOAz4GC_z91VyCrIieAb" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: left">Prepaid insurance</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">236,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">340,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--PrepaidTaxes_iI_pn3p0_maPEAOAz4GC_zdmq4l3G0Emf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">VAT prepaid to Mexican tax authorities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,531,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,096,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OtherPrepaidExpenseCurrent_iI_pn3p0_maPEAOAz4GC_zQwxZAIZpNTi" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Other prepaid expenses and other current assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">148,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">105,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_pn3p0_mtPEAOAz4GC_zQqBZd3zmPog" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><b style="display: none">Total prepaid expenses and other current assets</b></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,915,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,541,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property and equipment, net</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_888_eus-gaap--PropertyPlantAndEquipmentTextBlock_pn3n3_zxuNNYxexi9h" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Property and Equipment (Details)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8BD_zs6Z0Myh0Hbi" style="display: none">Schedule of property and equipment, net</span></td><td>&#160;</td>
    <td colspan="2" id="xdx_49E_20250331_z9n1dCl0j75c" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_497_20240331_zR6mXFTmjlm" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March&#160;31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--MachineryAndEquipmentGross_iI_pn3p0_maPPAEGzAkZ_zUBy7HDgQ867" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: left">Manufacturing, lab, and other equipment</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">1,471,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">1,776,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentOther_iI_pn3p0_maPPAEGzAkZ_zxcA3GMgbZJa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Office equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">217,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">236,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--FurnitureAndFixturesGross_iI_pn3p0_maPPAEGzAkZ_z3NHH521HaSd" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Furniture and fixtures</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">121,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">128,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--LeaseholdImprovementsGross_iI_pn3p0_maPPAEGzAkZ_zbSBLjCOr9A1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Leasehold improvements</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">491,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">605,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--PropertyPlantAndEquipmentGross_iTI_pn3p0_mtPPAEGzAkZ_maPPAENzQSU_zKZxcPJYZCbd" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><b style="display: none">Property and equipment, gross</b></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,300,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,745,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3p0_di_msPPAENzQSU_zOs97KtK8Qfk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Less: accumulated depreciation</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(2,075,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(2,380,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3p0_mtPPAENzQSU_zK7EHdnHWqpf" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total property and equipment, net <span style="color: #EEEEEE">and equipment, net&#160;</span></span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">225,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">365,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of accrued expenses and other current liabilities</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_885_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zkHL2a7Xoyx9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Accrued Expenses and Other Current Liabilities (Details)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B5_zuEwrbCu4g82" style="display: none">Schedule of accrued expenses and other current liabilities</span></td><td>&#160;</td>
    <td colspan="2" id="xdx_49E_20250331_zU8fZsWO8wXj" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_491_20240331_z1rtcf5snPN1" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March&#160;31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_pn3p0_maAPAOAzS7o_zMaukLFPSq68" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: left">Salaries and related costs</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">1,737,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">1,419,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pn3p0_maAPAOAzS7o_zxgsIUe1e6v4" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">487,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">694,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AccountsPayableAndOtherAccruedLiabilities_iTI_pn3p0_mtAPAOAzS7o_zRhlHzF9G3Fk" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total accrued expenses and other current liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,224,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,113,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of lease information</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--LeaseCostTableTextBlock_pn3n3_zvNwdzhJdoV1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Leases (Details - Balance sheet information related to leases)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8BE_zVgwzlUfHuE5" style="display: none">Schedule of lease information</span></td><td>&#160;</td>
    <td colspan="2" id="xdx_49A_20250331_zgufW7mhuRC5" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_493_20240331_z7WQg1YtTAif" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">March 31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">March 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LeasesOperatingAbstract_iB_zhAvz7KwSmok" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="font-weight: bold; text-align: justify">Operating leases:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3p0_zC45qOjy3EG1" style="vertical-align: bottom; background-color: White">
    <td style="width: 66%; text-align: justify">Operating lease right-of-use assets</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">84,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">286,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pn3p0_zkl11NlOGgGk" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: justify">Operating lease liabilities &#8211; current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">58,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">198,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pn3p0_zALlRW1HaZgj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Operating lease liabilities &#8211; non-current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">27,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">87,000</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Other information related to leases is presented below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Year ended</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>March 31, 2025</b></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year ended<br/> March 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="font-weight: bold; text-align: left">Lease cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 66%; text-align: left">Operating lease cost</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--OperatingLeaseCost_pn3p0_c20240401__20250331_zBwtpOYMj9a7" style="width: 13%; text-align: right" title="Operating lease cost">365,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--OperatingLeaseCost_pn3p0_c20230401__20240331_zfY39wOUQiba" style="width: 13%; text-align: right" title="Operating lease cost">380,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Other information:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Operating cash flows from operating leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--OperatingLeaseRightOfUseAssetAmortizationExpense_iN_pn3p0_di_c20240401__20250331_zAZcXdqojH6j" style="text-align: right" title="Operating cash flows from operating leases">(174,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--OperatingLeaseRightOfUseAssetAmortizationExpense_iN_pn3p0_di_c20230401__20240331_z7WHCMHY2tmh" style="text-align: right" title="Operating cash flows from operating leases">(161,000</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; text-align: left">Weighted-average remaining lease term &#8211; operating leases (in months)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtM_c20250331_zRzeA2SONKLh" title="Weighted-average remaining lease term - operating leases (in months)">18.6</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtM_c20240331_z21BxoyaMxhe" title="Weighted-average remaining lease term - operating leases (in months)">19.7</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Weighted-average discount rate &#8211; operating leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pip0_dp_c20250331_zzOMOER59w7k" title="Weighted-average discount rate - operating leases">6</span>%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_901_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pip0_dp_c20240331_zOIx4b0dGIif" title="Weighted-average discount rate - operating leases">6</span>%</td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of minimum operating lease liabilities</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_887_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_pn3n3_zyWVFHP7mcj9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Leases (Details - Minimum operating lease payments)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8BC_zMJZyieoKFmi" style="display: none">Schedule of minimum operating lease liabilities</span></td><td>&#160;</td>
    <td colspan="2" id="xdx_49B_20250331_zvZ7p8HAJc2j" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">For Years Ending March 31,</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3p0_maLOLLPzr9e_zg9ESGkvQgDf" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 83%; text-align: left">2026</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">66,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3p0_maLOLLPzr9e_zyl3qcov8ATg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pn3p0_maLOLLPzr9e_zXwZBBpZM3s2" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">2028</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">9,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3p0_mtLOLLPzr9e_zzCztFJhxg8e" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total future minimum lease payments, undiscounted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">90,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3p0_di_zN7HJc4WNBEh" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Less: imputed interest</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(5,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--OperatingLeaseLiability_iI_pn3p0_zBzqBni5eROf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Total lease liability</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">85,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of weighted-average assumptions of fair value of employee stock options</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_886_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zY4u1rsQxBC1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock-Based Compensation (Details-Assumptions)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8BC_zxRpjcQAdiuh" style="display: none">Schedule of weighted-average assumptions of fair value of employee stock options</span></td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended March&#160;31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: left">Fair value of the Company&#8217;s common stock on date of grant</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240401__20250331_zGhb9ITzBBfg" style="width: 13%; text-align: right" title="Fair value of the Company common stock on date of grant">2.68</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230401__20240331_zQT76tpBxat2" style="width: 13%; text-align: right" title="Fair value of the Company common stock on date of grant">0.19</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240401__20250331_zz1tLX7P3m1h" title="Expected term">5.68</span> yrs</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230401__20240331_zNtg5cM8buT3" title="Expected term">5.56</span> yrs</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_c20240401__20250331_zAHBKkyLo7a2" title="Risk-free interest rate">4.57</span>%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_c20230401__20240331_zBmVeKzH6EEl" title="Risk-free interest rate">3.87</span>%</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pip0_dp_c20240401__20250331_zPNIAMZmm0Z5" title="Dividend yield">0.00</span>%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pip0_dp_c20230401__20240331_zYyY5GWkLyDj" title="Dividend yield">0.00</span>%</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>Volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20240401__20250331_zpjBiJ86d2wi" title="Volatility">109.91</span>%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20230401__20240331_zkYcvPwPB4cd" title="Volatility">98.40</span>%</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Fair value of options granted</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20240401__20250331_zWkfRIVKSqya" style="text-align: right" title="Fair value of options granted">2.23</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20230401__20240331_zyXYILnWUOD4" style="text-align: right" title="Fair value of options granted">0.15</td><td style="text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SNOA_ScheduleOfStockbasedAwardsOutstandingByPlanTableTextBlock', window );">Schedule of stock based awards outstanding by plan</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_882_ecustom--ScheduleOfStockbasedAwardsOutstandingByPlanTableTextBlock_zGog1iJpO2lc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 50%" summary="xdx: Disclosure - Stock-Based Compensation (Details-Plans)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8BA_zn1GUR3OtfLc" style="display: none">Schedule of stock based awards outstanding by plan</span></td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; font-weight: bold">Plan</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Stock Options</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 72%">2011 Plan</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20250331__us-gaap--PlanNameAxis__custom--Plan2011Member_zLSscwD521wg" style="width: 24%; text-align: right" title="Options outstanding">3,998</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>2016 Plan</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20250331__us-gaap--PlanNameAxis__custom--Plan2016Member_zhseAxtwgM5j" style="text-align: right" title="Options outstanding">38,942</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 1pt">2021 Plan</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20250331__us-gaap--PlanNameAxis__custom--Plan2021Member_zaRZrqjGQqB9" style="border-bottom: Black 1pt solid; text-align: right" title="Options outstanding">30,141</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20250331_zcMREqnMHgh7" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding">73,081</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of options activity</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_881_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_pn3n3_zSphkuHyCIVj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock-Based Compensation (Details-Option activity)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span id="xdx_8BF_zYoPp0tHSJnk" style="display: none">Schedule of options activity</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of<br/> Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted-<br/> Average<br/> Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted-<br/> Average<br/> Contractual Term</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Aggregate<br/> Intrinsic<br/> Value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 40%">Outstanding at April 1, 2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pip0_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zx9V5kvM8KD3" style="width: 11%; text-align: right" title="Number of options outstanding, beginning balance">51,675</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pip0_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zVFOi2NIYw16" style="width: 11%; text-align: right" title="Weighted-average exercise price options outstanding, beginning balance">62.60</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Options granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pip0_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zKZ1qZMvkHa6" style="text-align: right" title="Number of options granted">49,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pip0_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z12GzOa621Y1" style="text-align: right" title="Weighted-average exercise price, options granted">2.68</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Options exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pip0_di0_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z8CdCaZvxUol" style="text-align: right" title="Number of options exercised">(27,750</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pip0_d0_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zBHb21k4LAZb" style="text-align: right" title="Weighted-average exercise price, options exercised">2.99</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Options forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pip0_di_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zCoWwKK0Syta" style="text-align: right" title="Number of options forfeited">(250</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pip0_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zisavVve5yL4" style="text-align: right" title="Weighted-average exercise price, options forfeited">3.60</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Options expired</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pip0_di_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zkzyXbnj5cO2" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options expired">(94</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pip0_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zM1KFBXrAAv3" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted-average exercise price, options expired">1,485.96</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Outstanding at March 31, 2025</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pip0_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zsJbOoemMG29" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options outstanding, ending balance">73,081</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pip0_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zhtM1O6FwxM9" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-average exercise price options outstanding, ending balance">43.27</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zTNjH8QDnwOh" title="Weighted- average contractual term outstanding">8.82</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_pip0_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zg8EMUdCHLDe" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value per share, outstanding">2.19</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 2.5pt">Exercisable at March 31, 2025</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pip0_c20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zW1C8HV0YNn9" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options, exercisable">39,751</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pip0_c20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zYki2puJa73b" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-average exercise price, exercisable">74.86</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z7P2HxCcDvoi" title="Weighted- average contractual term, exercisable">7.71</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableInPeriodGrantDateIntrinsicValue_pip0_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zBANKWSBcXd6" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value per share, exercisable">2.19</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of unvested restricted stock activity</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_885_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_pn3n3_zNHiu2hCpU8i" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock-Based Compensation (Details-Restricted stock activity)">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span id="xdx_8B8_zLuSztfe4RUj" style="display: none">Schedule of unvested restricted stock activity</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1.8pt 0 0; text-align: center"><b>Number&#160;of</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1.8pt 0 0; text-align: center"><b>Shares</b></p></td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1.8pt 0 0; text-align: center"><b>Weighted</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1.8pt 0 0; text-align: center"><b>Average Award</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1.8pt 0 0; text-align: center"><b>Date Fair Value</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1.8pt 0 0; text-align: center"><b>per Share</b></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Unvested restricted stock awards outstanding at April 1, 2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pip0_d0_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zucBrBhKZoA8" style="text-align: right" title="Number of unvested restricted stock awards outstanding, beginning balance">&#8211;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pip0_d0_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zXq3ujbUAXXf" style="text-align: right" title="Weighted-average award date fair value per share, unvested RSAs outstanding, beginning balance">&#8211;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 66%; text-align: left">Restricted stock awards granted</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pip0_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zuse3bs8vKrd" style="width: 13%; text-align: right" title="Number of restricted stock awards granted">54,538</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pip0_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zYJzBOqrstdg" style="width: 13%; text-align: right" title="Weighted-average award date fair value per share, unvested RSAs granted">2.92</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Restricted stock awards vested</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pip0_di_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zNlWPajOM1qa" style="border-bottom: Black 1pt solid; text-align: right" title="Number of restricted stock awards vested">(9,538</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pip0_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zspybwAIX0A1" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted-average award date fair value per share, unvested RSAs vested">4.08</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Unvested restricted stock awards outstanding at March 31, 2025</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pip0_d0_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zTz3dcreSpfl" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of unvested restricted stock awards outstanding, ending balance">45,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pip0_d0_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zvKukhiSkyRd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-average award date fair value per share, unvested RSAs outstanding, ending balance">2.68</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SNOA_ScheduleOfStockbasedAwardsOutstandingByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SNOA_ScheduleOfStockbasedAwardsOutstandingByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SNOA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of income tax provision from domestic and foreign sources</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_889_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_pn3n3_zcjFSUccZDn9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details-Income source)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B2_z5FF0boDHmEf" style="display: none">Schedule of income tax provision from domestic and foreign sources</span></td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended March&#160;31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%">Domestic</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--ProfitLoss_pn3p0_c20240401__20250331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zaqDwFXvz53h" style="width: 13%; text-align: right" title="Income before income taxes">(161,000</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--ProfitLoss_pn3p0_c20230401__20240331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zfy1yQUfOI45" style="width: 13%; text-align: right" title="Income before income taxes">(364,000</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Foreign</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ProfitLoss_pn3p0_c20240401__20250331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zmKIf3SeJEt8" style="border-bottom: Black 1pt solid; text-align: right" title="Income before income taxes">(2,749,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ProfitLoss_pn3p0_c20230401__20240331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zpQOWqkgmACd" style="border-bottom: Black 1pt solid; text-align: right" title="Income before income taxes">(4,559,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 2.5pt">Totals</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--ProfitLoss_pn3p0_c20240401__20250331_zL608gH8ruN4" style="border-bottom: Black 2.5pt double; text-align: right" title="Income before income taxes">(2,910,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--ProfitLoss_pn3p0_c20230401__20240331_zwRRhstxQIgh" style="border-bottom: Black 2.5pt double; text-align: right" title="Income before income taxes">(4,923,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of federal, state and foreign income tax provisions</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_88B_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_pn3n3_zY3IfRNnScvg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details-Income tax expense)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B8_zK0DBnlPZPF4" style="display: none">Schedule of federal, state and foreign income tax provisions</span></td><td>&#160;</td>
    <td colspan="2" id="xdx_499_20240401__20250331_zLPdh3S4pOu9" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_492_20230401__20240331_z6oO3rsxphrf" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended March&#160;31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_iB" style="vertical-align: bottom">
    <td>Current:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_pn3p0_zIiMUP5oZdub" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%">State</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">(2,000</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">(2,000</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_iB_zurQPAtm8yfa" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>Deferred:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredForeignIncomeTaxExpenseBenefit_pn3p0_zW00FLkegDSl" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Foreign</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(548,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">198,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DeferredIncomeTaxExpenseBenefit_pn3p0_zkoNXLQiTdf3" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 2.5pt">Total income tax (expense) benefit</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(550,000</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">196,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of reconciliation of federal income tax rate to effective rate</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_881_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zLZHeGGJZM7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details-Reconciliation of tax rate)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B4_z25lFhUBWLG3" style="display: none">Schedule of reconciliation of federal    income
tax rate to effective rate</span></td><td>&#160;</td>
    <td colspan="2" id="xdx_491_20240401__20250331_z6UIQyLeALFh" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_492_20230401__20240331_zm0B4uZCEXcg" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year&#160;Ended&#160;March&#160;31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pip0_dp_marate_zPKHIxaxLhfg" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: left">Expected federal statutory rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right">21.0%</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right">21.0%</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_iN_pip0_dpi_zLGNa2ul5tS" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">State income taxes, net of federal benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.1%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.2%</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_pip0_dp_zq7UbDuEbcV3" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Foreign earnings taxed at different rates</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.7%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.9%</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpense_iN_pip0_dpi_zX26ez95xmM5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Effect of permanent differences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7.4%</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5.8%</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_pip0_dp_zcpP6WRnYoO3" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Effect of intercompany interest permanent differences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(30.2%</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(20.1%</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_ecustom--TrueupsOfStateDeferredAssets_pip0_dp_z1qn3IWDXl72" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">True-up of state deferred assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(68.4%</td><td style="padding-bottom: 1pt; text-align: left">)&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1.5%</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_iN_dpi_zwRb7XBckbC6" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td><b style="display: none">Total effective rate</b></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(78.2%</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.7%</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pip0_dp_zqgwwIqZ9PR3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Change in valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(59.3%</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2.3%</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pip0_dp_mtrate_zp1DtXOARE7e" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 2.5pt">Totals</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">(18.9%</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">4.0%</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of deferred tax assets</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_884_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_pn3n3_zMbRIQ1dE2a" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details-Deferred taxes)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B5_zFibXnib7PU" style="display: none">Schedule of deferred tax assets</span></td><td>&#160;</td>
    <td colspan="2" id="xdx_491_20250331_z5oBANAgAPQ1" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_49B_20240331_zHpcMumE8sni" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March&#160;31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsGrossAbstract_iB" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Deferred tax assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_i01I_pn3p0_maDTAGz412_zRUpdLmRE6Di" style="vertical-align: bottom; background-color: White">
    <td style="width: 66%; text-align: left">Net operating loss carryforwards</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">26,456,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">28,692,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_i01I_pn3p0_maDTAGz412_zaF4wlPfWEJ5" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Research and development tax credit carryforwards</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,749,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,796,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_i01I_pn3p0_maDTAGz412_zhtpPCQnkvC5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">879,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">913,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_i01I_pn3p0_maDTAGz412_z8KAJqvbqdDa" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Reserves and accruals</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">618,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">659,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseOther_i01I_pn3p0_d0_maDTAGz412_z6yxVYR8k8cc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">41,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">52,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--DeferredTaxAssetsLeaseLiability_i01I_pn3p0_maDTAGz412_zjeSqDemov7e" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Lease liability</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">10,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">22,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--DeferredTaxAssetsGross_i01TI_pn3p0_mtDTAGz412_maDTANzqCr_zmB7ZrzLMHd6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Gross deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">29,753,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">32,134,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsValuationAllowance_i01NI_pn3p0_di_msDTANzqCr_zKS1XlHQajH" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Less valuation allowance</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(29,062,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(30,836,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsNet_i01TI_pn3p0_mtDTANzqCr_maDTALNzfiK_zFtiYZAiwxp9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Total deferred tax assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">691,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">1,298,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--DeferredTaxLiabilitiesAbstract_i01B" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Deferred tax liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--DeferredTaxLiabilitiesPropertyPlantAndEquipment_i02NI_pn3p0_di_maDITLzfJx_zRys7CZb6wh6" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Fixed assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(10,000</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--DeferredTaxLiabilitiesPrepaidExpenses_i02NI_pn3p0_di_maDITLzfJx_z2P9APkIY1qe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Prepaid expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(86,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(121,000</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40C_ecustom--DeferredTaxLiabilitiesRightOfUseAsset_i02NI_pn3p0_di_maDITLzfJx_zLmjoR5HOfA3" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Right of use asset</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(10,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(22,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--DeferredIncomeTaxLiabilities_i02NTI_pn3p0_di_mtDITLzfJx_msDTALNzfiK_zBs9h4F8yDXb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Gross deferred tax liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(102,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(153,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsLiabilitiesNet_i02TI_pn3p0_d0_mtDTALNzfiK_zPIPHtQKKgv7" style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 2.5pt">Net deferred tax assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">589,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,145,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Disaggregation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of disaggregated revenue by source</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_881_eus-gaap--DisaggregationOfRevenueTableTextBlock_pn3n3_zG7aKFsAn6Li" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Revenue Disaggregation (Details - Disaggregation of revenue)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B2_zDo0500DkMY" style="display: none">Schedule of disaggregated revenue by  source</span></td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended March 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Product:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-left: 10pt; width: 66%; text-align: left">Human Care</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20240401__20250331__us-gaap--StatementBusinessSegmentsAxis__custom--HumanCareMember__srt--ProductOrServiceAxis__us-gaap--ProductMember_zbMuKtD4qDf2" style="width: 13%; text-align: right" title="Revenues">12,079,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20230401__20240331__us-gaap--StatementBusinessSegmentsAxis__custom--HumanCareMember__srt--ProductOrServiceAxis__us-gaap--ProductMember_z3G9EVURUamd" style="width: 13%; text-align: right" title="Revenues">10,110,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Animal Care</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20240401__20250331__us-gaap--StatementBusinessSegmentsAxis__custom--AnimalCareMember__srt--ProductOrServiceAxis__us-gaap--ProductMember_z2ec75gSQ7P3" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues">1,653,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20230401__20240331__us-gaap--StatementBusinessSegmentsAxis__custom--AnimalCareMember__srt--ProductOrServiceAxis__us-gaap--ProductMember_zi4RFG28E6V6" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues">2,203,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left">Total Product Revenue</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20240401__20250331__srt--ProductOrServiceAxis__us-gaap--ProductMember_ze5f1aVNo9jb" style="text-align: right" title="Revenues">13,732,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20230401__20240331__srt--ProductOrServiceAxis__us-gaap--ProductMember_zuOZtvvttFw5" style="text-align: right" title="Revenues">12,313,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt">Service/Royalty</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20240401__20250331__srt--ProductOrServiceAxis__us-gaap--ServiceMember__us-gaap--StatementBusinessSegmentsAxis__custom--ServiceAndRoyaltyMember_zQxKYFNwyoEk" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues">556,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20230401__20240331__srt--ProductOrServiceAxis__us-gaap--ServiceMember__us-gaap--StatementBusinessSegmentsAxis__custom--ServiceAndRoyaltyMember_ztIKU2csL1ml" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues">422,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20240401__20250331_zVNwjt92tag8" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenues">14,288,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20230401__20240331_z2tLug2zuoQd" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenues">12,735,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock', window );">Schedule of revenues by geographic region</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_881_eus-gaap--ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_pn3n3_zhVgq0GAig38" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Revenue Disaggregation (Details - Geographic regions)">
  <tr style="vertical-align: bottom">
    <td><span id="xdx_8B4_zCeSA7dcCsne" style="display: none">Schedule of revenues by geographic region</span></td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Year Ended March 31,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="width: 66%; text-align: left">United States</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20240401__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__country--US_z9btNfmBsoK9" style="width: 13%; text-align: right" title="Revenues">2,611,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20230401__20240331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__country--US_zvRAAqzLQbB3" style="width: 13%; text-align: right" title="Revenues">3,058,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Europe</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20240401__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__srt--EuropeMember_zsnbz3JUVMJ6" style="text-align: right" title="Revenues">5,523,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20230401__20240331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__srt--EuropeMember_zKC94FNbtO5h" style="text-align: right" title="Revenues">4,781,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td>Asia</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20240401__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__srt--AsiaMember_zmWtWTGuRhA" style="text-align: right" title="Revenues">2,317,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20230401__20240331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__srt--AsiaMember_zuAakEMFLsQ1" style="text-align: right" title="Revenues">2,298,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Latin America</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20240401__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__srt--LatinAmericaMember_zE2pJaE0as7b" style="text-align: right" title="Revenues">2,962,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20230401__20240331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__srt--LatinAmericaMember_zFA9UIPKkVyd" style="text-align: right" title="Revenues">1,726,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(238,238,238)">
    <td style="text-align: left; padding-bottom: 1pt">Rest of the World</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20240401__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__custom--RestOfTheWorldMember_zenVN9BBNG07" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues">875,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20230401__20240331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__custom--RestOfTheWorldMember_znhzNmIb6zW9" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues">872,000</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20240401__20250331_zDcse8CR7OM" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenues">14,288,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20230401__20240331_zfxc6Qh44bMg" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenues">12,735,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the names of foreign countries from which revenue is material and the amount of revenue from external customers attributed to those countries. An entity may also provide subtotals of geographic information about groups of countries.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization and Recent Developments (Details Narrative) - shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Aug. 29, 2024</div></th>
<th class="th"><div>Aug. 28, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock outstanding</a></td>
<td class="nump">1,634,265<span></span>
</td>
<td class="nump">1,058,447<span></span>
</td>
<td class="nump">21,174,693<span></span>
</td>
<td class="nump">780,371<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liquidity and Financial Condition (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 3,457<span></span>
</td>
<td class="nump">$ 4,835<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">197,806<span></span>
</td>
<td class="nump">194,349<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SNOA_WorkingCapital', window );">Working capital</a></td>
<td class="nump">8,552<span></span>
</td>
<td class="nump">8,829<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="nump">88<span></span>
</td>
<td class="nump">2,398<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">$ (88)<span></span>
</td>
<td class="num">$ (2,398)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SNOA_WorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SNOA_WorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SNOA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - Customer Concentration Risk [Member]<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Revenue Benchmark [Member] | Customer A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SNOA_ConcentrationRiskPercentage2', window );">Concentration risk, percentage</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">17.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Revenue Benchmark [Member] | Customer B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SNOA_ConcentrationRiskPercentage2', window );">Concentration risk, percentage</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Revenue Benchmark [Member] | Customer C [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SNOA_ConcentrationRiskPercentage2', window );">Concentration risk, percentage</a></td>
<td class="nump">18.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">14.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Accounts Receivable [Member] | Customer B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SNOA_ConcentrationRiskPercentage2', window );">Concentration risk, percentage</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">13.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Accounts Receivable [Member] | Customer D [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SNOA_ConcentrationRiskPercentage2', window );">Concentration risk, percentage</a></td>
<td class="nump">24.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">17.00%<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">% <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents less than
    10%</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SNOA_ConcentrationRiskPercentage2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SNOA_ConcentrationRiskPercentage2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SNOA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=SNOA_CustomerAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=SNOA_CustomerAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=SNOA_CustomerBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=SNOA_CustomerBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=SNOA_CustomerCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=SNOA_CustomerCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=SNOA_CustomerDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=SNOA_CustomerDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details-Useful lives)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful asset life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful asset life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful asset life</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details - Earnings per share) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (3,457)<span></span>
</td>
<td class="num">$ (4,835)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average number of shares: basic</a></td>
<td class="nump">1,241<span></span>
</td>
<td class="nump">455<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average number of shares: diluted</a></td>
<td class="nump">1,241<span></span>
</td>
<td class="nump">455<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share: basic</a></td>
<td class="num">$ (2.79)<span></span>
</td>
<td class="num">$ (10.63)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share: diluted</a></td>
<td class="num">$ (2.79)<span></span>
</td>
<td class="num">$ (10.63)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details - Antidilutive shares) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive shares</a></td>
<td class="nump">118<span></span>
</td>
<td class="nump">52<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember', window );">Equity Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive shares</a></td>
<td class="nump">73<span></span>
</td>
<td class="nump">52<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=SNOA_CommonStockUnitsMember', window );">Common Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive shares</a></td>
<td class="nump">45<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=SNOA_CommonStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=SNOA_CommonStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Inventory valuation reserves</a></td>
<td class="nump">$ 298,000<span></span>
</td>
<td class="nump">$ 296,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet', window );">Transfers in or out of level 3</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment of long lived assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">1,814,000<span></span>
</td>
<td class="nump">1,871,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketingExpense', window );">Advertising costs</a></td>
<td class="nump">190,000<span></span>
</td>
<td class="nump">156,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">14,288,000<span></span>
</td>
<td class="nump">12,735,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="nump">$ 4,376,000<span></span>
</td>
<td class="nump">$ 2,723,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherComprehensiveIncomeMember', window );">Other Comprehensive Income (Loss) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SNOA_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationLossAdjustmentBeforeTaxPortionAttributableToParent', window );">Foreign currency translation adjustment loss</a></td>
<td class="nump">$ 1,653,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SNOA_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainAdjustmentBeforeTaxPortionAttributableToParent', window );">Foreign currency translation adjustment gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 695,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherOperatingIncomeExpenseMember', window );">Other Operating Income (Expense) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainBeforeTax', window );">Foreign currency transaction gain</a></td>
<td class="nump">243,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionLossBeforeTax', window );">Foreign currency transaction loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">825,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=SNOA_ProbableCreditLossesMember', window );">Probable Credit Losses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Allowance for doubtful accounts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=SNOA_PotentialDiscountsReturnsDistributorFeesAndRebatesMember', window );">Potential Discounts Returns Distributor Fees And Rebates [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Allowance for doubtful accounts</a></td>
<td class="nump">8,000<span></span>
</td>
<td class="nump">27,000<span></span>
</td>
<td class="nump">16,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ShippingAndHandlingMember', window );">Shipping and Handling [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">18,000<span></span>
</td>
<td class="nump">28,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=SNOA_InvekraMember', window );">Invekra [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
<td class="nump">$ 69,000<span></span>
</td>
<td class="nump">$ 152,000<span></span>
</td>
<td class="nump">$ 199,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SNOA_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainAdjustmentBeforeTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SNOA_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainAdjustmentBeforeTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SNOA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SNOA_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationLossAdjustmentBeforeTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Foreign currency translation loss</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SNOA_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationLossAdjustmentBeforeTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SNOA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transfer of financial instrument classified as an asset into (out of) level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized loss recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation reserve for inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryValuationReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services. Costs of public relations and corporate promotions are typically considered to be marketing costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherOperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherOperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=SNOA_ProbableCreditLossesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=SNOA_ProbableCreditLossesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=SNOA_PotentialDiscountsReturnsDistributorFeesAndRebatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=SNOA_PotentialDiscountsReturnsDistributorFeesAndRebatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ShippingAndHandlingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ShippingAndHandlingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=SNOA_InvekraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=SNOA_InvekraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounts Receivable (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableGrossCurrent', window );">Accounts receivable</a></td>
<td class="nump">$ 2,240<span></span>
</td>
<td class="nump">$ 2,925<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Total accounts receivable, net</a></td>
<td class="nump">2,232<span></span>
</td>
<td class="nump">2,898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=SNOA_PotentialDiscountsReturnsDistributorFeesAndRebatesMember', window );">Potential Discounts Returns Distributor Fees And Rebates [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Less: discounts, rebates, distributor fees and returns</a></td>
<td class="num">$ (8)<span></span>
</td>
<td class="num">$ (27)<span></span>
</td>
<td class="num">$ (16)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesAndLoansReceivableLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 40<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481628/310-20-40-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesAndLoansReceivableLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableGrossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableGrossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=SNOA_PotentialDiscountsReturnsDistributorFeesAndRebatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=SNOA_PotentialDiscountsReturnsDistributorFeesAndRebatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 1,395<span></span>
</td>
<td class="nump">$ 1,802<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">1,818<span></span>
</td>
<td class="nump">1,213<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Inventories, gross</a></td>
<td class="nump">3,213<span></span>
</td>
<td class="nump">3,015<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Less: allowance for obsolete and excess inventory</a></td>
<td class="num">(298)<span></span>
</td>
<td class="num">(296)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventories</a></td>
<td class="nump">$ 2,915<span></span>
</td>
<td class="nump">$ 2,719<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation reserve for inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryValuationReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="nump">$ 236<span></span>
</td>
<td class="nump">$ 340<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidTaxes', window );">VAT prepaid to Mexican tax authorities</a></td>
<td class="nump">1,531<span></span>
</td>
<td class="nump">3,096<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other prepaid expenses and other current assets</a></td>
<td class="nump">148<span></span>
</td>
<td class="nump">105<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total prepaid expenses and other current assets</a></td>
<td class="nump">$ 1,915<span></span>
</td>
<td class="nump">$ 3,541<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MachineryAndEquipmentGross', window );">Manufacturing, lab, and other equipment</a></td>
<td class="nump">$ 1,471<span></span>
</td>
<td class="nump">$ 1,776<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentOther', window );">Office equipment</a></td>
<td class="nump">217<span></span>
</td>
<td class="nump">236<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FurnitureAndFixturesGross', window );">Furniture and fixtures</a></td>
<td class="nump">121<span></span>
</td>
<td class="nump">128<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseholdImprovementsGross', window );">Leasehold improvements</a></td>
<td class="nump">491<span></span>
</td>
<td class="nump">605<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">2,300<span></span>
</td>
<td class="nump">2,745<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(2,075)<span></span>
</td>
<td class="num">(2,380)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net and equipment, net&#160;</a></td>
<td class="nump">$ 225<span></span>
</td>
<td class="nump">$ 365<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FurnitureAndFixturesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FurnitureAndFixturesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseholdImprovementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseholdImprovementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MachineryAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MachineryAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of other physical assets used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">$ 138<span></span>
</td>
<td class="nump">$ 176<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Salaries and related costs</a></td>
<td class="nump">$ 1,737<span></span>
</td>
<td class="nump">$ 1,419<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">487<span></span>
</td>
<td class="nump">694<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilities', window );">Total accrued expenses and other current liabilities</a></td>
<td class="nump">$ 2,224<span></span>
</td>
<td class="nump">$ 2,113<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred and payable to vendors for goods and services received, and accrued liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(10)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt (Details Narrative) - Insurance Premium Financing [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Feb. 01, 2025</div></th>
<th class="th"><div>Feb. 06, 2024</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt face amount</a></td>
<td class="nump">$ 274<span></span>
</td>
<td class="nump">$ 373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Debt interest rate</a></td>
<td class="nump">7.97%<span></span>
</td>
<td class="nump">8.42%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDateRangeEnd1', window );">Final payment date</a></td>
<td class="text">Nov.  01,  2025<span></span>
</td>
<td class="text">Nov.  01,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromShortTermDebt', window );">Debt initial payment</a></td>
<td class="nump">$ 28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPaymentTerms', window );">Debt payment terms</a></td>
<td class="text">nine monthly installment payments<span></span>
</td>
<td class="text">nine monthly installment payments<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPayment', window );">Periodic payment</a></td>
<td class="nump">$ 28<span></span>
</td>
<td class="nump">$ 42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDateRangeStart1', window );">First installment beginning date</a></td>
<td class="text">Mar.  01,  2025<span></span>
</td>
<td class="text">Mar.  01,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLongTermDebtCurrent', window );">Outstanding principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 220<span></span>
</td>
<td class="nump">$ 323<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDateRangeEnd1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Latest date the outstanding debt instruments are required to be repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDateRangeEnd1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDateRangeStart1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Earliest date the outstanding debt instruments are required to be repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDateRangeStart1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPaymentTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the payment terms of the debt instrument (for example, whether periodic payments include principal and frequency of payments) and discussion about any contingencies associated with the payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPaymentTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments including both interest and principal payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt classified as other, payable within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(13)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=SNOA_InsurancePremiumFinancingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=SNOA_InsurancePremiumFinancingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details - Balance sheet information related to leases) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesOperatingAbstract', window );"><strong>Operating leases:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 84<span></span>
</td>
<td class="nump">$ 286<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities &#8211; current</a></td>
<td class="nump">58<span></span>
</td>
<td class="nump">198<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities &#8211; non-current</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">365<span></span>
</td>
<td class="nump">380<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Operating cash flows from operating leases</a></td>
<td class="num">$ (174)<span></span>
</td>
<td class="num">$ (161)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term - operating leases (in months)</a></td>
<td class="text">18 months 18 days<span></span>
</td>
<td class="text">19 months 21 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate - operating leases</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesOperatingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesOperatingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Details - Minimum operating lease payments)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2026</a></td>
<td class="nump">$ 66<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2027</a></td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2028</a></td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future minimum lease payments, undiscounted</a></td>
<td class="nump">90<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liability</a></td>
<td class="nump">$ 85<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details Narrative)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Annual salaries</a></td>
<td class="nump">$ 586<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SNOA_PotentialSeverancePayments', window );">Potential severance payments</a></td>
<td class="nump">$ 1,300<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SNOA_PotentialSeverancePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SNOA_PotentialSeverancePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SNOA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OfficersCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary and wage arising from service rendered by officer. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OfficersCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Details Narrative) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 20, 2024</div></th>
<th class="th"><div>Jan. 11, 2024</div></th>
<th class="th"><div>Dec. 15, 2023</div></th>
<th class="th"><div>Oct. 26, 2023</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Aug. 29, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">24,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Convertible preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">714,286<span></span>
</td>
<td class="nump">714,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Convertible preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sale of stock, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,079<span></span>
</td>
<td class="nump">$ 1,784<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=SNOA_MaximGroupLLCMember', window );">Maxim Group L L C [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued new, shares</a></td>
<td class="nump">816,894<span></span>
</td>
<td class="nump">96,154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SNOA_ProceedsFromIssuanceOfCommonStockGross', window );">Proceeds from sale of stock, gross</a></td>
<td class="nump">$ 3,325<span></span>
</td>
<td class="nump">$ 392<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sale of stock, net</a></td>
<td class="nump">$ 3,079<span></span>
</td>
<td class="nump">$ 338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=SNOA_PublicOfferingMember', window );">Public Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued new, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">425,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SNOA_ProceedsFromIssuanceOfCommonStockGross', window );">Proceeds from sale of stock, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sale of stock, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,446<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=SNOA_PlacementAgencyAgreementMember', window );">Placement Agency Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Legal fees and other expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=SNOA_EquityDistributionAgreementMember', window );">Equity Distribution Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Legal fees and other expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Convertible preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">714,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Convertible preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SNOA_ProceedsFromIssuanceOfCommonStockGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SNOA_ProceedsFromIssuanceOfCommonStockGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SNOA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(6))<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=SNOA_MaximGroupLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=SNOA_MaximGroupLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=SNOA_PublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=SNOA_PublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=SNOA_PlacementAgencyAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=SNOA_PlacementAgencyAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=SNOA_EquityDistributionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=SNOA_EquityDistributionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details-Assumptions) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Fair value of the Company common stock on date of grant</a></td>
<td class="nump">$ 2.68<span></span>
</td>
<td class="nump">$ 0.19<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">5 years 8 months 4 days<span></span>
</td>
<td class="text">5 years 6 months 21 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.57%<span></span>
</td>
<td class="nump">3.87%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">109.91%<span></span>
</td>
<td class="nump">98.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Fair value of options granted</a></td>
<td class="nump">$ 2.23<span></span>
</td>
<td class="nump">$ 0.15<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stock-Based Compensation (Details-Plans)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding</a></td>
<td class="nump">73,081<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=SNOA_Plan2011Member', window );">Plan 2011 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding</a></td>
<td class="nump">3,998<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=SNOA_Plan2016Member', window );">Plan 2016 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding</a></td>
<td class="nump">38,942<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=SNOA_Plan2021Member', window );">Plan 2021 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding</a></td>
<td class="nump">30,141<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=SNOA_Plan2011Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=SNOA_Plan2011Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=SNOA_Plan2016Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=SNOA_Plan2016Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=SNOA_Plan2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=SNOA_Plan2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details-Option activity) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted-average exercise price, options granted</a></td>
<td class="nump">$ 2.68<span></span>
</td>
<td class="nump">$ 0.19<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding, ending balance</a></td>
<td class="nump">73,081<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember', window );">Equity Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding, beginning balance</a></td>
<td class="nump">51,675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-average exercise price options outstanding, beginning balance</a></td>
<td class="nump">$ 62.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options granted</a></td>
<td class="nump">49,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted-average exercise price, options granted</a></td>
<td class="nump">$ 2.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of options exercised</a></td>
<td class="num">(27,750)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted-average exercise price, options exercised</a></td>
<td class="nump">$ 2.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Number of options forfeited</a></td>
<td class="num">(250)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted-average exercise price, options forfeited</a></td>
<td class="nump">$ 3.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Number of options expired</a></td>
<td class="num">(94)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted-average exercise price, options expired</a></td>
<td class="nump">$ 1,485.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding, ending balance</a></td>
<td class="nump">73,081<span></span>
</td>
<td class="nump">51,675<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-average exercise price options outstanding, ending balance</a></td>
<td class="nump">$ 43.27<span></span>
</td>
<td class="nump">$ 62.60<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted- average contractual term outstanding</a></td>
<td class="text">8 years 9 months 25 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue', window );">Aggregate intrinsic value per share, outstanding</a></td>
<td class="nump">$ 2.19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of options, exercisable</a></td>
<td class="nump">39,751<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted-average exercise price, exercisable</a></td>
<td class="nump">$ 74.86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted- average contractual term, exercisable</a></td>
<td class="text">7 years 8 months 15 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SNOA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableInPeriodGrantDateIntrinsicValue', window );">Aggregate intrinsic value per share, exercisable</a></td>
<td class="nump">$ 2.19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SNOA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableInPeriodGrantDateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SNOA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableInPeriodGrantDateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SNOA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The grant-date intrinsic value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details-Restricted stock activity) - Restricted Stock [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2025 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of unvested restricted stock awards outstanding, beginning balance | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-average award date fair value per share, unvested RSAs outstanding, beginning balance | $ / shares</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Number of restricted stock awards granted | shares</a></td>
<td class="nump">54,538<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average award date fair value per share, unvested RSAs granted | $ / shares</a></td>
<td class="nump">$ 2.92<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of restricted stock awards vested | shares</a></td>
<td class="num">(9,538)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average award date fair value per share, unvested RSAs vested | $ / shares</a></td>
<td class="nump">$ 4.08<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of unvested restricted stock awards outstanding, ending balance | shares</a></td>
<td class="nump">45,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-average award date fair value per share, unvested RSAs outstanding, ending balance | $ / shares</a></td>
<td class="nump">$ 2.68<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details Narrative) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="5">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Sep. 02, 2016</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">$ 224<span></span>
</td>
<td class="nump">$ 516<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense', window );">Stock based compensation options exercised</a></td>
<td class="nump">123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember', window );">Equity Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation costs</a></td>
<td class="nump">$ 250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average amortization period</a></td>
<td class="text">1 year 6 months 29 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price</a></td>
<td class="nump">$ 2.19<span></span>
</td>
<td class="nump">$ 3.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=SNOA_Plan2016Member', window );">Plan 2016 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares initially authorized for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,222<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Increase in shares authorized for issuance</a></td>
<td class="nump">62,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,372<span></span>
</td>
<td class="nump">5,266<span></span>
</td>
<td class="nump">243<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future issuance</a></td>
<td class="nump">9,670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=SNOA_Plan2021Member', window );">Plan 2021 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Increase in shares authorized for issuance</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future issuance</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=SNOA_Plan2024Member', window );">Plan 2024 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Increase in shares authorized for issuance</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future issuance</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options, after deduction of related income tax (expense) benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=SNOA_Plan2016Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=SNOA_Plan2016Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=SNOA_Plan2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=SNOA_Plan2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=SNOA_Plan2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=SNOA_Plan2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details-Income source) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Income before income taxes</a></td>
<td class="num">$ (2,910)<span></span>
</td>
<td class="num">$ (4,923)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Income before income taxes</a></td>
<td class="num">(161)<span></span>
</td>
<td class="num">(364)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign Tax Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Income before income taxes</a></td>
<td class="num">$ (2,749)<span></span>
</td>
<td class="num">$ (4,559)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details-Income tax expense) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="num">$ (2)<span></span>
</td>
<td class="num">$ (2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Foreign</a></td>
<td class="num">(548)<span></span>
</td>
<td class="nump">198<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total income tax (expense) benefit</a></td>
<td class="num">$ (550)<span></span>
</td>
<td class="nump">$ 196<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details-Reconciliation of tax rate)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Expected federal statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income taxes, net of federal benefit</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Foreign earnings taxed at different rates</a></td>
<td class="nump">6.70%<span></span>
</td>
<td class="nump">7.90%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense', window );">Effect of permanent differences</a></td>
<td class="num">(7.40%)<span></span>
</td>
<td class="num">(5.80%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther', window );">Effect of intercompany interest permanent differences</a></td>
<td class="num">(30.20%)<span></span>
</td>
<td class="num">(20.10%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SNOA_TrueupsOfStateDeferredAssets', window );">True-up of state deferred assets</a></td>
<td class="num">(68.40%)<span></span>
</td>
<td class="num">(1.50%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent', window );">Total effective rate</a></td>
<td class="num">(78.20%)<span></span>
</td>
<td class="nump">1.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(59.30%)<span></span>
</td>
<td class="nump">2.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Totals</a></td>
<td class="num">(18.90%)<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SNOA_TrueupsOfStateDeferredAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SNOA_TrueupsOfStateDeferredAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SNOA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of reported income tax benefit (expense) from difference to income tax expense (benefit) computed by applying statutory federal (national) income tax rate to pretax income (loss) from continuing operation, attributable to other reconciling items. Excludes state and local income tax expense (benefit), federal tax expense (benefit), statutory income tax expense (benefit) outside of country of domicile, tax credit, nondeductible expense, deduction, income tax settlement, income tax contingency, and cross-border tax law.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Details-Deferred taxes) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 26,456<span></span>
</td>
<td class="nump">$ 28,692<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development tax credit carryforwards</a></td>
<td class="nump">1,749<span></span>
</td>
<td class="nump">1,796<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">879<span></span>
</td>
<td class="nump">913<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals', window );">Reserves and accruals</a></td>
<td class="nump">618<span></span>
</td>
<td class="nump">659<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther', window );">Other deferred tax assets</a></td>
<td class="nump">41<span></span>
</td>
<td class="nump">52<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SNOA_DeferredTaxAssetsLeaseLiability', window );">Lease liability</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred tax assets</a></td>
<td class="nump">29,753<span></span>
</td>
<td class="nump">32,134<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less valuation allowance</a></td>
<td class="num">(29,062)<span></span>
</td>
<td class="num">(30,836)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax assets</a></td>
<td class="nump">691<span></span>
</td>
<td class="nump">1,298<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Fixed assets</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses', window );">Prepaid expenses</a></td>
<td class="num">(86)<span></span>
</td>
<td class="num">(121)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_SNOA_DeferredTaxLiabilitiesRightOfUseAsset', window );">Right of use asset</a></td>
<td class="num">(10)<span></span>
</td>
<td class="num">(22)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Gross deferred tax liabilities</a></td>
<td class="num">(102)<span></span>
</td>
<td class="num">(153)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets</a></td>
<td class="nump">$ 589<span></span>
</td>
<td class="nump">$ 1,145<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SNOA_DeferredTaxAssetsLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SNOA_DeferredTaxAssetsLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SNOA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_SNOA_DeferredTaxLiabilitiesRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">SNOA_DeferredTaxLiabilitiesRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>SNOA_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from provisions, reserves, allowances, and accruals, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 107,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Research credit carryforwards</a></td>
<td class="nump">950<span></span>
</td>
<td class="nump">$ 1,006<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">42,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign Tax Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=SNOA_CaliforniaResearchAndDevelopmentMember', window );">California Research And Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Effective Income Tax Rate Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Research credit carryforwards</a></td>
<td class="nump">$ 790<span></span>
</td>
<td class="nump">$ 790<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=SNOA_CaliforniaResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=SNOA_CaliforniaResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan (Details Narrative) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitContributions', window );">Company contributions to 401(k) plan</a></td>
<td class="nump">$ 88<span></span>
</td>
<td class="nump">$ 82<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitContributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for pension and other postretirement benefits. Includes, but is not limited to, employer contribution to fund plan asset and payment to retiree.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitContributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Disaggregation (Details - Disaggregation of revenue) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 14,288<span></span>
</td>
<td class="nump">$ 12,735<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">13,732<span></span>
</td>
<td class="nump">12,313<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=SNOA_HumanCareMember', window );">Human Care [Member] | Product [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">12,079<span></span>
</td>
<td class="nump">10,110<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=SNOA_AnimalCareMember', window );">Animal Care [Member] | Product [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">1,653<span></span>
</td>
<td class="nump">2,203<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=SNOA_ServiceAndRoyaltyMember', window );">Service And Royalty [Member] | Service [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 556<span></span>
</td>
<td class="nump">$ 422<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=SNOA_HumanCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=SNOA_HumanCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=SNOA_AnimalCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=SNOA_AnimalCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=SNOA_ServiceAndRoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=SNOA_ServiceAndRoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Disaggregation (Details - Geographic regions) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 14,288<span></span>
</td>
<td class="nump">$ 12,735<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueSegmentMember', window );">Revenue, Segment Benchmark [Member] | UNITED STATES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">2,611<span></span>
</td>
<td class="nump">3,058<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueSegmentMember', window );">Revenue, Segment Benchmark [Member] | Europe [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">5,523<span></span>
</td>
<td class="nump">4,781<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueSegmentMember', window );">Revenue, Segment Benchmark [Member] | Asia [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">2,317<span></span>
</td>
<td class="nump">2,298<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueSegmentMember', window );">Revenue, Segment Benchmark [Member] | Latin America [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">2,962<span></span>
</td>
<td class="nump">1,726<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueSegmentMember', window );">Revenue, Segment Benchmark [Member] | Rest Of The World [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 875<span></span>
</td>
<td class="nump">$ 872<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_AsiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_AsiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_LatinAmericaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_LatinAmericaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=SNOA_RestOfTheWorldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=SNOA_RestOfTheWorldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>121</ContextCount>
  <ElementCount>321</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>51</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="sonoma_i10k-033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="sonoma_i10k-033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="sonoma_i10k-033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="sonoma_i10k-033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/ConsolidatedStatementsOfComprehensiveLoss</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="sonoma_i10k-033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="sonoma_i10k-033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="sonoma_i10k-033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="sonoma_i10k-033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>999007 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/CybersecurityRiskManagementAndStrategyDisclosure</Role>
      <ShortName>Cybersecurity Risk Management and Strategy Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="sonoma_i10k-033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>999008 - Disclosure - Organization and Recent Developments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/OrganizationAndRecentDevelopments</Role>
      <ShortName>Organization and Recent Developments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="sonoma_i10k-033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>999009 - Disclosure - Liquidity and Financial Condition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/LiquidityAndFinancialCondition</Role>
      <ShortName>Liquidity and Financial Condition</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="sonoma_i10k-033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>999010 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="sonoma_i10k-033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>999011 - Disclosure - Accounts Receivable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/AccountsReceivable</Role>
      <ShortName>Accounts Receivable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="sonoma_i10k-033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>999012 - Disclosure - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/Inventories</Role>
      <ShortName>Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="sonoma_i10k-033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>999013 - Disclosure - Prepaid Expenses and Other Current Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/PrepaidExpensesAndOtherCurrentAssets</Role>
      <ShortName>Prepaid Expenses and Other Current Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="sonoma_i10k-033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>999014 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/PropertyAndEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="sonoma_i10k-033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>999015 - Disclosure - Accrued Expenses and Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/AccruedExpensesAndOtherCurrentLiabilities</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="sonoma_i10k-033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>999016 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/Debt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="sonoma_i10k-033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>999017 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="sonoma_i10k-033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>999018 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="sonoma_i10k-033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>999019 - Disclosure - Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders??? Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="sonoma_i10k-033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>999020 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/Stock-basedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="sonoma_i10k-033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>999021 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="sonoma_i10k-033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>999022 - Disclosure - Employee Benefit Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/EmployeeBenefitPlan</Role>
      <ShortName>Employee Benefit Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="sonoma_i10k-033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>999023 - Disclosure - Revenue Disaggregation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/RevenueDisaggregation</Role>
      <ShortName>Revenue Disaggregation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="sonoma_i10k-033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>999025 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="sonoma_i10k-033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>999026 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="sonoma_i10k-033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>999027 - Disclosure - Accounts Receivable (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/AccountsReceivableTables</Role>
      <ShortName>Accounts Receivable (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/AccountsReceivable</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="sonoma_i10k-033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>999028 - Disclosure - Inventories (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/InventoriesTables</Role>
      <ShortName>Inventories (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/Inventories</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="sonoma_i10k-033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>999029 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/PrepaidExpensesAndOtherCurrentAssetsTables</Role>
      <ShortName>Prepaid Expenses and Other Current Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/PrepaidExpensesAndOtherCurrentAssets</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="sonoma_i10k-033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>999030 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/PropertyAndEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/PropertyAndEquipment</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="sonoma_i10k-033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>999031 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/AccruedExpensesAndOtherCurrentLiabilities</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="sonoma_i10k-033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>999032 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/Leases</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="sonoma_i10k-033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>999033 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/Stock-basedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/Stock-basedCompensation</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="sonoma_i10k-033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>999034 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/IncomeTaxes</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="sonoma_i10k-033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>999035 - Disclosure - Revenue Disaggregation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/RevenueDisaggregationTables</Role>
      <ShortName>Revenue Disaggregation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/RevenueDisaggregation</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="sonoma_i10k-033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>999036 - Disclosure - Organization and Recent Developments (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/OrganizationAndRecentDevelopmentsDetailsNarrative</Role>
      <ShortName>Organization and Recent Developments (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/OrganizationAndRecentDevelopments</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="sonoma_i10k-033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>999037 - Disclosure - Liquidity and Financial Condition (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/LiquidityAndFinancialConditionDetailsNarrative</Role>
      <ShortName>Liquidity and Financial Condition (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/LiquidityAndFinancialCondition</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="sonoma_i10k-033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>999038 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="sonoma_i10k-033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>999039 - Disclosure - Summary of Significant Accounting Policies (Details-Useful lives)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-usefulLives</Role>
      <ShortName>Summary of Significant Accounting Policies (Details-Useful lives)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="sonoma_i10k-033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>999040 - Disclosure - Summary of Significant Accounting Policies (Details - Earnings per share)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-EarningsPerShare</Role>
      <ShortName>Summary of Significant Accounting Policies (Details - Earnings per share)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="sonoma_i10k-033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>999041 - Disclosure - Summary of Significant Accounting Policies (Details - Antidilutive shares)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-AntidilutiveShares</Role>
      <ShortName>Summary of Significant Accounting Policies (Details - Antidilutive shares)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="sonoma_i10k-033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>999042 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>Summary of Significant Accounting Policies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="sonoma_i10k-033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>999043 - Disclosure - Accounts Receivable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/AccountsReceivableDetails</Role>
      <ShortName>Accounts Receivable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/AccountsReceivableTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="sonoma_i10k-033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>999044 - Disclosure - Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/InventoriesDetails</Role>
      <ShortName>Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/InventoriesTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="sonoma_i10k-033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>999045 - Disclosure - Prepaid Expenses and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails</Role>
      <ShortName>Prepaid Expenses and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/PrepaidExpensesAndOtherCurrentAssetsTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="sonoma_i10k-033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>999046 - Disclosure - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/PropertyAndEquipmentDetails</Role>
      <ShortName>Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/PropertyAndEquipmentTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="sonoma_i10k-033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>999047 - Disclosure - Property and Equipment (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/PropertyAndEquipmentDetailsNarrative</Role>
      <ShortName>Property and Equipment (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/PropertyAndEquipmentTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="sonoma_i10k-033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>999048 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="sonoma_i10k-033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>999049 - Disclosure - Debt (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/DebtDetailsNarrative</Role>
      <ShortName>Debt (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/Debt</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="sonoma_i10k-033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>999050 - Disclosure - Leases (Details - Balance sheet information related to leases)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/LeasesDetails-BalanceSheetInformationRelatedToLeases</Role>
      <ShortName>Leases (Details - Balance sheet information related to leases)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/LeasesTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="sonoma_i10k-033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>999051 - Disclosure - Leases (Details - Minimum operating lease payments)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/LeasesDetails-MinimumOperatingLeasePayments</Role>
      <ShortName>Leases (Details - Minimum operating lease payments)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/LeasesTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="sonoma_i10k-033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>999052 - Disclosure - Commitments and Contingencies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>Commitments and Contingencies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="sonoma_i10k-033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>999053 - Disclosure - Stockholders??? Equity (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/StockholdersEquityDetailsNarrative</Role>
      <ShortName>Stockholders??? Equity (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/StockholdersEquity</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="sonoma_i10k-033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>999054 - Disclosure - Stock-Based Compensation (Details-Assumptions)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/Stock-basedCompensationDetails-assumptions</Role>
      <ShortName>Stock-Based Compensation (Details-Assumptions)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/Stock-basedCompensationTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="sonoma_i10k-033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>999055 - Disclosure - Stock-Based Compensation (Details-Plans)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/Stock-basedCompensationDetails-plans</Role>
      <ShortName>Stock-Based Compensation (Details-Plans)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/Stock-basedCompensationTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="sonoma_i10k-033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>999056 - Disclosure - Stock-Based Compensation (Details-Option activity)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/Stock-basedCompensationDetails-optionActivity</Role>
      <ShortName>Stock-Based Compensation (Details-Option activity)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/Stock-basedCompensationTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="sonoma_i10k-033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>999057 - Disclosure - Stock-Based Compensation (Details-Restricted stock activity)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/Stock-basedCompensationDetails-restrictedStockActivity</Role>
      <ShortName>Stock-Based Compensation (Details-Restricted stock activity)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/Stock-basedCompensationTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="sonoma_i10k-033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>999058 - Disclosure - Stock-Based Compensation (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/Stock-basedCompensationDetailsNarrative</Role>
      <ShortName>Stock-Based Compensation (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/Stock-basedCompensationTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="sonoma_i10k-033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>999059 - Disclosure - Income Taxes (Details-Income source)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/IncomeTaxesDetails-incomeSource</Role>
      <ShortName>Income Taxes (Details-Income source)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/IncomeTaxesTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="sonoma_i10k-033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>999060 - Disclosure - Income Taxes (Details-Income tax expense)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/IncomeTaxesDetails-incomeTaxExpense</Role>
      <ShortName>Income Taxes (Details-Income tax expense)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/IncomeTaxesTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="sonoma_i10k-033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>999061 - Disclosure - Income Taxes (Details-Reconciliation of tax rate)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/IncomeTaxesDetails-reconciliationOfTaxRate</Role>
      <ShortName>Income Taxes (Details-Reconciliation of tax rate)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/IncomeTaxesTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="sonoma_i10k-033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>999062 - Disclosure - Income Taxes (Details-Deferred taxes)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes</Role>
      <ShortName>Income Taxes (Details-Deferred taxes)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/IncomeTaxesTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="sonoma_i10k-033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>999063 - Disclosure - Income Taxes (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/IncomeTaxesDetailsNarrative</Role>
      <ShortName>Income Taxes (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/IncomeTaxesTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="sonoma_i10k-033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>999064 - Disclosure - Employee Benefit Plan (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/EmployeeBenefitPlanDetailsNarrative</Role>
      <ShortName>Employee Benefit Plan (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/EmployeeBenefitPlan</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="sonoma_i10k-033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>999065 - Disclosure - Revenue Disaggregation (Details - Disaggregation of revenue)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/RevenueDisaggregationDetails-DisaggregationOfRevenue</Role>
      <ShortName>Revenue Disaggregation (Details - Disaggregation of revenue)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/RevenueDisaggregationTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="sonoma_i10k-033125.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>999066 - Disclosure - Revenue Disaggregation (Details - Geographic regions)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://sonomapharma.com/role/RevenueDisaggregationDetails-GeographicRegions</Role>
      <ShortName>Revenue Disaggregation (Details - Geographic regions)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://sonomapharma.com/role/RevenueDisaggregationTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>snoa-20250331.xsd</File>
    <File>snoa-20250331_cal.xml</File>
    <File>snoa-20250331_def.xml</File>
    <File>snoa-20250331_lab.xml</File>
    <File>snoa-20250331_pre.xml</File>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="sonoma_i10k-033125.htm">sonoma_i10k-033125.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>acuicyn.jpg</File>
    <File>derm.jpg</File>
    <File>lasercyn.jpg</File>
    <File>lumacyn.jpg</File>
    <File>microcyn.jpg</File>
    <File>microcynvs.jpg</File>
    <File>nancyn.jpg</File>
    <File>ocucyn.jpg</File>
    <File>regenacyn.jpg</File>
    <File>reliefacyn.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="574">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="9">http://xbrl.sec.gov/cyd/2024</BaseTaxonomy>
    <BaseTaxonomy items="38">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>96
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "sonoma_i10k-033125.htm": {
   "nsprefix": "SNOA",
   "nsuri": "http://sonomapharma.com/20250331",
   "dts": {
    "schema": {
     "local": [
      "snoa-20250331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "snoa-20250331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "snoa-20250331_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "snoa-20250331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "snoa-20250331_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "sonoma_i10k-033125.htm"
     ]
    }
   },
   "keyStandard": 297,
   "keyCustom": 24,
   "axisStandard": 20,
   "axisCustom": 0,
   "memberStandard": 28,
   "memberCustom": 22,
   "hidden": {
    "total": 48,
    "http://fasb.org/us-gaap/2024": 35,
    "http://xbrl.sec.gov/dei/2024": 4,
    "http://sonomapharma.com/20250331": 9
   },
   "contextCount": 121,
   "entityCount": 1,
   "segmentCount": 51,
   "elementCount": 500,
   "unitCount": 4,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 574,
    "http://xbrl.sec.gov/dei/2024": 38,
    "http://xbrl.sec.gov/cyd/2024": 9,
    "http://xbrl.sec.gov/ecd/2024": 4
   },
   "report": {
    "R1": {
     "role": "http://sonomapharma.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "From2024-04-01to2025-03-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-04-01to2025-03-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://sonomapharma.com/role/ConsolidatedBalanceSheets",
     "longName": "00000002 - Statement - CONSOLIDATED BALANCE SHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "AsOf2025-03-31",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-03-31",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://sonomapharma.com/role/ConsolidatedBalanceSheetsParenthetical",
     "longName": "00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "AsOf2025-03-31",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-03-31",
      "name": "us-gaap:PreferredStockSharesOutstanding",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:PreferredStockSharesIssued",
       "span",
       "span",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://sonomapharma.com/role/ConsolidatedStatementsOfComprehensiveLoss",
     "longName": "00000004 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS",
     "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "From2024-04-01to2025-03-31",
      "name": "us-gaap:Revenues",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-04-01to2025-03-31",
      "name": "us-gaap:Revenues",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://sonomapharma.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity",
     "longName": "00000005 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY",
     "shortName": "CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows",
     "longName": "00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "From2024-04-01to2025-03-31",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-04-01to2025-03-31",
      "name": "us-gaap:Depreciation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "From2025-01-012025-03-31",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2025-01-012025-03-31",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://sonomapharma.com/role/CybersecurityRiskManagementAndStrategyDisclosure",
     "longName": "999007 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure",
     "shortName": "Cybersecurity Risk Management and Strategy Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "From2024-04-01to2025-03-31",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-04-01to2025-03-31",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://sonomapharma.com/role/OrganizationAndRecentDevelopments",
     "longName": "999008 - Disclosure - Organization and Recent Developments",
     "shortName": "Organization and Recent Developments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "From2024-04-01to2025-03-31",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-04-01to2025-03-31",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://sonomapharma.com/role/LiquidityAndFinancialCondition",
     "longName": "999009 - Disclosure - Liquidity and Financial Condition",
     "shortName": "Liquidity and Financial Condition",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "From2024-04-01to2025-03-31",
      "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-04-01to2025-03-31",
      "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://sonomapharma.com/role/SummaryOfSignificantAccountingPolicies",
     "longName": "999010 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "From2024-04-01to2025-03-31",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-04-01to2025-03-31",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://sonomapharma.com/role/AccountsReceivable",
     "longName": "999011 - Disclosure - Accounts Receivable",
     "shortName": "Accounts Receivable",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "From2024-04-01to2025-03-31",
      "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-04-01to2025-03-31",
      "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://sonomapharma.com/role/Inventories",
     "longName": "999012 - Disclosure - Inventories",
     "shortName": "Inventories",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "From2024-04-01to2025-03-31",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-04-01to2025-03-31",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://sonomapharma.com/role/PrepaidExpensesAndOtherCurrentAssets",
     "longName": "999013 - Disclosure - Prepaid Expenses and Other Current Assets",
     "shortName": "Prepaid Expenses and Other Current Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "From2024-04-01to2025-03-31",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-04-01to2025-03-31",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://sonomapharma.com/role/PropertyAndEquipment",
     "longName": "999014 - Disclosure - Property and Equipment",
     "shortName": "Property and Equipment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "From2024-04-01to2025-03-31",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-04-01to2025-03-31",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://sonomapharma.com/role/AccruedExpensesAndOtherCurrentLiabilities",
     "longName": "999015 - Disclosure - Accrued Expenses and Other Current Liabilities",
     "shortName": "Accrued Expenses and Other Current Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "From2024-04-01to2025-03-31",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-04-01to2025-03-31",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://sonomapharma.com/role/Debt",
     "longName": "999016 - Disclosure - Debt",
     "shortName": "Debt",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "From2024-04-01to2025-03-31",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-04-01to2025-03-31",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://sonomapharma.com/role/Leases",
     "longName": "999017 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "From2024-04-01to2025-03-31",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-04-01to2025-03-31",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://sonomapharma.com/role/CommitmentsAndContingencies",
     "longName": "999018 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "From2024-04-01to2025-03-31",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-04-01to2025-03-31",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://sonomapharma.com/role/StockholdersEquity",
     "longName": "999019 - Disclosure - Stockholders\u2019 Equity",
     "shortName": "Stockholders\u2019 Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "From2024-04-01to2025-03-31",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-04-01to2025-03-31",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://sonomapharma.com/role/Stock-basedCompensation",
     "longName": "999020 - Disclosure - Stock-Based Compensation",
     "shortName": "Stock-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "From2024-04-01to2025-03-31",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-04-01to2025-03-31",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://sonomapharma.com/role/IncomeTaxes",
     "longName": "999021 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "From2024-04-01to2025-03-31",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-04-01to2025-03-31",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://sonomapharma.com/role/EmployeeBenefitPlan",
     "longName": "999022 - Disclosure - Employee Benefit Plan",
     "shortName": "Employee Benefit Plan",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "From2024-04-01to2025-03-31",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-04-01to2025-03-31",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://sonomapharma.com/role/RevenueDisaggregation",
     "longName": "999023 - Disclosure - Revenue Disaggregation",
     "shortName": "Revenue Disaggregation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "From2024-04-01to2025-03-31",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-04-01to2025-03-31",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "999025 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "25",
     "firstAnchor": {
      "contextRef": "From2024-04-01to2025-03-31",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-04-01to2025-03-31",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesTables",
     "longName": "999026 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "From2024-04-01to2025-03-31",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:ConcentrationRiskCreditRisk",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-04-01to2025-03-31",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:ConcentrationRiskCreditRisk",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://sonomapharma.com/role/AccountsReceivableTables",
     "longName": "999027 - Disclosure - Accounts Receivable (Tables)",
     "shortName": "Accounts Receivable (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "From2024-04-01to2025-03-31",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-04-01to2025-03-31",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://sonomapharma.com/role/InventoriesTables",
     "longName": "999028 - Disclosure - Inventories (Tables)",
     "shortName": "Inventories (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "From2024-04-01to2025-03-31",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-04-01to2025-03-31",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://sonomapharma.com/role/PrepaidExpensesAndOtherCurrentAssetsTables",
     "longName": "999029 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)",
     "shortName": "Prepaid Expenses and Other Current Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "From2024-04-01to2025-03-31",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-04-01to2025-03-31",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://sonomapharma.com/role/PropertyAndEquipmentTables",
     "longName": "999030 - Disclosure - Property and Equipment (Tables)",
     "shortName": "Property and Equipment (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "From2024-04-01to2025-03-31",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-04-01to2025-03-31",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://sonomapharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables",
     "longName": "999031 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)",
     "shortName": "Accrued Expenses and Other Current Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "From2024-04-01to2025-03-31",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-04-01to2025-03-31",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://sonomapharma.com/role/LeasesTables",
     "longName": "999032 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "From2024-04-01to2025-03-31",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-04-01to2025-03-31",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://sonomapharma.com/role/Stock-basedCompensationTables",
     "longName": "999033 - Disclosure - Stock-Based Compensation (Tables)",
     "shortName": "Stock-Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "From2024-04-01to2025-03-31",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-04-01to2025-03-31",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://sonomapharma.com/role/IncomeTaxesTables",
     "longName": "999034 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "From2024-04-01to2025-03-31",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-04-01to2025-03-31",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://sonomapharma.com/role/RevenueDisaggregationTables",
     "longName": "999035 - Disclosure - Revenue Disaggregation (Tables)",
     "shortName": "Revenue Disaggregation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "From2024-04-01to2025-03-31",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-04-01to2025-03-31",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://sonomapharma.com/role/OrganizationAndRecentDevelopmentsDetailsNarrative",
     "longName": "999036 - Disclosure - Organization and Recent Developments (Details Narrative)",
     "shortName": "Organization and Recent Developments (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "AsOf2025-03-31",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockSharesIssued",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-08-29",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "unique": true
     }
    },
    "R37": {
     "role": "http://sonomapharma.com/role/LiquidityAndFinancialConditionDetailsNarrative",
     "longName": "999037 - Disclosure - Liquidity and Financial Condition (Details Narrative)",
     "shortName": "Liquidity and Financial Condition (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "From2024-04-01to2025-03-31",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-03-31",
      "name": "SNOA:WorkingCapital",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "unique": true
     }
    },
    "R38": {
     "role": "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails",
     "longName": "999038 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "From2024-04-012025-03-31_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueNetMember_custom_CustomerAMember",
      "name": "SNOA:ConcentrationRiskPercentage2",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "b",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "us-gaap:ConcentrationRiskCreditRisk",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-04-012025-03-31_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueNetMember_custom_CustomerAMember",
      "name": "SNOA:ConcentrationRiskPercentage2",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "b",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "us-gaap:ConcentrationRiskCreditRisk",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-usefulLives",
     "longName": "999039 - Disclosure - Summary of Significant Accounting Policies (Details-Useful lives)",
     "shortName": "Summary of Significant Accounting Policies (Details-Useful lives)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "AsOf2025-03-31_us-gaap_OfficeEquipmentMember",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "SNOA:PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-03-31_us-gaap_OfficeEquipmentMember",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "SNOA:PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-EarningsPerShare",
     "longName": "999040 - Disclosure - Summary of Significant Accounting Policies (Details - Earnings per share)",
     "shortName": "Summary of Significant Accounting Policies (Details - Earnings per share)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "From2024-04-01to2025-03-31",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R41": {
     "role": "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-AntidilutiveShares",
     "longName": "999041 - Disclosure - Summary of Significant Accounting Policies (Details - Antidilutive shares)",
     "shortName": "Summary of Significant Accounting Policies (Details - Antidilutive shares)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "From2024-04-01to2025-03-31",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-04-01to2025-03-31",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
     "longName": "999042 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)",
     "shortName": "Summary of Significant Accounting Policies (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "AsOf2025-03-31",
      "name": "us-gaap:InventoryValuationReserves",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:InventoryPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-04-01to2025-03-31",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "unique": true
     }
    },
    "R43": {
     "role": "http://sonomapharma.com/role/AccountsReceivableDetails",
     "longName": "999043 - Disclosure - Accounts Receivable (Details)",
     "shortName": "Accounts Receivable (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "AsOf2025-03-31",
      "name": "us-gaap:AccountsReceivableGrossCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-03-31",
      "name": "us-gaap:AccountsReceivableGrossCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://sonomapharma.com/role/InventoriesDetails",
     "longName": "999044 - Disclosure - Inventories (Details)",
     "shortName": "Inventories (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "AsOf2025-03-31",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-03-31",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://sonomapharma.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails",
     "longName": "999045 - Disclosure - Prepaid Expenses and Other Current Assets (Details)",
     "shortName": "Prepaid Expenses and Other Current Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "AsOf2025-03-31",
      "name": "us-gaap:PrepaidInsurance",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-03-31",
      "name": "us-gaap:PrepaidInsurance",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://sonomapharma.com/role/PropertyAndEquipmentDetails",
     "longName": "999046 - Disclosure - Property and Equipment (Details)",
     "shortName": "Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "AsOf2025-03-31",
      "name": "us-gaap:MachineryAndEquipmentGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-03-31",
      "name": "us-gaap:MachineryAndEquipmentGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://sonomapharma.com/role/PropertyAndEquipmentDetailsNarrative",
     "longName": "999047 - Disclosure - Property and Equipment (Details Narrative)",
     "shortName": "Property and Equipment (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "From2024-04-01to2025-03-31",
      "name": "us-gaap:DepreciationAndAmortization",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-04-01to2025-03-31",
      "name": "us-gaap:DepreciationAndAmortization",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://sonomapharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails",
     "longName": "999048 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)",
     "shortName": "Accrued Expenses and Other Current Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "AsOf2025-03-31",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-03-31",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://sonomapharma.com/role/DebtDetailsNarrative",
     "longName": "999049 - Disclosure - Debt (Details Narrative)",
     "shortName": "Debt (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "AsOf2025-02-01_custom_InsurancePremiumFinancingMember",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-02-01_custom_InsurancePremiumFinancingMember",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://sonomapharma.com/role/LeasesDetails-BalanceSheetInformationRelatedToLeases",
     "longName": "999050 - Disclosure - Leases (Details - Balance sheet information related to leases)",
     "shortName": "Leases (Details - Balance sheet information related to leases)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "AsOf2025-03-31",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-04-01to2025-03-31",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "unique": true
     }
    },
    "R51": {
     "role": "http://sonomapharma.com/role/LeasesDetails-MinimumOperatingLeasePayments",
     "longName": "999051 - Disclosure - Leases (Details - Minimum operating lease payments)",
     "shortName": "Leases (Details - Minimum operating lease payments)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "AsOf2025-03-31",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-03-31",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://sonomapharma.com/role/CommitmentsAndContingenciesDetailsNarrative",
     "longName": "999052 - Disclosure - Commitments and Contingencies (Details Narrative)",
     "shortName": "Commitments and Contingencies (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "From2024-04-01to2025-03-31",
      "name": "us-gaap:OfficersCompensation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-04-01to2025-03-31",
      "name": "us-gaap:OfficersCompensation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://sonomapharma.com/role/StockholdersEquityDetailsNarrative",
     "longName": "999053 - Disclosure - Stockholders\u2019 Equity (Details Narrative)",
     "shortName": "Stockholders\u2019 Equity (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "AsOf2025-03-31",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-08-29",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "unique": true
     }
    },
    "R54": {
     "role": "http://sonomapharma.com/role/Stock-basedCompensationDetails-assumptions",
     "longName": "999054 - Disclosure - Stock-Based Compensation (Details-Assumptions)",
     "shortName": "Stock-Based Compensation (Details-Assumptions)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "From2024-04-01to2025-03-31",
      "name": "us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-04-01to2025-03-31",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://sonomapharma.com/role/Stock-basedCompensationDetails-plans",
     "longName": "999055 - Disclosure - Stock-Based Compensation (Details-Plans)",
     "shortName": "Stock-Based Compensation (Details-Plans)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "AsOf2025-03-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "SNOA:ScheduleOfStockbasedAwardsOutstandingByPlanTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-03-31_custom_Plan2011Member",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "SNOA:ScheduleOfStockbasedAwardsOutstandingByPlanTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "unique": true
     }
    },
    "R56": {
     "role": "http://sonomapharma.com/role/Stock-basedCompensationDetails-optionActivity",
     "longName": "999056 - Disclosure - Stock-Based Compensation (Details-Option activity)",
     "shortName": "Stock-Based Compensation (Details-Option activity)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "From2024-04-01to2025-03-31",
      "name": "us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-04-012025-03-31_us-gaap_StockOptionMember689261046",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "unique": true
     }
    },
    "R57": {
     "role": "http://sonomapharma.com/role/Stock-basedCompensationDetails-restrictedStockActivity",
     "longName": "999057 - Disclosure - Stock-Based Compensation (Details-Restricted stock activity)",
     "shortName": "Stock-Based Compensation (Details-Restricted stock activity)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "AsOf2024-03-31_us-gaap_RestrictedStockMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-03-31_us-gaap_RestrictedStockMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://sonomapharma.com/role/Stock-basedCompensationDetailsNarrative",
     "longName": "999058 - Disclosure - Stock-Based Compensation (Details Narrative)",
     "shortName": "Stock-Based Compensation (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "From2024-04-01to2025-03-31",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-04-01to2025-03-31",
      "name": "us-gaap:StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "unique": true
     }
    },
    "R59": {
     "role": "http://sonomapharma.com/role/IncomeTaxesDetails-incomeSource",
     "longName": "999059 - Disclosure - Income Taxes (Details-Income source)",
     "shortName": "Income Taxes (Details-Income source)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "From2024-04-01to2025-03-31",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-04-01to2025-03-31",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://sonomapharma.com/role/IncomeTaxesDetails-incomeTaxExpense",
     "longName": "999060 - Disclosure - Income Taxes (Details-Income tax expense)",
     "shortName": "Income Taxes (Details-Income tax expense)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "From2024-04-01to2025-03-31",
      "name": "us-gaap:CurrentStateAndLocalTaxExpenseBenefit",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-04-01to2025-03-31",
      "name": "us-gaap:CurrentStateAndLocalTaxExpenseBenefit",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://sonomapharma.com/role/IncomeTaxesDetails-reconciliationOfTaxRate",
     "longName": "999061 - Disclosure - Income Taxes (Details-Reconciliation of tax rate)",
     "shortName": "Income Taxes (Details-Reconciliation of tax rate)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "From2024-04-01to2025-03-31",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-04-01to2025-03-31",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes",
     "longName": "999062 - Disclosure - Income Taxes (Details-Deferred taxes)",
     "shortName": "Income Taxes (Details-Deferred taxes)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "AsOf2025-03-31",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-03-31",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://sonomapharma.com/role/IncomeTaxesDetailsNarrative",
     "longName": "999063 - Disclosure - Income Taxes (Details Narrative)",
     "shortName": "Income Taxes (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "AsOf2025-03-31_us-gaap_DomesticCountryMember",
      "name": "us-gaap:OperatingLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-03-31_us-gaap_DomesticCountryMember",
      "name": "us-gaap:OperatingLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://sonomapharma.com/role/EmployeeBenefitPlanDetailsNarrative",
     "longName": "999064 - Disclosure - Employee Benefit Plan (Details Narrative)",
     "shortName": "Employee Benefit Plan (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "From2024-04-01to2025-03-31",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitContributions",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-04-01to2025-03-31",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitContributions",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://sonomapharma.com/role/RevenueDisaggregationDetails-DisaggregationOfRevenue",
     "longName": "999065 - Disclosure - Revenue Disaggregation (Details - Disaggregation of revenue)",
     "shortName": "Revenue Disaggregation (Details - Disaggregation of revenue)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "From2024-04-01to2025-03-31",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-04-012025-03-31_us-gaap_ProductMember",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "unique": true
     }
    },
    "R66": {
     "role": "http://sonomapharma.com/role/RevenueDisaggregationDetails-GeographicRegions",
     "longName": "999066 - Disclosure - Revenue Disaggregation (Details - Geographic regions)",
     "shortName": "Revenue Disaggregation (Details - Geographic regions)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "From2024-04-01to2025-03-31",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-04-012025-03-31_us-gaap_SalesRevenueSegmentMember_country_US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sonoma_i10k-033125.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsNotesAndLoansReceivableLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsNotesAndLoansReceivableLineItems",
     "presentation": [
      "http://sonomapharma.com/role/AccountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts, Notes, Loans and Financing Receivable [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r252",
      "r837"
     ]
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "presentation": [
      "http://sonomapharma.com/role/AccruedExpensesAndOtherCurrentLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Expenses and Other Current Liabilities",
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r393"
     ]
    },
    "us-gaap_AccountsPayableAndOtherAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndOtherAccruedLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://sonomapharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://sonomapharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://sonomapharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails",
      "http://sonomapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued expenses and other current liabilities",
        "totalLabel": "Total accrued expenses and other current liabilities",
        "documentation": "Amount of liabilities incurred and payable to vendors for goods and services received, and accrued liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r602"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://sonomapharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r736"
     ]
    },
    "us-gaap_AccountsReceivableGrossCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableGrossCurrent",
     "crdr": "debit",
     "calculation": {
      "http://sonomapharma.com/role/AccountsReceivableDetails": {
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://sonomapharma.com/role/AccountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts receivable",
        "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r252",
      "r690"
     ]
    },
    "us-gaap_AccountsReceivableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableMember",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable [Member]",
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold."
       }
      }
     },
     "auth_ref": [
      "r671"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://sonomapharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://sonomapharma.com/role/AccountsReceivableDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://sonomapharma.com/role/AccountsReceivableDetails",
      "http://sonomapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts receivable, net",
        "totalLabel": "Total accounts receivable, net",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r835"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://sonomapharma.com/role/PropertyAndEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://sonomapharma.com/role/PropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: accumulated depreciation",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r149",
      "r534"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r166",
      "r167",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://sonomapharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedBalanceSheets",
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated other comprehensive loss",
        "negatedLabel": "Accumulated other comprehensive loss",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r18",
      "r76",
      "r156",
      "r530",
      "r569",
      "r570"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r9",
      "r18",
      "r448",
      "r451",
      "r482",
      "r565",
      "r566",
      "r813",
      "r814",
      "r815",
      "r823",
      "r824",
      "r825",
      "r826"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://sonomapharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid-in capital",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r584",
      "r823",
      "r824",
      "r825",
      "r826",
      "r888",
      "r940"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee stock-based compensation",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r42",
      "r352"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdvertisingCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdvertisingCostsPolicyTextBlock",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Advertising Costs",
        "documentation": "Disclosure of accounting policy for advertising cost."
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://sonomapharma.com/role/AccountsReceivableDetails": {
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://sonomapharma.com/role/AccountsReceivableDetails",
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Allowance for doubtful accounts",
        "negatedLabel": "Less: discounts, rebates, distributor fees and returns",
        "documentation": "Amount of allowance for credit loss on accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r256",
      "r261",
      "r262",
      "r263",
      "r908"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "SNOA_AnimalCareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sonomapharma.com/20250331",
     "localname": "AnimalCareMember",
     "presentation": [
      "http://sonomapharma.com/role/RevenueDisaggregationDetails-DisaggregationOfRevenue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Animal Care [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r786"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-AntidilutiveShares"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive shares",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r208"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-AntidilutiveShares"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-AntidilutiveShares"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-AntidilutiveShares"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://sonomapharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r439"
     ]
    },
    "srt_AsiaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "AsiaMember",
     "presentation": [
      "http://sonomapharma.com/role/RevenueDisaggregationDetails-GeographicRegions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asia [Member]"
       }
      }
     },
     "auth_ref": [
      "r942",
      "r943",
      "r944",
      "r945"
     ]
    },
    "us-gaap_AssetImpairmentCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetImpairmentCharges",
     "crdr": "debit",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of long lived assets",
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r31"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://sonomapharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r125",
      "r151",
      "r182",
      "r211",
      "r216",
      "r240",
      "r243",
      "r258",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r441",
      "r445",
      "r461",
      "r526",
      "r623",
      "r706",
      "r707",
      "r736",
      "r764",
      "r848",
      "r849",
      "r898"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://sonomapharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r160",
      "r182",
      "r258",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r441",
      "r445",
      "r461",
      "r736",
      "r848",
      "r849",
      "r898"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r786"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r776",
      "r778",
      "r786"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLocation",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r776",
      "r778",
      "r786"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorName",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r776",
      "r778",
      "r786"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-optionActivity",
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-restrictedStockActivity",
      "http://sonomapharma.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r355",
      "r356",
      "r357",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of presentation",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "SNOA_CaliforniaResearchAndDevelopmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sonomapharma.com/20250331",
     "localname": "CaliforniaResearchAndDevelopmentMember",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "California Research And Development [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://sonomapharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r147",
      "r688"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and cash equivalents, beginning of year",
        "periodEndLabel": "Cash and cash equivalents, end of year",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r86",
      "r178"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net increase (decrease) in cash and cash equivalents",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r86"
     ]
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-cash operating and financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://sonomapharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r152",
      "r153",
      "r154",
      "r182",
      "r202",
      "r203",
      "r205",
      "r207",
      "r213",
      "r214",
      "r258",
      "r297",
      "r299",
      "r300",
      "r301",
      "r304",
      "r305",
      "r321",
      "r322",
      "r325",
      "r328",
      "r335",
      "r461",
      "r577",
      "r578",
      "r579",
      "r580",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r611",
      "r632",
      "r650",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r802",
      "r819",
      "r827"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://sonomapharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r153",
      "r154",
      "r213",
      "r321",
      "r322",
      "r323",
      "r325",
      "r328",
      "r333",
      "r335",
      "r577",
      "r578",
      "r579",
      "r580",
      "r715",
      "r802",
      "r819"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://sonomapharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies (Note 11)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r118",
      "r527",
      "r610"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://sonomapharma.com/role/CommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r289",
      "r290",
      "r672",
      "r840",
      "r845"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r754",
      "r755",
      "r756",
      "r758",
      "r759",
      "r760",
      "r761",
      "r823",
      "r824",
      "r826",
      "r888",
      "r939",
      "r940"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://sonomapharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://sonomapharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r611"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://sonomapharma.com/role/OrganizationAndRecentDevelopmentsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares outstanding",
        "verboseLabel": "Common stock outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r65",
      "r611",
      "r629",
      "r940",
      "r941"
     ]
    },
    "SNOA_CommonStockUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sonomapharma.com/20250331",
     "localname": "CommonStockUnitsMember",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-AntidilutiveShares"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Units [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://sonomapharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, $0.0001 par value; 50,000,000 and 24,000,000 shares authorized at March 31, 2025 and 2024, respectively, 1,634,265 and 780,371 shares issued and outstanding at March 31, 2025 and 2024, respectively (Note 1) (Note 12)",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r529",
      "r736"
     ]
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CompensationAndEmployeeBenefitPlansTextBlock",
     "presentation": [
      "http://sonomapharma.com/role/EmployeeBenefitPlan"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Benefit Plan",
        "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r105",
      "r106",
      "r107"
     ]
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://sonomapharma.com/role/ConsolidatedStatementsOfComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive loss",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r113",
      "r162",
      "r164",
      "r170",
      "r521",
      "r540"
     ]
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Loss",
        "documentation": "Disclosure of accounting policy for comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://sonomapharma.com/role/RevenueDisaggregationDetails-GeographicRegions",
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r26",
      "r45",
      "r46",
      "r250",
      "r671"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://sonomapharma.com/role/RevenueDisaggregationDetails-GeographicRegions",
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r26",
      "r45",
      "r46",
      "r250",
      "r572",
      "r671"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r26",
      "r45",
      "r46",
      "r250",
      "r671",
      "r804"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration of Credit Risk and Major Customers",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r131"
     ]
    },
    "SNOA_ConcentrationRiskPercentage2": {
     "xbrltype": "percentItemType",
     "nsuri": "http://sonomapharma.com/20250331",
     "localname": "ConcentrationRiskPercentage2",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration risk, percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r26",
      "r45",
      "r46",
      "r250",
      "r671"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Principles of Consolidation",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r698"
     ]
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertiblePreferredStockMember",
     "presentation": [
      "http://sonomapharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Preferred Stock [Member]",
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option."
       }
      }
     },
     "auth_ref": [
      "r321",
      "r322",
      "r325",
      "r758",
      "r759",
      "r760",
      "r761"
     ]
    },
    "SNOA_ConvertiblePreferredStockPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://sonomapharma.com/20250331",
     "localname": "ConvertiblePreferredStockPolicyTextBlock",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Preferred Stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostOfGoodsAndServicesSold",
     "crdr": "debit",
     "calculation": {
      "http://sonomapharma.com/role/ConsolidatedStatementsOfComprehensiveLoss": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of revenues",
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r80",
      "r490"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r184",
      "r185",
      "r308",
      "r323",
      "r483",
      "r486",
      "r525",
      "r695",
      "r697"
     ]
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CountryRegion",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentFederalStateAndLocalTaxExpenseBenefitAbstract",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-incomeTaxExpense"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current:"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-incomeTaxExpense"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State",
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r806",
      "r821",
      "r887"
     ]
    },
    "SNOA_CustomerAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sonomapharma.com/20250331",
     "localname": "CustomerAMember",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer A [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "SNOA_CustomerBMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sonomapharma.com/20250331",
     "localname": "CustomerBMember",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer B [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "SNOA_CustomerCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sonomapharma.com/20250331",
     "localname": "CustomerCMember",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer C [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CustomerConcentrationRiskMember",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r250"
     ]
    },
    "SNOA_CustomerDMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sonomapharma.com/20250331",
     "localname": "CustomerDMember",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer D [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://sonomapharma.com/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r784",
      "r796"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://sonomapharma.com/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r784",
      "r796"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://sonomapharma.com/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r780",
      "r792"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://sonomapharma.com/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r781",
      "r793"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://sonomapharma.com/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r781",
      "r793"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r779",
      "r791"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://sonomapharma.com/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r782",
      "r794"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://sonomapharma.com/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r783",
      "r795"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://sonomapharma.com/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r783",
      "r795"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://sonomapharma.com/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r785",
      "r797"
     ]
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://sonomapharma.com/role/Debt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r180",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r295",
      "r296",
      "r306",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r317",
      "r318",
      "r319",
      "r470"
     ]
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://sonomapharma.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt face amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r307",
      "r470",
      "r471",
      "r713",
      "r714",
      "r734"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateDuringPeriod": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateDuringPeriod",
     "presentation": [
      "http://sonomapharma.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt interest rate",
        "documentation": "The average effective interest rate during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r316",
      "r895"
     ]
    },
    "us-gaap_DebtInstrumentMaturityDateRangeEnd1": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentMaturityDateRangeEnd1",
     "presentation": [
      "http://sonomapharma.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Final payment date",
        "documentation": "Latest date the outstanding debt instruments are required to be repaid, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "us-gaap_DebtInstrumentMaturityDateRangeStart1": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentMaturityDateRangeStart1",
     "presentation": [
      "http://sonomapharma.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "First installment beginning date",
        "documentation": "Earliest date the outstanding debt instruments are required to be repaid, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "us-gaap_DebtInstrumentPaymentTerms": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentPaymentTerms",
     "presentation": [
      "http://sonomapharma.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt payment terms",
        "documentation": "Description of the payment terms of the debt instrument (for example, whether periodic payments include principal and frequency of payments) and discussion about any contingencies associated with the payment."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r57"
     ]
    },
    "us-gaap_DebtInstrumentPeriodicPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentPeriodicPayment",
     "crdr": "debit",
     "presentation": [
      "http://sonomapharma.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Periodic payment",
        "documentation": "Amount of the required periodic payments including both interest and principal payments."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r47"
     ]
    },
    "SNOA_DeferredConsiderationCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sonomapharma.com/20250331",
     "localname": "DeferredConsiderationCurrent",
     "crdr": "debit",
     "calculation": {
      "http://sonomapharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current portion of deferred consideration, net of discount"
       }
      }
     },
     "auth_ref": []
    },
    "SNOA_DeferredConsiderationNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sonomapharma.com/20250331",
     "localname": "DeferredConsiderationNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://sonomapharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred consideration, net of discount, less current portion"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "presentation": [
      "http://sonomapharma.com/role/PrepaidExpensesAndOtherCurrentAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of prepaid expenses and other current assets",
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredFederalStateAndLocalTaxExpenseBenefitAbstract",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-incomeTaxExpense"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-incomeTaxExpense"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign",
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r821",
      "r886"
     ]
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://sonomapharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred tax asset, net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r399",
      "r400"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-incomeTaxExpense"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total income tax (expense) benefit",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r137",
      "r821"
     ]
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Gross deferred tax liabilities",
        "label": "Deferred Tax Liabilities, Gross",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r62",
      "r117",
      "r416"
     ]
    },
    "us-gaap_DeferredRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredRevenue",
     "crdr": "credit",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Deferred revenue",
        "label": "Deferred Revenue",
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r809"
     ]
    },
    "us-gaap_DeferredRevenueCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredRevenueCurrent",
     "crdr": "credit",
     "calculation": {
      "http://sonomapharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred revenue, current portion",
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r808"
     ]
    },
    "us-gaap_DeferredRevenueNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredRevenueNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://sonomapharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred revenue, net of current portion",
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r809"
     ]
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gross deferred tax assets",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r417"
     ]
    },
    "us-gaap_DeferredTaxAssetsGrossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGrossAbstract",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred tax assets:"
       }
      }
     },
     "auth_ref": []
    },
    "SNOA_DeferredTaxAssetsLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sonomapharma.com/20250331",
     "localname": "DeferredTaxAssetsLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred tax assets",
        "label": "Deferred Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r882"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred tax assets",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r882"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net operating loss carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r884"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "calculation": {
      "http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development tax credit carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r884"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-based compensation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r884"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseOther",
     "crdr": "debit",
     "calculation": {
      "http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other deferred tax assets",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from provisions, reserves, allowances, and accruals, classified as other."
       }
      }
     },
     "auth_ref": [
      "r884"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals",
     "crdr": "debit",
     "calculation": {
      "http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reserves and accruals",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals."
       }
      }
     },
     "auth_ref": [
      "r884"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r418"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesAbstract",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred tax liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesPrepaidExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesPrepaidExpenses",
     "crdr": "credit",
     "calculation": {
      "http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses",
        "label": "Deferred Tax Liabilities, Prepaid Expenses",
        "documentation": "Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses."
       }
      }
     },
     "auth_ref": [
      "r884"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Fixed assets",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": [
      "r884"
     ]
    },
    "SNOA_DeferredTaxLiabilitiesRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sonomapharma.com/20250331",
     "localname": "DeferredTaxLiabilitiesRightOfUseAsset",
     "crdr": "credit",
     "calculation": {
      "http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-deferredTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Right of use asset",
        "label": "DeferredTaxLiabilitiesRightOfUseAsset"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r32"
     ]
    },
    "us-gaap_DepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationAndAmortization",
     "crdr": "debit",
     "presentation": [
      "http://sonomapharma.com/role/PropertyAndEquipmentDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation and amortization",
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r32"
     ]
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisaggregationOfRevenueLineItems",
     "presentation": [
      "http://sonomapharma.com/role/RevenueDisaggregationDetails-DisaggregationOfRevenue",
      "http://sonomapharma.com/role/RevenueDisaggregationDetails-GeographicRegions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disaggregation of Revenue [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r346",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisaggregationOfRevenueTable",
     "presentation": [
      "http://sonomapharma.com/role/RevenueDisaggregationDetails-DisaggregationOfRevenue",
      "http://sonomapharma.com/role/RevenueDisaggregationDetails-GeographicRegions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disaggregation of Revenue [Table]",
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r346",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "presentation": [
      "http://sonomapharma.com/role/RevenueDisaggregationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of disaggregated revenue by source",
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r851"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r350",
      "r354",
      "r384",
      "r385",
      "r387",
      "r724"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r778"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r776",
      "r778",
      "r786"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r776",
      "r778",
      "r786",
      "r788"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r777"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r765"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r778"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r778"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-incomeSource",
      "http://sonomapharma.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Domestic Tax Jurisdiction [Member]",
        "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r402"
     ]
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfComprehensiveLoss",
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-EarningsPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss per share: basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r200",
      "r202",
      "r205",
      "r206",
      "r207",
      "r210",
      "r435",
      "r438",
      "r455",
      "r456",
      "r522",
      "r541",
      "r701"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfComprehensiveLoss",
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-EarningsPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss per share: diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r202",
      "r205",
      "r206",
      "r207",
      "r210",
      "r435",
      "r438",
      "r455",
      "r456",
      "r522",
      "r541",
      "r701"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss per Share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r23",
      "r209"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effect of exchange rate on cash and cash equivalents",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r463"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://sonomapharma.com/role/IncomeTaxesDetails-reconciliationOfTaxRate": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-reconciliationOfTaxRate"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Totals",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r402",
      "r726"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://sonomapharma.com/role/IncomeTaxesDetails-reconciliationOfTaxRate": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-reconciliationOfTaxRate"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected federal statutory rate",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r183",
      "r402",
      "r426",
      "r726"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-reconciliationOfTaxRate"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in valuation allowance",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r407",
      "r726",
      "r822",
      "r879"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-reconciliationOfTaxRate"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign earnings taxed at different rates",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile."
       }
      }
     },
     "auth_ref": [
      "r403",
      "r406",
      "r726",
      "r822",
      "r879"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationLineItems",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-incomeSource",
      "http://sonomapharma.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r402",
      "r403",
      "r726"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-reconciliationOfTaxRate"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Effect of permanent differences",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r408",
      "r409",
      "r822",
      "r879"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-reconciliationOfTaxRate"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effect of intercompany interest permanent differences",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r726",
      "r822",
      "r879",
      "r881"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-reconciliationOfTaxRate"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Total effective rate",
        "label": "Effective Income Tax Rate Reconciliation, Other Reconciling Items, Percent",
        "documentation": "Percentage of reported income tax benefit (expense) from difference to income tax expense (benefit) computed by applying statutory federal (national) income tax rate to pretax income (loss) from continuing operation, attributable to other reconciling items. Excludes state and local income tax expense (benefit), federal tax expense (benefit), statutory income tax expense (benefit) outside of country of domicile, tax credit, nondeductible expense, deduction, income tax settlement, income tax contingency, and cross-border tax law."
       }
      }
     },
     "auth_ref": [
      "r880"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-reconciliationOfTaxRate"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "State income taxes, net of federal benefit",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r405",
      "r726",
      "r822",
      "r879"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationTable",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-incomeSource",
      "http://sonomapharma.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation [Table]",
        "documentation": "Disclosure of information about income tax rate reconciliation between amount of reported income tax expense (benefit) attributable to continuing operation to amount of income tax expense(benefit) that would result from applying statutory federal (national) tax rate to pretax income (loss) from continuing operation."
       }
      }
     },
     "auth_ref": [
      "r402",
      "r403",
      "r726"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://sonomapharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://sonomapharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Salaries and related costs",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized compensation costs",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r386"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average amortization period",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r386"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r771"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityDomain",
     "presentation": [
      "http://sonomapharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r801"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r798"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r786"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r799"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r141",
      "r166",
      "r167",
      "r168",
      "r186",
      "r187",
      "r188",
      "r190",
      "r195",
      "r197",
      "r199",
      "r212",
      "r259",
      "r260",
      "r277",
      "r336",
      "r424",
      "r425",
      "r432",
      "r433",
      "r434",
      "r436",
      "r437",
      "r438",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r454",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r472",
      "r474",
      "r482",
      "r539",
      "r565",
      "r566",
      "r567",
      "r584",
      "r650"
     ]
    },
    "SNOA_EquityDistributionAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sonomapharma.com/20250331",
     "localname": "EquityDistributionAgreementMember",
     "presentation": [
      "http://sonomapharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Distribution Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_EuropeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "EuropeMember",
     "presentation": [
      "http://sonomapharma.com/role/RevenueDisaggregationDetails-GeographicRegions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Europe [Member]"
       }
      }
     },
     "auth_ref": [
      "r942",
      "r943",
      "r944",
      "r945"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Extension",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Assets and Liabilities",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet",
     "crdr": "debit",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transfers in or out of level 3",
        "documentation": "Amount of transfer of financial instrument classified as an asset into (out of) level 3 of the fair value hierarchy."
       }
      }
     },
     "auth_ref": [
      "r890",
      "r891"
     ]
    },
    "us-gaap_ForeignCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCountryMember",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-incomeSource",
      "http://sonomapharma.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign Tax Jurisdiction [Member]",
        "documentation": "Designated foreign jurisdiction entitled to levy and collect income tax outside country of domicile."
       }
      }
     },
     "auth_ref": [
      "r402",
      "r403"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyTransactionGainBeforeTax",
     "crdr": "credit",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign currency transaction gain",
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain recognized in the income statement."
       }
      }
     },
     "auth_ref": [
      "r893",
      "r894"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyTransactionLossBeforeTax",
     "crdr": "debit",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign currency transaction loss",
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized loss recognized in the income statement."
       }
      }
     },
     "auth_ref": [
      "r893",
      "r894"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign Currency Reporting",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r462"
     ]
    },
    "us-gaap_FurnitureAndFixturesGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FurnitureAndFixturesGross",
     "crdr": "debit",
     "calculation": {
      "http://sonomapharma.com/role/PropertyAndEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://sonomapharma.com/role/PropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Furniture and fixtures",
        "documentation": "Amount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-usefulLives"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GrossProfit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GrossProfit",
     "crdr": "credit",
     "calculation": {
      "http://sonomapharma.com/role/ConsolidatedStatementsOfComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gross profit",
        "label": "Gross Profit",
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r81",
      "r124",
      "r182",
      "r258",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r461",
      "r703",
      "r706",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r848"
     ]
    },
    "SNOA_HumanCareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sonomapharma.com/20250331",
     "localname": "HumanCareMember",
     "presentation": [
      "http://sonomapharma.com/role/RevenueDisaggregationDetails-DisaggregationOfRevenue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Human Care [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r776",
      "r778",
      "r786"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of Long-Lived Assets",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r96"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://sonomapharma.com/role/ConsolidatedStatementsOfComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations before income taxes",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r120",
      "r124",
      "r523",
      "r536",
      "r703",
      "r706",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r278",
      "r285",
      "r286",
      "r458",
      "r459",
      "r460",
      "r562",
      "r564",
      "r635",
      "r684",
      "r729",
      "r910"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r285",
      "r286",
      "r458",
      "r459",
      "r460",
      "r562",
      "r564",
      "r635",
      "r684",
      "r729",
      "r910"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-incomeSource",
      "http://sonomapharma.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Axis]",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r177",
      "r402",
      "r403",
      "r413",
      "r421",
      "r726",
      "r883"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-incomeSource",
      "http://sonomapharma.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r177",
      "r402",
      "r403",
      "r413",
      "r421",
      "r726",
      "r883"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r183",
      "r396",
      "r402",
      "r410",
      "r411",
      "r412",
      "r414",
      "r420",
      "r427",
      "r429",
      "r430",
      "r431",
      "r582",
      "r726"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://sonomapharma.com/role/ConsolidatedStatementsOfComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Income tax (expense) benefit",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r138",
      "r198",
      "r199",
      "r211",
      "r224",
      "r243",
      "r401",
      "r402",
      "r428",
      "r542",
      "r726"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r397",
      "r398",
      "r414",
      "r415",
      "r419",
      "r423",
      "r576"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts receivable, net",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "crdr": "debit",
     "calculation": {
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred revenue",
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r488",
      "r817"
     ]
    },
    "us-gaap_IncreaseDecreaseInDeferredCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInDeferredCompensation",
     "crdr": "debit",
     "calculation": {
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred consideration, net of discount",
        "documentation": "The increase (decrease) during the reporting period in the obligation created by employee agreements whereby earned compensation will be paid in the future."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInDeferredIncomeTaxes",
     "crdr": "credit",
     "calculation": {
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Deferred income tax expense",
        "label": "Increase (Decrease) in Deferred Income Taxes",
        "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Inventories, net",
        "label": "Increase (Decrease) in Inventories",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease liabilities",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r805",
      "r817"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Other Accounts Payable",
        "documentation": "Amount of increase (decrease) in obligations classified as other, payable within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued expenses and other current liabilities",
        "label": "Increase (Decrease) in Other Accounts Payable and Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "crdr": "credit",
     "calculation": {
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Operating lease right-of-use asset",
        "label": "Increase (Decrease) in Other Operating Assets",
        "documentation": "Amount of increase (decrease) in operating assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "crdr": "credit",
     "calculation": {
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other current assets",
        "label": "Increase (Decrease) in Prepaid Expense",
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "SNOA_IncreaseDecreaseInWithholdingTaxPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sonomapharma.com/20250331",
     "localname": "IncreaseDecreaseInWithholdingTaxPayable",
     "crdr": "debit",
     "calculation": {
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Withholding tax payable",
        "label": "IncreaseDecreaseInWithholdingTaxPayable"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "SNOA_InsurancePremiumFinancingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sonomapharma.com/20250331",
     "localname": "InsurancePremiumFinancingMember",
     "presentation": [
      "http://sonomapharma.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insurance Premium Financing [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "SNOA_InsurancePremiumsFinanced": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sonomapharma.com/20250331",
     "localname": "InsurancePremiumsFinanced",
     "crdr": "credit",
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Insurance premiums financed",
        "label": "InsurancePremiumsFinanced"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid for interest",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r175",
      "r176"
     ]
    },
    "SNOA_InvekraMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sonomapharma.com/20250331",
     "localname": "InvekraMember",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Invekra [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryDisclosureTextBlock",
     "presentation": [
      "http://sonomapharma.com/role/Inventories"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventories",
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory."
       }
      }
     },
     "auth_ref": [
      "r264"
     ]
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://sonomapharma.com/role/InventoriesDetails": {
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://sonomapharma.com/role/InventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finished goods",
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r693"
     ]
    },
    "us-gaap_InventoryGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryGross",
     "crdr": "debit",
     "calculation": {
      "http://sonomapharma.com/role/InventoriesDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://sonomapharma.com/role/InventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Inventories, gross",
        "label": "Inventory, Gross",
        "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r810"
     ]
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://sonomapharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      },
      "http://sonomapharma.com/role/InventoriesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedBalanceSheets",
      "http://sonomapharma.com/role/InventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventories, net",
        "totalLabel": "Total inventories",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r689",
      "r736"
     ]
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryPolicyTextBlock",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Inventories",
        "label": "Inventory, Policy [Policy Text Block]",
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r146",
      "r158",
      "r264",
      "r265",
      "r266",
      "r489",
      "r699"
     ]
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryRawMaterialsNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://sonomapharma.com/role/InventoriesDetails": {
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://sonomapharma.com/role/InventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Raw materials",
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r694"
     ]
    },
    "us-gaap_InventoryValuationReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryValuationReserves",
     "crdr": "credit",
     "calculation": {
      "http://sonomapharma.com/role/InventoriesDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://sonomapharma.com/role/InventoriesDetails",
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory valuation reserves",
        "negatedLabel": "Less: allowance for obsolete and excess inventory",
        "documentation": "Amount of valuation reserve for inventory."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r810"
     ]
    },
    "srt_LatinAmericaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "LatinAmericaMember",
     "presentation": [
      "http://sonomapharma.com/role/RevenueDisaggregationDetails-GeographicRegions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Latin America [Member]"
       }
      }
     },
     "auth_ref": [
      "r942",
      "r943",
      "r944",
      "r945"
     ]
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://sonomapharma.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of lease information",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r896"
     ]
    },
    "us-gaap_LeaseholdImprovementsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseholdImprovementsGross",
     "crdr": "debit",
     "calculation": {
      "http://sonomapharma.com/role/PropertyAndEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://sonomapharma.com/role/PropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasehold improvements",
        "documentation": "Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeasesOperatingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeasesOperatingAbstract",
     "presentation": [
      "http://sonomapharma.com/role/LeasesDetails-BalanceSheetInformationRelatedToLeases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating leases:"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://sonomapharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LegalFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LegalFees",
     "crdr": "debit",
     "presentation": [
      "http://sonomapharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal fees and other expenses",
        "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings."
       }
      }
     },
     "auth_ref": [
      "r807"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://sonomapharma.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of minimum operating lease liabilities",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r897"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://sonomapharma.com/role/LeasesDetails-MinimumOperatingLeasePayments": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://sonomapharma.com/role/LeasesDetails-MinimumOperatingLeasePayments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total future minimum lease payments, undiscounted",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r480"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://sonomapharma.com/role/LeasesDetails-MinimumOperatingLeasePayments": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://sonomapharma.com/role/LeasesDetails-MinimumOperatingLeasePayments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r480"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://sonomapharma.com/role/LeasesDetails-MinimumOperatingLeasePayments": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://sonomapharma.com/role/LeasesDetails-MinimumOperatingLeasePayments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2028",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r480"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://sonomapharma.com/role/LeasesDetails-MinimumOperatingLeasePayments": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://sonomapharma.com/role/LeasesDetails-MinimumOperatingLeasePayments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2027",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r480"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://sonomapharma.com/role/LeasesDetails-MinimumOperatingLeasePayments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: imputed interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r480"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://sonomapharma.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r473"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://sonomapharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r52",
      "r53",
      "r54",
      "r58",
      "r59",
      "r60",
      "r63",
      "r182",
      "r258",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r442",
      "r445",
      "r446",
      "r461",
      "r609",
      "r702",
      "r764",
      "r848",
      "r898",
      "r899"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://sonomapharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders\u2019 equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r119",
      "r532",
      "r736",
      "r820",
      "r838",
      "r892"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://sonomapharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r145",
      "r182",
      "r258",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r442",
      "r445",
      "r446",
      "r461",
      "r736",
      "r848",
      "r898",
      "r899"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
     "presentation": [
      "http://sonomapharma.com/role/AccountsReceivable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable",
        "documentation": "The entire disclosure for claims held for amounts due to entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses."
       }
      }
     },
     "auth_ref": [
      "r470",
      "r834"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MachineryAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MachineryAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://sonomapharma.com/role/PropertyAndEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://sonomapharma.com/role/PropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Manufacturing, lab, and other equipment",
        "documentation": "Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment."
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "us-gaap_MachineryAndEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MachineryAndEquipmentMember",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-usefulLives"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Machinery and Equipment [Member]",
        "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]"
       }
      }
     },
     "auth_ref": [
      "r250",
      "r718",
      "r746",
      "r751",
      "r851",
      "r909",
      "r911",
      "r912",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925",
      "r926",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932",
      "r933",
      "r934",
      "r935",
      "r936",
      "r937",
      "r938"
     ]
    },
    "us-gaap_MarketingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketingExpense",
     "crdr": "debit",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Advertising costs",
        "documentation": "Expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services. Costs of public relations and corporate promotions are typically considered to be marketing costs."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "SNOA_MaximGroupLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sonomapharma.com/20250331",
     "localname": "MaximGroupLLCMember",
     "presentation": [
      "http://sonomapharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maxim Group L L C [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://sonomapharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r291",
      "r292",
      "r293",
      "r294",
      "r349",
      "r392",
      "r457",
      "r487",
      "r561",
      "r563",
      "r571",
      "r599",
      "r600",
      "r655",
      "r657",
      "r659",
      "r660",
      "r662",
      "r682",
      "r683",
      "r709",
      "r715",
      "r723",
      "r730",
      "r731",
      "r732",
      "r733",
      "r747",
      "r850",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://sonomapharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r291",
      "r292",
      "r293",
      "r294",
      "r349",
      "r392",
      "r457",
      "r487",
      "r561",
      "r563",
      "r571",
      "r599",
      "r600",
      "r655",
      "r657",
      "r659",
      "r660",
      "r662",
      "r682",
      "r683",
      "r709",
      "r715",
      "r723",
      "r730",
      "r731",
      "r732",
      "r747",
      "r850",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905"
     ]
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "auth_ref": [
      "r250",
      "r718",
      "r746",
      "r751",
      "r851",
      "r909",
      "r911",
      "r912",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925",
      "r926",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932",
      "r933",
      "r934",
      "r935",
      "r936",
      "r937",
      "r938"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r174"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r174"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from investing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows",
      "http://sonomapharma.com/role/LiquidityAndFinancialConditionDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "negatedLabel": "Net cash used in operating activities",
        "label": "Net cash used in operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r87",
      "r88"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from operating activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://sonomapharma.com/role/ConsolidatedStatementsOfComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      },
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows",
      "http://sonomapharma.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://sonomapharma.com/role/ConsolidatedStatementsOfComprehensiveLoss",
      "http://sonomapharma.com/role/LiquidityAndFinancialConditionDetailsNarrative",
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-EarningsPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "label": "Net loss",
        "negatedLabel": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r88",
      "r121",
      "r143",
      "r161",
      "r163",
      "r168",
      "r182",
      "r189",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r198",
      "r199",
      "r204",
      "r258",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r435",
      "r438",
      "r456",
      "r461",
      "r538",
      "r631",
      "r648",
      "r649",
      "r762",
      "r848"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recent Accounting Standards",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r790"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r790"
     ]
    },
    "us-gaap_OfficeEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OfficeEquipmentMember",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-usefulLives"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Office Equipment [Member]",
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OfficersCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OfficersCompensation",
     "crdr": "debit",
     "presentation": [
      "http://sonomapharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual salaries",
        "documentation": "Amount of expense for salary and wage arising from service rendered by officer. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold."
       }
      }
     },
     "auth_ref": [
      "r816"
     ]
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://sonomapharma.com/role/ConsolidatedStatementsOfComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://sonomapharma.com/role/ConsolidatedStatementsOfComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r703",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://sonomapharma.com/role/LeasesDetails-BalanceSheetInformationRelatedToLeases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r477",
      "r735"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://sonomapharma.com/role/LeasesDetails-MinimumOperatingLeasePayments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total lease liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r476"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://sonomapharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedBalanceSheets",
      "http://sonomapharma.com/role/LeasesDetails-BalanceSheetInformationRelatedToLeases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease liabilities, current portion",
        "verboseLabel": "Operating lease liabilities \u2013 current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r476"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://sonomapharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedBalanceSheets",
      "http://sonomapharma.com/role/LeasesDetails-BalanceSheetInformationRelatedToLeases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease liabilities, less current portion",
        "verboseLabel": "Operating lease liabilities \u2013 non-current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r476"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://sonomapharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedBalanceSheets",
      "http://sonomapharma.com/role/LeasesDetails-BalanceSheetInformationRelatedToLeases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease, right of use assets",
        "verboseLabel": "Operating lease right-of-use assets",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r475"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "presentation": [
      "http://sonomapharma.com/role/LeasesDetails-BalanceSheetInformationRelatedToLeases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Operating cash flows from operating leases",
        "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r818"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://sonomapharma.com/role/LeasesDetails-BalanceSheetInformationRelatedToLeases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-average discount rate - operating leases",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r479",
      "r735"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://sonomapharma.com/role/LeasesDetails-BalanceSheetInformationRelatedToLeases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-average remaining lease term - operating leases (in months)",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r478",
      "r735"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net operating loss carryforwards",
        "label": "Operating Loss Carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r422"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://sonomapharma.com/role/OrganizationAndRecentDevelopments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization and Recent Developments",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r112",
      "r573",
      "r574"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://sonomapharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://sonomapharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://sonomapharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other assets",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r150"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://sonomapharma.com/role/ConsolidatedStatementsOfComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign currency translation adjustments",
        "documentation": "Amount before tax, after reclassification adjustments of gain (loss) on foreign currency translation adjustments, on foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r9",
      "r113"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign currency translation adjustment",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r9",
      "r113"
     ]
    },
    "SNOA_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainAdjustmentBeforeTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sonomapharma.com/20250331",
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainAdjustmentBeforeTaxPortionAttributableToParent",
     "crdr": "credit",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign currency translation adjustment gain"
       }
      }
     },
     "auth_ref": []
    },
    "SNOA_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationLossAdjustmentBeforeTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sonomapharma.com/20250331",
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationLossAdjustmentBeforeTaxPortionAttributableToParent",
     "crdr": "debit",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign currency translation adjustment loss",
        "documentation": "Foreign currency translation loss"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossTaxAbstract",
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other comprehensive loss:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeMember",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss) [Member]",
        "documentation": "Primary financial statement caption in which reported facts about other comprehensive income have been included."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "us-gaap_OtherCurrentAssetsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCurrentAssetsTextBlock",
     "presentation": [
      "http://sonomapharma.com/role/PrepaidExpensesAndOtherCurrentAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expenses and Other Current Assets",
        "documentation": "The entire disclosure for other current assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLongTermDebtCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLongTermDebtCurrent",
     "crdr": "credit",
     "presentation": [
      "http://sonomapharma.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding principal amount",
        "documentation": "Amount of long-term debt classified as other, payable within one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r53",
      "r608"
     ]
    },
    "us-gaap_OtherOperatingIncomeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherOperatingIncomeExpenseMember",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Operating Income (Expense) [Member]",
        "documentation": "Primary financial statement caption encompassing other operating income (expense)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherOperatingIncomeExpenseNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherOperatingIncomeExpenseNet",
     "crdr": "credit",
     "calculation": {
      "http://sonomapharma.com/role/ConsolidatedStatementsOfComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other income (expense), net",
        "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherPrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://sonomapharma.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://sonomapharma.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other prepaid expenses and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r811",
      "r839"
     ]
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r778"
     ]
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "SNOA_PaymentsForFractionalSharesRelatedToReversesplit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sonomapharma.com/20250331",
     "localname": "PaymentsForFractionalSharesRelatedToReversesplit",
     "crdr": "credit",
     "calculation": {
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments for fractional shares related to reverse-split",
        "label": "PaymentsForFractionalSharesRelatedToReversesplit"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r84"
     ]
    },
    "us-gaap_PensionAndOtherPostretirementBenefitContributions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PensionAndOtherPostretirementBenefitContributions",
     "crdr": "credit",
     "presentation": [
      "http://sonomapharma.com/role/EmployeeBenefitPlanDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company contributions to 401(k) plan",
        "documentation": "Amount of cash outflow for pension and other postretirement benefits. Includes, but is not limited to, employer contribution to fund plan asset and payment to retiree."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "SNOA_PlacementAgencyAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sonomapharma.com/20250331",
     "localname": "PlacementAgencyAgreementMember",
     "presentation": [
      "http://sonomapharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Placement Agency Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "SNOA_Plan2011Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sonomapharma.com/20250331",
     "localname": "Plan2011Member",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-plans"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan 2011 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "SNOA_Plan2016Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sonomapharma.com/20250331",
     "localname": "Plan2016Member",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-plans",
      "http://sonomapharma.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan 2016 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "SNOA_Plan2021Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sonomapharma.com/20250331",
     "localname": "Plan2021Member",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-plans",
      "http://sonomapharma.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan 2021 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "SNOA_Plan2024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sonomapharma.com/20250331",
     "localname": "Plan2024Member",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan 2024 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-plans",
      "http://sonomapharma.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-plans",
      "http://sonomapharma.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878"
     ]
    },
    "SNOA_PotentialDiscountsReturnsDistributorFeesAndRebatesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sonomapharma.com/20250331",
     "localname": "PotentialDiscountsReturnsDistributorFeesAndRebatesMember",
     "presentation": [
      "http://sonomapharma.com/role/AccountsReceivableDetails",
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Potential Discounts Returns Distributor Fees And Rebates [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "SNOA_PotentialSeverancePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sonomapharma.com/20250331",
     "localname": "PotentialSeverancePayments",
     "crdr": "debit",
     "presentation": [
      "http://sonomapharma.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Potential severance payments"
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r772"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r774"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://sonomapharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, par value",
        "verboseLabel": "Convertible preferred stock, par value",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r321"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://sonomapharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares authorized",
        "verboseLabel": "Convertible preferred stock, shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r611"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r321"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r611",
      "r629",
      "r940",
      "r941"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://sonomapharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible preferred stock, $0.0001 par value; 714,286 shares authorized at March 31, 2025 and 2024, respectively, no shares issued and outstanding at March 31, 2025 and 2024",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r528",
      "r736"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://sonomapharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      },
      "http://sonomapharma.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedBalanceSheets",
      "http://sonomapharma.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses and other current assets",
        "totalLabel": "Total prepaid expenses and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r812"
     ]
    },
    "us-gaap_PrepaidInsurance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidInsurance",
     "crdr": "debit",
     "calculation": {
      "http://sonomapharma.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://sonomapharma.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid insurance",
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r691",
      "r710",
      "r839"
     ]
    },
    "us-gaap_PrepaidTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidTaxes",
     "crdr": "debit",
     "calculation": {
      "http://sonomapharma.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://sonomapharma.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "VAT prepaid to Mexican tax authorities",
        "documentation": "Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r692",
      "r711",
      "r839"
     ]
    },
    "SNOA_ProbableCreditLossesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sonomapharma.com/20250331",
     "localname": "ProbableCreditLossesMember",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Probable Credit Losses [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "SNOA_ProceedsFromAtthemarketSaleOfCommonStockNetOfOfferingExpensesShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://sonomapharma.com/20250331",
     "localname": "ProceedsFromAtthemarketSaleOfCommonStockNetOfOfferingExpensesShares",
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:ProceedsFromAtthemarketSaleOfCommonStockNetOfOfferingExpensesShares]"
       }
      }
     },
     "auth_ref": []
    },
    "SNOA_ProceedsFromInsurancePremiumsFinanced": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sonomapharma.com/20250331",
     "localname": "ProceedsFromInsurancePremiumsFinanced",
     "crdr": "debit",
     "calculation": {
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insurance premiums financed"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows",
      "http://sonomapharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of common stock, net of offering expenses",
        "verboseLabel": "Proceeds from sale of stock, net",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "SNOA_ProceedsFromIssuanceOfCommonStockGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sonomapharma.com/20250331",
     "localname": "ProceedsFromIssuanceOfCommonStockGross",
     "crdr": "debit",
     "presentation": [
      "http://sonomapharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from sale of stock, gross"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromShortTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromShortTermDebt",
     "crdr": "debit",
     "presentation": [
      "http://sonomapharma.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt initial payment",
        "documentation": "The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from exercise of employee stock options",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r13"
     ]
    },
    "us-gaap_ProductInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProductInformationLineItems",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProductMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProductMember",
     "presentation": [
      "http://sonomapharma.com/role/RevenueDisaggregationDetails-DisaggregationOfRevenue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product [Member]",
        "documentation": "Article or substance produced by nature, labor or machinery."
       }
      }
     },
     "auth_ref": [
      "r716"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://sonomapharma.com/role/AccountsReceivableDetails",
      "http://sonomapharma.com/role/RevenueDisaggregationDetails-DisaggregationOfRevenue",
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r247",
      "r490",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r686",
      "r716",
      "r745",
      "r747",
      "r748",
      "r752",
      "r753",
      "r846",
      "r847",
      "r851",
      "r909",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925",
      "r926",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932",
      "r933",
      "r934",
      "r935",
      "r936",
      "r937",
      "r938"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://sonomapharma.com/role/AccountsReceivableDetails",
      "http://sonomapharma.com/role/RevenueDisaggregationDetails-DisaggregationOfRevenue",
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "auth_ref": [
      "r247",
      "r490",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r686",
      "r716",
      "r745",
      "r747",
      "r748",
      "r752",
      "r753",
      "r846",
      "r847",
      "r851",
      "r909",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925",
      "r926",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932",
      "r933",
      "r934",
      "r935",
      "r936",
      "r937",
      "r938"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-incomeSource"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income before income taxes",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r161",
      "r163",
      "r173",
      "r182",
      "r189",
      "r195",
      "r198",
      "r199",
      "r258",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r435",
      "r438",
      "r440",
      "r443",
      "r444",
      "r456",
      "r461",
      "r523",
      "r537",
      "r583",
      "r631",
      "r648",
      "r649",
      "r727",
      "r728",
      "r763",
      "r815",
      "r848"
     ]
    },
    "SNOA_PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://sonomapharma.com/20250331",
     "localname": "PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of property and equipment estimated useful life"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-usefulLives"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r481"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://sonomapharma.com/role/PropertyAndEquipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r132",
      "r135",
      "r136"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://sonomapharma.com/role/PropertyAndEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://sonomapharma.com/role/PropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Property and equipment, gross",
        "label": "Property, Plant and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r148",
      "r535"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-usefulLives"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r481"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://sonomapharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      },
      "http://sonomapharma.com/role/PropertyAndEquipmentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedBalanceSheets",
      "http://sonomapharma.com/role/PropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment, net",
        "totalLabel": "Total property and equipment, net and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r481",
      "r524",
      "r535",
      "r736"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentOther",
     "crdr": "debit",
     "calculation": {
      "http://sonomapharma.com/role/PropertyAndEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://sonomapharma.com/role/PropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Office equipment",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of other physical assets used in the normal conduct of business to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Property and Equipment",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r132",
      "r135",
      "r533"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://sonomapharma.com/role/PropertyAndEquipmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of property and equipment, net",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-usefulLives"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r481"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-usefulLives"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Useful asset life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "SNOA_PublicOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sonomapharma.com/20250331",
     "localname": "PublicOfferingMember",
     "presentation": [
      "http://sonomapharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Public Offering [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://sonomapharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r291",
      "r292",
      "r293",
      "r294",
      "r348",
      "r349",
      "r380",
      "r381",
      "r382",
      "r392",
      "r457",
      "r484",
      "r485",
      "r487",
      "r561",
      "r563",
      "r571",
      "r599",
      "r600",
      "r655",
      "r657",
      "r659",
      "r660",
      "r662",
      "r682",
      "r683",
      "r709",
      "r715",
      "r723",
      "r730",
      "r731",
      "r732",
      "r733",
      "r747",
      "r756",
      "r844",
      "r850",
      "r889",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://sonomapharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "auth_ref": [
      "r291",
      "r292",
      "r293",
      "r294",
      "r348",
      "r349",
      "r380",
      "r381",
      "r382",
      "r392",
      "r457",
      "r484",
      "r485",
      "r487",
      "r561",
      "r563",
      "r571",
      "r599",
      "r600",
      "r655",
      "r657",
      "r659",
      "r660",
      "r662",
      "r682",
      "r683",
      "r709",
      "r715",
      "r723",
      "r730",
      "r731",
      "r732",
      "r733",
      "r747",
      "r756",
      "r844",
      "r850",
      "r889",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905"
     ]
    },
    "us-gaap_ReceivablesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReceivablesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivables [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReceivablesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReceivablesPolicyTextBlock",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts Receivable",
        "label": "Receivable [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable."
       }
      }
     },
     "auth_ref": [
      "r253",
      "r254",
      "r255",
      "r257",
      "r836"
     ]
    },
    "us-gaap_RepaymentsOfOtherShortTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepaymentsOfOtherShortTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Principal payments on short-term debt",
        "label": "Repayments of Other Short-Term Debt",
        "documentation": "Amount of cash outflow for the payment of debt classified as other, maturing within one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "auth_ref": [
      "r184",
      "r185",
      "r308",
      "r323",
      "r483",
      "r486",
      "r525",
      "r696",
      "r697"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://sonomapharma.com/role/ConsolidatedStatementsOfComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfComprehensiveLoss",
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development",
        "verboseLabel": "Research and development expenses",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r395",
      "r684",
      "r706",
      "r906"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r394"
     ]
    },
    "SNOA_RestOfTheWorldMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sonomapharma.com/20250331",
     "localname": "RestOfTheWorldMember",
     "presentation": [
      "http://sonomapharma.com/role/RevenueDisaggregationDetails-GeographicRegions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rest Of The World [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockMember",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-restrictedStockActivity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock [Member]",
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://sonomapharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedBalanceSheets",
      "http://sonomapharma.com/role/LiquidityAndFinancialConditionDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated deficit",
        "negatedLabel": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r103",
      "r531",
      "r568",
      "r570",
      "r581",
      "r612",
      "r736"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r186",
      "r187",
      "r188",
      "r190",
      "r195",
      "r197",
      "r199",
      "r259",
      "r260",
      "r277",
      "r424",
      "r425",
      "r432",
      "r433",
      "r434",
      "r436",
      "r437",
      "r438",
      "r447",
      "r449",
      "r450",
      "r452",
      "r454",
      "r472",
      "r474",
      "r565",
      "r567",
      "r584",
      "r940"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "presentation": [
      "http://sonomapharma.com/role/RevenueDisaggregationDetails-DisaggregationOfRevenue",
      "http://sonomapharma.com/role/RevenueDisaggregationDetails-GeographicRegions",
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Revenues",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r123",
      "r211",
      "r217",
      "r218",
      "r238",
      "r243",
      "r247",
      "r248",
      "r250",
      "r345",
      "r346",
      "r490"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "presentation": [
      "http://sonomapharma.com/role/RevenueDisaggregation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Disaggregation",
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r347"
     ]
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueRecognitionPolicyTextBlock",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Recognition",
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources."
       }
      }
     },
     "auth_ref": [
      "r633",
      "r685",
      "r700"
     ]
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Revenues",
     "crdr": "credit",
     "calculation": {
      "http://sonomapharma.com/role/ConsolidatedStatementsOfComprehensiveLoss": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r123",
      "r169",
      "r182",
      "r211",
      "r217",
      "r218",
      "r238",
      "r243",
      "r247",
      "r248",
      "r250",
      "r258",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r461",
      "r523",
      "r706",
      "r848"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r790"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r790"
     ]
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://sonomapharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SalesRevenueNetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SalesRevenueNetMember",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Benchmark [Member]",
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r250",
      "r803"
     ]
    },
    "us-gaap_SalesRevenueSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SalesRevenueSegmentMember",
     "presentation": [
      "http://sonomapharma.com/role/RevenueDisaggregationDetails-GeographicRegions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue, Segment Benchmark [Member]",
        "documentation": "Revenue from specified business segment, when it serves as benchmark in concentration of risk calculation. Includes, but is not limited to, revenue from contract with customer and other sources."
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable",
     "presentation": [
      "http://sonomapharma.com/role/AccountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts and Financing Receivables [Table]",
        "documentation": "Disclosure of information about accounts and financing receivables. Includes, but is not limited to, amount of receivable and allowance for credit loss."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r72",
      "r252",
      "r837"
     ]
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
     "presentation": [
      "http://sonomapharma.com/role/AccountsReceivableTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of accounts receivable",
        "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r72"
     ]
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://sonomapharma.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of accrued expenses and other current liabilities",
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-AntidilutiveShares"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of antidilutive shares",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of federal, state and foreign income tax provisions",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r885"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of deferred tax assets",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r882"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of computation of earnings per share",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r828"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of reconciliation of federal income tax rate to effective rate",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r404",
      "r726",
      "r879"
     ]
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of income tax provision from domestic and foreign sources",
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions."
       }
      }
     },
     "auth_ref": [
      "r821"
     ]
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "presentation": [
      "http://sonomapharma.com/role/InventoriesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of inventories",
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r73",
      "r74",
      "r75"
     ]
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of unvested restricted stock activity",
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units."
       }
      }
     },
     "auth_ref": [
      "r109"
     ]
    },
    "us-gaap_ScheduleOfProductInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfProductInformationTable",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails",
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature of Operation, Product Information, Concentration of Risk [Table]",
        "documentation": "Disclosure of information about concentration risk of product within nature of operation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-usefulLives"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r481"
     ]
    },
    "us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock",
     "presentation": [
      "http://sonomapharma.com/role/RevenueDisaggregationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of revenues by geographic region",
        "documentation": "Tabular disclosure of the names of foreign countries from which revenue is material and the amount of revenue from external customers attributed to those countries. An entity may also provide subtotals of geographic information about groups of countries."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r91"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-optionActivity",
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-plans",
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-restrictedStockActivity",
      "http://sonomapharma.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r351",
      "r353",
      "r355",
      "r356",
      "r357",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of options activity",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r12",
      "r108"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of weighted-average assumptions of fair value of employee stock options",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r111"
     ]
    },
    "us-gaap_ScheduleOfShortTermDebtTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShortTermDebtTable",
     "presentation": [
      "http://sonomapharma.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt [Table]",
        "documentation": "Disclosure of information about short-term debt arrangement. Includes, but is not limited to, description of arrangement, lender, repayment term, weighted-average interest rate, borrowed amount, and description and amount of refinancing of short-term obligation when obligation is excluded from current liability."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://sonomapharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock, Class of Stock [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r35",
      "r36",
      "r37",
      "r38",
      "r39",
      "r99",
      "r101",
      "r102",
      "r103",
      "r152",
      "r153",
      "r154",
      "r213",
      "r321",
      "r322",
      "r323",
      "r325",
      "r328",
      "r333",
      "r335",
      "r577",
      "r578",
      "r579",
      "r580",
      "r715",
      "r802",
      "r819"
     ]
    },
    "SNOA_ScheduleOfStockbasedAwardsOutstandingByPlanTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://sonomapharma.com/20250331",
     "localname": "ScheduleOfStockbasedAwardsOutstandingByPlanTableTextBlock",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of stock based awards outstanding by plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of concentration of risk",
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r25",
      "r26",
      "r27",
      "r45",
      "r114"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r766"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12gTitle",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r770"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r769"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r775"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentDomain",
     "presentation": [
      "http://sonomapharma.com/role/RevenueDisaggregationDetails-DisaggregationOfRevenue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r123",
      "r124",
      "r125",
      "r211",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r250",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r287",
      "r288",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r705",
      "r706",
      "r707",
      "r712",
      "r750",
      "r909",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925",
      "r926",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932",
      "r933",
      "r934",
      "r935",
      "r936",
      "r937",
      "r938"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://sonomapharma.com/role/RevenueDisaggregationDetails-GeographicRegions"
     ],
     "auth_ref": [
      "r248",
      "r249",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r596",
      "r597",
      "r598",
      "r656",
      "r658",
      "r661",
      "r663",
      "r670",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r687",
      "r717",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r749",
      "r756",
      "r851",
      "r909",
      "r911",
      "r912",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925",
      "r926",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932",
      "r933",
      "r934",
      "r935",
      "r936",
      "r937",
      "r938"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r246",
      "r248",
      "r704",
      "r705",
      "r708"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://sonomapharma.com/role/ConsolidatedStatementsOfComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling, general and administrative",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "SNOA_ServiceAndRoyaltyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://sonomapharma.com/20250331",
     "localname": "ServiceAndRoyaltyMember",
     "presentation": [
      "http://sonomapharma.com/role/RevenueDisaggregationDetails-DisaggregationOfRevenue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Service And Royalty [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ServiceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ServiceMember",
     "presentation": [
      "http://sonomapharma.com/role/RevenueDisaggregationDetails-DisaggregationOfRevenue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Service [Member]",
        "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service."
       }
      }
     },
     "auth_ref": [
      "r716"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows",
      "http://sonomapharma.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-restrictedStockActivity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-average award date fair value per share, unvested RSAs granted",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r370"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-restrictedStockActivity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of unvested restricted stock awards outstanding, beginning balance",
        "periodEndLabel": "Number of unvested restricted stock awards outstanding, ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r367",
      "r368"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-restrictedStockActivity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted-average award date fair value per share, unvested RSAs outstanding, beginning balance",
        "periodEndLabel": "Weighted-average award date fair value per share, unvested RSAs outstanding, ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r367",
      "r368"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-restrictedStockActivity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of restricted stock awards vested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r371"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-restrictedStockActivity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-average award date fair value per share, unvested RSAs vested",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r371"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-assumptions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend yield",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r381"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-assumptions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Volatility",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r380"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-assumptions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk-free interest rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r382"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-optionActivity",
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-plans",
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-restrictedStockActivity",
      "http://sonomapharma.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r351",
      "r353",
      "r355",
      "r356",
      "r357",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase in shares authorized for issuance",
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares initially authorized for issuance",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r725"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares available for future issuance",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "SNOA_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableInPeriodGrantDateIntrinsicValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://sonomapharma.com/20250331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableInPeriodGrantDateIntrinsicValue",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-optionActivity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate intrinsic value per share, exercisable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-optionActivity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of options, exercisable",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r361"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-optionActivity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-average exercise price, exercisable",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r361"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-optionActivity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of options expired",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements."
       }
      }
     },
     "auth_ref": [
      "r366"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-optionActivity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of options forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired."
       }
      }
     },
     "auth_ref": [
      "r859"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-optionActivity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-average exercise price, options forfeited",
        "documentation": "Weighted average price of options that were either forfeited or expired."
       }
      }
     },
     "auth_ref": [
      "r859"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-optionActivity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate intrinsic value per share, outstanding",
        "documentation": "The grant-date intrinsic value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r373"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-optionActivity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of options granted",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r363"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-assumptions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of options granted",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r373"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-optionActivity",
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-plans"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options outstanding",
        "periodStartLabel": "Number of options outstanding, beginning balance",
        "periodEndLabel": "Number of options outstanding, ending balance",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r359",
      "r360"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-optionActivity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted-average exercise price options outstanding, beginning balance",
        "periodEndLabel": "Weighted-average exercise price options outstanding, ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r359",
      "r360"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-optionActivity",
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-restrictedStockActivity",
      "http://sonomapharma.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r355",
      "r356",
      "r357",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-optionActivity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-average exercise price, options exercised",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r364"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-optionActivity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-average exercise price, options expired",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired."
       }
      }
     },
     "auth_ref": [
      "r366"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-assumptions",
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-optionActivity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of the Company common stock on date of grant",
        "verboseLabel": "Weighted-average exercise price, options granted",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r363"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r350",
      "r358",
      "r377",
      "r378",
      "r379",
      "r380",
      "r383",
      "r388",
      "r389",
      "r390",
      "r391"
     ]
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharePrice",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-assumptions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r379"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-optionActivity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted- average contractual term, exercisable",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-optionActivity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted- average contractual term outstanding",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r110"
     ]
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance, shares",
        "periodEndLabel": "Ending balance, shares",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "SNOA_ShippingAndHandlingCost1PolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://sonomapharma.com/20250331",
     "localname": "ShippingAndHandlingCost1PolicyTextBlock",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shipping and Handling Costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShippingAndHandlingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShippingAndHandlingMember",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shipping and Handling [Member]",
        "documentation": "Packing and transport of product."
       }
      }
     },
     "auth_ref": [
      "r852"
     ]
    },
    "us-gaap_ShortTermBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermBorrowings",
     "crdr": "credit",
     "calculation": {
      "http://sonomapharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-term debt",
        "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r116",
      "r736",
      "r907"
     ]
    },
    "us-gaap_ShortTermDebtLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermDebtLineItems",
     "presentation": [
      "http://sonomapharma.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermDebtTypeAxis",
     "presentation": [
      "http://sonomapharma.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt, Type [Axis]",
        "documentation": "Information by type of short-term debt arrangement."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r841",
      "r842",
      "r843"
     ]
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermDebtTypeDomain",
     "presentation": [
      "http://sonomapharma.com/role/DebtDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r841",
      "r842",
      "r843"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r179"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r773"
     ]
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State and Local Jurisdiction [Member]",
        "documentation": "Designated state or local jurisdiction entitled to levy and collect income tax."
       }
      }
     },
     "auth_ref": [
      "r402"
     ]
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://sonomapharma.com/role/RevenueDisaggregationDetails-DisaggregationOfRevenue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r123",
      "r124",
      "r125",
      "r142",
      "r211",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r250",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r279",
      "r287",
      "r288",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r705",
      "r706",
      "r707",
      "r712",
      "r750",
      "r909",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925",
      "r926",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932",
      "r933",
      "r934",
      "r935",
      "r936",
      "r937",
      "r938"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://sonomapharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r152",
      "r153",
      "r154",
      "r182",
      "r202",
      "r203",
      "r205",
      "r207",
      "r213",
      "r214",
      "r258",
      "r297",
      "r299",
      "r300",
      "r301",
      "r304",
      "r305",
      "r321",
      "r322",
      "r325",
      "r328",
      "r335",
      "r461",
      "r577",
      "r578",
      "r579",
      "r580",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r611",
      "r632",
      "r650",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r802",
      "r819",
      "r827"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r65",
      "r69",
      "r70",
      "r141",
      "r166",
      "r167",
      "r168",
      "r186",
      "r187",
      "r188",
      "r190",
      "r195",
      "r197",
      "r199",
      "r212",
      "r259",
      "r260",
      "r277",
      "r336",
      "r424",
      "r425",
      "r432",
      "r433",
      "r434",
      "r436",
      "r437",
      "r438",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r454",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r472",
      "r474",
      "r482",
      "r539",
      "r565",
      "r566",
      "r567",
      "r584",
      "r650"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://sonomapharma.com/role/RevenueDisaggregationDetails-GeographicRegions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r248",
      "r249",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r596",
      "r597",
      "r598",
      "r656",
      "r658",
      "r661",
      "r663",
      "r670",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r687",
      "r717",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r749",
      "r756",
      "r851",
      "r909",
      "r911",
      "r912",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925",
      "r926",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932",
      "r933",
      "r934",
      "r935",
      "r936",
      "r937",
      "r938"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r186",
      "r187",
      "r188",
      "r212",
      "r474",
      "r490",
      "r575",
      "r595",
      "r601",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r611",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r630",
      "r633",
      "r634",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r650",
      "r757"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r186",
      "r187",
      "r188",
      "r212",
      "r251",
      "r474",
      "r490",
      "r575",
      "r595",
      "r601",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r611",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r630",
      "r633",
      "r634",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r650",
      "r757"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://sonomapharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from the sale of common stock, net of offering expenses, shares",
        "verboseLabel": "Stock issued new, shares",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r64",
      "r65",
      "r103",
      "r577",
      "r650",
      "r665"
     ]
    },
    "SNOA_StockIssuedDuringPeriodSharesNewIssues1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://sonomapharma.com/20250331",
     "localname": "StockIssuedDuringPeriodSharesNewIssues1",
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from the At-the-Market sale of common stock, net of offering expenses, shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-restrictedStockActivity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock based compensation related to restricted stock grants, shares",
        "verboseLabel": "Number of restricted stock awards granted",
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r103"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesReverseStockSplits",
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments for fractional shares related to reverse-split, shares",
        "label": "Stock Issued During Period, Shares, Reverse Stock Splits",
        "documentation": "Reduction in the number of shares during the period as a result of a reverse stock split."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-optionActivity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from the exercise of employee stock options, shares",
        "negatedLabel": "Number of options exercised",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r64",
      "r65",
      "r103",
      "r364"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from the sale of common stock, net of offering expenses",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r64",
      "r65",
      "r103",
      "r584",
      "r650",
      "r665",
      "r763"
     ]
    },
    "SNOA_StockIssuedDuringPeriodValueNewIssues1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sonomapharma.com/20250331",
     "localname": "StockIssuedDuringPeriodValueNewIssues1",
     "crdr": "credit",
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from the At-the-Market sale of common stock, net of offering expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "crdr": "credit",
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock based compensation related to restricted stock grants",
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r64",
      "r65",
      "r103"
     ]
    },
    "SNOA_StockIssuedDuringPeriodValueReverseStockSplits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sonomapharma.com/20250331",
     "localname": "StockIssuedDuringPeriodValueReverseStockSplits",
     "crdr": "debit",
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments for fractional shares related to reverse-split",
        "label": "StockIssuedDuringPeriodValueReverseStockSplits"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from the exercise of employee stock options",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r65",
      "r69",
      "r70",
      "r103"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense",
     "crdr": "credit",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock based compensation options exercised",
        "documentation": "Value of stock issued as a result of the exercise of stock options, after deduction of related income tax (expense) benefit."
       }
      }
     },
     "auth_ref": []
    },
    "SNOA_StockIssuedDuringPeriodValuesReverseStockSplits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sonomapharma.com/20250331",
     "localname": "StockIssuedDuringPeriodValuesReverseStockSplits",
     "crdr": "credit",
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:StockIssuedDuringPeriodValuesReverseStockSplits]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockOptionMember",
     "presentation": [
      "http://sonomapharma.com/role/Stock-basedCompensationDetails-optionActivity",
      "http://sonomapharma.com/role/Stock-basedCompensationDetailsNarrative",
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-AntidilutiveShares"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Option [Member]",
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)."
       }
      }
     },
     "auth_ref": [
      "r756"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://sonomapharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedBalanceSheets",
      "http://sonomapharma.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 equity",
        "periodStartLabel": "Beginning balance, value",
        "periodEndLabel": "Ending balance, value",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r69",
      "r70",
      "r92",
      "r613",
      "r629",
      "r651",
      "r652",
      "r736",
      "r764",
      "r820",
      "r838",
      "r892",
      "r940"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 Equity:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://sonomapharma.com/role/StockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 Equity",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r181",
      "r320",
      "r322",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r334",
      "r336",
      "r453",
      "r653",
      "r654",
      "r669"
     ]
    },
    "us-gaap_SubsequentEventsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsPolicyPolicyTextBlock",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events",
        "documentation": "Disclosure of accounting policy for reporting subsequent events."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://sonomapharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubstantialDoubtAboutGoingConcernTextBlock",
     "presentation": [
      "http://sonomapharma.com/role/LiquidityAndFinancialCondition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liquidity and Financial Condition",
        "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research credit carryforwards",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r422"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "SNOA_TrueupsOfStateDeferredAssets": {
     "xbrltype": "percentItemType",
     "nsuri": "http://sonomapharma.com/20250331",
     "localname": "TrueupsOfStateDeferredAssets",
     "presentation": [
      "http://sonomapharma.com/role/IncomeTaxesDetails-reconciliationOfTaxRate"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "True-up of state deferred assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://sonomapharma.com/role/StockholdersEquityDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r439"
     ]
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "US",
     "presentation": [
      "http://sonomapharma.com/role/RevenueDisaggregationDetails-GeographicRegions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r30",
      "r129",
      "r130",
      "r133",
      "r134"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfComprehensiveLoss",
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-EarningsPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-average number of shares: diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r201",
      "r207"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedStatementsOfComprehensiveLoss",
      "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-EarningsPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted-average number of shares: basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r200",
      "r207"
     ]
    },
    "SNOA_WithholdingTaxPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sonomapharma.com/20250331",
     "localname": "WithholdingTaxPayable",
     "crdr": "credit",
     "calculation": {
      "http://sonomapharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://sonomapharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Withholding tax payable"
       }
      }
     },
     "auth_ref": []
    },
    "SNOA_WorkingCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://sonomapharma.com/20250331",
     "localname": "WorkingCapital",
     "crdr": "debit",
     "presentation": [
      "http://sonomapharma.com/role/LiquidityAndFinancialConditionDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Working capital"
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://sonomapharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r800"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-16"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-21"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205-40/tableOfContent"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480581/330-10-S99-2"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "710",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/710/tableOfContent"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "712",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/712/tableOfContent"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/715/tableOfContent"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "270",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-6"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "35",
   "Topic": "720",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483406/720-35-50-1"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/606/tableOfContent"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481569/310-20-50-1"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/330/tableOfContent"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-1"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-4"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-4"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-6"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/830/tableOfContent"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478345/912-310-45-11"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "330",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478411/912-330-50-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(10)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r803": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r804": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "SubTopic": "825",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r805": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r806": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r807": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(6))",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r808": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r809": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r810": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r811": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r812": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r813": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r814": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r815": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r816": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r817": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r818": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r819": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r820": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r821": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r822": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r823": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r824": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r825": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r826": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r827": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r828": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r829": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r830": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r831": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r832": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r833": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r834": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/310-10/tableOfContent"
  },
  "r835": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r836": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r837": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "40",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481628/310-20-40-7"
  },
  "r838": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r839": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r840": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r841": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r842": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r843": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r844": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r845": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r846": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r847": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r848": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r849": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r850": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r851": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r852": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r853": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r854": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r855": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r856": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r857": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r858": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r859": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r860": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r861": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r862": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r863": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r864": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r865": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r866": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r867": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r868": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r869": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r870": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r871": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r872": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r873": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r874": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r875": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r876": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r877": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r878": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r879": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r880": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r881": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r882": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r883": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r884": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r885": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r886": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r887": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r888": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r889": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r890": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r891": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r892": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r893": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1"
  },
  "r894": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1"
  },
  "r895": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r896": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r897": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r898": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r899": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r900": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r901": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r902": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r903": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r904": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r905": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r906": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r907": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r908": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r909": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r910": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r911": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r912": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r913": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r914": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r915": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r916": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r917": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r918": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r919": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r920": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r921": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r922": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r923": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r924": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r925": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r926": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r927": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r928": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r929": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r930": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r931": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r932": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r933": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r934": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r935": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r936": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r937": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r938": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r939": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r940": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r941": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r942": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r943": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r944": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r945": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>97
<FILENAME>0001683168-25-004546-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001683168-25-004546-xbrl.zip
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M,]/>_H7^S+_H\BQPXDPSFG7+@+)ACE^RA/K%=8@A>3E72L94@JHS=IV@?48
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M&/-^/UQRQK!Q&7F)$.!S=HX'4G9S)HN0"7;QG$I,8^+!RR8ZE5"=K@U&&DC
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MVDD\SC8Q8IO-!AP5;S V79EG/Y?G]#:N H#TF&H\]>Y%7: XUZ!FO?3\_'N
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MJ@@FF8(^KA9?O4.[V!;W%<\E-ZKMUYM5)J;*"FO'A1N^MGKN>VF]I.\[#XM
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M)^1%DGJ"4F!^V@L^MY=H[O;S!5^T)P9&^[G;A\@KA'O@JB'1)GW7!2EL3/;
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M]FSL;*S)=IDYWI%<WUR=)_S'2-K-#,P=P9;BWNAQ&9,)WGE:WT74"]6H&1I
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ML32<WC/\9!K[;5':')R_L.7 JCL:( OWHOLWH>52GA;#Z=)[^GSY4'89$J@
MYC5X<[AUT6Q4NI ?CY,X7^24X(#-V\[_]M>X[HGW13OA'ZE<=5$>:'-CN_ZI
M9_Z$67,:/)03LKGN4&MN(!+7.^VBPL6,F3D\+#L^[E-.?9-IE+D3'J=D%LP#
M((EU&K) M6LF DK4AWZ]\'V=41 C,9%:&Q&K)MI.C,I)&2R.A:U2 !*,FC"&
ME_FF5\=6XKK=.2>%N<R2KE#S_+J/#A1RUN*Z9=PQGIJWW5$<Q4N+3@IRG!BL
M>4YF]IIN9W\XS>\1%JMHS5\!H*>F*PY4!2PVD$!&>&RBN5W=R+>G>J?:!2[=
M?%0H\# *IPLM$ X8)EV??:.G,_"D8C^!!$?J(%H; F,0V2^F?!)-S2B 7*JG
M<Z<?<1LMS$6>+67>.H3@A?.T2'\MT\$JR=+"S%=663TM:_D2W<Q#;V*>R*+$
MW583$A3/= WFLY*[RN) ?WF(\ RS8C^P].T@T$"9D>K/ETRZ5U@Q%ZPAN3NO
MP%)8+]*= OA/TX7]=_DD-O BVR' _Y+6#&9[_GR-W(#YWZJ+^/]5UR_UV]QN
M[?!W[,/FI]5!<;4@:G_&F,0IUWE]L&;.?>18CE/B?J!=]'!6=3V70)2?_D&_
M6%V7G80!CT?^2.R#-)-D8<&3_.&H@V<W)2-DLSQ6D[3U;LV+::G?$,@/LTS$
M"TQN"N1\TNER-WA83XVY8K@"Y"]^XE72=_+R-K/V[X+2Z<R0JGQ.![GEU6R;
MQ%J%I44Q3/)D5N:T3IJ:G<6$B)6U._=IBLQVG0=*J:'Z5_QKRU"MZ!6[Z^'4
MA_$T-ULS'U$5+W^I+9#:/G'-[:L>LM)UH_JHZB#R1KP_1CNCT37J>PI1:-75
MF ::DW&R@R+Q'"HTRL:P1-GM*\I+H_+*L"<[@WP-6B_]<;["502C)2&I4FA4
MR=6=K<*K5"Y-YQ"D#W3U;+4G]9@_Y]+G-@L+;VZJ*VMH-:XDVSI@N2GIE1:9
M&>4X7-VZ\/"YDP[,K7;6?=4W72PQ2:9U UMS[EB6QGZ,68#J'D3T5R/YY>C.
M^(&TIFXF#,Q_ X26%F.#:4@OLBYR+MA]1[P:@R]=NQ@";3VD(7\5XH#A^=8I
M ![48PH@,(?,3WY_'#OEO-B%GA>-@ME6?!-*8RAOV[9U2XL3F_F6^[9(J0M)
MT#^N*S<U7AJMZCM_U$*-S#,-ZR92X^'0@]UIY<J]XG<;EC3[4LLUD[?H3LVN
MZG_IG"_2+)5:@2+EX*:([#4.[51KW[)';'[-F^E5?L@S3]BCV%_3QY%XZ?*J
M?S!3)T[JX_1>R-Y=YN<GW7,,GOZ>7_L7)K.-_I7_>/&6RY^9J^  %;^FZ/!H
MV<VGWQH2\@1AHQTXMQQ3^C3L1R;V/NL)&8DPMD]1HAI="C?Q""SG-W@RUX7A
MG[^9\VG#\(HY];NJUKPM/NY ]$V&\IG. (E%"H#]GX^[J2G;8;AHSOM%]\=O
M\6]^"P;B94Y*A4#A(S.2_&,LNJ<5@B3D*KQ2E2YY8KOV@7*4XT;JZ=D/';KT
M?YP0S_P_YWX<VFGCN25J-].AF(Z:P^K!H6AI7(N1OHI@?BQC1RLV)OO+%0^0
M/]*#14F*X)K[T0A\L_7CLVFEQ4NXZ*PCU,> ^R49<'56YSL=BW;WK<SBZ,HY
M22%P=IPC *47>N-=<2=X2A[$L^::'OC]78&@>9?@:R^_.><7L76/2-E-M'EE
M%LU5WC0\6U#_^L%"WDNIBP$FYV;0*CVU/+N4E-@IK1Z6:Q3 ;F(/*"-@!#C#
M--G=&Y2T_7JAB5H8ZG8$7[%<=E4(3%\49=-\<@A;G2(R#(._G&&[P\AW"=X&
MC<;#JSM8:\]PKT+>S,^-[/-DJK*Y+\VW@4<,,8V]Q!2F1%=F)J,(\ $H7WQ#
MTT>0,:W1-9KTX7,$?YG^$'?S1>,2BCU;G>O%B(A>*#-Y[?_J\!'7.5FA#/3?
M)E:+[IXN@^-**(!U58SJ/ E' 4QCB@BP< K@)B-Y[N)*<TNV2#CTSYQF>+W4
MP]I9UVU8KB?HJC\+>YH.7X3=FI0JCXEOX?1P>GNJ7:& DZKJ#;%Z*1Y/J7MP
MZ*O)&^OY<4</TGWUM:5^O-.!*FLRI7\:^\ATDDO%=I)C1Y/J&Q4"B JTC[M\
MDH=3O8;K9!I*,^*0H_LF:6=U+<+D^SS_IK:J'!TZ!T%(FV0X<T+\T4NO?[O<
MP*/YY#B)AP:;:]O-F!MLHF[->SM&N<3A1*W:M[9C6P^GLV=X /W71T6;]GTB
MYB@^GZ@^SGT)NB("6#HIO EG)U( -[J,;;YUZ"7"DE))#--BS4RK' /&CU\\
MPJ!],*T:06IEFCY2/]Q']LK8P1$I>ZA=8>'<D[MF6-^@QQ(,:5K@XEYX&QIX
M5"F0?,1^%$EB5  20IHT-#94Q0_3X48Q::]3W].QO3VHT FL6SHJTUQZ:1PT
M<6=@NZF]$6AW:A)IM7VX^IT"8%Q,V+4;4/H6BR\$=\CP@O96^(&[$0LE';**
M:MX7F'\()X9O+M1)A+ML#K7!E_=(C]X,;ZV.6$ET6WL,JTM7N9DYT8]D^J5N
MEF;D1IO\[>HNSL1VJ2VMTP+7W6S)#709S0\>-KT;[DQ+?Y?;*6BFD3!\8@@G
M)L.(818R/.&N2@=M#G.9H-+!E]6[4)=CE.((F5NQ[7*->NA,#Q('9S;K9WL@
MDZ!8GCIF9I<P,N5X]I)<(Y.S +\S[C<<%6@+'%[3(Q9U>LQ=*RUH)!0M6'U^
ME#2N&]Y;V .0UCBS:$H]@36G '1^*]ZR0"..7\0O$^IS)2HEG);+>]8=NCI=
M!]B;WG!("2@YB@H)$Y,H )5-MSDZL>^:\1U+Y6)F2/F7LN8#QXTKM?_Z4=-B
MM0&.]5S)1DL4 *?4BO3<)K4?:COVWM.NZ?:JCXYO6Q7)T/TT^-&#YEV^VM'"
MZ5/(<I!6IP %X&#A3-PG_EY;DTKP\'$.B!BK*TW[.0HIT#T]8Y<8D +1F$_/
MR6^L^CI^I#;2.C8:#&K.*)%2>(KB??C\'^W=$_&,9TQ$&5SJMM0;B.W.MFV(
M[.@*^6^!T]!X_-\QNS%GI;&PB@FY._><C#G1@P7( .PK16H^&[(1Z/G/F"XY
M^[W((_3A:7(3,/O-QG29J$WBP*9^K]V?XJON=0CH]K9,J1!]G<BG)^J\]*-(
MIRGWB.-??Z-E^-LMER7HJH5&W0M+^V6:U_,'3\##R:(- GSGH1OF\?.B821.
M G<FK$V45C0_@W6_;+%N\(N@_@(DF.F(W0-T=L/+DW@:X=UA$.1\ *K=7_G
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MG&H./N]V(?GVJ?YZUM4MKB_[>=W#R1$ 3>C__AO@:@4-V]MKAU(##@@&#\5
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MYD]50$M>]G=JIM?/@)3)_P-02P,$%     @ +(#16A("&3V2L0  @;<   @
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M,1W+<\L<#,>0!Y@;XHFF<BO?,[J7#05]L8<[/[(QR2UN9]R8YH '?@:8?+3
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MW'E.[S$6?97/57!'Y/3 /B:I :,KI5HS:1 @K=C2DZKYR3?NQ=/>1^(EIDV
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MT\K'2GH*'%R1]T]/\]N"8RR/5>U"!2JLLBCN7O%$+EB'_T?8SQ"J\TS90R_
MR>&0:9$>\G7X]V,'"N#"OZBN9N/R+ZF+#,%NW>(5:P1M(_>0>DAI8A0*;S3[
MMYJBMJ@IBG_Q9E']C#3AN1GL#G@.=JEV^Y+[VZ PLSQ!S /E1-?^]NC,@.[S
M?_>@?L8_K+!&&W? R)$ Q;2>/@>A7%=EPW_^Q!',UX-,"@-TPE&1@0W1EX38
M-E18-U&1+JSJ_@]MADQYZY"+MJ"E^Q' .86R1+DS=8A=!W!/;@;>./[+<$D!
MV-VFK_DY3B1A\__91QQ+ 3BS)H?#J-!9Z;9P<LV/K0_V$[[WI-60:L*F4 =<
M>S63;@U,%$ 3Z$P@5U[B* Z. 7\X;J8 0D:>M]SY!5[N25[__;$"RH$7V$![
MDDH+*AQZ0QX'_^DZ-C'F#+%&%(]'$3\47MDP*3]A[/SZZ'[I02GAC';)[(5,
MBL<E_J9R$?Z(O-6:EQLFV[,7+&7D%-98/U:_$TXVGZYKG*L]28+DC19<<NR%
M>$S\XX=I1]SM%J)!/ZQU0SN>I9@V],@HX3TH@)'V#+S3_\52?:=\4G(]/K1%
M4P54SLK&^Y/B3J+/7L%7P N\-/K94=2N%:6=,?8%=)'5@81-)=G1E?"\9;<[
M<5'GKY\ST+][%X"<R9M0N<=-!?%CQ;;2Q.9WT@7!6=LANM]!VABGEC?=H[$?
M]ZZ_M=]GM^'#WJQ):C^83!%SM:CALY.9(X%>WDQ(@D14*TY=]^JV9U@V\5]4
MO[H5SJ#, ,GZTEN;-'0U+@X?$YT,WC*\1,^CZLW'!)-)T)W:-OZ_TMUE_Y/N
M?O4_B4'_+2W]OHD*A53\I]7OB@J%<\UGK!K)2B'U_^AZ6?.?%FU8.>R>U!Q4
MZ'1K&P&%^!MXA%>:!HZ4*(!N2\UQ:KRO)ZF1*\]$F"_=69OX&_OE#EA/>R[4
M^5OS<CRVY(U,N6WC*S,?$'QF6G)WHQPUSE@(QFFB$_X;_1<V^T9JE1BDL"(2
M_Y8+NH:(=H)9#I4-XNXBY7?^W1B$ L!\7C-YXWLV>5@![4"U3 CPR/?X@JY?
M\C4- &VBRKU.:!P7S#+GO+7>HV+S7$[MGG8MB7_,OQC2+92$D$>FNL,[VZO/
MD#/P3BO#G*5\DHHG6'": HB$\Q&I&B9P$71R"#P3=OI#O@G_7@_&PM_I$'*P
M6]8"IW8A:A%@'#2&S&M%E.MMKL@MFQ&H/<EX%\-_\76:;8W3ZB+#^]6VYI][
M*/-A8C:. (QKO]ST<PW5/IK?E*IPE9#JENXG;T-;U7OY"-F[5V8E*BN;&S2P
M*:8X5V&<Y6H.A;B%]HJ_V_R5+J]HY==&:G?JA>-*?>1].*'2$I% YA"98-_0
M:X1<[T*K+@?O(DO5RS'OZS\!&D\[HI5#2Q1@'.L$V8=W%G EK9"E,PL]8_JO
M$O%JA1.U2;U:UV;C'K^RO\#W.O  ^6F7:I00,+9Q7B@1$?!E?A[CTY@Z?7.D
MZH;JWEM%7GV].H]3PA6<<3$$<BG?'W/M'_H[DEW<DX\BK3U_S"Y[**VUA>YC
M1:^-^'XYW#$@U)7[&H'U,ZVF]N/O=(M4:%( RRA2?%47>7!ZOFYI@5FMT)E,
M7_53&L3L.IF54<-.*&Y/[31X8'8ST%+1E^Y^V\GDSTR-M TSQ#4RDS.0UB<[
M6XSEU\>X5;_&E!7X PV_K7W>V;R+KE:RWG'$IPM '?:X=%?)ZMWRA>R6-)3N
M?"Q0[767=J2,GOY>]9XQE3O2B F_!#-=1]"B=!*W.)/YJH3.Z5W&M&^?9=CP
M$T)^)<U7YB0MP-H9B=F O"Z]B[?2'#_1P_"OZ2=IG-I"CT[%OK$27OT"III3
MY??3Y [YO, 9\CD%,%I, 6SXH-$D:O\\DXE472OX?G(;':_9$O+OG/HP7 #^
MP[AB8'(82_R;_7!ND 3&=AA0 ),OR+[+*5OU?B>MYL%HKGE+]5$-9GDG-3X6
M$(O(6/O#34\7(.-JGK\FEE6]R8_N@07 'F]-CP71; !9MQ-,V!NR?'\_YK+\
MYY3W5LY;J70%M'4?C=?%EZ)&'.BI 2UELL:3NV.O5G54?Y8[)3D%9&A.:Z(F
M[MIHAVI >\N+YI#\>'"'LM$:9(%N*U^WU8*C_.;5[T>\YM>M?I3WV[S2N5![
MM8)1^C%N"^.7XA!03Q:)"G1\J\4[2;^"]!GL/G9[<XPV,N:X6*W(-SK.J263
MKRP"KM7)9H][PJ+&)[S>)?QX,6[9M_"\^H77EP \I9F32LS8F5"A1Y)@T>F>
M]$IV=O7CU#%=0OZ=2$RO@\:;=[WRWSLL'1N/^8A]GD6:4*B2!-0KI4DM:?@.
MR\-BX3+_ Z?.5,F]_8[5VCC+V8FQWL(=R+KO=,\[DY_O':,4[$0YBKE9+O.1
M;;@R+O'93;26]J2%F,OA-)QXW[[MDQ:3KM)@V(J9<#X*:R,;!Y"^J<LFW9\J
M8"$9A^H6FDI_Q:@Y&%VZK;62N2)16[$MOKW[6ZMWVZB7R;RPE(PR]I(EM$?7
M;RR>5^!C_B'B.-5[_XK,(B_CN(H(,=NL-3!5A-X"$OE&RD*-)J&0J7^9]J+5
MA? +WYMF6G(6)TV6=B^%J(Z-&J69C)=;&Q2?Y86K);XHJ_P^T"O-83QS.USU
MODG',(M5?/S8X3B-)-K5IOUUR?TLL6K))XJ]'$D?@W%PX7T)AA !?(Z*L$X\
M!7!C\"P!*746=\-VZ$[R.;D'BR6IK^0/^Y7H]F'#LF),&?L6J2)A=Z#Q;C.=
M+:\8QF9?F5ZM0HMJ*7&;*)NGA+?FMNF5>'KYQ37M@N@80@(=DJ+AY CK4>N;
MN#3S.@2&+<%3ULORZJO\%:6KATBOLEO&K"C^ML22T7?FJ\94@2W[3H4-/DD*
MX$T[-B_N(]EH8WP5R'19Y7[SB<3?3&V[&),P@;?G+[>'-R7'M$N.D/@J<PT(
M-^\T>J74-M%Y)BQCZ12X<QC4? @@F0+3 [;O)"-B\.< \HA\7;GL@D'<^1X#
M&VU2%RU_8Z^\2GAMRA6@XF8[W_AH]R>+/A7N]A'[#"TAL R73T+&=,P4]@)4
M97R%O9T/GUNX+%L9T-5Y9*S'33]ESWCOU:Q($)Y4^I,L2[HW2F(+J)^F[8I7
M=M*779\*:VVZ$.T^F*I^^>9EE;61UNK=I8_U.C=C5#AF\K]_RAO0R9TW]%"L
M/GUM<$F19ZK"^[.B<Y!0%^C&Y@VR=,HADHWHY_Y0)(0^@/N2F=31^Q.3GR"&
MNG@PDTO]4;UAGS?DU:?\= :COJ_(3#(-Z?JO.O[BBI;%K]M? FM.CQ,^C3?]
M;L7%K\LCB\@WUS/:>49VRMS<,;4U]<^YG_7>3_FZ#BBW&5!FU:4::PO>OU5.
M[3-G$V6ABF=J$**H74\]!? G:_UK6U?JW[ G&/=D0\=20_NEVO5G]__[*!0Y
MPAOL8G(<XYEJ(=EHRN3FZ3\40#\37O\L@MI>7EO8$^V&3S91)4MT\QL%T#I*
M ;"0T,,HJ;QW)3.)#W)R(:2L8,2O;#J2?X6S-^9FQ_KC,Y&"MSRM?A7VJ4JJ
MP8? @>;*YOT@6)$U.T;Z(RP<^>V;C7$(S7GA;2&EDPDCW=7XGUEMD(FO'6/C
M,QYU78;%:'ZPWMLKC.;3]9EA<6O;'*6^ZR)V^@@ONMV!*H8'RTYLIGESISSM
MNW'8Y&/?M!.349@$M>,6S_Y]YI'1WNXV5'8WWE5A=4)_ _P\H!';)?>_N 7_
MI ) 9T>^0)!(B'685&_<%'5^T"G=ELHQ+-S0?>,!2%)7-%R[^2)4Y$BMXBO1
M>?U0Z12K'W<(I3,W'RQ8-]A:F>K&]?!IL?W#(IO6J_5M+>X8L_4X7B]J4[/]
M1D"%Z:YH5D\YZ_,D4X+\H*/HCO$=K]]""D<RAW*Q[Z6"DJ):+?H0 &DD-S'5
M7=M*O]N/5;OC@YO,C7IU?BC-W66>?'Z5]L;/<O4=0L7+?C">FI^WVE#9WX L
MC@U\/*6E@8D7TNELC0ST'C+WPCQ>FXPLU/ B0[^8NP1Q$36,?QYL!3MZR\P-
M##VOR2U8\[356IY$S)&''MY AGKZ9)X<%HYW?WDIUK:OL=)D._/:TL/&K'(X
M59[SV_FVW:7MV]>C)%.K/CY/2WW$L7PD,VQ4H^WVQ^+L^<D+=GX?OJ 4P\JA
M$.]G5BPIUWY;:U@K3C#[F3C.M#$ZU&&F)=?S_P<#\0@CX$!!^:_'__O8E0O9
MQ,ABU2*Q]Q_JKW"^D]S(8:@;<F41[>'DM-+<++K=A)S1P<@6X>;[NC+-O;N?
MC ZEJ3Z QOE.%UT%?>6;3)Z!C6>]: '5^NB<<GKN:Q7-1C^E<B:Q;Q6REX#M
M54H30@LO-T6JZ;U:(;Y+#?EE,**EY7MJB9#:PH4P)_>NX/J6/@US@B%R^9 7
MTZ$/+8\@V--\2T0L:+S.DT !U/I'_EFZ%:(&=^G3*16"COL;PZKP^6HM;]ZW
MFGV^KUQX2>J8262]$B9HSU'N8GL/I5V+6-J1(/+*P%B'7$"P=YEE@BC"#(P_
M1%WJ%J%,C=-#?MAA"\Q:YBC6T*W"G39Z)@"Y!;L]'2MUUK"$DZ( 0#IDF8/K
MQ!:QU.:L4^R)YIJ9^#THD'I)IFQP 6ZKH87B=I64TSB03".P>QL_F5'=,)YX
M\ORY'E\N:)_R^5[)56*+'N<.#:/$GOE*-WY5][%UN3/2_%T^!5"HRW.]T9_G
M^303=$0*_LYLIY[TA-'-"$GC^@R9['9KGZW0STUX3V,@Z,0D8I/:\:.H<AM%
M<9DY*^IHIL3P@^*YL;@B&!K$BPSQ/54-"-:OJX[0'K5/5;W-SRF0S:QP+H?P
M@P' AG^/X&H,Q=Y=(0;]RM6N26")6(/MZP2<QD)*UYK7\_I*&ED?O'"*+:7E
MZ%"0G10?./V[G[G <?Y?QD89J/Q;;+T$NT.:GKU _@ W_Q8%J@%#^^;U1((Q
M6E3KLJV*R@#EVFT*;4]4_=#@CGO:@PS,4SXUEX='3#?1EJ50 .NV[?IUU,EZ
M@B 4O=7"00U5JM7USP@B*_%@''(9" 0M?RRB *S_CLC3LX4NZ/&-01)T+Q8V
MV3"!G#ED^^??G[YL1#&3GV<,<K_;@*Y:2<[)'S];UPV.C?0H=N4Q@LV'&H^]
MS3/C\R#"RUZ0DE2IM(D^'KPN%X2'[_PK&?D/E<$ >#GL#7EP0&-[= F;<*->
MB +@1:*AL2L&,VIBE:S%O=>K_ZQ!? YD3H"GTO?C"3ZXWVYIA&=Z\'GD.@5P
M3N*LR)#<ID,!Z(0=PV-E3PK<25L4@%;*'P+\OWZJ>,Z=\_ YJ42;7&P"NDD=
MO?>\"J>!\/XZB'6>.XJ<:$X$=RTP'Z*O?>YS*K'J8CG0/<W<4T!2Y1E*G2!=
MTEOV<+0%_(Q+9)'^&<=:N\CQS;ZG#B$@%H,\7J\W;0F^\2XD[\TRV,Q2+V^Z
M946!:X^6=QL72O-(64[]K%!)UU;]J*J9AS';XR.BQ]/J(F('6MS=F*TQ.GLD
M.2SJ1 '\([/,?'6L[C@#F$Q,9H0ZQ2-^H/=UR4*3DTM#U45]:C"1/:<*:_+D
MTQ?L(T(&ZBHZV.1Q7>\3Q Z$WF/ARR9_Q,B.'D@&*3^.&(Q,_KS:SC:*6BR[
M,;W,"ZS,?(K#X67+L9Q*ROZ%/;YR'QP<!9D+U_B6&T#BGN#@+A*D=^J=(,[(
M<DQLN,"G&0J6\-TB.PVN3C&HOG$QB9:0G6[SHP"D#@RV")7U0F0E&2IT0*D1
ML7O4]JQ4K,!#^HQJIL]37[%(-#V:>#>O/40*E)2V-(+J_"J35@!W@[N>@VEF
M]^^WHQMNRN$3UN:;)2[")N<EB</81#,8,.!\GS4N*JQ$/#.X>-X5,Q*(X&OI
MXAV1_:AP7*T;?-B8EN1BZ%UJ+)D ]9M3%"P/: B^Y]HVB4S!C@[(P[R>O[D)
M=7"QJMBP,%JK.CI$[EC&)F:Y[S,2D #T<ITG"G*O.R!>71T;(;8=#;*T;5<Z
M>TM6!I-_ 1D/W9V>C6X?3/F<^9UJ)BDZ^IDDS>O&+5<)>6YZ]@2SM85\@6 D
MV)8@Z"M@9A>UJ2FUK2W'8'E>CO[-3IE/VAL[I<IZIX2"B2*#6Y4CBVOAJM\U
M5L=C2T("\.H%#YK#9RY,7S:2)&)E^K[V%PJY?$.F]GC6AUK)F+ K!ZN SP0$
M0R]R1TL4E=WM6T4>SQ)0OU%@%)YQ1_EC?VB@M\^2XZH6O=V14QTL;'(M<YO7
MGSS2+/<UR8X">#L,BYH\Z LSS'T:5:Z=ZN51ECO30K0;1[P+B+_<)?G&MJR)
M?;63:L.GD\/HCF<(8<2F0J($YAU!KB'3+_6]W=L'&FWWU4)9P8SD>>Z0 &BP
M/"H=YHN)9K:M?OK!KM+/:RUN@E"#<D1@0H7H5MYY$G=+)]N:+$8'YHN*G.%
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M$.)/\^R3M%GOEN.L:2F5(1%@)\LRV'W9$_+@1QF[O&I<5A1/N>TA9=Z);AC
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M^021P-A+U[_HYB]%!,1)Z!(!,!7(&1WX+J';J,H;V%/ DQ38,S/!9;--!,S
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MOV8 =&0DQ."1,0' @$O<YZB[@/^T3/$^5V:Y;X9Z";I.OQHQ+&.,1W+.2P1
MGV9L%UBI%UP @(Z8QQ8CH)*@QOPZDNJ0>,SYE% %3FUJ9\>^X?T!^=6X@J>W
MJG..2+:.($-A)SF8Z]'+%;QC>Y\'Q])^U?^!C@9R8ZJ$H*K5+>,[]F.W6N]8
MY[HE<%"?<B%0=\F:/F=R?11WVE(!T;UE4&+9 MS]'/7_9 ,881YJ6_F(.+N
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MV:%&&$W@K6@#K&V!6#3B/B8#=08&;CQB$9(U*L]5.BXKU4DNM7L(+Q>G?*=
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MFF[A)'4>G52D6R6-"#$L:BQ#55O77FX"O8+ !8[ 1O/RN8J(XN"AQ0, D@!
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M 'Z#U! H?E-??/CNS!*U]AJ'L@YY!M-""2)##"AI:,K#I3O#LRE/U3^Z4]6
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M%+AN5.!7RE_P5@NFG^ 6EJ6^[JK$?7RZ^G=3G+VQYR2>E?*?_!5F<O\  G3
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MJF P[H/6Y\WG>8+&5U66EA8^WTIU-5<'K3J^E2LK'B(****8PHHHH ",TTQ
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M,!<'%%_:M(158@NUAE!#JG=GXYG!!1X(A%5!0G!/!GVM\PT6MB\C4ZY_K&D
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M+J$=,#']]./J(+/FHEDCL?B'0$5R6[HT?]]@Z<MH@WKF<+%Z TE$ T/O\;?
M3%E5IM,M"JE?YTZ&V=QA6>(>@[X;16DINTU2>.!V 1Y8! _5D\E,0Q"MZ&OY
MF$'L#DV<5F8+:V42Z" E([O^Q;VFL*98"D(WO:H7 9U#>U)"3R8>[]ZR813[
M*U(>VJ)]$6+S?NK32*S%-JXOU^7:2&N]C'MIPD-NC<S25W]T:EI3!-\9I^BK
M?.S_+LG5&E!:3\9(*_^:_)_^'+;9O'KH\)$IG?VS *[ V=FUQX.D1#O:BN3"
M\J3X8]V-ZYV^'&R[\KU,?9])$!1K7-53BLYL,%,]@!YRIG$JOOF&W]HM*K?\
M<CK[#ZX$%]QT/--4W^DZ.W-ETX94LSUO/B(+R8PT.#!$,'@DXN@T[DKJY#*G
M^O>QMTXN!R]DI#?JZ2\[1&>P(1^&ENVD1(RB#.#*4Y:C&78?=OC&K+DEY[\\
M>>1-,NCCNBJ,XAV.%D\W>S-9(OZ'/,%P?1(QOKB=0.=YOK)W]0@\>AZ!![S#
MMDZ7_G;"+W7VO 9FW4-D=,X=F&Q2X%ANMER$X=.ZARVKE<L!=R_I_KYUENO6
M=Y>;#(+CF!N:P_I!=-O:)J_ILFNC]EG7:"\H_9W<W> &E=D>XYVXVRT-Y6-G
M"Q*:S96]=;75#2H\(>3D3D$Q$&'KI8J'^258@VFL6I%5 V]P<=[13P.+,+'4
MH-MCXD04$7WT_ODW$CKUA)9!?Z?A;OP_W\GF!2RKB-F1X0&5Q*X4ICDUUU(5
MF8]:*G%  >F!% \NR?WXAB?,&!0F1UT'?2A\RZJBKL[P>:$OJYPSQP-?/Z0,
MT6)V(ZIPN?F^9TX+TB+<DD=+AB9N2?&KN9'#B[B+1&[N&@6?KZL:@<P@6CQ@
M#N.8]2AJ]V,],LG*MJZI98-^\P$[GZ<687:M25X(1F86/?X.]$DYO[4#F]$R
M>< 1#@&Y3;7CA^*82'*#UJE[DQQ*O.<MV;^0]2P[^0 ,T<W,%%V_TES;HNCM
MN9K.5%.IV.XOEZ:GC8A&G21>X8$MP6$?9H2'SQU$T0W&2+.ZF_#SV,@ZL2SB
M<O+QN\TD'4O(;8E_F%Z'8J[TAC8(*5Y/H)?@QMGE,V$TY3QT^L4SJIZ;5X*;
MK;,GYXX34&M5$.E6N='LG%6#?:[00;9E3,+SO(75B!Y ZLY?#GIIO9$Z-/NV
M9LR)'V-*W53(YF( 'B#=0VZ&R$BM/#7T=7XU<:9!Y^%97/VTL;$>[.UG'VN,
MYE-1^T;FM5GMK10$MH"Q8R51L(*=%-_\+S(J.;85L\8FB[L%^[YY39J?K/:'
MQF/2XJ58VE9:\FHXV#;%&X?I9FPO1*W/*Q;?W1#GOS5YW)7:\D'Z\1-PR&W'
M0W4Q='JI*81A[^[/E:7L^N.H= S%SE0K(+9 *AR"0)Z%A$)K#1 3?VP+7T:]
M=INFK1)Y+;)*2BS]=AI6KA=1'2XX3#]OC+*'=S]&)=#2T=XP[-I\V66EUV=/
MQ+,I-1<U>8J>]#&*:^)5?69!A1R@< VHV;1>,[<$O-8FD\3!#'QOQ 8WG@TF
M_W[BV"8IXQPE-:3!S:0>V5#6M!%ERNH;"EU^@,X_#T*!7%?!U%BYL8.J2&$5
M9/SZPE"RF!_;U^P*P^LXVZ]. /K99D9N=(D!TF$ON7#)H\BX:8Q[[/;OV$,E
M:8MS?IXGY]^*!(Y:[]Q1!&0P>I,&/K5QUH[-I\\7MP[H[[H@OI$C6<"18F&I
M[PXBZE=RYTNRK*:\:#*$'IC>- RQI&@655?![DS O/)":89^P%^+DT@[4$=8
M+QT]-JA.1"R*(7#HDE< 7_;W[]+(9QSNH3WB:1E$$6:R.]_:.15L/8;()G)J
M5-\;C_99:$>)C(L/*2'V7SZ&%O=XH+>8_NP&S&OSM L0L3X I^M :6T,*:Z=
MX%!%+9QC!V)7)E*E\;.W?W+"W24S'[I_>Q0F6SC1NZ&BQ]<>4BT7\)51\QF7
M*E)U!132Q+K"$_)NXEI:;$=Q^'KCFO/5B"VA75?= [/&7+8AAIH<[?V@NR_2
MN* A899P:&#GBF7H_@$>J&ZM''CTP%LF$KUVDA:&.-.8T5)-YU:MA= 58*1[
M)=BU3^P_X0&OYC#&WZ+YS+IVJF5G9B?%PYS=;\MU3/T[.ESBZPV]FLN@OIZG
M2MK,<!CQ@>0TN0;Z/!$/A.:#X=$D=@ZH#!K8R;XP'F P\67>"Y<NQP-AL0]A
M)SM0U"]OO]X3.VX<O3(:#^1KXX%N/:7??\";J[C6_?%NW,1J*AZH&R?T'J9P
MBP[K=<2G29BE9>G?9E-+73T,T G!JF.@PU6M6+7/Y;C>L?>6747CU5EX8*5P
MS*_W:9)EUU6C/AXX=_'FJ,3Y@7=Q"VP#==MX8( )W P]'F]TF"5I:YW94?R]
MYL =K@]%I>S@Z+&O"(8F\FPN2<R[MCZ63U5N*_F1J*R")S&N-^8&=>1*".(D
MQEP6O%2FB*([LEE"1#6[RWC];/@2U_$FY(LBT'LA/FR202PVE_-D_<J3JT4[
M8J6_KE=)M%/[*Z?]N-Z<JO?Q[IIW.J.FB=2EY'_X'T*B368(\DKBRL5A4]/8
MNB8EC,[5CJFMG26&Y+,\)R[_I+ 4U0K#-4B<Y)>]4.QPU-*UV839XBC'76S5
MM'4KQO</'/2S8TP;23N^LI-8O::["#W,0!>72$!&/JVSV><@?&L%Q;N>S74W
MW+J6S/JCO'>>.1_RZG19JNC65O'\KPQLV':DK: J)!DQU3\.D^,L<#<JS"^9
M.[.DR9 =J2K;VY>M\DYZY>E _*KW]:?V5P<64"6.N%WM&X/D1I4MC2$*KG45
M-0]O;27I)'RJ(PUNIZZ/TE#WTG,6CZ\>@4@O\C__[=A,U,Y)BU#E+.8;J^@*
MR)7ZOGKH& #KB+9EMTJ_>BY)N7\\D6;D]5 A+\5W:,EQ4Z7 PVF'_8.8AOC,
M:LP1A.1&FK^R) M+;[NXS6ZW@7A:]+V:U ;V;]A"#N>-+J;VMB&R)T1UY^);
M-]C(AKHXB+[G2)YF(=1"*#*)HAO  B:C;E!/6Q+=I^K\>"  "BL[:[V..!]U
M[9,;I D30H2!145WGDCT_W*,:F+B0I4F#'>FV/U\5*S[IN=W^NA72(.3NM**
MQJ9>_U<.0"XP _995RM],<270\:Z9UREY5SYJS]YOLVNS#^ZJ!H/>+:F.T5>
M%!4=+6$#IZ\V<*[D^H7ZE\'UMGE(P5L.!YE]/R>K:2L4Z6AX['%!4_6"H;K/
M#5GEFG?8:SJ5^Y]4#%_O\-V>-8H+"-*P9:7X)+ 609NDT_I0Y<?'L,PMOB>>
M6UUL ]D9,0[WXTMG%@>I2K]S\\_TLI)"#4YMJ;66--5&6GSE=P3#@W<,%6?Q
M0)/ZY/M7,48\1Q()&D9>F,G[(\ES8USQANK-S%.(RT>(D*PBWJP2%2G/ \A0
MW'<G>,&@F+&D+#,.S3@CY2ZWD7/XCJ+\/-BT%X)9T\4EK>]E\\8-GY1^@AIL
M5<%0R&@DSM61U09RYG JON9W9Z+L-/Q>W>_Q)2W'1_3RH*5C=!_$+WXW%EKD
MD%4F_<UGT"#?XN7*^JVXRH//TR"&4M)8'C_.9E%%#,]">OG1E[6O,OY7X-[)
MT98[XA/G"156M=N.(G\'U[^H(=QO-D;+T*$Q;"-(KFC7 L/;XP=KO]-?1[:P
M4IDF95&^HVT.OGVRK=_P5DXF>M@PM?F)\J0CG3+.^E$.>ST+SP%O[6N]5^=.
M!CPMGXXVD"Z_9OJU3#0C2R[*GMO"OC%[Z9U_F9ZEGOZ;F:*,2%BB&BI0MOC(
M&S"RN32;"NIN?I3L_G>IYR[K]R0GQD]Z0XI.@&F:UO;THC3M38+N:#O)^3K#
M>,IC[Q@T\M#K FY3+28G&H;#&OPA38A[_5K#F4^(C:YG1.Y ZDP*SKA/G0+Q
M#*GIKAY4UZZU5).8KH1,%T)PMZ@,JDJL;X5ZC%5IJ]ULB'RNLF[N=<$=];CW
MK$ ,\FU\Z6OL[K/6BK#G/4_,A]Y"Z3@]24%V;6]KZ5 '.K5_WL$KJ*-D!HKZ
M14)II-K1P4M#U5@Y\7:9P:(_)#E\QU-T@?F\4F>KH"@;\\R$4-]-!=8/O]3X
M7ZE.77^8X7YX@:8:JZX_\Z1--A6/):7&(/JD>F2E]9P1$-1I*JX!*F^TYQ\K
M^/,(CO7\@\,#ITQ#P_;7NPW4]V9*&0B8_;WDGS?\%J9O_*)%I1H3Y)!R>= !
M+%?1T_2TD/R%IHL8D?W?SS;#GR:]'1JUX[H!L8@Z\=M,K$]M%*18,\GZ&Q,R
M_S)7&S@TV)1GD@O/%YB#Q%_#G++B#MF ;9^GA(9"X) EKP:.#K%!(9B>JBVB
MN->_7XY)=13T%:L<FC?Q1,<_Y46-H:*VBK^WT8)\0\IRW]#HTC[.W@1&!%-N
M_2Z>>0CGKH8HKVI&:1"<#_5%[ QK^ZXV]-/RT6/4B&!JCQA<2^#GN7FL3JC<
M649#+V^,>MS;^3KM0"O.;OJ^&VL?W[DS59IZ/5S=X_0[*O50-GC"_5UZ;'MZ
MR;(U(NZK674K&_&FC@+CF\>Q2&9L,"TF_,HZ%@_ BT$O-/YUQY4S9/=U7.H[
M*-L'&?=5AZYP&(G)]F_?V!U5P:3DIJV;3 ]I%WBYT]ZO5,B D1+=)MP$1O'P
M:E]4=GWWWM'K&^GWFP9OBC58 )^_/&ZL9=8M8WMG'M3-9\42WRWEC+8XG7<'
M52TMR6#VWPW:.:NN=\ IOVJB*$^X?ZP?=<OTBR1.<46>R!FZK>.J)U:T!W"_
M$0*C'O8Q:T;3> !DN[N4M>:V^ 15*2H N['%[S3P2ZB[,V&G,?4I,LK(3 K]
MPCF]VA[>U<KT<]JE3MC%[II+7ZZVJVR1L@E++ROPV$E><A@C*[4Z]2;-3&Q3
M)NSTT]"18[@S[DP548:FA%UN0'.?+R$/H(N%/A)XX(X9'C :/LWC+OF?/E=
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M[Q;W.M%*N+T+]E,.GHH ^B&^3,F>,C7WL_SSGSHBP ?JFS^1ER BP#$L4JP
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MW-ZZ\$\;K,.:G &NT%ES.V:YD:*"I?ESE!WMC74Z3]0NR!.M>M4,'W< 8$&
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M:UVF/0I@QPOJE2YB^@PK999VCGUY^X%>>^'_QS^4_O\\B%/_#U!+ P04
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MP2/]APL&UNV_"=CP"!\Y$''$E9&,'7"I.0.0\;XF_*WI^4##I0+!_^DXC4)
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M6^2;FZ>O+A@PAK8WTY\V<_,B^OSY!31@0F0U@M]5CIUDE]E]N-]X3;>CG,U
M+#YSCR*YXX=![K#U=J@4DTAH$SM>A-IO!ZH;@[DBQRH'J+*YQ64;Z1=')0%A
M]8OZX0^K#EAH7D4\:7^3F*R=&2"% Q@>\!K3*5Q#Q+>[!50IG/G)\!@'@0I#
M>^X9CN3E&$#7D5LV?R11<P?U*.GLY@95E39Y%NEF\89=JBTW\J-!1^U.=%8)
M(.>:.%FI8^7?@)(R<02\M'YR"QB+_^[<.S,+!'$KX%ZXCLM* IP6L3KJ34<*
M5-O,(^,L$QS]V6_)%CHK2(;-J8QDRKU(A?ZH=P[@J[KZFJ0/Y2R]&G@,/C7
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MT1]OFDJXU[EPL0JGE:9G/#?PHG:\NX0FF]>XH[]FX_@3FC=>=411!I@M8:
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MK,P*OA6EO41ZQ@N2GA96+3M*@E(_*A<9C%J8AAZ)^I1+N2:=:9:+;16*$JS
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M*C#E ]4/ ]KKU'&V+UI3R=V^$K@@F$&&R/ZY3B9OC067,K.6NL[IFX/6L+'
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M$:W3H%7%V+%D_W(9#C1#M76&>UWJ<6'RZ>LQ9AKK-Y!AQM"NF]7E!:'[PLG
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MTAFU*_36@'J0UZ$O3']5P0J^_<2EW=1%X$U@RGGLA^U++.N:$\270DM%423
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M-S2P9KPTF#8_/*G:'Z$K-?J.2C5C/N*"AP^!<071;NV7KPS:UQU?=_A[8VA
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M<&I9YP6=;T-$E+^ ;T]:_N8KO_9J4W[G7JG _^O/(?XO%N75W/\!4$L#!!0
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MJ8B99;T8Q^X0+4X<F\?L\GPN]S]S,-,--!+".2##G&^;)]DC=>+OS:D5^2L
M2HQDD=%9/6)Q!&ON(\5U3U:)_C*F1)[]4[93686$B>(0"GTM0 &P4VLKC/P]
MZ9>3NFH+3KV4KS@U4'[E0*^!C[\H %M?Z/>FN#4=@:7HZB3\43KSC;DHQX3=
MA*M)8ID8&IDR*NZ) W9O=<G-Q 3M>/BUZD1*$_%V6*M$@W6T4-I=*E]V%;P!
M9PM!AL=,]+QQKZ/Q$@/*8[\IY^CGH!YG=T>XC!,*IFU?KD*(+0K QEV^5L1Z
MI@!ZO)1=5+:<AAVKRY:+XY O*'*_:5"TM;=#I4A&'@:GFT AU4"0B9-*[14
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MJ[QJR79/GPC?- [=+&AW$<AO%+5:Z!U*:@V.#9;EA1=;[[;]8MA@!96H5]Q
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M9VB5D:6/NS&WWO5?Y67N -]B/"%J]NU,$T73(R+ID3V\IS9[C&W2QA-[RU_
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M1ZI2Y^>%NIR=BKZTHIYE$WM^D%SLXGQ6>LDKT5&2ORI/WU=K\ 3,O90^P)N
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MT-T,CJQ NAHC$QL^:YLX%?@>GL3+".[J#^$][>]D<M*] [PI$A3<6(FP.'3
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MS/&=5EK),X[JUV&4-O>$OC*\C9M!>(KS$$[V'4E&@6?^(5,7G5NT?:V@G@<
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M=!23X#_G@IE'B+W0B:EAY]1!.93L42;V>"FGT91_* 35[.'\_.1T?T3K\4R
M] )GIL5LK2CJJ$5H/?NU[A@L!M\(Q-X8M+=XW7,4RP-H. P_4]+'DS-H#>U;
MH(J81]8)$O)4/&(G-%T"Q;DI3@).I@2&!KJY/GM+//#T5V4<3P <6"8CQ;NV
M*;3?2+TTHDOS  A$FUD5HB;U9@IF5GN$/T[.&2D4,\=/] M%:8FL!\W2@)'P
M+V%R_#ID'XU&J.,'[%QX8U):NI,&@T/1X&BD>.BI* -DV9KRITQKC5U5J:!3
M,PVW\ S_QD<YQ;VH9^*>AQ4GHR<.T2LB\_GY8O0--?=#(3FU8(?87 %&<U>H
M@"[R71E,9?= .'%Z:YZ-UCKU)S,4R)(GO)4]\2<AX6:C[O,/UW#>3VH'GF93
M"6DA-U:($47/4<]B\_.]#\#H1Q/<38JI@DQWYBJ(@S>';^4:R#9[".X;QG23
MX/U!+<<@]H.#_!=)^[J<<40Q)LHX9PI 6M>DGUL=VAU)FXL:R5 FJ^%=/^@^
M/@'V YWTF]QO8))I-S;>6;+,IN..C>0[B5_C7S]-"  4TA*T"G]P,_BTA2@G
MV +_J1ZI/#>*N"5"&Z5W7^J-ICH\Z?3$'8[K]*\RS#>W_RS'V^1P-'DKY>&O
M6Y>@.NE:YIWO:-84??1;>BY>E0ODX,-V5R1&L8(BEB9"-:M5IE');\2_:/QD
M7UZ*\93R^-@/B!9NHVM$%L8P"U[;)[6S0K(M'7__T0@"&VZ,Y4>_>#GAE+T1
MI<(IU3S51BV9YY%KQGXWD\;N2F&6@)5OOK#]U7LW#6V(^K6^BZB/J(70@MHM
MW!EQ,NYF!'=;_<I]].Z@?C1H043K\9;>=E)K*4MB_:3M%A'/0+2 V4F,%SH5
M258K_HO/3EJS0;R].777)^,?G&^ZF[>L4SM3?H&[/JGIR"IE$*]39CDWCC[W
M+%9XZF Q"-E1JIZPG6W?,CFQ%[I8D4%YVZ_"/D:FWM8'N0EI390SPO;'T.H<
MP"2G*+*9()UB_HPO>"]5)L.:I+TX.UO K/FIW[':\CZ%> S'?N<T+OS2X4=!
M>QVD 9!*\DB6LS"B"3UK:" @UCOMBNX'68AK\RO66$J9320L?;AT!8^V#INZ
M*;M&#$,C"W><M"E"_@&0Z# C$$P\A,B*S:NM\1^L R/G[<<@^E@DZAH?_ZM
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M>I8E;MSG5CA'M;U+#)VGMB(SJS-891J6H-]P0YM&]*4U3S&X79<.[ J9)"$
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MPT$6+"A=XJFHN/9JE-E::+Y28=A)5,]AO5">X,6>!Q_^M'NEE!_MUJ'C@$G
M3V^PDF3*]L>G+F^?62\'4KNQU25J-#4&/XA8YY#0FI:I^['J%.[YAZTIDLF0
MH^T;Q3=>2T&Q#9X#X!SBEO@. ,?E&4NK]-&BE";NLUC&W=[<U&.K*C3==G9_
M[73_.G&:>X UF&GGP:7\6<.*A:L&AJ<-K/\%JNFUP&H+D&A;U%LKBRAX<E:
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M%]CN3E!RIV_0BTI*_;U."4Z13]")IP[&-C7+*D&\%3J; _>G767L]^=XX.3
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M;T4HKMDQ@RQ[OG+FTU-F'E;M*V7F=O&MUM0ULJC(F#N[XKVH J;FQ"M5O\\
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M,L[)25/W-U1Z1L798QSOK<P$@^?\%L7.$HMI/PJ8N4?I+/;%*32\LRDZ^_8
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M[:]\ECYGGT9IG%@W9;HJWZ@&K\:NVL($8_ 'I$>H>X*N9RI7=+J6RWS=1?N
MR% S0F?[<P"8#0J1288494KJUWVUM3=^>]+\+'A'B4?HS[08A")GJM7;/8]
M7EA+X"S]'XD?BM;DI9>X2B =<9&9/PZ7$>_;(@A2''+TSSX!-M\$:Q9)<U->
M:4T>PDP:*X5]"&/EQ6W?DTG]P';#L=Z6],;N#R"ZH0NB$N[^4,(:'960N;#
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M&2WTOS+W.Z 6$8A_8$W^26H$VP$1R7+X3J<>B^H!E29^W/7,G]WB2[K%+S"
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M/DTHRJLN_-9\=X@6^;K:J*/YY8U0<('!#:Z.$N@'4+X,1_0(R/DT\!+-2=:
M,F"/\.3O(7G22%XTGT,.A8YR[];@H^<5ET<81R# O:Y2&.&-[.];T3/MNHD
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MJ(UV V=)C1ZW80"TLKWV']\56%OL1Y$,OF*W=IAJ^">][Z2;!OW*/G;9]X)
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M ::G6"/\JZ*?T<.!H?\ ,/-^M2?^8GXB9WTFO_ 4?$3^#=0E/_'J0/\ >/\
MA52Y^&NIW8.(1^;?X5]V#X$Z8/\ EC'^52)\$-*08,:CZ"N^E]'[@:'_ #"-
M_P#<2I_\D9/Q!SQ_\O5_X#'_ "/SSUGX#:UJ#EH_*B9AP?F_PKF+;]E[Q'IW
MC'3M02>U46%S'<,RJ^X[6!(QC!_,5^FH^"&D-_RS7\JBG^!&E2 XBCY]17JX
M+P9X2PM15*&&::::]^;U7K(B?'N<RBXRJ*SW]V/^1\XZ+X^TNS@072WT+#@E
MX2<?]\YK<M?B?X=D49U)% _O1.O_ ++7K.J?LVZ==E]L2C<>PKG[O]E:S=F
M4<^U?I]."AHCY"I.4W>1RMM\1_#\APNLV2C/\3$?S%6$^(7A^WY.MZ;U_P">
MM;+?LH6VTX0?E4$O[)T);_5#_OFMN;R,XJQ4C^)WAX')UO3@#_TTJ7_A;OAF
MU4L^MV9 Y^3<W\A4J_LF0G.8A^5/C_9.B0C]T,?2ES!9G-?$?XOZ5XST%-(T
MAIKN2XF1I9/+*(BJ<]\$DD#M7MOP1M&M?#<&X%<J.#7)>&/V9K;2;Y9&B7@Y
MY'2O6M#T>/1K-(D& @P*DHT>M%"]!10 4444 %%%% !1110 =:,"BB@ P/04
MFP4M% !TI"H-+10 4444 %%%% !@4FT'M2T4  &**** #K2;!GI2T4 (4![4
MGE+Z4ZB@!OE+Z4>4OI3J* &B)0>E. Q110 4444 %%%% '__V5!+ P04
M"  L@-%:TW!BZ&Q$  #710  #@   ')E;&EE9F%C>6XN:G!GG+MG5!-1]SX:
MI$J5WHM4$1'IG=AH(B @(#5*ATB37J,@O0D(*"TB(*) I(0B$'J77D(O >DE
MH09(N?C^RO]^N!_NO3NSU\HZF3/K[)E=GF>?"7&:N RX\41+5PM 0D(""+SZ
M (AS@$> :R0D_X[_%E)RTG]"049&2DY)04GY3ZFNTURGHJ*FHJ2DIJ.FIJ&]
M$LKK] QTM/3_OO^[R+_I_V9=';14E%2T_Y^%V I@I"*1!TR0D@@"KC&2D#*2
M$#L!_   "3G)?P3PWT)RC92,G.)J2=0T5R? ;UPMGY3TVM5BR<G(KGX-N_H=
M0,9(SG13^@$%L]$K2D%O%IEWJ0540@\KVUB-1]'"LG9O(JY3L[%S<'*)B(K=
M$K\M)Z^@J*2L\NBQII:VCNX3D^>F9N8O+"SM'1R=G%U<W7Q\_?P# H."(]]'
M1<?$QL6GI7_,R,SZ]#G[:V%1\;>2[Z4_JJIKX+5U]0V_VSLZN[I[>OOZQ\8G
M)J>0TS.S*ZC5M;_K&YM;VYC#H^.3TS/L^<4_NT@ I"3_(_^/=C%>V77MZAF0
M4?ZSB^1:P+\3&,G(;TI3,#TPHGSES2PH\XZ*Y6%J067;=2%98S2KW9M1:C9A
MN141S#_3_F/9_SO#(OY_6?:_AOT?NV8!M*0D5P^/E!$ !.!Q7^-O ;[^V,D>
M;(FI"<G9*1'W!'.F/:0P .RJ0A\L(IYA2RZ=<(:8XK7,<!(TXO,*KZJ(5C7J
ML^*?CLO1F4X]?O==N$QV\KHI^&%VT^>3058,>R01X"+%'ZAJJI!]EKBO9@7Q
MN9Z7KW>KS/UEA_UKHZ[HMF%S?S7S9U!X0)P)O&YY#(+QB^QZ(#N<Z:FIZA8&
MU@S]M 2'Q18",A)33AV]<4?Z_+4&C1[A@7D]7^I[" //,!-3J* N\N;A\C?J
MFJR'$H2YV6.KM[7"1 !<!HHOT2,"Z/Z6/=8 BW.LPO+X@%)W2RX?IDJI=4@>
MG/%;CX*$&+"W;$L\.US)\;@U(@ E+D0$1'Q8O),H/ +E6'W=ZWUA<H'G*TLY
MB2&= D5J_/Z*>)) H#9.$#NH"8$_4ZGH[B&HW3+$BD^^-X+*ZC72,CQX3=6#
MQ^_H76K%'+%4XQB.H):C(%%%'*O8X^1'C?I- 'O W"%$_/8@%,<JV[Z?Z%R%
M2(2A$XSU&.P1T--H_O-WSEC*DAKMR>?F4@6A#Q1K$R1W;\P$Q5:TM&B)J:T"
M\B>#@7Q;X\K//RGS>L\V&NUTZ_XL=(OO\N2V9&M7@9:RG&">ROR:[1N^?,X"
M'K7805'%^+V^4)(7MIPPYF&C@5H"&C05E!\G?/ Q^'(M_M;_*KW8:71N%SK!
M?%9'Q AR*(CL1\)BWWF\@%I>I)Q^ &)<Y6]NCZ;@8N&'^3"Q+(_59B\47TG*
MI[JA,F_+R5Y0[%2',%N--Q&02NY:,\/#I^ES,=& P7]6URR,'+ZTJQGLZR5D
M;/1MAZXA1"WSK<74MY,ZEGU+]#183/5^)C53\H(Y-=:>QJ\[DFWPQ*\@Q$-]
MT<YM!]52\3BC@DTFV[4VWI/9SB.2B1_Y.KQ#]]3!/W\K*>%^+J?,2G5!V7'R
M&-+.[)CV!2&SR5!'_E@_D@IN2=&Y9WGN]E8^17-Z&S(U_C+W#VOM5!-S,$/;
MSU)D*X>YPL>LZRI/:U-1>:I=L_*(PJ)MMN#\O,!\!W:S]#LC_8@?VSI"FV[B
M?[L/<I3Q$JU !T[/XP-6MUJDMZTE"+1IIE(2=V?C5XJA0O"?JB%^OZ:GHQW"
M'\I>]Y8%OIA>:Q";K^#YD?I!]N#%I-G((;A]W"5Z>SE*S=LB@!D'#?Z&^)0(
MLSY9KZZ8^]O6 _?2S_7A&!/J&S:R!-P?O76=NW2;:N<%NV($F9VV073#P#!7
M6/PQR4UC!IX)B=RIB<N$MJ5:T\P6P=F*J"">7^W7!]LSE%I7X_?DH'$RV*J7
MF [Y6%(1&F=@+"P%Z*CN%9B#DJL]B.9WOA-$!+B"=YI-GJ9H8^[<Z[R64MFY
MQF!LB6BY6ZY2$_3M!&C2BX%7<LB;53<V:ILZ!^_V!]1>/RG/4>TQ1'D@X$,O
M_NIP;%E-Y:[*;[TX8QU*'G*ZK6$_W Q*=E88N]'C/Y[27UU&V"RG DX +TO.
MS5Y_'6[SY&M)J/&]^Z;5YZ3BHDGVU#PW3SVFE C@.A.^_/J6[?_N@32G'\0(
MK%I?I-M<B #^7/->2T2% Y)O4E?ZQY[CS&AE[O[P5OS%T6D: "?>LHS'$@''
MTB .,%G;ZOH 7;66#CD1$.<#_1C"B,R7B+E1<; 6Q)G2=:C<'!:'P7]3X38?
MQA]+/-883P-+=0JG\,S8-U<3 9M@2T$#RLJNH+'Y\]*EO#2=@$33D.0;*;:W
MM>V"?;^+Q% ;@,5='MU:!+0D!2+W'-&7[>7H(UL,HK+0>L$MG&FTPE/P]SBL
M0FYG2RA>(;WW:&]!6#I-8TN8-CT16?7GC64]--GR_6_GMF'VA2(O/9':A)#;
M76IV.D42I'D5)=$FB8SS7(-/!GF2MRWY8X$,+>X'LQ(V$=A0C=\8\OQ/=^DZ
M:VUY1S4[%0[$E%-Q#<(!2G__^OOW"".G6M!ZP%FIU9XNJ5FAYV,(<=O "G=Z
M27J+%7T3;;;4N,[*VRNXHO/::F^HK00*,N-)H!;!*)YJC)R$ =NJ-D]_.S4$
MX O4\Z;R-C19&OW7@9]DDK[0.B23AS43 62]5TDP&_<$#X.XJ [3!'80&*?&
M!49+6@Q_3=<PG7_'W%IK](Y1LVOF<10M;7Q@U6(R-WCO*(FS?BQ%LF[GW"-L
M]<VC-&_LE/QNU%+ZR!1\G,PZF41M2A+7U<%''KI6I\'UM LC,GWC%UGI,^VI
MII9.E00K6X?*;? ([@&G2T3NVED%91>FC%.$I2H952SY5-G0[FI!@=;SX!;>
MBIM1PKGXM[63W)67G6O(3=N?Z#.+*373T^_N]I=*\&CY@/JDH&<!M,SYLB!Z
M(J!-4NR>Z^+MSPI%PR%,LM\[W*]_:#CN$T7,C.T[9=/6C/%<5,)@_5NS[T.'
MQ[ >V2\XSFN'H(;8H%)<\6#$95@13WA&)7A9=?(E[07$\/P NF5=7+-ODN4Y
M5/-ZP^_!4=V&;?K3B\?^9OELOQ-#QRQR(?X@ MR"T%%_0^=M3Z8Q"3V#VX;<
MUHN2Q:OP*2:#Y48+8<IV*11WSU? 1 !Y_Y1E+IVGEXI#1%5(*0^C[1#4USQK
MYW>'"X*_H<E)>+;D$T.)_#26IBL!E71;F82\-L*P7$"%^M;7M_^C2E*S:D1
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MM^_:Y73F:+VPZ2("OB!GPQG-LQ[;+$-SE+<2_6'&T=WU\D&R?UK P[/:K41
M55UKLTDG](:H3X%!C\$ES[.@(S?#V[\.F=3>SGW4>'.?^KIHBV!,3(LCY+J+
M/X2M2?$'=JG++-LP=L_=#NM=MC WHT>QX<HZ #A0KP+,BQG[5]/FXC>NZF0U
M5G+5,!%$@:/*OX[.+%R5V&/H$C+.[YZ:'OHF%U6Y+G7&^:MD!T0W$\J W0BZ
M?+X-93J1FM&:,T%,RE-Y"HROC]]]-78<=Z/"\I90ANEOBLZ<:"UOVV*JKH=[
M.]MAF48&N2[*XC.-"SXB(;Y(Q.]Y?&U5GI3[UTSU+M%G.QG=))RL)9YG)D(4
MWV>?'- Z3CZZ1QY3<&!YH]?"_%WV87$#)D-1)86:Y_S+&BGS\14(013B/Q$!
M:R\,O\"R0N]4J W."/6%AFM=#7]F]XRV_\<TRC-Q#!-XTO>0A8V="[ZF9G(6
MJ0>:P6)3__L:@7G/! ,:=:2>+4L$I,1C"3@H5J]"A@&]EAP3303P_P6]#(6(
MA',NI4YP8(B L/CSVT2 O@/20T2ZM[#T0VHEF@I W["VL2D1PX(_2%USLBJ,
M0Q) G"\P8^*0[,GV>VZU#7Q$ .<+OL7G2X-N:Y6L?:Q_>\]+,#(UA;04@6(<
M,"@#CN5L^:0[Q<<W^Q1V>VZAR^ZF/CVFI#Z(SR&QBS_K]W,I3YF#^^;2J=D7
M]$[G[_;I0O. ."::E5 5]:Z,\K/X/<F* X$)9YW]\GE]'^:GQF9'-U]_$/.N
MV_=5]4GSX,EYJOR2(#MZ<C!GU<IE^':N,XNK>5?ER?;1YIV#5TJI4C?C_F8*
MY@30E7(?:LE(3S6T4!*6^!DTA /K[H_4A$ 9!WX$YDM[V_/\9IV_B;K[[,EN
M[[6;+\.=6E'?W:!H_1;*[>"PDZ2-6%Q 0/&2FP]8OP11S#[SM2E37##-T8CJ
MYF?'UT?)N=YF!-KP-EMR+"E*7?;%^%?$I!\ONR'ASWCQ)!E3#D=3AZC=#)-[
M:"5YC##/%0#I,]%[E ^KJI[_&7(9C)-^42[L'NX0@1+)J^ :,Z++U?<_M=.=
MXX@+Q<Z\F>:]OASY HA&PZ*SSG9HMK,G:SS=>6?GYUW.C.9D])@'J(ZHW<TR
ME6927T2L<O#$IS^YPH+^."4TXAU*4J5[B+ (9'6IWK3,C;M]_6Y!YK9>9NHG
ML<%[053T/E&F'*B<U>%IY[9\=4S4>N7W012;%=:],,<PY9GTM*J5%;R)Z5/$
M(::PTCJ-E&<U?J-TU_.G\YWF&*M//I"V!P1.-P)WPK/:2?F!J-0UBBE)MBV8
M0+)2FG.VSD-/G<?&W>L/%5:Z[+$EI\O8D!(+,+MNZ;;B;X_$[QY2Y7+GWVH^
M-'9'*!61OD[F>DYNKM1W+*^>@F/.NJ)UT34F):[L?+='RULSY154"MYURCY.
MG7_4\)R9IUWN+GV040WL22NF!,?LLY+<X.VKF5_I")83O?5Z#]9O->.X&N#R
M++*F^G%19&INKD-V7YGZF;^R\*_R[;^>J74KP*3?8MTT-O<WAT.79CQ9 J[[
MN9T>,.LR_2D$^_2K0+L;H+$Z=$TEM706Z*7=P:\X7@QO=VG1MJV04V.<4/8L
MZBI$RKH$7Z3.WOOB215/\H,(N*$,_Q PE_T7*B:S%LRG)98.G9^>Q$>AZ\(%
MA7T;$XB !_*G]S%F.<N& !!8I>L$D5.T-2H_.#G9L1N_*$]ZI^<7*V9X5Y(]
M!X+200?]CODW89_O+G8&G8#BCX0O4036F4<<MG-R21H/KOQ^_HJ&DT=6,/'K
M)P,4_2) [ /#S^BDJ1@#$-MVD%_EQ,#E"YR,C=W!$T^N3=WO5C;X:#T?::;K
M9[N'K3U_]'"%G&01E *H8B)@+PQ=U6E5@U!'-^GYI^LQ@B>O/8[7M4^-J6IB
M*CV^%:85FGG6WE+-_I9;-W_CV9@1G*;!S_TV:L.XJ0&BT%9B[I+WN99JT6+Z
M>ZNSW;1]I#44)S$\C7P\Y5!5S\>1O*H]'^5Q<+??(DY8 0;/70G0O<M->:!D
M/\3A]UO:L[R9P7R[IM%P7^-M [XVG-EUWVRC^^(YPXV$/TP],D$:;IS,X29K
M_1+*"XFWT[PHP-.[#W\7WN5\06%F\D'[NSH6EJJFN7PPX[O#H%%9*C)Y^K.@
M"Z5<TC@%%\^_-(Q?-+58^]"P2%?_D<7.8MSKMC;K@27#GA%Z_:@K,YRO&J.>
MF)TT^"<X#-[DW1<GXA"5)J?J#TT+3*$$*%;VJ&W)H[\%87/5?$^EL_*0YWS(
ME5J7F5[NWKA8?C0SR##\3P5_AV[*?OQY3,>*6LE";I 'O<JQ_/'!;@\1(-@?
M1AYLX7/&7WJ*$R'L 4$C)R>;MPJ"J25&-,IN?8T'_%-4.# W5 ZAL44$%,2?
M4YI!.[4V*6K'9YEOF>%7%O[FEY_P>H- H1 EK&MH\')/#X[6O,^R),:I#L,^
MQV[4R$8$2(.-(?Y_ BG1A(R.^/"SWD-9A@235&3AW"H-R;2F D3^YYM:^]62
M)^45*=B?NREXV8\,@VXA[^J169+#.2%59=#0"1E1EM3X7QC<@GC%)^O58MW<
M9*E.#8D&=_"EE$XM>\! I&H]?K*^VR"(\[5/'S4)V:]!4PQE5).KO4?6Z+RK
MSYS-$\M%AH5*/XYSEE+R8=OGE1L%%>RK4C$B&$@[1SQ.<X3 BR@($JZR<7M_
M>YO;)-@J>K'^?(UV(=!T]2_KD2^$'F>$TJ$U(HP Z6W<14(\I?;2B(#"JF_G
M_&3+HL!$+T-.6.' H8KI]]MPA_&P=") <JA?B<. /0TYR6^]N2B:T"DA1_Z8
M?6KZJ& AKV&(@Z_8@$&))X**=1U2L[%'XXY^,C;4+GZ\Z5=NQEEQ$]QNJ1IH
M1QJ:;_EAK,%)4R<K4S@_'OP=^ZK<9FE+@RM['35NW#CQ^K.4']5'2&<;2D;+
MZ5'?S,U8763>^0%(%M*F>:*OVLH/IVP?9K&-FO@R;FI[I/?H<S[5/@T;:<D?
MFK>&&)$W?S]K*CLM/8<=W#H*G37H2=>C8X\]]9EVC]E[!]OB.L@IM;$I?F<"
MW?MII6<55$3J_5Z.TJ\Z@PR6^X+Y,-\;&CBJ9N2XVG+==78Q1QEJ..E>V%@7
M^K+&@X23-W:(:O<![ ,1 &[A"Y7(63F++4?P8S-7;7]CG IY)\P8L;J^+;L[
M?B*]C7E5XT_I63@P^;IJR-$K'#65Q!9W*8N5F:6I]QSU[1)UZ;ME\?GS1V;\
ME$CX3QO<JXR5[RNOXHKIM?Z"+9%FB&^?I_@^"A235\RRJ=EP!NKRK3=5]RQM
M%UUPG2RQW'_Z>#5"HB]<(%'SUO'P(6S8+C3#U"DI9=K(\!06Y[\1,/NJ!^D*
M>X@^2VYQAL96NV6''LX-A_!D';J1,%TP?[3*;#3WZWX>N\_QS;]V_JT7?*/E
M5R'CS\"/D<-7,_&'DP>SSKL0=)+<7/G#L_9@^9^+!L-J+:[9#/)_I1I5'4@W
M9/H^:)Q]FN?M;O[#;39%! C!)+T3U]86]HI3!.%-^/3PF[::IRYRRG;HDZB3
MZ:[BO:9G5KKB>G$<>Z:.BT\B9N82[TIW<>\)G3ZZ?!1=-2Y5Y!@_ZU)0.^&Q
MN"]?;RCUQY36*:F$)MJ];0%$]F%R=Y$4GX^@MLPSU[WB(#$X%7;;&@5D;?^A
M[(+5>=D>!_U<;5!4',U;GT'/I?#>)3I8C= WO15)U5TZGF>Q]FDO(HK,F>8[
M?QBU/:O6ETAD',B?9ATW#JVJR='^OM.F%S0W@2Z%+\W0V,P^#N=NT&<;X^7-
MIK$:YYK^6OWNYH-:O9=?:M(4UMHC-M[90-J2]$Y=&[%Y*W,0*M>+U_E"]2X@
MO6Q5B5K'PZ%I&X</K]AOA,8(L%HG<^?\7FH'SI2T\0DV5+6,-C$[AM=1G3W[
MH9S,2?'P?$XW2<FN$02H8(D L&XN<N!3-!BW9J.^E1=AA3J,GB9GF9V9568,
M4!PQ3OQ\^=;+G(>D=37^]X2;27S>BSYQ26ZSI^WPX. *5_P%W]S7DBRR&&7\
M.!3GBQQO^4?"Q8]9CS02G\8)V%H4A .I+^Q/[8B U%<:$;4#\&]XPU]7S-PU
M^/\P\W<G#_Z'F3-C<,XKQ>BS_[Q#>$11VR*N<7)"V;.OP07BU_JO%PL)Q4>%
MI#M=7G8(8.JJD^>B-FG%W5!S^P.>>B*@Q\TI,4L.(?10S?RE-XZ)"-B%RVI=
M/X.I/-D]GU-M_,"AZ)"8Z#?X&).AQA!<66K;43RKI_YG]($G=5::+L=MP>2B
M]%96K:5.!?;3<OGFD[)1"BI;9=./S&\I'FSK\N<YBSCH:2>%CX*JEZ(1,H'7
MCMKR;\6O2TH\:V#G\B_@.!*N:K#KM!< 4#S9LX^V:;DG8-Z/H+^"8%(N^3P8
MKT8,0Y+[@9R$\Q$7-[=Y,FI%6U4/V)^_YG%*T?+ $[XCX;H2H3?@D+G[,5[A
M \7'5252-;3;QQUG=Z%["A]^ =*H2]>\TVV[:6*]/SW1Z,XQV_(+";Z.S+7W
MB&%8X:?N M0V1/_9FC(S^]IC )]]_@! _655^?)[(66^[&0UZ&[X/($[G< 5
MTW;QIY8K:2$_HY"R4R% IFAXHU^!_9W>39(ZYVGZDU.SP@!:L8U\UE5E&9)N
M[YV#BZGG%^4-,E]M-'\+]F]7TQ98>_12)CHXC\MWO1UTCNH*<ZUP55VR.=@H
M[:-]5&PR"_</AV"GY[!U[5S).?PQ32:>\L<:3^;Q6<;0E]M6K^*>)T?RA%N;
MCX"JZF(J:AAFH.UL6?Y'L]96,S)-)MVCO3&#;V1*4MN&->![[(N"U;JH]]ML
MA->73?"C;I"GY+O\R<@*<"8;6E^X;JI T&8,F,O]DM)5+!^@YE0[A(U_L:OR
M9>OP$KF(Y]I;MT_Y(Q(;D9"4K-@ES6K&L8Q,P&G&?M4_R#YU!UN/'QS0E2F>
MIAL*A[MII4O(BGUOV^K%[?001+[-K/,V$$P/2]U"\7Y.5YCM5Y.CGR'3!?Z;
M%)[\Y^;!C<#HC<=6>79S]YLQC["@?O&2.>WU6(OQD'F59%UJ4VWOQI0F\ 9D
M6I]DHDDO=7CVRO5']$,\>U*BSPA2:(WRXBV$\(2:>! *)#SC9G;41$,^ ?[U
M>#=&U<':>[O)N3A,X_Y6F!,UO"'T]#R/TR0>%K1K!IF-'E\U3ZS)8[I<&6I>
M^3MA\2K%F$WFH=SY"W?=]XGU1BTN:R=JP7SC/02IB15\OIKY=Y=JZWEP,%M>
M"*V/V@.'S'6J3^S42D,K]5=,L1PD%_X'4B66''XM<'_)%G.6?,(;/-8W*;?
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MP#9J+ JD*)2/G&^I6?E()AZ4#]UX'*V 9,:&#7D5"D/.A=6D,.C!8K,ET=3
ML#Q: <:<IZMP452/]FJMBJ;@*0A7P*7 SY58%]5X'&=A- 54'08%!'-^L!I+
MHQK?9FNC&3S+"13PR_F[RE9'-5@O BLS8E&B5( OY\,Z )\>BQQWG3L[1*G'
MI0!PSGU5=Z5;UUNU$WK%];0P1@&VG.-)"-*UL,D.A&@VG[S/3UR$"Z1"GQFV
MQ:52#S1_!K FYV%8W^9\1]&.AOV\/TP,IOR0FD'VR1DL2,_PJ&%+-@V^,OAW
MH(#C.Y.-N-H99MDR=HIVB7N+ZC H0)US ^6A#M,P:)1(@*NQ"9/1^#8[25K<
M%-=A4, WY]FI/&FJF^X&VY=2ITQ+/'>'Z12P+-[(5'@Z50-YE'UH43.+./>=
MC0BIWI161*\ ;,X_5+Y#+7;Z[U/0P#8'=@.C&#5( TH%,//GQ@Z"*<YI:AA?
M ".5-:%O0CN7O@% F44!V/QAL8/ 3C;!?JHP%0UQ<X@A)SQ&3'FQ+A#6PKJ,
M5P'TG.?I,.BS.#6#"V(-_\OA+QI/*1 K )S?.'4(8#VDJKM1/*H91 ;-J<],
MG-LV7DBD &#.!Y7>1!Z)#4.YE*N!:P(<!(7NV /@)0@/ _@NYVVJ!-!#6P,'
MPC6*]5!DV*0PS;>)M&*RA,@9\LK!+*-7P+3RDIAD5YE,0>PV$?"*Z\XUMO6P
M!3TP8]@JOM>GF$H!QX(+9(MP'(9R!7S:X5L3N\S8IHI  ;&<DZ@0,3V&40*K
MX&:F8M!4"!7 RSF""J]TTB@>X9!<W'2E0B?+D+CB]-PA3@6<E8_5[5=A,C'0
M5;* 1T/?%/H;3%<,6(@YPZN];[<FCP+<.<_18;CWZ0#.J_\_-Z_X1\SO9WAI
MR+=5+ST@^WS"B7C<]B0,6S.\A#"7HD[T;.6O8/:;K6-')"*%BL<V92G)YE28
M<"0",3,G)??V*PB16Y((YMU(^4B 1SS!/DTD8XATH,!UCVBYC19U+0<6;+^B
MR;="_FO8"@6TKJV9,OU*%@_VJ;R&W5"[ZMJ=KI"O9/8P3B1O]:=N^KE8^)U]
M4O83&$Z99[BY]VFKGD,.'G*^I:845<$B?G4BOHX(ZO3..N>]-UMN[36MH\0^
M&^HI$?$U4*+D4>:B]'D9N?@0A>E"-=&2QYTK$RWDZ6+;XU%(8Q5$->$OUT&*
MJ:7$X6>HR]0YQ"E_\T:%8/^TM5(AB,C%1RWC*Y[(5DHXR1+]:%8$]L]NJZ$?
MT0?(PZ\7V+VKE=D1N?@H2C1\KCM8SKB?]'\59T(>&;K#SD*\B2VT"<Z;) .)
M;8M#/)]//";F*/+E^$MHF@FU'F0/8OE,:G5B!#U*_*#ZI07#8^*./>P(2K#"
M7W!HO'U!?<.HO_E\$H@C0%*EZ)31A5!BP+!%//$H+>9IK2LI6F$"]> W0;88
ME8?GK3R?N1Q^>XPL?(^R:RSW-L_P GDY YOSM\'\@<\]ZF#63UN5#VZ3LE?%
MREZU4ME!L;*#5BH[+%9VV"YEJ>/0X)7DKS#0S%3(TM@VJ#YV8=HO1IXP 72(
M[X17KKBK;%M_B*P-QDQMZ"'E$[ABS^BNOV)8_LPTD(>H6F&*O[").5DN(=DL
M&"5Q;5 [W$ :]31B%U,Q""J$;3#H#FV)(SEN;S,-9W%4&Y06COBST]Z[7+E/
MA[9'U;->D:J)T!:I>E&HZD4+5>T5YFJO7;DZ0#994N82-,,<(V:N86":N-DM
MTY>J4K?!M"^^@]P!8CAM0SZX#<KV7>(@.Z]M07@;U)UC]D1,+"8Q=(=L;Y?6
MNCRZ#<J+79B3Y<,:_T29;:4U+XEK@]K13HH!=3FQ<)!>>.(U4O\ S4$S D>H
M%T4M@J-\8 Y>$"^R+8B#037V$-N]EF7WU#45C$N1M=2^GXBW%F=Q8+CX@+93
MM L>SPZL*HML;(LI72NO9HR<28TY][$U],4(>"IU^H9L']_C9QG#>W%+H$I=
MHX:UPM[@.BUE@PO(:[<I 45PD]9QG'4FQA:_9M3I>YYP7+)'[,V1C2?+Q*SY
M'D.+&$UWHD/WT9UDL5?O"*+^Z RI*JMB69YQ+$GF&YMX7*6$%W(U+^FOVTI5
M&<*;V5_,UMJJ/G8A <3Q$ ?_C]W*EEN=O*V01\?!KRF[9N(L"G61'=3'^&Z
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M<'+9*W^\J6XYJ/%&)&S79;1J=J#'1B;@ E%?)6C>_W@B5&M)^WP1=8\?;=G
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MM)Y68EI4IY$K+.HJ[_/448G6DTA'I/=<$QUWEU3X*N*C,Z)O^ I>I&K--NG
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M)-6YK86BTV-S:T,ZY^5&+3#]QAJJ<$+>*")V!?8T3E%8ZGIGWP,N@CC%T65
M4G:F-@O#S6J3L+2R%W@1A[%J4FJCZ))]]H:TV6?6 L,^:ZB2^(Q:D%V<99+>
M:=?"Q(--V&,2!#_C-*=^NKR_<I/E[.K*W>(I>%5'K@PKQ7$4T1@3>[%$0XH
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M3I<&/V59-(QQ.DTOE#.;(N6<6@T>Z8Q8A=VG2@$MF08<VO&YDLG:2L@+F3H
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M/R:_QR3.(BOCU<K^V&4R2,TUE290YAG@2GD85SJ(4"5@3/S$WGN/B^T%A?9
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MQ3WM$EAY06W_8J%Y59M*&.I8=64>XSS#PA[Y!B=NXG^.9JOF_)E=K+M.:S=
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M-*"6L0"I"<AFK\1UE"0-T_ZG&_HG^L_U/]'_F-,%./V7_P]02P,$%     @
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M5VE,%FEPQ;4ZK%QM'6/)>.ZQD/\ZOB'LCG=D'(W#](XE[93_=DZ#5,P4R=#
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MNEN:0U6.<N<TBHFJ]G\0CX&57FH,53G*-=0@XIX5GOM5[9C1KBKJUE"5HUQ
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M1?' I%S_7+O+Z*G0DL%W6M+,\J-/JVH-[ENZ?.17B,]\!1:"JE$RD*%EC^\
M$T@#Z#@5:_2VD&@FHG8JZ6CP<LYW@,@L_#[/!-=1Z-L?"\I4>-GG!SD:-!6
M/CU*IT4M/,6<;V^.EZ*^R[JE$QD=D(PQTSD-,T5]YQ/:"SB:75'O@08TH23F
M!Q/IAO$8!5S3L3BD)!NS'13> UZ"_/ZV45L]H4^[$L-@D[:.!B_S_J#@N6K=
M+JR#-]Y&F ;!=M%Z>[RT_7!=M]M%VR5W#9BM/<KW6<I7^9VT8*QT7> 5 A@(
M/K-^T!$M3K*WY(F$J7FJJ=KC%0[HBI5><G1@[AXCEMP3MCJ)&(N^"A]=S9-^
M6V.\X@%=(='(C(Y'U1Y2B+8Q3A@3'5Z%@:XHP32!#EA3+INS'F8-@J[ J"4^
MX#M9;9F&F#$T)'@5#@;:IH:W:2AL?+_3Y%%<ZO@\O_>>\P.-PK*G:(M7V\!:
MV1HI'%G.%*LNR*QG)L6KA3#P+N2@S0]T+>IR\1FA4L( 6\\+V'-$&!9-9+B/
M<"F+9$PT"7TM@EHBO#H,71$%Z !]9G6QT Y@DQVAFD-_L]X!6&%OBF5 \FIP
M46UMC%<= J[EA@.72F9T/$K1IB9_X49+O'H279%028L.PW0^EQ.<3W6/SB_#
M4V]-^0Y8XE=C3070XA6KZ H57"/HX-V2Q*,AF9][+!3VJJGOIZLT$)%&_.8F
M:ABHP8/0XI7"Z H>7"/HX)58DW9ZD0>$D4=1/>6)9%XU5U$L'&IF"WXEU#YJ
MV'6$5WRC\YSLIBMTC)N"VIP-,8MV=$5*+?$!7\E,+@?=73(P*X)TA1BJC4$!
M=RIR]T;J]9$DU"_5!JJ$\;Z'A_%._JW2W[\?PWK'O/EQ7<^89'<N3^(WA,EL
M-]#+H)K^<,. [32$OJM6V<UR%4W3Y#%B],_=!#<!V:0[X(!AF$J<1$XF8[=$
MK:#!CA$>&+&J*IQ$2Y\,32-;EVQH(QYK!\5M[$1I/>UK]EL>B!@[VK@'B!;*
M<0E(^%:G)<*.01X&.&<WN0:/IAU.28 =K3PD4([M;999/E52==G57'S ZYC[
M$_M6OJNG-%M4;(+"&MA^,?^@NYC?W?/_?#J_YI?RV07_TZ>;V_-?SZ_O+G\[
MGUS-[I R;F4&SBW3YMNXD@#KF4)ZCVG<%W8MD"_1!E4W7ANJ@CFPJL5\\G^,
MHKDTS1'V1'T2WT6!=O=1TV#?B.W@,$N/#M!'QA>F&Q8M=$]SE4;85UP["%KD
M.V"[_];-+T^! \@-J"'!OO3:(6F4'7TNW7+U\<^+Q&MG?"$.(IG((V=7M]=H
MR;!OM6:]U_<@@!;0L;HC02"J&9&02Q=P7J?S%0VID$R42C."!J7'OMK:HF>G
M%W08&^)9+(3XU]F>"^!+VM!V/A, !,N-L>^X'3%LRGO(* H7F)IH^2#5YAXR
MT6$G\K+$%J0%]"5S-_(NN+R9*WLJ*J"O\\P]\0E91(QL\RB1^/R9R\V534./
M;40-+IE,AE-R5092UH1P:(P&@)$^BIU(S&Z8[$'_![R4;*7.9\X)/XAH[Z9*
M O3D95V&A5)P>TA_SB -R5(8)E%!Y<L?9'^O-4-/@&8'8*N0!SP3"X_EXOWQ
MQ(NIKP9/T1P]6YH=B%JAT;?N.G=G-$@3W4.>D@ ]HUH_6&J"HP/S.Q$90<E\
M^L3W\"7)2I3.%HV7*\,<LNP&/6F:'8B=E.0JM/D(M'BJM>X(/:W:(/":%(4.
ML"Y^0V21-5O8H1V@)V#K<)^%*P8=R"ZGS#_>.9!8S5;1FG.GD,<1.%127?"[
M+5WFI0/\C2QO[\DBB=-P+O\59*J?_W<:RY#[[#XLLI"(HKS\+TG"Z$.:B(PD
M]U$6JV _/<?B SWW6[_AA ,;^FAMD;@(WN/_"E*Q9;7*86L)&_Q#Z(GM;'TB
M1E'TBXKMJGB1/7KADL27H2:NK>)/]H.%/]FOT^N/YW>3RVO^A]GI?_XZNSH[
MO[W[5V\=Q7^=G/_7Y\O[?Z '?W5+:P(BQXK!S9F[5R01JPMQ#TL@UI@(H\QV
M*V0:L;A5B<HF6&0L^!0FTK(.P*/4UC%,*B-*I?P2^^5TFL@ 9 -([ Y1*%:^
MZ3.%8-%.=HBPM$M2<FA$LCE6V3KC6Q=M*])<6.K:FSL&B&ZPU4V/[0*5_';0
MXP4^$6%JT1XYZTVQ_6B[(*&4&/WRH,C08\+%0(;M:-L%(Y FT/&J)^4Q :5J
MC^U VP4AO>SHT  2ZQBG%;P+;-_:3E/,5D/HF.XIZ=#XFU7CDC!^KJ$U8302
M!@&6H'H#6#QT=7_*&G\K,R((>*8Z4 #%V,QB7L]2)HQLDC$98GY-OLJ_:"]<
M(')G=D305(6JPXT5M,EM-EJ[H]>@=V8_[ B?0B$C%04 C:&W+:@(:B@Q=@")
M&1(;:3#PJ T*2T":U-A1([T042D#?8G;O1O&]Y'B&BF9?_!B46IV);QDI<YO
M"3]JQ30A>8!M)N@M\:-E*'LQI',>_\O8,2K@975?(*"/-MUZ=4OBA%$_R3,J
M3;]Z;"[#B+N=CC3=8<>W#'):,JK+5;"SI7 XM(W]8<>I#'.Z<A_OX5Q8"L\$
M9,<C$!OH\2[@X86"#_JH/- @&#"JIOB7(4_Z-RSR"9G+"#H.^B-9>>P+2>Z\
M@,B\2\4[D1P?L\6"L%+8=+:,*6X!@_2,'O0"NR(,J$6$&[;(=<1BDJ4(6P<T
M44%JVPEZ;$S_*[=:-YAQA!U C@=!N;47].B9_C!KM(.^W1G.D !488?1[L B
MFLRZBH8_AT>]><N_S=8R"/[\F3"?QKKHQ@Y=H8?@#'+EUNK)[9D_#,3:OM#C
M>8:9_P< <N<W?9NP*T>L7PW^!WD7/@^15^,>S_HV(#I@TVIC?R0,G8H?\>+'
MBR#ZJL@^_*-%M,CT[M?)Q=7L=Z2LPZ7(@ZU05J$@+51HIB#!"[]_/U&.\LGF
M,U_:+\-M[JBIG]"GK)Z54;XN?;E3&$@)9-.XU%%CZ#OEN'8_MS :W@ X[+NR
M>(\,?1J0"J_WT6"S<9RO.>,^!Q\,8ZH=?4R=$8Z 3Z7^U6.AV@K;,VY40"*-
MX(Y@5J1SJKHM&(Z[+>VQ7>3VB*->9>B(<H$9X=R=D>R_E^%9?G@OI4Y4 PPD
MQ_:_VR/>5@H]:"-D4])J\M9I'!.=31I*C^TJB#IX="I]::.GD#+WD0-5Q 'W
MX8S[(/SX9Z\B![>3J>]'*9\Z?.(0^J1/U@"CQG;XZP"+"5>UDE[8'+\,G[B"
M(T;M#A45,FP/P!'P;U'+"P/^AI&U1^?&DB!F2G07O1'P;]?."QL"Q3D8=G6$
MTJ/[]HTP''2:<G"+EV?48@N[\3:VFWP[/;K_WPC ZC35^0'MB;"'*":.S?8V
M444E)-]G*1>,>@\TD%>BOB-%T2FZ ^*>AH]6IYAC2N&HV)3J=YH\"L< KACA
MA:Y</P0YF!K=,;$[_%9RXN,\IB7@2OR[&-<:YQB++M =&\=8%_3Z<O#(("KV
M"!'%J#Y-XR1:$=8)9T-'Z*Z*(Z -TATZYG!G@R'<,EQR6!S#(:/W0H]?"D<A
MK#!]Q /YZVC[<L=5LO<  >@,??[S$TH1 N__,Z6,<"'XN$XV-X$7)OS4*IQ
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MI;+"G/Q7D#D=<HU-Y__-A9>IJ<@B$I$(SS<1DVWS0O/B%'(?W4B4%$\Z&(P
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M2Y[*'UH]E5^=B.XFY?ZV?LJOIKL>L8J^;!F6H&YYS)/[B30QL5QSI58*SW)
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MZ,*T_V(?IGV[[7T2B\;'@.WV?H\!V\> [6/ ]C%@^QBP?0S8/@9L'P.VO]6
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MKBZ+9CJC;P]F,<CK[.:9_EK'[C,I('^KCR?%)32,DPQJO8[0]*'NPLR X*M
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M\HSUJ 1SD[0C["*8E\4%R'#8!FATPK"%$2.ZON)C6__5C&/2C$A0H7!*T-E
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M).SHC:X9UZ?J_&H!'=POXU&:/%4G8$WPV)\4..![_DWWS5WXR[*G/_I'+TK
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M(BF^N#'1;V"9?DU G6ZZXZMO;6OOA[7:]&>S=&'8A#LAL&4.KZ7(05YZB*1
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M2F(C1;WZ5J>Z<7%B[>YEJY/P?)/;6*3+5MH:L"RW7#'\ZVUL%:S*CQNLRA?
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M?!#COJ Z<,YB8:/QJ_CGD][TFH_?XNNUU],JQFI7O%UJ]% \00S"/,[NP7+
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M^YZE)33;>OGTRACTC?13M?5B6U5:?R!6;9LBY)+#J=8 4]\2XT(>EZ6,596
M<#4K&PD?A-"_R#/)>B4@H!.=2WLHM%SA*LGB2X.O-*<#=/=@6YE*/)Y(&"'T
M4YP"E+TJ13&"\:KAAIK>WU1R63YDAB>F\!^.4[7U<KL_-M2W>BC_WDNS;ZUF
M:3&]L'O657?@LEVNY,Y[6'TP+F<U%4^2R>CX:DJ](S?V[OKAH&?;,R6()4X2
M!@^UI7>GNY&+&R#@>5;,<8]3#!UYD4@\.R)GX7-L\]'W)-VQ>)/2331/804K
M7/K"!50%C&7>$A%&9J^V6Y'(7D1[$!0Q,XA]1=]VL0KN<&#D/PD/YI6O;"6
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M3(E1"1J:1F/0&9!>'\L8(X](KB]-P/*2BD)AECE5^8/AO**R2>2Q-Y6AF(B
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M%5$R^N:/U,13&UO1.N%!QG;CZX??$*C>JQ/J:_DG5@3"6;PT&I<D)O4EUJ.
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M% 6ZHNZZP..$._7Y?Y>Q=786*[&Q^+5<X?W8!,3LJ ;$(V@,?'&0-@!1>?H
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M0'^(1?:5YCE1/,(8$8*05TS_Q+=OMPZF?H4<GB7Z]?(=4$L#!!0    ( "R
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M1@82@9SZ,(=W\82KL6 ]E-E-F4&B?<AWVT?;8L>[T3Y*_.6.4R6I'2L/!C+
MJ!A7,.)31LZ\V%+J-5>&4ABJF7T9,^\+-9 WW@BW^0X[$Q8W$19'AU].&BH=
M 8EY:5^^ACAS))" RI1G85T:*$#!S:1U=0PIH9P>&C*6#+#*(D9DW&6TT,W&
MP[0$%<704PDZ@#-69S+AA?-T9&4BN9$4'^G;A6,V179+2PSN:L ZNG=5KZV
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M;+CWJ"N^I5J5VMY_/?C9+$2H9S*.*]B5 @@P:81I,3%>&!\LDS")O%)),\W
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MZ .RQ8? H9-QZ8):O*!OZK5ON*$PH)<_RV%71I-+;6[O+62I1W&<2O<@C>
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MBW=I[ 4RCL]X-+,,ZL0AW @$MYD?ZZ2H0SR.SF1TX3D39O'"$5?&BUL5^:W
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MVL1"*GBZ#IXN!Q(=:19>N %4+QK*BC0 FH3@Y-K"]S.8,H&M*]4#,' )?!5
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M, )IY0*1*UN"DDE,Y%:6R,WZ1J-^L-X #*_$ANM-8_% ^GZF5+R8Y2$NF'^
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MM"?NVHCX(C[ZLD=O3#DH6[\48KE+GIB9T&(<KC[6-S:6FWUMMR/1]9PWE(3
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M,K6M7,,R]2Y4:NR^!!5..($T%"/J_@8:(>A/I(7!]''^,ZG[DL0.G@EV_C5
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M0QR5<FU5N&V<=O]"'SQN!(0\],HYH#;(=2H=%TF0C=#,!&<5NK,R%0JG 2<
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MZ)UEIL 2;RBYJ*\R75%I8/2=]E*?K>)8Y9B85?9H3 \F4B:#FDTU@8-U'4F
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M\-*Z9<'+A3MSEU;$9P2L3Z%??0;5\89].XZ<7]?P=C?^&O770"))?EW+Z.E
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M@)J:,KIEDN&0*M@Y.'L:Q$P[L)TBAD5I]@4:$LB(4<)Q;R[)K1XN-[*($Y&
M:D<BZ'/UJ$R=RAQJ6GT*9_!_WBEY"4F7PCJC:C%<*T*F+%M?")!PX.N5-^*?
MT7VS)]'TXR@MSC2NL#1CL>%DMJ'E7B85I;;&H&;\%6**SP6U#RAW(2D]RE*J
MT^M'8M%+4;GGVCC=R:!8S3ZN+R"CGFI>6Q+F;#SLAGX) X:!=UMOKHOF5>/O
M;?TRB\#-+1RWCV&W0#,"M'A$0$[Z 1'H604E;W6:96>WF)-:\.E((F5>/&"%
M(G=EL+HSHU0/UEO6]@]R6PV\R%U'>SVZ<,= +*K3G3Q=(&U)Y'6)J6!@)[IC
MJF.B!6AO*+N"*+3(1X^2@BU9"%4"!HXR0Y=LB%21,4 _;B8U9,^@PXR#B+$7
M8(#B.:KJU9$39&85B)7WD[+AN7</26.J2A9Y:]D!"L.F:(>@RE8UY5A3+GD4
M[= ;*D9HBX%[-,+$=% $,G-X_ W^6=T!+*#G!2)P=$6R00KOX/&#V(4A/F:@
M7>$>0+Z2$V=J6J2QWAH:?1:8^?%4NE=W_T,(H$%UI.U3AKJ%>S8?R5EK[$RY
MP!,C6&4BV(7]-%9/8G*>CRX!H6KB^"%:)]F!4RO$*N9Q+62^CUEY4K@KBX&0
M6 VG']=4)3VMGA6@$-:1$!W(R8*L6:  20J=1- =ABH6T"5\9@>#R081EH<C
M7PVC8+FF0R-1J^.B'/01H[8& E0/AQ2NG%>@/NEQ$*)""^F2[\'%.ON4(N/[
M6I\Q XR,_7  G0JW*"5HF'#EPT%0(DMW;/>-^^H#'<6#'8$*&G&(PG H(T1M
M[P>!Z(9UQ+&W'J5FU12V&PKDA$,D[?ZEPD(BKQ]&6!M^%,GUS.M!'CG]1X(^
M(C.R)UNUT6*-/3K6^X,V:US*(&_NM0AW4X"S8?^NRM07 :^FH,Z$-OPAU5&F
M48:JJJ B'YY5 D/T)WL=L;"SAJ88%DAQ1 4IBL=V0#]:_R[E* MN84\K&=4+
M/(CM"QFDD<ZH2TQ8"" 92V/7H#[&6!VWNG[=)(1J6^IX1+-4A5D1GZSY@AU_
MJ+KZ'D$0Q_F,.-X$D5<?J64>:>U69UK+ )<R!Z\HW).B.<->87ZRC-"(&>?)
M^$TA+(U7P1Z(*/7I'_,.J<B>[SDZ.@<C+U0#!"REX\N^%_/#B#?FJVS3T7&J
MRJF0^LJKH1PA^MA7WI("O.,MVN?P?POF43#/9Z9[]@'1O0*#?)P%F";)1<YV
M'MHN(<FEU/XFS!+$!+^FJJUK8"OB#X:8$@?)R$&LV82MV 2Q6H)+-DOE]:)R
M_QREWS(;XT*T_'-6!Y9H&3; D)E?7CODC"A2<L_/+F/'WOR"B[00CFVW@W$6
MKJT$1 =>\ERM$E$Y*S/(V_$Q8+#G<9#;!'\L\KX"DT-Z @QCA1UVGR<N>8*Y
M(C?,=\S2AA*.K)QLV6E6S/@]DVG[/08\'$0I7W(GC(<2F7C;23;LKW=XNC8%
MAE15-+LO"S@)*+2!9/Z-C5GH1QF_MCOXP3ZJZ0]'>/?Z\Q%S-SV2JE),@: \
MDUT<&?E=87S=K]4?Z_PA*]0&8&H0@UG(7OQ]JE@26<D+F\K8)0>.X)N81!*%
M/H"J5(65X=13%0JB(HXF;/5,UF)K:#0QX\@JFCL-\E/#.S!@WCQ:X$VT)Y8"
M*!!%K@O 8W?(H5K\:"^+=1639YC#A34 ;!I+@B18#')5GR)7%=?.1L Y5!!6
M)IIY,:4XZ!#?%<8Q!7*%8YX^QUD7:ZD2NI3=@K%$\(R+:2^(D11U%$L"&=T_
M6(%.%CHU^7T6/C4I;I$EB<DB6NU5-KTI&?_S'[O-QLZ;V/YWRD'B9U1<W&"E
MNGU1C(X)V!P,VT?D+DBP<-\8!.AD@>@49OX&HSC8CH5)#)@.P",J)/&Y]J"E
M<E*(KD>25LD!6:1'Q3ER48(<#)M$(+CW4A; ,8AJ"-*7%!1UH47H-SK5A94R
M'=^EIJ9::GA5& 1(]! H3ZCU".GF%="!CV(95;QQ!JNCXKT38AH$-BF]HCSA
M1T4LCB3WXM-7*#!I$8[-M0*)4C5F!>3\R" 7',M8#EG%36[ +5YXJM!C&9?3
MU>#B''H]ZLB%A^V/+:Q)@ !%UEP@E936A>\JB<- <D#LG%YD.MB&_0?F$TX*
M*#A+C(,E%%<Z I#$S!C,EH"#Q.!"DX!8A;%! @D#AB326E0 )ZH589Q1/IHA
MUP,PJA3 $HB0Y"1#,4T5]9D=];+CH82).)O$NN,DO"[)M5'4.V1A*#D1ZJE&
M)ZD3V_KP0X*$O:T<P&I2)?G%UN08-4Y""-W\L QMPPA4Q4!R@AH"?@5+< $%
M4*K9!!N".IOY+N5V<(P6MCP3?Z%U@'0@"YL3D7DA1YA,/\.P7I3-IO:+K].X
M6@HK91DKS")6??Q;Q$WM5'%33Q WM57%3:T$ G4F;94D*U PC? OQ3@NY+HI
M%X95+CD;JBW+$1''*"6TQ&P<KI]T/7/6,J1:5:[R:$),')B\WA;E/A<FIQD"
MRKV#;7+GEUSID5>8L4:3M&]^B!E^5^J]LR1<L/F"?B]JEK9%J$@:,OH+P'FV
MX2J3*MKU4A]-XTI<'827N7A@,&S,8D'F#*^AT8',TMI8JI[& 'LN 1$ZH;JZ
MV$%7$QTCBD8QFBY8X41)@;:B9,?;'%"-ZOIS@'1-U[U"D9"TMR ==H'E<]8V
MQ1Q@GB"F(IBI?[ ;BT5&9+(@!)NY**2G&KHH[!RDXCY6=> TY)"BV0"I+UB1
MO?&V3,%^A?GR.Y"_;:9BC$I*NIK0W^&\<I<&W'=FA<?4>\,!%)E^2?RKJ&:0
MK2X,^J&"4!1U/7+MHR&9C2P(/X;!. >JB*3W.$N<#URK7.F*<\>!X2&PE8>@
MIE9HK%EI?3GE8*TK-G6NW%]N^EF,=%+,Q>7TXM[8R/4!Z 0@&\:ZH:42KR>,
M/MJX,7F616,5ASBJ])@T$$$ :.<0M%(V+*YB0ITI4X'OHMOB\QVN(V%_0#WW
M<^'(3\KT7*(<%KMXE#&(RJIP$4,OR+TG2A_VU)EFVE\:&[6Y^;Z+?D:@!,YW
MP4E0,387<^CCM+_(PJY; +(YLR@XD/""0;_H 8$EK6[:)&PT,F67':QMA?']
M.+"_8,49)*BM.M6O:]4RB%%>&9'KC^C\L:CN))G QEDY!<YBR;)-F UY  0Z
MP>52P(G&=*>Z-[29OZ@00F"B#KNKN;:(\8B118+#P,Q!S<HS P?C4>@,?/:-
M B"Y-;9H9L;0*1P[ZIDFNCC;98V+LZ#^U943<@CIWX;.9IK5R8Y?<"H38(>&
M5CYMA)HR=1"?S<0-YGI.(5'=K"@$-(!^("U9Y@8CRB?B?#@UA/8-9D-F1-%$
M5J-RR@02@PKN$0=D(PNR4/I6A>YR>%"^3V&!1!P#LZ0H;5VI9B*'=,*BBQE*
M6<L-C7-*00>LEGQ)RF009Q0!KR.[U/,,=M5]XHGHE$V#EI(A :W--UV082&<
MNBO5)X@RSN&[0:P8)MFVLT1=],/ QBTZ-@J$ISI2&>RM,/V8X,YXY /@X"PH
M&G$>16LCB<Z3,@4+SV-*D0W3),XRD[-"0Z5VDC*% &L888&'()>=9]AQ+"H,
M1"$AJBZ3IGUN*+5!GB-B[-%@'&-W^B 3$#*S+OKX<3=>(&O%$;*W3>@CX2D-
M,G<<@I&%\H]B[&&OMT[8N5#NHK[T I12X*&-+2]X+$>X848$--!M/$3QE-";
MTA-4-"@)*>T2%#'"27P/R]I,19-HJUR9Q J7DZ$D DX8DYP!8&)0*D7-D+H!
M_^#.(EYFVPLCBTK)";2<2/M"8&T0*N<DD3X[JIV0DX=%(/ET*:<3<TX0$RC-
M'5@JEP:Z%)RR[<LDX;HYI'M0<H/,1E(Z7I7%4&4QZ%9X0V9MB#[XG!=0&8,,
M[ASOPO.QT!N ,X!?%5\+"V!YAK@1*H$HZ0,=B*7W0\5&:;FM.BV&,)_H&5=K
ME,JG!&P*]"5'"9.L(#*19">KX+!&%#Q38&A!K(*^DC#![P9IXF()A_RT)SKQ
M_+3G'<D>U]I",)4QJ]RW%WFX:5T%P<8"4%1P(T%E F]YCAB/"M* .]8.QNH@
M80%.!%JXRL:)L7K>+)Q=Y6P"K3A2Q **GJ3"J!#H,9=JTLY83GL>6_3E2'@1
MNG1'OD!S-06X]E)ETL**([I*:E$D76&MKW!4PAVBN8S,NWEQ3:4@H]&/@@/R
MH/U)FQK)PV4Y#6QNBP)M<^<\EY(12.(G6S+K:RKV<R*6+[>=6BK03ZVI8+JW
MVUGNF3^N<<W18N#[6 ^CQ/*IU83D\$<F9\32%R<Y(D.HQ35* 4EAZVANY>J^
M7DQM/H*^7YYYH /+R3YO1(^9_2*4V9>_<)3ZW#DD@S-&NJ\N[*WZ^+>('-BM
M(@>>(')@NXH<6 T$HM2"8[)0Y[ZJTL2XYY;G %,AZSW1AD@ WS%;Y\]2S-(/
M)(:0/XM*,[?8IZV*:)*7QQ>7&&K7K#?JY"40+&P@2+1[@%HNT3TJH]=V,IX?
M3S@%IH6+FNU&:=](*10Z6E4_B#9FWS-#FZT1+Y<XN:X"H]S9G'\0D?[!GSWR
M0"01DG.V&))4HD6ID=XZE7&FXFQ4%CR(>VK%P/Y3J:O?T6"YI5KY@@37%AV$
M6(Y9<#RMKD;',JPY95X9GU-/,/2!]X/DE513JL*/\2C93$9"G3?$LZ$D-E(X
MX*C0P<B- ^))IS8%AZ@5B"!(*=Q&Q8=VB*#3R68']T\Q! Z2G=T9N7O)DCNV
M7;A3+"B-GGCU.3N_PKE9V;G!A_]IM#8VMVT5]T$2/"_$%OT^5H-.]&.;&UN;
M^CG*D\=H5E=$W R,6XWI>S*.AI- !9?%L+DLA@J:5<H^I:-&6 &I*P?"[['
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M:U:V08>1,8:A)PP45G1T^N,-;&9$L5*4=CT9WZ#K!Z!#CAREH%U9QD@KK$0
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MG42<QAHV1H^3<+E$6V+IB?1-X]09G=N@Z'"'2I=6#=>>\\HG%J)V6Z[_AX*
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MWVA#JSS*/_(+=?6XK)7(U[P<R.!6[C+"7AZS=WK[00E.(K'"CY%AR+Q#Q_]
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MH![>:1I%9/L3V&S!N\R]P>W#+UD7STY%\J>CVP</=/  R+N@#E^HVO';;EB
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M#QVO8"W2[V0U9DS'%SW'4+@Y.CTF!6K\XG(*#T[PL(=SXN<AXTV5)<&9 <Y
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MOJ0GG&-92%%!(K[XPNDC2/:Y$X1'GUAT%X4B ,A(1M<]/LK$Y#,:G36?.._
MK2$)3KH9KX='Q52P$DR"] !VH&[J6S2Q+N+"'13 ,!'IQ@OMN_! !I"Q(N=
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M%3E@C8*^N:\R<?M>V;U)0K76(#"H.84/8SI*!!\D!2)?3=,8:423>QQ@D1J
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M@&^EVC+&A/ (^,,8/7YISICT4 DQ91P)0K,>,$\"GM& AUI!YB$H+ER/$ P
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M#V3JEM)1S!*]HC>%]9D>\6B7[M&VL8C>3$RBR\(88:V:.AGU0 ZA6NRLBJ+
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MG_P!?SSXDTT2N$W-9$5Z*YTJNX@8A<TU74HT1G8(MQU6/*QX6/&PXM*HQ+)
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MXEE>5]9M$/CQ&%+,";RAU:_E3)QAH:^L@6S[5E:QF$3[4.33&2%I3::PP$\
M*!9?/24JH6'OII50+,G414&90?LJ,YP\//YZ;L:9-IF8.M-P&(*KS "SH!M_
MN\(PY*9B,HXD$NGR^:3%WU[>6W+7MHJS)&IO\A%&UB?EG_ FRH+FMNB9H.RE
M4_Y1Y)7KFOQU@\'QT))BV%>DGBJ[76FZ@HGX@!^3=<2+#H9Z/7+Y]4OA0VM-
M5_*1-WY[JSA(/ ,VU,M2BI#;N^[=12V\6$_%V-W$DYW:S$N GQ0#=BOLX&NB
M(?=9 HNL3$PB[3=]SW<Y]EKV=L,VNUO_*1[=V]MXKD!-^?PT'GW_J?=J?:?+
M<2@(@5DHHF&P[XZ'JMF]$:Z'TOFM^?,NGVE4,_??,N763:9\V;ZY/KVMW]8;
M9\V;;[?79YV;V];MV>5])_,#GVG>G'TY:]=OX5GE[KI]>MGAFYU*I=M=[W U
M=IM+CF<^M/OBT\6X+Y*EQ[/P8AL'7,&= R\PGHR-/&%\KO]R(*...$ BY(IB
M'B"J$;S6 ;(GQ:#V@2M&$_V9JL0\-1:BLYJ%*M3><_G[K]L?OX73W&ZR&F$=
M5K-PO'JU^JW7[\B]ZO#-L9H5"F$NYAC4;3&:5=N/.0IU^?;YS$DA*$:S43YS
M4'O_4+7WCM8<$^E8A&]BAY+%X12[HP>OX31;6T)YDUALH%083)J348_HK<'"
M2 M+<E%/=: :J;?*IZ<_:U]^#!X<WKX <94NCX6:#/:O*,FJJX%@\<O%42A+
MP-"97M\*CYE?S]]*ZX!ABQ)ON<Q8"Q]BJJPO#.Y'$WYKWFF\H^1?F"_KCA("
M2V1K@O!5&_UMDK%%H.F5C&U!:?U2/OW=G [N#%[<"\9VE@AC6P##K%YO_ZZ<
M9_K%P1_*V%:HR//S57>7K:TZR M#EO9!<OFU)Z,EPM(."OYN*/C!4<EE7>D[
MXK.OB+<QJ^4^E_5?MU+2@R+\1;PA0Q\.I;QQ+OLT/ 1M50>2F]_=66OP='/^
M_/V"_'C%RMWY4/1ZL%UP(+Y*F+B0;*9EI#!Q8JEI6P'A"GE7B*?$ORA6NUX>
M638"_SS3=% -U.I$UXG:GW9T4378QRNJ1/^ET!R]BO1K8IA8N,R2]8#G7FDZ
M_8MIZG)O0IMB=K0K$.*JZ:?96_.7T6N/AM_KTDY4]%IGYOK6H3G3/2<G.@?=
MY_*Y*(G;6\.&F PJV7EAZ4(^Z<DQ>XD9.X\8J]AN$M5_A?+V*HWGQH7/0]8>
MJ03_4B;XP4!X+:\(H%QV<#G4?HH_].F&Q@Y%=IA7UQZ#MMN1VA6\-.$[C<DL
M$TT]S:?Y"*6.?TJD?@?N?Q5/3+@XDT]RO,B<AGJ8++*Q/6\8)-M<?MD<DO)A
M#LEKS"$1#G-($IE;L<&!&/;1DAM]\N<./<EF(@T]^5QIGM?;L%_X0ZOZ]7/K
MHE:_;EO#[5+U;S>-SH]-[QN,,PZ$#X>C%@RN[I^UP*'*2#-36*O]UQC)LI%Q
M+-NA@NA?67<J3+G+\SE[*LQ3I_U#O7@4I6;LJ3#!F/@_CN'@7HR(803HV:@E
M-<M>ONV+^*W[RK*)%J&9 IO<4%)G</P-IT+7,[G80ATVIQ M%4U%';3R+!M=
MKU=BI*ETKN$EP<!P=R;JWVOYQ^N[GT1>.M=F'P%TMC: *D#/: 2)RI4H2PVU
M*HYE4U1L8)5NGIK-A];O7D-X<\!:'YNNB2G**I'L-&(;2OSO[Q=&9:#FZH,W
M!Z7J^BBU>N"Z#;C;EMC\5KWK?U'X-P>X#%#/]Z?BTQ>)W$S%USY>C)E2Z^_*
M]W"$>4PO!GCB([V6[H@)$[H+*E'^[>G_?.+>_94YP5GJZ"SA;D5E0MY'S-T)
M&_ZT!X!W58MHAXH!;5<R,3BC?*(;D=4#?). K\NF#_!,%IX<E7MT%S[A]VIP
MWA107WE+;U2J)3Z)<.F.6'+JG\0"M@'5"O4(':":L ;&K-,#6),%:XT,Y+Y\
MP-:$P7I!\T,.,$T2IG0>P):!NA4MX^#N/9SA<(;#&7;K#$%IGT)P/:1G-!8Z
MQX; :HEN,%=Q5VYW9^7Z648T)BUSU-_D4'(A]_<*T)R*BJCV2=H?219"I(HS
M(#J^K)Q?*3 -9GU)[U2XELI>Z"_4L +P0SO01/7N+PVIM1]N+L?U07G4RCN5
ML*?D7E8Q2@)W:8&;5< >S8&C%#)=?!D\5DR#6E[S63%: Y9XB.F&]L&Z"^?R
M)R(68[:K62@"S>8*Z4(Q: C\<O1+"&EV"*O_6KZW6(CA_>.Q0?K'\O/Q4)8D
M @L K63EYYZN9+*%,AZME.5Y]VP'\&^:+A?D0B3"7!JBGB/2) ;O93.9=#D3
MU.WM@"$OQI 5&><Q420X,#^'&XD6-?*E<CH?.+8U820)"R8>\&,=%A(U)6$.
M91*=<2&D<_P6Q/X?AC!)XLO<[2<Q0K&8+A>#JL<W+TH"*_9J\V9:PS F1*I-
M="SE(;JL232%H4F>Z%^,[NST]I1O31\&OV_C3!1?UG)"5D$M,S]PQZS$.5J#
M@J5@N-*U/B&2-<\'$X<-N!;LOM.GVCV\!V>FT\?PE]I@0'3_5-%D[/< FST!
M*Z^^^O*8D>'>WF;M/M(J%NY^W9\/[WN.W??2*U@P$S? $%;"+5JE6E33L12S
M(_%B_Z!L/@T+1F4G2:#?3I! 7$R(: P6BQ&-P3\>H'%(RR]/UJ2L=6R_>,-!
MYGLI!,_./:##2^@KJK/E -!H "UE#@#=+88U)_!?V 3U-5A1H+EPUB7]"2AL
MHXC6 M^=R?<_F\)9\6PR'&PDRK,URZ%B'L-_CB]%_0%4U;=D1V17WNJ<.LQO
MV(Z0OVD-M7@WN_U,EM@1+[F0#5D5[6:K$M&DX).U*<HQQ[0LV!3E0IK/1_9C
M_O$"):J$SA\D](;H:D[B;,Z@*,5K/#0_ISNRR_>/1X6HM'4PUQ,&:.D T%UB
M5G-LZ(7#(;;/A@)-">](/K>5HM'10C@RU4]ZHD$DU"1!B:--&*\)*)>&;)(V
MT1_E/F%0OB9][5ZEJU" =V<W\G!6*S<?/E_'&1>^W:!%?316M"DA3(<]IF>F
MO;?M0[\A"IIG,P?^$H=AEX4#PT[ _[-I-K0YU;2<1*?8;. TB@,>O80P#V9?
MP@ M' #Z9CC=' ^+U]GU%7G82KUVF1%P30Q3E_LXD@B?JCR)NG2NXQ"0V;7Q
M7;[];/2S^>$^N<SI.;A%=973">N"8&J<[IR::;?<O2[2\0.[1WBN?[P:-<\F
M_$XWZR^??BN/GRZ'TQ\W@N,O?\%MO&;*32@($W67"YFDJC?X;#HO1,X-_^.E
M4E0Q?\@0V'1 .RE"BVZE")E$JC$*06- #\@1G]J$#'^@MF0!FCT =+?9UQQC
M2B*S?ZN,*=#T*&UD")H]X6/9#+39\_7/F2'-JH*1VWG_>L29:&^(S Y>]D2X
M^B'.G#! #W'FA %Z,)N2T#NV*CO7-;=B5:X*?!*F5_ HP0."O04$FT.7)!+6
MMXHN@0IQ)G30]JRD%#_G9*FH/!=?:83DZFY[[NSM0* EVK[/>F/]::WQ:2K.
M1-?X6F[$&:?QCW.XCGA*"Q\U>>5P@[MZ@[G##>[F#:[HGN*3B6LJHA%:[ A\
MU"A;Q&&M)2&R1I$$JJTQM^./QK+(?")J\LZ!3^P]GYAC! E/;7Y51A#8 [5,
MLSMR3G9'/EH/U*>G+Y^UYL_"EUD<,V3.;[[\$,%=3G.[:'2[J3>5R(U,YT&?
M2&+-;Z%R>IEO7XZ^W:_1R#3A*%BD[J5KYK]DD\I_*98R::%X",DG+2H/GMPM
MMGM[04Y+-ID.HT(Z&[W#Z)]^Y\GTA(QCT&23[1E:SJ6%W*:N?=YZ.=QX0K&4
M;*)=0+/I(K::/Z# %AG]W'TFD?U32/-"Y+Z>&PIW".MWY\FIOTX?A?O+7S=Q
M\G8.W7FV4WT0NSO/1HRBPF6C^=D\NZM>BG]8=YZ<X^7(KV=N"4EU_"SQA72I
M?&C/D["YE3VD=KUFQXMPNEK'$DNBWZ>0SA0/=EC2U'5P9B0+4.'0[W,'V)6I
MN0QK3MPGD3ZU9584:%$4HUD4UP1L!H/01]IC13:-KMR\$NQ7;>40P5<Q02L<
M4:6P#>=N#3R:$TUF:UG*8-W2!9GFTY7D[HR</RAMH5"^O9)VOLC@2IS2\GK$
M U"*V>V)BJ78^HMP*?".#03<+M)>R%BYY56\2Q%B&2X%O4OM&<" C9DTL]J7
MZZ?Q]\IIL>":-/%N\,6V2Q1?5W2X)VO'Y)+J,IHM;:K_V)OR>475!PYM9EY$
M6RL5@A?3U1IVC)!$F]%-!63_2.HZ. <2!NBA[FN7V-42.R:)5J/;846!YDLA
M8B\F^K?6&#=GU)^)WI<-(G7E*R&VMCN;C0K-8?7AH7H:9TK:#@56B 4/=-03
M7V=23F,0VT6"\PTWB':+L9%@"0IM.#OMJC4]/WOHE[[GE@1B5E_@:_9["H1;
MPD9+5"ZVTF@IIHOYP[2UA+6!W*%Y[::;I21!9&M8,+DDNM&6L@="2YC0#EZ"
MA %Z:$:[<YPKW)C))=%?=IM<:0?&)MP^]_.%L_/'\PMAYR,NA[$)!W:S'O_.
M'_H>[FTS\404U7R\3.XY_U;Q8!(F39@'DS!A@.8. -US3A>NV.;C=5EX12ZV
MJ<$)]T+]X;PV^_*Y&"=!Z# X(6G?>R;!P0D;\: /<]J7\YKX?*H\_%F#$V([
MTPM)53*4T_G#*-3$Y?PA56&W&H\G8Z8D4=EPF.F=.+$=RAJ2!6CA4-:PD]PK
MW/0H)%'HL$W.M&MS$XJ5W,U]1U#/'^2==[ ?YB8<N% LMGZ(.R<,T$/<.6&
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M-YUMPK]A\^R^C[7!,1@CG(A;WS':#0)N3.)-M#J,+^ZI:'T!B%<1;SP;(0S
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MRY;3R$IR:<H ;40@]#'@!F+*ZC?!L1XRM.$ XB8BB;\_%* $]PCLCG!_94Y
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MF=9E8QB7,?J8ESUXD6?\<:2:2U_6K<6=*>HII?M@0 +@9R9R <)*2@ ]J4,
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M<\&/R-!J/F,;U?C+U!65)$9S072[V,K]8RJRX3ET()>'N_S[^1;77/!>LUL
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MI'X^<N$^.92*Z1\+Z+Q\],9F]^I7[IO>:W-P=]?BZ_QG[<NN-6 TK'RME31
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M+D;\F?20/Z#>CM.N.2VVWF_XPJ+UOE.FWW:XN%3PAXL?1L@>/H&Z>+!ND3;
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M!1JWYQ'Q&<\85UX<H <(N(_5"@IBF6[/Z%&M9"]I#T6O@0=@'SCJ?3(9&N_
M)N!P+F[^0$L5==+-B+@62_0,T4."S)%65?0&?S+2'0EV@'[\ZW=')O$8>Z(
MT -I%R)0PS%CCQ4'/:#,..N[&<3SZ(.B!G-T,5*9#4_FFEC/AQPX'09E11S<
M:\!]EP"3=MB*!6Y=D(4!))S[$H>^C(6B;Z?V;Y")0>Y10$K7@IYT(C!A0Z4\
MH1:'^IR@RS%3)]1'UD$:F1'[&^C^5!V@*>&W=K,R6!:RM,@X7:^,.$B"?.=]
MC-4\JZ&CX# \"#8W.'LJ%T6F05_"+&+H(T7%;)#US$O.Z$)_1+J90(#K=F.O
M]2:B3'7W0;N7+@?A.L,.B9P*Z>EV-@'G;[47>]D?-TEKNGVH^!!&>-KT$-&M
MCDTS=$ #<:!CU,(^SAO#T8DCA=AF/0%V;E$Y8P!<*:3P,0 3,KD4R2 ;?'+?
M5,9:G<;@_O@1AX2&S;/*2D32A])+>%:6HI5&993<\"W?IH:I%&A^"<D\$OT<
MK]C=@?6DC^B:DMJ3;SM7B]I\(TB6E11]J6O>M,_UF^>;_D>O^.NW9[4,!,2_
MJ;IO1V=;J><#OHT+#!0;P##O1E URD89:E73XAO.,G*QZ !S6ID!GIZF&*K5
M9(E[\\$,B!!%OM!X[.NI47^<>51H/5%D"MEN%?4^U 5Q')%"#%8-'<-L&/M;
M(6_,6&A,>E2R@602 NDH3^^8\XZH$@ @SI:@MP>0EA);EQ8^@.C""#?GC=.'
MC]GXJ=5T +V7K#]1$FG%]7F325Z,<)\,6J_Y"!"_T,_\&:)BME");Z8)K6:N
MIGD3M$=I:,Z5IYN95KON[]U-A/8RE=>K<HJXB7RVDH]-UGY-/VD:_2D^8;UM
M+5T.A(Z;G KSO[2.H.*X;[QR=@\>6/+-KCFYTO//RKPUF&[D?,?XV2]"A7LN
MBLUG??CK-Z)2K'1!DS!X1=^LK8B,AM/ HD?$ +ZM9&T71WS!"^#%J0C)LTS(
MKQTH'.A#4L9CQ:L:+2]B)D!T%&+'M%X6<6^/S)BSO@7/TV ^):!/X88CRSFF
M:IQ4Y!)K ,>R! I_BD%/%PZ^M@1K!MM\"A%7I$#IP.53^"%:@T"IS-E'%ERH
M"13W0/UMUL86QR^C[C@Q]HDC07Z/D:\RV"T@N$;(BQ U"ZD10#\I"B28+DM6
M!R5-WA-T1;'!P,CG_JNKV-59D-_C'[(8 /+_*&J&?D8<T'>C?5B?(//]<)\7
M!Y@2?1Q/W-(@O7(@^F8-7FL/_.P-\U7[@#- +B9FFEY<_M:9=^<6)6N^%72E
M7.B:=[?/C_G+FE'42FG/ZT/?:@8H\.\UQ%FRC/7&X_6:R"?IG-[>GXO%Q7TQ
MR7@](E8X"P0UR&\>O,\(M%FT&?C0__N5=ZZX6"MTP[K57Y[TLXK\4,E?.&G9
M)7/X_ -65EI%KAO6]MV[:[^>WXZ,^;2Z[BI6'P28&)77^2BN8" 2&9XG\?]E
M*'_9>75VXLWL!\^CG+A6(^1UH74,5-K#H$"FZ2V.\N\@9+DA[UEO7EKP:*/?
MAC_P#R/JZ G]"'W[UR6H!\70D*!&O OH=^AL'!6*7$7N[ZU<43[M*P*&2^,J
M#F"?Q:\AN55%4@CSAY3E[.BYKNW:HC*7=^ED9$X['F#7G'8NSEGMZ;GYYDSL
MV<*HSW+Y/Z&L&22U_'$)B*U%[=R(0BB8R!GQS>0#6 EIXJ\QO&(@$\11VO\)
MJQG['_]J5GA@1.767_&>O.>VUH-N*:]15EN(]-D+V6*I$N*OA]X2&W5+88<;
MD+\_5[T:T$RYFN9%%[/50FF;%YWB[-05[*^D0Q7(4L,5YE*)G/2!>[28[0Y\
M#K[[A08CCJQ@1##V\ ^-B& 0/>(G;OG@XJ8P6PNND_6V<.RD/<#>K-9V5HT]
M6^K!AJ)Z78SO)N/YC7DCY.V@;^ TG- ,.1=Z%FLMD?K8@97&+;)Q.L[5K\<W
MO=9@E472:UH6GU[I+-?3>I7<6L+0EH%D+6MN).K$U]Q*/IVML-E\D5T5?7A/
M1)J?["LI<&8@=M!IL!>#D?@XKDHI<&8C%<X,+/*V\%K)/6LW-VQI+SESB9%2
M*1X*7R[;2#F=C11+8596BCSY8V?MTV)V9V<E];"=,%B,P145@4G%$4O'^TJ@
M-4YBTIQ4.XB1@-KSP>D'U[HTH-60RMW((PR^NAKS:BJ68EYN=$[/1>6I=]&0
M8E]N2_DEOF;HYM>T3I)ZG9>MLZ4U 9UDXCWB -?;0#6II;C2!O+'E=JF<GW]
MT,EALVD<K_C8-& >7?[I3,6Q?%'3WM=AT\(J;!IX>67XAW]6V\U1:;AC-EUB
MK%23NA!?Q*3+EI_4:%QI^6SNN%S8-8_Z!BOZ*X.^L,,?T:_2NF ?S7/9K.Y'
M.WVY:XYS9XO*>=GL*-OH]%FKP__RS_V#_C(S)FU^SSK\JS'3&T\^9.U\HL[D
MUY_IC;OK\,]_:8=_,?\P-P;GK_57AY_WO\,?$>LS5^8:S;JNGF]CX-).1SH2
M#&]/+4[ R_(9"*L JMG5>+3?)[[ C111N9M^"//V!)C4UQ/Z' QN)"VZN/(.
MJN<RI-*N!WB<NGAD/7=;Q6NU7'3Q6ATMP'K_@[TM KHL\ 24V3[J8-79)G5M
MM="ZMK069)6\_2FS8_&^T3+NAELH>7.OED8&][CF[:QKOK0^_ER-&NT;OI:D
MYHT+[F_5*K=]+>98KW9EOZO-#JNTS%=%]E,NMF_[_"D7VYZ$2;?XB]CG#7>A
M/>GQ)K@AI,O7*>4?6$@JD15"L:&MV#H?'XW;D:"J>RK)AEJ^CEOW8]+MW;3>
M=+((?X!_- 8<.0%^LF E3S[*7%\:&\_7KEEC077ZRW^H$>[*DOZT-,YSU6DI
M_CW[K,Z4DNR5L(A29,U4TN33-@F]OD5"C\9#_3)"SXU.GNK/XOG=Q\<A$WK,
M_)@EA)Y2 KZ43X_0MYRBAA=&&"E+=)"%U(14$-JTCAQ<TI".6\/0B00T4F)+
M**'ULP(?GVR)C_EER-9;965KG@&Y*$S;3W#P%CL+N>OIPT5;_K-(QLZK'/C>
MZ3)R&-WPL_"Q>6KE*4O9/-3,3JK9OI!A\MMEF"_2?<L89OJ2UT^KDZNWD])W
M8YB@3ER%87QU#*:@*CRGC5;@%8Q!POYW&PRS73]M>;G [FL+]L(Q,\LL(J#W
MZ]>S!VY];EE> /&U&B:R-J:22ZF*FF6K*W-%9"9]/\F2W:$;9>9*^<OKF\?:
M:WWX#<DROAJDDDO)54_@P:Q%DU]2XA&#7[)E\)E*KN@9=-T@T!<BVGM'I7B6
M6/7&0]#4G-EE29_0-1\?WIK/S8O!U0F[,WBX B#@B%?3O,[5:GUP(>W5,O9R
M&;S>;XH3YT&"!C 3FGWFG.PCKJS'.."0R^9%[$8;HC8"#!LWG"O&A:.8<1@6
MU<*2M7!7K*G;?8JZ)O-^4&A LYS8!X^=\V,"%*01I!CH\'>A0X]A:;JB GPG
M+XP)'OE?(@:P^1M_V)[TS0->B[5<+\0U+,0-?0G8;@ZJM1?1W#4YW$:3Q#EZ
M6( P!C&1<>T +SU+<6AM[#W_!\C>!@('T..,:RM8>KNV+H@81FR&_G#@]715
MD2R44((3!) Y])0R!)'6>J"-KH/!=C >+GS5P4:%<9VZAH%.D5< P*>NEX7
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M"%]SO 5RO%&L7DNEWC<R3XD/-P-87E#:MA X56,$F4?DC,M:F *;9>#>\3'
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MQ@C.-FV(?*!]9B(![CS@OF;TF0*7#,3P(2P882[T#1U=-,%E!H*Q?A+Q.,1
M4Y$7LH"O"0,(<:N"/D*DCA8.E PT[!K69$R@VY54D0A6F5P&_4(3H*0$<K%
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M_AK#*P9R=%;BHN6IU$VXR&$ALW][W_R4;R^&H\KZ/!&]S?UC"Q\#K%1%'&"
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M)\$<!"\UB+*@4"N2W17@DK3P[Q!11#%W6 ;2VEB(@A(16\U#2A4!YI%A5WV
M6X/X$_%S$,J7F/.'ZD>:S\$Z_=H8TOJ*H6O4I42C(ZZOA7DG3=?;"DH1\[0X
MWLB)<_M^"^:>Q/Q&4H<X.46J-9FV:GD[4D>>QT:.S3U;8Y[/25O1WRS2:**)
MM4<#R;YWS_&OTCL-R4M]JU.P S^5ZQB/XX4-W6YWW*G;/HAZY@A]E1\VQUS!
MBQ?#=_CO+:Q0DA44DRMHFNU&_"#"4-&-+J;JH\OX]&:8SXUJ+H!(SSR:\+M-
M.-G1B #,O=AC$WM[8E[K#K7QO7P$T("<K"NLJ+1:)$_$B<,M($>?ZX_@_>!'
MPF_T +YDN#V)"6\)J@TO\"-Y, @A"&*>(, &DB--,7,B!.X_JV-R:+(A)PE!
M478EM.X((2RW1$+&P-T@&@R0OB*V0C&1CSA5>0?1ALE^Y@<D?A8++;&.N;HG
M<XBD(=Q,-""9ON =L802RKG48S0E7";8>$+$'( 6&Y!YF [*/"RRS,-;XH^H
M>EE:$6=X1G8P_&BH] ?RA QY;^0X?]-<'GP/H+]^ES]LQ1IQA8%HR&9TD;P%
M6]O&\6\U[L+6$,<+E 7C;J-NI)F4POT1;J(YS(:XZ*749QYH"BAQP)[BD_%T
M(L%!(9^A2-2TU;$Y W:NR?VXKS^8/\G%A148$I8&/03;U)B_X]RU<<R=]O$%
MWR%7%ORST=$-S=*U>(QF/+)XO.Z<)._$LT&9@=6Y/BGT9LF)^!:%;6K@53-%
M8^2X<]N&B#F?WOX&S;IB^9#$!<2DAT%BYT#W \5$KH,L1A*EL3;F9$3HU-7N
MQDA1MZ?J(QK@<)P=5"3LM428L_ZI)]19MEJ@/(]SFL[)C$ABNN% A9OLQIU/
MI-\0DN2C(TCCX1/--%\PC(*L]S"Q5%2Q_28W*Z1 *YW@)\L S?0+:CX6&A\O
M>6S8JJ)ITB5['<UZNS]3QR_"L"\E'T>O]8)5+:NV)*COK\_5]N/Y1>?U3+5?
M1\6BI%UTFEU9;3X]VO+Y=>&OW]/[R[']W>C:ZEN\>#\3VI5.?BQ'NL6E??'3
M1PE^HCA]LM:KJ>LJ$K66J)I3'?*S::=#/C[TWW,.O-D=9/P[F _UOWZ+]!\S
M)5HS_V;RFOP!;#R-XM, $FP87<U:@M['JVQ#_Y,^?[^(%KU3V\L'4V"8'=Z5
MK])_^/)CK=(^% +,SB- [[R;W4!N ?WY]^!H@BM3(+B=85$.5CWB(?(A4[O9
M@#N'9@8:,(;@:,EC)%&2W)VSB9*QJH6Z7"J1^R'^A&OL'K4A?QYN]?K1Y2&H
MI-_K?Z__O?[W^M_K?Z__O?[W^M_K;W_]1>%KX3M\O?GP]4S,.O,=L][SL-$!
MM(280X_@P=] 4,F__D2$(>-&&&J%^P:%6[5:W?0FHF]I,'FL;$#@A$^PP(FO
M-F2FB,YDZ=E&3R=AZC.(6$&X"NUM1X<%PT #.Q60TCG%Y(AW0C%)@B [K@RS
M0 W4@J),B639T9!;2X&<X3[QN ]'7HTDR1> B"2)'[(X_36BV9I0D0>A!L@-
M!,#2>$&+I">ZI8]U#'^#IHX"X-VR4J]$S^EMP L)"C99'.&'6Q8K\_:5<[,2
M[A&,' R,</Z 'T!40$C\0SZHD?.X?2')5_P_/P_8-P-8I>]()=*37B?Z<?WH
MTJ$%DFX;\U6@ZZTXJ^,D$1B Z536/32*8,TK6.:-;3I19K>F%;*"246?/J_*
M'E 4)VZX=TT?:%Q+5%2\ 2 _^-")6L2=F 6)/C>11I*F\>_Q;VA-5%>G73DT
M# T-LE4D5M4+RQ!WJT,<IDMI-)2-OZ>5BC2M&@[UAVXZ5D>T*QR?<<X]T9WC
M!Z,@+\Q.EW"H!\Y-^GQ (!LBXBS./<&"WCN8=W#Z-<>Q!G"I#SL*2;:!HFZO
M#MMDRT!1F@6<Q?;&EF>2C[RCZ('O%L!G=I2>ES)!HHZJ I*.G8.](@;MZZ89
MY8 9!%)*=)G$%8NVJ9!BYQ*MC/X2:2-.OA*+S6#JFW=<5A#?PVA'9HP5&3!N
M87R'7RM[MR4I4R"A5(3,D%7I\07M74!R$Q9T%XU!90/F)I SOCP1X%<OV:IE
M:S0_CP:9YQ[/1% ZA,F;7C58L"D2OL'PMI6>ZB3\M6WH%D"^=W[/ZN2=FE)W
M<\?<K<;=0!X@%&2FR9V2HH7B32<H+WM!>09_)W>'"<-YNZ5G\3ULL:/%@HY&
MLH*<3'B[)SN5H))./\*BSJ#)C5CT]DA#2 D.4-7<E#AXS(3* $DE7>M5Y^5Q
M]]7^?<:<5V-Y#7F/*I8D%LEK;*DT!]*G*=#J(B:*)+82PM>X9/J$"PN/9 )B
M(QYB1=5T3FAZ^4(QK_S#3X?.<PS6HJ9KHZYN^W[(=70+,DI(7A_5119A925%
M!2)!PX[25"R.3QWS#A(=7!B3^8LY? _K/GK*.O0$RRND!Q0YN]C'=R.QQ=F-
M/$!-4X'T0XOK6%;O[Y.3P6!PK!C'^ K" J/7$;'*=RSIW9.VJ[P>R;IDD_35
MX]@3JXAP.V7@FY!>8+3<&AH-X<,9;13']-2#$S-.F LE A&"7JHXP$6'*0^R
MNJ2.\R_35SRB:+$!0)-I#:S.E"@4V! GY^!JY" 2LHE7 ..YJDG'<:Z %0^-
MY@?-E2SI5"H-F\-OU=L@ &W#P@+4!K#QZ42<*\)&\),8?2K6?&6=RR62"?Z
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M_/,PR%S8-9GSV61ZN^+[2L&@-%%\TG]"!A[9/9@IZTMFF%2QEU)ZT8#QNE5
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M?W:LKOK[_P=02P$"% ,4    "  L@-%:4?ANRPEF  !#:   "P
M    @ $     86-U:6-Y;BYJ<&=02P$"% ,4    "  L@-%:$@(9/9*Q  "!
MMP  "               @ $R9@  9&5R;2YJ<&=02P$"% ,4    "  L@-%:
MJLHZN!U#  !E10  #               @ 'J%P$ ;&%S97)C>6XN:G!G4$L!
M A0#%     @ +(#16B>/R*E<4@  OU,   L              ( !,5L! &QU
M;6%C>6XN:G!G4$L! A0#%     @ +(#16GOV^RP8;@  $G(   P
M     ( !MJT! &UI8W)O8WEN+FIP9U!+ 0(4 Q0    ( "R T5K(Y-@J^F(
M (1E   .              "  ?@; @!M:6-R;V-Y;G9S+FIP9U!+ 0(4 Q0
M   ( "R T5IW*<UX,R\  )4R   *              "  1Y_ @!N86YC>6XN
M:G!G4$L! A0#%     @ +(#16BVX8ISOHP  #ZD   H              ( !
M>:X" &]C=6-Y;BYJ<&=02P$"% ,4    "  L@-%:L_I-=$95   _5@  #0
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M,#(U,#,S,5]D968N>&UL4$L! A0#%     @ +(#16C\@/H]&8   AI0% !4
M             ( !2C<$ '-N;V$M,C R-3 S,S%?;&%B+GAM;%!+ 0(4 Q0
M   ( "R T5HPMK/\I$4  *F?!  5              "  <.7! !S;F]A+3(P
M,C4P,S,Q7W!R92YX;6Q02P$"% ,4    "  L@-%: 1["H<P(  "J)@  $0
M            @ &:W00 <V]N;VUA7V5X,3 S,"YH=&U02P$"% ,4    "  L
M@-%:B9Y&9MU,   ER@$ $0              @ &5Y@0 <V]N;VUA7V5X,3 S
M,2YH=&U02P$"% ,4    "  L@-%:4NKLU] A   RY0  $0
M@ &A,P4 <V]N;VUA7V5X,3DP,"YH=&U02P$"% ,4    "  L@-%:JQ^44)H"
M  #$"   $0              @ &@504 <V]N;VUA7V5X,C,P,2YH=&U02P$"
M% ,4    "  L@-%:ZH!'6P0'  "K(   $0              @ %I6 4 <V]N
M;VUA7V5X,S$P,2YH=&U02P$"% ,4    "  L@-%:#8\$51@'  #A'P  $0
M            @ &<7P4 <V]N;VUA7V5X,S$P,BYH=&U02P$"% ,4    "  L
M@-%:>RE:W>4#   [$P  $0              @ 'C9@4 <V]N;VUA7V5X,S(P
M,2YH=&U02P$"% ,4    "  L@-%:.PT+O-$" @ 2>A  %@
M@ 'W:@4 <V]N;VUA7VDQ,&LM,#,S,3(U+FAT;5!+!08     %P 7 (<%  #\
%;0<    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>sonoma_i10k-033125_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:SNOA="http://sonomapharma.com/20250331"
  xmlns:country="http://xbrl.sec.gov/country/2024"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="snoa-20250331.xsd" xlink:type="simple"/>
    <context id="From2024-04-01to2025-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
        </entity>
        <period>
            <instant>2025-06-16</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="From2023-04-012024-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="From2023-04-012024-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2023-04-012024-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2023-04-012024-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2023-04-012024-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-04-012025-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-04-012025-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-04-012025-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-04-012025-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-08-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
        </entity>
        <period>
            <instant>2024-08-28</instant>
        </period>
    </context>
    <context id="AsOf2024-08-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
        </entity>
        <period>
            <instant>2024-08-29</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_InvekraMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">SNOA:InvekraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_InvekraMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">SNOA:InvekraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_custom_InvekraMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">SNOA:InvekraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_ProbableCreditLossesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">SNOA:ProbableCreditLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_ProbableCreditLossesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">SNOA:ProbableCreditLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_custom_ProbableCreditLossesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">SNOA:ProbableCreditLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_PotentialDiscountsReturnsDistributorFeesAndRebatesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">SNOA:PotentialDiscountsReturnsDistributorFeesAndRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_PotentialDiscountsReturnsDistributorFeesAndRebatesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">SNOA:PotentialDiscountsReturnsDistributorFeesAndRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_custom_PotentialDiscountsReturnsDistributorFeesAndRebatesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">SNOA:PotentialDiscountsReturnsDistributorFeesAndRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="From2024-04-012025-03-31_us-gaap_ShippingAndHandlingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2023-04-012024-03-31_us-gaap_ShippingAndHandlingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-04-012025-03-31_us-gaap_OtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2023-04-012024-03-31_us-gaap_OtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-04-012025-03-31_us-gaap_OtherOperatingIncomeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2023-04-012024-03-31_us-gaap_OtherOperatingIncomeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-04-012025-03-31_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueNetMember_custom_CustomerAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">SNOA:CustomerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2023-04-012024-03-31_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueNetMember_custom_CustomerAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">SNOA:CustomerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-04-012025-03-31_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueNetMember_custom_CustomerBMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">SNOA:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2023-04-012024-03-31_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueNetMember_custom_CustomerBMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">SNOA:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-04-012025-03-31_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueNetMember_custom_CustomerCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">SNOA:CustomerCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2023-04-012024-03-31_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueNetMember_custom_CustomerCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">SNOA:CustomerCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-04-012025-03-31_us-gaap_CustomerConcentrationRiskMember_us-gaap_AccountsReceivableMember_custom_CustomerBMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">SNOA:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2023-04-012024-03-31_us-gaap_CustomerConcentrationRiskMember_us-gaap_AccountsReceivableMember_custom_CustomerBMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">SNOA:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-04-012025-03-31_us-gaap_CustomerConcentrationRiskMember_us-gaap_AccountsReceivableMember_custom_CustomerDMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">SNOA:CustomerDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2023-04-012024-03-31_us-gaap_CustomerConcentrationRiskMember_us-gaap_AccountsReceivableMember_custom_CustomerDMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">SNOA:CustomerDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_OfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_MachineryAndEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="From2024-04-012025-03-31_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2023-04-012024-03-31_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-04-012025-03-31_custom_CommonStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">SNOA:CommonStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2023-04-012024-03-31_custom_CommonStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">SNOA:CommonStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-02-01_custom_InsurancePremiumFinancingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">SNOA:InsurancePremiumFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-01</instant>
        </period>
    </context>
    <context id="From2025-01-302025-02-01_custom_InsurancePremiumFinancingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">SNOA:InsurancePremiumFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-30</startDate>
            <endDate>2025-02-01</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_InsurancePremiumFinancingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">SNOA:InsurancePremiumFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-02-06_custom_InsurancePremiumFinancingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">SNOA:InsurancePremiumFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-06</instant>
        </period>
    </context>
    <context id="From2024-02-052024-02-06_custom_InsurancePremiumFinancingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">SNOA:InsurancePremiumFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-05</startDate>
            <endDate>2024-02-06</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_InsurancePremiumFinancingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">SNOA:InsurancePremiumFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-08-29_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-29</instant>
        </period>
    </context>
    <context id="AsOf2024-08-29_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-29</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_ConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="From2023-10-252023-10-26_custom_PlacementAgencyAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SNOA:PlacementAgencyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-25</startDate>
            <endDate>2023-10-26</endDate>
        </period>
    </context>
    <context id="From2023-10-252023-10-26_custom_PublicOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">SNOA:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-25</startDate>
            <endDate>2023-10-26</endDate>
        </period>
    </context>
    <context id="From2023-12-142023-12-15_custom_EquityDistributionAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">SNOA:EquityDistributionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-14</startDate>
            <endDate>2023-12-15</endDate>
        </period>
    </context>
    <context id="From2024-01-102024-01-11_custom_MaximGroupLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SNOA:MaximGroupLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-10</startDate>
            <endDate>2024-01-11</endDate>
        </period>
    </context>
    <context id="From2024-11-192024-11-20_custom_MaximGroupLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">SNOA:MaximGroupLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-19</startDate>
            <endDate>2024-11-20</endDate>
        </period>
    </context>
    <context id="AsOf2016-09-02_custom_Plan2016Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SNOA:Plan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-09-02</instant>
        </period>
    </context>
    <context id="From2018-04-012019-03-31_custom_Plan2016Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SNOA:Plan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="From2019-04-012020-03-31_custom_Plan2016Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SNOA:Plan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012022-03-31_custom_Plan2016Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SNOA:Plan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2024-04-012025-03-31_custom_Plan2016Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SNOA:Plan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_Plan2016Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SNOA:Plan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="From2024-04-012025-03-31_custom_Plan2021Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SNOA:Plan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_Plan2021Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SNOA:Plan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="From2024-04-012025-03-31_custom_Plan2024Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SNOA:Plan2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_Plan2024Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SNOA:Plan2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="From2024-04-012025-03-31_us-gaap_StockOptionMember689261046">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_Plan2011Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">SNOA:Plan2011Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="From2024-04-012025-03-31_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="From2024-04-012025-03-31_us-gaap_DomesticCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2023-04-012024-03-31_us-gaap_DomesticCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-04-012025-03-31_us-gaap_ForeignCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2023-04-012024-03-31_us-gaap_ForeignCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_DomesticCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_StateAndLocalJurisdictionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_ForeignCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_CaliforniaResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">SNOA:CaliforniaResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_us-gaap_DomesticCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-31_custom_CaliforniaResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">SNOA:CaliforniaResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="From2024-04-012025-03-31_custom_HumanCareMember_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">SNOA:HumanCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2023-04-012024-03-31_custom_HumanCareMember_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">SNOA:HumanCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-04-012025-03-31_custom_AnimalCareMember_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">SNOA:AnimalCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2023-04-012024-03-31_custom_AnimalCareMember_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">SNOA:AnimalCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-04-012025-03-31_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2023-04-012024-03-31_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-04-012025-03-31_us-gaap_ServiceMember_custom_ServiceAndRoyaltyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">SNOA:ServiceAndRoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2023-04-012024-03-31_us-gaap_ServiceMember_custom_ServiceAndRoyaltyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">SNOA:ServiceAndRoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-04-012025-03-31_us-gaap_SalesRevenueSegmentMember_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2023-04-012024-03-31_us-gaap_SalesRevenueSegmentMember_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-04-012025-03-31_us-gaap_SalesRevenueSegmentMember_srt_EuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2023-04-012024-03-31_us-gaap_SalesRevenueSegmentMember_srt_EuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-04-012025-03-31_us-gaap_SalesRevenueSegmentMember_srt_AsiaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2023-04-012024-03-31_us-gaap_SalesRevenueSegmentMember_srt_AsiaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-04-012025-03-31_us-gaap_SalesRevenueSegmentMember_srt_LatinAmericaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:LatinAmericaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2023-04-012024-03-31_us-gaap_SalesRevenueSegmentMember_srt_LatinAmericaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:LatinAmericaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2024-04-012025-03-31_us-gaap_SalesRevenueSegmentMember_custom_RestOfTheWorldMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">SNOA:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2023-04-012024-03-31_us-gaap_SalesRevenueSegmentMember_custom_RestOfTheWorldMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">SNOA:RestOfTheWorldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367083</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <dei:AmendmentFlag contextRef="From2024-04-01to2025-03-31" id="Fact000003">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus contextRef="From2024-04-01to2025-03-31" id="Fact000004">2025</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="From2024-04-01to2025-03-31" id="Fact000005">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="From2024-04-01to2025-03-31" id="Fact000006">0001367083</dei:EntityCentralIndexKey>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2025-03-31"
      id="xdx2ixbrl0146"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2024-03-31"
      id="xdx2ixbrl0147"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0269"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-04-012024-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0277"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-04-012024-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0279"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-04-012024-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0280"
      unitRef="USD"
      xsi:nil="true"/>
    <SNOA:StockIssuedDuringPeriodValueNewIssues1
      contextRef="From2023-04-012024-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0285"
      unitRef="USD"
      xsi:nil="true"/>
    <SNOA:StockIssuedDuringPeriodValueNewIssues1
      contextRef="From2023-04-012024-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0287"
      unitRef="USD"
      xsi:nil="true"/>
    <SNOA:StockIssuedDuringPeriodValueNewIssues1
      contextRef="From2023-04-012024-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0288"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-04-012024-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0293"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-04-012024-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0295"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-04-012024-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0296"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2023-04-012024-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0299"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2023-04-012024-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0301"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2023-04-012024-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0302"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2023-04-012024-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0307"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2023-04-012024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0308"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2023-04-012024-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0309"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-04-012024-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0313"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-04-012024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0314"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-04-012024-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0316"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0319"
      unitRef="USD"
      xsi:nil="true"/>
    <SNOA:StockIssuedDuringPeriodValueNewIssues1
      contextRef="From2024-04-012025-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0327"
      unitRef="USD"
      xsi:nil="true"/>
    <SNOA:StockIssuedDuringPeriodValueNewIssues1
      contextRef="From2024-04-012025-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0329"
      unitRef="USD"
      xsi:nil="true"/>
    <SNOA:StockIssuedDuringPeriodValueNewIssues1
      contextRef="From2024-04-012025-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0330"
      unitRef="USD"
      xsi:nil="true"/>
    <SNOA:StockIssuedDuringPeriodValueReverseStockSplits
      contextRef="From2024-04-012025-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0335"
      unitRef="USD"
      xsi:nil="true"/>
    <SNOA:StockIssuedDuringPeriodValueReverseStockSplits
      contextRef="From2024-04-012025-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0337"
      unitRef="USD"
      xsi:nil="true"/>
    <SNOA:StockIssuedDuringPeriodValueReverseStockSplits
      contextRef="From2024-04-012025-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0338"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2024-04-012025-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0343"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2024-04-012025-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0345"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2024-04-012025-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0346"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-04-012025-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0351"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-04-012025-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0353"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-04-012025-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0354"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2024-04-012025-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0357"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2024-04-012025-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0359"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2024-04-012025-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0360"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2024-04-012025-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0365"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2024-04-012025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0366"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2024-04-012025-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0367"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-04-012025-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0371"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-04-012025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0372"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-04-012025-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0374"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0377"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2024-04-01to2025-03-31" id="Fact000013">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="From2024-04-01to2025-03-31" id="Fact000014">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="From2024-04-01to2025-03-31" id="Fact000015">2025-03-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="From2024-04-01to2025-03-31" id="Fact000016">--03-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport contextRef="From2024-04-01to2025-03-31" id="Fact000017">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2024-04-01to2025-03-31" id="Fact000018">001-33216</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2024-04-01to2025-03-31" id="Fact000019">SONOMA PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2024-04-01to2025-03-31" id="Fact000020">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2024-04-01to2025-03-31" id="Fact000021">68-0423298</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2024-04-01to2025-03-31" id="Fact000022">5445 Conestoga Court</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2024-04-01to2025-03-31" id="Fact000023">Suite 150</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2024-04-01to2025-03-31" id="Fact000024">Boulder</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2024-04-01to2025-03-31" id="Fact000025">CO</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2024-04-01to2025-03-31" id="Fact000026">80301</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2024-04-01to2025-03-31" id="Fact000027">800</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2024-04-01to2025-03-31" id="Fact000028">759-9305</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2024-04-01to2025-03-31" id="Fact000030">Common Stock, $0.0001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2024-04-01to2025-03-31" id="Fact000032">SNOA</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2024-04-01to2025-03-31" id="Fact000034">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2024-04-01to2025-03-31" id="Fact000035">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="From2024-04-01to2025-03-31" id="Fact000036">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="From2024-04-01to2025-03-31" id="Fact000037">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2024-04-01to2025-03-31" id="Fact000038">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2024-04-01to2025-03-31" id="Fact000039">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2024-04-01to2025-03-31" id="Fact000040">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2024-04-01to2025-03-31" id="Fact000041">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="From2024-04-01to2025-03-31" id="Fact000042">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="From2024-04-01to2025-03-31" id="Fact000044">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="From2024-04-01to2025-03-31" id="Fact000045">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="AsOf2024-09-30"
      decimals="0"
      id="Fact000046"
      unitRef="USD">4047199</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="AsOf2025-06-16"
      decimals="INF"
      id="Fact000048"
      unitRef="Shares">1642765</dei:EntityCommonStockSharesOutstanding>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock contextRef="From2024-04-01to2025-03-31" id="Fact000053">&lt;b&gt;Risk Management and Strategy&lt;/b&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90C_ecyd--CybersecurityRiskManagementProcessesIntegratedTextBlock_c20240401__20250331_z3rVRRvdf7ug"&gt;We identify and address &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90B_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20240401__20250331_ziivd5w3h7wl"&gt;cybersecurity&lt;/span&gt; threats and
risks related to our business with an approach that includes assessments by our management and use of an outside consultant to manage
our information technology.&lt;/span&gt; In addition, we rely on operating systems and software from established and reliable &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_900_ecyd--CybersecurityRiskManagementThirdPartyEngagedFlag_dbT_c20240401__20250331_zfhxkhEJH5g7"&gt;third-party&lt;/span&gt; service providers
to provide security. We have employee policies in place designed to reduce risk of cyber-attacks and educate employees on protocol in
the event of a potential cybersecurity incident.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_900_ecyd--CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_c20240401__20250331_zkV6fBvn6hD8"&gt;Currently we are &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_900_ecyd--CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_dbF_c20240401__20250331_zGU9Jtn0LpJg"&gt;not aware&lt;/span&gt; of any risks from cybersecurity
threats, including as a result of any previous cybersecurity incidents, that have materially affected our business strategy,&lt;/span&gt; results of
operations or financial condition or are reasonably likely to have such a material effect. However, cyber-attacks are increasing in frequency,
sophistication and intensity, and despite our ongoing efforts we cannot eliminate all risks from cybersecurity threats, or provide assurances
that we have not experienced undetected cybersecurity incidents. Please refer to &#x201c;Risk Factors&#x201d; in Part I, Item 1A of this
Form 10-K for more information on the risks posed to us by cybersecurity threats.&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock contextRef="From2024-04-01to2025-03-31" id="Fact000054">We identify and address &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90B_ecyd--CybersecurityRiskManagementProcessesIntegratedFlag_dbT_c20240401__20250331_ziivd5w3h7wl"&gt;cybersecurity&lt;/span&gt; threats and
risks related to our business with an approach that includes assessments by our management and use of an outside consultant to manage
our information technology.</cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedFlag contextRef="From2024-04-01to2025-03-31" id="Fact000055">true</cyd:CybersecurityRiskManagementProcessesIntegratedFlag>
    <cyd:CybersecurityRiskManagementThirdPartyEngagedFlag contextRef="From2024-04-01to2025-03-31" id="Fact000056">true</cyd:CybersecurityRiskManagementThirdPartyEngagedFlag>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock contextRef="From2024-04-01to2025-03-31" id="Fact000057">Currently we are &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_900_ecyd--CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_dbF_c20240401__20250331_zGU9Jtn0LpJg"&gt;not aware&lt;/span&gt; of any risks from cybersecurity
threats, including as a result of any previous cybersecurity incidents, that have materially affected our business strategy,</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag contextRef="From2024-04-01to2025-03-31" id="Fact000058">false</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock contextRef="From2024-04-01to2025-03-31" id="Fact000061">&lt;b&gt;Governance&lt;/b&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_906_ecyd--CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_c20240401__20250331_zbHuE0YuWts1"&gt;The Board of Directors takes an active role, as a
whole, in overseeing management regarding our Company&#x2019;s risks, including cybersecurity risks.&lt;/span&gt; &lt;span class="xdx_phnt_RGlzY2xvc3VyZSAtIEN5YmVyc2VjdXJpdHkgUmlzayBNYW5hZ2VtZW50IGFuZCBTdHJhdGVneSBEaXNjbG9zdXJlAA__" id="xdx_90E_ecyd--CybersecurityRiskRoleOfManagementTextBlock_c20240401__20250331_zbzRGRCK0URh"&gt;Our management, including our Chief
Executive Officer and our Chief Financial Officer, keeps the Board of Directors apprised of significant risks facing our Company and the
approach being taken to understand, manage, and mitigate such risks, including with respect to potential cybersecurity threats.&lt;/span&gt;&lt;/p&gt;</cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock contextRef="From2024-04-01to2025-03-31" id="Fact000062">The Board of Directors takes an active role, as a
whole, in overseeing management regarding our Company&#x2019;s risks, including cybersecurity risks.</cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskRoleOfManagementTextBlock contextRef="From2024-04-01to2025-03-31" id="Fact000063">Our management, including our Chief
Executive Officer and our Chief Financial Officer, keeps the Board of Directors apprised of significant risks facing our Company and the
approach being taken to understand, manage, and mitigate such risks, including with respect to potential cybersecurity threats.</cyd:CybersecurityRiskRoleOfManagementTextBlock>
    <dei:AuditorFirmId contextRef="From2024-04-01to2025-03-31" id="Fact000064">215</dei:AuditorFirmId>
    <dei:AuditorName contextRef="From2024-04-01to2025-03-31" id="Fact000065">Frazier &amp; Deeter, LLC</dei:AuditorName>
    <dei:AuditorLocation contextRef="From2024-04-01to2025-03-31" id="Fact000066">Nashville, Tennessee</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000074"
      unitRef="USD">5374000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000075"
      unitRef="USD">3128000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000077"
      unitRef="USD">2232000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000078"
      unitRef="USD">2898000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000080"
      unitRef="USD">2915000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000081"
      unitRef="USD">2719000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000083"
      unitRef="USD">1915000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000084"
      unitRef="USD">3541000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <SNOA:DeferredConsiderationCurrent
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000086"
      unitRef="USD">212000</SNOA:DeferredConsiderationCurrent>
    <SNOA:DeferredConsiderationCurrent
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000087"
      unitRef="USD">262000</SNOA:DeferredConsiderationCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000089"
      unitRef="USD">12648000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000090"
      unitRef="USD">12548000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000092"
      unitRef="USD">225000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000093"
      unitRef="USD">365000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000095"
      unitRef="USD">84000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000096"
      unitRef="USD">286000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000098"
      unitRef="USD">589000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000099"
      unitRef="USD">1145000</us-gaap:DeferredIncomeTaxAssetsNet>
    <SNOA:DeferredConsiderationNoncurrent
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000101"
      unitRef="USD">73000</SNOA:DeferredConsiderationNoncurrent>
    <SNOA:DeferredConsiderationNoncurrent
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000102"
      unitRef="USD">330000</SNOA:DeferredConsiderationNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000104"
      unitRef="USD">74000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000105"
      unitRef="USD">66000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000107"
      unitRef="USD">13693000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000108"
      unitRef="USD">14740000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000116"
      unitRef="USD">953000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000117"
      unitRef="USD">607000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilities
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000119"
      unitRef="USD">2224000</us-gaap:AccountsPayableAndOtherAccruedLiabilities>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilities
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000120"
      unitRef="USD">2113000</us-gaap:AccountsPayableAndOtherAccruedLiabilities>
    <us-gaap:DeferredRevenueCurrent
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000122"
      unitRef="USD">641000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000123"
      unitRef="USD">478000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:ShortTermBorrowings
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000125"
      unitRef="USD">220000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000126"
      unitRef="USD">323000</us-gaap:ShortTermBorrowings>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000128"
      unitRef="USD">58000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000129"
      unitRef="USD">198000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000131"
      unitRef="USD">4096000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000132"
      unitRef="USD">3719000</us-gaap:LiabilitiesCurrent>
    <us-gaap:DeferredRevenueNoncurrent
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000134"
      unitRef="USD">17000</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:DeferredRevenueNoncurrent
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000135"
      unitRef="USD">87000</us-gaap:DeferredRevenueNoncurrent>
    <SNOA:WithholdingTaxPayable
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000137"
      unitRef="USD">5142000</SNOA:WithholdingTaxPayable>
    <SNOA:WithholdingTaxPayable
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000138"
      unitRef="USD">4710000</SNOA:WithholdingTaxPayable>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000140"
      unitRef="USD">27000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000141"
      unitRef="USD">87000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000143"
      unitRef="USD">9282000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000144"
      unitRef="USD">8603000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2025-03-31"
      decimals="INF"
      id="Fact000155"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2024-03-31"
      decimals="INF"
      id="Fact000157"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2025-03-31"
      decimals="INF"
      id="Fact000159"
      unitRef="Shares">714286</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-03-31"
      decimals="INF"
      id="Fact000161"
      unitRef="Shares">714286</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2025-03-31"
      decimals="INF"
      id="Fact000163"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2025-03-31"
      decimals="INF"
      id="Fact000165"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2024-03-31"
      decimals="INF"
      id="Fact000167"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2024-03-31"
      decimals="INF"
      id="Fact000169"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000152"
      unitRef="USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000153"
      unitRef="USD">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2025-03-31"
      decimals="INF"
      id="Fact000174"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-03-31"
      decimals="INF"
      id="Fact000176"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2025-03-31"
      decimals="INF"
      id="Fact000178"
      unitRef="Shares">50000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-03-31"
      decimals="INF"
      id="Fact000180"
      unitRef="Shares">24000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2025-03-31"
      decimals="INF"
      id="Fact000182"
      unitRef="Shares">1634265</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2025-03-31"
      decimals="INF"
      id="Fact000184"
      unitRef="Shares">1634265</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-03-31"
      decimals="INF"
      id="Fact000186"
      unitRef="Shares">780371</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-03-31"
      decimals="INF"
      id="Fact000188"
      unitRef="Shares">780371</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000171"
      unitRef="USD">0</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000172"
      unitRef="USD">0</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000190"
      unitRef="USD">206593000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000191"
      unitRef="USD">203209000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000193"
      unitRef="USD">-197806000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000194"
      unitRef="USD">-194349000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000196"
      unitRef="USD">-4376000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000197"
      unitRef="USD">-2723000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000199"
      unitRef="USD">4411000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000200"
      unitRef="USD">6137000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000202"
      unitRef="USD">13693000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000203"
      unitRef="USD">14740000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="From2024-04-01to2025-03-31"
      decimals="-3"
      id="Fact000205"
      unitRef="USD">14288000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000206"
      unitRef="USD">12735000</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="From2024-04-01to2025-03-31"
      decimals="-3"
      id="Fact000208"
      unitRef="USD">8823000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000209"
      unitRef="USD">7990000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit
      contextRef="From2024-04-01to2025-03-31"
      decimals="-3"
      id="Fact000211"
      unitRef="USD">5465000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000212"
      unitRef="USD">4745000</us-gaap:GrossProfit>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-04-01to2025-03-31"
      decimals="-3"
      id="Fact000217"
      unitRef="USD">1814000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000218"
      unitRef="USD">1871000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2024-04-01to2025-03-31"
      decimals="-3"
      id="Fact000220"
      unitRef="USD">7361000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000221"
      unitRef="USD">7575000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2024-04-01to2025-03-31"
      decimals="-3"
      id="Fact000223"
      unitRef="USD">9175000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000224"
      unitRef="USD">9446000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-04-01to2025-03-31"
      decimals="-3"
      id="Fact000226"
      unitRef="USD">-3710000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000227"
      unitRef="USD">-4701000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="From2024-04-01to2025-03-31"
      decimals="-3"
      id="Fact000229"
      unitRef="USD">803000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000230"
      unitRef="USD">-330000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2024-04-01to2025-03-31"
      decimals="-3"
      id="Fact000232"
      unitRef="USD">-2907000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000233"
      unitRef="USD">-5031000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2024-04-01to2025-03-31"
      decimals="-3"
      id="Fact000235"
      unitRef="USD">550000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000236"
      unitRef="USD">-196000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-04-01to2025-03-31"
      decimals="-3"
      id="Fact000238"
      unitRef="USD">-3457000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000239"
      unitRef="USD">-4835000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-04-01to2025-03-31"
      decimals="INF"
      id="Fact000241"
      unitRef="USDPShares">-2.79</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-04-01to2025-03-31"
      decimals="INF"
      id="Fact000243"
      unitRef="USDPShares">-2.79</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-04-012024-03-31"
      decimals="INF"
      id="Fact000245"
      unitRef="USDPShares">-10.63</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-04-012024-03-31"
      decimals="INF"
      id="Fact000247"
      unitRef="USDPShares">-10.63</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-04-01to2025-03-31"
      decimals="-3"
      id="Fact000249"
      unitRef="Shares">1241000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-04-01to2025-03-31"
      decimals="-3"
      id="Fact000251"
      unitRef="Shares">1241000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000253"
      unitRef="Shares">455000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000255"
      unitRef="Shares">455000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-04-01to2025-03-31"
      decimals="-3"
      id="Fact000260"
      unitRef="USD">-3457000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000261"
      unitRef="USD">-4835000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2024-04-01to2025-03-31"
      decimals="-3"
      id="Fact000263"
      unitRef="USD">-1653000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000264"
      unitRef="USD">695000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="From2024-04-01to2025-03-31"
      decimals="-3"
      id="Fact000266"
      unitRef="USD">-5110000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000267"
      unitRef="USD">-4140000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000275"
      unitRef="Shares">246678</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000270"
      unitRef="USD">200909000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000271"
      unitRef="USD">-189514000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact000272"
      unitRef="USD">-3418000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-03-31"
      decimals="-3"
      id="Fact000273"
      unitRef="USD">7977000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-04-012024-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000283"
      unitRef="Shares">425000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-04-012024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000278"
      unitRef="USD">1446000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000281"
      unitRef="USD">1446000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <SNOA:StockIssuedDuringPeriodSharesNewIssues1
      contextRef="From2023-04-012024-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000291"
      unitRef="Shares">96154</SNOA:StockIssuedDuringPeriodSharesNewIssues1>
    <SNOA:StockIssuedDuringPeriodValueNewIssues1
      contextRef="From2023-04-012024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000286"
      unitRef="USD">338000</SNOA:StockIssuedDuringPeriodValueNewIssues1>
    <SNOA:StockIssuedDuringPeriodValueNewIssues1
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000289"
      unitRef="USD">338000</SNOA:StockIssuedDuringPeriodValueNewIssues1>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-04-012024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000294"
      unitRef="USD">255000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000297"
      unitRef="USD">255000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2023-04-012024-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000305"
      unitRef="Shares">12539</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2023-04-012024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000300"
      unitRef="USD">261000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000303"
      unitRef="USD">261000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2023-04-012024-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact000310"
      unitRef="USD">695000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000311"
      unitRef="USD">695000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-04-012024-03-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000315"
      unitRef="USD">-4835000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000317"
      unitRef="USD">-4835000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000325"
      unitRef="Shares">780371</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000320"
      unitRef="USD">203209000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000321"
      unitRef="USD">-194349000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact000322"
      unitRef="USD">-2723000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000323"
      unitRef="USD">6137000</us-gaap:StockholdersEquity>
    <SNOA:StockIssuedDuringPeriodSharesNewIssues1
      contextRef="From2024-04-012025-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000333"
      unitRef="Shares">816894</SNOA:StockIssuedDuringPeriodSharesNewIssues1>
    <SNOA:StockIssuedDuringPeriodValueNewIssues1
      contextRef="From2024-04-012025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000328"
      unitRef="USD">3079000</SNOA:StockIssuedDuringPeriodValueNewIssues1>
    <SNOA:StockIssuedDuringPeriodValueNewIssues1
      contextRef="From2024-04-01to2025-03-31"
      decimals="-3"
      id="Fact000331"
      unitRef="USD">3079000</SNOA:StockIssuedDuringPeriodValueNewIssues1>
    <us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits
      contextRef="From2024-04-012025-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000341"
      unitRef="Shares">288</us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits>
    <SNOA:StockIssuedDuringPeriodValueReverseStockSplits
      contextRef="From2024-04-012025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000336"
      unitRef="USD">1000</SNOA:StockIssuedDuringPeriodValueReverseStockSplits>
    <SNOA:StockIssuedDuringPeriodValueReverseStockSplits
      contextRef="From2024-04-01to2025-03-31"
      decimals="-3"
      id="Fact000339"
      unitRef="USD">1000</SNOA:StockIssuedDuringPeriodValueReverseStockSplits>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2024-04-012025-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000349"
      unitRef="Shares">27750</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2024-04-012025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000344"
      unitRef="USD">82000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2024-04-01to2025-03-31"
      decimals="-3"
      id="Fact000347"
      unitRef="USD">82000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-04-012025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000352"
      unitRef="USD">170000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-04-01to2025-03-31"
      decimals="-3"
      id="Fact000355"
      unitRef="USD">170000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2024-04-012025-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000363"
      unitRef="Shares">9538</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2024-04-012025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000358"
      unitRef="USD">54000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2024-04-01to2025-03-31"
      decimals="-3"
      id="Fact000361"
      unitRef="USD">54000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2024-04-012025-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact000368"
      unitRef="USD">-1653000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="From2024-04-01to2025-03-31"
      decimals="-3"
      id="Fact000369"
      unitRef="USD">-1653000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-04-012025-03-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000373"
      unitRef="USD">-3457000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-04-01to2025-03-31"
      decimals="-3"
      id="Fact000375"
      unitRef="USD">-3457000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000383"
      unitRef="Shares">1634265</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000378"
      unitRef="USD">206593000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000379"
      unitRef="USD">-197806000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact000380"
      unitRef="USD">-4376000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000381"
      unitRef="USD">4411000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-04-01to2025-03-31"
      decimals="-3"
      id="Fact000388"
      unitRef="USD">-3457000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000389"
      unitRef="USD">-4835000</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation
      contextRef="From2024-04-01to2025-03-31"
      decimals="-3"
      id="Fact000394"
      unitRef="USD">138000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000395"
      unitRef="USD">176000</us-gaap:Depreciation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-04-01to2025-03-31"
      decimals="-3"
      id="Fact000397"
      unitRef="USD">224000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000398"
      unitRef="USD">516000</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="From2024-04-01to2025-03-31"
      decimals="-3"
      id="Fact000400"
      unitRef="USD">-357000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000401"
      unitRef="USD">109000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="From2024-04-01to2025-03-31"
      decimals="-3"
      id="Fact000403"
      unitRef="USD">-174000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000404"
      unitRef="USD">-161000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2024-04-01to2025-03-31"
      decimals="-3"
      id="Fact000409"
      unitRef="USD">-434000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000410"
      unitRef="USD">230000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2024-04-01to2025-03-31"
      decimals="-3"
      id="Fact000412"
      unitRef="USD">388000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000413"
      unitRef="USD">-184000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2024-04-01to2025-03-31"
      decimals="-3"
      id="Fact000415"
      unitRef="USD">-1086000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000416"
      unitRef="USD">-1107000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInDeferredCompensation
      contextRef="From2024-04-01to2025-03-31"
      decimals="-3"
      id="Fact000418"
      unitRef="USD">194000</us-gaap:IncreaseDecreaseInDeferredCompensation>
    <us-gaap:IncreaseDecreaseInDeferredCompensation
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000419"
      unitRef="USD">222000</us-gaap:IncreaseDecreaseInDeferredCompensation>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayable
      contextRef="From2024-04-01to2025-03-31"
      decimals="-3"
      id="Fact000421"
      unitRef="USD">416000</us-gaap:IncreaseDecreaseInOtherAccountsPayable>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayable
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000422"
      unitRef="USD">-278000</us-gaap:IncreaseDecreaseInOtherAccountsPayable>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
      contextRef="From2024-04-01to2025-03-31"
      decimals="-3"
      id="Fact000424"
      unitRef="USD">295000</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000425"
      unitRef="USD">19000</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <SNOA:IncreaseDecreaseInWithholdingTaxPayable
      contextRef="From2024-04-01to2025-03-31"
      decimals="-3"
      id="Fact000427"
      unitRef="USD">432000</SNOA:IncreaseDecreaseInWithholdingTaxPayable>
    <SNOA:IncreaseDecreaseInWithholdingTaxPayable
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000428"
      unitRef="USD">475000</SNOA:IncreaseDecreaseInWithholdingTaxPayable>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2024-04-01to2025-03-31"
      decimals="-3"
      id="Fact000430"
      unitRef="USD">-174000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000431"
      unitRef="USD">-161000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="From2024-04-01to2025-03-31"
      decimals="-3"
      id="Fact000433"
      unitRef="USD">181000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000434"
      unitRef="USD">355000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2024-04-01to2025-03-31"
      decimals="-3"
      id="Fact000436"
      unitRef="USD">-88000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000437"
      unitRef="USD">-2398000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2024-04-01to2025-03-31"
      decimals="-3"
      id="Fact000442"
      unitRef="USD">80000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000443"
      unitRef="USD">2000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2024-04-01to2025-03-31"
      decimals="-3"
      id="Fact000445"
      unitRef="USD">-80000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000446"
      unitRef="USD">-2000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2024-04-01to2025-03-31"
      decimals="-3"
      id="Fact000451"
      unitRef="USD">3079000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000452"
      unitRef="USD">1784000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2024-04-01to2025-03-31"
      decimals="-3"
      id="Fact000454"
      unitRef="USD">82000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000455"
      unitRef="USD">0</us-gaap:ProceedsFromStockOptionsExercised>
    <SNOA:PaymentsForFractionalSharesRelatedToReversesplit
      contextRef="From2024-04-01to2025-03-31"
      decimals="-3"
      id="Fact000457"
      unitRef="USD">1000</SNOA:PaymentsForFractionalSharesRelatedToReversesplit>
    <SNOA:PaymentsForFractionalSharesRelatedToReversesplit
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000458"
      unitRef="USD">-0</SNOA:PaymentsForFractionalSharesRelatedToReversesplit>
    <us-gaap:RepaymentsOfOtherShortTermDebt
      contextRef="From2024-04-01to2025-03-31"
      decimals="-3"
      id="Fact000460"
      unitRef="USD">404000</us-gaap:RepaymentsOfOtherShortTermDebt>
    <us-gaap:RepaymentsOfOtherShortTermDebt
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000461"
      unitRef="USD">481000</us-gaap:RepaymentsOfOtherShortTermDebt>
    <SNOA:ProceedsFromInsurancePremiumsFinanced
      contextRef="From2024-04-01to2025-03-31"
      decimals="-3"
      id="Fact000463"
      unitRef="USD">274000</SNOA:ProceedsFromInsurancePremiumsFinanced>
    <SNOA:ProceedsFromInsurancePremiumsFinanced
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000464"
      unitRef="USD">373000</SNOA:ProceedsFromInsurancePremiumsFinanced>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2024-04-01to2025-03-31"
      decimals="-3"
      id="Fact000466"
      unitRef="USD">3030000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000467"
      unitRef="USD">1676000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="From2024-04-01to2025-03-31"
      decimals="-3"
      id="Fact000469"
      unitRef="USD">-616000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000470"
      unitRef="USD">32000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2024-04-01to2025-03-31"
      decimals="-3"
      id="Fact000472"
      unitRef="USD">2246000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000473"
      unitRef="USD">-692000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000475"
      unitRef="USD">3128000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2023-03-31"
      decimals="-3"
      id="Fact000476"
      unitRef="USD">3820000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000478"
      unitRef="USD">5374000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000479"
      unitRef="USD">3128000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="From2024-04-01to2025-03-31"
      decimals="-3"
      id="Fact000484"
      unitRef="USD">11000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000485"
      unitRef="USD">22000</us-gaap:InterestPaidNet>
    <SNOA:InsurancePremiumsFinanced
      contextRef="From2024-04-01to2025-03-31"
      decimals="-3"
      id="Fact000490"
      unitRef="USD">274000</SNOA:InsurancePremiumsFinanced>
    <SNOA:InsurancePremiumsFinanced
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000491"
      unitRef="USD">373000</SNOA:InsurancePremiumsFinanced>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="From2024-04-01to2025-03-31" id="Fact000493">&lt;p id="xdx_80C_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zWw5nTTD2XO7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;NOTE&#160;1&#160;&#x2013; &lt;span id="xdx_82F_zC3DfNmjUtu3"&gt;Organization and Recent
Developments&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;Organization&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Sonoma Pharmaceuticals, Inc. (the &#x201c;Company&#x201d;)
was incorporated under the laws of the State of California in April 1999 and was reincorporated under the laws of the State of Delaware
in December 2006. The Company moved its principal office from Petaluma, California to Woodstock, Georgia in June 2020 and to Boulder,
Colorado in October 2022. The Company is a global healthcare leader for developing and producing stabilized hypochlorous acid (&#x201c;HOCl&#x201d;)
products for a wide range of applications, including wound care, eye, oral and nasal care, dermatological conditions, podiatry, animal
health care, and as a non-toxic disinfectant. The Company&#x2019;s products are clinically proven to reduce itch, pain, scarring, and irritation
safely and without damaging healthy tissue. In-vitro and clinical studies of HOCl show it to safely manage skin abrasions, lacerations,
minor irritations, cuts, and intact skin. The Company sells its products either directly or via partners in 55 countries worldwide.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Reverse Stock Split&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Effective August 29, 2024, the Company effected a
reverse stock split of its common stock, par value $0.0001 per share. Every twenty shares of common stock were reclassified and combined
into one share of common stock. No fractional shares were issued as a result of the reverse stock split. Instead, each fractional share
was settled with cash. The reverse stock split reduced the number of shares of the Company&#x2019;s common stock outstanding from &lt;span id="xdx_902_eus-gaap--CommonStockSharesOutstanding_iI_c20240828_zLcrIUVAGuY7" title="Common stock outstanding"&gt;21,174,693&lt;/span&gt;
to &lt;span id="xdx_905_eus-gaap--CommonStockSharesOutstanding_iI_c20240829_zp1zq9E67jSc" title="Common stock outstanding"&gt;1,058,447&lt;/span&gt;. The total number of authorized shares of common stock was not proportionally decreased and the par value per share of the
common stock continues to be $0.0001. The reverse stock split has been retroactively applied to all share and per share amounts in the
consolidated financial statements and accompanying footnotes.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-08-28"
      decimals="INF"
      id="Fact000495"
      unitRef="Shares">21174693</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-08-29"
      decimals="INF"
      id="Fact000497"
      unitRef="Shares">1058447</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:SubstantialDoubtAboutGoingConcernTextBlock contextRef="From2024-04-01to2025-03-31" id="Fact000499">&lt;p id="xdx_80E_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_zVYSDyEUIFBf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;NOTE&#160;2&#160;&#x2013; &lt;span id="xdx_824_zvtIywnGNETg"&gt;Liquidity and Financial
Condition&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company reported a net loss of $&lt;span id="xdx_907_eus-gaap--NetIncomeLoss_iN_pn3d_di_c20240401__20250331_zkAVQdrogdM1" title="Net loss"&gt;3,457,000&lt;/span&gt; and
$&lt;span id="xdx_902_eus-gaap--NetIncomeLoss_iN_pn3d_di_c20230401__20240331_zo9lYkMPw6E6" title="Net loss"&gt;4,835,000&lt;/span&gt; for the years ended March 31, 2025 and 2024, respectively. At March 31, 2025 and 2024, the Company&#x2019;s accumulated deficit
amounted to $&lt;span id="xdx_90C_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn3d_di_c20250331_zY7G5dAk9iBg" title="Accumulated deficit"&gt;197,806,000&lt;/span&gt; and $&lt;span id="xdx_905_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn3d_di_c20240331_zPy8nBijmeXd" title="Accumulated deficit"&gt;194,349,000&lt;/span&gt;, respectively. The Company had working capital of $&lt;span id="xdx_903_ecustom--WorkingCapital_iI_pn3d_c20250331_zhIEi1pBPDij" title="Working capital"&gt;8,552,000&lt;/span&gt; and $&lt;span id="xdx_90E_ecustom--WorkingCapital_iI_pn3d_c20240331_zFwcigRl0Hm9" title="Working capital"&gt;8,829,000&lt;/span&gt; as of March 31,
2025 and 2024, respectively. During the years ended March 31, 2025 and 2024, net cash used in operating activities amounted to $&lt;span id="xdx_901_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn3d_di_c20240401__20250331_zxNWV6j7Hlkb" title="Net cash used in operating activities"&gt;88,000&lt;/span&gt;
and $&lt;span id="xdx_902_eus-gaap--NetCashProvidedByUsedInOperatingActivities_pn3d_di_c20230401__20240331_zPpq9JAUOs3l" title="Net cash used in operating activities"&gt;2,398,000&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Management believes that the Company has access to
additional capital resources through possible public or private equity offerings, debt financings, corporate collaborations or other means;
however, the Company cannot provide any assurance that other new financings will be available on commercially acceptable terms, if needed.
If the economic climate in the U.S. deteriorates, the Company&#x2019;s ability to raise additional capital could be negatively impacted.
If the Company is unable to secure additional capital, it may be required to take additional measures to reduce costs in order to conserve
its cash in amounts sufficient to sustain operations and meet its obligations. These measures could cause significant delays in the Company&#x2019;s
continued efforts to commercialize its products, which is critical to the realization of its business plan and the future operations of
the Company. This uncertainty along with the Company&#x2019;s history of losses indicates that there is substantial doubt about the Company&#x2019;s
ability to continue as a going concern within one year after the date that the financial statements are issued. The accompanying consolidated
financial statements do not include any adjustments that may be necessary should the Company be unable to continue as a going concern.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;











</us-gaap:SubstantialDoubtAboutGoingConcernTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-04-01to2025-03-31"
      decimals="-3"
      id="Fact000501"
      unitRef="USD">-3457000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000503"
      unitRef="USD">-4835000</us-gaap:NetIncomeLoss>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000505"
      unitRef="USD">-197806000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000507"
      unitRef="USD">-194349000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <SNOA:WorkingCapital
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000509"
      unitRef="USD">8552000</SNOA:WorkingCapital>
    <SNOA:WorkingCapital
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000511"
      unitRef="USD">8829000</SNOA:WorkingCapital>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2024-04-01to2025-03-31"
      decimals="-3"
      id="Fact000513"
      unitRef="USD">-88000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000515"
      unitRef="USD">-2398000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2024-04-01to2025-03-31" id="Fact000521">&lt;p id="xdx_806_eus-gaap--SignificantAccountingPoliciesTextBlock_zhHolBDxX8Tk" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;NOTE&#160;3&#160;&#x2013; &lt;span id="xdx_821_zALFjH70BR3h"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--ConsolidationPolicyTextBlock_zFCMgRfKpc75" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_867_zWUv3pyVpebg"&gt;Principles of Consolidation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The accompanying consolidated financial statements
include the accounts of the Company and its wholly-owned subsidiaries, Aquamed Technologies, Inc. (&#x201c;Aquamed&#x201d;), Oculus Technologies
of Mexico S.A. de C.V. (&#x201c;OTM&#x201d;), and Sonoma Pharmaceuticals Netherlands, B.V. (&#x201c;SP Europe&#x201d;). Aquamed has no current
operations. All significant intercompany accounts and transactions have been eliminated in consolidation. The functional currency for
the Company's wholly-owned subsidiaries incorporated outside the United States (&#x201c;U.S.&#x201d;) is denominated in local currency.
All intercompany transactions and balances have been eliminated in consolidation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zWO4SrWVIK9i" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86E_z0OSA6GpE8dk"&gt;Basis of presentation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The accompanying consolidated financial statements
have been prepared by the Company pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;)
and are in conformity with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;). The Company&#x2019;s fiscal year end is
March 31. Unless otherwise stated, all years and dates refer to the fiscal year.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zbi6hHFy5V1j" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86D_z1JpcBObEDKg"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Cash and cash equivalents include cash on hand and
all highly liquid investments with an original maturity of three months or less when purchased. The Company&#x2019;s cash equivalents are
held in prime money market investments with strong sponsor organizations which are monitored on a continuous basis.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--UseOfEstimates_zARxaseIFqd9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86C_zuboPzXHnq0j"&gt;Use of Estimates&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The preparation of consolidated financial statements
in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities
and disclosures of contingent liabilities at the dates of the consolidated financial statements and the reported amounts of revenues and
expenses during the reporting periods. Actual results could differ from these estimates. Significant estimates and assumptions include
reserves and write-downs related to receivables and inventories, the valuation allowance relating to the Company&#x2019;s deferred tax
assets and the valuation of equity. Periodically, the Company evaluates and adjusts estimates accordingly.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;p id="xdx_84A_eus-gaap--RevenueRecognitionPolicyTextBlock_z1wMiCXxsrO2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_863_z48omwCJAjZ"&gt;Revenue Recognition&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company recognizes revenue in accordance with
Accounting Standards Codification (&#x201c;ASC&#x201d;), Topic 606 Revenue from Contracts with Customers (&#x201c;Topic 606&#x201d;). Revenue
is recognized when the Company transfers promised goods or services to the customer, in an amount that reflects the consideration which
the Company expects to receive in exchange for those goods or services. In determining the appropriate amount of revenue to be recognized
as the Company fulfills its obligations under the agreement, the Company performs the following steps: (i)&#160;identification of the
promised goods or services in the contract; (ii)&#160;determination of whether the promised goods or services are performance obligations,
including whether they are distinct in the context of the contract; (iii)&#160;measurement of the transaction price, including the constraint
on variable consideration; (iv)&#160;allocation of the transaction price to the performance obligations; and (v)&#160;recognition of revenue
when (or as) the Company satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable
that it will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company derives the majority of its revenue through
sales of its products directly to end users and to distributors. The Company also sells products to a customer base, including hospitals,
medical centers, doctors, pharmacies, distributors and wholesalers. The Company has also entered into agreements to license its technology
and products.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;











&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company considers customer purchase orders, which
in some cases are governed by master sales agreements, to be the contracts with a customer. For each contract, the Company considers the
promise to transfer products, each of which are distinct, to be the identified performance obligations. In determining the transaction
price the Company evaluates whether the price is subject to refund or adjustment to determine the net consideration to which it expects
to be entitled.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;For all of the Company&#x2019;s sales to non-consignment
distribution channels, revenue is recognized when control of the product is transferred to the customer (i.e. when its performance obligation
is satisfied), which typically occurs when title passes to the customer upon shipment but could occur when the customer receives the product
based on the terms of the agreement with the customer. For product sales to its value-added resellers, non-stocking distributors and end-user
customers, the Company grants return privileges to its customers, and because the Company has a long history with its customers, the Company
is able to estimate the amount of product that will be returned.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company has entered into consignment arrangements,
in which goods are left in the possession of another party to sell. As products are sold from the customer to third parties, the Company
recognizes revenue based on a variable percentage of a fixed price.&#160; Revenue recognized varies depending on whether a patient is
covered by insurance or is not covered by insurance.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Sales to stocking distributors are made under terms
with fixed pricing and limited rights of return (known as &#x201c;stock rotation&#x201d;) of the Company&#x2019;s products held in their
inventory. Revenue from sales to distributors is recognized upon the transfer of control to the distributor.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company assessed the promised goods and services
in the technical support contract with Invekra for a ten-year period as being a distinct service that Invekra can benefit from on its
own and as separately identifiable from any other promises within the contract. Given that the distinct service is not substantially the
same as other goods and services within the Invekra contract, the Company accounted for the distinct service as a performance obligation.
At March 31, 2025, 2024 and 2023, the Company had deferred revenue related to Invekra in the amounts of $&lt;span id="xdx_90A_eus-gaap--DeferredRevenue_iI_c20250331__srt--CounterpartyNameAxis__custom--InvekraMember_zO9rRnEo6sg6" title="Deferred revenue"&gt;69,000&lt;/span&gt;, $&lt;span id="xdx_901_eus-gaap--DeferredRevenue_iI_c20240331__srt--CounterpartyNameAxis__custom--InvekraMember_ziXOijcRWpwk" title="Deferred revenue"&gt;152,000&lt;/span&gt; and $&lt;span id="xdx_902_eus-gaap--DeferredRevenue_iI_c20230331__srt--CounterpartyNameAxis__custom--InvekraMember_zvSL9N13U10b" title="Deferred revenue"&gt;199,000&lt;/span&gt;,
respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--ConcentrationRiskCreditRisk_zqlCuFOr3dfi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86A_z4W2cjcpOXcj"&gt;Concentration of Credit Risk and Major Customers&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Financial instruments that potentially subject the
Company to concentration of credit risk consist principally of cash, cash equivalents and accounts receivable. Cash and cash equivalents
are maintained in financial institutions in the United States, Mexico and the Netherlands. The Company is exposed to credit risk in the
event of default by these financial institutions for amounts in excess of the Federal Deposit Insurance Corporation insured limits. Cash
and cash equivalents held in foreign banks are intentionally kept at minimal levels, and therefore have minimal credit risk associated
with them. We currently have $3,004,000 of deposits above federally insured limits.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following table shows major customers revenues
as a percentage of revenue:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_zURPyO22S4I1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B2_zFIfATK9pKB9" style="display: none"&gt;Schedule of concentration of risk&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the Year Ended March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 66%; text-align: left"&gt;Customer A&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b style="display: none"&gt;&lt;span style="display: none"&gt;&lt;/span&gt;&lt;span id="xdx_90D_ecustom--ConcentrationRiskPercentage2_pip0_dp_c20240401__20250331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerAMember_fKg_____zm3kWnC3lWsd" title="Concentration risk, percentage"&gt;0&lt;/span&gt;&lt;/b&gt;*%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;&lt;span id="xdx_90C_ecustom--ConcentrationRiskPercentage2_pip0_dp_c20230401__20240331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerAMember_zs1bdHhh0kR9" title="Concentration risk, percentage"&gt;17&lt;/span&gt;%&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Customer B&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_ecustom--ConcentrationRiskPercentage2_pip0_dp_c20240401__20250331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerBMember_z4KIjyeKukt9" title="Concentration risk, percentage"&gt;21&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_ecustom--ConcentrationRiskPercentage2_pip0_dp_c20230401__20240331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerBMember_zBZGw8JhTJu7" title="Concentration risk, percentage"&gt;15&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;Customer C&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_ecustom--ConcentrationRiskPercentage2_pip0_dp_c20240401__20250331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerCMember_zd6MRrjG5LH4" title="Concentration risk, percentage"&gt;18&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_905_ecustom--ConcentrationRiskPercentage2_pip0_dp_c20230401__20240331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerCMember_zrvShVJuihOl" title="Concentration risk, percentage"&gt;14&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following table shows major customers accounts
receivable balances as a percentage of net accounts receivables:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 66%; text-align: left"&gt;Customer B&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;&lt;b style="display: none"&gt;&lt;span id="xdx_90F_ecustom--ConcentrationRiskPercentage2_pip0_dp_c20240401__20250331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerBMember_fKg_____zSPeLzx9ieyc" title="Concentration risk, percentage"&gt;0&lt;/span&gt;&lt;/b&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;*%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;&lt;span id="xdx_907_ecustom--ConcentrationRiskPercentage2_pip0_dp_c20230401__20240331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerBMember_zhhrzMCrV01k" title="Concentration risk, percentage"&gt;13&lt;/span&gt;%&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Customer D&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_ecustom--ConcentrationRiskPercentage2_pip0_dp_c20240401__20250331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerDMember_zRqpvevFHgF6" title="Concentration risk, percentage"&gt;24&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_ecustom--ConcentrationRiskPercentage2_pip0_dp_c20230401__20240331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerDMember_zEwXw7xH1If5" title="Concentration risk, percentage"&gt;17&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 4%"&gt;&lt;span id="xdx_F09_zisvXV838286" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;* &lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_F19_zg6Uo3NevcBg" style="width: 96%"&gt;% &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Represents less than
    10%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8AB_zKPUBR4dA57j" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;











&lt;p id="xdx_84D_eus-gaap--ReceivablesPolicyTextBlock_zPTyarxsC5N9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_860_zTS6l5klpGF"&gt;Accounts Receivable&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Trade accounts receivable are recorded net of allowances
for cash discounts for prompt payment, doubtful accounts, and sales returns. Estimates for cash discounts and sales returns are based
on analysis of contractual terms and historical trends.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&#x2019;s policy is to reserve for uncollectible
accounts based on its best estimate of the amount of probable credit losses in its existing accounts receivable. The Company periodically
reviews its accounts receivable to determine whether an allowance for doubtful accounts is necessary based on an analysis of past due
accounts and other factors that may indicate that the realization of an account may be in doubt. Other factors that the Company considers
include its existing contractual obligations, historical payment patterns of its customers and individual customer circumstances, an analysis
of days sales outstanding by customer and geographic region, and a review of the local economic environment and its potential impact on
government funding and reimbursement practices. Account balances deemed to be uncollectible are charged to the allowance after all means
of collection have been exhausted and the potential for recovery is considered remote. The Company did &lt;span id="xdx_909_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pn3p0_do_c20250331__srt--ProductOrServiceAxis__custom--ProbableCreditLossesMember_zW7wAdkE2NY9" title="Allowance for doubtful accounts"&gt;&lt;span id="xdx_90F_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pn3p0_do_c20240331__srt--ProductOrServiceAxis__custom--ProbableCreditLossesMember_zYdQNrIU7HM7" title="Allowance for doubtful accounts"&gt;&lt;span id="xdx_903_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pn3p0_do_c20230331__srt--ProductOrServiceAxis__custom--ProbableCreditLossesMember_zOc54kajgLh9" title="Allowance for doubtful accounts"&gt;no&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;t deem it necessary to record
an allowance for doubtful accounts for probable credit losses at March 31, 2025, March 31, 2024 and March 31, 2023. Additionally, at March
31, 2025, 2024 and 2023, the Company has allowances of $&lt;span id="xdx_909_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pn3p0_c20250331__srt--ProductOrServiceAxis__custom--PotentialDiscountsReturnsDistributorFeesAndRebatesMember_zX36jruvOYM2" title="Allowance for doubtful accounts"&gt;8,000&lt;/span&gt;, $&lt;span id="xdx_90E_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pn3p0_c20240331__srt--ProductOrServiceAxis__custom--PotentialDiscountsReturnsDistributorFeesAndRebatesMember_zKceXqOGAQn7" title="Allowance for doubtful accounts"&gt;27,000&lt;/span&gt; and $&lt;span id="xdx_90B_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pn3p0_c20230331__srt--ProductOrServiceAxis__custom--PotentialDiscountsReturnsDistributorFeesAndRebatesMember_zPChwlnQfONi" title="Allowance for doubtful accounts"&gt;16,000&lt;/span&gt;, respectively, related to potential discounts, returns,
distributor fees and rebates. The allowances are included in accounts receivable, net in the accompanying consolidated balance sheets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--InventoryPolicyTextBlock_zZwKbfNYAqn2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86D_z1WH85EQNkGe"&gt;Inventories&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Inventories are stated at the lower of cost, cost
being determined on a standard cost basis (which approximates actual cost on a first-in, first-out basis), or net realizable value.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Due to changing market conditions, estimated future
requirements, age of the inventories on hand and production of new products, the Company regularly reviews inventory quantities on hand
and records a provision to write down excess and obsolete inventory to its estimated net realizable value. At March 31, 2025 and 2024,
the Company recorded provisions to reduce the carrying amounts of inventories to their net realizable value in the amounts of $&lt;span id="xdx_90D_eus-gaap--InventoryValuationReserves_iI_pn3p0_c20250331_zNTLPOQMjbl1" title="Inventory valuation reserves"&gt;298,000&lt;/span&gt;
and $&lt;span id="xdx_90E_eus-gaap--InventoryValuationReserves_iI_pn3p0_c20240331_zSpzd72K9l4f"&gt;296,000&lt;/span&gt;, respectively, which is included in inventories, net on the Company&#x2019;s accompanying consolidated balance sheets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zBuZLvGvya3i" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86E_zwRFaxwCdK11"&gt;Financial Assets and Liabilities&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Financial instruments, including cash and cash equivalents,
accounts receivable and accounts payable are carried at cost, which management believes approximates fair value due to the short-term
nature of these instruments. The fair value of capital lease obligations and approximates their carrying amounts as a market rate of interest
is attached to their repayment. The Company measures the fair value of financial assets and liabilities based on the exchange price that
would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset
or liability in an orderly transaction between market participants on the measurement date. The Company maximizes the use of observable
inputs and minimizes the use of unobservable inputs when measuring fair value. The Company uses three levels of inputs that may be used
to measure fair value:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Level&#160;1&#160;&#x2013; quoted prices in active
markets for identical assets or liabilities;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Level&#160;2&#160;&#x2013; quoted prices for similar
assets and liabilities in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived
valuations in which all significant inputs and significant value drivers are observable in active markets;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Level&#160;3&#160;&#x2013; inputs that are unobservable
(for example cash flow modeling inputs based on assumptions).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;











&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Level 3 liabilities are valued using unobservable
inputs to the valuation methodology that are significant to the measurement of the fair value of the liabilities. For fair value measurements
categorized within Level 3 of the fair value hierarchy, the Company&#x2019;s accounting and finance department, who report to the Chief
Financial Officer, determine its valuation policies and procedures. The development and determination of the unobservable inputs for Level
3 fair value measurements and fair value calculations are the responsibility of the Company&#x2019;s accounting and finance department
and are approved by the Chief Financial Officer.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of March 31, 2025 and 2024, there were &lt;span id="xdx_908_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_pn3p0_do_c20240401__20250331_zEuzx62r1c" title="Transfers in or out of level 3"&gt;&lt;span id="xdx_906_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_pn3p0_do_c20230401__20240331_z103ndt1RRJ2" title="Transfers in or out of level 3"&gt;no&lt;/span&gt;&lt;/span&gt; transfers
in or out of Level 3 from other levels in the fair value hierarchy.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zyAALfoPUln6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_860_zCNI749PVwT8"&gt;Property and Equipment&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Property and equipment are stated at cost less accumulated
depreciation. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the
respective assets. Depreciation of leasehold improvements is computed using the straight-line method over the lesser of the estimated
useful life of the improvement or the remaining term of the lease. Estimated useful asset life by classification is as follows:&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_88B_ecustom--PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock_z9YQN5p6tJKg" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details-Useful lives)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B9_zM2xeXOwrCCe" style="display: none"&gt;Schedule of property and equipment estimated useful life&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Years&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 86%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20250331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_z8tCHer5CRwh" title="Useful asset life"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Manufacturing, lab and other equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20250331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zdPY9cCcanw" title="Useful asset life"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20250331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zcEr4Z1vwZIb" title="Useful asset life"&gt;7&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Upon retirement or sale, the cost and related accumulated
depreciation are removed from the consolidated balance sheet and the resulting gain or loss is reflected in operations. Maintenance and
repairs are charged to operations as incurred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zczGeUAYV3Pf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86B_zJn9hugvmEM7"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company periodically reviews the carrying values
of its long-lived assets when events or changes in circumstances would indicate that it is more likely than not that their carrying values
may exceed their realizable values, and records impairment charges when considered necessary. Specific potential indicators of impairment
include, but are not necessarily limited to:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Symbol; font-size: 10pt"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a significant decrease in the fair value of an asset;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Symbol; font-size: 10pt"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a significant change in the extent or manner in which an asset is used or a significant physical change in an asset;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Symbol; font-size: 10pt"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a significant adverse change in legal factors or in the business climate that affects the value of an asset;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Symbol; font-size: 10pt"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;an adverse action or assessment by the U.S.&#160;Food and Drug Administration or another regulator; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Symbol; font-size: 10pt"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;an accumulation of costs significantly in excess of the amount originally expected to acquire or construct an asset; and operating or cash flow losses combined with a history of operating or cash flow losses or a projection or forecast that demonstrates continuing losses associated with an income-producing asset.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;











&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;When circumstances indicate that an impairment may
have occurred, the Company tests such assets for recoverability by comparing the estimated undiscounted future cash flows expected to
result from the use of such assets and their eventual disposition to their carrying amounts. In estimating these future cash flows, assets
and liabilities are grouped at the lowest level for which there are identifiable cash flows that are largely independent of the cash flows
generated by other such groups. If the undiscounted future cash flows are less than the carrying amount of the asset, an impairment loss,
measured as the excess of the carrying value of the asset over its estimated fair value, will be recognized. The cash flow estimates used
in such calculations are based on estimates and assumptions, using all available information that management believes is reasonable. The
Company did &lt;span id="xdx_90B_eus-gaap--AssetImpairmentCharges_pn3p0_do_c20240401__20250331_zCVjrL7UJIX5" title="Impairment of long lived assets"&gt;&lt;span id="xdx_90D_eus-gaap--AssetImpairmentCharges_pn3p0_do_c20230401__20240331_zVkJgRm2Mdkf" title="Impairment of long lived assets"&gt;no&lt;/span&gt;&lt;/span&gt;t record impairment losses for the years ended March 31, 2025 and 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--ResearchAndDevelopmentExpensePolicy_zrSsLGROXZac" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86E_zFthTNrrfmVi"&gt;Research and Development&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Research and development expenses are charged to operations
as incurred and consists primarily of personnel expenses, clinical and regulatory services and supplies. For the years ended March 31,
2025 and 2024, research and development expense amounted to $&lt;span id="xdx_900_eus-gaap--ResearchAndDevelopmentExpense_pn3p0_c20240401__20250331_zl6YV1lL8wLl" title="Research and development expenses"&gt;1,814,000&lt;/span&gt; and $&lt;span id="xdx_903_eus-gaap--ResearchAndDevelopmentExpense_pn3p0_c20230401__20240331_zTfBPPtLwtb1" title="Research and development expenses"&gt;1,871,000&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--AdvertisingCostsPolicyTextBlock_zLZeZWIZQEce" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86D_zxvr5GkT24Gh"&gt;Advertising Costs&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Advertising costs are charged to operations as incurred.
Advertising costs amounted to $&lt;span id="xdx_901_eus-gaap--MarketingExpense_pn3p0_c20240401__20250331_zm8yljMrOCJ3" title="Advertising costs"&gt;190,000&lt;/span&gt; and $&lt;span id="xdx_901_eus-gaap--MarketingExpense_pn3p0_c20230401__20240331_zy00uSelb4nl" title="Advertising costs"&gt;156,000&lt;/span&gt; for the years ended March 31, 2025 and 2024, respectively. Advertising costs are included
in selling, general and administrative expenses in the accompanying consolidated statements of comprehensive loss.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_848_ecustom--ShippingAndHandlingCost1PolicyTextBlock_zHYgmM3ZqYo5" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86B_zBBmV5Jyaq45"&gt;Shipping and Handling Costs&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company classifies amounts billed to customers
related to shipping and handling in sale transactions as product revenues. The corresponding shipping and handling costs incurred are
recorded in cost of product revenues. For the years ended March 31, 2025 and 2024, the Company recorded revenue related to shipping and
handling costs of $&lt;span id="xdx_90E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20240401__20250331__srt--ProductOrServiceAxis__us-gaap--ShippingAndHandlingMember_z1kK9aignMee" title="Revenues"&gt;18,000&lt;/span&gt; and $&lt;span id="xdx_90B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20230401__20240331__srt--ProductOrServiceAxis__us-gaap--ShippingAndHandlingMember_zEfQQNdAdq9" title="Revenues"&gt;28,000&lt;/span&gt;, respectively. These amounts are included in revenues in the accompanying consolidated statements
of comprehensive loss.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zByY8TNCHpb5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_861_zm6POr9eOYzg"&gt;Foreign Currency Reporting&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&#x2019;s subsidiary, OTM, uses the local
currency (Mexican Pesos) as its functional currency and its subsidiary, SP Europe, uses the local currency (Euro) as its functional currency.
Assets and liabilities are translated at exchange rates in effect at the balance sheet date, and revenue and expense accounts are translated
at average exchange rates during the period. Resulting translation adjustments amounted to losses of $&lt;span id="xdx_90E_ecustom--OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationLossAdjustmentBeforeTaxPortionAttributableToParent_pn3p0_c20240401__20250331__us-gaap--IncomeStatementLocationAxis__us-gaap--OtherComprehensiveIncomeMember_zbkTsSEsWFL" title="Foreign currency translation adjustment loss"&gt;1,653,000&lt;/span&gt; and gains of $&lt;span id="xdx_90D_ecustom--OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainAdjustmentBeforeTaxPortionAttributableToParent_pn3p0_c20230401__20240331__us-gaap--IncomeStatementLocationAxis__us-gaap--OtherComprehensiveIncomeMember_zMXOCNhpjITg" title="Foreign currency translation adjustment gain"&gt;695,000&lt;/span&gt;
for the years ended March 31, 2025 and 2024, respectively. These amounts were recorded in other comprehensive loss in the accompanying
consolidated statements of comprehensive loss for the years ended March 31, 2025 and 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Foreign currency transaction losses relate primarily
to trade payables and receivables and intercompany transactions between subsidiaries OTM and SP Europe. These transactions are expected
to be settled in the foreseeable future. The Company recorded foreign currency transaction gains of $&lt;span id="xdx_90C_eus-gaap--ForeignCurrencyTransactionGainBeforeTax_pn3p0_c20240401__20250331__us-gaap--IncomeStatementLocationAxis__us-gaap--OtherOperatingIncomeExpenseMember_zg09fRLQWx06" title="Foreign currency transaction gain"&gt;243,000&lt;/span&gt; and losses of $&lt;span id="xdx_904_eus-gaap--ForeignCurrencyTransactionLossBeforeTax_pn3p0_c20230401__20240331__us-gaap--IncomeStatementLocationAxis__us-gaap--OtherOperatingIncomeExpenseMember_zUrCXDQodvIc" title="Foreign currency transaction loss"&gt;825,000&lt;/span&gt; for
the years ended March 31, 2025 and 2024, respectively. The related amounts were recorded in other income (expense) in the accompanying
consolidated statements of comprehensive loss.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;











&lt;p id="xdx_84B_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zaj8FWd4iUY5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_869_z5PeiaDESwAl"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company accounts for share-based awards exchanged
for employee services at the estimated grant date fair value of the award. The Company estimates the fair value of employee stock option
awards using the Black-Scholes option pricing model. The Company amortizes the fair value of employee stock options on a straight-line
basis over the requisite service period of the awards.&#160; Compensation expense includes the impact of forfeitures for all stock options
as incurred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company accounts for equity instruments issued
to non-employees at their fair value on the measurement date. The measurement of stock-based compensation is subject to periodic adjustment
as the underlying equity instrument vests or becomes non-forfeitable. Non-employee stock-based compensation charges are amortized over
the vesting period or as earned.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--IncomeTaxPolicyTextBlock_zNsCtF9G88Tk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_861_zstvjz8290e3"&gt;Income Taxes&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Deferred tax assets and liabilities are determined
based on the differences between the financial reporting and tax bases of assets and liabilities and net operating loss and credit carryforwards
using enacted tax rates in effect for the year in which the differences are expected to impact taxable income. Valuation allowances are
established when necessary to reduce deferred tax assets to the amounts expected to be realized.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Tax benefits claimed or expected to be claimed on
a tax return are recorded in the Company&#x2019;s consolidated financial statements. A tax benefit from an uncertain tax position is only
recognized if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the
technical merits of the position. The tax benefits recognized in the consolidated financial statements from such a position are measured
based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate resolution. Uncertain tax
positions have had no impact on the Company&#x2019;s consolidated financial condition, results of comprehensive loss or cash flows.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zlrbnMPJy9x7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_865_zLOGtLVLckb4"&gt;Comprehensive Loss&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Other comprehensive loss includes all changes in stockholders&#x2019;
equity during a period from non-owner sources and is reported in the consolidated statements of changes in stockholders&#x2019; equity.
To date, other comprehensive loss consists of changes in accumulated foreign currency translation adjustments. Accumulated other comprehensive
losses at March 31, 2025 and 2024 were $&lt;span id="xdx_905_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_iNI_pn3p0_di_c20250331_zxCDSkwmUNEb" title="Accumulated other comprehensive loss"&gt;4,376,000&lt;/span&gt; and $&lt;span id="xdx_908_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_iNI_pn3p0_di_c20240331_zgzxoULws9Kc" title="Accumulated other comprehensive loss"&gt;2,723,000&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p id="xdx_84F_eus-gaap--EarningsPerSharePolicyTextBlock_zpJt2VoxNfvk" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_861_zWe7aV4iEVtg"&gt;Net Loss per Share&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company computes basic net loss per share by dividing
net loss per share available to common stockholders by the weighted average number of common shares outstanding for the period and excludes
the effects of any potentially dilutive securities. Diluted earnings per share, if presented, would include the dilution that would occur
upon the exercise or conversion of all potentially dilutive securities into common stock using the &#x201c;treasury stock&#x201d; and/or
&#x201c;if converted&#x201d; methods as applicable.&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_88F_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_pn3n3_zQMVT2I9u4s5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details - Earnings per share)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8BE_zLPDMRGi4yR4" style="display: none"&gt;Schedule of computation of earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20240401__20250331_zWUtF7nS72Hj" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20230401__20240331_zbQOYGMhuxv8" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the Year Ended March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; font-style: italic; text-align: justify"&gt;(In thousands, except per share data)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--NetIncomeLoss_zvPHG1sUVEZf" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 66%; text-align: justify; padding-bottom: 2.5pt"&gt;Net loss&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 13%; text-align: right"&gt;(3,457&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 13%; text-align: right"&gt;(4,835&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;Weighted-average shares outstanding: basic and diluted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20240401__20250331_zHmQpmxLzLe2" title="Weighted-average number of shares: basic"&gt;&lt;span id="xdx_906_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20240401__20250331_zCDm0AKmLbNf" title="Weighted-average number of shares: diluted"&gt;1,241&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20230401__20240331_zPC1HfhiTm8l" title="Weighted-average number of shares: basic"&gt;&lt;span id="xdx_90C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20230401__20240331_zM3Y70VsLL15" title="Weighted-average number of shares: diluted"&gt;455&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Net loss per share: basic and diluted&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--EarningsPerShareBasic_pip0_c20240401__20250331_zlxfDkaNIuOh" title="Net loss per share: basic"&gt;&lt;span id="xdx_908_eus-gaap--EarningsPerShareDiluted_pip0_c20240401__20250331_zuPDGioUbHCl" title="Net loss per share: diluted"&gt;(2.79&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--EarningsPerShareBasic_pip0_c20230401__20240331_zIXPvimnH9sj" title="Net loss per share: basic"&gt;&lt;span id="xdx_903_eus-gaap--EarningsPerShareDiluted_pip0_c20230401__20240331_z7gXdVrOEh5g" title="Net loss per share: diluted"&gt;(10.63&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;











&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The computation of basic and diluted loss per share
for the years ended March 31, 2025 and 2024 excludes the potentially dilutive securities summarized in the table below because their inclusion
would be anti-dilutive.&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_889_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_pn3n3_zX61miRCNuQg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details - Antidilutive shares)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8BF_zWNkXJhCOLd9" style="display: none"&gt;Schedule of antidilutive shares&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; font-style: italic"&gt;(In thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 66%; text-align: left"&gt;Common stock to be issued upon exercise of options&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20240401__20250331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zBk6aclmuVK3" style="width: 13%; text-align: right" title="Antidilutive shares"&gt;73&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20230401__20240331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_z0hBUAViGQkk" style="width: 13%; text-align: right" title="Antidilutive shares"&gt;52&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Common stock to be issued upon vesting of restricted stock units&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_d0_c20240401__20250331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockUnitsMember_ze0KvSHOnXyk" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive shares"&gt;45&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_d0_c20230401__20240331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockUnitsMember_zvW2tD8pJZB5" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive shares"&gt;&#x2013;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20240401__20250331_z61stojKYFSa" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive shares"&gt;118&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20230401__20240331_z052IKLT9YAg" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive shares"&gt;52&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p id="xdx_849_ecustom--ConvertiblePreferredStockPolicyTextBlock_zTSZEVEHfJB1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_863_zpJiJv2ta99c"&gt;Convertible Preferred Stock&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company applies the accounting standards for distinguishing
liabilities from equity when determining the classification and measurement of its preferred stock. Shares that are subject to mandatory
redemption (if any) are classified as liability instruments and are measured at fair value. The Company classifies conditionally redeemable
preferred shares, which includes preferred shares that feature redemption rights that are either within the control of the holder or subject
to redemption upon the occurrence of uncertain events not solely within the Company&#x2019;s control, as temporary equity. At all other
times, preferred shares are classified as stockholders' equity. There are &lt;span id="xdx_90B_eus-gaap--PreferredStockSharesIssued_iI_pip0_do_c20250331_zD131bkgvo27" title="Preferred stock, shares issued"&gt;no&lt;/span&gt; shares issued as of March 31, 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--SegmentReportingPolicyPolicyTextBlock_z8U1KU9n1Ug5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86F_z1x7JkOJP5u4"&gt;Segment Reporting&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company has one primary business activity and operate in one reportable
segment. The Company&#x2019;s chief operating decision maker (&#x201c;CODM&#x201d;) is its Chief Executive Officer (&#x201c;CEO&#x201d;) who
evaluates performance and makes operating decisions about allocating resources based on financial data presented on a consolidated basis.
The measures of profitability and the significant segment expenses reviewed by the CODM are consistent with these financial statements
and footnotes.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--SubsequentEventsPolicyPolicyTextBlock_z5blvubMPCZb" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86A_zG2oQtqrhGk6"&gt;Subsequent Events&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Management has evaluated subsequent events or transactions
occurring through the date these consolidated financial statements were issued. All events requiring disclosure have been incorporated
into the notes to the consolidated financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zaligiqAgjO1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_867_zbiuXHAVh7b2"&gt;Recent Accounting Standards&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company has evaluated all the recent accounting
standards and determined that none are material to it.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="From2024-04-01to2025-03-31" id="Fact000523">&lt;p id="xdx_841_eus-gaap--ConsolidationPolicyTextBlock_zFCMgRfKpc75" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_867_zWUv3pyVpebg"&gt;Principles of Consolidation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The accompanying consolidated financial statements
include the accounts of the Company and its wholly-owned subsidiaries, Aquamed Technologies, Inc. (&#x201c;Aquamed&#x201d;), Oculus Technologies
of Mexico S.A. de C.V. (&#x201c;OTM&#x201d;), and Sonoma Pharmaceuticals Netherlands, B.V. (&#x201c;SP Europe&#x201d;). Aquamed has no current
operations. All significant intercompany accounts and transactions have been eliminated in consolidation. The functional currency for
the Company's wholly-owned subsidiaries incorporated outside the United States (&#x201c;U.S.&#x201d;) is denominated in local currency.
All intercompany transactions and balances have been eliminated in consolidation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2024-04-01to2025-03-31" id="Fact000525">&lt;p id="xdx_840_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zWO4SrWVIK9i" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86E_z0OSA6GpE8dk"&gt;Basis of presentation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The accompanying consolidated financial statements
have been prepared by the Company pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;)
and are in conformity with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;). The Company&#x2019;s fiscal year end is
March 31. Unless otherwise stated, all years and dates refer to the fiscal year.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2024-04-01to2025-03-31" id="Fact000527">&lt;p id="xdx_845_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zbi6hHFy5V1j" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86D_z1JpcBObEDKg"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Cash and cash equivalents include cash on hand and
all highly liquid investments with an original maturity of three months or less when purchased. The Company&#x2019;s cash equivalents are
held in prime money market investments with strong sponsor organizations which are monitored on a continuous basis.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2024-04-01to2025-03-31" id="Fact000529">&lt;p id="xdx_84E_eus-gaap--UseOfEstimates_zARxaseIFqd9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86C_zuboPzXHnq0j"&gt;Use of Estimates&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The preparation of consolidated financial statements
in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities
and disclosures of contingent liabilities at the dates of the consolidated financial statements and the reported amounts of revenues and
expenses during the reporting periods. Actual results could differ from these estimates. Significant estimates and assumptions include
reserves and write-downs related to receivables and inventories, the valuation allowance relating to the Company&#x2019;s deferred tax
assets and the valuation of equity. Periodically, the Company evaluates and adjusts estimates accordingly.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="From2024-04-01to2025-03-31" id="Fact000531">&lt;p id="xdx_84A_eus-gaap--RevenueRecognitionPolicyTextBlock_z1wMiCXxsrO2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_863_z48omwCJAjZ"&gt;Revenue Recognition&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company recognizes revenue in accordance with
Accounting Standards Codification (&#x201c;ASC&#x201d;), Topic 606 Revenue from Contracts with Customers (&#x201c;Topic 606&#x201d;). Revenue
is recognized when the Company transfers promised goods or services to the customer, in an amount that reflects the consideration which
the Company expects to receive in exchange for those goods or services. In determining the appropriate amount of revenue to be recognized
as the Company fulfills its obligations under the agreement, the Company performs the following steps: (i)&#160;identification of the
promised goods or services in the contract; (ii)&#160;determination of whether the promised goods or services are performance obligations,
including whether they are distinct in the context of the contract; (iii)&#160;measurement of the transaction price, including the constraint
on variable consideration; (iv)&#160;allocation of the transaction price to the performance obligations; and (v)&#160;recognition of revenue
when (or as) the Company satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable
that it will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company derives the majority of its revenue through
sales of its products directly to end users and to distributors. The Company also sells products to a customer base, including hospitals,
medical centers, doctors, pharmacies, distributors and wholesalers. The Company has also entered into agreements to license its technology
and products.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;











&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company considers customer purchase orders, which
in some cases are governed by master sales agreements, to be the contracts with a customer. For each contract, the Company considers the
promise to transfer products, each of which are distinct, to be the identified performance obligations. In determining the transaction
price the Company evaluates whether the price is subject to refund or adjustment to determine the net consideration to which it expects
to be entitled.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;For all of the Company&#x2019;s sales to non-consignment
distribution channels, revenue is recognized when control of the product is transferred to the customer (i.e. when its performance obligation
is satisfied), which typically occurs when title passes to the customer upon shipment but could occur when the customer receives the product
based on the terms of the agreement with the customer. For product sales to its value-added resellers, non-stocking distributors and end-user
customers, the Company grants return privileges to its customers, and because the Company has a long history with its customers, the Company
is able to estimate the amount of product that will be returned.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company has entered into consignment arrangements,
in which goods are left in the possession of another party to sell. As products are sold from the customer to third parties, the Company
recognizes revenue based on a variable percentage of a fixed price.&#160; Revenue recognized varies depending on whether a patient is
covered by insurance or is not covered by insurance.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Sales to stocking distributors are made under terms
with fixed pricing and limited rights of return (known as &#x201c;stock rotation&#x201d;) of the Company&#x2019;s products held in their
inventory. Revenue from sales to distributors is recognized upon the transfer of control to the distributor.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company assessed the promised goods and services
in the technical support contract with Invekra for a ten-year period as being a distinct service that Invekra can benefit from on its
own and as separately identifiable from any other promises within the contract. Given that the distinct service is not substantially the
same as other goods and services within the Invekra contract, the Company accounted for the distinct service as a performance obligation.
At March 31, 2025, 2024 and 2023, the Company had deferred revenue related to Invekra in the amounts of $&lt;span id="xdx_90A_eus-gaap--DeferredRevenue_iI_c20250331__srt--CounterpartyNameAxis__custom--InvekraMember_zO9rRnEo6sg6" title="Deferred revenue"&gt;69,000&lt;/span&gt;, $&lt;span id="xdx_901_eus-gaap--DeferredRevenue_iI_c20240331__srt--CounterpartyNameAxis__custom--InvekraMember_ziXOijcRWpwk" title="Deferred revenue"&gt;152,000&lt;/span&gt; and $&lt;span id="xdx_902_eus-gaap--DeferredRevenue_iI_c20230331__srt--CounterpartyNameAxis__custom--InvekraMember_zvSL9N13U10b" title="Deferred revenue"&gt;199,000&lt;/span&gt;,
respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:DeferredRevenue
      contextRef="AsOf2025-03-31_custom_InvekraMember"
      decimals="0"
      id="Fact000537"
      unitRef="USD">69000</us-gaap:DeferredRevenue>
    <us-gaap:DeferredRevenue
      contextRef="AsOf2024-03-31_custom_InvekraMember"
      decimals="0"
      id="Fact000539"
      unitRef="USD">152000</us-gaap:DeferredRevenue>
    <us-gaap:DeferredRevenue
      contextRef="AsOf2023-03-31_custom_InvekraMember"
      decimals="0"
      id="Fact000541"
      unitRef="USD">199000</us-gaap:DeferredRevenue>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="From2024-04-01to2025-03-31" id="Fact000543">&lt;p id="xdx_84D_eus-gaap--ConcentrationRiskCreditRisk_zqlCuFOr3dfi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86A_z4W2cjcpOXcj"&gt;Concentration of Credit Risk and Major Customers&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Financial instruments that potentially subject the
Company to concentration of credit risk consist principally of cash, cash equivalents and accounts receivable. Cash and cash equivalents
are maintained in financial institutions in the United States, Mexico and the Netherlands. The Company is exposed to credit risk in the
event of default by these financial institutions for amounts in excess of the Federal Deposit Insurance Corporation insured limits. Cash
and cash equivalents held in foreign banks are intentionally kept at minimal levels, and therefore have minimal credit risk associated
with them. We currently have $3,004,000 of deposits above federally insured limits.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following table shows major customers revenues
as a percentage of revenue:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_zURPyO22S4I1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B2_zFIfATK9pKB9" style="display: none"&gt;Schedule of concentration of risk&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the Year Ended March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 66%; text-align: left"&gt;Customer A&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b style="display: none"&gt;&lt;span style="display: none"&gt;&lt;/span&gt;&lt;span id="xdx_90D_ecustom--ConcentrationRiskPercentage2_pip0_dp_c20240401__20250331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerAMember_fKg_____zm3kWnC3lWsd" title="Concentration risk, percentage"&gt;0&lt;/span&gt;&lt;/b&gt;*%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;&lt;span id="xdx_90C_ecustom--ConcentrationRiskPercentage2_pip0_dp_c20230401__20240331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerAMember_zs1bdHhh0kR9" title="Concentration risk, percentage"&gt;17&lt;/span&gt;%&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Customer B&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_ecustom--ConcentrationRiskPercentage2_pip0_dp_c20240401__20250331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerBMember_z4KIjyeKukt9" title="Concentration risk, percentage"&gt;21&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_ecustom--ConcentrationRiskPercentage2_pip0_dp_c20230401__20240331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerBMember_zBZGw8JhTJu7" title="Concentration risk, percentage"&gt;15&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;Customer C&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_ecustom--ConcentrationRiskPercentage2_pip0_dp_c20240401__20250331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerCMember_zd6MRrjG5LH4" title="Concentration risk, percentage"&gt;18&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_905_ecustom--ConcentrationRiskPercentage2_pip0_dp_c20230401__20240331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerCMember_zrvShVJuihOl" title="Concentration risk, percentage"&gt;14&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following table shows major customers accounts
receivable balances as a percentage of net accounts receivables:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 66%; text-align: left"&gt;Customer B&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;&lt;b style="display: none"&gt;&lt;span id="xdx_90F_ecustom--ConcentrationRiskPercentage2_pip0_dp_c20240401__20250331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerBMember_fKg_____zSPeLzx9ieyc" title="Concentration risk, percentage"&gt;0&lt;/span&gt;&lt;/b&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;*%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;&lt;span id="xdx_907_ecustom--ConcentrationRiskPercentage2_pip0_dp_c20230401__20240331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerBMember_zhhrzMCrV01k" title="Concentration risk, percentage"&gt;13&lt;/span&gt;%&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Customer D&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_ecustom--ConcentrationRiskPercentage2_pip0_dp_c20240401__20250331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerDMember_zRqpvevFHgF6" title="Concentration risk, percentage"&gt;24&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_ecustom--ConcentrationRiskPercentage2_pip0_dp_c20230401__20240331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerDMember_zEwXw7xH1If5" title="Concentration risk, percentage"&gt;17&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 4%"&gt;&lt;span id="xdx_F09_zisvXV838286" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;* &lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_F19_zg6Uo3NevcBg" style="width: 96%"&gt;% &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Represents less than
    10%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8AB_zKPUBR4dA57j" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;











</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock contextRef="From2024-04-01to2025-03-31" id="Fact000545">&lt;table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_zURPyO22S4I1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B2_zFIfATK9pKB9" style="display: none"&gt;Schedule of concentration of risk&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the Year Ended March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 66%; text-align: left"&gt;Customer A&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b style="display: none"&gt;&lt;span style="display: none"&gt;&lt;/span&gt;&lt;span id="xdx_90D_ecustom--ConcentrationRiskPercentage2_pip0_dp_c20240401__20250331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerAMember_fKg_____zm3kWnC3lWsd" title="Concentration risk, percentage"&gt;0&lt;/span&gt;&lt;/b&gt;*%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;&lt;span id="xdx_90C_ecustom--ConcentrationRiskPercentage2_pip0_dp_c20230401__20240331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerAMember_zs1bdHhh0kR9" title="Concentration risk, percentage"&gt;17&lt;/span&gt;%&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Customer B&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_ecustom--ConcentrationRiskPercentage2_pip0_dp_c20240401__20250331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerBMember_z4KIjyeKukt9" title="Concentration risk, percentage"&gt;21&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_ecustom--ConcentrationRiskPercentage2_pip0_dp_c20230401__20240331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerBMember_zBZGw8JhTJu7" title="Concentration risk, percentage"&gt;15&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;Customer C&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_ecustom--ConcentrationRiskPercentage2_pip0_dp_c20240401__20250331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerCMember_zd6MRrjG5LH4" title="Concentration risk, percentage"&gt;18&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_905_ecustom--ConcentrationRiskPercentage2_pip0_dp_c20230401__20240331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerCMember_zrvShVJuihOl" title="Concentration risk, percentage"&gt;14&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following table shows major customers accounts
receivable balances as a percentage of net accounts receivables:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 66%; text-align: left"&gt;Customer B&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;&lt;b style="display: none"&gt;&lt;span id="xdx_90F_ecustom--ConcentrationRiskPercentage2_pip0_dp_c20240401__20250331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerBMember_fKg_____zSPeLzx9ieyc" title="Concentration risk, percentage"&gt;0&lt;/span&gt;&lt;/b&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;*%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;&lt;span id="xdx_907_ecustom--ConcentrationRiskPercentage2_pip0_dp_c20230401__20240331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerBMember_zhhrzMCrV01k" title="Concentration risk, percentage"&gt;13&lt;/span&gt;%&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Customer D&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_ecustom--ConcentrationRiskPercentage2_pip0_dp_c20240401__20250331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerDMember_zRqpvevFHgF6" title="Concentration risk, percentage"&gt;24&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_ecustom--ConcentrationRiskPercentage2_pip0_dp_c20230401__20240331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerDMember_zEwXw7xH1If5" title="Concentration risk, percentage"&gt;17&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 4%"&gt;&lt;span id="xdx_F09_zisvXV838286" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;* &lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_F19_zg6Uo3NevcBg" style="width: 96%"&gt;% &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Represents less than
    10%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <SNOA:ConcentrationRiskPercentage2
      contextRef="From2024-04-012025-03-31_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueNetMember_custom_CustomerAMember"
      decimals="INF"
      id="Fact000547"
      unitRef="Pure">0</SNOA:ConcentrationRiskPercentage2>
    <SNOA:ConcentrationRiskPercentage2
      contextRef="From2023-04-012024-03-31_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueNetMember_custom_CustomerAMember"
      decimals="INF"
      id="Fact000549"
      unitRef="Pure">0.17</SNOA:ConcentrationRiskPercentage2>
    <SNOA:ConcentrationRiskPercentage2
      contextRef="From2024-04-012025-03-31_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueNetMember_custom_CustomerBMember"
      decimals="INF"
      id="Fact000551"
      unitRef="Pure">0.21</SNOA:ConcentrationRiskPercentage2>
    <SNOA:ConcentrationRiskPercentage2
      contextRef="From2023-04-012024-03-31_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueNetMember_custom_CustomerBMember"
      decimals="INF"
      id="Fact000553"
      unitRef="Pure">0.15</SNOA:ConcentrationRiskPercentage2>
    <SNOA:ConcentrationRiskPercentage2
      contextRef="From2024-04-012025-03-31_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueNetMember_custom_CustomerCMember"
      decimals="INF"
      id="Fact000555"
      unitRef="Pure">0.18</SNOA:ConcentrationRiskPercentage2>
    <SNOA:ConcentrationRiskPercentage2
      contextRef="From2023-04-012024-03-31_us-gaap_CustomerConcentrationRiskMember_us-gaap_SalesRevenueNetMember_custom_CustomerCMember"
      decimals="INF"
      id="Fact000557"
      unitRef="Pure">0.14</SNOA:ConcentrationRiskPercentage2>
    <SNOA:ConcentrationRiskPercentage2
      contextRef="From2024-04-012025-03-31_us-gaap_CustomerConcentrationRiskMember_us-gaap_AccountsReceivableMember_custom_CustomerBMember"
      decimals="INF"
      id="Fact000559"
      unitRef="Pure">0</SNOA:ConcentrationRiskPercentage2>
    <SNOA:ConcentrationRiskPercentage2
      contextRef="From2023-04-012024-03-31_us-gaap_CustomerConcentrationRiskMember_us-gaap_AccountsReceivableMember_custom_CustomerBMember"
      decimals="INF"
      id="Fact000561"
      unitRef="Pure">0.13</SNOA:ConcentrationRiskPercentage2>
    <SNOA:ConcentrationRiskPercentage2
      contextRef="From2024-04-012025-03-31_us-gaap_CustomerConcentrationRiskMember_us-gaap_AccountsReceivableMember_custom_CustomerDMember"
      decimals="INF"
      id="Fact000563"
      unitRef="Pure">0.24</SNOA:ConcentrationRiskPercentage2>
    <SNOA:ConcentrationRiskPercentage2
      contextRef="From2023-04-012024-03-31_us-gaap_CustomerConcentrationRiskMember_us-gaap_AccountsReceivableMember_custom_CustomerDMember"
      decimals="INF"
      id="Fact000565"
      unitRef="Pure">0.17</SNOA:ConcentrationRiskPercentage2>
    <us-gaap:ReceivablesPolicyTextBlock contextRef="From2024-04-01to2025-03-31" id="Fact000572">&lt;p id="xdx_84D_eus-gaap--ReceivablesPolicyTextBlock_zPTyarxsC5N9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_860_zTS6l5klpGF"&gt;Accounts Receivable&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Trade accounts receivable are recorded net of allowances
for cash discounts for prompt payment, doubtful accounts, and sales returns. Estimates for cash discounts and sales returns are based
on analysis of contractual terms and historical trends.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&#x2019;s policy is to reserve for uncollectible
accounts based on its best estimate of the amount of probable credit losses in its existing accounts receivable. The Company periodically
reviews its accounts receivable to determine whether an allowance for doubtful accounts is necessary based on an analysis of past due
accounts and other factors that may indicate that the realization of an account may be in doubt. Other factors that the Company considers
include its existing contractual obligations, historical payment patterns of its customers and individual customer circumstances, an analysis
of days sales outstanding by customer and geographic region, and a review of the local economic environment and its potential impact on
government funding and reimbursement practices. Account balances deemed to be uncollectible are charged to the allowance after all means
of collection have been exhausted and the potential for recovery is considered remote. The Company did &lt;span id="xdx_909_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pn3p0_do_c20250331__srt--ProductOrServiceAxis__custom--ProbableCreditLossesMember_zW7wAdkE2NY9" title="Allowance for doubtful accounts"&gt;&lt;span id="xdx_90F_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pn3p0_do_c20240331__srt--ProductOrServiceAxis__custom--ProbableCreditLossesMember_zYdQNrIU7HM7" title="Allowance for doubtful accounts"&gt;&lt;span id="xdx_903_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pn3p0_do_c20230331__srt--ProductOrServiceAxis__custom--ProbableCreditLossesMember_zOc54kajgLh9" title="Allowance for doubtful accounts"&gt;no&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;t deem it necessary to record
an allowance for doubtful accounts for probable credit losses at March 31, 2025, March 31, 2024 and March 31, 2023. Additionally, at March
31, 2025, 2024 and 2023, the Company has allowances of $&lt;span id="xdx_909_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pn3p0_c20250331__srt--ProductOrServiceAxis__custom--PotentialDiscountsReturnsDistributorFeesAndRebatesMember_zX36jruvOYM2" title="Allowance for doubtful accounts"&gt;8,000&lt;/span&gt;, $&lt;span id="xdx_90E_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pn3p0_c20240331__srt--ProductOrServiceAxis__custom--PotentialDiscountsReturnsDistributorFeesAndRebatesMember_zKceXqOGAQn7" title="Allowance for doubtful accounts"&gt;27,000&lt;/span&gt; and $&lt;span id="xdx_90B_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pn3p0_c20230331__srt--ProductOrServiceAxis__custom--PotentialDiscountsReturnsDistributorFeesAndRebatesMember_zPChwlnQfONi" title="Allowance for doubtful accounts"&gt;16,000&lt;/span&gt;, respectively, related to potential discounts, returns,
distributor fees and rebates. The allowances are included in accounts receivable, net in the accompanying consolidated balance sheets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:ReceivablesPolicyTextBlock>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="AsOf2025-03-31_custom_ProbableCreditLossesMember"
      decimals="-3"
      id="Fact000574"
      unitRef="USD">0</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="AsOf2024-03-31_custom_ProbableCreditLossesMember"
      decimals="-3"
      id="Fact000576"
      unitRef="USD">0</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="AsOf2023-03-31_custom_ProbableCreditLossesMember"
      decimals="-3"
      id="Fact000578"
      unitRef="USD">0</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="AsOf2025-03-31_custom_PotentialDiscountsReturnsDistributorFeesAndRebatesMember"
      decimals="-3"
      id="Fact000580"
      unitRef="USD">8000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="AsOf2024-03-31_custom_PotentialDiscountsReturnsDistributorFeesAndRebatesMember"
      decimals="-3"
      id="Fact000582"
      unitRef="USD">27000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="AsOf2023-03-31_custom_PotentialDiscountsReturnsDistributorFeesAndRebatesMember"
      decimals="-3"
      id="Fact000584"
      unitRef="USD">16000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:InventoryPolicyTextBlock contextRef="From2024-04-01to2025-03-31" id="Fact000586">&lt;p id="xdx_846_eus-gaap--InventoryPolicyTextBlock_zZwKbfNYAqn2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86D_z1WH85EQNkGe"&gt;Inventories&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Inventories are stated at the lower of cost, cost
being determined on a standard cost basis (which approximates actual cost on a first-in, first-out basis), or net realizable value.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Due to changing market conditions, estimated future
requirements, age of the inventories on hand and production of new products, the Company regularly reviews inventory quantities on hand
and records a provision to write down excess and obsolete inventory to its estimated net realizable value. At March 31, 2025 and 2024,
the Company recorded provisions to reduce the carrying amounts of inventories to their net realizable value in the amounts of $&lt;span id="xdx_90D_eus-gaap--InventoryValuationReserves_iI_pn3p0_c20250331_zNTLPOQMjbl1" title="Inventory valuation reserves"&gt;298,000&lt;/span&gt;
and $&lt;span id="xdx_90E_eus-gaap--InventoryValuationReserves_iI_pn3p0_c20240331_zSpzd72K9l4f"&gt;296,000&lt;/span&gt;, respectively, which is included in inventories, net on the Company&#x2019;s accompanying consolidated balance sheets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:InventoryValuationReserves
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000588"
      unitRef="USD">298000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryValuationReserves
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000589"
      unitRef="USD">296000</us-gaap:InventoryValuationReserves>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="From2024-04-01to2025-03-31" id="Fact000591">&lt;p id="xdx_84C_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zBuZLvGvya3i" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86E_zwRFaxwCdK11"&gt;Financial Assets and Liabilities&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Financial instruments, including cash and cash equivalents,
accounts receivable and accounts payable are carried at cost, which management believes approximates fair value due to the short-term
nature of these instruments. The fair value of capital lease obligations and approximates their carrying amounts as a market rate of interest
is attached to their repayment. The Company measures the fair value of financial assets and liabilities based on the exchange price that
would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset
or liability in an orderly transaction between market participants on the measurement date. The Company maximizes the use of observable
inputs and minimizes the use of unobservable inputs when measuring fair value. The Company uses three levels of inputs that may be used
to measure fair value:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Level&#160;1&#160;&#x2013; quoted prices in active
markets for identical assets or liabilities;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Level&#160;2&#160;&#x2013; quoted prices for similar
assets and liabilities in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived
valuations in which all significant inputs and significant value drivers are observable in active markets;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Level&#160;3&#160;&#x2013; inputs that are unobservable
(for example cash flow modeling inputs based on assumptions).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;











&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Level 3 liabilities are valued using unobservable
inputs to the valuation methodology that are significant to the measurement of the fair value of the liabilities. For fair value measurements
categorized within Level 3 of the fair value hierarchy, the Company&#x2019;s accounting and finance department, who report to the Chief
Financial Officer, determine its valuation policies and procedures. The development and determination of the unobservable inputs for Level
3 fair value measurements and fair value calculations are the responsibility of the Company&#x2019;s accounting and finance department
and are approved by the Chief Financial Officer.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of March 31, 2025 and 2024, there were &lt;span id="xdx_908_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_pn3p0_do_c20240401__20250331_zEuzx62r1c" title="Transfers in or out of level 3"&gt;&lt;span id="xdx_906_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_pn3p0_do_c20230401__20240331_z103ndt1RRJ2" title="Transfers in or out of level 3"&gt;no&lt;/span&gt;&lt;/span&gt; transfers
in or out of Level 3 from other levels in the fair value hierarchy.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
      contextRef="From2024-04-01to2025-03-31"
      decimals="-3"
      id="Fact000597"
      unitRef="USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000599"
      unitRef="USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2024-04-01to2025-03-31" id="Fact000601">&lt;p id="xdx_84C_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zyAALfoPUln6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_860_zCNI749PVwT8"&gt;Property and Equipment&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Property and equipment are stated at cost less accumulated
depreciation. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the
respective assets. Depreciation of leasehold improvements is computed using the straight-line method over the lesser of the estimated
useful life of the improvement or the remaining term of the lease. Estimated useful asset life by classification is as follows:&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_88B_ecustom--PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock_z9YQN5p6tJKg" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details-Useful lives)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B9_zM2xeXOwrCCe" style="display: none"&gt;Schedule of property and equipment estimated useful life&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Years&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 86%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20250331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_z8tCHer5CRwh" title="Useful asset life"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Manufacturing, lab and other equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20250331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zdPY9cCcanw" title="Useful asset life"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20250331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zcEr4Z1vwZIb" title="Useful asset life"&gt;7&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Upon retirement or sale, the cost and related accumulated
depreciation are removed from the consolidated balance sheet and the resulting gain or loss is reflected in operations. Maintenance and
repairs are charged to operations as incurred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <SNOA:PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock contextRef="From2024-04-01to2025-03-31" id="Fact000603">&lt;table cellpadding="0" cellspacing="0" id="xdx_88B_ecustom--PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock_z9YQN5p6tJKg" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details-Useful lives)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B9_zM2xeXOwrCCe" style="display: none"&gt;Schedule of property and equipment estimated useful life&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Years&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 86%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 12%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20250331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_z8tCHer5CRwh" title="Useful asset life"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Manufacturing, lab and other equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20250331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zdPY9cCcanw" title="Useful asset life"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20250331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zcEr4Z1vwZIb" title="Useful asset life"&gt;7&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</SNOA:PropertyAndEquipmentEstimatedUsefulLifeTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2025-03-31_us-gaap_OfficeEquipmentMember"
      id="Fact000605">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2025-03-31_us-gaap_MachineryAndEquipmentMember"
      id="Fact000607">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2025-03-31_us-gaap_FurnitureAndFixturesMember"
      id="Fact000609">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="From2024-04-01to2025-03-31" id="Fact000611">&lt;p id="xdx_84E_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zczGeUAYV3Pf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86B_zJn9hugvmEM7"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company periodically reviews the carrying values
of its long-lived assets when events or changes in circumstances would indicate that it is more likely than not that their carrying values
may exceed their realizable values, and records impairment charges when considered necessary. Specific potential indicators of impairment
include, but are not necessarily limited to:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Symbol; font-size: 10pt"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a significant decrease in the fair value of an asset;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Symbol; font-size: 10pt"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a significant change in the extent or manner in which an asset is used or a significant physical change in an asset;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Symbol; font-size: 10pt"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a significant adverse change in legal factors or in the business climate that affects the value of an asset;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Symbol; font-size: 10pt"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;an adverse action or assessment by the U.S.&#160;Food and Drug Administration or another regulator; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Symbol; font-size: 10pt"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;an accumulation of costs significantly in excess of the amount originally expected to acquire or construct an asset; and operating or cash flow losses combined with a history of operating or cash flow losses or a projection or forecast that demonstrates continuing losses associated with an income-producing asset.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;











&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;When circumstances indicate that an impairment may
have occurred, the Company tests such assets for recoverability by comparing the estimated undiscounted future cash flows expected to
result from the use of such assets and their eventual disposition to their carrying amounts. In estimating these future cash flows, assets
and liabilities are grouped at the lowest level for which there are identifiable cash flows that are largely independent of the cash flows
generated by other such groups. If the undiscounted future cash flows are less than the carrying amount of the asset, an impairment loss,
measured as the excess of the carrying value of the asset over its estimated fair value, will be recognized. The cash flow estimates used
in such calculations are based on estimates and assumptions, using all available information that management believes is reasonable. The
Company did &lt;span id="xdx_90B_eus-gaap--AssetImpairmentCharges_pn3p0_do_c20240401__20250331_zCVjrL7UJIX5" title="Impairment of long lived assets"&gt;&lt;span id="xdx_90D_eus-gaap--AssetImpairmentCharges_pn3p0_do_c20230401__20240331_zVkJgRm2Mdkf" title="Impairment of long lived assets"&gt;no&lt;/span&gt;&lt;/span&gt;t record impairment losses for the years ended March 31, 2025 and 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:AssetImpairmentCharges
      contextRef="From2024-04-01to2025-03-31"
      decimals="-3"
      id="Fact000617"
      unitRef="USD">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000619"
      unitRef="USD">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2024-04-01to2025-03-31" id="Fact000621">&lt;p id="xdx_845_eus-gaap--ResearchAndDevelopmentExpensePolicy_zrSsLGROXZac" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86E_zFthTNrrfmVi"&gt;Research and Development&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Research and development expenses are charged to operations
as incurred and consists primarily of personnel expenses, clinical and regulatory services and supplies. For the years ended March 31,
2025 and 2024, research and development expense amounted to $&lt;span id="xdx_900_eus-gaap--ResearchAndDevelopmentExpense_pn3p0_c20240401__20250331_zl6YV1lL8wLl" title="Research and development expenses"&gt;1,814,000&lt;/span&gt; and $&lt;span id="xdx_903_eus-gaap--ResearchAndDevelopmentExpense_pn3p0_c20230401__20240331_zTfBPPtLwtb1" title="Research and development expenses"&gt;1,871,000&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-04-01to2025-03-31"
      decimals="-3"
      id="Fact000623"
      unitRef="USD">1814000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000625"
      unitRef="USD">1871000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:AdvertisingCostsPolicyTextBlock contextRef="From2024-04-01to2025-03-31" id="Fact000627">&lt;p id="xdx_845_eus-gaap--AdvertisingCostsPolicyTextBlock_zLZeZWIZQEce" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86D_zxvr5GkT24Gh"&gt;Advertising Costs&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Advertising costs are charged to operations as incurred.
Advertising costs amounted to $&lt;span id="xdx_901_eus-gaap--MarketingExpense_pn3p0_c20240401__20250331_zm8yljMrOCJ3" title="Advertising costs"&gt;190,000&lt;/span&gt; and $&lt;span id="xdx_901_eus-gaap--MarketingExpense_pn3p0_c20230401__20240331_zy00uSelb4nl" title="Advertising costs"&gt;156,000&lt;/span&gt; for the years ended March 31, 2025 and 2024, respectively. Advertising costs are included
in selling, general and administrative expenses in the accompanying consolidated statements of comprehensive loss.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:AdvertisingCostsPolicyTextBlock>
    <us-gaap:MarketingExpense
      contextRef="From2024-04-01to2025-03-31"
      decimals="-3"
      id="Fact000629"
      unitRef="USD">190000</us-gaap:MarketingExpense>
    <us-gaap:MarketingExpense
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000631"
      unitRef="USD">156000</us-gaap:MarketingExpense>
    <SNOA:ShippingAndHandlingCost1PolicyTextBlock contextRef="From2024-04-01to2025-03-31" id="Fact000633">&lt;p id="xdx_848_ecustom--ShippingAndHandlingCost1PolicyTextBlock_zHYgmM3ZqYo5" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86B_zBBmV5Jyaq45"&gt;Shipping and Handling Costs&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company classifies amounts billed to customers
related to shipping and handling in sale transactions as product revenues. The corresponding shipping and handling costs incurred are
recorded in cost of product revenues. For the years ended March 31, 2025 and 2024, the Company recorded revenue related to shipping and
handling costs of $&lt;span id="xdx_90E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20240401__20250331__srt--ProductOrServiceAxis__us-gaap--ShippingAndHandlingMember_z1kK9aignMee" title="Revenues"&gt;18,000&lt;/span&gt; and $&lt;span id="xdx_90B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20230401__20240331__srt--ProductOrServiceAxis__us-gaap--ShippingAndHandlingMember_zEfQQNdAdq9" title="Revenues"&gt;28,000&lt;/span&gt;, respectively. These amounts are included in revenues in the accompanying consolidated statements
of comprehensive loss.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</SNOA:ShippingAndHandlingCost1PolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2024-04-012025-03-31_us-gaap_ShippingAndHandlingMember"
      decimals="-3"
      id="Fact000635"
      unitRef="USD">18000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-04-012024-03-31_us-gaap_ShippingAndHandlingMember"
      decimals="-3"
      id="Fact000637"
      unitRef="USD">28000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="From2024-04-01to2025-03-31" id="Fact000639">&lt;p id="xdx_848_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zByY8TNCHpb5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_861_zm6POr9eOYzg"&gt;Foreign Currency Reporting&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&#x2019;s subsidiary, OTM, uses the local
currency (Mexican Pesos) as its functional currency and its subsidiary, SP Europe, uses the local currency (Euro) as its functional currency.
Assets and liabilities are translated at exchange rates in effect at the balance sheet date, and revenue and expense accounts are translated
at average exchange rates during the period. Resulting translation adjustments amounted to losses of $&lt;span id="xdx_90E_ecustom--OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationLossAdjustmentBeforeTaxPortionAttributableToParent_pn3p0_c20240401__20250331__us-gaap--IncomeStatementLocationAxis__us-gaap--OtherComprehensiveIncomeMember_zbkTsSEsWFL" title="Foreign currency translation adjustment loss"&gt;1,653,000&lt;/span&gt; and gains of $&lt;span id="xdx_90D_ecustom--OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainAdjustmentBeforeTaxPortionAttributableToParent_pn3p0_c20230401__20240331__us-gaap--IncomeStatementLocationAxis__us-gaap--OtherComprehensiveIncomeMember_zMXOCNhpjITg" title="Foreign currency translation adjustment gain"&gt;695,000&lt;/span&gt;
for the years ended March 31, 2025 and 2024, respectively. These amounts were recorded in other comprehensive loss in the accompanying
consolidated statements of comprehensive loss for the years ended March 31, 2025 and 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Foreign currency transaction losses relate primarily
to trade payables and receivables and intercompany transactions between subsidiaries OTM and SP Europe. These transactions are expected
to be settled in the foreseeable future. The Company recorded foreign currency transaction gains of $&lt;span id="xdx_90C_eus-gaap--ForeignCurrencyTransactionGainBeforeTax_pn3p0_c20240401__20250331__us-gaap--IncomeStatementLocationAxis__us-gaap--OtherOperatingIncomeExpenseMember_zg09fRLQWx06" title="Foreign currency transaction gain"&gt;243,000&lt;/span&gt; and losses of $&lt;span id="xdx_904_eus-gaap--ForeignCurrencyTransactionLossBeforeTax_pn3p0_c20230401__20240331__us-gaap--IncomeStatementLocationAxis__us-gaap--OtherOperatingIncomeExpenseMember_zUrCXDQodvIc" title="Foreign currency transaction loss"&gt;825,000&lt;/span&gt; for
the years ended March 31, 2025 and 2024, respectively. The related amounts were recorded in other income (expense) in the accompanying
consolidated statements of comprehensive loss.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;











</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <SNOA:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationLossAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2024-04-012025-03-31_us-gaap_OtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact000641"
      unitRef="USD">1653000</SNOA:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationLossAdjustmentBeforeTaxPortionAttributableToParent>
    <SNOA:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2023-04-012024-03-31_us-gaap_OtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact000643"
      unitRef="USD">695000</SNOA:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainAdjustmentBeforeTaxPortionAttributableToParent>
    <us-gaap:ForeignCurrencyTransactionGainBeforeTax
      contextRef="From2024-04-012025-03-31_us-gaap_OtherOperatingIncomeExpenseMember"
      decimals="-3"
      id="Fact000645"
      unitRef="USD">243000</us-gaap:ForeignCurrencyTransactionGainBeforeTax>
    <us-gaap:ForeignCurrencyTransactionLossBeforeTax
      contextRef="From2023-04-012024-03-31_us-gaap_OtherOperatingIncomeExpenseMember"
      decimals="-3"
      id="Fact000647"
      unitRef="USD">825000</us-gaap:ForeignCurrencyTransactionLossBeforeTax>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="From2024-04-01to2025-03-31" id="Fact000653">&lt;p id="xdx_84B_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zaj8FWd4iUY5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_869_z5PeiaDESwAl"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company accounts for share-based awards exchanged
for employee services at the estimated grant date fair value of the award. The Company estimates the fair value of employee stock option
awards using the Black-Scholes option pricing model. The Company amortizes the fair value of employee stock options on a straight-line
basis over the requisite service period of the awards.&#160; Compensation expense includes the impact of forfeitures for all stock options
as incurred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company accounts for equity instruments issued
to non-employees at their fair value on the measurement date. The measurement of stock-based compensation is subject to periodic adjustment
as the underlying equity instrument vests or becomes non-forfeitable. Non-employee stock-based compensation charges are amortized over
the vesting period or as earned.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2024-04-01to2025-03-31" id="Fact000655">&lt;p id="xdx_841_eus-gaap--IncomeTaxPolicyTextBlock_zNsCtF9G88Tk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_861_zstvjz8290e3"&gt;Income Taxes&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Deferred tax assets and liabilities are determined
based on the differences between the financial reporting and tax bases of assets and liabilities and net operating loss and credit carryforwards
using enacted tax rates in effect for the year in which the differences are expected to impact taxable income. Valuation allowances are
established when necessary to reduce deferred tax assets to the amounts expected to be realized.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Tax benefits claimed or expected to be claimed on
a tax return are recorded in the Company&#x2019;s consolidated financial statements. A tax benefit from an uncertain tax position is only
recognized if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the
technical merits of the position. The tax benefits recognized in the consolidated financial statements from such a position are measured
based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate resolution. Uncertain tax
positions have had no impact on the Company&#x2019;s consolidated financial condition, results of comprehensive loss or cash flows.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="From2024-04-01to2025-03-31" id="Fact000657">&lt;p id="xdx_844_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_zlrbnMPJy9x7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_865_zLOGtLVLckb4"&gt;Comprehensive Loss&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Other comprehensive loss includes all changes in stockholders&#x2019;
equity during a period from non-owner sources and is reported in the consolidated statements of changes in stockholders&#x2019; equity.
To date, other comprehensive loss consists of changes in accumulated foreign currency translation adjustments. Accumulated other comprehensive
losses at March 31, 2025 and 2024 were $&lt;span id="xdx_905_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_iNI_pn3p0_di_c20250331_zxCDSkwmUNEb" title="Accumulated other comprehensive loss"&gt;4,376,000&lt;/span&gt; and $&lt;span id="xdx_908_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_iNI_pn3p0_di_c20240331_zgzxoULws9Kc" title="Accumulated other comprehensive loss"&gt;2,723,000&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000659"
      unitRef="USD">-4376000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000661"
      unitRef="USD">-2723000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2024-04-01to2025-03-31" id="Fact000663">&lt;p id="xdx_84F_eus-gaap--EarningsPerSharePolicyTextBlock_zpJt2VoxNfvk" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_861_zWe7aV4iEVtg"&gt;Net Loss per Share&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company computes basic net loss per share by dividing
net loss per share available to common stockholders by the weighted average number of common shares outstanding for the period and excludes
the effects of any potentially dilutive securities. Diluted earnings per share, if presented, would include the dilution that would occur
upon the exercise or conversion of all potentially dilutive securities into common stock using the &#x201c;treasury stock&#x201d; and/or
&#x201c;if converted&#x201d; methods as applicable.&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_88F_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_pn3n3_zQMVT2I9u4s5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details - Earnings per share)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8BE_zLPDMRGi4yR4" style="display: none"&gt;Schedule of computation of earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20240401__20250331_zWUtF7nS72Hj" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20230401__20240331_zbQOYGMhuxv8" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the Year Ended March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; font-style: italic; text-align: justify"&gt;(In thousands, except per share data)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--NetIncomeLoss_zvPHG1sUVEZf" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 66%; text-align: justify; padding-bottom: 2.5pt"&gt;Net loss&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 13%; text-align: right"&gt;(3,457&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 13%; text-align: right"&gt;(4,835&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;Weighted-average shares outstanding: basic and diluted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20240401__20250331_zHmQpmxLzLe2" title="Weighted-average number of shares: basic"&gt;&lt;span id="xdx_906_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20240401__20250331_zCDm0AKmLbNf" title="Weighted-average number of shares: diluted"&gt;1,241&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20230401__20240331_zPC1HfhiTm8l" title="Weighted-average number of shares: basic"&gt;&lt;span id="xdx_90C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20230401__20240331_zM3Y70VsLL15" title="Weighted-average number of shares: diluted"&gt;455&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Net loss per share: basic and diluted&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--EarningsPerShareBasic_pip0_c20240401__20250331_zlxfDkaNIuOh" title="Net loss per share: basic"&gt;&lt;span id="xdx_908_eus-gaap--EarningsPerShareDiluted_pip0_c20240401__20250331_zuPDGioUbHCl" title="Net loss per share: diluted"&gt;(2.79&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--EarningsPerShareBasic_pip0_c20230401__20240331_zIXPvimnH9sj" title="Net loss per share: basic"&gt;&lt;span id="xdx_903_eus-gaap--EarningsPerShareDiluted_pip0_c20230401__20240331_z7gXdVrOEh5g" title="Net loss per share: diluted"&gt;(10.63&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;











&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The computation of basic and diluted loss per share
for the years ended March 31, 2025 and 2024 excludes the potentially dilutive securities summarized in the table below because their inclusion
would be anti-dilutive.&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_889_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_pn3n3_zX61miRCNuQg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details - Antidilutive shares)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8BF_zWNkXJhCOLd9" style="display: none"&gt;Schedule of antidilutive shares&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; font-style: italic"&gt;(In thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 66%; text-align: left"&gt;Common stock to be issued upon exercise of options&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20240401__20250331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zBk6aclmuVK3" style="width: 13%; text-align: right" title="Antidilutive shares"&gt;73&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20230401__20240331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_z0hBUAViGQkk" style="width: 13%; text-align: right" title="Antidilutive shares"&gt;52&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Common stock to be issued upon vesting of restricted stock units&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_d0_c20240401__20250331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockUnitsMember_ze0KvSHOnXyk" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive shares"&gt;45&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_d0_c20230401__20240331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockUnitsMember_zvW2tD8pJZB5" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive shares"&gt;&#x2013;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20240401__20250331_z61stojKYFSa" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive shares"&gt;118&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20230401__20240331_z052IKLT9YAg" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive shares"&gt;52&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="From2024-04-01to2025-03-31" id="Fact000665">&lt;table cellpadding="0" cellspacing="0" id="xdx_88F_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_pn3n3_zQMVT2I9u4s5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details - Earnings per share)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8BE_zLPDMRGi4yR4" style="display: none"&gt;Schedule of computation of earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20240401__20250331_zWUtF7nS72Hj" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20230401__20240331_zbQOYGMhuxv8" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;For the Year Ended March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; font-style: italic; text-align: justify"&gt;(In thousands, except per share data)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--NetIncomeLoss_zvPHG1sUVEZf" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 66%; text-align: justify; padding-bottom: 2.5pt"&gt;Net loss&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 13%; text-align: right"&gt;(3,457&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 13%; text-align: right"&gt;(4,835&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;Weighted-average shares outstanding: basic and diluted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20240401__20250331_zHmQpmxLzLe2" title="Weighted-average number of shares: basic"&gt;&lt;span id="xdx_906_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20240401__20250331_zCDm0AKmLbNf" title="Weighted-average number of shares: diluted"&gt;1,241&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20230401__20240331_zPC1HfhiTm8l" title="Weighted-average number of shares: basic"&gt;&lt;span id="xdx_90C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20230401__20240331_zM3Y70VsLL15" title="Weighted-average number of shares: diluted"&gt;455&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Net loss per share: basic and diluted&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--EarningsPerShareBasic_pip0_c20240401__20250331_zlxfDkaNIuOh" title="Net loss per share: basic"&gt;&lt;span id="xdx_908_eus-gaap--EarningsPerShareDiluted_pip0_c20240401__20250331_zuPDGioUbHCl" title="Net loss per share: diluted"&gt;(2.79&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--EarningsPerShareBasic_pip0_c20230401__20240331_zIXPvimnH9sj" title="Net loss per share: basic"&gt;&lt;span id="xdx_903_eus-gaap--EarningsPerShareDiluted_pip0_c20230401__20240331_z7gXdVrOEh5g" title="Net loss per share: diluted"&gt;(10.63&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-04-01to2025-03-31"
      decimals="-3"
      id="Fact000667"
      unitRef="USD">-3457000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000668"
      unitRef="USD">-4835000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-04-01to2025-03-31"
      decimals="-3"
      id="Fact000670"
      unitRef="Shares">1241000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-04-01to2025-03-31"
      decimals="-3"
      id="Fact000672"
      unitRef="Shares">1241000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000674"
      unitRef="Shares">455000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000676"
      unitRef="Shares">455000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-04-01to2025-03-31"
      decimals="INF"
      id="Fact000678"
      unitRef="USDPShares">-2.79</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-04-01to2025-03-31"
      decimals="INF"
      id="Fact000680"
      unitRef="USDPShares">-2.79</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-04-012024-03-31"
      decimals="INF"
      id="Fact000682"
      unitRef="USDPShares">-10.63</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-04-012024-03-31"
      decimals="INF"
      id="Fact000684"
      unitRef="USDPShares">-10.63</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="From2024-04-01to2025-03-31" id="Fact000690">&lt;table cellpadding="0" cellspacing="0" id="xdx_889_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_pn3n3_zX61miRCNuQg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details - Antidilutive shares)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8BF_zWNkXJhCOLd9" style="display: none"&gt;Schedule of antidilutive shares&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; font-style: italic"&gt;(In thousands)&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 66%; text-align: left"&gt;Common stock to be issued upon exercise of options&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20240401__20250331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zBk6aclmuVK3" style="width: 13%; text-align: right" title="Antidilutive shares"&gt;73&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20230401__20240331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_z0hBUAViGQkk" style="width: 13%; text-align: right" title="Antidilutive shares"&gt;52&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Common stock to be issued upon vesting of restricted stock units&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_d0_c20240401__20250331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockUnitsMember_ze0KvSHOnXyk" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive shares"&gt;45&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_d0_c20230401__20240331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockUnitsMember_zvW2tD8pJZB5" style="border-bottom: Black 1pt solid; text-align: right" title="Antidilutive shares"&gt;&#x2013;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20240401__20250331_z61stojKYFSa" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive shares"&gt;118&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20230401__20240331_z052IKLT9YAg" style="border-bottom: Black 2.5pt double; text-align: right" title="Antidilutive shares"&gt;52&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-04-012025-03-31_us-gaap_StockOptionMember"
      decimals="-3"
      id="Fact000692"
      unitRef="Shares">73000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-04-012024-03-31_us-gaap_StockOptionMember"
      decimals="-3"
      id="Fact000694"
      unitRef="Shares">52000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-04-012025-03-31_custom_CommonStockUnitsMember"
      decimals="-3"
      id="Fact000696"
      unitRef="Shares">45000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-04-012024-03-31_custom_CommonStockUnitsMember"
      decimals="-3"
      id="Fact000698"
      unitRef="Shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-04-01to2025-03-31"
      decimals="-3"
      id="Fact000700"
      unitRef="Shares">118000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000702"
      unitRef="Shares">52000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <SNOA:ConvertiblePreferredStockPolicyTextBlock contextRef="From2024-04-01to2025-03-31" id="Fact000704">&lt;p id="xdx_849_ecustom--ConvertiblePreferredStockPolicyTextBlock_zTSZEVEHfJB1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_863_zpJiJv2ta99c"&gt;Convertible Preferred Stock&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company applies the accounting standards for distinguishing
liabilities from equity when determining the classification and measurement of its preferred stock. Shares that are subject to mandatory
redemption (if any) are classified as liability instruments and are measured at fair value. The Company classifies conditionally redeemable
preferred shares, which includes preferred shares that feature redemption rights that are either within the control of the holder or subject
to redemption upon the occurrence of uncertain events not solely within the Company&#x2019;s control, as temporary equity. At all other
times, preferred shares are classified as stockholders' equity. There are &lt;span id="xdx_90B_eus-gaap--PreferredStockSharesIssued_iI_pip0_do_c20250331_zD131bkgvo27" title="Preferred stock, shares issued"&gt;no&lt;/span&gt; shares issued as of March 31, 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</SNOA:ConvertiblePreferredStockPolicyTextBlock>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2025-03-31"
      decimals="INF"
      id="Fact000706"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="From2024-04-01to2025-03-31" id="Fact000708">&lt;p id="xdx_848_eus-gaap--SegmentReportingPolicyPolicyTextBlock_z8U1KU9n1Ug5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86F_z1x7JkOJP5u4"&gt;Segment Reporting&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company has one primary business activity and operate in one reportable
segment. The Company&#x2019;s chief operating decision maker (&#x201c;CODM&#x201d;) is its Chief Executive Officer (&#x201c;CEO&#x201d;) who
evaluates performance and makes operating decisions about allocating resources based on financial data presented on a consolidated basis.
The measures of profitability and the significant segment expenses reviewed by the CODM are consistent with these financial statements
and footnotes.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:SubsequentEventsPolicyPolicyTextBlock contextRef="From2024-04-01to2025-03-31" id="Fact000710">&lt;p id="xdx_84D_eus-gaap--SubsequentEventsPolicyPolicyTextBlock_z5blvubMPCZb" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86A_zG2oQtqrhGk6"&gt;Subsequent Events&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Management has evaluated subsequent events or transactions
occurring through the date these consolidated financial statements were issued. All events requiring disclosure have been incorporated
into the notes to the consolidated financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:SubsequentEventsPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2024-04-01to2025-03-31" id="Fact000712">&lt;p id="xdx_842_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zaligiqAgjO1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_867_zbiuXHAVh7b2"&gt;Recent Accounting Standards&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company has evaluated all the recent accounting
standards and determined that none are material to it.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock contextRef="From2024-04-01to2025-03-31" id="Fact000714">&lt;p id="xdx_80F_eus-gaap--LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_zrTV0gwgjkmf" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;NOTE&#160;4&#160;&#x2013; &lt;span id="xdx_82F_zVS6CHtSiAR3"&gt;Accounts Receivable&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Accounts receivable, net consists of the following:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_88A_eus-gaap--ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_pn3n3_zsLLptBzYht6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Accounts Receivable (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8BC_zQEh7Rl2tFKl" style="display: none"&gt;Schedule of accounts
    receivable&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20250331_zEzYUvCD1pm" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20240331_zuNI0FO9oKUb" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;March&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AccountsReceivableGrossCurrent_iI_pn3p0_maARNCzw0O_zkniCw3Vrj3a" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 66%; text-align: left"&gt;Accounts receivable&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;2,240,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;2,925,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iNI_pn3p0_di_hsrt--ProductOrServiceAxis__custom--PotentialDiscountsReturnsDistributorFeesAndRebatesMember_msARNCzw0O_z1IyPnEOwFc4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Less: discounts, rebates, distributor fees and returns&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(8,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(27,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AccountsReceivableNetCurrent_iTI_pn3p0_mtARNCzw0O_zD73MAMoB86d" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Total accounts receivable, net&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,232,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,898,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;











&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;

</us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock contextRef="From2024-04-01to2025-03-31" id="Fact000716">&lt;table cellpadding="0" cellspacing="0" id="xdx_88A_eus-gaap--ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_pn3n3_zsLLptBzYht6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Accounts Receivable (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8BC_zQEh7Rl2tFKl" style="display: none"&gt;Schedule of accounts
    receivable&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20250331_zEzYUvCD1pm" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20240331_zuNI0FO9oKUb" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;March&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AccountsReceivableGrossCurrent_iI_pn3p0_maARNCzw0O_zkniCw3Vrj3a" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 66%; text-align: left"&gt;Accounts receivable&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;2,240,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;2,925,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iNI_pn3p0_di_hsrt--ProductOrServiceAxis__custom--PotentialDiscountsReturnsDistributorFeesAndRebatesMember_msARNCzw0O_z1IyPnEOwFc4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Less: discounts, rebates, distributor fees and returns&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(8,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(27,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AccountsReceivableNetCurrent_iTI_pn3p0_mtARNCzw0O_zD73MAMoB86d" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Total accounts receivable, net&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,232,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,898,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
    <us-gaap:AccountsReceivableGrossCurrent
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000718"
      unitRef="USD">2240000</us-gaap:AccountsReceivableGrossCurrent>
    <us-gaap:AccountsReceivableGrossCurrent
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000719"
      unitRef="USD">2925000</us-gaap:AccountsReceivableGrossCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="AsOf2025-03-31_custom_PotentialDiscountsReturnsDistributorFeesAndRebatesMember"
      decimals="-3"
      id="Fact000721"
      unitRef="USD">8000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="AsOf2024-03-31_custom_PotentialDiscountsReturnsDistributorFeesAndRebatesMember"
      decimals="-3"
      id="Fact000722"
      unitRef="USD">27000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000724"
      unitRef="USD">2232000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000725"
      unitRef="USD">2898000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryDisclosureTextBlock contextRef="From2024-04-01to2025-03-31" id="Fact000731">&lt;p id="xdx_80E_eus-gaap--InventoryDisclosureTextBlock_zWsxCIu5N09e" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;NOTE&#160;5&#160;&#x2013; &lt;span id="xdx_822_z6liG334e382"&gt;Inventories&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Inventories, net consists of the following:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_885_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_pn3n3_zclZDn1Ampdl" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Inventories (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B0_ziSP6Up1QKal" style="display: none"&gt;Schedule of inventories&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20250331_zSUjscxoVyE2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20240331_zTeL1za7t7Yj" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;March&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--InventoryRawMaterialsNetOfReserves_iI_pn3p0_maIGzA0w_z0T6ta6jCeN8" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 66%; text-align: left"&gt;Raw materials&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;1,395,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;1,802,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--InventoryFinishedGoodsNetOfReserves_iI_pn3p0_maIGzA0w_zjTLh3wPMYD9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Finished goods&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,818,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,213,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--InventoryGross_iTI_pn3p0_mtIGzA0w_maINzHEX_zoa8ualtCGJf" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td&gt;&lt;b style="display: none"&gt;Inventories, gross&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,213,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,015,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--InventoryValuationReserves_iNI_pn3p0_di_msINzHEX_zXEz7igVfYO5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Less: allowance for obsolete and excess inventory&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(298,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(296,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--InventoryNet_iTI_pn3p0_mtINzHEX_zxOU6ZdhLTah" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Total inventories&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,915,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,719,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="From2024-04-01to2025-03-31" id="Fact000733">&lt;table cellpadding="0" cellspacing="0" id="xdx_885_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_pn3n3_zclZDn1Ampdl" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Inventories (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B0_ziSP6Up1QKal" style="display: none"&gt;Schedule of inventories&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20250331_zSUjscxoVyE2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20240331_zTeL1za7t7Yj" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;March&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--InventoryRawMaterialsNetOfReserves_iI_pn3p0_maIGzA0w_z0T6ta6jCeN8" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 66%; text-align: left"&gt;Raw materials&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;1,395,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;1,802,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--InventoryFinishedGoodsNetOfReserves_iI_pn3p0_maIGzA0w_zjTLh3wPMYD9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Finished goods&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,818,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,213,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--InventoryGross_iTI_pn3p0_mtIGzA0w_maINzHEX_zoa8ualtCGJf" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td&gt;&lt;b style="display: none"&gt;Inventories, gross&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,213,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,015,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--InventoryValuationReserves_iNI_pn3p0_di_msINzHEX_zXEz7igVfYO5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Less: allowance for obsolete and excess inventory&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(298,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(296,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--InventoryNet_iTI_pn3p0_mtINzHEX_zxOU6ZdhLTah" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Total inventories&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,915,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,719,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000735"
      unitRef="USD">1395000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000736"
      unitRef="USD">1802000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000738"
      unitRef="USD">1818000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000739"
      unitRef="USD">1213000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryGross
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000741"
      unitRef="USD">3213000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000742"
      unitRef="USD">3015000</us-gaap:InventoryGross>
    <us-gaap:InventoryValuationReserves
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000744"
      unitRef="USD">298000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryValuationReserves
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000745"
      unitRef="USD">296000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryNet
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000747"
      unitRef="USD">2915000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000748"
      unitRef="USD">2719000</us-gaap:InventoryNet>
    <us-gaap:OtherCurrentAssetsTextBlock contextRef="From2024-04-01to2025-03-31" id="Fact000750">&lt;p id="xdx_80E_eus-gaap--OtherCurrentAssetsTextBlock_z1PAeR0uqafh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;NOTE&#160;6&#160;&#x2013; &lt;span id="xdx_82F_zleE51adNMu"&gt;Prepaid Expenses and Other
Current Assets&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Prepaid expenses and other current assets consist
of the following:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_881_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_pn3n3_zmpfHru8uDW6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Prepaid Expenses and Other Current Assets (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B8_zRuyoXDE8aDi" style="display: none"&gt;Schedule of prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20250331_zyIttJz1rCjb" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20240331_zGv05CgxGUmg" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;March&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--PrepaidInsurance_iI_pn3p0_maPEAOAz4GC_z91VyCrIieAb" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 66%; text-align: left"&gt;Prepaid insurance&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;236,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;340,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--PrepaidTaxes_iI_pn3p0_maPEAOAz4GC_zdmq4l3G0Emf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;VAT prepaid to Mexican tax authorities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,531,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,096,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--OtherPrepaidExpenseCurrent_iI_pn3p0_maPEAOAz4GC_zQwxZAIZpNTi" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Other prepaid expenses and other current assets&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;148,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;105,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_pn3p0_mtPEAOAz4GC_zQqBZd3zmPog" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;b style="display: none"&gt;Total prepaid expenses and other current assets&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,915,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;3,541,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

</us-gaap:OtherCurrentAssetsTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock contextRef="From2024-04-01to2025-03-31" id="Fact000752">&lt;table cellpadding="0" cellspacing="0" id="xdx_881_eus-gaap--DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_pn3n3_zmpfHru8uDW6" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Prepaid Expenses and Other Current Assets (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B8_zRuyoXDE8aDi" style="display: none"&gt;Schedule of prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20250331_zyIttJz1rCjb" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20240331_zGv05CgxGUmg" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;March&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--PrepaidInsurance_iI_pn3p0_maPEAOAz4GC_z91VyCrIieAb" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 66%; text-align: left"&gt;Prepaid insurance&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;236,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;340,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--PrepaidTaxes_iI_pn3p0_maPEAOAz4GC_zdmq4l3G0Emf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;VAT prepaid to Mexican tax authorities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,531,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,096,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--OtherPrepaidExpenseCurrent_iI_pn3p0_maPEAOAz4GC_zQwxZAIZpNTi" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Other prepaid expenses and other current assets&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;148,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;105,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_pn3p0_mtPEAOAz4GC_zQqBZd3zmPog" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;b style="display: none"&gt;Total prepaid expenses and other current assets&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,915,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;3,541,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <us-gaap:PrepaidInsurance
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000754"
      unitRef="USD">236000</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000755"
      unitRef="USD">340000</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidTaxes
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000757"
      unitRef="USD">1531000</us-gaap:PrepaidTaxes>
    <us-gaap:PrepaidTaxes
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000758"
      unitRef="USD">3096000</us-gaap:PrepaidTaxes>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000760"
      unitRef="USD">148000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000761"
      unitRef="USD">105000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000763"
      unitRef="USD">1915000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000764"
      unitRef="USD">3541000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="From2024-04-01to2025-03-31" id="Fact000766">&lt;p id="xdx_80B_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_z0ItIUj1HwV9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;NOTE&#160;7&#160;&#x2013; &lt;span id="xdx_824_zVbZpxxLQum"&gt;Property and Equipment&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Property and equipment, net consists of the following:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_888_eus-gaap--PropertyPlantAndEquipmentTextBlock_pn3n3_zxuNNYxexi9h" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Property and Equipment (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8BD_zs6Z0Myh0Hbi" style="display: none"&gt;Schedule of property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20250331_z9n1dCl0j75c" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20240331_zR6mXFTmjlm" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;March&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--MachineryAndEquipmentGross_iI_pn3p0_maPPAEGzAkZ_zUBy7HDgQ867" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 66%; text-align: left"&gt;Manufacturing, lab, and other equipment&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;1,471,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;1,776,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentOther_iI_pn3p0_maPPAEGzAkZ_zxcA3GMgbZJa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Office equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;217,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;236,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--FurnitureAndFixturesGross_iI_pn3p0_maPPAEGzAkZ_z3NHH521HaSd" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;Furniture and fixtures&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;121,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;128,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--LeaseholdImprovementsGross_iI_pn3p0_maPPAEGzAkZ_zbSBLjCOr9A1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Leasehold improvements&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;491,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;605,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--PropertyPlantAndEquipmentGross_iTI_pn3p0_mtPPAEGzAkZ_maPPAENzQSU_zKZxcPJYZCbd" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td&gt;&lt;b style="display: none"&gt;Property and equipment, gross&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,300,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,745,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3p0_di_msPPAENzQSU_zOs97KtK8Qfk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Less: accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(2,075,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(2,380,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3p0_mtPPAENzQSU_zK7EHdnHWqpf" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total property and equipment, net &lt;span style="color: #EEEEEE"&gt;and equipment, net&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;225,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;365,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Depreciation expense amounted to $&lt;span id="xdx_901_eus-gaap--DepreciationAndAmortization_pn3p0_c20240401__20250331_zfwQMkQNAHb7" title="Depreciation and amortization"&gt;138,000&lt;/span&gt; and $&lt;span id="xdx_90C_eus-gaap--DepreciationAndAmortization_pn3p0_c20230401__20240331_zAPtBAVcPSpe" title="Depreciation and amortization"&gt;176,000&lt;/span&gt;
for the years ended March 31, 2025 and 2024, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;











</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="From2024-04-01to2025-03-31" id="Fact000768">&lt;table cellpadding="0" cellspacing="0" id="xdx_888_eus-gaap--PropertyPlantAndEquipmentTextBlock_pn3n3_zxuNNYxexi9h" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Property and Equipment (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8BD_zs6Z0Myh0Hbi" style="display: none"&gt;Schedule of property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20250331_z9n1dCl0j75c" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20240331_zR6mXFTmjlm" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;March&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--MachineryAndEquipmentGross_iI_pn3p0_maPPAEGzAkZ_zUBy7HDgQ867" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 66%; text-align: left"&gt;Manufacturing, lab, and other equipment&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;1,471,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;1,776,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentOther_iI_pn3p0_maPPAEGzAkZ_zxcA3GMgbZJa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Office equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;217,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;236,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--FurnitureAndFixturesGross_iI_pn3p0_maPPAEGzAkZ_z3NHH521HaSd" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;Furniture and fixtures&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;121,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;128,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--LeaseholdImprovementsGross_iI_pn3p0_maPPAEGzAkZ_zbSBLjCOr9A1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Leasehold improvements&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;491,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;605,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--PropertyPlantAndEquipmentGross_iTI_pn3p0_mtPPAEGzAkZ_maPPAENzQSU_zKZxcPJYZCbd" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td&gt;&lt;b style="display: none"&gt;Property and equipment, gross&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,300,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,745,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pn3p0_di_msPPAENzQSU_zOs97KtK8Qfk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Less: accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(2,075,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(2,380,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pn3p0_mtPPAENzQSU_zK7EHdnHWqpf" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total property and equipment, net &lt;span style="color: #EEEEEE"&gt;and equipment, net&#160;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;225,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;365,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:MachineryAndEquipmentGross
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000770"
      unitRef="USD">1471000</us-gaap:MachineryAndEquipmentGross>
    <us-gaap:MachineryAndEquipmentGross
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000771"
      unitRef="USD">1776000</us-gaap:MachineryAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentOther
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000773"
      unitRef="USD">217000</us-gaap:PropertyPlantAndEquipmentOther>
    <us-gaap:PropertyPlantAndEquipmentOther
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000774"
      unitRef="USD">236000</us-gaap:PropertyPlantAndEquipmentOther>
    <us-gaap:FurnitureAndFixturesGross
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000776"
      unitRef="USD">121000</us-gaap:FurnitureAndFixturesGross>
    <us-gaap:FurnitureAndFixturesGross
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000777"
      unitRef="USD">128000</us-gaap:FurnitureAndFixturesGross>
    <us-gaap:LeaseholdImprovementsGross
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000779"
      unitRef="USD">491000</us-gaap:LeaseholdImprovementsGross>
    <us-gaap:LeaseholdImprovementsGross
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000780"
      unitRef="USD">605000</us-gaap:LeaseholdImprovementsGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000782"
      unitRef="USD">2300000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000783"
      unitRef="USD">2745000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000785"
      unitRef="USD">2075000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000786"
      unitRef="USD">2380000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000788"
      unitRef="USD">225000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000789"
      unitRef="USD">365000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2024-04-01to2025-03-31"
      decimals="-3"
      id="Fact000791"
      unitRef="USD">138000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000793"
      unitRef="USD">176000</us-gaap:DepreciationAndAmortization>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="From2024-04-01to2025-03-31" id="Fact000799">&lt;p id="xdx_80D_eus-gaap--AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_zwQ0M4ycZMub" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;NOTE&#160;8&#160;&#x2013; &lt;span id="xdx_821_zWNSERa4bEph"&gt;Accrued Expenses and Other
Current Liabilities&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Accrued expenses and other current liabilities consist
of the following:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_885_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zkHL2a7Xoyx9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Accrued Expenses and Other Current Liabilities (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B5_zuEwrbCu4g82" style="display: none"&gt;Schedule of accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20250331_zU8fZsWO8wXj" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20240331_z1rtcf5snPN1" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;March&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_pn3p0_maAPAOAzS7o_zMaukLFPSq68" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 66%; text-align: left"&gt;Salaries and related costs&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;1,737,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;1,419,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pn3p0_maAPAOAzS7o_zxgsIUe1e6v4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;487,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;694,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--AccountsPayableAndOtherAccruedLiabilities_iTI_pn3p0_mtAPAOAzS7o_zRhlHzF9G3Fk" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Total accrued expenses and other current liabilities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,224,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,113,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="From2024-04-01to2025-03-31" id="Fact000801">&lt;table cellpadding="0" cellspacing="0" id="xdx_885_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zkHL2a7Xoyx9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Accrued Expenses and Other Current Liabilities (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B5_zuEwrbCu4g82" style="display: none"&gt;Schedule of accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20250331_zU8fZsWO8wXj" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20240331_z1rtcf5snPN1" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;March&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_pn3p0_maAPAOAzS7o_zMaukLFPSq68" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 66%; text-align: left"&gt;Salaries and related costs&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;1,737,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;1,419,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pn3p0_maAPAOAzS7o_zxgsIUe1e6v4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;487,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;694,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--AccountsPayableAndOtherAccruedLiabilities_iTI_pn3p0_mtAPAOAzS7o_zRhlHzF9G3Fk" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"&gt;Total accrued expenses and other current liabilities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,224,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,113,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000803"
      unitRef="USD">1737000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000804"
      unitRef="USD">1419000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000806"
      unitRef="USD">487000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000807"
      unitRef="USD">694000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilities
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000809"
      unitRef="USD">2224000</us-gaap:AccountsPayableAndOtherAccruedLiabilities>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilities
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000810"
      unitRef="USD">2113000</us-gaap:AccountsPayableAndOtherAccruedLiabilities>
    <us-gaap:DebtDisclosureTextBlock contextRef="From2024-04-01to2025-03-31" id="Fact000812">&lt;p id="xdx_809_eus-gaap--DebtDisclosureTextBlock_zf3iuuLFGDt6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;NOTE&#160;9&#160;&#x2013; &lt;span id="xdx_82A_zbSP1oDUQKbl"&gt;Debt&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;i&gt;Financing of Insurance Premiums&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On February 1, 2025, the Company entered into a note
agreement for $&lt;span id="xdx_908_eus-gaap--DebtInstrumentFaceAmount_iI_pn3p0_c20250201__us-gaap--ShortTermDebtTypeAxis__custom--InsurancePremiumFinancingMember_z6D9IZQbc1ce" title="Debt face amount"&gt;274,000&lt;/span&gt; with an interest rate of &lt;span id="xdx_906_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pip0_dp_c20250130__20250201__us-gaap--ShortTermDebtTypeAxis__custom--InsurancePremiumFinancingMember_zQLYfHKP5Zqf" title="Debt interest rate"&gt;7.97&lt;/span&gt;% per annum with final payment on &lt;span id="xdx_901_eus-gaap--DebtInstrumentMaturityDateRangeEnd1_dd_c20250130__20250201__us-gaap--ShortTermDebtTypeAxis__custom--InsurancePremiumFinancingMember_zi9ac9vuPvTh" title="Final payment date"&gt;November 1, 2025&lt;/span&gt;. This instrument was issued in
connection with financing insurance premiums. On February 5, 2025, the Company made an initial payment of $&lt;span id="xdx_900_eus-gaap--ProceedsFromShortTermDebt_pn3p0_c20250130__20250201__us-gaap--ShortTermDebtTypeAxis__custom--InsurancePremiumFinancingMember_zwMRdhRcd107" title="Debt initial payment"&gt;28,000&lt;/span&gt;. The note is payable
in &lt;span id="xdx_90E_eus-gaap--DebtInstrumentPaymentTerms_c20250130__20250201__us-gaap--ShortTermDebtTypeAxis__custom--InsurancePremiumFinancingMember_zBYRsQBFJ2sk" title="Debt payment terms"&gt;nine monthly installment payments&lt;/span&gt; of principal and interest of $&lt;span id="xdx_908_eus-gaap--DebtInstrumentPeriodicPayment_pn3p0_c20250130__20250201__us-gaap--ShortTermDebtTypeAxis__custom--InsurancePremiumFinancingMember_z1FOs0u9Hq98" title="Periodic payment"&gt;28,000&lt;/span&gt;, with the first monthly installment beginning &lt;span id="xdx_902_eus-gaap--DebtInstrumentMaturityDateRangeStart1_dd_c20250130__20250201__us-gaap--ShortTermDebtTypeAxis__custom--InsurancePremiumFinancingMember_zuDv6lc2s7T9" title="First installment beginning date"&gt;March 1, 2025&lt;/span&gt;.
At March 31, 2025, the outstanding principal on the note amounted to $&lt;span id="xdx_900_eus-gaap--OtherLongTermDebtCurrent_iI_pn3p0_c20250331__us-gaap--ShortTermDebtTypeAxis__custom--InsurancePremiumFinancingMember_zUlksarRYmBb" title="Outstanding principal amount"&gt;220,000&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On February 6, 2024, the Company entered into a note
agreement for $&lt;span id="xdx_90A_eus-gaap--DebtInstrumentFaceAmount_iI_pn3p0_c20240206__us-gaap--ShortTermDebtTypeAxis__custom--InsurancePremiumFinancingMember_zweZ8YEW6YD3" title="Debt face amount"&gt;373,000&lt;/span&gt; with an interest rate of &lt;span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pip0_dp_c20240205__20240206__us-gaap--ShortTermDebtTypeAxis__custom--InsurancePremiumFinancingMember_zMRZjv7rhtOj" title="Debt interest rate"&gt;8.42&lt;/span&gt;% per annum with final payment on &lt;span id="xdx_909_eus-gaap--DebtInstrumentMaturityDateRangeEnd1_dd_c20240205__20240206__us-gaap--ShortTermDebtTypeAxis__custom--InsurancePremiumFinancingMember_zmAyTBwnqGdb" title="Final payment date"&gt;November 1, 2024&lt;/span&gt;. This instrument was issued in
connection with financing insurance premiums. The note is payable in &lt;span id="xdx_901_eus-gaap--DebtInstrumentPaymentTerms_c20240205__20240206__us-gaap--ShortTermDebtTypeAxis__custom--InsurancePremiumFinancingMember_zJNB6Y6rdobh" title="Debt payment terms"&gt;nine monthly installment payments&lt;/span&gt; of principal and interest of $&lt;span id="xdx_90A_eus-gaap--DebtInstrumentPeriodicPayment_pn3p0_c20240205__20240206__us-gaap--ShortTermDebtTypeAxis__custom--InsurancePremiumFinancingMember_zJNI8vUL2LD6" title="Periodic payment"&gt;42,000&lt;/span&gt;,
with the first installment beginning &lt;span id="xdx_90F_eus-gaap--DebtInstrumentMaturityDateRangeStart1_dd_c20240205__20240206__us-gaap--ShortTermDebtTypeAxis__custom--InsurancePremiumFinancingMember_zpnF6FVVNUhi" title="First installment beginning date"&gt;March 1, 2024&lt;/span&gt;. At March 31, 2024, the outstanding principal on the note amounted to $&lt;span id="xdx_906_eus-gaap--OtherLongTermDebtCurrent_iI_pn3p0_c20240331__us-gaap--ShortTermDebtTypeAxis__custom--InsurancePremiumFinancingMember_zArR7BfJnsL7" title="Outstanding principal amount"&gt;323,000&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2025-02-01_custom_InsurancePremiumFinancingMember"
      decimals="-3"
      id="Fact000814"
      unitRef="USD">274000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="From2025-01-302025-02-01_custom_InsurancePremiumFinancingMember"
      decimals="INF"
      id="Fact000816"
      unitRef="Pure">0.0797</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentMaturityDateRangeEnd1
      contextRef="From2025-01-302025-02-01_custom_InsurancePremiumFinancingMember"
      id="Fact000818">2025-11-01</us-gaap:DebtInstrumentMaturityDateRangeEnd1>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="From2025-01-302025-02-01_custom_InsurancePremiumFinancingMember"
      decimals="-3"
      id="Fact000820"
      unitRef="USD">28000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:DebtInstrumentPaymentTerms
      contextRef="From2025-01-302025-02-01_custom_InsurancePremiumFinancingMember"
      id="Fact000822">nine monthly installment payments</us-gaap:DebtInstrumentPaymentTerms>
    <us-gaap:DebtInstrumentPeriodicPayment
      contextRef="From2025-01-302025-02-01_custom_InsurancePremiumFinancingMember"
      decimals="-3"
      id="Fact000824"
      unitRef="USD">28000</us-gaap:DebtInstrumentPeriodicPayment>
    <us-gaap:DebtInstrumentMaturityDateRangeStart1
      contextRef="From2025-01-302025-02-01_custom_InsurancePremiumFinancingMember"
      id="Fact000826">2025-03-01</us-gaap:DebtInstrumentMaturityDateRangeStart1>
    <us-gaap:OtherLongTermDebtCurrent
      contextRef="AsOf2025-03-31_custom_InsurancePremiumFinancingMember"
      decimals="-3"
      id="Fact000828"
      unitRef="USD">220000</us-gaap:OtherLongTermDebtCurrent>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2024-02-06_custom_InsurancePremiumFinancingMember"
      decimals="-3"
      id="Fact000830"
      unitRef="USD">373000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="From2024-02-052024-02-06_custom_InsurancePremiumFinancingMember"
      decimals="INF"
      id="Fact000832"
      unitRef="Pure">0.0842</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentMaturityDateRangeEnd1
      contextRef="From2024-02-052024-02-06_custom_InsurancePremiumFinancingMember"
      id="Fact000834">2024-11-01</us-gaap:DebtInstrumentMaturityDateRangeEnd1>
    <us-gaap:DebtInstrumentPaymentTerms
      contextRef="From2024-02-052024-02-06_custom_InsurancePremiumFinancingMember"
      id="Fact000836">nine monthly installment payments</us-gaap:DebtInstrumentPaymentTerms>
    <us-gaap:DebtInstrumentPeriodicPayment
      contextRef="From2024-02-052024-02-06_custom_InsurancePremiumFinancingMember"
      decimals="-3"
      id="Fact000838"
      unitRef="USD">42000</us-gaap:DebtInstrumentPeriodicPayment>
    <us-gaap:DebtInstrumentMaturityDateRangeStart1
      contextRef="From2024-02-052024-02-06_custom_InsurancePremiumFinancingMember"
      id="Fact000840">2024-03-01</us-gaap:DebtInstrumentMaturityDateRangeStart1>
    <us-gaap:OtherLongTermDebtCurrent
      contextRef="AsOf2024-03-31_custom_InsurancePremiumFinancingMember"
      decimals="-3"
      id="Fact000842"
      unitRef="USD">323000</us-gaap:OtherLongTermDebtCurrent>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="From2024-04-01to2025-03-31" id="Fact000844">&lt;p id="xdx_800_eus-gaap--LesseeOperatingLeasesTextBlock_zC5uS6PUIULd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;NOTE&#160;10&#160;&#x2013; &lt;span id="xdx_826_zY69HiYYyIW6"&gt;Leases&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&#x2019;s operating leases are comprised
primarily of facility leases. Balance sheet information related to the Company&#x2019;s leases is presented below:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--LeaseCostTableTextBlock_pn3n3_zvNwdzhJdoV1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Leases (Details - Balance sheet information related to leases)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8BE_zVgwzlUfHuE5" style="display: none"&gt;Schedule of lease information&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20250331_zgufW7mhuRC5" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20240331_z7WQg1YtTAif" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;March 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;March 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--LeasesOperatingAbstract_iB_zhAvz7KwSmok" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;Operating leases:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3p0_zC45qOjy3EG1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 66%; text-align: justify"&gt;Operating lease right-of-use assets&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;84,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;286,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pn3p0_zkl11NlOGgGk" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: justify"&gt;Operating lease liabilities &#x2013; current&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;58,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;198,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pn3p0_zALlRW1HaZgj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Operating lease liabilities &#x2013; non-current&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;27,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;87,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Other information related to leases is presented below:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Year ended&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;March 31, 2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; March 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Lease cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 66%; text-align: left"&gt;Operating lease cost&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--OperatingLeaseCost_pn3p0_c20240401__20250331_zBwtpOYMj9a7" style="width: 13%; text-align: right" title="Operating lease cost"&gt;365,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--OperatingLeaseCost_pn3p0_c20230401__20240331_zfY39wOUQiba" style="width: 13%; text-align: right" title="Operating lease cost"&gt;380,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;Other information:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Operating cash flows from operating leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--OperatingLeaseRightOfUseAssetAmortizationExpense_iN_pn3p0_di_c20240401__20250331_zAZcXdqojH6j" style="text-align: right" title="Operating cash flows from operating leases"&gt;(174,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--OperatingLeaseRightOfUseAssetAmortizationExpense_iN_pn3p0_di_c20230401__20240331_z7WHCMHY2tmh" style="text-align: right" title="Operating cash flows from operating leases"&gt;(161,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Weighted-average remaining lease term &#x2013; operating leases (in months)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtM_c20250331_zRzeA2SONKLh" title="Weighted-average remaining lease term - operating leases (in months)"&gt;18.6&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtM_c20240331_z21BxoyaMxhe" title="Weighted-average remaining lease term - operating leases (in months)"&gt;19.7&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Weighted-average discount rate &#x2013; operating leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pip0_dp_c20250331_zzOMOER59w7k" title="Weighted-average discount rate - operating leases"&gt;6&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pip0_dp_c20240331_zOIx4b0dGIif" title="Weighted-average discount rate - operating leases"&gt;6&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AA_zOYTYpaACjg1" style="font: 10pt Times New Roman, Times, Serif; margin: 0 180.1pt 0 0"&gt;&#160;&lt;/p&gt;











&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;As of March 31, 2025, the annual future minimum lease payments of the Company&#x2019;s
operating lease liabilities were as follows:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_887_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_pn3n3_zyWVFHP7mcj9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Leases (Details - Minimum operating lease payments)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8BC_zMJZyieoKFmi" style="display: none"&gt;Schedule of minimum operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20250331_zvZ7p8HAJc2j" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;For Years Ending March 31,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3p0_maLOLLPzr9e_zg9ESGkvQgDf" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 83%; text-align: left"&gt;2026&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;66,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3p0_maLOLLPzr9e_zyl3qcov8ATg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2027&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pn3p0_maLOLLPzr9e_zXwZBBpZM3s2" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;2028&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;9,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3p0_mtLOLLPzr9e_zzCztFJhxg8e" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Total future minimum lease payments, undiscounted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;90,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3p0_di_zN7HJc4WNBEh" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Less: imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(5,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--OperatingLeaseLiability_iI_pn3p0_zBzqBni5eROf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total lease liability&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;85,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LeaseCostTableTextBlock contextRef="From2024-04-01to2025-03-31" id="Fact000846">&lt;table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--LeaseCostTableTextBlock_pn3n3_zvNwdzhJdoV1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Leases (Details - Balance sheet information related to leases)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8BE_zVgwzlUfHuE5" style="display: none"&gt;Schedule of lease information&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20250331_zgufW7mhuRC5" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20240331_z7WQg1YtTAif" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;March 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;March 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--LeasesOperatingAbstract_iB_zhAvz7KwSmok" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="font-weight: bold; text-align: justify"&gt;Operating leases:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3p0_zC45qOjy3EG1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 66%; text-align: justify"&gt;Operating lease right-of-use assets&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;84,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;286,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pn3p0_zkl11NlOGgGk" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: justify"&gt;Operating lease liabilities &#x2013; current&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;58,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;198,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pn3p0_zALlRW1HaZgj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Operating lease liabilities &#x2013; non-current&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;27,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;87,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Other information related to leases is presented below:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Year ended&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;March 31, 2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Year ended&lt;br/&gt; March 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Lease cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 66%; text-align: left"&gt;Operating lease cost&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--OperatingLeaseCost_pn3p0_c20240401__20250331_zBwtpOYMj9a7" style="width: 13%; text-align: right" title="Operating lease cost"&gt;365,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--OperatingLeaseCost_pn3p0_c20230401__20240331_zfY39wOUQiba" style="width: 13%; text-align: right" title="Operating lease cost"&gt;380,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;Other information:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Operating cash flows from operating leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--OperatingLeaseRightOfUseAssetAmortizationExpense_iN_pn3p0_di_c20240401__20250331_zAZcXdqojH6j" style="text-align: right" title="Operating cash flows from operating leases"&gt;(174,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--OperatingLeaseRightOfUseAssetAmortizationExpense_iN_pn3p0_di_c20230401__20240331_z7WHCMHY2tmh" style="text-align: right" title="Operating cash flows from operating leases"&gt;(161,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Weighted-average remaining lease term &#x2013; operating leases (in months)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtM_c20250331_zRzeA2SONKLh" title="Weighted-average remaining lease term - operating leases (in months)"&gt;18.6&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtM_c20240331_z21BxoyaMxhe" title="Weighted-average remaining lease term - operating leases (in months)"&gt;19.7&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Weighted-average discount rate &#x2013; operating leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pip0_dp_c20250331_zzOMOER59w7k" title="Weighted-average discount rate - operating leases"&gt;6&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pip0_dp_c20240331_zOIx4b0dGIif" title="Weighted-average discount rate - operating leases"&gt;6&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000851"
      unitRef="USD">84000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000852"
      unitRef="USD">286000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000854"
      unitRef="USD">58000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000855"
      unitRef="USD">198000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000857"
      unitRef="USD">27000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact000858"
      unitRef="USD">87000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseCost
      contextRef="From2024-04-01to2025-03-31"
      decimals="-3"
      id="Fact000860"
      unitRef="USD">365000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000862"
      unitRef="USD">380000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="From2024-04-01to2025-03-31"
      decimals="-3"
      id="Fact000864"
      unitRef="USD">174000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact000866"
      unitRef="USD">161000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2025-03-31" id="Fact000868">P18M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2024-03-31" id="Fact000870">P19M21D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="AsOf2025-03-31"
      decimals="INF"
      id="Fact000872"
      unitRef="Pure">0.06</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="AsOf2024-03-31"
      decimals="INF"
      id="Fact000874"
      unitRef="Pure">0.06</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="From2024-04-01to2025-03-31" id="Fact000880">&lt;table cellpadding="0" cellspacing="0" id="xdx_887_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_pn3n3_zyWVFHP7mcj9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Leases (Details - Minimum operating lease payments)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8BC_zMJZyieoKFmi" style="display: none"&gt;Schedule of minimum operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20250331_zvZ7p8HAJc2j" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;For Years Ending March 31,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3p0_maLOLLPzr9e_zg9ESGkvQgDf" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 83%; text-align: left"&gt;2026&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;66,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3p0_maLOLLPzr9e_zyl3qcov8ATg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2027&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pn3p0_maLOLLPzr9e_zXwZBBpZM3s2" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;2028&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;9,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3p0_mtLOLLPzr9e_zzCztFJhxg8e" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Total future minimum lease payments, undiscounted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;90,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3p0_di_zN7HJc4WNBEh" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Less: imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(5,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--OperatingLeaseLiability_iI_pn3p0_zBzqBni5eROf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total lease liability&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;85,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000882"
      unitRef="USD">66000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000884"
      unitRef="USD">15000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000886"
      unitRef="USD">9000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000888"
      unitRef="USD">90000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000890"
      unitRef="USD">5000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000892"
      unitRef="USD">85000</us-gaap:OperatingLeaseLiability>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2024-04-01to2025-03-31" id="Fact000894">&lt;p id="xdx_809_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zIznzNyWyJjh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;NOTE&#160;11&#160;&#x2013; &lt;span id="xdx_823_zZJKuFOPQlz2"&gt;Commitments and Contingencies&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Legal Matters&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company may be involved in legal matters arising
in the ordinary course of business including matters involving proprietary technology. While management believes that such matters are
currently insignificant, matters arising in the ordinary course of business for which the Company is or could become involved in litigation
may have a material adverse effect on its business and financial condition of comprehensive loss.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Employment Agreements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company has employment agreements in place with
two of its key executives. These executive employment agreements provide, among other things, for the payment of up to eighteen months
of severance compensation for terminations under certain circumstances.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of March 31, 2025, with respect to these agreements,
aggregated annual salaries was $&lt;span id="xdx_907_eus-gaap--OfficersCompensation_pn3p0_c20240401__20250331_zlQsSql2MIYi" title="Annual salaries"&gt;586,000&lt;/span&gt; and potential severance payments to these key executives was $&lt;span id="xdx_90A_ecustom--PotentialSeverancePayments_iI_pn3p0_c20250331_z9m8vl2LFuya" title="Potential severance payments"&gt;1,300,000&lt;/span&gt;, if triggered.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:OfficersCompensation
      contextRef="From2024-04-01to2025-03-31"
      decimals="-3"
      id="Fact000896"
      unitRef="USD">586000</us-gaap:OfficersCompensation>
    <SNOA:PotentialSeverancePayments
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000898"
      unitRef="USD">1300000</SNOA:PotentialSeverancePayments>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2024-04-01to2025-03-31" id="Fact000900">&lt;p id="xdx_80E_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zNBRq5QPJgRi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;NOTE&#160;12&#160;&#x2013; &lt;span id="xdx_82F_zs30ER1LAR56"&gt;Stockholders&#x2019; Equity&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Authorized Capital&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Effective August 29, 2024, the Company increased its
authorized shares from &lt;span id="xdx_90B_eus-gaap--CommonStockSharesAuthorized_iI_pip0_c20240829__srt--RangeAxis__srt--MinimumMember_zCSblRwPg4Kj" title="Common stock, shares authorized"&gt;24,000,000&lt;/span&gt; to &lt;span id="xdx_909_eus-gaap--CommonStockSharesAuthorized_iI_pip0_c20240829__srt--RangeAxis__srt--MaximumMember_zpDGzBELJzz8" title="Common stock, shares authorized"&gt;50,000,000&lt;/span&gt; shares of common stock with a par value of $&lt;span id="xdx_90C_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20240829_zMVH3ouVABuh" title="Common stock, par value"&gt;0.0001&lt;/span&gt; per share.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Additionally, the Company is authorized to issue &lt;span id="xdx_903_eus-gaap--PreferredStockSharesAuthorized_iI_pip0_c20250331__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zGMo66xNomC" title="Convertible preferred stock, shares authorized"&gt;714,286&lt;/span&gt;
shares of convertible preferred stock with a par value of $&lt;span id="xdx_909_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20250331__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zwr5d8BXwey6" title="Convertible preferred stock, par value"&gt;0.0001&lt;/span&gt; per share.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Description of Common Stock&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Each share of common stock has the right to one vote.
The holders of common stock are entitled to dividends when funds are legally available and when declared by the board of directors.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;











&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Description of Series B Convertible Preferred
Stock&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On October 18, 2016, the Company&#x2019;s board of
directors approved, and the Company entered into, a Section 382 rights agreement, or the Rights Agreement, with Computershare Inc., or
the Rights Agent. The Rights Agreement provides for a dividend of one preferred stock purchase right, or a Right, for each share of common
stock, par value $0.0001 per share, of the Company outstanding on November 1, 2016, or the Record Date. Each Right entitles the holder
to purchase from the Company one one-thousandth of a share of Series B Preferred Stock, par value $0.0001 per share, or the Preferred
Stock, for a purchase price of $10.00, subject to adjustment as provided in the Rights Agreement. The description and terms of the rights
are set forth in the Rights Agreement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In connection with the adoption of the Rights Agreement,
the Company&#x2019;s board of directors adopted a Certificate of Designation of Series B Preferred Stock. The Certificate of Designation
was filed with the Secretary of State of the State of Delaware and became effective on October 18, 2016.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&#x2019;s board of directors adopted the
Rights Agreement to protect shareholder value by guarding against a potential limitation on the Company&#x2019;s ability to use its net
operating loss carryforwards, or NOLs, and other tax benefits, which may be used to reduce potential future income tax obligations. The
Company has experienced and continues to experience substantial operating losses, and under the Internal Revenue Code of 1986, as amended,
and rules promulgated thereunder, the Company may &#x201c;carry forward&#x201d; these NOLs and other tax benefits in certain circumstances
to offset any current and future earnings and thus reduce our income tax liability, subject to certain requirements and restrictions.
To the extent that the NOLs and other tax benefits do not otherwise become limited, the Company believes that it will be able to carry
forward a significant amount of NOLs and other tax benefits, and therefore these NOLs and other tax benefits could be a substantial asset
to the Company. However, if the Company experiences an &#x201c;ownership change,&#x201d; as defined in Section 382 of the Code, its ability
to use its NOLs and other tax benefits will be substantially limited. Generally, an ownership change would occur if our shareholders who
own, or are deemed to own, 5% or more of the Company&#x2019;s common stock increase their collective ownership in the Company by more than
50% over a rolling three-year period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Sale of Common Stock&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On October 26, 2023, the Company entered into a placement
agency agreement with Maxim Group LLC (&#x201c;Maxim&#x201d;) pursuant to which Maxim agreed to use its reasonable best efforts to solicit
offers to purchase up to an aggregate of 425,000 shares of the Company&#x2019;s common stock, par value $0.0001 per share.&#160; The Company
agreed to pay Maxim a cash fee equal to 8.0% of the gross proceeds from the offering, plus reimbursement of up to $&lt;span id="xdx_903_eus-gaap--LegalFees_pn3p0_c20231025__20231026__us-gaap--TypeOfArrangementAxis__custom--PlacementAgencyAgreementMember_zgkJeKmteNn3" title="Legal fees and other expenses"&gt;75,000&lt;/span&gt; of legal fees
and other expenses. Additionally, on October 26, 2023, the Company entered into a securities purchase agreement with the purchasers party
thereto for the sale and issuance of an aggregate of up to 425,000 shares of the Company&#x2019;s common stock at a public offering price
of $4.00 per share. The closing of the offering occurred on October 30, 2023. In connection with the offering, the Company sold &lt;span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20231025__20231026__us-gaap--SubsidiarySaleOfStockAxis__custom--PublicOfferingMember_zSqya5SkFv61" title="Stock issued new, shares"&gt;425,000&lt;/span&gt;
shares of the Company&#x2019;s common stock for aggregate gross proceeds of $&lt;span id="xdx_905_ecustom--ProceedsFromIssuanceOfCommonStockGross_pn3p0_c20231025__20231026__us-gaap--SubsidiarySaleOfStockAxis__custom--PublicOfferingMember_z5Zvy5nyafxl" title="Proceeds from sale of stock, gross"&gt;1,700,000&lt;/span&gt; and net proceeds of $&lt;span id="xdx_900_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn3p0_c20231025__20231026__us-gaap--SubsidiarySaleOfStockAxis__custom--PublicOfferingMember_zETqH2yfExl7" title="Proceeds from sale of stock, net"&gt;1,446,000&lt;/span&gt;, after deducting
placement agent fees and other estimated offering expenses paid by the Company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On December 15, 2023, the Company entered into an
Equity Distribution Agreement (the &#x201c;Agreement&#x201d;), with Maxim pursuant to which the Company may offer and sell, from time to
time, through Maxim, as sales agent or principal, shares of its common stock, $0.0001 par value per share. Subject to the terms and conditions
of the Agreement, Maxim will use commercially reasonable efforts consistent with its normal trading and sales practices, applicable state
and federal law, rules and regulations and the rules of the Nasdaq Capital Market to sell shares from time to time based upon the Company&#x2019;s
instructions, including any price, time or size limits specified by the Company. Under the Agreement, Maxim may sell shares by any method
deemed to be an &#x201c;at the market&#x201d; offering as defined in Rule 415 under the U.S. Securities Act of 1933, as amended, or any
other method permitted by law, including in privately negotiated transactions. Maxim&#x2019;s obligations to sell shares under the Agreement
are subject to satisfaction of certain conditions, including customary closing conditions for transactions of this nature. The Company
will pay Maxim a commission of 3% of the aggregate gross proceeds from each sale of shares and has agreed to provide Maxim with customary
indemnification and contribution rights. The Company also agreed to reimburse Maxim for certain specified expenses of up to $&lt;span id="xdx_90B_eus-gaap--LegalFees_pn3p0_c20231214__20231215__us-gaap--TypeOfArrangementAxis__custom--EquityDistributionAgreementMember_zNJUJvAUgosh" title="Legal fees and other expenses"&gt;20,000&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;











&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;In
connection with the&lt;/span&gt; A&lt;span style="font-family: Times New Roman, Times, Serif"&gt;greement that the Company entered into on December
15, 2023 with Maxim, on January 11, 2024, the Company sold &lt;span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20240110__20240111__dei--LegalEntityAxis__custom--MaximGroupLLCMember_zSmkghBrYNS8" title="Stock issued new, shares"&gt;96,154&lt;/span&gt; shares of its common stock for gross proceeds of $&lt;span id="xdx_909_ecustom--ProceedsFromIssuanceOfCommonStockGross_pn3p0_c20240110__20240111__dei--LegalEntityAxis__custom--MaximGroupLLCMember_z1jGynMJqfx3" title="Proceeds from sale of stock, gross"&gt;392,000&lt;/span&gt; and net proceeds
of $&lt;span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn3p0_c20240110__20240111__dei--LegalEntityAxis__custom--MaximGroupLLCMember_zkG4yvQpN5Ff" title="Proceeds from sale of stock, net"&gt;338,000&lt;/span&gt; after deducting commissions and other estimated offering expenses paid by the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In connection with the Agreement that the Company
entered into on December 15, 2023 with Maxim, as amended, from May 13, 2024 to November 20, 2024 the Company sold &lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20241119__20241120__dei--LegalEntityAxis__custom--MaximGroupLLCMember_zdXXzV6fRGLf" title="Stock issued new, shares"&gt;816,894&lt;/span&gt; shares of its
common stock for gross proceeds of $&lt;span id="xdx_90B_ecustom--ProceedsFromIssuanceOfCommonStockGross_pn3p0_c20241119__20241120__dei--LegalEntityAxis__custom--MaximGroupLLCMember_zATTioopjeic" title="Proceeds from sale of stock, gross"&gt;3,325,000&lt;/span&gt; and net proceeds of $&lt;span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn3p0_c20241119__20241120__dei--LegalEntityAxis__custom--MaximGroupLLCMember_zZpbSZerThTc" title="Proceeds from sale of stock, net"&gt;3,079,000&lt;/span&gt; after deducting commissions and other offering expenses paid
by the Company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-08-29_srt_MinimumMember"
      decimals="INF"
      id="Fact000902"
      unitRef="Shares">24000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-08-29_srt_MaximumMember"
      decimals="INF"
      id="Fact000904"
      unitRef="Shares">50000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-08-29"
      decimals="INF"
      id="Fact000906"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2025-03-31_us-gaap_ConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000908"
      unitRef="Shares">714286</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2025-03-31_us-gaap_ConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact000910"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:LegalFees
      contextRef="From2023-10-252023-10-26_custom_PlacementAgencyAgreementMember"
      decimals="-3"
      id="Fact000916"
      unitRef="USD">75000</us-gaap:LegalFees>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-10-252023-10-26_custom_PublicOfferingMember"
      decimals="INF"
      id="Fact000918"
      unitRef="Shares">425000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <SNOA:ProceedsFromIssuanceOfCommonStockGross
      contextRef="From2023-10-252023-10-26_custom_PublicOfferingMember"
      decimals="-3"
      id="Fact000920"
      unitRef="USD">1700000</SNOA:ProceedsFromIssuanceOfCommonStockGross>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2023-10-252023-10-26_custom_PublicOfferingMember"
      decimals="-3"
      id="Fact000922"
      unitRef="USD">1446000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:LegalFees
      contextRef="From2023-12-142023-12-15_custom_EquityDistributionAgreementMember"
      decimals="-3"
      id="Fact000924"
      unitRef="USD">20000</us-gaap:LegalFees>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-01-102024-01-11_custom_MaximGroupLLCMember"
      decimals="INF"
      id="Fact000930"
      unitRef="Shares">96154</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <SNOA:ProceedsFromIssuanceOfCommonStockGross
      contextRef="From2024-01-102024-01-11_custom_MaximGroupLLCMember"
      decimals="-3"
      id="Fact000932"
      unitRef="USD">392000</SNOA:ProceedsFromIssuanceOfCommonStockGross>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2024-01-102024-01-11_custom_MaximGroupLLCMember"
      decimals="-3"
      id="Fact000934"
      unitRef="USD">338000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2024-11-192024-11-20_custom_MaximGroupLLCMember"
      decimals="INF"
      id="Fact000936"
      unitRef="Shares">816894</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <SNOA:ProceedsFromIssuanceOfCommonStockGross
      contextRef="From2024-11-192024-11-20_custom_MaximGroupLLCMember"
      decimals="-3"
      id="Fact000938"
      unitRef="USD">3325000</SNOA:ProceedsFromIssuanceOfCommonStockGross>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2024-11-192024-11-20_custom_MaximGroupLLCMember"
      decimals="-3"
      id="Fact000940"
      unitRef="USD">3079000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="From2024-04-01to2025-03-31" id="Fact000942">&lt;p id="xdx_802_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zqaVTI7J934i" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;NOTE&#160;13&#160;&#x2013; &lt;span id="xdx_82E_zjPQGi9SFVM1"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;2016 Stock Plan&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On September 2, 2016, upon recommendation of the board,
the stockholders approved the Company&#x2019;s 2016 Equity Incentive Plan (the &#x201c;2016 Plan&#x201d;). The 2016 Plan is effective as
of September 2, 2016 and has a ten year term.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The 2016 Plan provides for the grant of options, including
incentive stock options as defined in Section 422 of the Internal Revenue Code to employees, stock appreciation rights, restricted awards,
performance share awards and performance compensation awards to employees, non-employee directors, advisors and consultants.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Options issued under the 2016 Plan generally have
a ten-year term.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In accordance with the 2016 Plan, the stated exercise
price of an employee incentive stock option or a non-statutory stock option shall not be less than 100% of the estimated fair market value
of a share of common stock on the date of grant. An employee who owns more than 10% of the total combined voting power of all classes
of outstanding stock of the Company shall not be eligible for the grant of an employee incentive stock option unless such grant satisfies
the requirements of Section 422(c)(5) of the Internal Revenue Code.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Shares subject to awards that expire unexercised or
are forfeited or terminated for any other reason will again become available for issuance under the 2016 Plan. No participant in the 2016
Plan can receive more than 11,112 option grants, or other awards with respect to more than 13,334 shares in the aggregate in any calendar
year.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The board has authorized &lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pip0_c20160902__us-gaap--PlanNameAxis__custom--Plan2016Member_zxqGZiKKFJWh" title="Shares initially authorized for issuance"&gt;2,222&lt;/span&gt; of the Company&#x2019;s
common stock for issuance under the 2016 Plan, in addition to automatic increases provided for in the 2016 Plan through April 1, 2026.
The number of shares of the Company&#x2019;s common stock reserved for issuance under the 2016 Plan will automatically increase, with no
further action by the stockholders, at the beginning of each fiscal year by an amount equal to the lesser of (i) 8% of the outstanding
shares of the Company&#x2019;s common stock on the last day of the immediately preceding year, or (ii) an amount determined by the Company&#x2019;s
board of directors. During the year ended March 31, 2019, the board of directors approved an increase of &lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_pip0_c20180401__20190331__us-gaap--PlanNameAxis__custom--Plan2016Member_zCvCujZ2cDWc" title="Increase in shares authorized for issuance"&gt;243&lt;/span&gt; shares authorized for issuance.
During the year ended March 31, 2020, the board of directors approved an increase of &lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_pip0_c20190401__20200331__us-gaap--PlanNameAxis__custom--Plan2016Member_zXVt45xp6Gv5" title="Increase in shares authorized for issuance"&gt;5,266&lt;/span&gt; shares authorized for issuance. During the
year ended March 31, 2022, the board of directors approved an increase of &lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_pip0_c20210401__20220331__us-gaap--PlanNameAxis__custom--Plan2016Member_zAvMSHuQS47c" title="Increase in shares authorized for issuance"&gt;8,372&lt;/span&gt; shares authorized for issuance. During the year ended
March 31, 2025, the board of directors approved an increase of &lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_pip0_c20240401__20250331__us-gaap--PlanNameAxis__custom--Plan2016Member_z3ysErvDxxOg" title="Increase in shares authorized for issuance"&gt;62,429&lt;/span&gt; shares authorized for issuance.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;At March 31, 2025 there were &lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pip0_c20250331__us-gaap--PlanNameAxis__custom--Plan2016Member_zoaKrrBxjFh6" title="Shares available for future issuance"&gt;9,670&lt;/span&gt; shares available
for future issuance.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;











&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;2021 Stock Plan&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On September 21, 2021, upon recommendation of the
board, the stockholders approved the Company&#x2019;s 2021 Equity Incentive Plan (the &#x201c;2021 Plan&#x201d;). The 2021 Plan is effective
as of September 21, 2021 and has a five year term.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The 2021 Plan provides for the grant of options, including
incentive stock options as defined in Section 422 of the Internal Revenue Code to employees, stock appreciation rights, restricted awards,
performance share awards and performance compensation awards to employees, non-employee directors, advisors and consultants.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Options issued under the 2021 Plan generally have
a ten-year term.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In accordance with the 2021 Plan, the stated exercise
price of an employee incentive stock option or a non-statutory stock option shall not be less than 100% of the estimated fair market value
of a share of common stock on the date of grant. An employee who owns more than 10% of the total combined voting power of all classes
of outstanding stock of the Company shall not be eligible for the grant of an employee incentive stock option unless such grant satisfies
the requirements of Section 422(c)(5) of the Internal Revenue Code.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Shares subject to awards that expire unexercised or
are forfeited or terminated for any other reason will again become available for issuance under the 2021 Plan.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The board has authorized &lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_pip0_c20240401__20250331__us-gaap--PlanNameAxis__custom--Plan2021Member_zzQUdcMErmH" title="Increase in shares authorized for issuance"&gt;50,000&lt;/span&gt; shares of the Company&#x2019;s
common stock for issuance under the 2021 Plan.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;At March 31, 2025, there were &lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pip0_do_c20250331__us-gaap--PlanNameAxis__custom--Plan2021Member_zRLuMUs7S8P1" title="Shares available for future issuance"&gt;no&lt;/span&gt; shares available
for future issuance.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;2024 Stock Plan&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On August 23, 2024, upon recommendation of the board,
the stockholders approved the Company&#x2019;s 2024 Equity Incentive Plan (the &#x201c;2024 Plan&#x201d;). The 2024 Plan is effective as
of August 23, 2024 and has a five year term.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The 2024 Plan provides for the grant of options, including
incentive stock options as defined in Section 422 of the Internal Revenue Code to employees, stock appreciation rights, restricted awards,
performance share awards and performance compensation awards to employees, non-employee directors, advisors and consultants.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Options issued under the 2024 Plan generally have
a ten-year term.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In accordance with the 2024 Plan, the stated exercise
price of an employee incentive stock option or a non-statutory stock option shall not be less than 100% of the estimated fair market value
of a share of common stock on the date of grant. An employee who owns more than 10% of the total combined voting power of all classes
of outstanding stock of the Company shall not be eligible for the grant of an employee incentive stock option unless such grant satisfies
the requirements of Section 422(c)(5) of the Internal Revenue Code.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Shares subject to awards that expire unexercised or
are forfeited or terminated for any other reason will again become available for issuance under the 2024 Plan.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;











&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The board has authorized &lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_pip0_c20240401__20250331__us-gaap--PlanNameAxis__custom--Plan2024Member_zexGw4wqr2y4" title="Increase in shares authorized for issuance"&gt;50,000&lt;/span&gt; shares of the Company&#x2019;s
common stock for issuance under the 2024 Plan, in addition to automatic increases provided for in the 2024 Plan through April 1, 2029.
The number of shares of the Company&#x2019;s common stock reserved for issuance under the 2024 Plan will automatically increase, with no
further action by the stockholders, at the beginning of each fiscal year by an amount equal to the lesser of (i) 5% of the outstanding
shares of the Company&#x2019;s common stock on the last day of the immediately preceding year, or (ii) an amount determined by the Company&#x2019;s
board of directors.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;At March 31, 2025, there were &lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pip0_c20250331__us-gaap--PlanNameAxis__custom--Plan2024Member_z2upLwOU6v24" title="Shares available for future issuance"&gt;5,000&lt;/span&gt; shares available
for future issuance.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Stock-Based Compensation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company issues service, performance and market-based
stock options to employees and non-employees. The Company estimates the fair value of service and performance stock option awards using
the Black-Scholes option pricing model. The Company estimates the fair value of market-based stock option awards using a Monte-Carlo simulation.
Compensation expense for stock option awards is amortized on a straight-line basis over the awards&#x2019; vesting period. Compensation
expense includes the impact of forfeitures as they are incurred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The expected term of the stock options represents
the average period the stock options are expected to remain outstanding and is based on the expected term calculated using the approach
prescribed by&#160;SEC Staff Accounting Bulletin No.&#160;110 for &#x201c;plain vanilla&#x201d; options. The expected stock price volatility
for the Company&#x2019;s stock options was determined by using an average of the historical volatilities of the Company. The Company will
continue to analyze the stock price volatility and expected term assumptions as more data for the Company&#x2019;s common stock and exercise
patterns become available. The risk-free interest rate assumption is based on the U.S. Treasury instruments whose term was consistent
with the expected term of the Company&#x2019;s stock options. The expected dividend assumption is based on the Company&#x2019;s history
and expectation of dividend payouts.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company estimated the fair value of employee and
non-employee stock options using the Black-Scholes option pricing model. The fair value of employee stock options is being amortized on
a straight-line basis over the requisite service periods of the respective awards. The fair value of employee stock options was estimated
using the following weighted-average assumptions:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_886_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zY4u1rsQxBC1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock-Based Compensation (Details-Assumptions)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8BC_zxRpjcQAdiuh" style="display: none"&gt;Schedule of weighted-average assumptions of fair value of employee stock options&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Year Ended March&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 66%; text-align: left"&gt;Fair value of the Company&#x2019;s common stock on date of grant&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240401__20250331_zGhb9ITzBBfg" style="width: 13%; text-align: right" title="Fair value of the Company common stock on date of grant"&gt;2.68&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230401__20240331_zQT76tpBxat2" style="width: 13%; text-align: right" title="Fair value of the Company common stock on date of grant"&gt;0.19&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected term&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240401__20250331_zz1tLX7P3m1h" title="Expected term"&gt;5.68&lt;/span&gt; yrs&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230401__20240331_zNtg5cM8buT3" title="Expected term"&gt;5.56&lt;/span&gt; yrs&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_c20240401__20250331_zAHBKkyLo7a2" title="Risk-free interest rate"&gt;4.57&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_c20230401__20240331_zBmVeKzH6EEl" title="Risk-free interest rate"&gt;3.87&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pip0_dp_c20240401__20250331_zPNIAMZmm0Z5" title="Dividend yield"&gt;0.00&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pip0_dp_c20230401__20240331_zYyY5GWkLyDj" title="Dividend yield"&gt;0.00&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td&gt;Volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20240401__20250331_zpjBiJ86d2wi" title="Volatility"&gt;109.91&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20230401__20240331_zkYcvPwPB4cd" title="Volatility"&gt;98.40&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Fair value of options granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20240401__20250331_zWkfRIVKSqya" style="text-align: right" title="Fair value of options granted"&gt;2.23&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20230401__20240331_zyXYILnWUOD4" style="text-align: right" title="Fair value of options granted"&gt;0.15&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AD_zibMZQ3bT4Oi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the years ended March 31, 2025 and 2024, the
Company incurred $&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensation_pn3p0_c20240401__20250331_ztOeGi3NmJva" title="Stock-based compensation"&gt;224,000&lt;/span&gt; and $&lt;span id="xdx_906_eus-gaap--ShareBasedCompensation_pn3p0_c20230401__20240331_zhxIVoMAiJLb" title="Stock-based compensation"&gt;516,000&lt;/span&gt;, respectively of stock-based compensation expense. All stock-based compensation expense incurred
is included in selling, general and administrative expense in the accompanying consolidated statements of comprehensive loss.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;At March 31, 2025, there were unrecognized compensation
costs of $&lt;span id="xdx_90F_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pn3p0_c20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zIJ36kpkF3za" title="Unrecognized compensation costs"&gt;250,000&lt;/span&gt; related to stock options which is expected to be recognized over a weighted-average amortization period of &lt;span id="xdx_904_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zTrGlGieQKqi" title="Weighted average amortization period"&gt;1.58&lt;/span&gt; years.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;











&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Stock-Based Award Activity&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Stock-based awards outstanding at March 31, 2025 under
the various plans are as follows:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_882_ecustom--ScheduleOfStockbasedAwardsOutstandingByPlanTableTextBlock_zGog1iJpO2lc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 50%" summary="xdx: Disclosure - Stock-Based Compensation (Details-Plans)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8BA_zn1GUR3OtfLc" style="display: none"&gt;Schedule of stock based awards outstanding by plan&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;Plan&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Stock Options&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 72%"&gt;2011 Plan&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20250331__us-gaap--PlanNameAxis__custom--Plan2011Member_zLSscwD521wg" style="width: 24%; text-align: right" title="Options outstanding"&gt;3,998&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;2016 Plan&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20250331__us-gaap--PlanNameAxis__custom--Plan2016Member_zhseAxtwgM5j" style="text-align: right" title="Options outstanding"&gt;38,942&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;2021 Plan&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20250331__us-gaap--PlanNameAxis__custom--Plan2021Member_zaRZrqjGQqB9" style="border-bottom: Black 1pt solid; text-align: right" title="Options outstanding"&gt;30,141&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20250331_zcMREqnMHgh7" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding"&gt;73,081&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0"&gt;Stock options award activity is as follows:&lt;/p&gt;

&lt;p style="margin: 0"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_881_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_pn3n3_zSphkuHyCIVj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock-Based Compensation (Details-Option activity)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8BF_zYoPp0tHSJnk" style="display: none"&gt;Schedule of options activity&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Number of&lt;br/&gt; Shares&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted-&lt;br/&gt; Average&lt;br/&gt; Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted-&lt;br/&gt; Average&lt;br/&gt; Contractual Term&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Aggregate&lt;br/&gt; Intrinsic&lt;br/&gt; Value&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 40%"&gt;Outstanding at April 1, 2024&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pip0_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zx9V5kvM8KD3" style="width: 11%; text-align: right" title="Number of options outstanding, beginning balance"&gt;51,675&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pip0_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zVFOi2NIYw16" style="width: 11%; text-align: right" title="Weighted-average exercise price options outstanding, beginning balance"&gt;62.60&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Options granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pip0_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zKZ1qZMvkHa6" style="text-align: right" title="Number of options granted"&gt;49,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pip0_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z12GzOa621Y1" style="text-align: right" title="Weighted-average exercise price, options granted"&gt;2.68&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;Options exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pip0_di0_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z8CdCaZvxUol" style="text-align: right" title="Number of options exercised"&gt;(27,750&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pip0_d0_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zBHb21k4LAZb" style="text-align: right" title="Weighted-average exercise price, options exercised"&gt;2.99&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Options forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pip0_di_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zCoWwKK0Syta" style="text-align: right" title="Number of options forfeited"&gt;(250&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pip0_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zisavVve5yL4" style="text-align: right" title="Weighted-average exercise price, options forfeited"&gt;3.60&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Options expired&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pip0_di_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zkzyXbnj5cO2" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options expired"&gt;(94&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pip0_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zM1KFBXrAAv3" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted-average exercise price, options expired"&gt;1,485.96&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Outstanding at March 31, 2025&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pip0_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zsJbOoemMG29" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options outstanding, ending balance"&gt;73,081&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pip0_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zhtM1O6FwxM9" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-average exercise price options outstanding, ending balance"&gt;43.27&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zTNjH8QDnwOh" title="Weighted- average contractual term outstanding"&gt;8.82&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_pip0_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zg8EMUdCHLDe" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value per share, outstanding"&gt;2.19&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Exercisable at March 31, 2025&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pip0_c20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zW1C8HV0YNn9" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options, exercisable"&gt;39,751&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pip0_c20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zYki2puJa73b" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-average exercise price, exercisable"&gt;74.86&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z7P2HxCcDvoi" title="Weighted- average contractual term, exercisable"&gt;7.71&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableInPeriodGrantDateIntrinsicValue_pip0_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zBANKWSBcXd6" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value per share, exercisable"&gt;2.19&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The aggregate intrinsic value of stock options is
calculated as the difference between the exercise price of the underlying stock options and the fair value of the Company&#x2019;s common
stock, or $&lt;span id="xdx_908_eus-gaap--SharePrice_iI_pip0_c20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zJpIuheUoJa5"&gt;2.19&lt;/span&gt; and $&lt;span id="xdx_904_eus-gaap--SharePrice_iI_pip0_c20240331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zIeqOGEM4xSl"&gt;3.40&lt;/span&gt; per share at March 31, 2025 and 2024, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Restricted stock award activity is as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p style="margin: 0"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_885_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_pn3n3_zNHiu2hCpU8i" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock-Based Compensation (Details-Restricted stock activity)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8B8_zLuSztfe4RUj" style="display: none"&gt;Schedule of unvested restricted stock activity&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1.8pt 0 0; text-align: center"&gt;&lt;b&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1.8pt 0 0; text-align: center"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1.8pt 0 0; text-align: center"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1.8pt 0 0; text-align: center"&gt;&lt;b&gt;Average Award&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1.8pt 0 0; text-align: center"&gt;&lt;b&gt;Date Fair Value&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1.8pt 0 0; text-align: center"&gt;&lt;b&gt;per Share&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;Unvested restricted stock awards outstanding at April 1, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pip0_d0_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zucBrBhKZoA8" style="text-align: right" title="Number of unvested restricted stock awards outstanding, beginning balance"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pip0_d0_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zXq3ujbUAXXf" style="text-align: right" title="Weighted-average award date fair value per share, unvested RSAs outstanding, beginning balance"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 66%; text-align: left"&gt;Restricted stock awards granted&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pip0_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zuse3bs8vKrd" style="width: 13%; text-align: right" title="Number of restricted stock awards granted"&gt;54,538&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pip0_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zYJzBOqrstdg" style="width: 13%; text-align: right" title="Weighted-average award date fair value per share, unvested RSAs granted"&gt;2.92&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Restricted stock awards vested&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pip0_di_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zNlWPajOM1qa" style="border-bottom: Black 1pt solid; text-align: right" title="Number of restricted stock awards vested"&gt;(9,538&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pip0_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zspybwAIX0A1" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted-average award date fair value per share, unvested RSAs vested"&gt;4.08&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Unvested restricted stock awards outstanding at March 31, 2025&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pip0_d0_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zTz3dcreSpfl" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of unvested restricted stock awards outstanding, ending balance"&gt;45,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pip0_d0_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zvKukhiSkyRd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-average award date fair value per share, unvested RSAs outstanding, ending balance"&gt;2.68&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;A tax benefit of $&lt;span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense_pn3p0_c20240401__20250331_z4UcHHZeO55e" title="Stock based compensation options exercised"&gt;123,000&lt;/span&gt; has been recognized relating
to stock-based compensation as a result of non-qualified stock options and restricted stock exercised during the year ending March 31,
2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company issues new shares of common stock upon
exercise of stock options or release of restricted stock awards.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;











</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2016-09-02_custom_Plan2016Member"
      decimals="INF"
      id="Fact000944"
      unitRef="Shares">2222</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="From2018-04-012019-03-31_custom_Plan2016Member"
      decimals="INF"
      id="Fact000946"
      unitRef="Shares">243</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="From2019-04-012020-03-31_custom_Plan2016Member"
      decimals="INF"
      id="Fact000948"
      unitRef="Shares">5266</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="From2021-04-012022-03-31_custom_Plan2016Member"
      decimals="INF"
      id="Fact000950"
      unitRef="Shares">8372</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="From2024-04-012025-03-31_custom_Plan2016Member"
      decimals="INF"
      id="Fact000952"
      unitRef="Shares">62429</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2025-03-31_custom_Plan2016Member"
      decimals="INF"
      id="Fact000954"
      unitRef="Shares">9670</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="From2024-04-012025-03-31_custom_Plan2021Member"
      decimals="INF"
      id="Fact000960"
      unitRef="Shares">50000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2025-03-31_custom_Plan2021Member"
      decimals="INF"
      id="Fact000962"
      unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="From2024-04-012025-03-31_custom_Plan2024Member"
      decimals="INF"
      id="Fact000968"
      unitRef="Shares">50000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2025-03-31_custom_Plan2024Member"
      decimals="INF"
      id="Fact000970"
      unitRef="Shares">5000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2024-04-01to2025-03-31" id="Fact000972">&lt;table cellpadding="0" cellspacing="0" id="xdx_886_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zY4u1rsQxBC1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock-Based Compensation (Details-Assumptions)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8BC_zxRpjcQAdiuh" style="display: none"&gt;Schedule of weighted-average assumptions of fair value of employee stock options&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Year Ended March&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 66%; text-align: left"&gt;Fair value of the Company&#x2019;s common stock on date of grant&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240401__20250331_zGhb9ITzBBfg" style="width: 13%; text-align: right" title="Fair value of the Company common stock on date of grant"&gt;2.68&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230401__20240331_zQT76tpBxat2" style="width: 13%; text-align: right" title="Fair value of the Company common stock on date of grant"&gt;0.19&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected term&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240401__20250331_zz1tLX7P3m1h" title="Expected term"&gt;5.68&lt;/span&gt; yrs&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230401__20240331_zNtg5cM8buT3" title="Expected term"&gt;5.56&lt;/span&gt; yrs&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_c20240401__20250331_zAHBKkyLo7a2" title="Risk-free interest rate"&gt;4.57&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pip0_dp_c20230401__20240331_zBmVeKzH6EEl" title="Risk-free interest rate"&gt;3.87&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pip0_dp_c20240401__20250331_zPNIAMZmm0Z5" title="Dividend yield"&gt;0.00&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pip0_dp_c20230401__20240331_zYyY5GWkLyDj" title="Dividend yield"&gt;0.00&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td&gt;Volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20240401__20250331_zpjBiJ86d2wi" title="Volatility"&gt;109.91&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pip0_dp_c20230401__20240331_zkYcvPwPB4cd" title="Volatility"&gt;98.40&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Fair value of options granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20240401__20250331_zWkfRIVKSqya" style="text-align: right" title="Fair value of options granted"&gt;2.23&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20230401__20240331_zyXYILnWUOD4" style="text-align: right" title="Fair value of options granted"&gt;0.15&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2024-04-01to2025-03-31"
      decimals="INF"
      id="Fact000974"
      unitRef="USDPShares">2.68</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2023-04-012024-03-31"
      decimals="INF"
      id="Fact000976"
      unitRef="USDPShares">0.19</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2024-04-01to2025-03-31" id="Fact000978">P5Y8M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2023-04-012024-03-31" id="Fact000980">P5Y6M21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2024-04-01to2025-03-31"
      decimals="INF"
      id="Fact000982"
      unitRef="Pure">0.0457</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2023-04-012024-03-31"
      decimals="INF"
      id="Fact000984"
      unitRef="Pure">0.0387</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2024-04-01to2025-03-31"
      decimals="INF"
      id="Fact000986"
      unitRef="Pure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2023-04-012024-03-31"
      decimals="INF"
      id="Fact000988"
      unitRef="Pure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2024-04-01to2025-03-31"
      decimals="INF"
      id="Fact000990"
      unitRef="Pure">1.0991</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2023-04-012024-03-31"
      decimals="INF"
      id="Fact000992"
      unitRef="Pure">0.9840</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2024-04-01to2025-03-31"
      decimals="INF"
      id="Fact000994"
      unitRef="USDPShares">2.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2023-04-012024-03-31"
      decimals="INF"
      id="Fact000996"
      unitRef="USDPShares">0.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-04-01to2025-03-31"
      decimals="-3"
      id="Fact000998"
      unitRef="USD">224000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact001000"
      unitRef="USD">516000</us-gaap:ShareBasedCompensation>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="AsOf2025-03-31_us-gaap_StockOptionMember"
      decimals="-3"
      id="Fact001002"
      unitRef="USD">250000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="From2024-04-012025-03-31_us-gaap_StockOptionMember689261046"
      id="Fact001004">P1Y6M29D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <SNOA:ScheduleOfStockbasedAwardsOutstandingByPlanTableTextBlock contextRef="From2024-04-01to2025-03-31" id="Fact001010">&lt;table cellpadding="0" cellspacing="0" id="xdx_882_ecustom--ScheduleOfStockbasedAwardsOutstandingByPlanTableTextBlock_zGog1iJpO2lc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 50%" summary="xdx: Disclosure - Stock-Based Compensation (Details-Plans)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8BA_zn1GUR3OtfLc" style="display: none"&gt;Schedule of stock based awards outstanding by plan&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;Plan&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Stock Options&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 72%"&gt;2011 Plan&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20250331__us-gaap--PlanNameAxis__custom--Plan2011Member_zLSscwD521wg" style="width: 24%; text-align: right" title="Options outstanding"&gt;3,998&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;2016 Plan&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20250331__us-gaap--PlanNameAxis__custom--Plan2016Member_zhseAxtwgM5j" style="text-align: right" title="Options outstanding"&gt;38,942&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;2021 Plan&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20250331__us-gaap--PlanNameAxis__custom--Plan2021Member_zaRZrqjGQqB9" style="border-bottom: Black 1pt solid; text-align: right" title="Options outstanding"&gt;30,141&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c20250331_zcMREqnMHgh7" style="border-bottom: Black 2.5pt double; text-align: right" title="Options outstanding"&gt;73,081&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</SNOA:ScheduleOfStockbasedAwardsOutstandingByPlanTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2025-03-31_custom_Plan2011Member"
      decimals="INF"
      id="Fact001012"
      unitRef="Shares">3998</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2025-03-31_custom_Plan2016Member"
      decimals="INF"
      id="Fact001014"
      unitRef="Shares">38942</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2025-03-31_custom_Plan2021Member"
      decimals="INF"
      id="Fact001016"
      unitRef="Shares">30141</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2025-03-31"
      decimals="INF"
      id="Fact001018"
      unitRef="Shares">73081</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2024-04-01to2025-03-31" id="Fact001020">&lt;table cellpadding="0" cellspacing="0" id="xdx_881_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_pn3n3_zSphkuHyCIVj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock-Based Compensation (Details-Option activity)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8BF_zYoPp0tHSJnk" style="display: none"&gt;Schedule of options activity&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Number of&lt;br/&gt; Shares&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted-&lt;br/&gt; Average&lt;br/&gt; Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted-&lt;br/&gt; Average&lt;br/&gt; Contractual Term&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Aggregate&lt;br/&gt; Intrinsic&lt;br/&gt; Value&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 40%"&gt;Outstanding at April 1, 2024&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pip0_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zx9V5kvM8KD3" style="width: 11%; text-align: right" title="Number of options outstanding, beginning balance"&gt;51,675&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pip0_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zVFOi2NIYw16" style="width: 11%; text-align: right" title="Weighted-average exercise price options outstanding, beginning balance"&gt;62.60&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Options granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pip0_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zKZ1qZMvkHa6" style="text-align: right" title="Number of options granted"&gt;49,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pip0_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z12GzOa621Y1" style="text-align: right" title="Weighted-average exercise price, options granted"&gt;2.68&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;Options exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pip0_di0_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z8CdCaZvxUol" style="text-align: right" title="Number of options exercised"&gt;(27,750&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pip0_d0_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zBHb21k4LAZb" style="text-align: right" title="Weighted-average exercise price, options exercised"&gt;2.99&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Options forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pip0_di_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zCoWwKK0Syta" style="text-align: right" title="Number of options forfeited"&gt;(250&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pip0_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zisavVve5yL4" style="text-align: right" title="Weighted-average exercise price, options forfeited"&gt;3.60&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Options expired&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pip0_di_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zkzyXbnj5cO2" style="border-bottom: Black 1pt solid; text-align: right" title="Number of options expired"&gt;(94&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pip0_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zM1KFBXrAAv3" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted-average exercise price, options expired"&gt;1,485.96&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Outstanding at March 31, 2025&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pip0_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zsJbOoemMG29" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options outstanding, ending balance"&gt;73,081&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pip0_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zhtM1O6FwxM9" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-average exercise price options outstanding, ending balance"&gt;43.27&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zTNjH8QDnwOh" title="Weighted- average contractual term outstanding"&gt;8.82&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_pip0_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zg8EMUdCHLDe" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value per share, outstanding"&gt;2.19&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Exercisable at March 31, 2025&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pip0_c20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zW1C8HV0YNn9" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of options, exercisable"&gt;39,751&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pip0_c20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zYki2puJa73b" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-average exercise price, exercisable"&gt;74.86&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z7P2HxCcDvoi" title="Weighted- average contractual term, exercisable"&gt;7.71&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableInPeriodGrantDateIntrinsicValue_pip0_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zBANKWSBcXd6" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value per share, exercisable"&gt;2.19&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact001022"
      unitRef="Shares">51675</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact001024"
      unitRef="USDPShares">62.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2024-04-012025-03-31_us-gaap_StockOptionMember689261046"
      decimals="INF"
      id="Fact001026"
      unitRef="Shares">49500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2024-04-012025-03-31_us-gaap_StockOptionMember689261046"
      decimals="INF"
      id="Fact001028"
      unitRef="USDPShares">2.68</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2024-04-012025-03-31_us-gaap_StockOptionMember689261046"
      decimals="INF"
      id="Fact001030"
      unitRef="Shares">27750</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2024-04-012025-03-31_us-gaap_StockOptionMember689261046"
      decimals="INF"
      id="Fact001032"
      unitRef="USDPShares">2.99</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="From2024-04-012025-03-31_us-gaap_StockOptionMember689261046"
      decimals="INF"
      id="Fact001034"
      unitRef="Shares">250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2024-04-012025-03-31_us-gaap_StockOptionMember689261046"
      decimals="INF"
      id="Fact001036"
      unitRef="USDPShares">3.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="From2024-04-012025-03-31_us-gaap_StockOptionMember689261046"
      decimals="INF"
      id="Fact001038"
      unitRef="Shares">94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2024-04-012025-03-31_us-gaap_StockOptionMember689261046"
      decimals="INF"
      id="Fact001040"
      unitRef="USDPShares">1485.96</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2025-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact001042"
      unitRef="Shares">73081</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2025-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact001044"
      unitRef="USDPShares">43.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2024-04-012025-03-31_us-gaap_StockOptionMember689261046"
      id="Fact001046">P8Y9M25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue
      contextRef="From2024-04-012025-03-31_us-gaap_StockOptionMember689261046"
      decimals="INF"
      id="Fact001048"
      unitRef="USDPShares">2.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2025-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact001050"
      unitRef="Shares">39751</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2025-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact001052"
      unitRef="USDPShares">74.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2024-04-012025-03-31_us-gaap_StockOptionMember689261046"
      id="Fact001054">P7Y8M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <SNOA:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableInPeriodGrantDateIntrinsicValue
      contextRef="From2024-04-012025-03-31_us-gaap_StockOptionMember689261046"
      decimals="INF"
      id="Fact001056"
      unitRef="USDPShares">2.19</SNOA:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableInPeriodGrantDateIntrinsicValue>
    <us-gaap:SharePrice
      contextRef="AsOf2025-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact001057"
      unitRef="USDPShares">2.19</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="AsOf2024-03-31_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact001058"
      unitRef="USDPShares">3.40</us-gaap:SharePrice>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock contextRef="From2024-04-01to2025-03-31" id="Fact001060">&lt;table cellpadding="0" cellspacing="0" id="xdx_885_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_pn3n3_zNHiu2hCpU8i" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock-Based Compensation (Details-Restricted stock activity)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8B8_zLuSztfe4RUj" style="display: none"&gt;Schedule of unvested restricted stock activity&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1.8pt 0 0; text-align: center"&gt;&lt;b&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1.8pt 0 0; text-align: center"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1.8pt 0 0; text-align: center"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1.8pt 0 0; text-align: center"&gt;&lt;b&gt;Average Award&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1.8pt 0 0; text-align: center"&gt;&lt;b&gt;Date Fair Value&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1.8pt 0 0; text-align: center"&gt;&lt;b&gt;per Share&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;Unvested restricted stock awards outstanding at April 1, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pip0_d0_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zucBrBhKZoA8" style="text-align: right" title="Number of unvested restricted stock awards outstanding, beginning balance"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pip0_d0_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zXq3ujbUAXXf" style="text-align: right" title="Weighted-average award date fair value per share, unvested RSAs outstanding, beginning balance"&gt;&#x2013;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 66%; text-align: left"&gt;Restricted stock awards granted&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pip0_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zuse3bs8vKrd" style="width: 13%; text-align: right" title="Number of restricted stock awards granted"&gt;54,538&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pip0_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zYJzBOqrstdg" style="width: 13%; text-align: right" title="Weighted-average award date fair value per share, unvested RSAs granted"&gt;2.92&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Restricted stock awards vested&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pip0_di_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zNlWPajOM1qa" style="border-bottom: Black 1pt solid; text-align: right" title="Number of restricted stock awards vested"&gt;(9,538&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pip0_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zspybwAIX0A1" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted-average award date fair value per share, unvested RSAs vested"&gt;4.08&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Unvested restricted stock awards outstanding at March 31, 2025&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pip0_d0_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zTz3dcreSpfl" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of unvested restricted stock awards outstanding, ending balance"&gt;45,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pip0_d0_c20240401__20250331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zvKukhiSkyRd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-average award date fair value per share, unvested RSAs outstanding, ending balance"&gt;2.68&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2024-03-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      id="Fact001062"
      unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2024-03-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      id="Fact001064"
      unitRef="USDPShares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2024-04-012025-03-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      id="Fact001066"
      unitRef="Shares">54538</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2024-04-012025-03-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      id="Fact001068"
      unitRef="USDPShares">2.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="From2024-04-012025-03-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      id="Fact001070"
      unitRef="Shares">9538</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2024-04-012025-03-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      id="Fact001072"
      unitRef="USDPShares">4.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2025-03-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      id="Fact001074"
      unitRef="Shares">45000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2025-03-31_us-gaap_RestrictedStockMember"
      decimals="INF"
      id="Fact001076"
      unitRef="USDPShares">2.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense
      contextRef="From2024-04-01to2025-03-31"
      decimals="-3"
      id="Fact001078"
      unitRef="USD">123000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2024-04-01to2025-03-31" id="Fact001084">&lt;p id="xdx_804_eus-gaap--IncomeTaxDisclosureTextBlock_zedWN5cZZZs6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;NOTE&#160;14&#160;&#x2013; &lt;span id="xdx_823_zJW1lCrxp84k"&gt;Income Taxes&lt;/span&gt; &lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The income tax provision (benefit) is based on the
following net taxable loss before income taxes, which are from domestic and foreign sources:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_889_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_pn3n3_zcjFSUccZDn9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details-Income source)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B2_z5FF0boDHmEf" style="display: none"&gt;Schedule of income tax provision from domestic and foreign sources&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Year Ended March&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 66%"&gt;Domestic&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ProfitLoss_pn3p0_c20240401__20250331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zaqDwFXvz53h" style="width: 13%; text-align: right" title="Income before income taxes"&gt;(161,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ProfitLoss_pn3p0_c20230401__20240331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zfy1yQUfOI45" style="width: 13%; text-align: right" title="Income before income taxes"&gt;(364,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Foreign&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ProfitLoss_pn3p0_c20240401__20250331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zmKIf3SeJEt8" style="border-bottom: Black 1pt solid; text-align: right" title="Income before income taxes"&gt;(2,749,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ProfitLoss_pn3p0_c20230401__20240331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zpQOWqkgmACd" style="border-bottom: Black 1pt solid; text-align: right" title="Income before income taxes"&gt;(4,559,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Totals&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ProfitLoss_pn3p0_c20240401__20250331_zL608gH8ruN4" style="border-bottom: Black 2.5pt double; text-align: right" title="Income before income taxes"&gt;(2,910,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ProfitLoss_pn3p0_c20230401__20240331_zwRRhstxQIgh" style="border-bottom: Black 2.5pt double; text-align: right" title="Income before income taxes"&gt;(4,923,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The federal, state and foreign income tax provisions
are summarized as follows:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_88B_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_pn3n3_zY3IfRNnScvg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details-Income tax expense)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B8_zK0DBnlPZPF4" style="display: none"&gt;Schedule of federal, state and foreign income tax provisions&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20240401__20250331_zLPdh3S4pOu9" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20230401__20240331_z6oO3rsxphrf" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Year Ended March&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_iB" style="vertical-align: bottom"&gt;
    &lt;td&gt;Current:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_pn3p0_zIiMUP5oZdub" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 66%"&gt;State&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;(2,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;(2,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_iB_zurQPAtm8yfa" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td&gt;Deferred:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DeferredForeignIncomeTaxExpenseBenefit_pn3p0_zW00FLkegDSl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Foreign&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(548,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;198,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredIncomeTaxExpenseBenefit_pn3p0_zkoNXLQiTdf3" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total income tax (expense) benefit&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(550,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;196,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;A reconciliation of the statutory federal income tax
rate to the Company&#x2019;s effective tax rate for continuing operations is as follows:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_881_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zLZHeGGJZM7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details-Reconciliation of tax rate)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B4_z25lFhUBWLG3" style="display: none"&gt;Schedule of reconciliation of federal    income
tax rate to effective rate&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20240401__20250331_z6UIQyLeALFh" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20230401__20240331_zm0B4uZCEXcg" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Year&#160;Ended&#160;March&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pip0_dp_marate_zPKHIxaxLhfg" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 66%; text-align: left"&gt;Expected federal statutory rate&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;21.0%&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;21.0%&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_iN_pip0_dpi_zLGNa2ul5tS" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;State income taxes, net of federal benefit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.1%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.2%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_pip0_dp_zq7UbDuEbcV3" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;Foreign earnings taxed at different rates&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.7%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.9%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpense_iN_pip0_dpi_zX26ez95xmM5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Effect of permanent differences&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(7.4%&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(5.8%&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_pip0_dp_zcpP6WRnYoO3" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;Effect of intercompany interest permanent differences&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(30.2%&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(20.1%&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--TrueupsOfStateDeferredAssets_pip0_dp_z1qn3IWDXl72" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;True-up of state deferred assets&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(68.4%&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1.5%&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_iN_dpi_zwRb7XBckbC6" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td&gt;&lt;b style="display: none"&gt;Total effective rate&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(78.2%&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.7%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pip0_dp_zqgwwIqZ9PR3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Change in valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(59.3%&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2.3%&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pip0_dp_mtrate_zp1DtXOARE7e" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Totals&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(18.9%&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;4.0%&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;















&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The tax effects of temporary differences that give
rise to significant components of our deferred tax assets consist of:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_884_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_pn3n3_zMbRIQ1dE2a" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details-Deferred taxes)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B5_zFibXnib7PU" style="display: none"&gt;Schedule of deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20250331_z5oBANAgAPQ1" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20240331_zHpcMumE8sni" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;March&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DeferredTaxAssetsGrossAbstract_iB" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;Deferred tax assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_i01I_pn3p0_maDTAGz412_zRUpdLmRE6Di" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 66%; text-align: left"&gt;Net operating loss carryforwards&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;26,456,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;28,692,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_i01I_pn3p0_maDTAGz412_zaF4wlPfWEJ5" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;Research and development tax credit carryforwards&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,749,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,796,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_i01I_pn3p0_maDTAGz412_zhtpPCQnkvC5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Stock-based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;879,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;913,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_i01I_pn3p0_maDTAGz412_z8KAJqvbqdDa" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;Reserves and accruals&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;618,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;659,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseOther_i01I_pn3p0_d0_maDTAGz412_z6yxVYR8k8cc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Other deferred tax assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;41,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;52,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--DeferredTaxAssetsLeaseLiability_i01I_pn3p0_maDTAGz412_zjeSqDemov7e" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Lease liability&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;10,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;22,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--DeferredTaxAssetsGross_i01TI_pn3p0_mtDTAGz412_maDTANzqCr_zmB7ZrzLMHd6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Gross deferred tax assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;29,753,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;32,134,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DeferredTaxAssetsValuationAllowance_i01NI_pn3p0_di_msDTANzqCr_zKS1XlHQajH" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Less valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(29,062,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(30,836,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DeferredTaxAssetsNet_i01TI_pn3p0_mtDTANzqCr_maDTALNzfiK_zFtiYZAiwxp9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Total deferred tax assets&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;691,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,298,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--DeferredTaxLiabilitiesAbstract_i01B" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Deferred tax liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--DeferredTaxLiabilitiesPropertyPlantAndEquipment_i02NI_pn3p0_di_maDITLzfJx_zRys7CZb6wh6" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;Fixed assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(6,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(10,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredTaxLiabilitiesPrepaidExpenses_i02NI_pn3p0_di_maDITLzfJx_z2P9APkIY1qe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Prepaid expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(86,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(121,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--DeferredTaxLiabilitiesRightOfUseAsset_i02NI_pn3p0_di_maDITLzfJx_zLmjoR5HOfA3" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Right of use asset&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(10,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(22,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--DeferredIncomeTaxLiabilities_i02NTI_pn3p0_di_mtDITLzfJx_msDTALNzfiK_zBs9h4F8yDXb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Gross deferred tax liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(102,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(153,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DeferredTaxAssetsLiabilitiesNet_i02TI_pn3p0_d0_mtDTALNzfiK_zPIPHtQKKgv7" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Net deferred tax assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;589,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,145,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of March 31, 2025, we have net operating loss carryforwards
for federal, state and foreign income tax purposes of approximately $&lt;span id="xdx_902_eus-gaap--OperatingLossCarryforwards_iI_pn3p0_c20250331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zfq1HKeJ42D" title="Net operating loss carryforwards"&gt;107,700,000&lt;/span&gt;, $&lt;span id="xdx_908_eus-gaap--OperatingLossCarryforwards_iI_pn3p0_c20250331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--StateAndLocalJurisdictionMember_zhHglQJqAhal" title="Net operating loss carryforwards"&gt;42,800,000&lt;/span&gt; and $&lt;span id="xdx_904_eus-gaap--OperatingLossCarryforwards_iI_pn3p0_c20250331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zve7MpTT3qd4" title="Net operating loss carryforwards"&gt;800,000&lt;/span&gt;, respectively. Due to the Tax
Cuts and Job Act, federal NOL generated after March 31, 2018 have an indefinite life. Federal NOL generated on and before March 31, 2017
began to expire in 2024, if not utilized. State NOLs will begin to expire in the year 2026, if not utilized. Foreign NOLs will carry forward
for 10 years.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 467.4pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of March 31, 2025, we had federal and California
research and development credit carryforward of approximately $&lt;span id="xdx_901_eus-gaap--TaxCreditCarryforwardAmount_iI_pn3p0_c20250331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zWvzoyaJ6Nz2" title="Research credit carryforwards"&gt;950,000&lt;/span&gt; and $&lt;span id="xdx_905_eus-gaap--TaxCreditCarryforwardAmount_iI_pn3p0_c20250331__us-gaap--IncomeTaxAuthorityAxis__custom--CaliforniaResearchAndDevelopmentMember_zHEI3RDlYn2a" title="Research credit carryforwards"&gt;790,000&lt;/span&gt;, respectively. As of March 31, 2024, we had federal
and California research and development credit carryforward of approximately $&lt;span id="xdx_908_eus-gaap--TaxCreditCarryforwardAmount_iI_pn3p0_c20240331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_ziW095B2ybtd" title="Research credit carryforwards"&gt;1,006,000&lt;/span&gt; and $&lt;span id="xdx_90D_eus-gaap--TaxCreditCarryforwardAmount_iI_pn3p0_c20240331__us-gaap--IncomeTaxAuthorityAxis__custom--CaliforniaResearchAndDevelopmentMember_zishS8NiTAL2" title="Research credit carryforwards"&gt;790,000&lt;/span&gt; respectively. The federal research
and development credits began to expire in 2024 while the California research and development credits have no expiration date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Section 382 of the Internal Revenue Code limits the
use of the federal net operating losses in certain situations where changes occur in stock ownership of a company. If the Company should
have an ownership change of more than 50% of the value of the Company's capital stock, utilization of the carryforwards could be restricted.
The Company is not aware of any changes in ownership that would result in a change in control under Internal Revenue Code section 382.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company released the valuation allowance recorded
against its Netherlands deferred tax assets as of March 31, 2024. Given its recent history of earnings, current earnings and anticipated
future earnings, the Company concluded that there is sufficient positive evidence available to reach a conclusion that the valuation allowance
is no longer needed in the Netherlands. The release of the valuation allowance resulted in the recognition of deferred tax assets of $114,000.
The Company, after considering all available evidence, fully reserved against all deferred tax assets in the U.S. since it is more likely
than not such benefits will not be realized in future periods. The Company will continue to evaluate its deferred tax assets to determine
whether any changes in circumstances could affect the realization of their future benefit.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;











&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company has filed tax returns for federal, state
and foreign jurisdictions. The Company&#x2019;s evaluation of uncertain tax matters was performed for tax years ended through March 31,
2025. Generally, the Company is subject to audit for the years ended March 31, 2023, 2022 and 2021. The Company has elected to retain
its existing accounting policy with respect to the treatment of interest and penalties attributable to income taxes, and continues to
reflect interest and penalties attributable to income taxes, to the extent they arise, as a component of its income tax provision or benefit
as well as its outstanding income tax assets and liabilities. The Company believes that its income tax positions and deductions would
be sustained on audit and does not anticipate any adjustments to result in a material change to its financial position.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock contextRef="From2024-04-01to2025-03-31" id="Fact001086">&lt;table cellpadding="0" cellspacing="0" id="xdx_889_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_pn3n3_zcjFSUccZDn9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details-Income source)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B2_z5FF0boDHmEf" style="display: none"&gt;Schedule of income tax provision from domestic and foreign sources&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Year Ended March&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 66%"&gt;Domestic&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ProfitLoss_pn3p0_c20240401__20250331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zaqDwFXvz53h" style="width: 13%; text-align: right" title="Income before income taxes"&gt;(161,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ProfitLoss_pn3p0_c20230401__20240331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zfy1yQUfOI45" style="width: 13%; text-align: right" title="Income before income taxes"&gt;(364,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Foreign&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ProfitLoss_pn3p0_c20240401__20250331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zmKIf3SeJEt8" style="border-bottom: Black 1pt solid; text-align: right" title="Income before income taxes"&gt;(2,749,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ProfitLoss_pn3p0_c20230401__20240331__us-gaap--IncomeTaxAuthorityAxis__us-gaap--ForeignCountryMember_zpQOWqkgmACd" style="border-bottom: Black 1pt solid; text-align: right" title="Income before income taxes"&gt;(4,559,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Totals&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ProfitLoss_pn3p0_c20240401__20250331_zL608gH8ruN4" style="border-bottom: Black 2.5pt double; text-align: right" title="Income before income taxes"&gt;(2,910,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ProfitLoss_pn3p0_c20230401__20240331_zwRRhstxQIgh" style="border-bottom: Black 2.5pt double; text-align: right" title="Income before income taxes"&gt;(4,923,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:ProfitLoss
      contextRef="From2024-04-012025-03-31_us-gaap_DomesticCountryMember"
      decimals="-3"
      id="Fact001088"
      unitRef="USD">-161000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2023-04-012024-03-31_us-gaap_DomesticCountryMember"
      decimals="-3"
      id="Fact001090"
      unitRef="USD">-364000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2024-04-012025-03-31_us-gaap_ForeignCountryMember"
      decimals="-3"
      id="Fact001092"
      unitRef="USD">-2749000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2023-04-012024-03-31_us-gaap_ForeignCountryMember"
      decimals="-3"
      id="Fact001094"
      unitRef="USD">-4559000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2024-04-01to2025-03-31"
      decimals="-3"
      id="Fact001096"
      unitRef="USD">-2910000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact001098"
      unitRef="USD">-4923000</us-gaap:ProfitLoss>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="From2024-04-01to2025-03-31" id="Fact001100">&lt;table cellpadding="0" cellspacing="0" id="xdx_88B_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_pn3n3_zY3IfRNnScvg" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details-Income tax expense)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B8_zK0DBnlPZPF4" style="display: none"&gt;Schedule of federal, state and foreign income tax provisions&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20240401__20250331_zLPdh3S4pOu9" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20230401__20240331_z6oO3rsxphrf" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Year Ended March&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_iB" style="vertical-align: bottom"&gt;
    &lt;td&gt;Current:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_pn3p0_zIiMUP5oZdub" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 66%"&gt;State&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;(2,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;(2,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_iB_zurQPAtm8yfa" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td&gt;Deferred:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DeferredForeignIncomeTaxExpenseBenefit_pn3p0_zW00FLkegDSl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Foreign&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(548,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;198,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--DeferredIncomeTaxExpenseBenefit_pn3p0_zkoNXLQiTdf3" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total income tax (expense) benefit&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(550,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;196,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="From2024-04-01to2025-03-31"
      decimals="-3"
      id="Fact001105"
      unitRef="USD">-2000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact001106"
      unitRef="USD">-2000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="From2024-04-01to2025-03-31"
      decimals="-3"
      id="Fact001111"
      unitRef="USD">-548000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact001112"
      unitRef="USD">198000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="From2024-04-01to2025-03-31"
      decimals="-3"
      id="Fact001114"
      unitRef="USD">-550000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact001115"
      unitRef="USD">196000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="From2024-04-01to2025-03-31" id="Fact001117">&lt;table cellpadding="0" cellspacing="0" id="xdx_881_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zLZHeGGJZM7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details-Reconciliation of tax rate)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B4_z25lFhUBWLG3" style="display: none"&gt;Schedule of reconciliation of federal    income
tax rate to effective rate&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20240401__20250331_z6UIQyLeALFh" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20230401__20240331_zm0B4uZCEXcg" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Year&#160;Ended&#160;March&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pip0_dp_marate_zPKHIxaxLhfg" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 66%; text-align: left"&gt;Expected federal statutory rate&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;21.0%&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;21.0%&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_iN_pip0_dpi_zLGNa2ul5tS" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;State income taxes, net of federal benefit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.1%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.2%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_pip0_dp_zq7UbDuEbcV3" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;Foreign earnings taxed at different rates&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.7%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7.9%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpense_iN_pip0_dpi_zX26ez95xmM5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Effect of permanent differences&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(7.4%&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(5.8%&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_pip0_dp_zcpP6WRnYoO3" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;Effect of intercompany interest permanent differences&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(30.2%&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(20.1%&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--TrueupsOfStateDeferredAssets_pip0_dp_z1qn3IWDXl72" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;True-up of state deferred assets&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(68.4%&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1.5%&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_iN_dpi_zwRb7XBckbC6" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td&gt;&lt;b style="display: none"&gt;Total effective rate&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(78.2%&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.7%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pip0_dp_zqgwwIqZ9PR3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Change in valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(59.3%&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2.3%&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pip0_dp_mtrate_zp1DtXOARE7e" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Totals&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(18.9%&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;4.0%&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2024-04-01to2025-03-31"
      decimals="INF"
      id="Fact001119"
      unitRef="Pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2023-04-012024-03-31"
      decimals="INF"
      id="Fact001120"
      unitRef="Pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="From2024-04-01to2025-03-31"
      decimals="INF"
      id="Fact001122"
      unitRef="Pure">-0.001</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="From2023-04-012024-03-31"
      decimals="INF"
      id="Fact001123"
      unitRef="Pure">-0.002</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="From2024-04-01to2025-03-31"
      decimals="INF"
      id="Fact001125"
      unitRef="Pure">0.067</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="From2023-04-012024-03-31"
      decimals="INF"
      id="Fact001126"
      unitRef="Pure">0.079</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="From2024-04-01to2025-03-31"
      decimals="INF"
      id="Fact001128"
      unitRef="Pure">0.074</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="From2023-04-012024-03-31"
      decimals="INF"
      id="Fact001129"
      unitRef="Pure">0.058</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
      contextRef="From2024-04-01to2025-03-31"
      decimals="INF"
      id="Fact001131"
      unitRef="Pure">-0.302</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
      contextRef="From2023-04-012024-03-31"
      decimals="INF"
      id="Fact001132"
      unitRef="Pure">-0.201</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <SNOA:TrueupsOfStateDeferredAssets
      contextRef="From2024-04-01to2025-03-31"
      decimals="INF"
      id="Fact001134"
      unitRef="Pure">-0.684</SNOA:TrueupsOfStateDeferredAssets>
    <SNOA:TrueupsOfStateDeferredAssets
      contextRef="From2023-04-012024-03-31"
      decimals="INF"
      id="Fact001135"
      unitRef="Pure">-0.015</SNOA:TrueupsOfStateDeferredAssets>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="From2024-04-01to2025-03-31"
      decimals="INF"
      id="Fact001137"
      unitRef="Pure">0.782</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="From2023-04-012024-03-31"
      decimals="INF"
      id="Fact001138"
      unitRef="Pure">-0.017</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2024-04-01to2025-03-31"
      decimals="INF"
      id="Fact001140"
      unitRef="Pure">-0.593</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2023-04-012024-03-31"
      decimals="INF"
      id="Fact001141"
      unitRef="Pure">0.023</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2024-04-01to2025-03-31"
      decimals="INF"
      id="Fact001143"
      unitRef="Pure">-0.189</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2023-04-012024-03-31"
      decimals="INF"
      id="Fact001144"
      unitRef="Pure">0.040</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2024-04-01to2025-03-31" id="Fact001152">&lt;table cellpadding="0" cellspacing="0" id="xdx_884_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_pn3n3_zMbRIQ1dE2a" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details-Deferred taxes)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B5_zFibXnib7PU" style="display: none"&gt;Schedule of deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20250331_z5oBANAgAPQ1" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20240331_zHpcMumE8sni" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;March&#160;31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--DeferredTaxAssetsGrossAbstract_iB" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;Deferred tax assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_i01I_pn3p0_maDTAGz412_zRUpdLmRE6Di" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 66%; text-align: left"&gt;Net operating loss carryforwards&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;26,456,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;28,692,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_i01I_pn3p0_maDTAGz412_zaF4wlPfWEJ5" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;Research and development tax credit carryforwards&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,749,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,796,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_i01I_pn3p0_maDTAGz412_zhtpPCQnkvC5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Stock-based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;879,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;913,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_i01I_pn3p0_maDTAGz412_z8KAJqvbqdDa" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;Reserves and accruals&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;618,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;659,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseOther_i01I_pn3p0_d0_maDTAGz412_z6yxVYR8k8cc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Other deferred tax assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;41,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;52,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--DeferredTaxAssetsLeaseLiability_i01I_pn3p0_maDTAGz412_zjeSqDemov7e" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Lease liability&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;10,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;22,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--DeferredTaxAssetsGross_i01TI_pn3p0_mtDTAGz412_maDTANzqCr_zmB7ZrzLMHd6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Gross deferred tax assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;29,753,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;32,134,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DeferredTaxAssetsValuationAllowance_i01NI_pn3p0_di_msDTANzqCr_zKS1XlHQajH" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Less valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(29,062,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(30,836,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DeferredTaxAssetsNet_i01TI_pn3p0_mtDTANzqCr_maDTALNzfiK_zFtiYZAiwxp9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Total deferred tax assets&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;691,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,298,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--DeferredTaxLiabilitiesAbstract_i01B" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Deferred tax liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--DeferredTaxLiabilitiesPropertyPlantAndEquipment_i02NI_pn3p0_di_maDITLzfJx_zRys7CZb6wh6" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;Fixed assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(6,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(10,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--DeferredTaxLiabilitiesPrepaidExpenses_i02NI_pn3p0_di_maDITLzfJx_z2P9APkIY1qe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Prepaid expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(86,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(121,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--DeferredTaxLiabilitiesRightOfUseAsset_i02NI_pn3p0_di_maDITLzfJx_zLmjoR5HOfA3" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Right of use asset&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(10,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(22,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--DeferredIncomeTaxLiabilities_i02NTI_pn3p0_di_mtDITLzfJx_msDTALNzfiK_zBs9h4F8yDXb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Gross deferred tax liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(102,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(153,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DeferredTaxAssetsLiabilitiesNet_i02TI_pn3p0_d0_mtDTALNzfiK_zPIPHtQKKgv7" style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Net deferred tax assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;589,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,145,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact001157"
      unitRef="USD">26456000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact001158"
      unitRef="USD">28692000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact001160"
      unitRef="USD">1749000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact001161"
      unitRef="USD">1796000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact001163"
      unitRef="USD">879000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact001164"
      unitRef="USD">913000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact001166"
      unitRef="USD">618000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact001167"
      unitRef="USD">659000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact001169"
      unitRef="USD">41000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact001170"
      unitRef="USD">52000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther>
    <SNOA:DeferredTaxAssetsLeaseLiability
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact001172"
      unitRef="USD">10000</SNOA:DeferredTaxAssetsLeaseLiability>
    <SNOA:DeferredTaxAssetsLeaseLiability
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact001173"
      unitRef="USD">22000</SNOA:DeferredTaxAssetsLeaseLiability>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact001175"
      unitRef="USD">29753000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact001176"
      unitRef="USD">32134000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact001178"
      unitRef="USD">29062000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact001179"
      unitRef="USD">30836000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact001181"
      unitRef="USD">691000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact001182"
      unitRef="USD">1298000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact001187"
      unitRef="USD">6000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact001188"
      unitRef="USD">10000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPrepaidExpenses
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact001190"
      unitRef="USD">86000</us-gaap:DeferredTaxLiabilitiesPrepaidExpenses>
    <us-gaap:DeferredTaxLiabilitiesPrepaidExpenses
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact001191"
      unitRef="USD">121000</us-gaap:DeferredTaxLiabilitiesPrepaidExpenses>
    <SNOA:DeferredTaxLiabilitiesRightOfUseAsset
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact001193"
      unitRef="USD">10000</SNOA:DeferredTaxLiabilitiesRightOfUseAsset>
    <SNOA:DeferredTaxLiabilitiesRightOfUseAsset
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact001194"
      unitRef="USD">22000</SNOA:DeferredTaxLiabilitiesRightOfUseAsset>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact001196"
      unitRef="USD">102000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact001197"
      unitRef="USD">153000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact001199"
      unitRef="USD">589000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="AsOf2024-03-31"
      decimals="-3"
      id="Fact001200"
      unitRef="USD">1145000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2025-03-31_us-gaap_DomesticCountryMember"
      decimals="-3"
      id="Fact001202"
      unitRef="USD">107700000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2025-03-31_us-gaap_StateAndLocalJurisdictionMember"
      decimals="-3"
      id="Fact001204"
      unitRef="USD">42800000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2025-03-31_us-gaap_ForeignCountryMember"
      decimals="-3"
      id="Fact001206"
      unitRef="USD">800000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="AsOf2025-03-31_us-gaap_DomesticCountryMember"
      decimals="-3"
      id="Fact001208"
      unitRef="USD">950000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="AsOf2025-03-31_custom_CaliforniaResearchAndDevelopmentMember"
      decimals="-3"
      id="Fact001210"
      unitRef="USD">790000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="AsOf2024-03-31_us-gaap_DomesticCountryMember"
      decimals="-3"
      id="Fact001212"
      unitRef="USD">1006000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="AsOf2024-03-31_custom_CaliforniaResearchAndDevelopmentMember"
      decimals="-3"
      id="Fact001214"
      unitRef="USD">790000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock contextRef="From2024-04-01to2025-03-31" id="Fact001220">&lt;p id="xdx_808_eus-gaap--CompensationAndEmployeeBenefitPlansTextBlock_zSA62saGIjH6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;NOTE&#160;15&#160;&#x2013; &lt;span id="xdx_826_zVp4npyxuGrb"&gt;Employee Benefit Plan&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company has a program to contribute and administer
a qualified 401(k) plan. Under the 401(k) plan, the Company matches employee contributions to the plan up to 4% of the employee&#x2019;s
salary. Company contributions to the plan amounted to an aggregate of $&lt;span id="xdx_901_eus-gaap--PensionAndOtherPostretirementBenefitContributions_pn3p0_c20240401__20250331_znY7Eb9LV075" title="Company contributions to 401(k) plan"&gt;88,000&lt;/span&gt; and $&lt;span id="xdx_900_eus-gaap--PensionAndOtherPostretirementBenefitContributions_pn3p0_c20230401__20240331_zeqX3ySD2Ypk" title="Company contributions to 401(k) plan"&gt;82,000&lt;/span&gt; for the years ended March 31, 2025 and 2024,
respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <us-gaap:PensionAndOtherPostretirementBenefitContributions
      contextRef="From2024-04-01to2025-03-31"
      decimals="-3"
      id="Fact001222"
      unitRef="USD">88000</us-gaap:PensionAndOtherPostretirementBenefitContributions>
    <us-gaap:PensionAndOtherPostretirementBenefitContributions
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact001224"
      unitRef="USD">82000</us-gaap:PensionAndOtherPostretirementBenefitContributions>
    <us-gaap:RevenueFromContractWithCustomerTextBlock contextRef="From2024-04-01to2025-03-31" id="Fact001226">&lt;p id="xdx_808_eus-gaap--RevenueFromContractWithCustomerTextBlock_zJ0nuwunqaQ3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;NOTE&#160;16 &#x2013; &lt;span id="xdx_82E_zAXtTEVvYdf1"&gt;Revenue Disaggregation&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company generates product revenues from products
which are sold into the human and animal healthcare markets, and the Company generates service revenues from laboratory testing services
which are provided to medical device manufacturers.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The following table presents the Company&#x2019;s disaggregated revenues
by source:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_881_eus-gaap--DisaggregationOfRevenueTableTextBlock_pn3n3_zG7aKFsAn6Li" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Revenue Disaggregation (Details - Disaggregation of revenue)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B2_zDo0500DkMY" style="display: none"&gt;Schedule of disaggregated revenue by  source&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Year Ended March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Product:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="padding-left: 10pt; width: 66%; text-align: left"&gt;Human Care&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20240401__20250331__us-gaap--StatementBusinessSegmentsAxis__custom--HumanCareMember__srt--ProductOrServiceAxis__us-gaap--ProductMember_zbMuKtD4qDf2" style="width: 13%; text-align: right" title="Revenues"&gt;12,079,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20230401__20240331__us-gaap--StatementBusinessSegmentsAxis__custom--HumanCareMember__srt--ProductOrServiceAxis__us-gaap--ProductMember_z3G9EVURUamd" style="width: 13%; text-align: right" title="Revenues"&gt;10,110,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Animal Care&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20240401__20250331__us-gaap--StatementBusinessSegmentsAxis__custom--AnimalCareMember__srt--ProductOrServiceAxis__us-gaap--ProductMember_z2ec75gSQ7P3" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues"&gt;1,653,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20230401__20240331__us-gaap--StatementBusinessSegmentsAxis__custom--AnimalCareMember__srt--ProductOrServiceAxis__us-gaap--ProductMember_zi4RFG28E6V6" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues"&gt;2,203,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;Total Product Revenue&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20240401__20250331__srt--ProductOrServiceAxis__us-gaap--ProductMember_ze5f1aVNo9jb" style="text-align: right" title="Revenues"&gt;13,732,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20230401__20240331__srt--ProductOrServiceAxis__us-gaap--ProductMember_zuOZtvvttFw5" style="text-align: right" title="Revenues"&gt;12,313,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Service/Royalty&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20240401__20250331__srt--ProductOrServiceAxis__us-gaap--ServiceMember__us-gaap--StatementBusinessSegmentsAxis__custom--ServiceAndRoyaltyMember_zQxKYFNwyoEk" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues"&gt;556,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20230401__20240331__srt--ProductOrServiceAxis__us-gaap--ServiceMember__us-gaap--StatementBusinessSegmentsAxis__custom--ServiceAndRoyaltyMember_ztIKU2csL1ml" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues"&gt;422,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20240401__20250331_zVNwjt92tag8" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenues"&gt;14,288,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20230401__20240331_z2tLug2zuoQd" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenues"&gt;12,735,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following table shows the Company&#x2019;s revenues
by geographic region:&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_881_eus-gaap--ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_pn3n3_zhVgq0GAig38" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Revenue Disaggregation (Details - Geographic regions)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B4_zCeSA7dcCsne" style="display: none"&gt;Schedule of revenues by geographic region&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Year Ended March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 66%; text-align: left"&gt;United States&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20240401__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__country--US_z9btNfmBsoK9" style="width: 13%; text-align: right" title="Revenues"&gt;2,611,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20230401__20240331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__country--US_zvRAAqzLQbB3" style="width: 13%; text-align: right" title="Revenues"&gt;3,058,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Europe&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20240401__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__srt--EuropeMember_zsnbz3JUVMJ6" style="text-align: right" title="Revenues"&gt;5,523,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20230401__20240331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__srt--EuropeMember_zKC94FNbtO5h" style="text-align: right" title="Revenues"&gt;4,781,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td&gt;Asia&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20240401__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__srt--AsiaMember_zmWtWTGuRhA" style="text-align: right" title="Revenues"&gt;2,317,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20230401__20240331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__srt--AsiaMember_zuAakEMFLsQ1" style="text-align: right" title="Revenues"&gt;2,298,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Latin America&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20240401__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__srt--LatinAmericaMember_zE2pJaE0as7b" style="text-align: right" title="Revenues"&gt;2,962,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20230401__20240331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__srt--LatinAmericaMember_zFA9UIPKkVyd" style="text-align: right" title="Revenues"&gt;1,726,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Rest of the World&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20240401__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__custom--RestOfTheWorldMember_zenVN9BBNG07" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues"&gt;875,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20230401__20240331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__custom--RestOfTheWorldMember_znhzNmIb6zW9" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues"&gt;872,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20240401__20250331_zDcse8CR7OM" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenues"&gt;14,288,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20230401__20240331_zfxc6Qh44bMg" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenues"&gt;12,735,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="From2024-04-01to2025-03-31" id="Fact001228">&lt;table cellpadding="0" cellspacing="0" id="xdx_881_eus-gaap--DisaggregationOfRevenueTableTextBlock_pn3n3_zG7aKFsAn6Li" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Revenue Disaggregation (Details - Disaggregation of revenue)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B2_zDo0500DkMY" style="display: none"&gt;Schedule of disaggregated revenue by  source&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Year Ended March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Product:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="padding-left: 10pt; width: 66%; text-align: left"&gt;Human Care&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20240401__20250331__us-gaap--StatementBusinessSegmentsAxis__custom--HumanCareMember__srt--ProductOrServiceAxis__us-gaap--ProductMember_zbMuKtD4qDf2" style="width: 13%; text-align: right" title="Revenues"&gt;12,079,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20230401__20240331__us-gaap--StatementBusinessSegmentsAxis__custom--HumanCareMember__srt--ProductOrServiceAxis__us-gaap--ProductMember_z3G9EVURUamd" style="width: 13%; text-align: right" title="Revenues"&gt;10,110,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Animal Care&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20240401__20250331__us-gaap--StatementBusinessSegmentsAxis__custom--AnimalCareMember__srt--ProductOrServiceAxis__us-gaap--ProductMember_z2ec75gSQ7P3" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues"&gt;1,653,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20230401__20240331__us-gaap--StatementBusinessSegmentsAxis__custom--AnimalCareMember__srt--ProductOrServiceAxis__us-gaap--ProductMember_zi4RFG28E6V6" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues"&gt;2,203,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left"&gt;Total Product Revenue&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20240401__20250331__srt--ProductOrServiceAxis__us-gaap--ProductMember_ze5f1aVNo9jb" style="text-align: right" title="Revenues"&gt;13,732,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20230401__20240331__srt--ProductOrServiceAxis__us-gaap--ProductMember_zuOZtvvttFw5" style="text-align: right" title="Revenues"&gt;12,313,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Service/Royalty&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20240401__20250331__srt--ProductOrServiceAxis__us-gaap--ServiceMember__us-gaap--StatementBusinessSegmentsAxis__custom--ServiceAndRoyaltyMember_zQxKYFNwyoEk" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues"&gt;556,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20230401__20240331__srt--ProductOrServiceAxis__us-gaap--ServiceMember__us-gaap--StatementBusinessSegmentsAxis__custom--ServiceAndRoyaltyMember_ztIKU2csL1ml" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues"&gt;422,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20240401__20250331_zVNwjt92tag8" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenues"&gt;14,288,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20230401__20240331_z2tLug2zuoQd" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenues"&gt;12,735,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2024-04-012025-03-31_custom_HumanCareMember_us-gaap_ProductMember"
      decimals="-3"
      id="Fact001230"
      unitRef="USD">12079000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-04-012024-03-31_custom_HumanCareMember_us-gaap_ProductMember"
      decimals="-3"
      id="Fact001232"
      unitRef="USD">10110000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2024-04-012025-03-31_custom_AnimalCareMember_us-gaap_ProductMember"
      decimals="-3"
      id="Fact001234"
      unitRef="USD">1653000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-04-012024-03-31_custom_AnimalCareMember_us-gaap_ProductMember"
      decimals="-3"
      id="Fact001236"
      unitRef="USD">2203000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2024-04-012025-03-31_us-gaap_ProductMember"
      decimals="-3"
      id="Fact001238"
      unitRef="USD">13732000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-04-012024-03-31_us-gaap_ProductMember"
      decimals="-3"
      id="Fact001240"
      unitRef="USD">12313000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2024-04-012025-03-31_us-gaap_ServiceMember_custom_ServiceAndRoyaltyMember"
      decimals="-3"
      id="Fact001242"
      unitRef="USD">556000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-04-012024-03-31_us-gaap_ServiceMember_custom_ServiceAndRoyaltyMember"
      decimals="-3"
      id="Fact001244"
      unitRef="USD">422000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2024-04-01to2025-03-31"
      decimals="-3"
      id="Fact001246"
      unitRef="USD">14288000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact001248"
      unitRef="USD">12735000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock contextRef="From2024-04-01to2025-03-31" id="Fact001250">&lt;table cellpadding="0" cellspacing="0" id="xdx_881_eus-gaap--ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_pn3n3_zhVgq0GAig38" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Revenue Disaggregation (Details - Geographic regions)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span id="xdx_8B4_zCeSA7dcCsne" style="display: none"&gt;Schedule of revenues by geographic region&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Year Ended March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="width: 66%; text-align: left"&gt;United States&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20240401__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__country--US_z9btNfmBsoK9" style="width: 13%; text-align: right" title="Revenues"&gt;2,611,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20230401__20240331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__country--US_zvRAAqzLQbB3" style="width: 13%; text-align: right" title="Revenues"&gt;3,058,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Europe&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20240401__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__srt--EuropeMember_zsnbz3JUVMJ6" style="text-align: right" title="Revenues"&gt;5,523,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20230401__20240331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__srt--EuropeMember_zKC94FNbtO5h" style="text-align: right" title="Revenues"&gt;4,781,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td&gt;Asia&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20240401__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__srt--AsiaMember_zmWtWTGuRhA" style="text-align: right" title="Revenues"&gt;2,317,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20230401__20240331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__srt--AsiaMember_zuAakEMFLsQ1" style="text-align: right" title="Revenues"&gt;2,298,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Latin America&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20240401__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__srt--LatinAmericaMember_zE2pJaE0as7b" style="text-align: right" title="Revenues"&gt;2,962,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20230401__20240331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__srt--LatinAmericaMember_zFA9UIPKkVyd" style="text-align: right" title="Revenues"&gt;1,726,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(238,238,238)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Rest of the World&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20240401__20250331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__custom--RestOfTheWorldMember_zenVN9BBNG07" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues"&gt;875,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20230401__20240331__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__custom--RestOfTheWorldMember_znhzNmIb6zW9" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues"&gt;872,000&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20240401__20250331_zDcse8CR7OM" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenues"&gt;14,288,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20230401__20240331_zfxc6Qh44bMg" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenues"&gt;12,735,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2024-04-012025-03-31_us-gaap_SalesRevenueSegmentMember_country_US"
      decimals="-3"
      id="Fact001252"
      unitRef="USD">2611000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-04-012024-03-31_us-gaap_SalesRevenueSegmentMember_country_US"
      decimals="-3"
      id="Fact001254"
      unitRef="USD">3058000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2024-04-012025-03-31_us-gaap_SalesRevenueSegmentMember_srt_EuropeMember"
      decimals="-3"
      id="Fact001256"
      unitRef="USD">5523000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-04-012024-03-31_us-gaap_SalesRevenueSegmentMember_srt_EuropeMember"
      decimals="-3"
      id="Fact001258"
      unitRef="USD">4781000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2024-04-012025-03-31_us-gaap_SalesRevenueSegmentMember_srt_AsiaMember"
      decimals="-3"
      id="Fact001260"
      unitRef="USD">2317000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-04-012024-03-31_us-gaap_SalesRevenueSegmentMember_srt_AsiaMember"
      decimals="-3"
      id="Fact001262"
      unitRef="USD">2298000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2024-04-012025-03-31_us-gaap_SalesRevenueSegmentMember_srt_LatinAmericaMember"
      decimals="-3"
      id="Fact001264"
      unitRef="USD">2962000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-04-012024-03-31_us-gaap_SalesRevenueSegmentMember_srt_LatinAmericaMember"
      decimals="-3"
      id="Fact001266"
      unitRef="USD">1726000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2024-04-012025-03-31_us-gaap_SalesRevenueSegmentMember_custom_RestOfTheWorldMember"
      decimals="-3"
      id="Fact001268"
      unitRef="USD">875000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-04-012024-03-31_us-gaap_SalesRevenueSegmentMember_custom_RestOfTheWorldMember"
      decimals="-3"
      id="Fact001270"
      unitRef="USD">872000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2024-04-01to2025-03-31"
      decimals="-3"
      id="Fact001272"
      unitRef="USD">14288000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-04-012024-03-31"
      decimals="-3"
      id="Fact001274"
      unitRef="USD">12735000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="From2025-01-012025-03-31" id="Fact001275">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="From2025-01-012025-03-31" id="Fact001276">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="From2025-01-012025-03-31" id="Fact001277">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="From2025-01-012025-03-31" id="Fact001278">false</ecd:NonRule10b51ArrTrmntdFlag>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Fact000547"
          xlink:label="Fact000547"
          xlink:type="locator"/>
        <link:footnote id="Footnote000566" xlink:label="Footnote000566" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">% <xhtml:span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents less than
    10%</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000547"
          xlink:to="Footnote000566"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000559"
          xlink:label="Fact000559"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000559"
          xlink:to="Footnote000566"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
